[{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-entity-compliance-guide-safe-handling-statements-labeling-shell-eggs-and-refrigeration-shell\u0022\u003ESmall Entity Compliance Guide: Safe Handling Statements on Labeling of Shell Eggs and the Refrigeration of Shell Eggs Held for Retail Distribution\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/01\/2001","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Egg\/Egg Product, Retail Food Protection","field_topics":"","topics-product":"Egg\/Egg Product, Retail Food Protection","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1954\u0022\u003EFDA-2020-D-1954\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:00:51-04:00\u0022\u003E2024-10-01 07:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-entity-compliance-guide-standard-identity-white-chocolate\u0022\u003ESmall Entity Compliance Guide: Standard of Identity for White Chocolate\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/16\/2008","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Chocolate\/Cocoa Product","field_topics":"","topics-product":"Chocolate\/Cocoa Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-N-0361\u0022\u003EFDA-2008-N-0361\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:00:55-04:00\u0022\u003E2024-10-01 07:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/draft-guidance-industry-and-fda-staff-whole-grain-label-statements\u0022\u003EDraft Guidance for Industry and FDA Staff: Whole Grain Label Statements\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/17\/2006","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"04\/18\/2006","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2006-D-0298\u0022\u003EFDA-2006-D-0298\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:00:59-04:00\u0022\u003E2024-10-01 07:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-voluntary-labeling-indicating-whether-foods-have-or-have-not-been-derived\u0022\u003EGuidance for Industry: Voluntary Labeling Indicating Whether Foods Have or Have Not Been Derived from Genetically Engineered Plants\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/120958\/download\u0022\u003EPDF (137.72 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (137.72 KB) of Guidance for Industry: Voluntary Labeling Indicating Whether Foods Have or Have Not Been Derived from Genetically Engineered Plants\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/11\/2019","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Bioengineering \/ GMOs, Labeling","field_topics":"","topics-product":"Bioengineering \/ GMOs, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2000-D-0075\u0022\u003EFDA-2000-D-0075\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-10T15:42:17-04:00\u0022\u003E2025-03-10 15:42\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-questions-and-answers-regarding-food-allergen-labeling-edition-5\u0022\u003EGuidance for Industry: Questions and Answers Regarding Food Allergen Labeling (Edition 5)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/117410\/download\u0022\u003EPDF (1.28 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.28 MB) of Guidance for Industry: Questions and Answers Regarding Food Allergen Labeling (Edition 5)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/06\/2025","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Allergens, Labeling","field_topics":"","topics-product":"Allergens, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0099\u0022\u003EFDA-2022-D-0099\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-26T11:49:32-04:00\u0022\u003E2025-03-26 11:49\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-interim-procedures-qualified-health-claims-labeling-conventional-human-food-and\u0022\u003EGuidance for Industry: Interim Procedures for Qualified Health Claims in the Labeling of Conventional Human Food and Human Dietary Supplements\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/11\/2003","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2003-N-0103\u0022\u003EFDA-2003-N-0103\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Dietary Supplements, Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:01:03-04:00\u0022\u003E2024-10-01 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-fdas-implementation-qualified-health-claims\u0022\u003EGuidance for Industry: FDA\u0026#039;s Implementation of Qualified Health Claims\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"05\/12\/2006","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:01:04-04:00\u0022\u003E2024-10-01 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-13-evaluation-effectiveness-new-animal-drugs-use-free-choice-feeds-medicated-block\u0022\u003ECVM GFI #13 Evaluation of Effectiveness of New Animal Drugs for Use in Free-Choice Feeds-Medicated Block\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"12\/31\/1984","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Feed, Target Animal \u2013 Effectiveness","field_topics":"","topics-product":"Animal Feed, Target Animal \u2013 Effectiveness","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0624\u0022\u003EFDA-2021-D-0624\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222021-07-27T06:56:03-04:00\u0022\u003E2021-07-27 06:56\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-frequently-asked-questions-about-medical-foods-third-edition\u0022\u003EGuidance for Industry: Frequently Asked Questions About Medical Foods - Third Edition\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/97726\/download\u0022\u003EPDF (307.15 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (307.15 KB) of Guidance for Industry: Frequently Asked Questions About Medical Foods - Third Edition\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/15\/2023","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0880\u0022\u003EFDA-2013-D-0880\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:01:07-04:00\u0022\u003E2024-10-01 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-summary-table-recommended-toxicological-testing-additives-used-food\u0022\u003EGuidance for Industry: Summary Table of Recommended Toxicological Testing for Additives Used in Food\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"06\/01\/2006","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1936\u0022\u003EFDA-2020-D-1936\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:01:08-04:00\u0022\u003E2024-10-01 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-23-medicated-free-choice-feeds-manufacturing-control\u0022\u003ECVM GFI #23 Medicated Free Choice Feeds--Manufacturing Control\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"06\/30\/1985","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Current Good Manufacturing Practice (CGMP)","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Current Good Manufacturing Practice (CGMP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0623\u0022\u003EFDA-2021-D-0623\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222021-07-27T06:55:07-04:00\u0022\u003E2021-07-27 06:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-24-drug-combinations-use-animals\u0022\u003ECVM GFI #24 Drug Combinations for Use in Animals\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/30\/1983","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Target Animal \u2013 Effectiveness","field_topics":"","topics-product":"Target Animal \u2013 Effectiveness","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0627\u0022\u003EFDA-2021-D-0627\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222021-07-27T07:01:03-04:00\u0022\u003E2021-07-27 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-frequently-asked-questions-about-fdas-regulation-infant-formula\u0022\u003EGuidance for Industry: Frequently Asked Questions about FDA\u0026#039;s Regulation of Infant Formula\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/01\/2006","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Infant Formula \u0026amp; Foods","field_topics":"","topics-product":"Infant Formula \u0026amp; Foods","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1937\u0022\u003EFDA-2020-D-1937\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:01:08-04:00\u0022\u003E2024-10-01 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-pre-petition-consultations-food-additives-and-color-additives\u0022\u003EGuidance for Industry: Pre-Petition Consultations for Food Additives and Color Additives\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"04\/01\/2005","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives, Ingredients","field_topics":"","topics-product":"Food \u0026amp; Color Additives, Ingredients","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1944\u0022\u003EFDA-2020-D-1944\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:01:10-04:00\u0022\u003E2024-10-01 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-37-evaluation-effectiveness-new-animal-drugs-use-poultry-feed-pigmentation\u0022\u003ECVM GFI #37 Evaluation of Effectiveness of New Animal Drugs for Use in Poultry Feed for Pigmentation\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/29\/1984","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Feed, Target Animal \u2013 Effectiveness","field_topics":"","topics-product":"Animal Feed, Target Animal \u2013 Effectiveness","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0626\u0022\u003EFDA-2021-D-0626\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222021-07-27T07:01:09-04:00\u0022\u003E2021-07-27 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-38-guideline-effectiveness-evaluation-topicalotic-animal-drugs\u0022\u003ECVM GFI #38 Guideline for Effectiveness Evaluation of Topical\/Otic Animal Drugs\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/20\/1984","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Target Animal \u2013 Effectiveness","field_topics":"","topics-product":"Target Animal \u2013 Effectiveness","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0625\u0022\u003EFDA-2021-D-0625\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222021-07-27T07:01:06-04:00\u0022\u003E2021-07-27 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-45-guideline-uniform-labeling-drugs-dairy-and-beef-cattle\u0022\u003ECVM GFI #45 Guideline for Uniform Labeling of Drugs for Dairy and Beef Cattle\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/31\/1993","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0620\u0022\u003EFDA-2021-D-0620\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222021-07-27T06:55:10-04:00\u0022\u003E2021-07-27 06:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-49-evaluating-target-animal-safety-and-effectiveness-antibacterial-new-animal-drugs-bovine\u0022\u003ECVM GFI #49 Evaluating Target Animal Safety and Effectiveness of Antibacterial New Animal Drugs for Bovine Mastitis\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/177318\/download\u0022\u003EPDF (398.88 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (398.88 KB) of CVM GFI #49 Evaluating Target Animal Safety and Effectiveness of Antibacterial New Animal Drugs for Bovine Mastitis\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/04\/2024","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Drugs, Clinical - Antimicrobial, Target Animal \u2013 Effectiveness, Target Animal \u2013 Safety, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA)","field_topics":"Premarket","topics-product":"Premarket, Animal Drugs, Clinical - Antimicrobial, Target Animal \u2013 Effectiveness, Target Animal \u2013 Safety, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA)","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"02\/03\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1993-D-0285\u0022\u003EFDA-1993-D-0285\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222024-12-03T08:50:03-05:00\u0022\u003E2024-12-03 08:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-53-evaluation-utility-food-additives-diet-fed-aquatic-animals\u0022\u003ECVM GFI #53 Evaluation of the Utility of Food Additives in Diet Fed to Aquatic Animals\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"04\/30\/1994","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Food Additives, Aquaculture","field_topics":"","topics-product":"Animal Food Additives, Aquaculture","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0618\u0022\u003EFDA-2021-D-0618\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222025-02-05T12:19:16-05:00\u0022\u003E2025-02-05 12:19\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-55-supportive-data-cat-food-labels-bearing-reduces-urinary-ph-claims-protocol-development\u0022\u003ECVM GFI #55 Supportive Data for Cat Food Labels Bearing \u0026quot;Reduces Urinary pH Claims: Protocol Development\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"05\/31\/1994","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Feed","field_topics":"","topics-product":"Animal Feed","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1994-D-0230\u0022\u003EFDA-1994-D-0230\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T11:45:21-04:00\u0022\u003E2019-04-16 11:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-and-fda-dear-manufacturer-letter-regarding-food-labeling\u0022\u003EGuidance for Industry and FDA: Dear Manufacturer Letter Regarding Food Labeling\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"01\/01\/2007","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1998-N-0050\u0022\u003EFDA-1998-N-0050\u003C\/a\u003E","field_communication_type":"Industry Letter","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:01:11-04:00\u0022\u003E2024-10-01 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-and-fda-dear-manufacturer-letter-regarding-sugar-free-claims\u0022\u003EGuidance for Industry and FDA: Dear Manufacturer Letter Regarding Sugar Free Claims\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/03\/2007","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1930\u0022\u003EFDA-2020-D-1930\u003C\/a\u003E","field_communication_type":"Industry Letter","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:01:11-04:00\u0022\u003E2024-10-01 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-labeling-guide-restaurants-and-retail-establishments-selling-away-home-foods-part\u0022\u003EGuidance for Industry: A Labeling Guide for Restaurants and Retail Establishments Selling Away-From-Home Foods - Part I\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/31\/2008","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling, Retail Food Protection","field_topics":"","topics-product":"Labeling, Retail Food Protection","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:01:13-04:00\u0022\u003E2024-10-01 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-entity-compliance-guide-trans-fatty-acids-nutrition-labeling-nutrient-content-claims-and\u0022\u003ESmall Entity Compliance Guide: Trans Fatty Acids in Nutrition Labeling, Nutrient Content Claims, and Health Claims\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/20\/2003","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2003-D-0035\u0022\u003EFDA-2003-D-0035\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:01:13-04:00\u0022\u003E2024-10-01 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-notification-health-claim-or-nutrient-content-claim-based-authoritative-statement\u0022\u003EGuidance for Industry: Notification of a Health Claim or Nutrient Content Claim Based on an Authoritative Statement of a Scientific Body\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"06\/11\/1998","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1998-D-0102\u0022\u003EFDA-1998-D-0102\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:01:14-04:00\u0022\u003E2024-10-01 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-exemptions-warning-label-requirement-juice\u0022\u003EGuidance for Industry: Exemptions from the Warning Label Requirement for Juice\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/07\/2002","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"HACCP, Juice, Labeling","field_topics":"","topics-product":"HACCP, Juice, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2001-D-0138\u0022\u003EFDA-2001-D-0138\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:01:15-04:00\u0022\u003E2024-10-01 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-frequently-asked-questions-about-gras-substances-intended-use-human-or-animal-food\u0022\u003EGuidance for Industry: Frequently Asked Questions About GRAS for Substances Intended for Use in Human or Animal Food\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/101042\/download\u0022\u003EPDF (117.29 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (117.29 KB) of Guidance for Industry: Frequently Asked Questions About GRAS for Substances Intended for Use in Human or Animal Food\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/30\/2016","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives, GRAS","field_topics":"","topics-product":"Food \u0026amp; Color Additives, GRAS","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1908\u0022\u003EFDA-2020-D-1908\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Animal \u0026amp; Veterinary, Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:01:16-04:00\u0022\u003E2024-10-01 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-guide-minimize-microbial-food-safety-hazards-fresh-fruits-and-vegetables\u0022\u003EGuidance for Industry: Guide to Minimize Microbial Food Safety Hazards for Fresh Fruits and Vegetables\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/117408\/download\u0022\u003EPDF (98.28 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (98.28 KB) of Guidance for Industry: Guide to Minimize Microbial Food Safety Hazards for Fresh Fruits and Vegetables\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/25\/1998","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Fruit\/Fruit Product , Vegetable Products","field_topics":"","topics-product":"Fruit\/Fruit Product , Vegetable Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1997-N-0152\u0022\u003EFDA-1997-N-0152\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:01:19-04:00\u0022\u003E2024-10-01 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-and-fda-staff-guidance-records-access-authority-provided-title-iii-subtitle-public\u0022\u003EGuidance for Industry and FDA Staff: Guidance for Records Access Authority Provided in Title III, Subtitle A, of the Public Health Security and Bioterrorism Preparedness and Response Act of 2002\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Records","field_topics":"","topics-product":"Records","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-G-0002\u0022\u003EFDA-2004-G-0002\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:01:19-04:00\u0022\u003E2024-10-01 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-implementation-section-10809-farm-security-and-investment-act-2002-regarding\u0022\u003EGuidance for Industry: Implementation of Section 10809 of the Farm Security and Investment Act of 2002 Regarding the Petition Process to Request Approval of Labeling for Foods that Have Been Treated with Irradiation\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/07\/2002","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2002-D-0189\u0022\u003EFDA-2002-D-0189\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:01:21-04:00\u0022\u003E2024-10-01 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-entity-compliance-guide-nutrient-content-claims-definition-high-potency-and-definition\u0022\u003ESmall Entity Compliance Guide: Nutrient Content Claims Definition for \u201cHigh Potency\u201d and Definition for \u201cAntioxidant\u201d for Use in Nutrient Content Claims for Dietary Supplements and Conventional Foods\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/18\/2008","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1995-N-0400\u0022\u003EFDA-1995-N-0400\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Human Foods Program","field_regulated_product_field":"Dietary Supplements, Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:01:22-04:00\u0022\u003E2024-10-01 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-guidelines-determining-metric-equivalents-household-measures\u0022\u003EGuidance for Industry: Guidelines for Determining Metric Equivalents of Household Measures\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/30\/1993","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling, Nutrition Label","field_topics":"","topics-product":"Labeling, Nutrition Label","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1977-0001\u0022\u003EFDA-2020-D-1977-0001\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T09:01:56-04:00\u0022\u003E2024-10-01 09:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-guide-developing-and-using-data-bases-nutrition-labeling\u0022\u003EGuidance for Industry: Guide for Developing and Using Data Bases for Nutrition Labeling\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/01\/1998","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling, Nutrition Label","field_topics":"","topics-product":"Labeling, Nutrition Label","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1961\u0022\u003EFDA-2020-D-1961\u003C\/a\u003E","field_communication_type":"Manual","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:01:24-04:00\u0022\u003E2024-10-01 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-entity-compliance-guide-serving-sizes-reference-amount-baking-powder-baking-soda-and-pectin\u0022\u003ESmall Entity Compliance Guide: Serving Sizes Reference Amount for Baking Powder, Baking Soda, and Pectin\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/01\/2001","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Bakery Product\/Mix, Labeling, Nutrition Label","field_topics":"","topics-product":"Bakery Product\/Mix, Labeling, Nutrition Label","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1955\u0022\u003EFDA-2020-D-1955\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:01:25-04:00\u0022\u003E2024-10-01 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-small-businesses-submission-comments-cfsan-rulemaking\u0022\u003EGuidance for Small Businesses: Submission of Comments for CFSAN Rulemaking\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/20\/2002","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"Rulemaking ","topics-product":"Rulemaking , ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:07:05-04:00\u0022\u003E2024-10-01 07:07\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clinical-investigations-devices-indicated-treatment-urinary-incontinence-guidance-industry-and-fda\u0022\u003EClinical Investigations of Devices Indicated for the Treatment of Urinary Incontinence - Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71054\/download\u0022\u003EPDF (627.62 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (627.62 KB) of Clinical Investigations of Devices Indicated for the Treatment of Urinary Incontinence - Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/07\/2011","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Pediatric Product Development","field_topics":"Premarket","topics-product":"Premarket, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0457\u0022\u003EFDA-2008-D-0457\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222025-01-31T14:24:31-05:00\u0022\u003E2025-01-31 14:24\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clinical-trial-considerations-vertebral-augmentation-devices-treat-spinal-insufficiency-fractures\u0022\u003EClinical Trial Considerations: Vertebral Augmentation Devices to Treat Spinal Insufficiency Fractures - Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/23\/2004","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-19T10:25:53-04:00\u0022\u003E2020-03-19 10:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-questions-and-answers-juice-haccp-regulation-2003\u0022\u003EGuidance for Industry: Questions and Answers on Juice HACCP Regulation (2003)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/03\/2003","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"HACCP, Juice","field_topics":"","topics-product":"HACCP, Juice","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1951\u0022\u003EFDA-2020-D-1951\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:01:26-04:00\u0022\u003E2024-10-01 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/dental-composite-resin-devices-premarket-notification-510k-submissions\u0022\u003EDental Composite Resin Devices - Premarket Notification (510(k)) Submissions: Guidance for Industry and Food and Drug Administration Staff\u00a0\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71305\/download\u0022\u003EPDF (427.29 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (427.29 KB) of Dental Composite Resin Devices - Premarket Notification (510(k)) Submissions: Guidance for Industry and Food and Drug Administration Staff\u00a0\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/02\/2026","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Dental ","field_topics":"Premarket","topics-product":"Premarket, 510(k), Dental ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-2511\u0022\u003EFDA-2024-D-2511\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222026-09-01T10:26:51-04:00\u0022\u003E2026-09-01 10:26\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/premarket-notification-510k-submissions-chemical-indicators-guidance-industry-and-fda-staff\u0022\u003EPremarket Notification [510(k)] Submissions for Chemical Indicators - Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72010\/download\u0022\u003EPDF (608.45 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (608.45 KB) of Premarket Notification [510(k)] Submissions for Chemical Indicators - Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/18\/2003","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-19T10:23:05-04:00\u0022\u003E2020-03-19 10:23\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/needlesticks-medical-device-reporting-guidance-user-facilities-manufacturers-and-importers\u0022\u003ENeedlesticks - Medical Device Reporting Guidance for User Facilities, Manufacturers, and Importers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71528\/download\u0022\u003EPDF (33.84 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (33.84 KB) of Needlesticks - Medical Device Reporting Guidance for User Facilities, Manufacturers, and Importers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/11\/2002","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Adverse Event Reporting System (FAERS)","topics-product":"Adverse Event Reporting System (FAERS), ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-19T10:00:06-04:00\u0022\u003E2020-03-19 10:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/menstrual-tampons-and-pads-information-premarket-notification-submissions-510ks-guidance-industry\u0022\u003EMenstrual Tampons and Pads: Information for Premarket Notification Submissions (510(k)s) - Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71254\/download\u0022\u003EPDF (303.32 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (303.32 KB) of Menstrual Tampons and Pads: Information for Premarket Notification Submissions (510(k)s) - Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/26\/2005","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k)","field_topics":"Premarket","topics-product":"Premarket, 510(k)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-19T10:45:08-04:00\u0022\u003E2020-03-19 10:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/draft-guidance-industry-control-listeria-monocytogenes-ready-eat-foods\u0022\u003EDraft Guidance for Industry: Control of Listeria monocytogenes in Ready-To-Eat Foods\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/102633\/download\u0022\u003EPDF (852.17 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (852.17 KB) of Draft Guidance for Industry: Control of Listeria monocytogenes in Ready-To-Eat Foods\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/17\/2017","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Listeria","field_topics":"","topics-product":"Listeria","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"07\/26\/2017","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0096\u0022\u003EFDA-2008-D-0096\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:01:28-04:00\u0022\u003E2024-10-01 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-refusal-inspection-or-access-haccp-records-pertaining-safe-and-sanitary-processing\u0022\u003EGuidance for Industry: Refusal of Inspection or Access to HACCP Records Pertaining to the Safe and Sanitary Processing of Fish and Fishery Products\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/01\/2001","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"HACCP, Records, Seafood\/Seafood Product","field_topics":"","topics-product":"HACCP, Records, Seafood\/Seafood Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2000-D-0278\u0022\u003EFDA-2000-D-0278\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:01:28-04:00\u0022\u003E2024-10-01 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/procedures-handling-post-approval-studies-imposed-pma-order\u0022\u003EProcedures for Handling Post-Approval Studies Imposed by PMA Order: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71327\/download\u0022\u003EPDF (438.61 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (438.61 KB) of Procedures for Handling Post-Approval Studies Imposed by PMA Order: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/07\/2022","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2005-D-0027\u0022\u003EFDA-2005-D-0027\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222022-10-07T09:19:31-04:00\u0022\u003E2022-10-07 09:19\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-seafood-haccp-transition-guidance\u0022\u003EGuidance for Industry: Seafood HACCP Transition Guidance\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"12\/01\/1999","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"HACCP, Seafood\/Seafood Product","field_topics":"","topics-product":"HACCP, Seafood\/Seafood Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1999-D-3543\u0022\u003EFDA-1999-D-3543\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:01:30-04:00\u0022\u003E2024-10-01 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/criteria-significant-risk-investigations-magnetic-resonance-diagnostic-devices-guidance-industry-and\u0022\u003ECriteria for Significant Risk Investigations of Magnetic Resonance Diagnostic Devices - Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71385\/download\u0022\u003EPDF (77.94 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (77.94 KB) of Criteria for Significant Risk Investigations of Magnetic Resonance Diagnostic Devices - Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/19\/2014","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-24T09:20:48-04:00\u0022\u003E2020-03-24 09:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-implementation-section-403t-federal-food-drug-and-cosmetic-act-21-usc-343t\u0022\u003EGuidance for Industry: Implementation of Section 403(t) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 343(t)) Regarding the Use of the Term \u0026quot;Catfish\u0026quot;\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"12\/06\/2002","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Seafood\/Seafood Product","field_topics":"","topics-product":"Seafood\/Seafood Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2002-D-0174\u0022\u003EFDA-2002-D-0174\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:01:31-04:00\u0022\u003E2024-10-01 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-entity-compliance-guide-statement-identity-nutrition-labeling-and-ingredient-labeling-dietary\u0022\u003ESmall Entity Compliance Guide: Statement of Identity, Nutrition Labeling and Ingredient Labeling of Dietary Supplements\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"01\/03\/1999","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1959\u0022\u003EFDA-2020-D-1959\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Human Foods Program","field_regulated_product_field":"Dietary Supplements","changed":"\u003Ctime datetime=\u00222024-10-01T14:47:11-04:00\u0022\u003E2024-10-01 14:47\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-use-bayesian-statistics-medical-device-clinical-trials\u0022\u003EGuidance for the Use of Bayesian Statistics in Medical Device Clinical Trials\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/04\/2010","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs","field_health_topics":"","term_node_tid":"","field_topics":"Biostatistics","topics-product":"Biostatistics, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-01-19T15:22:54-05:00\u0022\u003E2020-01-19 15:22\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-and-fda-staff-spinal-system-510ks\u0022\u003EGuidance for Industry and FDA Staff: Spinal System 510(k)s\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71604\/download\u0022\u003EPDF (377.97 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (377.97 KB) of Guidance for Industry and FDA Staff: Spinal System 510(k)s\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/02\/2004","field_issuing_office_taxonomy":"Center for Devices and Radiological Health,Office of Product Evaluation and Quality","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-24T15:10:02-04:00\u0022\u003E2020-03-24 15:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/medical-devices-sharps-injury-prevention-features-guidance-industry-and-fda-staff\u0022\u003EMedical Devices with Sharps Injury Prevention Features - Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71142\/download\u0022\u003EPDF (265.11 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (265.11 KB) of Medical Devices with Sharps Injury Prevention Features - Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/08\/2005","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222026-01-14T08:57:32-05:00\u0022\u003E2026-01-14 08:57\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-resorbable-adhesion-barrier-devices-use-abdominal-andor-pelvic-surgery-guidance-industry\u0022\u003EGuidance for Resorbable Adhesion Barrier Devices for Use in Abdominal and\/or Pelvic Surgery - Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71607\/download\u0022\u003EPDF (379.25 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (379.25 KB) of Guidance for Resorbable Adhesion Barrier Devices for Use in Abdominal and\/or Pelvic Surgery - Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/17\/2002","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222025-01-31T14:37:46-05:00\u0022\u003E2025-01-31 14:37\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/non-clinical-engineering-tests-and-recommended-labeling-intravascular-stents-and-associated-delivery\u0022\u003ENon-Clinical Engineering Tests and Recommended Labeling for Intravascular Stents and Associated Delivery Systems - Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71639\/download\u0022\u003EPDF (596.67 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (596.67 KB) of Non-Clinical Engineering Tests and Recommended Labeling for Intravascular Stents and Associated Delivery Systems - Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/17\/2010","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222025-01-31T14:20:47-05:00\u0022\u003E2025-01-31 14:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-substantiation-dietary-supplement-claims-made-under-section-403r-6-federal-food\u0022\u003EGuidance for Industry: Substantiation for Dietary Supplement Claims Made Under Section 403(r) (6) of the Federal Food, Drug, and Cosmetic Act\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"01\/05\/2009","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-D-0303\u0022\u003EFDA-2004-D-0303\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Dietary Supplements","changed":"\u003Ctime datetime=\u00222025-02-05T17:43:46-05:00\u0022\u003E2025-02-05 17:43\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-refrigerated-carrot-juice-and-other-refrigerated-low-acid-juices\u0022\u003EGuidance for Industry: Refrigerated Carrot Juice and Other Refrigerated Low-Acid Juices\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"06\/05\/2007","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Juice","field_topics":"","topics-product":"Juice","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2007-D-0030\u0022\u003EFDA-2007-D-0030\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:01:32-04:00\u0022\u003E2024-10-01 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/statistical-guidance-reporting-results-studies-evaluating-diagnostic-tests-guidance-industry-and-fda\u0022\u003EStatistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests - Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71147\/download\u0022\u003EPDF (336.84 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (336.84 KB) of Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests - Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/12\/2007","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Biostatistics","topics-product":"Biostatistics, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-19T13:15:02-04:00\u0022\u003E2020-03-19 13:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/letter-state-regulatory-agencies-and-firms-produce-treated-not-pasteurized-and-untreated-juice-and\u0022\u003ELetter to State Regulatory Agencies and Firms That Produce Treated (but not Pasteurized) and Untreated Juice and Cider\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/22\/2005","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Juice","field_topics":"","topics-product":"Juice","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1938\u0022\u003EFDA-2020-D-1938\u003C\/a\u003E","field_communication_type":"Industry Letter","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:01:33-04:00\u0022\u003E2024-10-01 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-recommendations-processors-apple-juice-or-cider-use-ozone-pathogen-reduction\u0022\u003EGuidance for Industry: Recommendations to Processors of Apple Juice or Cider on the Use of Ozone for Pathogen Reduction Purposes\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/01\/2004","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Juice","field_topics":"","topics-product":"Juice","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-D-0531\u0022\u003EFDA-2004-D-0531\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:01:35-04:00\u0022\u003E2024-10-01 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/surgical-masks-premarket-notification-510k-submissions\u0022\u003ESurgical Masks - Premarket Notification [510(k)] Submissions: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71660\/download\u0022\u003EPDF (224.92 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (224.92 KB) of Surgical Masks - Premarket Notification [510(k)] Submissions: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/04\/2004","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2003-D-0305\u0022\u003EFDA-2003-D-0305\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-02-28T12:40:02-05:00\u0022\u003E2020-02-28 12:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-juice-hazard-analysis-critical-control-point-hazards-and-controls-guidance-first\u0022\u003EGuidance for Industry: Juice Hazard Analysis Critical Control Point Hazards and Controls Guidance, First Edition\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/03\/2004","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"HACCP, Juice","field_topics":"","topics-product":"HACCP, Juice","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2002-D-0298\u0022\u003EFDA-2002-D-0298\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:01:37-04:00\u0022\u003E2024-10-01 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clinical-data-presentations-orthopedic-device-applications-guidance-industry-and-fda-staff\u0022\u003EClinical Data Presentations for Orthopedic Device Applications - Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71670\/download\u0022\u003EPDF (582.42 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (582.42 KB) of Clinical Data Presentations for Orthopedic Device Applications - Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/01\/2004","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222025-01-31T14:13:16-05:00\u0022\u003E2025-01-31 14:13\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/early-collaboration-meetings-under-fda-modernization-act-fdama-final-guidance-industry-and-cdrh\u0022\u003EEarly Collaboration Meetings Under the FDA Modernization Act (FDAMA); Final Guidance for Industry and for CDRH Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71676\/download\u0022\u003EPDF (79.69 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (79.69 KB) of Early Collaboration Meetings Under the FDA Modernization Act (FDAMA); Final Guidance for Industry and for CDRH Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/27\/2001","field_issuing_office_taxonomy":"Center for Devices and Radiological Health,Office of Product Evaluation and Quality","field_health_topics":"","term_node_tid":"Investigational Device Exemption (IDE)","field_topics":"Premarket","topics-product":"Premarket, Investigational Device Exemption (IDE)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222023-08-10T16:01:16-04:00\u0022\u003E2023-08-10 16:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-and-fda-staff-vocal-fold-medialization-devices-premarket-notification-510k\u0022\u003EGuidance for Industry and FDA Staff: Vocal Fold Medialization Devices - Premarket Notification [510(k)] Submissions\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71688\/download\u0022\u003EPDF (426.72 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (426.72 KB) of Guidance for Industry and FDA Staff: Vocal Fold Medialization Devices - Premarket Notification [510(k)] Submissions\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/12\/2004","field_issuing_office_taxonomy":"Center for Devices and Radiological Health,Office of Product Evaluation and Quality","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-24T15:15:13-04:00\u0022\u003E2020-03-24 15:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-evidence-based-review-system-scientific-evaluation-health-claims\u0022\u003EGuidance for Industry: Evidence-Based Review System for the Scientific Evaluation of Health Claims\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"01\/16\/2009","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2007-D-0371\u0022\u003EFDA-2007-D-0371\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:01:40-04:00\u0022\u003E2024-10-01 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-questions-and-answers-juice-haccp-regulation\u0022\u003EGuidance for Industry: Questions and Answers on Juice HACCP Regulation\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/31\/2001","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"HACCP, Juice","field_topics":"","topics-product":"HACCP, Juice","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:01:42-04:00\u0022\u003E2024-10-01 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-testing-metallic-plasma-sprayed-coatings-orthopedic-implants-support\u0022\u003EGuidance for Industry on the Testing of Metallic Plasma Sprayed Coatings on Orthopedic Implants to Support Reconsideration of Postmarket Surveillance Requirements - Guidance for Industry and for FDA Reviewers\/Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/74184\/download\u0022\u003EPDF (37.99 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (37.99 KB) of Guidance for Industry on the Testing of Metallic Plasma Sprayed Coatings on Orthopedic Implants to Support Reconsideration of Postmarket Surveillance Requirements - Guidance for Industry and for FDA Reviewers\/Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/01\/2000","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Postmarket","topics-product":"Postmarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-18T15:25:05-04:00\u0022\u003E2020-03-18 15:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-entity-compliance-guide-final-rule-declaring-dietary-supplements-containing-ephedrine\u0022\u003ESmall Entity Compliance Guide: Final Rule Declaring Dietary Supplements Containing Ephedrine Alkaloids Adulterated Because They Present an Unreasonable Risk\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/17\/2008","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1995-N-0054\u0022\u003EFDA-1995-N-0054\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Human Foods Program","field_regulated_product_field":"Dietary Supplements","changed":"\u003Ctime datetime=\u00222024-10-01T14:46:31-04:00\u0022\u003E2024-10-01 14:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-standardized-training-curriculum-application-haccp-principles-juice-processing\u0022\u003EGuidance for Industry: Standardized Training Curriculum for Application of HACCP Principles to Juice Processing\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"06\/13\/2003","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"HACCP, Juice","field_topics":"","topics-product":"HACCP, Juice","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2002-D-0227\u0022\u003EFDA-2002-D-0227\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:01:43-04:00\u0022\u003E2024-10-01 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/content-investigational-device-exemptions-solutions-hypothermic-flushing-transport-and-storage\u0022\u003EContent of Investigational Device Exemptions for Solutions for Hypothermic Flushing, Transport and Storage of Organs for Transplantation - Guidance for Industry and FDA Reviewers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71703\/download\u0022\u003EPDF (133.33 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (133.33 KB) of Content of Investigational Device Exemptions for Solutions for Hypothermic Flushing, Transport and Storage of Organs for Transplantation - Guidance for Industry and FDA Reviewers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/15\/2001","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Investigational Device Exemption (IDE)","field_topics":"Premarket","topics-product":"Premarket, Investigational Device Exemption (IDE)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-19T09:38:33-04:00\u0022\u003E2020-03-19 09:38\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-entity-compliance-guide-label-warning-statements-iron-containing-supplements-and-drugs\u0022\u003ESmall Entity Compliance Guide: Label Warning Statements for Iron-Containing Supplements and Drugs\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/17\/2003","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1997-D-0056\u0022\u003EFDA-1997-D-0056\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Human Foods Program","field_regulated_product_field":"Dietary Supplements","changed":"\u003Ctime datetime=\u00222024-10-01T14:47:09-04:00\u0022\u003E2024-10-01 14:47\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-document-dura-substitute-devices-guidance-industry\u0022\u003EGuidance Document for Dura Substitute Devices - Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71729\/download\u0022\u003EPDF (65.56 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (65.56 KB) of Guidance Document for Dura Substitute Devices - Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/08\/2000","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-18T15:36:54-04:00\u0022\u003E2020-03-18 15:36\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-160600-payment-expert-witnesses\u0022\u003ECPG Sec. 160.600 Payment of Expert Witnesses\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/15\/1987","field_issuing_office_taxonomy":"Office of Regulatory Affairs","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222024-10-24T14:52:18-04:00\u0022\u003E2024-10-24 14:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-160700-reconditioning-foods-adulterated-under-402a4\u0022\u003ECPG Sec. 160.700 Reconditioning of Foods Adulterated Under 402(a)(4)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/20\/1989","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T08:03:38-04:00\u0022\u003E2024-10-01 08:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-160750-drug-and-device-products-including-biologics-and-animal-drugs-found-violation-gmprs\u0022\u003ECPG Sec. 160.750 Drug and Device Products (Including Biologics and Animal Drugs) Found in Violation of GMPRs - Reconditioning\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/31\/1996","field_issuing_office_taxonomy":"Office of Regulatory Affairs","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222024-10-24T14:52:15-04:00\u0022\u003E2024-10-24 14:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-section-216-food-and-drug-administration-modernization-act-1997-guidance-industry-and-fda\u0022\u003EGuidance on Section 216 of the Food and Drug Administration Modernization Act of 1997 - Guidance for Industry and for FDA Reviewers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71743\/download\u0022\u003EPDF (190.71 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (190.71 KB) of Guidance on Section 216 of the Food and Drug Administration Modernization Act of 1997 - Guidance for Industry and for FDA Reviewers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/08\/2000","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-18T15:38:49-04:00\u0022\u003E2020-03-18 15:38\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-215100-ind-filings-completion-applicable-portions-prior-final-action-license-applications-or\u0022\u003ECPG Sec. 215.100 IND Filings; Completion of Applicable Portions Prior to Final Action on License Applications or License Supplements, Deleted 03\/28\/2000, Outdated and Obsolete\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/27\/2000","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222018-12-01T09:46:29-05:00\u0022\u003E2018-12-01 09:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-220100-shipment-biologicals-medical-emergency\u0022\u003ECPG Sec. 220.100 - IS Shipment Biologicals for Medical Emergency\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/31\/2000","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"Investigational New Drug Application (INDA)","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Investigational New Drug Application (INDA)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Drugs, Biologics","changed":"\u003Ctime datetime=\u00222018-12-01T09:20:40-05:00\u0022\u003E2018-12-01 09:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-230110-registration-blood-banks-other-firms-collecting-manufacturing-preparing-or-processing\u0022\u003ECPG Sec. 230.110- Registration of Blood Banks, Other Firms Collecting, Manufacturing, Preparing or Processing Human Blood or Blood Products\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/16\/2000","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222018-12-01T09:46:36-05:00\u0022\u003E2018-12-01 09:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-230120-human-blood-and-blood-products-drugs\u0022\u003ECPG 230.120- Human Blood and Blood Products as Drugs\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/30\/1980","field_issuing_office_taxonomy":"Office of Regulatory Affairs","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222024-10-24T14:52:30-04:00\u0022\u003E2024-10-24 14:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-230130-adequate-space-determination-donor-suitability-obsolete-withdrawn-7162018\u0022\u003ECPG 230.130- Adequate Space for Determination of Donor Suitability (Obsolete, Withdrawn on 7\/16\/2018)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222018-12-01T09:46:42-05:00\u0022\u003E2018-12-01 09:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-submission-premarket-notifications-photon-emitting-brachytherapy-sources-guidance-industry\u0022\u003EGuidance for the Submission of Premarket Notifications for Photon-Emitting Brachytherapy Sources - Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71747\/download\u0022\u003EPDF (84.33 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (84.33 KB) of Guidance for the Submission of Premarket Notifications for Photon-Emitting Brachytherapy Sources - Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/01\/2000","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-18T15:30:09-04:00\u0022\u003E2020-03-18 15:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-231100-platelets-pooled-obsolete-and-was-withdrawn-7162018\u0022\u003ECPG Sec. 231.100- *Platelets, Pooled* is obsolete and was withdrawn on 7\/16\/2018.\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222018-12-01T09:46:44-05:00\u0022\u003E2018-12-01 09:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-231110-quality-control-testing-platelets-and-cryoprecipitated-antihemophilic-factor\u0022\u003ECPG Sec. 231.110- Quality Control Testing of *Platelets* [ ] and Cryoprecipitated Antihemophilic Factor [ ]\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222018-12-01T09:46:47-05:00\u0022\u003E2018-12-01 09:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-231120-time-period-separation-platelets-platelet-rich-plasma-when-preparing-platelets-and\u0022\u003ECPG Sec. 231.120- Time Period for Separation of Platelets from Platelet-Rich Plasma When Preparing *Platelets* and Fresh Frozen Plasma* is obsolete and was withdrawn on 7\/16\/2018.\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222018-12-01T09:46:50-05:00\u0022\u003E2018-12-01 09:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-231130-storage-platelets-five-5-days-obsolete-and-was-withdrawn-7162018\u0022\u003ECPG Sec. 231.130- Storage of *Platelets* [ ] for up to five (5) Days is obsolete and was withdrawn on 7\/16\/2018.\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222018-12-01T09:46:53-05:00\u0022\u003E2018-12-01 09:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/1-consolidated-annual-report-device-product-line-1-card-guidance-industry-and-cdrh-reviewers\u0022\u003E1-Consolidated Annual Report for a Device product line (1-CARD) - Guidance for Industry and CDRH Reviewers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71752\/download\u0022\u003EPDF (124.68 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (124.68 KB) of 1-Consolidated Annual Report for a Device product line (1-CARD) - Guidance for Industry and CDRH Reviewers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/05\/2000","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-18T15:30:18-04:00\u0022\u003E2020-03-18 15:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-250100-source-plasma-guidelines-informed-consent-forms-obsolete-withdrawn-11282017\u0022\u003ECPG Sec. 250.100 Source Plasma \u2013 Guidelines for Informed Consent Forms (Obsolete, Withdrawn on 11\/28\/2017)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222023-09-29T13:05:12-04:00\u0022\u003E2023-09-29 13:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-251100-schedule-physical-examination-donors-receiving-immunization-injections-obsolete\u0022\u003ECPG Sec. 251.100 Schedule of Physical Examination for Donors Receiving Immunization Injections (Obsolete, Withdrawn on 11\/28\/2017)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/30\/1980","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222023-09-29T13:05:10-04:00\u0022\u003E2023-09-29 13:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-252100-source-plasma-regulatory-action-based-overbleeding-obsolete-withdrawn-11282017\u0022\u003ECPG Sec. 252.100 Source Plasma - Regulatory Action Based on Overbleeding (Obsolete, Withdrawn on 11\/28\/2017)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222023-09-29T13:05:13-04:00\u0022\u003E2023-09-29 13:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-252110-volume-limits-automated-collection-source-plasma-obsolete-withdrawn-11282017\u0022\u003ECPG Sec. 252.110 Volume Limits for Automated Collection of Source Plasma (Obsolete, Withdrawn on 11\/28\/2017)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/05\/2000","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222023-09-29T13:05:03-04:00\u0022\u003E2023-09-29 13:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-253100-use-units-plasma-and-fresh-frozen-plasma-which-have-been-thawed\u0022\u003ECPG Sec. 253.100- Use of Units of *Plasma and Fresh Frozen Plasma* Which Have Been Thawed\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222018-12-01T13:07:41-05:00\u0022\u003E2018-12-01 13:07\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-254100-source-plasma-use-units-donors-subsequently-found-be-reactive-serologic-test-syphilis\u0022\u003ECPG Sec. 254.100 Source Plasma - Use of Units from Donors Subsequently Found to be Reactive to a Serologic Test for Syphilis (Obsolete, Withdrawn on 11\/28\/2017)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222023-09-29T13:05:05-04:00\u0022\u003E2023-09-29 13:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-500100-additives-labeling-adequate-directions-many-uses\u0022\u003ECPG Sec 500.100 Additives - Labeling with Adequate Directions for Many Uses\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/01\/1980","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T08:47:01-05:00\u0022\u003E2025-03-05 08:47\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-255100-quantitative-testing-serum-proteins-plasmapheresis-donors-obsolete-withdrawn-11282017\u0022\u003ECPG Sec. 255.100 Quantitative Testing for Serum Proteins in Plasmapheresis Donors (Obsolete, Withdrawn on 11\/28\/2017)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222023-09-29T13:05:01-04:00\u0022\u003E2023-09-29 13:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-500200-food-additives-gras\u0022\u003ECPG Sec 500.200 Food Additives -\u0026quot;GRAS\u0026quot;\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Ingredients","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Ingredients","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T12:01:32-05:00\u0022\u003E2025-03-05 12:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-500250-food-additives-labeling-directions-necessary-safe-use\u0022\u003ECPG Sec 500.250 Food Additives - Labeling Directions Necessary for Safe Use: CPG Sec 500.250 Food Additives\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/01\/1996","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Ingredients","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Ingredients","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T11:53:31-05:00\u0022\u003E2025-03-05 11:53\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-256100-plasmapheresis-48-hour-period-between-plasmapheresis-procedures-obsolete-withdrawn\u0022\u003ECPG Sec. 256.100 Plasmapheresis - 48-hour Period Between Plasmapheresis Procedures (Obsolete, Withdrawn on 11\/28\/2017)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222023-09-29T13:05:09-04:00\u0022\u003E2023-09-29 13:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-500300-approved-fda-use-phrase-objectionable-marketing-or-labeling-food-additive\u0022\u003ECPG Sec 500.300 \u0026quot;Approved by FDA\u0026quot; - Use of Phrase Objectionable in Marketing or Labeling of a Food Additive\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/01\/1996","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Ingredients","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Ingredients","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T12:01:36-05:00\u0022\u003E2025-03-05 12:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-premarket-submissions-orthokeratology-rigid-gas-permeable-contact-lenses-guidance-industry\u0022\u003EGuidance for Premarket Submissions of Orthokeratology Rigid Gas Permeable Contact Lenses - Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72074\/download\u0022\u003EPDF (291.05 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (291.05 KB) of Guidance for Premarket Submissions of Orthokeratology Rigid Gas Permeable Contact Lenses - Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/09\/2000","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222023-08-17T10:29:46-04:00\u0022\u003E2023-08-17 10:29\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-257100-deferral-source-plasma-donors-due-red-cell-loss-during-collection-source-plasma\u0022\u003ECPG Sec. 257.100 Deferral of Source Plasma Donors Due To Red Cell Loss During Collection of Source Plasma by Automated Plasmapheresis (Obsolete, Withdrawn on 11\/28\/2017)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222023-09-29T13:05:07-04:00\u0022\u003E2023-09-29 13:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-500400-use-calcium-chloride-drying-agent-such-products-packaged-potato-chips-and-peanuts\u0022\u003ECPG Sec 500.400 Use of Calcium Chloride as a Drying Agent in Such Products as Packaged Potato Chips and Peanuts\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Ingredients","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Ingredients","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T11:55:47-05:00\u0022\u003E2025-03-05 11:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-275100-immune-milk-withdrawn-1302020\u0022\u003ECPG Sec 275.100 Immune Milk (Withdrawn 1\/30\/2020) : CPG Sec 275.100 Immune Milk\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T08:04:11-04:00\u0022\u003E2024-10-01 08:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-manufacturers-seeking-marketing-clearance-ear-nose-and-throat-endoscope-sheaths-used\u0022\u003EGuidance for Manufacturers Seeking Marketing Clearance of Ear, Nose, and Throat Endoscope Sheaths Used as Protective Barriers: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71758\/download\u0022\u003EPDF (80.59 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (80.59 KB) of Guidance for Manufacturers Seeking Marketing Clearance of Ear, Nose, and Throat Endoscope Sheaths Used as Protective Barriers: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/11\/2000","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-18T15:25:15-04:00\u0022\u003E2020-03-18 15:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-500425-use-color-additives-paper-and-paperboard-intended-use-food\u0022\u003ECPG Sec 500.425 Use of Color Additives in Paper and Paperboard Intended for Use with Food\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Ingredients","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Ingredients","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T11:56:46-05:00\u0022\u003E2025-03-05 11:56\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-280100-stability-requirements-licensed-in-vitro-diagnostic-products\u0022\u003ECPG Sec. 280.100 - Stability Requirements - Licensed In Vitro Diagnostic Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/140688\/download\u0022\u003EPDF (73.86 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (73.86 KB) of CPG Sec. 280.100 - Stability Requirements - Licensed In Vitro Diagnostic Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/31\/2020","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222024-11-05T16:09:02-05:00\u0022\u003E2024-11-05 16:09\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-500450-volatile-n-nitrosamines-rubber-baby-bottle-nipples\u0022\u003ECPG Sec 500.450 Volatile N-Nitrosamines in Rubber Baby Bottle Nipples\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Ingredients","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Ingredients","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T11:57:31-05:00\u0022\u003E2025-03-05 11:57\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-280110-microbiological-control-requirements-licensed-anti-human-globulin-and-blood-grouping\u0022\u003ECPG Sec. 280.110- Microbiological Control Requirements-Licensed Anti-Human Globulin and Blood Grouping Reagents\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/140689\/download\u0022\u003EPDF (53.39 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (53.39 KB) of CPG Sec. 280.110- Microbiological Control Requirements-Licensed Anti-Human Globulin and Blood Grouping Reagents\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/31\/2020","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222024-11-05T16:08:58-05:00\u0022\u003E2024-11-05 16:08\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-505100-bakery-products-candy-catch-all-or-shotgun-ingredients-declaration\u0022\u003ECPG Sec 505.100 Bakery Products, Candy - \u0026quot;Catch-All\u0026quot; or \u0026quot;Shotgun\u0026quot; Ingredients Declaration\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Bakery Product\/Mix","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Bakery Product\/Mix","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T14:31:03-05:00\u0022\u003E2025-03-05 14:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-300100-inspection-manufacturers-device-components\u0022\u003ECPG Sec. 300.100 Inspection of Manufacturers of Device Components\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/23\/1987","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222021-05-03T14:31:08-04:00\u0022\u003E2021-05-03 14:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-505200-butter-featured-product-name\u0022\u003ECPG Sec 505.200 \u0026quot;Butter\u0026quot; Featured in Product Name\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/08\/1988","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Bakery Product\/Mix","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Bakery Product\/Mix","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T14:23:02-05:00\u0022\u003E2025-03-05 14:23\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-505300-butter-nut-bread\u0022\u003ECPG Sec 505.300 \u0026quot;Butter-Nut\u0026quot; Bread\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/08\/1988","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Bakery Product\/Mix","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Bakery Product\/Mix","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T14:24:02-05:00\u0022\u003E2025-03-05 14:24\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-300300-ineffective-devices-502fi-labeling-requirements\u0022\u003ECPG Sec. 300.300 Ineffective Devices - 502(f)(I) Labeling Requirements\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Labeling","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222021-05-04T17:45:16-04:00\u0022\u003E2021-05-04 17:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-505350-honey-bread-honey-buns\u0022\u003ECPG Sec 505.350 Honey Bread, Honey Buns\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/08\/1988","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Bakery Product\/Mix","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Bakery Product\/Mix","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T14:26:46-05:00\u0022\u003E2025-03-05 14:26\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-505400-chow-mein-noodles-chinese-noodles-and-other-oriental-noodles-labeling\u0022\u003ECPG Sec 505.400 Chow Mein Noodles, Chinese Noodles and Other Oriental Noodles (Labeling)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/01\/1996","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Bakery Product\/Mix","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Bakery Product\/Mix","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T14:31:09-05:00\u0022\u003E2025-03-05 14:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-content-premarket-notifications-penile-rigidity-implants-guidance-industry-and-fda-staff\u0022\u003EGuidance for the Content of Premarket Notifications for Penile Rigidity Implants - Guidance for Industry and for FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71772\/download\u0022\u003EPDF (105.01 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (105.01 KB) of Guidance for the Content of Premarket Notifications for Penile Rigidity Implants - Guidance for Industry and for FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/15\/2000","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k)","field_topics":"Premarket","topics-product":"Premarket, 510(k)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-18T15:15:25-04:00\u0022\u003E2020-03-18 15:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-510100-beverage-bases\u0022\u003ECPG Sec 510.100 Beverage Bases\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/01\/1988","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Beverage Bases\/Conc\/Nectar","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Beverage Bases\/Conc\/Nectar","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T14:31:12-05:00\u0022\u003E2025-03-05 14:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-300600-commercial-distribution-regard-premarket-notification-section-510k\u0022\u003ECPG Sec. 300.600 Commercial Distribution with Regard to Premarket Notification (Section 510(k))\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/23\/1987","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222021-05-03T14:35:03-04:00\u0022\u003E2021-05-03 14:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-510150-apple-juice-apple-juice-concentrates-and-apple-juice-products-adulteration-patulin\u0022\u003ECPG Sec 510.150 Apple Juice, Apple Juice Concentrates, and Apple Juice Products - Adulteration with Patulin\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Beverage Bases\/Conc\/Nectar","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Beverage Bases\/Conc\/Nectar","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T14:45:47-05:00\u0022\u003E2025-03-05 14:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-510200-brandy-containing-methyl-alcohol-food-additive\u0022\u003ECPG Sec 510.200 Brandy Containing Methyl Alcohol - Food Additive\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/01\/1980","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Beverage Bases\/Conc\/Nectar","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Beverage Bases\/Conc\/Nectar","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T14:33:31-05:00\u0022\u003E2025-03-05 14:33\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-document-preparation-ides-spinal-systems-guidance-industry-andor-fda-staff\u0022\u003EGuidance Document for the Preparation of IDEs for Spinal Systems - Guidance for Industry and\/or FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71777\/download\u0022\u003EPDF (99.71 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (99.71 KB) of Guidance Document for the Preparation of IDEs for Spinal Systems - Guidance for Industry and\/or FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/12\/2000","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Labeling, Pediatric Product Development","field_topics":"","topics-product":"Labeling, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222024-04-11T11:27:46-04:00\u0022\u003E2024-04-11 11:27\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-510300-unfermented-beverages-use-word-champagne\u0022\u003ECPG Sec 510.300 Unfermented Beverages - Use of Word \u0026quot;Champagne\u0026quot;\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/01\/1980","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Beverage Bases\/Conc\/Nectar","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Beverage Bases\/Conc\/Nectar","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T14:45:51-05:00\u0022\u003E2025-03-05 14:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-510400-dealcoholized-wine-and-malt-beverages-labeling\u0022\u003ECPG Sec 510.400 Dealcoholized Wine and Malt Beverages - Labeling\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Beverage Bases\/Conc\/Nectar","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Beverage Bases\/Conc\/Nectar","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T14:45:55-05:00\u0022\u003E2025-03-05 14:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-310100-pacemaker-reuse\u0022\u003ECPG Sec. 310.100 Pacemaker Reuse\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Cardiovascular ","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Cardiovascular ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222021-05-03T14:16:13-04:00\u0022\u003E2021-05-03 14:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-510450-labeling-diluted-wines-and-cider-less-7-alcohol\u0022\u003ECPG Sec 510.450 Labeling - Diluted Wines and Cider with Less Than 7% Alcohol\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/01\/1996","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Beverage Bases\/Conc\/Nectar","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Beverage Bases\/Conc\/Nectar","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T14:36:01-05:00\u0022\u003E2025-03-05 14:36\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/content-and-format-premarket-notification-510k-submissions-liquid-chemical-sterilantshigh-level\u0022\u003EContent and Format of Premarket Notification [510(k)] Submissions for Liquid Chemical Sterilants\/High Level Disinfectants - Guidance for Industry and FDA Reviewers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72097\/download\u0022\u003EPDF (238.24 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (238.24 KB) of Content and Format of Premarket Notification [510(k)] Submissions for Liquid Chemical Sterilants\/High Level Disinfectants - Guidance for Industry and FDA Reviewers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/02\/2000","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k)","field_topics":"Premarket","topics-product":"Premarket, 510(k)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-18T15:15:11-04:00\u0022\u003E2020-03-18 15:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-510600-dimethylnitrosamine-malt-beverages\u0022\u003ECPG Sec 510.600 Dimethylnitrosamine in Malt Beverages\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Beverage Bases\/Conc\/Nectar","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Beverage Bases\/Conc\/Nectar","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T14:38:01-05:00\u0022\u003E2025-03-05 14:38\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-cardiovascular-intravascular-filter-510k-submissions-guidance-industry-and-fda-staff\u0022\u003EGuidance for Cardiovascular Intravascular Filter 510(k) Submissions - Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/25\/1999","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Cardiovascular ","field_topics":"Premarket","topics-product":"Premarket, Cardiovascular ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-18T15:10:12-04:00\u0022\u003E2020-03-18 15:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-510700-fortification-standardized-juices\u0022\u003ECPG Sec 510.700 Fortification of Standardized Juices\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/01\/1996","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Beverage Bases\/Conc\/Nectar","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Beverage Bases\/Conc\/Nectar","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T14:45:58-05:00\u0022\u003E2025-03-05 14:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-515200-malt-extract-malt-syrup-malted-cereal-syrup-liquid-malt-dried-malt\u0022\u003ECPG Sec 515.200 Malt Extract; Malt Syrup; Malted Cereal Syrup; Liquid Malt; Dried Malt\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/01\/1996","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Candy\/Gum (without chocolate)","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Candy\/Gum (without chocolate)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T14:44:46-05:00\u0022\u003E2025-03-05 14:44\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-320100-ear-piercing-devices\u0022\u003ECPG Sec. 320.100 Ear Piercing Devices\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/23\/1987","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222021-05-03T14:35:07-04:00\u0022\u003E2021-05-03 14:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-325100-karaya-gum-powder-and-related-devices-use-ostomates\u0022\u003ECPG Sec. 325.100 Karaya Gum Powder and Related Devices for Use by Ostomates\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/24\/1987","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Safety - Issues, Errors, and Problems","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Safety - Issues, Errors, and Problems","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222021-05-03T14:31:12-04:00\u0022\u003E2021-05-03 14:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-515300-honey-source-declaration\u0022\u003ECPG Sec 515.300 Honey - Source Declaration\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/01\/1980","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Candy\/Gum (without chocolate)","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Candy\/Gum (without chocolate)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T14:45:32-05:00\u0022\u003E2025-03-05 14:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-515350-candy-mixed-trinkets-and-sold-vending-machines\u0022\u003ECPG Sec 515.350 Candy - Mixed with Trinkets and Sold in Vending Machines\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/01\/1980","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Candy\/Gum (without chocolate)","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Candy\/Gum (without chocolate)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T14:46:31-05:00\u0022\u003E2025-03-05 14:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-515400-raw-sugar\u0022\u003ECPG Sec 515.400 Raw Sugar\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Candy\/Gum (without chocolate)","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Candy\/Gum (without chocolate)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T14:47:31-05:00\u0022\u003E2025-03-05 14:47\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-682200-use-antibiotic-drug-residue-products-animal-feed-feed-withdrawn-2202020\u0022\u003ECPG Sec. 682.200 The Use of Antibiotic Drug Residue By-Products in Animal Feed Feed (Withdrawn 2\/20\/2020)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/30\/1982","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Feed","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Feed","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0645\u0022\u003EFDA-2021-D-0645\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222021-07-27T07:31:06-04:00\u0022\u003E2021-07-27 07:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-515425-sugar-water-damaged-reconditioning\u0022\u003ECPG Sec 515.425 Sugar - Water Damaged - Reconditioning\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Candy\/Gum (without chocolate)","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Candy\/Gum (without chocolate)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T14:48:31-05:00\u0022\u003E2025-03-05 14:48\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-document-powered-muscle-stimulator-510ks-guidance-industry-fda-reviewersstaff-and\u0022\u003EGuidance Document for Powered Muscle Stimulator 510(k)s - Guidance for Industry, FDA Reviewers\/Staff and Compliance\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71804\/download\u0022\u003EPDF (54.69 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (54.69 KB) of Guidance Document for Powered Muscle Stimulator 510(k)s - Guidance for Industry, FDA Reviewers\/Staff and Compliance\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/08\/1999","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222023-02-15T12:33:01-05:00\u0022\u003E2023-02-15 12:33\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-515500-barley-sugar-definition-and-barley-sugar-candy\u0022\u003ECPG Sec 515.500 Barley Sugar - Definition, and Barley Sugar Candy\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/01\/1980","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Candy\/Gum (without chocolate)","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Candy\/Gum (without chocolate)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T14:49:17-05:00\u0022\u003E2025-03-05 14:49\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-515600-candied-citron-labeling\u0022\u003ECPG Sec 515.600 Candied Citron - Labeling\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Candy\/Gum (without chocolate)","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Candy\/Gum (without chocolate)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T14:50:01-05:00\u0022\u003E2025-03-05 14:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-585325-corn-cob-canned-quantity-contents-declaration\u0022\u003ECPG Sec 585.325 Corn on the Cob, Canned - Quantity of Contents Declaration\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/28\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Vegetable Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Vegetable Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-24T13:35:31-04:00\u0022\u003E2025-03-24 13:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-510k-submissions-keratoprostheses-guidance-industry-and-fda-reviewersstaff\u0022\u003EGuidance on 510(k) Submissions for Keratoprostheses - Guidance for Industry and for FDA Reviewers\/Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71810\/download\u0022\u003EPDF (37.92 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (37.92 KB) of Guidance on 510(k) Submissions for Keratoprostheses - Guidance for Industry and for FDA Reviewers\/Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/02\/1999","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-18T14:40:11-04:00\u0022\u003E2020-03-18 14:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-estimating-dietary-intake-substances-food\u0022\u003EGuidance for Industry: Estimating Dietary Intake of Substances in Food\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/01\/2006","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives, Ingredients","field_topics":"","topics-product":"Food \u0026amp; Color Additives, Ingredients","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-02-05T17:33:16-05:00\u0022\u003E2025-02-05 17:33\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-dermabrasion-devices-guidance-industry\u0022\u003EGuidance for Dermabrasion Devices - Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71819\/download\u0022\u003EPDF (20.25 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (20.25 KB) of Guidance for Dermabrasion Devices - Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/1999","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-18T14:40:14-04:00\u0022\u003E2020-03-18 14:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-345200-diaphragms-rx-devices\u0022\u003ECPG Sec. 345.200 Diaphragms - Rx Devices\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/24\/1987","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Labeling","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222021-05-03T14:31:04-04:00\u0022\u003E2021-05-03 14:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-350100-packaging-technologies-and-tamper-resistant-packaging-requirements-contact-lens\u0022\u003ECPG Sec. 350.100 Packaging Technologies and Tamper-Resistant Packaging Requirements for Contact Lens Solutions and Tablets\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/21\/1988","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"","changed":"\u003Ctime datetime=\u00222021-05-03T14:25:11-04:00\u0022\u003E2021-05-03 14:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-550400-grenadine\u0022\u003ECPG Sec 550.400 Grenadine\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Fruit\/Fruit Product ","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Fruit\/Fruit Product ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T14:23:01-04:00\u0022\u003E2025-03-17 14:23\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-preparation-premarket-notification-application-surgical-mesh-guidance-industry-andor-fda\u0022\u003EGuidance for the Preparation of a Premarket Notification Application for a Surgical Mesh - Guidance for Industry and\/or for FDA Reviewers\/Staff and\/or Compliance\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71828\/download\u0022\u003EPDF (35.51 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (35.51 KB) of Guidance for the Preparation of a Premarket Notification Application for a Surgical Mesh - Guidance for Industry and\/or for FDA Reviewers\/Staff and\/or Compliance\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/1999","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-18T14:36:15-04:00\u0022\u003E2020-03-18 14:36\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-515800-labeling-products-purporting-be-chocolate-or-chocolate-flavored\u0022\u003ECPG Sec 515.800 Labeling of Products Purporting to be \u0026quot;Chocolate\u0026quot; or \u0026quot;Chocolate Flavored\u0026quot;\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"05\/12\/1988","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Chocolate\/Cocoa Product","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Chocolate\/Cocoa Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T15:01:03-05:00\u0022\u003E2025-03-05 15:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-520100-canned-foods-use-term-solid-pack\u0022\u003ECPG Sec 520.100 Canned Foods, Use of the Term \u0026quot;Solid Pack\u0026quot;\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Canned Foods, Fruit\/Fruit Product ","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Canned Foods, Fruit\/Fruit Product ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T14:54:01-05:00\u0022\u003E2025-03-05 14:54\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-520200-canned-foods-seam-defects\u0022\u003ECPG Sec 520.200 Canned Foods - Seam Defects\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/30\/1980","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Canned Foods","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Canned Foods","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T14:55:01-05:00\u0022\u003E2025-03-05 14:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-355300-ion-generating-devices\u0022\u003ECPG Sec. 355.300 Ion Generating Devices\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Radiological Health","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Radiological Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222021-05-05T14:16:21-04:00\u0022\u003E2021-05-05 14:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-550475-jellies-nonstandardized\u0022\u003ECPG Sec 550.475 Jellies, Nonstandardized\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/28\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Fruit\/Fruit Product ","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Fruit\/Fruit Product ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T14:26:31-04:00\u0022\u003E2025-03-17 14:26\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/premarket-notification-510k-submissions-testing-skin-sensitization-chemicals-natural-rubber-products\u0022\u003EPremarket Notification [510(k)] Submissions for Testing for Skin Sensitization To Chemicals In Natural Rubber Products - Guidance for Industry and FDA Reviewers\/Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71835\/download\u0022\u003EPDF (181.83 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (181.83 KB) of Premarket Notification [510(k)] Submissions for Testing for Skin Sensitization To Chemicals In Natural Rubber Products - Guidance for Industry and FDA Reviewers\/Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/12\/1999","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222025-01-31T13:57:16-05:00\u0022\u003E2025-01-31 13:57\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-585500-mushrooms-canned-or-dried-freeze-dried-or-dehydrated-adulteration-involving-maggots\u0022\u003ECPG Sec 585.500 Mushrooms, Canned or Dried (Freeze-Dried or Dehydrated) - Adulteration Involving Maggots, Mites, Decomposition\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/28\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Vegetable Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Vegetable Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-24T19:49:02-04:00\u0022\u003E2025-03-24 19:49\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-520300-acidified-low-acid-canned-foods-adulteration-due-high-ph\u0022\u003ECPG Sec 520.300 Acidified Low-Acid Canned Foods - Adulteration Due to High pH\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/28\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Canned Foods","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Canned Foods","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T14:56:01-05:00\u0022\u003E2025-03-05 14:56\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-585525-mushroom-mycelium-fitness-food-labeling\u0022\u003ECPG Sec 585.525: Mushroom Mycelium - Fitness for Food; Labeling\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"12\/08\/1988","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Vegetable Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Vegetable Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-24T19:50:01-04:00\u0022\u003E2025-03-24 19:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-525100-whole-ground-allspice-adulteration-mold-insect-rodent-filth\u0022\u003ECPG Sec 525.100 Whole \u0026amp; Ground Allspice - Adulteration by Mold; Insect \u0026amp; Rodent Filth\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/28\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Dressing\/Condiment","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Dressing\/Condiment","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T14:57:31-05:00\u0022\u003E2025-03-05 14:57\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-390100-definition-commerce-21-cfr-10003d\u0022\u003ECPG Sec. 390.100 Definition of \u0026quot;Commerce\u0026quot; - 21 CFR 1000.3(d)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222018-12-01T11:44:55-05:00\u0022\u003E2018-12-01 11:44\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-550550-maraschino-cherries\u0022\u003ECPG Sec 550.550 Maraschino Cherries\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/30\/1980","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Fruit\/Fruit Product ","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Fruit\/Fruit Product ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T14:29:02-04:00\u0022\u003E2025-03-17 14:29\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-submission-premarket-notifications-emission-computed-tomography-devices-and-accessories\u0022\u003EGuidance for the Submission of Premarket Notifications for Emission Computed Tomography Devices and Accessories (SPECT and PET) and Nuclear Tomography Systems : Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71845\/download\u0022\u003EPDF (97.38 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (97.38 KB) of Guidance for the Submission of Premarket Notifications for Emission Computed Tomography Devices and Accessories (SPECT and PET) and Nuclear Tomography Systems : Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/02\/1998","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Radiology","field_topics":"Premarket","topics-product":"Premarket, Radiology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222023-12-13T18:45:37-05:00\u0022\u003E2023-12-13 18:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-550575-marmalade\u0022\u003ECPG Sec 550.575 Marmalade\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/30\/1980","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Fruit\/Fruit Product ","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Fruit\/Fruit Product ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T14:31:03-04:00\u0022\u003E2025-03-17 14:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-390225-early-defects-or-noncompliance-21-cfr-10046\u0022\u003ECPG Sec. 390.225 Early Defects or Noncompliance - 21 CFR 1004.6\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/03\/2013","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222024-11-14T16:25:35-05:00\u0022\u003E2024-11-14 16:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-585600-peas-and-carrots-labeling-canned-mixture\u0022\u003ECPG Sec 585.600 Peas and Carrots, Labeling of Canned Mixture\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"12\/08\/1988","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Vegetable Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Vegetable Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-24T20:05:01-04:00\u0022\u003E2025-03-24 20:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-390300-assessment-civil-penalties-against-manufacturers-and-importers-electronic-products\u0022\u003ECPG Sec. 390.300 Assessment of Civil Penalties Against Manufacturers and Importers of Electronic Products\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"04\/01\/2005","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Radiation-Emitting Products, Medical Devices","changed":"\u003Ctime datetime=\u00222018-12-01T12:16:46-05:00\u0022\u003E2018-12-01 12:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-585625-canned-peas-label-designation-sizes\u0022\u003ECPG Sec 585.625 Canned Peas - Label Designation of Sizes\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"12\/08\/1988","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Vegetable Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Vegetable Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-25T11:32:46-04:00\u0022\u003E2025-03-25 11:32\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-390400-examples-electronic-products-subject-reporting-requirements-under-21-cfr-100015a\u0022\u003ECPG Sec. 390.400 Examples of Electronic Products Subject to the Reporting Requirements Under 21 CFR 1000.15(a)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/01\/2005","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222021-05-05T13:46:14-04:00\u0022\u003E2021-05-05 13:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-585650-canned-pimentos-and-red-sweet-peppers-seeds-should-be-removed\u0022\u003ECPG Sec 585.650 Canned Pimentos and Red Sweet Peppers - Seeds Should be Removed\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"12\/08\/1988","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Vegetable Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Vegetable Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-25T11:35:01-04:00\u0022\u003E2025-03-25 11:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-390425-records-and-reports-applicability-21-cfr-10021\u0022\u003ECPG Sec. 390.425 Records and Reports; Applicability - 21 CFR 1002.1\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Records","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Records","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222021-05-05T14:20:19-04:00\u0022\u003E2021-05-05 14:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-585710-potato-chips-ingredients-labeling\u0022\u003ECPG Sec 585.710 Potato Chips, Ingredients - Labeling\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"12\/08\/1988","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Vegetable Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Vegetable Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-25T11:37:46-04:00\u0022\u003E2025-03-25 11:37\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-submission-premarket-notifications-radionuclide-dose-calibrators-guidance-industry\u0022\u003EGuidance for the Submission of Premarket Notifications For Radionuclide Dose Calibrators - Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71864\/download\u0022\u003EPDF (47.65 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (47.65 KB) of Guidance for the Submission of Premarket Notifications For Radionuclide Dose Calibrators - Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/19\/1998","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-18T13:10:07-04:00\u0022\u003E2020-03-18 13:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-585725-pumpkin-labeling-articles-made-certain-varieties-squash\u0022\u003ECPG Sec 585.725 \u0026quot;Pumpkin\u0026quot; - Labeling Articles Made from Certain Varieties of Squash\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"12\/08\/1988","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Vegetable Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Vegetable Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-25T11:39:02-04:00\u0022\u003E2025-03-25 11:39\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-585750-sauerkraut-definition-adulteration-thrips\u0022\u003ECPG Sec 585.750 Sauerkraut - Definition; Adulteration by Thrips\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/28\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Vegetable Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Vegetable Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-25T12:10:47-04:00\u0022\u003E2025-03-25 12:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-550605-olives-stuffed-minced-pimentos-labeling\u0022\u003ECPG Sec 550.605 Olives Stuffed with Minced Pimentos - Labeling\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/28\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Fruit\/Fruit Product ","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Fruit\/Fruit Product ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T14:45:01-04:00\u0022\u003E2025-03-17 14:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-391200-warning-statement-advertisements-high-intensity-mercury-vapor-discharge-lamps-are-not\u0022\u003ECPG Sec. 391.200 Warning Statement in Advertisements for High-Intensity Mercury Vapor Discharge Lamps that are not Self-Extinguishing (21 CFR 1040.30(e)(3)*)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Advertising","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Advertising","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222021-05-05T14:50:17-04:00\u0022\u003E2021-05-05 14:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/non-automated-sphygmomanometer-blood-pressure-cuff-guidance-version-1-guidance-industry\u0022\u003ENon-Automated Sphygmomanometer (Blood Pressure Cuff) Guidance - Version 1 - Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71873\/download\u0022\u003EPDF (53.08 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (53.08 KB) of Non-Automated Sphygmomanometer (Blood Pressure Cuff) Guidance - Version 1 - Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/18\/1998","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-18T13:08:12-04:00\u0022\u003E2020-03-18 13:08\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-550625-oranges-artificial-coloring\u0022\u003ECPG Sec 550.625 Oranges - Artificial Coloring\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/30\/1980","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Fruit\/Fruit Product ","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Fruit\/Fruit Product ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T15:15:47-04:00\u0022\u003E2025-03-17 15:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-585800-squash-seeds-labeling-pumpkin-seeds\u0022\u003ECPG Sec 585.800 Squash Seeds - Labeling as Pumpkin Seeds\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"12\/08\/1988","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Vegetable Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Vegetable Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-25T13:02:46-04:00\u0022\u003E2025-03-25 13:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-393200-lasers-medical-devices-facelift-wrinkle-removal-acupuncture-auricular-stimulation-etc\u0022\u003ECPG Sec. 393.200 Laser(s) as Medical Devices for Facelift, Wrinkle Removal, Acupuncture, Auricular Stimulation, etc. (CPG 7133.21)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222021-05-04T17:46:18-04:00\u0022\u003E2021-05-04 17:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-550650-peaches-canned-frozen-adulteration-due-insects-and-mold\u0022\u003ECPG Sec 550.650 Peaches, Canned, Frozen - Adulteration Due to Insects and Mold\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/28\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Fruit\/Fruit Product ","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Fruit\/Fruit Product ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T15:17:16-04:00\u0022\u003E2025-03-17 15:17\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-394100-retention-microwave-oven-test-records\u0022\u003ECPG Sec. 394.100 Retention of Microwave Oven Test Records\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"Records","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Records","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222018-12-01T12:44:53-05:00\u0022\u003E2018-12-01 12:44\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/aqueous-shunts-510k-submissions-guidance-industry-and-fda-reviewersstaff\u0022\u003EAqueous Shunts - 510(k) Submissions - Guidance for Industry and for FDA Reviewers\/Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71885\/download\u0022\u003EPDF (57.2 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (57.2 KB) of Aqueous Shunts - 510(k) Submissions - Guidance for Industry and for FDA Reviewers\/Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/15\/1998","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-18T13:00:20-04:00\u0022\u003E2020-03-18 13:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-585850-sweet-potatoes-sirup-pack\u0022\u003ECPG Sec 585.850 Sweet Potatoes - Sirup Pack\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"12\/08\/1988","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-25T13:06:01-04:00\u0022\u003E2025-03-25 13:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-396100-applicability-sunlamp-performance-standard-uva-tanning-products\u0022\u003ECPG Sec. 396.100 Applicability of the Sunlamp Performance Standard To UVA Tanning Products\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Radiation-Emitting Products, Medical Devices","changed":"\u003Ctime datetime=\u00222018-12-01T12:17:07-05:00\u0022\u003E2018-12-01 12:17\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-525400-hollandaise-sauce-common-or-usual-name\u0022\u003ECPG Sec 525.400 Hollandaise Sauce - Common or Usual Name\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Dressing\/Condiment","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Dressing\/Condiment","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T15:05:31-05:00\u0022\u003E2025-03-05 15:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-396200-exemption-certain-sunlamp-product-purchaser-records\u0022\u003ECPG Sec. 396.200 Exemption for Certain Sunlamp Product Purchaser Records\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Radiation-Emitting Products, Medical Devices","changed":"\u003Ctime datetime=\u00222018-12-01T12:17:10-05:00\u0022\u003E2018-12-01 12:17\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/medical-devices-containing-materials-derived-animal-sources-except-in-vitro-diagnostic-devices\u0022\u003EMedical Devices Containing Materials Derived from Animal Sources (Except for In Vitro Diagnostic Devices): Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/87251\/download\u0022\u003EPDF (602.81 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (602.81 KB) of Medical Devices Containing Materials Derived from Animal Sources (Except for In Vitro Diagnostic Devices): Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/15\/2019","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Laboratory Tests","field_topics":"Premarket","topics-product":"Premarket, Laboratory Tests","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-1574\u0022\u003EFDA-2013-D-1574\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222019-08-01T20:37:42-04:00\u0022\u003E2019-08-01 20:37\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-396300-defective-suntanning-booths-and-bed\u0022\u003ECPG Sec. 396.300 Defective Suntanning Booths and Bed\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/2005","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Radiation-Emitting Products, Medical Devices","changed":"\u003Ctime datetime=\u00222018-12-01T12:17:16-05:00\u0022\u003E2018-12-01 12:17\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-396400-policy-warned-sunlamp-products\u0022\u003ECPG Sec. 396.400 Policy on Warned on Sunlamp Products\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Labeling","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222021-05-03T14:20:03-04:00\u0022\u003E2021-05-03 14:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-398100-definition-general-purpose-radiographic-x-ray-system-21-cfr-102030b\u0022\u003ECPG Sec. 398.100 Definition of General Purpose Radiographic X-Ray System - 21 CFR 1020.30(b)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/2005","field_issuing_office_taxonomy":"Office of Regulatory Affairs\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Radiology","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Radiology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222021-05-06T13:35:03-04:00\u0022\u003E2021-05-06 13:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-587100-label-declaration-certification-exempt-color-additives\u0022\u003ECPG Sec 587.100 Label Declaration of Certification-Exempt Color Additives\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-25T13:09:02-04:00\u0022\u003E2025-03-25 13:09\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-525575-prepared-mustard-composition\u0022\u003ECPG Sec 525.575 Prepared Mustard - Composition\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/28\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Dressing\/Condiment","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Dressing\/Condiment","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T15:08:47-05:00\u0022\u003E2025-03-05 15:08\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-398200-hazardous-diagnostic-x-ray-systems\u0022\u003ECPG Sec. 398.200 Hazardous Diagnostic X-ray Systems\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Radiology","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Radiology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222021-05-03T14:21:03-04:00\u0022\u003E2021-05-03 14:21\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-587200-uncertified-or-delisted-colors-foods-export-eg-fdc-red-2\u0022\u003ECPG Sec 587.200 Uncertified or Delisted Colors in Foods for Export - (e.g., FD\u0026amp;C Red #2)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-25T13:09:46-04:00\u0022\u003E2025-03-25 13:09\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-398300-registration-assemblers-diagnostic-x-ray-systems-device-manufacturers\u0022\u003ECPG Sec. 398.300 Registration of Assemblers of Diagnostic X-Ray Systems as Device Manufacturers\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Office of Regulatory Affairs\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Radiology","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Radiology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222021-05-06T13:35:15-04:00\u0022\u003E2021-05-06 13:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-398325-regulatory-actions-against-assemblers-noncompliant-diagnostic-x-ray-equipment\u0022\u003ECPG Sec. 398.325 Regulatory Actions Against Assemblers Noncompliant Diagnostic X-Ray Equipment\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/2005","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222018-12-01T12:17:36-05:00\u0022\u003E2018-12-01 12:17\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-lead-candy-likely-be-consumed-frequently-small-children\u0022\u003EGuidance for Industry: Lead in Candy Likely To Be Consumed Frequently by Small Children: Recommended Maximum Level and Enforcement Policy\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/24\/2006","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Candy\/Gum (without chocolate), Lead","field_topics":"","topics-product":"Candy\/Gum (without chocolate), Lead","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2005-D-0084\u0022\u003EFDA-2005-D-0084\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:01:49-04:00\u0022\u003E2024-10-01 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-525650-labeling-seasonings\u0022\u003ECPG Sec 525.650 Labeling of Seasonings\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/30\/1980","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Dressing\/Condiment","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Dressing\/Condiment","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T16:17:31-05:00\u0022\u003E2025-03-06 16:17\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-398375-obligations-factory-based-manufacturers-and-assemblers-diagnostic-x-ray-equipment\u0022\u003ECPG Sec. 398.375 Obligations of Factory-based Manufacturers and Assemblers of Diagnostic X-ray Equipment Under the Performance Standard for Diagnostic X-ray Equipment\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"Radiology","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Radiology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222018-12-01T12:17:39-05:00\u0022\u003E2018-12-01 12:17\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-100100-responsibility-reporting-possible-or-potential-violations-laws-administered-fda\u0022\u003ECPG Sec. 100.100 Responsibility for Reporting Possible or Potential Violations of Laws Administered by FDA, Regulations Issued by FDA, Other Possible or Potential Hazards to the Public Health\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/01\/1987","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Food \u0026amp; Color Additives","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Administrative \/ Procedural, Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Food \u0026amp; Beverages, Biologics, Drugs, Medical Devices, Radiation-Emitting Products, Animal \u0026amp; Veterinary, Dietary Supplements, Cosmetics","changed":"\u003Ctime datetime=\u00222018-12-01T09:31:33-05:00\u0022\u003E2018-12-01 09:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-398400-automatic-adjustment-x-ray-field-size-selected-spot-film-size-21-cfr-102031g1\u0022\u003ECPG Sec. 398.400 Automatic Adjustment of the X-ray Field Size to the Selected Spot-Film Size - 21 CFR 1020.31(g)(1)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/30\/1980","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"Radiology","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Radiology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222018-12-01T12:17:45-05:00\u0022\u003E2018-12-01 12:17\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-100200-fda-jurisdiction-over-products-composed-interstate-ingredients\u0022\u003ECPG Sec 100.200 FDA Jurisdiction Over Products Composed of Interstate Ingredients\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/31\/1989","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222024-10-01T08:06:10-04:00\u0022\u003E2024-10-01 08:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-100300-non-fda-regulated-products-involving-communicable-disease-hazards\u0022\u003ECPG Sec. 100.300 *Non-FDA Regulated Products Involving Communicable Disease Hazards*\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/01\/1987","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives, Safety - Issues, Errors, and Problems","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Food \u0026amp; Color Additives, Safety - Issues, Errors, and Problems","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Food \u0026amp; Beverages, Biologics, Drugs, Medical Devices, Radiation-Emitting Products, Tobacco, Animal \u0026amp; Veterinary, Dietary Supplements, Cosmetics","changed":"\u003Ctime datetime=\u00222018-12-01T09:31:39-05:00\u0022\u003E2018-12-01 09:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-590500-packaging-technologies-and-tamper-resistant-packaging-requirements-cosmetic-products\u0022\u003ECPG Sec 590.500 Packaging Technologies and Tamper-Resistant Packaging Requirements for Cosmetic Products\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Cosmetics","changed":"\u003Ctime datetime=\u00222025-03-25T13:13:02-04:00\u0022\u003E2025-03-25 13:13\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-letter-manufacturers-importers-and-distributors-imported-candy-and-candy-wrappers\u0022\u003EGuidance for Industry: Letter to Manufacturers, Importers, and Distributors of Imported Candy and Candy Wrappers\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"06\/13\/1995","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Candy\/Gum (without chocolate), Import, Lead","field_topics":"","topics-product":"Candy\/Gum (without chocolate), Import, Lead","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-2006\u0022\u003EFDA-2020-D-2006\u003C\/a\u003E","field_communication_type":"Industry Letter","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:01:51-04:00\u0022\u003E2024-10-01 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-525750-spices-definitions\u0022\u003ECPG Sec 525.750 Spices - Definitions\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/01\/1980","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Dressing\/Condiment","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Dressing\/Condiment","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T16:31:42-05:00\u0022\u003E2025-03-06 16:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-398450-applicability-positive-beam-limitation-pbl-requirements-when-pbl-provided-other\u0022\u003ECPG Sec. 398.450 Applicability of Positive Beam Limitation (PBL) Requirements When PBL is Provided on \u0026quot;Other than Stationary General Purpose\u0026quot; Radiographic System\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/31\/1983","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Radiology","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Radiology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222021-05-03T14:40:08-04:00\u0022\u003E2021-05-03 14:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-100350-fda-jurisdiction-indian-reservations\u0022\u003ECPG Sec. 100.350 FDA Jurisdiction on Indian Reservations\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/31\/1987","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Food \u0026amp; Beverages, Biologics, Drugs, Medical Devices, Radiation-Emitting Products, Tobacco, Animal \u0026amp; Veterinary, Dietary Supplements, Cosmetics","changed":"\u003Ctime datetime=\u00222018-12-01T09:31:44-05:00\u0022\u003E2018-12-01 09:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-590600-wigs-compliance-policy-guide-712805\u0022\u003ECPG Sec 590.600 Wigs Compliance Policy Guide 7128.05\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/01\/1986","field_issuing_office_taxonomy":"Office of Regulatory Affairs","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Cosmetics","changed":"\u003Ctime datetime=\u00222025-03-25T13:18:43-04:00\u0022\u003E2025-03-25 13:18\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-525800-tomato-sauce-or-tomato-hot-sauce-labeling\u0022\u003ECPG Sec 525.800 Tomato Sauce or Tomato Hot Sauce Labeling\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/28\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Dressing\/Condiment","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Dressing\/Condiment","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T16:31:37-05:00\u0022\u003E2025-03-06 16:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-100500-common-carrier-relabeler-repacker-reprocessor-etc\u0022\u003ECPG Sec. 100.500 - Common Carrier as a Relabeler, Repacker, Reprocessor, etc.\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/30\/1989","field_issuing_office_taxonomy":"Office of Regulatory Affairs","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222024-10-24T14:52:13-04:00\u0022\u003E2024-10-24 14:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-605100-use-statements-regarding-nada-approval-fda-labeling-and-advertising-new-animal-drugs\u0022\u003ECPG Sec. 605.100 - Use of Statements Regarding NADA Approval by FDA in Labeling and Advertising of New Animal Drugs (Withdrawn 2\/20\/2020)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/31\/1986","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Drugs, Labeling","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Drugs, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222020-02-20T09:35:44-05:00\u0022\u003E2020-02-20 09:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-555100-alcohol-use-synthetic-alcohol-foods\u0022\u003ECPG Sec 555.100 Alcohol; Use of Synthetic Alcohol in Foods\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"01\/31\/1989","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T15:34:47-04:00\u0022\u003E2025-03-17 15:34\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-channels-trade-policy-commodities-residues-pesticide-chemicals-which-tolerances\u0022\u003EGuidance for Industry: Channels of Trade Policy for Commodities With Residues of Pesticide Chemicals, for Which Tolerances Have Been Revoked, Suspended, or Modified by the Environmental Protection Agency Pursuant to Dietary Risk Considerations\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"05\/18\/2005","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Pesticide","field_topics":"","topics-product":"Pesticide","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2003-D-0430\u0022\u003EFDA-2003-D-0430\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Dietary Supplements, Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:01:53-04:00\u0022\u003E2024-10-01 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-100550-status-and-responsibilities-contract-sterilizers-engaged-sterilization-drugs-and\u0022\u003ECPG Sec. 100.550 Status and Responsibilities of Contract Sterilizers Engaged in the Sterilization of Drugs and Devices\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/02\/2006","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222024-11-14T16:25:16-05:00\u0022\u003E2024-11-14 16:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-607100-adequate-directions-use-species-designation-animal-drugs-and-veterinary-devices\u0022\u003ECPG Sec. 607.100 - Adequate Directions for Use (Species Designation) - Animal Drugs and Veterinary Devices\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Devices, Animal Drugs, Labeling","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Devices, Animal Drugs, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0629\u0022\u003EFDA-2021-D-0629\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222021-07-27T07:05:10-04:00\u0022\u003E2021-07-27 07:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-555200-adulterated-food-mixed-good-food\u0022\u003ECPG Sec 555.200 Adulterated Food Mixed with Good Food\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/30\/1980","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T15:35:46-04:00\u0022\u003E2025-03-17 15:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-398600-certification-and-identification-x-ray-components-sections-10102-and-102030e\u0022\u003ECPG Sec. 398.600 Certification and Identification of X-ray Components - Sections 1010.2 and 1020.30(e)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Radiation-Emitting Products, Medical Devices","changed":"\u003Ctime datetime=\u00222018-12-01T12:17:57-05:00\u0022\u003E2018-12-01 12:17\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-100600-status-facial-tissues-paper-napkins-paper-towels-and-similar-paper-products\u0022\u003ECPG Sec 100.600 Status of Facial Tissues, Paper Napkins, Paper Towels and Similar Paper Products\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/30\/1989","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222024-10-01T14:47:13-04:00\u0022\u003E2024-10-01 14:47\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-398700-reloaders-x-ray-tube-housing-assemblies-applicability-medical-device-establishment\u0022\u003ECPG Sec. 398.700 Reloaders of X-ray Tube Housing Assemblies; Applicability of Medical Device Establishment Registration, Device Listing and Biennial Inspection\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/2005","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Radiation-Emitting Products, Medical Devices","changed":"\u003Ctime datetime=\u00222018-12-01T12:18:00-05:00\u0022\u003E2018-12-01 12:18\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-channels-trade-policy-commodities-vinclozolin-residues\u0022\u003EGuidance for Industry: Channels of Trade Policy for Commodities with Vinclozolin Residues\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"06\/12\/2002","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Pesticide","field_topics":"","topics-product":"Pesticide","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2001-D-0094\u0022\u003EFDA-2001-D-0094\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:01:57-04:00\u0022\u003E2024-10-01 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-100700-gwqap-pre-award-evaluation-inadequate-information-evaluate-prospective-supplier\u0022\u003ECPG Sec. 100.700 GWQAP Pre-Award Evaluation - Inadequate Information to Evaluate Prospective Supplier\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"04\/24\/2005","field_issuing_office_taxonomy":"Office of Regulatory Affairs","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222024-10-24T14:52:11-04:00\u0022\u003E2024-10-24 14:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-400200-consistent-application-cgmp-determinations\u0022\u003ECPG Sec. 400.200 Consistent Application of CGMP Determinations\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/None found\u0022\u003ENone found\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T15:25:17-04:00\u0022\u003E2020-05-06 15:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-608200-prescription-use-certain-injectable-animal-drugs\u0022\u003ECPG Sec. 608.200 Prescription Use of Certain Injectable Animal Drugs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/121159\/download\u0022\u003EPDF (24.7 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (24.7 KB) of CPG Sec. 608.200 Prescription Use of Certain Injectable Animal Drugs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/2019","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Drugs","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-05-07T10:35:27-04:00\u0022\u003E2019-05-07 10:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cardiac-monitor-guidance-including-cardiotachometer-and-rate-alarm-guidance-industry\u0022\u003ECardiac Monitor Guidance (including Cardiotachometer and Rate Alarm) - Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71947\/download\u0022\u003EPDF (80.92 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (80.92 KB) of Cardiac Monitor Guidance (including Cardiotachometer and Rate Alarm) - Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/04\/1998","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Cardiovascular ","field_topics":"Premarket","topics-product":"Premarket, Cardiovascular ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-18T12:52:02-04:00\u0022\u003E2020-03-18 12:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-400210-radiofrequency-identification-feasibility-studies-and-pilot-programs-drugs\u0022\u003ECPG Sec. 400.210, Radiofrequency Identification Feasibility Studies and Pilot Programs for Drugs\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"01\/31\/2012","field_issuing_office_taxonomy":"Office of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222026-05-04T19:46:22-04:00\u0022\u003E2026-05-04 19:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-100800-guaranties-over-printed-signatures\u0022\u003ECPG Sec. 100.800 Guaranties Over Printed Signatures\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/30\/1989","field_issuing_office_taxonomy":"Office of Regulatory Affairs","field_health_topics":"","term_node_tid":"Records","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Records","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222024-10-24T14:52:12-04:00\u0022\u003E2024-10-24 14:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-608300-lay-use-animal-capture-and-euthanasia-drugs-withdrawn-2202020\u0022\u003ECPG Sec. 608.300 Lay Use of *Animal Capture and Euthanasia* Drugs (Withdrawn 2\/20\/2020)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Drugs","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222020-02-20T09:36:41-05:00\u0022\u003E2020-02-20 09:36\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-100900-international-memoranda-understanding\u0022\u003ECPG Sec 100.900 International Memoranda of Understanding\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"06\/06\/1995","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Tobacco Products","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222024-10-01T08:06:31-04:00\u0022\u003E2024-10-01 08:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-400325-candy-pills-representation-drug\u0022\u003ECPG Sec. 400.325 Candy \u0026quot;Pills\u0026quot; Representation as Drug\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/01\/1980","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/None found\u0022\u003ENone found\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T15:20:20-04:00\u0022\u003E2020-05-06 15:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-100950-international-partnership-agreements-compliance-activities\u0022\u003ECPG Sec. 100.950 International Partnership Agreements for Compliance Activities\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"06\/28\/2000","field_issuing_office_taxonomy":"Office of Regulatory Affairs","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222024-10-24T14:52:09-04:00\u0022\u003E2024-10-24 14:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-400335-fructose-containing-drugs\u0022\u003ECPG Sec. 400.335 Fructose-Containing Drugs\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"05\/22\/1987","field_issuing_office_taxonomy":"Office of Regulatory Affairs","field_health_topics":"","term_node_tid":"Labeling","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-10-24T14:51:52-04:00\u0022\u003E2024-10-24 14:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/diagnostic-ecg-guidance-including-non-alarming-st-segment-measurement-guidance-industry\u0022\u003EDiagnostic ECG Guidance (Including Non-Alarming ST Segment Measurement) - Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71957\/download\u0022\u003EPDF (82.31 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (82.31 KB) of Diagnostic ECG Guidance (Including Non-Alarming ST Segment Measurement) - Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/04\/1998","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-18T13:00:15-04:00\u0022\u003E2020-03-18 13:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-110200-export-fda-regulated-products-us-foreign-trade-zones\u0022\u003ECPG Sec. 110.200 Export of FDA Regulated Products from U.S. Foreign Trade Zones\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/30\/1989","field_issuing_office_taxonomy":"Office of Regulatory Affairs","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222024-10-24T14:52:09-04:00\u0022\u003E2024-10-24 14:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-555400-aflatoxins-human-food\u0022\u003ECPG Sec 555.400 Aflatoxins in Human Food\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/149666\/download\u0022\u003EPDF (153.15 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (153.15 KB) of CPG Sec 555.400 Aflatoxins in Human Food\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/01\/2021","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0242\u0022\u003EFDA-2021-D-0242\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T15:41:12-04:00\u0022\u003E2025-03-17 15:41\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-400500-identical-or-similar-product-names\u0022\u003ECPG Sec. 400.500 Identical or Similar Product Names\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/None found\u0022\u003ENone found\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T15:35:19-04:00\u0022\u003E2020-05-06 15:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-110500-food-and-drug-guaranty-imports\u0022\u003ECPG Sec. 110.500 Food and Drug Guaranty - Imports\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/30\/1980","field_issuing_office_taxonomy":"Office of Regulatory Affairs","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222024-10-24T14:52:27-04:00\u0022\u003E2024-10-24 14:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-400600-drugs-declaration-quantity-active-ingredient-both-metric-and-apothecary-systems\u0022\u003ECPG Sec. 400.600 Drugs - Declaration of Quantity of Active Ingredient by Both Metric and Apothecary Systems\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/01\/1980","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-07T22:20:12-04:00\u0022\u003E2020-05-07 22:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/generalspecific-intended-use-guidance-industry\u0022\u003EGeneral\/Specific Intended Use - Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71966\/download\u0022\u003EPDF (75.67 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (75.67 KB) of General\/Specific Intended Use - Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/03\/1998","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Pediatric Product Development","field_topics":"Premarket","topics-product":"Premarket, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222024-04-11T11:03:01-04:00\u0022\u003E2024-04-11 11:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-110600-fda-authority-over-products-foreign-origin-located-foreign-trade-zones-bonded\u0022\u003ECPG Sec. 110.600 FDA Authority Over Products of Foreign Origin Located in Foreign Trade Zones, Bonded Warehouses or on Bonded Carriers\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/30\/1989","field_issuing_office_taxonomy":"Office of Regulatory Affairs","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222024-10-24T14:52:25-04:00\u0022\u003E2024-10-24 14:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-615200-proper-drug-use-and-residue-avoidance-non-veterinarians\u0022\u003ECPG Sec. 615.200 Proper Drug Use and Residue Avoidance by Non-Veterinarians\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/08\/1993","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Drugs, Human Food Safety","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Drugs, Human Food Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0643\u0022\u003EFDA-2021-D-0643\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222021-07-27T07:25:03-04:00\u0022\u003E2021-07-27 07:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-400700-drug-product-entries-periodic-publications\u0022\u003ECPG Sec. 400.700 Drug Product Entries in Periodic Publications\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/01\/1989","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-07T22:35:17-04:00\u0022\u003E2020-05-07 22:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-antimicrobial-food-additives\u0022\u003EGuidance for Industry: Antimicrobial Food Additives\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"06\/30\/1999","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives, Ingredients","field_topics":"","topics-product":"Food \u0026amp; Color Additives, Ingredients","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1999-D-1298\u0022\u003EFDA-1999-D-1298\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:01:58-04:00\u0022\u003E2024-10-01 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-110700-seizures-us-customs-service-prohibited-articles-foreign-origin-not-intended-entry\u0022\u003ECPG Sec. 110.700 Seizures by the U.S. Customs Service of Prohibited Articles of Foreign Origin Not Intended for Entry into the United States\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/30\/1989","field_issuing_office_taxonomy":"Office of Regulatory Affairs","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222024-10-24T14:52:22-04:00\u0022\u003E2024-10-24 14:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-channels-trade-policy-commodities-methyl-parathion-residues\u0022\u003EGuidance for Industry: Channels of Trade Policy for Commodities with Methyl Parathion Residues\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/30\/2000","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Pesticide","field_topics":"","topics-product":"Pesticide","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2000-D-0028\u0022\u003EFDA-2000-D-0028\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:00-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-615300-responsibility-illegal-drug-residues-meat-milk-and-eggs\u0022\u003ECPG Sec. 615.300 Responsibility for Illegal Drug Residues in Meat, Milk and Eggs\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"06\/30\/1982","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Drugs, Human Food Safety","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Drugs, Human Food Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0646\u0022\u003EFDA-2021-D-0646\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222021-07-27T07:31:10-04:00\u0022\u003E2021-07-27 07:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-400800-collection-and-charitable-distribution-drugs\u0022\u003ECPG Sec. 400.800 Collection and Charitable Distribution of Drugs\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/01\/1980","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-10-24T14:51:55-04:00\u0022\u003E2024-10-24 14:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-section-110800-post-detention-sampling-guidance-industry\u0022\u003ECPG Section 110.800 Post Detention Sampling Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/137109\/download\u0022\u003EPDF (46.48 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (46.48 KB) of CPG Section 110.800 Post Detention Sampling Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/24\/2020","field_issuing_office_taxonomy":"Office of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222024-11-05T16:08:48-05:00\u0022\u003E2024-11-05 16:08\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-400900-class-i-recalls-prescription-drugs\u0022\u003ECPG Sec. 400.900 Class I Recalls of Prescription Drugs\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/01\/1980","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/None found\u0022\u003ENone found\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222020-05-06T15:35:05-04:00\u0022\u003E2020-05-06 15:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-110900-imported-products-lack-english-labeling\u0022\u003ECPG Sec 110.900 Imported Products - Lack of English Labeling\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/20\/1996","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Labeling","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222024-10-01T08:06:44-04:00\u0022\u003E2024-10-01 08:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-625200-availability-bulk-chemicals-animal-drug-use-withdrawn-4142022\u0022\u003ECPG Sec. 625.200 Availability of Bulk Chemicals for Animal Drug Use (Withdrawn 4\/14\/2022)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/30\/1980","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Drugs","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0647\u0022\u003EFDA-2021-D-0647\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222022-04-14T06:04:05-04:00\u0022\u003E2022-04-14 06:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-410100-finished-dosage-form-drug-products-bulk-containers-applications-current-good\u0022\u003ECPG Sec. 410.100 *Finished Dosage Form Drug Products in Bulk Containers - Applications of Current Good Manufacturing Practice Regulations*\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/04\/1987","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-10-24T14:51:59-04:00\u0022\u003E2024-10-24 14:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-555600-filth-insects-rodents-and-other-pests-foods\u0022\u003ECPG Sec 555.600 Filth from Insects, Rodents, and Other Pests in Foods\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/13\/2002","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T15:48:16-04:00\u0022\u003E2025-03-17 15:48\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-120100-fraud-untrue-statements-material-facts-bribery-and-illegal-gratuities\u0022\u003ECPG Sec. 120.100 Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"06\/30\/1991","field_issuing_office_taxonomy":"Office of Regulatory Affairs\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research,Office of Regulatory Policy","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222024-10-24T14:52:36-04:00\u0022\u003E2024-10-24 14:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-555650-reconditioning-foods-diversion-animal-feed\u0022\u003ECPG Sec 555.650 Reconditioning Foods by Diversion for Animal Feed\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T15:49:16-04:00\u0022\u003E2025-03-17 15:49\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-120500-health-fraud-factors-considering-regulatory-action\u0022\u003ECPG Sec 120.500 Health Fraud - Factors in Considering Regulatory Action\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-E-0163\u0022\u003EFDA-2012-E-0163\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222024-10-01T08:06:59-04:00\u0022\u003E2024-10-01 08:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/noise-claims-hearing-aid-labeling-guidance-industry\u0022\u003ENoise Claims in Hearing Aid Labeling - Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71982\/download\u0022\u003EPDF (144.98 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (144.98 KB) of Noise Claims in Hearing Aid Labeling - Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/20\/1998","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-18T12:52:52-04:00\u0022\u003E2020-03-18 12:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-130100-inspectional-authority-refusal-permit-inspection\u0022\u003ECPG Sec. 130.100 Inspectional Authority; Refusal to Permit Inspection.\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/30\/1980","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222018-12-01T09:32:59-05:00\u0022\u003E2018-12-01 09:32\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec625400-reconditioning-new-animal-drugs-seized-under-section-501a5-withdrawn-2202020\u0022\u003ECPG Sec.625.400 Reconditioning of New Animal Drugs Seized Under Section 501(a)(5) (Withdrawn 2\/20\/2020)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Drugs","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222020-02-20T09:46:17-05:00\u0022\u003E2020-02-20 09:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-420200-compendium-revisions-and-deletions\u0022\u003ECPG Sec. 420.200 Compendium Revisions and Deletions\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/30\/1980","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-10-24T14:52:02-04:00\u0022\u003E2024-10-24 14:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-527250-cheese-cheese-products-misbranding-involving-net-contents\u0022\u003ECPG Sec 527.250 Cheese \u0026amp; Cheese Products - Misbranding Involving Net Contents\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/28\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Dairy","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Dairy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:14:48-05:00\u0022\u003E2025-03-06 21:14\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-555750-seeds-sprouting-prior-food-use-ie-dried-mung-beans-alfalfa-seeds-etc\u0022\u003ECPG Sec 555.750 Seeds for Sprouting Prior to Food Use, i.e., Dried Mung Beans, Alfalfa Seeds, Etc.\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"01\/31\/1989","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T15:50:16-04:00\u0022\u003E2025-03-17 15:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-action-levels-poisonous-or-deleterious-substances-human-food-and-animal-feed\u0022\u003EGuidance for Industry: Action Levels for Poisonous or Deleterious Substances in Human Food and Animal Feed\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/31\/2000","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Animal Feed, Sanitation","field_topics":"","topics-product":"Animal Feed, Sanitation","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1956\u0022\u003EFDA-2020-D-1956\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Animal \u0026amp; Veterinary, Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:02-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-130200-inspection-firms-when-legal-action-pending\u0022\u003ECPG Sec. 130.200 Inspection of Firms when Legal Action is Pending\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/30\/1989","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222018-12-01T09:33:04-05:00\u0022\u003E2018-12-01 09:33\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-527350-eggnog-egg-nog-flavored-milk-common-or-usual-names\u0022\u003ECPG Sec 527.350 Eggnog; Egg Nog Flavored Milk - Common or Usual Names\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/28\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Dairy","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Dairy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:16:14-05:00\u0022\u003E2025-03-06 21:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-420300-changes-compendial-specifications-and-nda-supplements-withdrawn-83012\u0022\u003ECPG Sec. 420.300 Changes in Compendial Specifications and NDA Supplements withdrawn on 8\/30\/12\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/30\/1980","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222018-12-01T10:38:59-05:00\u0022\u003E2018-12-01 10:38\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-555800-polysorbates-20-40-60-65-80-85-common-or-usual-names\u0022\u003ECPG Sec 555.800 Polysorbates 20, 40, 60, 65, 80, 85 - Common or Usual Names\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"01\/31\/1989","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T16:40:17-04:00\u0022\u003E2025-03-17 16:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-130300-fda-access-results-quality-assurance-program-audits-and-inspections\u0022\u003ECPG Sec. 130.300 FDA Access to Results of Quality Assurance Program Audits and Inspections\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"06\/01\/2007","field_issuing_office_taxonomy":"Office of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222026-02-03T09:23:03-05:00\u0022\u003E2026-02-03 09:23\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-420400-performance-tests-compendial-requirements-compendial-products\u0022\u003ECPG Sec. 420.400 Performance of Tests for Compendial Requirements on Compendial Products\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/01\/1980","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222020-05-01T14:15:23-04:00\u0022\u003E2020-05-01 14:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-527400-whole-milk-lowfat-milk-skim-milk-aflatoxin-m1\u0022\u003ECPG Sec 527.400 Whole Milk, Lowfat Milk, Skim Milk - Aflatoxin M1\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/28\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Dairy","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Dairy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:17:07-05:00\u0022\u003E2025-03-06 21:17\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-document-nonprescription-sunglasses-guidance-industry\u0022\u003EGuidance Document For Nonprescription Sunglasses - Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71989\/download\u0022\u003EPDF (71.93 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (71.93 KB) of Guidance Document For Nonprescription Sunglasses - Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/08\/1998","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-18T12:45:20-04:00\u0022\u003E2020-03-18 12:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-130400-use-microfiche-andor-microfilm-method-records-retention\u0022\u003ECPG Sec. 130.400 Use of Microfiche and\/or Microfilm for Method of Records Retention\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/07\/2004","field_issuing_office_taxonomy":"Office of Regulatory Affairs","field_health_topics":"","term_node_tid":"Records","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Records","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222024-10-24T14:52:24-04:00\u0022\u003E2024-10-24 14:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-625600-orders-post-approval-record-reviews\u0022\u003ECPG Sec. 625.600 Orders for Post-Approval Record Reviews\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"06\/24\/1992","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Drugs, Records","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Drugs, Records","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-05-08T06:45:07-04:00\u0022\u003E2019-05-08 06:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-527450-milk-milk-products-containing-penicillin\u0022\u003ECPG Sec 527.450 Milk \u0026amp; Milk Products Containing Penicillin\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/30\/1980","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Dairy","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Dairy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:17:49-05:00\u0022\u003E2025-03-06 21:17\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-420500-interference-compendial-tests\u0022\u003ECPG Sec. 420.500 Interference with Compendial Tests\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222018-12-01T11:47:11-05:00\u0022\u003E2018-12-01 11:47\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-140100-seizure-books-constitute-misleading-labeling\u0022\u003ECPG Sec. 140.100 Seizure of Books that Constitute Misleading Labeling\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/30\/1989","field_issuing_office_taxonomy":"Office of Regulatory Affairs","field_health_topics":"","term_node_tid":"Labeling","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222024-10-24T14:52:21-04:00\u0022\u003E2024-10-24 14:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-634100-drugs-packaged-infusion-or-injection-food-producing-animals-withdrawn-2202020\u0022\u003ECPG Sec. 634.100 Drugs Packaged for Infusion or Injection of Food-Producing Animals (Withdrawn 2\/20\/2020)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/22\/1994","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Policy, Legislation, and International Affairs,Office of Global Policy and Strategy","field_health_topics":"","term_node_tid":"Animal Drugs","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222020-02-20T09:45:51-05:00\u0022\u003E2020-02-20 09:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-425100-computerized-drug-processing-cgmp-applicability-hardware-and-software\u0022\u003ECPG Sec. 425.100 Computerized Drug Processing; CGMP Applicability to Hardware and Software*\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/04\/1987","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222020-04-09T16:25:12-04:00\u0022\u003E2020-04-09 16:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-555875-water-food-products-ingredient-or-adulterant\u0022\u003ECPG Sec 555.875 Water in Food Products (Ingredient or Adulterant)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"01\/31\/1989","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T16:43:16-04:00\u0022\u003E2025-03-17 16:43\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-527500-malted-milk\u0022\u003ECPG Sec 527.500 Malted Milk\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/31\/1996","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Dairy","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Dairy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:18:49-05:00\u0022\u003E2025-03-06 21:18\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec140500-metric-declarations-quantity-contents-product-labels\u0022\u003ECPG Sec.140.500 Metric Declarations of Quantity of Contents on Product Labels\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Labeling","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Human Foods Program","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222024-10-01T08:07:35-04:00\u0022\u003E2024-10-01 08:07\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-635100-large-volume-parenterals-lvps-animal-use\u0022\u003ECPG Sec. 635.100 Large Volume Parenterals (LVPs) for Animal Use\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/121169\/download\u0022\u003EPDF (29.64 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (29.64 KB) of CPG Sec. 635.100 Large Volume Parenterals (LVPs) for Animal Use\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/2019","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Drugs","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-05-17T13:36:00-04:00\u0022\u003E2019-05-17 13:36\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-425200-computerized-drug-processing-vendor-responsibility\u0022\u003ECPG Sec. 425.200 Computerized Drug Processing; Vendor Responsibility\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/04\/1987","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-09T16:35:11-04:00\u0022\u003E2020-04-09 16:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-560100-importation-unlabeled-foods-exemption-under-21-cfr-101100d\u0022\u003ECPG Sec 560.100 Importation of Unlabeled Foods - Exemption Under *21 CFR 101.100(d)*\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/18\/1989","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Import","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Import","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T16:45:31-04:00\u0022\u003E2025-03-17 16:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-527600-use-ddvp-dichlorvos-strips-milkhouses-and-milkrooms\u0022\u003ECPG Sec 527.600 Use of DDVP (dichlorvos) Strips in Milkhouses and Milkrooms\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/31\/1996","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Dairy","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Dairy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:19:49-05:00\u0022\u003E2025-03-06 21:19\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-document-powered-suction-pump-510ks-guidance-industry-and-fda-reviewersstaff\u0022\u003EGuidance Document for Powered Suction Pump 510(k)s - Guidance for Industry and FDA Reviewers\/Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71745\/download\u0022\u003EPDF (35.4 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (35.4 KB) of Guidance Document for Powered Suction Pump 510(k)s - Guidance for Industry and FDA Reviewers\/Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/29\/1998","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-18T12:40:12-04:00\u0022\u003E2020-03-18 12:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-150100-requests-portions-intermediate-or-end-products-resulting-fda-sample-analysis\u0022\u003ECPG Sec. 150.100 Requests for Portions of Intermediate or End Products Resulting from FDA Sample Analysis\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/22\/1988","field_issuing_office_taxonomy":"Office of Regulatory Affairs","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222024-10-24T14:52:19-04:00\u0022\u003E2024-10-24 14:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-637100-plastic-containers-injectable-animal-drugs-withdrawn-2202020\u0022\u003ECPG Sec. 637.100 Plastic Containers for Injectable Animal Drugs (Withdrawn 2\/20\/2020)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Drugs","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222020-02-20T09:47:07-05:00\u0022\u003E2020-02-20 09:47\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-425300-computerized-drug-processing-source-code-process-control-application-programs\u0022\u003ECPG Sec. 425.300 Computerized Drug Processing; Source Code for Process Control Application Programs\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"04\/15\/1987","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222018-12-01T10:39:05-05:00\u0022\u003E2018-12-01 10:39\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-530500-wheat-germ-containing-non-wheat-germ-tissue\u0022\u003ECPG Sec 530.500 Wheat Germ Containing Non-Wheat Germ Tissue\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/28\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Dietary Supplements, Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:20:48-05:00\u0022\u003E2025-03-06 21:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-638100-process-validation-requirements-drug-products-subject-pre-market-approval\u0022\u003ECPG Sec. 638.100 Process Validation Requirements for Drug Products Subject to Pre-Market Approval\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Drugs","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-05-08T07:05:08-04:00\u0022\u003E2019-05-08 07:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-150500-analytical-methodology-used-fda-drugs\u0022\u003ECPG Sec. 150.500 Analytical Methodology Used by FDA - Drugs\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222024-10-01T08:08:07-04:00\u0022\u003E2024-10-01 08:08\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-425400-computerized-drug-processing-inputoutput-checking\u0022\u003ECPG Sec. 425.400 Computerized Drug Processing; Input\/Output Checking\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/04\/1987","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-09T16:55:13-04:00\u0022\u003E2020-04-09 16:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-640100-anthelmintics-withdrawn-2202020\u0022\u003ECPG Sec. 640.100 Anthelmintics (Withdrawn 2\/20\/2020)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Policy, Legislation, and International Affairs,Office of Global Policy and Strategy","field_health_topics":"","term_node_tid":"Anthelmintics","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Anthelmintics","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222020-02-20T09:45:48-05:00\u0022\u003E2020-02-20 09:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-160100-regulatory-actions-and-small-business\u0022\u003ECPG Sec. 160.100 Regulatory Actions and Small Business\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/28\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222024-10-01T08:08:08-04:00\u0022\u003E2024-10-01 08:08\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-425500-computerized-drug-processing-identification-persons-batch-production-and-control\u0022\u003ECPG Sec. 425.500 Computerized Drug Processing; Identification of \u0026quot;Persons\u0026quot; on Batch Production and Control Records\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/04\/1987","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-09T16:55:11-04:00\u0022\u003E2020-04-09 16:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-560250-imports-importer-can-be-required-reveal-identity-ingredients\u0022\u003ECPG Sec 560.250 Imports - Importer can be Required to Reveal Identity of Ingredients\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/19\/1989","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Import","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Import","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T17:05:46-04:00\u0022\u003E2025-03-17 17:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-641100-products-control-fleas-and-ticks-containing-pesticide-withdrawn-2202020\u0022\u003ECPG Sec. 641.100 *Products for Control of Fleas and Ticks* Containing a Pesticide (Withdrawn 2\/20\/2020)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222020-02-20T09:47:13-05:00\u0022\u003E2020-02-20 09:47\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-160200-fda-use-income-tax-information-irs-compliance-activity\u0022\u003ECPG Sec. 160.200 FDA Use of Income Tax Information from IRS in Compliance Activity\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"04\/20\/1988","field_issuing_office_taxonomy":"Office of Regulatory Affairs","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222024-10-24T14:52:24-04:00\u0022\u003E2024-10-24 14:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-430100-unit-dose-labeling-solid-and-liquid-oral-dosage-forms\u0022\u003ECPG Sec 430.100 Unit Dose Labeling for Solid and Liquid Oral Dosage Forms\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"01\/31\/1984","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research,Office of Pharmaceutical Quality","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-07T21:50:20-04:00\u0022\u003E2020-05-07 21:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-560300-reconditioning-imported-insect-infested-insect-damaged-or-moldy-coffee-beans\u0022\u003ECPG Sec 560.300 Reconditioning of Imported, Insect Infested, Insect Damaged or Moldy Coffee Beans\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/19\/1989","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Import","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Import","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T17:08:31-04:00\u0022\u003E2025-03-17 17:08\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-160300-requests-records-under-section-703\u0022\u003ECPG Sec. 160.300 Requests for Records Under Section 703\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/30\/1989","field_issuing_office_taxonomy":"Office of Regulatory Affairs","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222024-10-24T14:52:21-04:00\u0022\u003E2024-10-24 14:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-642100-drugs-odor-control-and-conception-pet-animals\u0022\u003ECPG Sec. 642.100 *Drugs for Odor Control and Conception in Pet Animals*\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Drugs","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0630\u0022\u003EFDA-2021-D-0630\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222021-07-27T07:05:07-04:00\u0022\u003E2021-07-27 07:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-430200-repacking-drug-products-testingexamination-under-cgmps\u0022\u003ECPG Sec. 430.200 Repacking of Drug Products - Testing\/Examination under CGMPs\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/01\/1981","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-09T17:05:03-04:00\u0022\u003E2020-04-09 17:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-560350-coffee-and-cocoa-bean-sweeps\u0022\u003ECPG Sec 560.350 Coffee and Cocoa Bean Sweeps\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/19\/1989","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Import","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Import","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T17:10:17-04:00\u0022\u003E2025-03-17 17:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-160400-section-305-meeting-report-criminal-violation\u0022\u003ECPG Sec. 160.400 *Section 305 Meeting* Before Report of Criminal Violation\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/30\/1989","field_issuing_office_taxonomy":"Office of Regulatory Affairs","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222024-10-24T14:52:17-04:00\u0022\u003E2024-10-24 14:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-643100-oral-iron-products-baby-pigs-withdrawn-2202020\u0022\u003ECPG Sec. 643.100 Oral Iron Products for Baby Pigs (Withdrawn 2\/20\/2020)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222020-02-20T09:45:21-05:00\u0022\u003E2020-02-20 09:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-430300-labeling-shipping-containers-drugs\u0022\u003ECPG Sec. 430.300 Labeling Shipping Containers of Drugs\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"05\/22\/1987","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/None found\u0022\u003ENone found\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T15:45:35-04:00\u0022\u003E2020-05-06 15:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-540100-capelin-prohibited-being-labeled-smelt-revoked-82396\u0022\u003ECPG Sec 540.100 Capelin - Prohibited from Being Labeled as Smelt (Revoked 8\/23\/96)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/22\/1996","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:23:25-05:00\u0022\u003E2025-03-06 21:23\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-430400-urinary-preparations-misbranding-lack-rx-legend-and-claims\u0022\u003ECPG Sec. 430.400 Urinary Preparations - Misbranding - Lack of Rx Legend and Claims\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/None found\u0022\u003ENone found\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"","changed":"\u003Ctime datetime=\u00222020-05-06T15:50:34-04:00\u0022\u003E2020-05-06 15:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-160500-answering-inquiries-status-criminal-referrals\u0022\u003ECPG Sec. 160.500 Answering Inquiries on Status of Criminal Referrals\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/31\/1996","field_issuing_office_taxonomy":"Office of Regulatory Affairs","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222024-10-24T14:52:16-04:00\u0022\u003E2024-10-24 14:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-540150-caviar-use-term-labeling\u0022\u003ECPG Sec 540.150 Caviar, Use of Term - Labeling\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/29\/1989","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Seafood\/Seafood Product","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Seafood\/Seafood Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:24:12-05:00\u0022\u003E2025-03-06 21:24\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-540200-chubs-hot-process-smoked-added-nitrite-adulteration-involving-food-additives-sodium\u0022\u003ECPG Sec 540.200 Chubs, Hot Process Smoked with Added Nitrite - Adulteration Involving Food Additives, Sodium Nitrite\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/28\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Seafood\/Seafood Product","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Seafood\/Seafood Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:25:07-05:00\u0022\u003E2025-03-06 21:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-560450-imported-low-acid-canned-foods-manufacturer-not-registered-andor-no-scheduled-process\u0022\u003ECPG Sec 560.450 Imported Low-Acid Canned Foods (Manufacturer Not Registered and\/or No Scheduled Process Filed)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/01\/1980","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Import","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Import","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T17:16:33-04:00\u0022\u003E2025-03-17 17:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-651100-ethylenediamine-dihydroiodide-eddi\u0022\u003ECPG Sec. 651.100 Ethylenediamine Dihydroiodide (EDDI)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/126537\/download\u0022\u003EPDF (43.63 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (43.63 KB) of CPG Sec. 651.100 Ethylenediamine Dihydroiodide (EDDI)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/01\/2019","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Drugs","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0628\u0022\u003EFDA-2021-D-0628\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222021-07-27T07:05:04-04:00\u0022\u003E2021-07-27 07:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-540250-clams-mussels-oysters-fresh-frozen-or-canned-paralytic-shellfish-poison\u0022\u003ECPG Sec 540.250 Clams, Mussels, Oysters, Fresh, Frozen or Canned - Paralytic Shellfish Poison\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/28\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Seafood\/Seafood Product","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Seafood\/Seafood Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:26:08-05:00\u0022\u003E2025-03-06 21:26\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-560500-jams-jellies-and-related-products-imports\u0022\u003ECPG Sec 560.500 Jams, Jellies and Related Products - Imports\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/01\/1980","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Import","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Import","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T17:18:01-04:00\u0022\u003E2025-03-17 17:18\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-653100-animal-grooming-aids\u0022\u003ECPG Sec. 653.100 Animal Grooming Aids\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/121177\/download\u0022\u003EPDF (23.15 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (23.15 KB) of CPG Sec. 653.100 Animal Grooming Aids\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/2019","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-05-07T10:46:16-04:00\u0022\u003E2019-05-07 10:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-442100-new-drugs-export\u0022\u003ECPG Sec. 442.100 New Drugs - Export\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/01\/1980","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/None found\u0022\u003ENone found\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T16:05:08-04:00\u0022\u003E2020-05-06 16:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-540285-crabmeat-products-labeling-crabmeat-products-added-fish-or-other-seafood-ingredients\u0022\u003ECPG Sec 540.285 Crabmeat Products - Labeling; Crabmeat Products with Added Fish or Other Seafood Ingredients - Labeling\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/30\/1980","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Seafood\/Seafood Product","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Seafood\/Seafood Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:28:07-05:00\u0022\u003E2025-03-06 21:28\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-560600-clams-mussels-oysters-fresh-or-frozen-adulteration-bacteriological-contamination\u0022\u003ECPG Sec 560.600 Clams, Mussels, Oysters; Fresh or Frozen - Adulteration by Bacteriological Contamination\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations","field_health_topics":"","term_node_tid":"Import","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Import","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T17:19:16-04:00\u0022\u003E2025-03-17 17:19\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-654100-dimethyl-sulfoxide-dmso-animal-use-withdrawn-2202020\u0022\u003ECPG Sec. 654.100 Dimethyl Sulfoxide (DMSO) for Animal Use (Withdrawn 2\/20\/2020)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Drugs","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222020-02-20T09:47:04-05:00\u0022\u003E2020-02-20 09:47\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-444100-recovery-investigational-new-drugs-clinical-investigators\u0022\u003ECPG Sec. 444.100 Recovery of Investigational New Drugs from Clinical Investigators\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/01\/1980","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/None found\u0022\u003ENone found\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T16:10:02-04:00\u0022\u003E2020-05-06 16:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-540300-crabmeat-product-name-revoked-82396\u0022\u003ECPG Sec 540.300 Crabmeat - Product Name (Revoked 8\/23\/96)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/22\/1996","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:29:18-05:00\u0022\u003E2025-03-06 21:29\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-560700-processing-imported-frozen-products-multiple-sizes-eg-shrimp-prawns-etc-withdrawn\u0022\u003ECPG Sec 560.700 - Processing of Imported Frozen Products of Multiple Sizes (e.g., Shrimp, Prawns, Etc.) (Withdrawn 6\/6\/2008)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"06\/06\/2008","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Import","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Import","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T17:20:03-04:00\u0022\u003E2025-03-17 17:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-654200-teat-dips-and-udder-washes-dairy-cows-and-goats\u0022\u003ECPG Sec. 654.200 Teat Dips and Udder Washes for Dairy Cows and Goats\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0632\u0022\u003EFDA-2021-D-0632\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222021-07-27T07:10:15-04:00\u0022\u003E2021-07-27 07:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-446100-regulatory-action-regarding-approved-new-drugs-and-antibiotic-drug-products-subjected\u0022\u003ECPG Sec. 446.100 Regulatory Action Regarding Approved New Drugs and Antibiotic Drug Products Subjected to Additional Processing or other Manipulations\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"01\/18\/1991","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/None found\u0022\u003ENone found\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T16:20:02-04:00\u0022\u003E2020-05-06 16:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-540350-common-or-usual-names-crustaceans-revoked-82396\u0022\u003ECPG Sec 540.350 Common or Usual Names for Crustaceans (Revoked 8\/23\/96)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/22\/1996","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:30:08-05:00\u0022\u003E2025-03-06 21:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-540375-canned-salmon-adulteration-involving-decomposition-withdrawn-3222010\u0022\u003ECPG Sec 540.375 Canned Salmon - Adulteration Involving Decomposition (Withdrawn 3\/22\/2010)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/21\/2010","field_issuing_office_taxonomy":"Office of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:31:49-05:00\u0022\u003E2025-03-06 21:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-562100-acetic-acid-use-foods-labeling-foods-which-used\u0022\u003ECPG Sec 562.100 Acetic Acid - Use in Foods - Labeling of Foods in Which Used\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/01\/1989","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T17:22:16-04:00\u0022\u003E2025-03-17 17:22\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-655100-devices-use-animals\u0022\u003ECPG Sec. 655.100 Devices for Use in Animals\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"06\/01\/1987","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Policy, Legislation, and International Affairs,Office of Global Policy and Strategy","field_health_topics":"","term_node_tid":"Animal Devices","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Devices","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-05-08T07:45:30-04:00\u0022\u003E2019-05-08 07:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-540390-canned-shrimp-labeling-size-designations-and-corresponding-counts\u0022\u003ECPG Sec 540.390 Canned Shrimp - Labeling, Size Designations and Corresponding Counts\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/29\/1989","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Seafood\/Seafood Product","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Seafood\/Seafood Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:32:49-05:00\u0022\u003E2025-03-06 21:32\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-562200-foods-fpla-compliance\u0022\u003ECPG Sec 562.200 Foods - FPLA Compliance\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Labeling","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T17:23:16-04:00\u0022\u003E2025-03-17 17:23\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-655200-adequate-directions-use-animal-drugs-veterinary-devices-withdrawn-2202020\u0022\u003ECPG Sec. 655.200 Adequate Directions for Use - Animal Drugs \u0026amp; Veterinary Devices (Withdrawn 2\/20\/2020)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/30\/1980","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Devices, Animal Drugs, Labeling","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Devices, Animal Drugs, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222020-02-20T09:46:32-05:00\u0022\u003E2020-02-20 09:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-540400-shrimp-fresh-or-frozen-raw-headless-peeled-or-breaded-revoked-122496\u0022\u003ECPG Sec 540.400 Shrimp - Fresh or Frozen, Raw, Headless, Peeled or Breaded (Revoked 12\/24\/96)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"12\/23\/1996","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Seafood\/Seafood Product","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Seafood\/Seafood Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:33:49-05:00\u0022\u003E2025-03-06 21:33\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-562300-foods-net-weight\u0022\u003ECPG Sec 562.300 Foods - Net Weight\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Labeling","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T17:24:16-04:00\u0022\u003E2025-03-17 17:24\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-655300-barking-dog-collar-withdrawn-2202020\u0022\u003ECPG Sec. 655.300 Barking Dog Collar (Withdrawn 2\/20\/2020)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"06\/01\/1987","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Policy, Legislation, and International Affairs,Office of Global Policy and Strategy","field_health_topics":"","term_node_tid":"Animal Devices","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Devices","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222020-02-20T09:51:27-05:00\u0022\u003E2020-02-20 09:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-450200-drugs-general-provisions-and-administrative-procedures-recognition-safe-and-effective\u0022\u003ECPG Sec. 450.200 Drugs - General Provisions and Administrative Procedures for Recognition as Safe and Effective\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-09T17:20:33-04:00\u0022\u003E2020-04-09 17:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-540410-shrimp-frozen-raw-breaded-or-lightly-breaded-misbranding-involving-non-compliance\u0022\u003ECPG Sec 540.410 Shrimp - Frozen, Raw, Breaded or Lightly Breaded, Misbranding Involving Non-Compliance with Standards\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/28\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Seafood\/Seafood Product","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Seafood\/Seafood Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:34:33-05:00\u0022\u003E2025-03-06 21:34\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-562400-foreign-language-declarations-food-labels\u0022\u003ECPG Sec 562.400 Foreign Language Declarations on Food Labels\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Labeling","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T17:54:31-04:00\u0022\u003E2025-03-17 17:54\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-450300-otc-drugs-general-provisions-and-administrative-procedures-marketing-combination\u0022\u003ECPG Sec. 450.300 OTC Drugs - General Provisions and Administrative Procedures for Marketing Combination Products\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/None found\u0022\u003ENone found\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-08T10:20:37-04:00\u0022\u003E2020-05-08 10:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-655400-status-syringes-and-needles-animal-use-withdrawn-2202020\u0022\u003ECPG Sec. 655.400 The Status of Syringes and Needles for Animal Use (Withdrawn 2\/20\/2020)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"06\/01\/1987","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Devices","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Devices","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222020-02-20T09:51:13-05:00\u0022\u003E2020-02-20 09:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-540420-raw-breaded-shrimp-microbiological-criteria-evaluating-compliance-current-good\u0022\u003ECPG Sec 540.420 Raw Breaded Shrimp - Microbiological Criteria for Evaluating Compliance with Current Good Manufacturing Practice Regulations\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Seafood\/Seafood Product","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Seafood\/Seafood Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:35:19-05:00\u0022\u003E2025-03-06 21:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-562450-identity-foods-use-terms-such-fresh-frozen-dried-canned-etc\u0022\u003ECPG Sec 562.450 Identity of Foods - Use of Terms Such as Fresh, Frozen, Dried, Canned, Etc.\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/01\/1980","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Labeling","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T17:55:31-04:00\u0022\u003E2025-03-17 17:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-660100-failure-register-withdrawn-2202020\u0022\u003ECPG Sec. 660.100 Failure to Register (Withdrawn 2\/20\/2020)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/30\/1980","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222020-02-20T09:50:11-05:00\u0022\u003E2020-02-20 09:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-450400-labeling-and-distribution-otc-drugs-vending-machines\u0022\u003ECPG Sec. 450.400 Labeling and Distribution of OTC Drugs in Vending Machines\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"05\/22\/1987","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/None found\u0022\u003ENone found\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-08T10:25:16-04:00\u0022\u003E2020-05-08 10:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-540450-imitation-breaded-shrimp\u0022\u003ECPG Sec 540.450 *Imitation Breaded Shrimp*\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/30\/1989","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Seafood\/Seafood Product","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Seafood\/Seafood Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:36:08-05:00\u0022\u003E2025-03-06 21:36\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-562550-safety-and-labeling-waxed-coated-fruits-and-vegetables\u0022\u003ECPG Sec 562.550 Safety and Labeling of Waxed (Coated) Fruits and Vegetables\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Labeling","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T17:56:31-04:00\u0022\u003E2025-03-17 17:56\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-665100-common-or-usual-names-animal-feed-ingredients-withdrawn-162025\u0022\u003ECPG Sec. 665.100 Common or Usual Names for Animal Feed Ingredients (Withdrawn 1\/6\/2025)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Feed, Labeling","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Feed, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0633\u0022\u003EFDA-2021-D-0633\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222025-01-06T13:07:02-05:00\u0022\u003E2025-01-06 13:07\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-450500-tamper-resistant-packaging-requirements-certain-over-counter-human-drug-products\u0022\u003ECPG Sec. 450.500 Tamper-Resistant Packaging Requirements for Certain Over-the-Counter Human Drug Products\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"05\/21\/1992","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-09T17:35:15-04:00\u0022\u003E2020-04-09 17:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-540475-snapper-labeling\u0022\u003ECPG Sec 540.475 Snapper - Labeling\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/01\/1980","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Seafood\/Seafood Product","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Seafood\/Seafood Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:37:08-05:00\u0022\u003E2025-03-06 21:37\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-562600-preservatives-use-nonstandardized-foods-label-declaration\u0022\u003ECPG Sec 562.600 Preservatives; Use in Nonstandardized Foods; Label Declaration\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/01\/1989","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Labeling","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T17:57:31-04:00\u0022\u003E2025-03-17 17:57\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/redbook-2000-i-introduction\u0022\u003ERedbook 2000: I Introduction\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/01\/2007","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-01-16T11:24:10-05:00\u0022\u003E2025-01-16 11:24\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-665300-use-type-medicated-article-proprietary-names-names-medicated-feeds\u0022\u003ECPG Sec. 665.300 Use of Type A Medicated Article Proprietary Names in the Names of Medicated Feeds\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/121190\/download\u0022\u003EPDF (47.62 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (47.62 KB) of CPG Sec. 665.300 Use of Type A Medicated Article Proprietary Names in the Names of Medicated Feeds\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/2019","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Labeling, Medicated Feed","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Labeling, Medicated Feed","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-05-07T10:50:49-04:00\u0022\u003E2019-05-07 10:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-562650-processing-use-term-section-405-fdc-act\u0022\u003ECPG Sec 562.650 \u0026quot;Processing\u0026quot; - Use of Term in Section 405 of the FD\u0026amp;C Act\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"01\/31\/1989","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Labeling","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T17:58:31-04:00\u0022\u003E2025-03-17 17:58\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-450550-control-and-accountability-labeling-associated-tamper-resistant-packaging-over\u0022\u003ECPG Sec. 450.550 Control and Accountability of Labeling Associated with Tamper-Resistant Packaging of Over-the-Counter Drug Products\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/01\/1983","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-09T17:50:08-04:00\u0022\u003E2020-04-09 17:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-540500-tuna-sable-salmon-shad-smoked-cured-adulteration-involving-food-additives-sodium\u0022\u003ECPG Sec 540.500 Tuna, Sable, Salmon, Shad-Smoked Cured, Adulteration Involving Food Additives, Sodium Nitrite\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Seafood\/Seafood Product","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Seafood\/Seafood Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:37:49-05:00\u0022\u003E2025-03-06 21:37\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-666100-alternate-feeding-different-medicated-feeds\u0022\u003ECPG Sec. 666.100 Alternate Feeding of Different Medicated Feeds\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/121191\/download\u0022\u003EPDF (22.87 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (22.87 KB) of CPG Sec. 666.100 Alternate Feeding of Different Medicated Feeds\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/2019","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Medicated Feed","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Medicated Feed","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-05-07T10:51:12-04:00\u0022\u003E2019-05-07 10:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-454100-otc-ear-drop-preparations\u0022\u003ECPG Sec. 454.100 OTC Ear Drop Preparations\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"05\/22\/1987","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/None found\u0022\u003ENone found\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-08T10:35:09-04:00\u0022\u003E2020-05-08 10:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-562700-labeling-food-bearing-residues-pesticide-chemicals\u0022\u003ECPG Sec 562.700 Labeling of Food Bearing Residues of Pesticide Chemicals\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/01\/1989","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Labeling","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T17:59:31-04:00\u0022\u003E2025-03-17 17:59\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-540525-scombrotoxin-histamine-forming-fish-and-fishery-products-decomposition-and-histamine\u0022\u003ECPG Sec 540.525 Scombrotoxin (Histamine)-forming Fish and Fishery Products \u2013 Decomposition and Histamine (CPG 7108.24)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/182955\/download\u0022\u003EPDF (402.44 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (402.44 KB) of CPG Sec 540.525 Scombrotoxin (Histamine)-forming Fish and Fishery Products \u2013 Decomposition and Histamine (CPG 7108.24)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/01\/2024","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Seafood\/Seafood Product","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Seafood\/Seafood Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0367\u0022\u003EFDA-2021-D-0367\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:38:34-05:00\u0022\u003E2025-03-06 21:38\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-670100-refusals-formula-information-during-inspection-feed-mills-manufacturing-feeds\u0022\u003ECPG Sec. 670.100 Refusals of Formula Information During Inspection of Feed Mills Manufacturing Feeds Requiring Approved Medicated Feed Applications (Withdrawn 6\/30\/2020)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"05\/31\/1986","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Medicated Feed","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Medicated Feed","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222020-06-30T13:15:12-04:00\u0022\u003E2020-06-30 13:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-562750-labeling-food-articles-distributed-solely-puerto-rico\u0022\u003ECPG Sec 562.750 Labeling of Food Articles Distributed Solely in Puerto Rico\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/01\/1989","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Labeling","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T18:01:31-04:00\u0022\u003E2025-03-17 18:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-540550-kipper-and-kipper-unsplit-definitions\u0022\u003ECPG Sec 540.550 Kipper and Kipper Unsplit - Definitions\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/30\/1989","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Seafood\/Seafood Product","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Seafood\/Seafood Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:39:28-05:00\u0022\u003E2025-03-06 21:39\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-455100-inert-glandular-preparations-otc-inadequate-full-disclosure-and-claims\u0022\u003ECPG Sec. 455.100 Inert Glandular Preparations *(OTC)*, Inadequate Full Disclosure and Claims\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"05\/22\/1987","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/None found\u0022\u003ENone found\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-08T10:35:57-04:00\u0022\u003E2020-05-08 10:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-670200-status-vitamins-and-minerals-type-b-and-c-medicated-feed-and-non-medicated-feed\u0022\u003ECPG Sec. 670.200 Status of Vitamins and Minerals in Type B and C Medicated Feed and in Non-Medicated Feed (Withdrawn 2\/20\/2020)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"05\/31\/1986","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Medicated Feed","field_topics":"","topics-product":"Medicated Feed","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222020-02-20T09:50:37-05:00\u0022\u003E2020-02-20 09:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-562800-vending-machine-food-labeling\u0022\u003ECPG Sec 562.800 Vending Machine Food - Labeling\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/01\/1989","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Labeling","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T18:01:37-04:00\u0022\u003E2025-03-17 18:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-540575-fish-fresh-and-frozen-adulteration-involving-decomposition-withdrawn-7182008\u0022\u003ECPG Sec 540.575 Fish - Fresh and Frozen - Adulteration Involving Decomposition (Withdrawn 7\/18\/2008)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/18\/2008","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Seafood\/Seafood Product","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Seafood\/Seafood Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:40:07-05:00\u0022\u003E2025-03-06 21:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-456100-non-rx-drugs-anti-obesity-preparations\u0022\u003ECPG Sec. 456.100 Non-Rx Drugs Anti-Obesity Preparations\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/None found\u0022\u003ENone found\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-08T10:35:29-04:00\u0022\u003E2020-05-08 10:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-670500-ammoniated-cottonseed-meal-interpretation-21-cfr\u0022\u003ECPG Sec. 670.500 Ammoniated Cottonseed Meal - Interpretation of 21 CFR\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Feed","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Feed","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0634\u0022\u003EFDA-2021-D-0634\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222021-07-27T07:11:03-04:00\u0022\u003E2021-07-27 07:11\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-675100-diversion-contaminated-food-animal-use\u0022\u003ECPG Sec. 675.100 Diversion of Contaminated Food for Animal Use\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Feed","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Feed","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0635\u0022\u003EFDA-2021-D-0635\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222021-07-27T07:16:09-04:00\u0022\u003E2021-07-27 07:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-565100-fda-jurisdiction-over-meat-and-poultry-products\u0022\u003ECPG Sec 565.100 FDA Jurisdiction Over Meat and Poultry Products\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations","field_health_topics":"","term_node_tid":"Meat\/Meat Products \u0026amp; Poultry","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Meat\/Meat Products \u0026amp; Poultry","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-18T14:07:46-04:00\u0022\u003E2025-03-18 14:07\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-457100-pangamic-acid-and-pangamic-acid-products-unsafe-food-and-drug-use\u0022\u003ECPG Sec. 457.100 Pangamic Acid and Pangamic Acid Products Unsafe for Food and Drug Use\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-16T09:50:09-04:00\u0022\u003E2020-04-16 09:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-675200-diversion-adulterated-food-acceptable-animal-feed-use\u0022\u003ECPG Sec. 675.200 Diversion of Adulterated Food to Acceptable Animal Feed Use\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Feed","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Feed","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0636\u0022\u003EFDA-2021-D-0636\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222021-07-27T07:16:03-04:00\u0022\u003E2021-07-27 07:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-565200-red-meat-adulterated-pcbs\u0022\u003ECPG Sec 565.200 Red Meat Adulterated with PCBs\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/10\/1987","field_issuing_office_taxonomy":"Office of Inspections and Investigations","field_health_topics":"","term_node_tid":"Meat\/Meat Products \u0026amp; Poultry","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Meat\/Meat Products \u0026amp; Poultry","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-18T14:08:46-04:00\u0022\u003E2025-03-18 14:08\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-460100-hospital-pharmacies-status-drug-manufacturer\u0022\u003ECPG Sec. 460.100 Hospital Pharmacies - Status as Drug Manufacturer\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/01\/1980","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/None found\u0022\u003ENone found\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-08T10:40:28-04:00\u0022\u003E2020-05-08 10:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-675300-moisture-damaged-grain\u0022\u003ECPG Sec. 675.300 Moisture Damaged Grain\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Feed","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Feed","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0637\u0022\u003EFDA-2021-D-0637\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222021-07-27T07:16:12-04:00\u0022\u003E2021-07-27 07:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-567100-antipasto-common-or-usual-name\u0022\u003ECPG Sec 567.100 Antipasto, Common or Usual Name\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/01\/1987","field_issuing_office_taxonomy":"Office of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-18T14:10:47-04:00\u0022\u003E2025-03-18 14:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-460200-pharmacy-compounding-withdrawn-december-4-2013\u0022\u003ECPG Sec. 460.200 Pharmacy Compounding (Withdrawn December 4, 2013)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"12\/03\/2013","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222018-12-01T10:39:57-05:00\u0022\u003E2018-12-01 10:39\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-540600-fish-shellfish-crustaceans-and-other-aquatic-animals-fresh-frozen-or-processed-methyl\u0022\u003ECPG Sec 540.600 Fish, Shellfish, Crustaceans and other Aquatic Animals - Fresh, Frozen or Processed - Methyl Mercury\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/06\/2007","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Seafood\/Seafood Product","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Seafood\/Seafood Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:41:48-05:00\u0022\u003E2025-03-06 21:41\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-680100-tracers-animal-feed-withdrawn-10192022\u0022\u003ECPG Sec. 680.100 Tracers in Animal Feed (Withdrawn 10\/19\/2022)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"04\/04\/1993","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Feed","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Feed","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222022-10-19T06:04:02-04:00\u0022\u003E2022-10-19 06:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-567200-pork-and-beans-and-similar-bean-products-labeling\u0022\u003ECPG Sec 567.200 Pork and Beans and Similar Bean Products - Labeling\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/01\/1987","field_issuing_office_taxonomy":"Office of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-18T14:11:46-04:00\u0022\u003E2025-03-18 14:11\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-540750-use-seafood-list-determine-acceptable-seafood-names\u0022\u003ECPG Sec 540.750 - Use of The Seafood List to Determine Acceptable Seafood Names\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/139978\/download\u0022\u003EPDF (85.59 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (85.59 KB) of CPG Sec 540.750 - Use of The Seafood List to Determine Acceptable Seafood Names\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/13\/2020","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Seafood\/Seafood Product","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Seafood\/Seafood Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-3004\u0022\u003EFDA-2016-D-3004\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:45:07-05:00\u0022\u003E2025-03-06 21:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-460300-return-unused-prescription-drugs-pharmacy-stock\u0022\u003ECPG Sec. 460.300 Return of Unused Prescription Drugs to Pharmacy Stock\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/01\/1980","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/None found\u0022\u003ENone found\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-08T10:50:17-04:00\u0022\u003E2020-05-08 10:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-680200-cgmp-regulations-medicated-feeds-daily-inventory-requirements-withdrawn-2202020\u0022\u003ECPG Sec. 680.200 CGMP Regulations for Medicated Feeds - Daily Inventory Requirements (Withdrawn 2\/20\/2020)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"06\/30\/1986","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Medicated Feed","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Medicated Feed","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222020-02-20T09:51:39-05:00\u0022\u003E2020-02-20 09:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-567300-bouillon-bouillon-cubes-granulated-bouillon\u0022\u003ECPG Sec 567.300 *Bouillon, Bouillon Cubes, Granulated Bouillon*\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/01\/1987","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-18T14:12:46-04:00\u0022\u003E2025-03-18 14:12\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-460400-computerized-prescription-recordkeeping-pharmacies\u0022\u003ECPG Sec. 460.400 Computerized Prescription Recordkeeping by Pharmacies\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/30\/1980","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-08T12:05:27-04:00\u0022\u003E2020-04-08 12:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-460425-prescription-status-when-telephoned-recording-machine\u0022\u003ECPG Sec. 460.425 Prescription Status when Telephoned to Recording Machine\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/30\/1980","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-08T12:10:14-04:00\u0022\u003E2020-04-08 12:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-460450-status-mail-order-filling-prescriptions\u0022\u003ECPG Sec. 460.450 Status of Mail-Order Filling of Prescriptions\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"05\/21\/1987","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-08T12:15:16-04:00\u0022\u003E2020-04-08 12:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-460500-prescription-drugs-ships-medicine-chests\u0022\u003ECPG Sec. 460.500 Prescription Drugs for Ship\u0026#039;s Medicine Chests\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/30\/1980","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-08T12:20:39-04:00\u0022\u003E2020-04-08 12:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-545200-confectionery-decorations-nutritive-and-non-nutritive\u0022\u003ECPG Sec 545.200 Confectionery Decorations (Nutritive and Non-Nutritive)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"06\/27\/1988","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:46:07-05:00\u0022\u003E2025-03-06 21:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-680400-medicated-feeds-combined-batches\u0022\u003ECPG Sec. 680.400 Medicated Feeds -- Combined Batches\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"05\/31\/1986","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Medicated Feed","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Medicated Feed","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0644\u0022\u003EFDA-2021-D-0644\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222021-07-27T07:25:07-04:00\u0022\u003E2021-07-27 07:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-570100-jordan-almonds-common-or-usual-name\u0022\u003ECPG Sec 570.100 Jordan Almonds - Common or Usual Name\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"12\/02\/1988","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Nuts \u0026amp; Nut Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Nuts \u0026amp; Nut Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-21T16:37:16-04:00\u0022\u003E2025-03-21 16:37\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-460600-content-uniformity-testing-tablets-and-capsules\u0022\u003ECPG Sec. 460.600 Content Uniformity Testing of Tablets and Capsules\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/02\/1987","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-01T14:15:17-04:00\u0022\u003E2020-05-01 14:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-680500-unsafe-contamination-animal-feed-drug-carryover-withdrawn-1302023\u0022\u003ECPG Sec. 680.500 Unsafe Contamination of Animal Feed from Drug Carryover (Withdrawn 1\/30\/2023)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Feed","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Feed","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0638\u0022\u003EFDA-2021-D-0638\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222023-01-27T08:52:05-05:00\u0022\u003E2023-01-27 08:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-460700-controlled-release-dosage-form-drugs-rate-release-active-ingredients\u0022\u003ECPG Sec. 460.700 Controlled Release Dosage Form Drugs - Rate of Release of Active Ingredients\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222018-12-01T11:49:44-05:00\u0022\u003E2018-12-01 11:49\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-680600-sequencing-means-prevent-unsafe-drug-contamination-production-storage-and\u0022\u003ECPG Sec. 680.600 Sequencing as a Means to Prevent Unsafe Drug Contamination in the Production, Storage, and Distribution of Feeds (Withdrawn 1\/30\/2023)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Feed","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Feed","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0639\u0022\u003EFDA-2021-D-0639\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222023-01-27T08:52:01-05:00\u0022\u003E2023-01-27 08:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-681100-order-post-approval-record-reviews-withdrawn-2202020\u0022\u003ECPG Sec. 681.100 Order for Post-Approval Record Reviews (Withdrawn 2\/20\/2020)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"06\/24\/1992","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Feed, Records","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Feed, Records","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222020-02-20T09:50:02-05:00\u0022\u003E2020-02-20 09:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-570250-cashews-insect-infested-reconditioning\u0022\u003ECPG Sec 570.250 Cashews, Insect Infested - Reconditioning\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"12\/02\/1988","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Nuts \u0026amp; Nut Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Nuts \u0026amp; Nut Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-21T16:39:16-04:00\u0022\u003E2025-03-21 16:39\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-682100-use-drug-contaminated-products-animal-feed-withdrawn-2202020\u0022\u003ECPG Sec. 682.100 Use of Drug-Contaminated Products in Animal Feed (Withdrawn 2\/20\/2020)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/30\/1980","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Feed","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Feed","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222020-02-20T09:50:14-05:00\u0022\u003E2020-02-20 09:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-480100-requirements-expiration-dating-and-stability-testing\u0022\u003ECPG Sec. 480.100 Requirements for Expiration Dating and Stability Testing\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-08T12:30:36-04:00\u0022\u003E2020-04-08 12:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-685100-recycled-animal-waste\u0022\u003ECPG Sec. 685.100 Recycled Animal Waste\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Feed","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Feed","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0640\u0022\u003EFDA-2021-D-0640\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222021-07-27T07:20:07-04:00\u0022\u003E2021-07-27 07:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-687500-silage-ingredients\u0022\u003ECPG Sec. 687.500 Silage Ingredients\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Feed","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Feed","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0641\u0022\u003EFDA-2021-D-0641\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222021-07-27T07:21:03-04:00\u0022\u003E2021-07-27 07:21\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-688100-unapproved-additives-exported-grains\u0022\u003ECPG Sec. 688.100 Unapproved Additives for Exported Grains\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"01\/31\/1982","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Feed, Export","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Feed, Export","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-05-08T11:16:27-04:00\u0022\u003E2019-05-08 11:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-689100-direct-fed-microbial-products\u0022\u003ECPG Sec. 689.100 Direct-Fed Microbial Products\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Feed","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Feed","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0642\u0022\u003EFDA-2021-D-0642\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222021-07-27T07:25:10-04:00\u0022\u003E2021-07-27 07:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-690100-nutritional-supplements-companion-animals-withdrawn-2202020\u0022\u003ECPG Sec. 690.100 Nutritional Supplements for Companion Animals (Withdrawn 2\/20\/2020)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Feed","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Feed","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222020-02-20T09:55:38-05:00\u0022\u003E2020-02-20 09:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-690200-pet-food-labeling-withdrawn-2202020\u0022\u003ECPG Sec. 690.200 Pet Food Labeling (Withdrawn 2\/20\/2020)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/30\/1980","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Labeling, Pet Food","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Labeling, Pet Food","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222020-02-20T09:55:42-05:00\u0022\u003E2020-02-20 09:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-690400-water-and-gravy-pet-food-withdrawn-2202020\u0022\u003ECPG Sec. 690.400 Water and Gravy in Pet Food (Withdrawn 2\/20\/2020)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/01\/1980","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Pet Food","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Pet Food","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222020-02-20T09:55:50-05:00\u0022\u003E2020-02-20 09:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-690500-uncooked-meat-animal-food-withdrawn-4302019\u0022\u003ECPG Sec. 690.500 Uncooked Meat for Animal Food (Withdrawn 4\/30\/2019)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"05\/23\/1989","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Feed","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Feed","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-05-08T11:26:33-04:00\u0022\u003E2019-05-08 11:26\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-690600-rodent-contaminated-pet-foods-direct-reference-seizure-authority-withdrawn-2202020\u0022\u003ECPG Sec. 690.600 Rodent Contaminated Pet Foods - *Direct Reference Seizure Authority* (Withdrawn 2\/20\/2020)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/01\/1996","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Pet Food","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Pet Food","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222020-02-20T09:55:27-05:00\u0022\u003E2020-02-20 09:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-650100-animal-drugs-euthanasia-withdrawn-5232024\u0022\u003ECPG Sec. 650.100 Animal Drugs for Euthanasia (Withdrawn 5\/23\/2024)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Drugs","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0631\u0022\u003EFDA-2021-D-0631\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222024-05-23T09:38:16-04:00\u0022\u003E2024-05-23 09:38\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-570550-reconditioning-tree-nuts-contaminated-e-coli\u0022\u003ECPG Sec 570.550 Reconditioning - Tree Nuts Contaminated with E. coli\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"12\/09\/1988","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Nuts \u0026amp; Nut Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Nuts \u0026amp; Nut Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-21T16:46:46-04:00\u0022\u003E2025-03-21 16:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-665200-checklist-labeling-custom-mixed-medicated-feeds-withdrawn-7232019\u0022\u003ECPG Sec. 665.200 Checklist Labeling for Custom Mixed Medicated Feeds (Withdrawn 7\/23\/2019)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Labeling, Medicated Feed","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Labeling, Medicated Feed","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-07-23T12:01:02-04:00\u0022\u003E2019-07-23 12:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-570700-mixed-nuts-misbranding-involving-food-standards\u0022\u003ECPG Sec 570.700 Mixed Nuts - Misbranding Involving Food Standards\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Nuts \u0026amp; Nut Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Nuts \u0026amp; Nut Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-21T16:47:46-04:00\u0022\u003E2025-03-21 16:47\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/redbook-2000-iii-recommended-toxicity-studies\u0022\u003ERedbook 2000: III Recommended Toxicity Studies\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/01\/2007","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Information Sheet","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:04-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/redbook-2000-iv-introduction-guidelines-toxicity-studies\u0022\u003ERedbook 2000: IV. A. Introduction to Guidelines for Toxicity Studies\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/01\/2003","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:05-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-578100-starches-common-or-usual-names\u0022\u003ECPG Sec 578.100 Starches - Common or Usual Names\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/01\/1980","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Grain\/Grain Product","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Grain\/Grain Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-21T16:50:17-04:00\u0022\u003E2025-03-21 16:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/redbook-2000-ivb1-general-guidelines-designing-and-conducting-toxicity-studies\u0022\u003ERedbook 2000: IV.B.1. General Guidelines for Designing and Conducting Toxicity Studies\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/01\/2003","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:08-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/redbook-2000-ivb3-pathology-considerations-toxicity-studies\u0022\u003ERedbook 2000: IV.B.3. Pathology Considerations in Toxicity Studies\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/01\/2000","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:09-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/redbook-2000-ivb4-statistical-considerations-toxicity-studies\u0022\u003ERedbook 2000: IV.B.4. Statistical Considerations in Toxicity Studies\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"06\/01\/2007","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:12-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/redbook-2000-ivc1-short-term-tests-genetic-toxicity\u0022\u003ERedbook 2000: IV.C.1. Short-Term Tests for Genetic Toxicity\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/01\/2007","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:13-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/redbook-2000-ivc10-neurotoxicity-studies\u0022\u003ERedbook 2000: IV.C.10. Neurotoxicity Studies\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/01\/2000","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:14-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-578350-wheat-human-consumption-reconditioning\u0022\u003ECPG Sec 578.350 Wheat for Human Consumption - Reconditioning\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/01\/1980","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Grain\/Grain Product","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Grain\/Grain Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-21T16:54:01-04:00\u0022\u003E2025-03-21 16:54\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/redbook-2000-ivc1a-bacterial-reverse-mutation-test\u0022\u003ERedbook 2000: IV.C.1.a. Bacterial Reverse Mutation Test\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/01\/2000","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:16-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/redbook-2000-ivc1b-in-vitro-mammalian-chromosomal-aberration-test\u0022\u003ERedbook 2000: IV.C.1.b. In vitro Mammalian Chromosomal Aberration Test\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/01\/2003","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:18-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/redbook-2000-ivc1c-mouse-lymphoma-thymidine-kinase-gene-mutation-assay\u0022\u003ERedbook 2000: IV.C.1.c Mouse Lymphoma Thymidine Kinase Gene Mutation Assay\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"04\/01\/2006","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:19-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/redbook-2000-ivc1d-mammalian-erythrocyte-micronucleus-test\u0022\u003ERedbook 2000: IV.C.1.d. Mammalian Erythrocyte Micronucleus Test\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/01\/2000","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:21-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-578500-dimethylnitrosamine-dmna-barley-malt\u0022\u003ECPG Sec 578.500 Dimethylnitrosamine (DMNA) in Barley Malt\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/28\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Grain\/Grain Product","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Grain\/Grain Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-24T11:54:31-04:00\u0022\u003E2025-03-24 11:54\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/redbook-2000-ivc3a-short-term-toxicity-studies-rodents\u0022\u003ERedbook 2000: IV.C.3.a. Short-Term Toxicity Studies with Rodents\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/01\/2003","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:22-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-578600-unapproved-additives-exported-grains\u0022\u003ECPG Sec 578.600 Unapproved Additives for Exported Grains\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Grain\/Grain Product","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Grain\/Grain Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-24T11:55:46-04:00\u0022\u003E2025-03-24 11:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/redbook-2000-ivc3b-short-term-toxicity-studies-non-rodents\u0022\u003ERedbook 2000: IV.C.3.b. Short-Term Toxicity Studies with Non-Rodents\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/01\/2003","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:23-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-585100-artichoke-jerusalem-artichoke-common-or-usual-name\u0022\u003ECPG Sec 585.100 Artichoke; Jerusalem Artichoke - Common or Usual Name\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"12\/08\/1988","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Vegetable Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Vegetable Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-24T11:58:16-04:00\u0022\u003E2025-03-24 11:58\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/redbook-2000-ivc4a-subchronic-toxicity-studies-rodents\u0022\u003ERedbook 2000: IV.C.4.a. Subchronic Toxicity Studies with Rodents\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/01\/2003","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:24-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/redbook-2000-ivc4b-subchronic-toxicity-studies-non-rodents\u0022\u003ERedbook 2000: IV.C.4.b. Subchronic Toxicity Studies with Non-Rodents\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/01\/2003","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:26-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/redbook-2000-ivc5b-one-year-toxicity-studies-non-rodents\u0022\u003ERedbook 2000: IV.C.5.b. One-Year Toxicity Studies with Non-Rodents\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/01\/2003","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:27-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/redbook-2000-ivc5a-chronic-toxicity-studies-rodents\u0022\u003ERedbook 2000: IV.C.5.a. Chronic Toxicity Studies with Rodents\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/01\/2007","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:28-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/redbook-2000-ivc6-carcinogenicity-studies-rodents\u0022\u003ERedbook 2000: IV.C.6. Carcinogenicity Studies with Rodents\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"01\/01\/2006","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:30-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/redbook-2000-ivc7-combined-chronic-toxicitycarcinogenicity-studies-rodents\u0022\u003ERedbook 2000: IV.C.7. Combined Chronic Toxicity\/Carcinogenicity Studies with Rodents\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/01\/2007","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:31-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/redbook-2000-ivc8-utero-exposure-phase-addition-carcinogenicity-studies-or-chronic-toxicity-studies\u0022\u003ERedbook 2000: IV.C.8. In-Utero Exposure Phase for Addition to Carcinogenicity Studies or Chronic Toxicity Studies with Rodents\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/01\/2007","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:31-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/redbook-2000-ivc9aguidelines-reproduction-studies\u0022\u003ERedbook 2000: IV.C.9.a.Guidelines for Reproduction Studies\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/01\/2000","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:33-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/redbook-2000-ivc9b-guidelines-developmental-toxicity-studies\u0022\u003ERedbook 2000: IV.C.9.b. Guidelines for Developmental Toxicity Studies\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/01\/2000","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:35-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/redbook-2000-vib-epidemiology\u0022\u003ERedbook 2000: VI.B Epidemiology\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/01\/2001","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:36-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/redbook-2000-vii-glossary-acronyms-and-definitions\u0022\u003ERedbook 2000: VII Glossary, Acronyms and Definitions\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"04\/25\/2004","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:37-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/redbook-2000-ivb2-guidelines-reporting-results-toxicity-studies\u0022\u003ERedbook 2000: IV.B.2 Guidelines for Reporting the Results of Toxicity Studies\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/01\/2003","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:37-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/commercially-distributed-analyte-specific-reagents-asrs-frequently-asked-questions\u0022\u003ECommercially Distributed Analyte Specific Reagents (ASRs): Frequently Asked Questions: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71127\/download\u0022\u003EPDF (138.61 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (138.61 KB) of Commercially Distributed Analyte Specific Reagents (ASRs): Frequently Asked Questions: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/13\/2007","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP)","field_topics":"Premarket","topics-product":"Premarket, Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2006-D-0357\u0022\u003EFDA-2006-D-0357\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-02-28T13:16:01-05:00\u0022\u003E2020-02-28 13:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/establishing-performance-characteristics-in-vitro-diagnostic-devices-detection-or-detection-and\u0022\u003EEstablishing the Performance Characteristics of In Vitro Diagnostic Devices for the Detection or Detection and Differentiation of Influenza Viruses - Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71519\/download\u0022\u003EPDF (289.02 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (289.02 KB) of Establishing the Performance Characteristics of In Vitro Diagnostic Devices for the Detection or Detection and Differentiation of Influenza Viruses - Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/14\/2011","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Pediatric Product Development","field_topics":"","topics-product":"Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0095\u0022\u003EFDA-2008-D-0095\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222024-04-11T11:27:31-04:00\u0022\u003E2024-04-11 11:27\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/third-party-review-guidance-vitreous-aspiration-and-cutting-device-premarket-notification-510k\u0022\u003EThird Party Review Guidance For Vitreous Aspiration and Cutting Device Premarket Notification (510(k))\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"01\/30\/1997","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-18T10:45:24-04:00\u0022\u003E2020-03-18 10:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/checklist-information-usually-submitted-investigational-device-exemptions-ide-application-refractive\u0022\u003EChecklist of Information Usually Submitted in an Investigational Device Exemptions (IDE) Application for Refractive Surgery Lasers [excimer]\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/09\/1996","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Investigational Device Exemption (IDE)","field_topics":"Premarket","topics-product":"Premarket, Investigational Device Exemption (IDE)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222025-01-31T14:11:16-05:00\u0022\u003E2025-01-31 14:11\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/1993-draft-redbook-ii\u0022\u003E1993 Draft Redbook II\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/01\/1993","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:38-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-document-preparation-premarket-notification-ceramic-ball-hip-systems\u0022\u003EGuidance Document For The Preparation of Premarket Notification For Ceramic Ball Hip Systems\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72249\/download\u0022\u003EPDF (36.84 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (36.84 KB) of Guidance Document For The Preparation of Premarket Notification For Ceramic Ball Hip Systems\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/09\/1995","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-17T13:10:13-04:00\u0022\u003E2020-03-17 13:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-prior-notice-imported-food-questions-and-answers-edition-4\u0022\u003EGuidance for Industry: Prior Notice of Imported Food Questions and Answers (Edition 4)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/161541\/download\u0022\u003EPDF (538.12 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (538.12 KB) of Guidance for Industry: Prior Notice of Imported Food Questions and Answers (Edition 4)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/13\/2023","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003ECenter for Veterinary Medicine","field_health_topics":"","term_node_tid":"Import","field_topics":"","topics-product":"Import","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"10\/13\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-N-0179\u0022\u003EFDA-2011-N-0179\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:39-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/suggested-format-ide-progress-report\u0022\u003ESuggested Format For IDE Progress Report\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"05\/31\/1996","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Investigational Device Exemption (IDE)","field_topics":"Premarket","topics-product":"Premarket, Investigational Device Exemption (IDE)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222023-08-10T16:04:01-04:00\u0022\u003E2023-08-10 16:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/thermal-endometrial-ablation-devices-submission-guidance-ide\u0022\u003EThermal Endometrial Ablation Devices (Submission Guidance for an IDE)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/13\/1996","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-17T15:40:12-04:00\u0022\u003E2020-03-17 15:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/reviewer-guidance-nebulizers-metered-dose-inhalers-spacers-and-actuators\u0022\u003EReviewer Guidance for Nebulizers, Metered Dose Inhalers, Spacers and Actuators\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/30\/1993","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-17T12:35:56-04:00\u0022\u003E2020-03-17 12:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/510k-checklist-sterile-lubricating-jelly-used-transurethral-surgical-instruments\u0022\u003E510(k) Checklist for Sterile Lubricating Jelly Used With Transurethral Surgical Instruments\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/18\/1994","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-17T13:05:11-04:00\u0022\u003E2020-03-17 13:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/addendum-guidance-premarket-notification-510k-submissions-sterilizers-intended-use-health-care\u0022\u003EAddendum to: Guidance on Premarket Notification [510(k)] Submissions for Sterilizers Intended for Use in Health Care Facilities\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/18\/1995","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-17T15:30:18-04:00\u0022\u003E2020-03-17 15:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/hysteroscopic-and-laparoscopic-insufflators-submission-guidance-510k\u0022\u003EHysteroscopic and Laparoscopic Insufflators: Submission Guidance for a 510(k)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/31\/1995","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-17T15:20:49-04:00\u0022\u003E2020-03-17 15:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-and-fda-establishing-and-maintaining-list-us-dairy-product-manufacturersprocessors\u0022\u003EGuidance for Industry and FDA: Establishing and Maintaining a List of U.S. Dairy Product Manufacturers\/Processors with Interest in Exporting to Chile\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/118782\/download\u0022\u003EPDF (64.85 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (64.85 KB) of Guidance for Industry and FDA: Establishing and Maintaining a List of U.S. Dairy Product Manufacturers\/Processors with Interest in Exporting to Chile\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/27\/2018","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Export","field_topics":"","topics-product":"Export","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2006-N-0183\u0022\u003EFDA-2006-N-0183\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-10T15:04:01-04:00\u0022\u003E2025-03-10 15:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-document-preparation-premarket-notification-510k-applications-exercise-equipment\u0022\u003EGuidance Document for the Preparation of Premarket Notification [510(K)] Applications for Exercise Equipment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72390\/download\u0022\u003EPDF (30.5 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (30.5 KB) of Guidance Document for the Preparation of Premarket Notification [510(K)] Applications for Exercise Equipment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/25\/1995","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-17T15:23:35-04:00\u0022\u003E2020-03-17 15:23\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-preparation-premarket-notification-extended-laparoscopy-devices-eld\u0022\u003EGuidance for the Preparation of a Premarket Notification for Extended Laparoscopy Devices (ELD)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72392\/download\u0022\u003EPDF (11.56 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (11.56 KB) of Guidance for the Preparation of a Premarket Notification for Extended Laparoscopy Devices (ELD)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/29\/1994","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-17T13:00:44-04:00\u0022\u003E2020-03-17 13:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/changes-or-modifications-during-conduct-clinical-investigation-final-guidance-industry-and-cdrh\u0022\u003EChanges or Modifications During the Conduct of a Clinical Investigation; Final Guidance for Industry and CDRH Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72429\/download\u0022\u003EPDF (506.78 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (506.78 KB) of Changes or Modifications During the Conduct of a Clinical Investigation; Final Guidance for Industry and CDRH Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/28\/2001","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Investigational Device Exemption (IDE)","field_topics":"Premarket","topics-product":"Premarket, Investigational Device Exemption (IDE)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222023-08-10T15:45:31-04:00\u0022\u003E2023-08-10 15:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-document-preparation-premarket-notification-510k-applications-heating-and-cooling-devices\u0022\u003EGuidance Document for the Preparation of Premarket Notification [510(k)] Applications for Heating and Cooling Devices\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72413\/download\u0022\u003EPDF (14.05 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (14.05 KB) of Guidance Document for the Preparation of Premarket Notification [510(k)] Applications for Heating and Cooling Devices\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/25\/1995","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-17T15:15:11-04:00\u0022\u003E2020-03-17 15:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-food-security-preventive-measures-importers-and-filers\u0022\u003EGuidance for Industry: Food Security Preventive Measures for Importers and Filers\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/01\/2007","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Import, Defense \u0026amp; Security","field_topics":"","topics-product":"Import, Defense \u0026amp; Security","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1926\u0022\u003EFDA-2020-D-1926\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:41-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-and-fda-letter-industry-state-and-local-food-regulators-and-inspectors-regarding\u0022\u003EGuidance for Industry and FDA: Letter to Industry, State and Local Food Regulators and Inspectors Regarding Web-based ALERT Training\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/22\/2007","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Industry Letter","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:41-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-content-premarket-notification-510k-submissions-piston-syringes\u0022\u003EGuidance on the Content of Premarket Notification [510(K)] Submissions for Piston Syringes\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/31\/1993","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-17T11:23:18-04:00\u0022\u003E2020-03-17 11:23\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-content-premarket-notifications-conventional-and-antimicrobial-foley-catheters\u0022\u003EGuidance for the Content of Premarket Notifications for Conventional and Antimicrobial Foley Catheters\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/11\/1994","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Antimicrobial Resistance","field_topics":"Premarket","topics-product":"Premarket, Antimicrobial Resistance","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-17T13:07:14-04:00\u0022\u003E2020-03-17 13:07\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/determination-intended-use-510k-devices-guidance-cdrh-staff-update-k98-1\u0022\u003EDetermination of Intended Use for 510(k) Devices - Guidance for CDRH Staff (Update to K98-1)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72446\/download\u0022\u003EPDF (275 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (275 KB) of Determination of Intended Use for 510(k) Devices - Guidance for CDRH Staff (Update to K98-1)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/02\/2002","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-19T10:00:09-04:00\u0022\u003E2020-03-19 10:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/immunotoxicity-testing-guidance\u0022\u003EImmunotoxicity Testing Guidance\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"05\/05\/1999","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-18T14:53:49-04:00\u0022\u003E2020-03-18 14:53\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pediatric-expertise-advisory-panels-guidance-industry-and-fda-staff\u0022\u003EPediatric Expertise for Advisory Panels - Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72451\/download\u0022\u003EPDF (39.46 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (39.46 KB) of Pediatric Expertise for Advisory Panels - Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/02\/2003","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Pediatric Product Development","field_topics":"Advisory Committees","topics-product":"Advisory Committees, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2003-D-0147\u0022\u003EFDA-2003-D-0147\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222024-04-08T11:36:04-04:00\u0022\u003E2024-04-08 11:36\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/otc-denture-cushions-pads-reliners-repair-kits-and-partially-fabricated-denture-kits-guidance\u0022\u003EOTC Denture Cushions, Pads, Reliners, Repair Kits, and Partially Fabricated Denture Kits - Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72467\/download\u0022\u003EPDF (93.73 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (93.73 KB) of OTC Denture Cushions, Pads, Reliners, Repair Kits, and Partially Fabricated Denture Kits - Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/17\/1998","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-P-5124\u0022\u003EFDA-2017-P-5124\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-02-28T12:25:17-05:00\u0022\u003E2020-02-28 12:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-content-premarket-notifications-ureteral-stents\u0022\u003EGuidance for the Content of Premarket Notifications for Ureteral Stents\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/09\/1993","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-17T11:05:03-04:00\u0022\u003E2020-03-17 11:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-content-premarket-notifications-biopsy-devices-used-gastroenterology-and-urology\u0022\u003EGuidance for the Content of Premarket Notifications for Biopsy Devices Used in Gastroenterology and Urology\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/09\/1993","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-17T11:10:08-04:00\u0022\u003E2020-03-17 11:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/revised-procedures-adding-lens-finishing-laboratories-approved-premarket-approval-applications-class\u0022\u003ERevised Procedures for Adding Lens Finishing Laboratories to Approved Premarket Approval Applications for Class III Rigid Gas Permeable Contact Lenses for Extended Wear - Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72479\/download\u0022\u003EPDF (46.55 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (46.55 KB) of Revised Procedures for Adding Lens Finishing Laboratories to Approved Premarket Approval Applications for Class III Rigid Gas Permeable Contact Lenses for Extended Wear - Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/10\/1998","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-18T12:30:30-04:00\u0022\u003E2020-03-18 12:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-document-preparation-premarket-notification-510k-applications-mechanical-and-powered\u0022\u003EGuidance Document for the Preparation of Premarket Notification [510(k)] Applications for Mechanical and Powered Wheelchairs, and Motorized Three-Wheeled Vehicles\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72525\/download\u0022\u003EPDF (19.46 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (19.46 KB) of Guidance Document for the Preparation of Premarket Notification [510(k)] Applications for Mechanical and Powered Wheelchairs, and Motorized Three-Wheeled Vehicles\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/25\/1995","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-17T15:15:06-04:00\u0022\u003E2020-03-17 15:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/device-labeling-guidance-g91-1-blue-book-memo\u0022\u003EDevice Labeling Guidance #G91-1 (Blue Book Memo)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/07\/1991","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Labeling","field_topics":"Premarket","topics-product":"Premarket, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-17T10:40:06-04:00\u0022\u003E2020-03-17 10:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-food-security-preventive-measures-guidance-retail-food-stores-and-food-service\u0022\u003EGuidance for Industry: Food Security Preventive Measures Guidance for Retail Food Stores and Food Service Establishments\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/01\/2007","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Defense \u0026amp; Security, Retail Food Protection","field_topics":"","topics-product":"Defense \u0026amp; Security, Retail Food Protection","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1927\u0022\u003EFDA-2020-D-1927\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:43-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/uniform-contraceptive-labeling-guidance-industry\u0022\u003EUniform Contraceptive Labeling - Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72591\/download\u0022\u003EPDF (93.67 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (93.67 KB) of Uniform Contraceptive Labeling - Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/22\/1998","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-18T12:30:02-04:00\u0022\u003E2020-03-18 12:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/testing-guidance-male-condoms-made-new-material-non-latex\u0022\u003ETesting Guidance for Male Condoms Made From New Material (Non-Latex)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"06\/28\/1995","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-17T15:15:09-04:00\u0022\u003E2020-03-17 15:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-document-washers-and-washer-disinfectors-intended-processing-reusable-medical-devices\u0022\u003EGuidance Document For Washers And Washer-Disinfectors Intended For Processing Reusable Medical Devices\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"06\/01\/1998","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-18T12:23:21-04:00\u0022\u003E2020-03-18 12:23\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/supplements-approved-applications-class-iii-medical-devices-use-published-literature-use-previously\u0022\u003ESupplements to Approved Applications for Class III Medical Devices: Use of Published Literature, Use of Previously Submitted Materials, and Priority Review : Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"05\/19\/1998","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-18T11:51:51-04:00\u0022\u003E2020-03-18 11:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-content-premarket-notifications-esophageal-and-tracheal-prostheses-guidance-industry\u0022\u003EGuidance For The Content Of Premarket Notifications For Esophageal And Tracheal Prostheses - Guidance For Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72632\/download\u0022\u003EPDF (52.1 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (52.1 KB) of Guidance For The Content Of Premarket Notifications For Esophageal And Tracheal Prostheses - Guidance For Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/27\/1998","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-18T11:52:04-04:00\u0022\u003E2020-03-18 11:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/draft-guidance-industry-regulatory-procedures-manual-chapter-9-subchapter-recommending-customs\u0022\u003EDraft Guidance for Industry: Regulatory Procedures Manual Chapter 9 Subchapter on Recommending Customs\u0026#039; Seizure and Destruction of Imported Human and Animal Food That Has Not Been Reconditioned\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/05\/2002","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Import","field_topics":"","topics-product":"Import","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"01\/06\/2003","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2002-D309\u0022\u003EFDA-2002-D309\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Animal \u0026amp; Veterinary, Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:43-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-guidelines-evaluation-hysteroscopic-sterilization-devices\u0022\u003EGuidance (\u0026#039;Guidelines\u0026#039;) for Evaluation of Hysteroscopic Sterilization Devices\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73025\/download\u0022\u003EPDF (19.79 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (19.79 KB) of Guidance (\u0026#039;Guidelines\u0026#039;) for Evaluation of Hysteroscopic Sterilization Devices\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/09\/1978","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-17T09:21:36-04:00\u0022\u003E2020-03-17 09:21\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/abbreviated-510k-program\u0022\u003EThe Abbreviated 510(k) Program: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72646\/download\u0022\u003EPDF (282.19 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (282.19 KB) of The Abbreviated 510(k) Program: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/13\/2019","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"510(k)","field_topics":"Premarket","topics-product":"Premarket, 510(k)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-4015\u0022\u003EFDA-2019-D-4015\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222019-09-13T09:15:52-04:00\u0022\u003E2019-09-13 09:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-preparation-food-contact-substance-notifications-administrative\u0022\u003EGuidance for Industry: Preparation of Food Contact Substance Notifications (Administrative)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/153218\/download\u0022\u003EPDF (307.86 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (307.86 KB) of Guidance for Industry: Preparation of Food Contact Substance Notifications (Administrative)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/18\/2021","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives, Food Contact Substances (FCS), Ingredients","field_topics":"","topics-product":"Food \u0026amp; Color Additives, Food Contact Substances (FCS), Ingredients","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2000-D-0138\u0022\u003EFDA-2000-D-0138\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T15:29:16-05:00\u0022\u003E2025-03-06 15:29\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-content-and-organization-premarket-notification-medical-laser\u0022\u003EGuidance on the Content and Organization of a Premarket Notification for a Medical Laser\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72668\/download\u0022\u003EPDF (71.58 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (71.58 KB) of Guidance on the Content and Organization of a Premarket Notification for a Medical Laser\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/31\/1995","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Radiology","field_topics":"Premarket","topics-product":"Premarket, Radiology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-17T15:10:02-04:00\u0022\u003E2020-03-17 15:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-preparation-premarket-submissions-food-contact-substances-chemistry\u0022\u003EGuidance for Industry: Preparation of Premarket Submissions for Food Contact Substances (Chemistry Recommendations)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"12\/01\/2007","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives, Ingredients","field_topics":"","topics-product":"Food \u0026amp; Color Additives, Ingredients","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1925\u0022\u003EFDA-2020-D-1925\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:45-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-preparation-food-contact-substance-notifications-toxicology-recommendations\u0022\u003EGuidance for Industry: Preparation of Food Contact Substance Notifications (Toxicology Recommendations)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/153239\/download\u0022\u003EPDF (329.6 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (329.6 KB) of Guidance for Industry: Preparation of Food Contact Substance Notifications (Toxicology Recommendations)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/20\/2021","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives, Food Contact Substances (FCS), Ingredients","field_topics":"","topics-product":"Food \u0026amp; Color Additives, Food Contact Substances (FCS), Ingredients","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1999-D-0062\u0022\u003EFDA-1999-D-0062\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T15:31:04-05:00\u0022\u003E2025-03-06 15:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-submitting-requests-under-21-cfr-17039-threshold-regulation-substances-used-food\u0022\u003EGuidance for Industry: Submitting Requests under 21 CFR 170.39 Threshold of Regulation for Substances Used in Food-Contact Articles\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"04\/01\/2005","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives, Ingredients","field_topics":"","topics-product":"Food \u0026amp; Color Additives, Ingredients","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-N-0730\u0022\u003EFDA-2013-N-0730\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:47-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-document-testing-non-articulating-mechanically-locked-modular-implant-components\u0022\u003EGuidance Document for Testing Non-Articulating, \u0026#039;Mechanically Locked\u0026#039;, Modular Implant Components\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72680\/download\u0022\u003EPDF (50.71 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (50.71 KB) of Guidance Document for Testing Non-Articulating, \u0026#039;Mechanically Locked\u0026#039;, Modular Implant Components\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/30\/1995","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-17T13:15:02-04:00\u0022\u003E2020-03-17 13:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/procedures-class-ii-device-exemptions-premarket-notification-guidance-industry-and-cdrh-staff\u0022\u003EProcedures for Class II Device Exemptions from Premarket Notification, Guidance for Industry and CDRH Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72685\/download\u0022\u003EPDF (20.6 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (20.6 KB) of Procedures for Class II Device Exemptions from Premarket Notification, Guidance for Industry and CDRH Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/18\/1998","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-N-1129\u0022\u003EFDA-2017-N-1129\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-02-28T12:25:15-05:00\u0022\u003E2020-02-28 12:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/metal-expandable-biliary-stents-premarket-notification-510k-submissions\u0022\u003EMetal Expandable Biliary Stents - Premarket Notification (510(k)) Submissions: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72693\/download\u0022\u003EPDF (442.2 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (442.2 KB) of Metal Expandable Biliary Stents - Premarket Notification (510(k)) Submissions: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/26\/2019","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Gastroenterology-Urology ","field_topics":"Premarket","topics-product":"Premarket, 510(k), Gastroenterology-Urology ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1771\u0022\u003EFDA-2018-D-1771\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222026-10-29T07:07:07-04:00\u0022\u003E2026-10-29 07:07\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/information-keratome-manufacturers-regarding-lasik-final-guidance-industry\u0022\u003EInformation for Keratome Manufacturers Regarding LASIK - Final Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72327\/download\u0022\u003EPDF (209.66 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (209.66 KB) of Information for Keratome Manufacturers Regarding LASIK - Final Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/20\/2001","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Postmarket","topics-product":"Postmarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-19T09:45:02-04:00\u0022\u003E2020-03-19 09:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/kit-certification-510ks\u0022\u003EKit Certification for 510(k)s\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"06\/30\/1997","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-24T15:35:42-04:00\u0022\u003E2020-03-24 15:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/convenience-kits-interim-regulatory-guidance\u0022\u003EConvenience Kits Interim Regulatory Guidance\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72720\/download\u0022\u003EPDF (31.23 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (31.23 KB) of Convenience Kits Interim Regulatory Guidance\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/19\/1997","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-18T11:15:08-04:00\u0022\u003E2020-03-18 11:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/non-invasive-blood-pressure-nibp-monitor-guidance\u0022\u003ENon-Invasive Blood Pressure (NIBP) Monitor Guidance\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/09\/1997","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-18T11:15:11-04:00\u0022\u003E2020-03-18 11:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-document-testing-orthopedic-implants-modified-metallic-surfaces-apposing-bone-or-bone\u0022\u003EGuidance Document for Testing Orthopedic Implants with Modified Metallic Surfaces Apposing Bone Or Bone Cement\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72781\/download\u0022\u003EPDF (26.73 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (26.73 KB) of Guidance Document for Testing Orthopedic Implants with Modified Metallic Surfaces Apposing Bone Or Bone Cement\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/27\/1994","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-17T12:55:05-04:00\u0022\u003E2020-03-17 12:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/reviewers-guidance-checklist-orthopedic-external-fixation-devices-version-5\u0022\u003EReviewers Guidance Checklist For Orthopedic External Fixation Devices Version #5\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72733\/download\u0022\u003EPDF (37.12 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (37.12 KB) of Reviewers Guidance Checklist For Orthopedic External Fixation Devices Version #5\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/20\/1997","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-19T10:10:19-04:00\u0022\u003E2020-03-19 10:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-food-security-preventive-measures-guidance-dairy-farms-bulk-milk-transporters-bulk\u0022\u003EGuidance for Industry: Food Security Preventive Measures Guidance for Dairy Farms, Bulk Milk Transporters, Bulk Milk Transfer Stations and Fluid Milk Processors\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/01\/2007","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Milk\/Milk Product","field_topics":"","topics-product":"Milk\/Milk Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1928\u0022\u003EFDA-2020-D-1928\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:49-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-preparing-claim-categorical-exclusion-or-environmental-assessment-submission-cfsan\u0022\u003EGuidance for Industry: Preparing a Claim of Categorical Exclusion or an Environmental Assessment for Submission to CFSAN\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"05\/16\/2006","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2003-D-0087\u0022\u003EFDA-2003-D-0087\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:49-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-food-security-preventive-measures-guidance-food-producers-processors-and\u0022\u003EGuidance for Industry: Food Security Preventive Measures Guidance for Food Producers, Processors, and Transporters\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/30\/2007","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Transportation","field_topics":"","topics-product":"Transportation","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1929\u0022\u003EFDA-2020-D-1929\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:51-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/510k-information-needed-hydroxyapatite-coated-orthopedic-implants\u0022\u003E510(K) Information Needed for Hydroxyapatite Coated Orthopedic Implants\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/19\/1997","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-18T10:45:26-04:00\u0022\u003E2020-03-18 10:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-appendix-preparing-claim-categorical-exclusion-or-environmental-assessment\u0022\u003EGuidance for Industry: Appendix A of Preparing a Claim of Categorical Exclusion or an Environmental Assessment for Submission to CFSAN \u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"05\/01\/2006","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:51-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-appendix-b-preparing-claim-categorical-exclusion-or-environmental-assessment\u0022\u003EGuidance for Industry: Appendix B for Preparing a Claim of Categorical Exclusion or an Environmental Assessment for Submission to CFSAN\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"05\/01\/2006","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:53-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-appendix-c-preparing-claim-categorical-exclusion-or-environmental-assessment\u0022\u003EGuidance for Industry: Appendix C of Preparing a Claim of Categorical Exclusion or an Environmental Assessment for Submission to CFSAN\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"05\/16\/2006","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:53-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-appendix-d-preparing-claim-categorical-exclusion-or-environmental-assessment\u0022\u003EGuidance for Industry: Appendix D of Preparing a Claim of Categorical Exclusion or an Environmental Assessment for Submission to CFSAN\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"05\/16\/2006","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:54-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-appendix-e-preparing-claim-categorical-exclusion-or-environmental-assessment\u0022\u003EGuidance for Industry: Appendix E of Preparing a Claim of Categorical Exclusion or an Environmental Assessment for Submission to CFSAN (40 CFR 1508.27)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"05\/16\/2006","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:55-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-preparing-claim-categorical-exclusion-or-environmental-assessment-submission-cfsan-1\u0022\u003EGuidance for Industry: Preparing a Claim of Categorical Exclusion or an Environmental Assessment for Submission to CFSAN - Attachment 1\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"05\/16\/2006","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:56-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-preparing-claim-categorical-exclusion-or-environmental-assessment-submission-cfsan-0\u0022\u003EGuidance for Industry: Preparing a Claim of Categorical Exclusion or an Environmental Assessment for Submission to CFSAN - Attachment 2\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"05\/16\/2006","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:56-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-templates-reporting-toxicology-data\u0022\u003EGuidance for Industry: Templates for Reporting Toxicology Data \u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"04\/11\/2005","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1941\u0022\u003EFDA-2020-D-1941\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:58-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-over-counter-otc-human-chorionic-gonadotropin-hcg-510ks-guidance-industry-and-fda\u0022\u003EGuidance for Over-the-Counter (OTC) Human Chorionic Gonadotropin (hCG) 510(k)s - Guidance for Industry and FDA Reviewers\/Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73757\/download\u0022\u003EPDF (63.86 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (63.86 KB) of Guidance for Over-the-Counter (OTC) Human Chorionic Gonadotropin (hCG) 510(k)s - Guidance for Industry and FDA Reviewers\/Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/21\/2000","field_issuing_office_taxonomy":"Center for Devices and Radiological Health,Office of Product Evaluation and Quality","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-24T15:25:26-04:00\u0022\u003E2020-03-24 15:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-recommendations-early-food-safety-evaluation-new-non-pesticidal-proteins-produced\u0022\u003EGuidance for Industry: Recommendations for the Early Food Safety Evaluation of New Non-Pesticidal Proteins Produced by New Plant Varieties Intended for Food Use\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"06\/19\/2006","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Bioengineering \/ GMOs","field_topics":"","topics-product":"Bioengineering \/ GMOs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-D-0044\u0022\u003EFDA-2004-D-0044\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:02:58-04:00\u0022\u003E2024-10-01 07:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/radiation-safety-considerations-x-ray-equipment-designed-hand-held-use\u0022\u003ERadiation Safety Considerations for X-Ray Equipment Designed for Hand-Held Use\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73890\/download\u0022\u003EPDF (163.6 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (163.6 KB) of Radiation Safety Considerations for X-Ray Equipment Designed for Hand-Held Use\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/23\/2008","field_issuing_office_taxonomy":"Center for Devices and Radiological Health,Office of Product Evaluation and Quality,Office of In Vitro Diagnostics and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Postmarket","topics-product":"Postmarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-24T12:06:45-04:00\u0022\u003E2020-03-24 12:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/procedures-renewal-and-amendment-certain-laser-light-show-variances-laser-notice-55\u0022\u003EProcedures for Renewal and Amendment of Certain Laser Light Show Variances (Laser Notice 55)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73900\/download\u0022\u003EPDF (230.36 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (230.36 KB) of Procedures for Renewal and Amendment of Certain Laser Light Show Variances (Laser Notice 55)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/24\/2007","field_issuing_office_taxonomy":"Center for Devices and Radiological Health,Office of Product Evaluation and Quality,Office of In Vitro Diagnostics and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222024-10-23T11:03:16-04:00\u0022\u003E2024-10-23 11:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/compliance-guide-cabinet-x-ray-systems\u0022\u003ECompliance Guide for Cabinet X-Ray Systems\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73918\/download\u0022\u003EPDF (624.92 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (624.92 KB) of Compliance Guide for Cabinet X-Ray Systems\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/18\/2007","field_issuing_office_taxonomy":"Center for Devices and Radiological Health,Office of Product Evaluation and Quality,Office of In Vitro Diagnostics and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-24T15:00:21-04:00\u0022\u003E2020-03-24 15:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/performance-standard-diagnostic-x-ray-systems-and-their-major-components-21cfr-102030-102031-102032\u0022\u003EPerformance Standard for Diagnostic X-Ray Systems and Their Major Components (21CFR 1020.30, 1020.31, 1020.32, 1020.33); Small Entity Compliance Guide\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73941\/download\u0022\u003EPDF (371.39 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (371.39 KB) of Performance Standard for Diagnostic X-Ray Systems and Their Major Components (21CFR 1020.30, 1020.31, 1020.32, 1020.33); Small Entity Compliance Guide\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/21\/2023","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Radiology","field_topics":"","topics-product":"Radiology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2001-N-0178\u0022\u003EFDA-2001-N-0178\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222023-02-21T12:18:16-05:00\u0022\u003E2023-02-21 12:18\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/approval-alternate-means-labeling-laser-products-laser-notice-53\u0022\u003EApproval of Alternate Means of Labeling for Laser Products (Laser Notice 53)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73953\/download\u0022\u003EPDF (31.62 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (31.62 KB) of Approval of Alternate Means of Labeling for Laser Products (Laser Notice 53)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/22\/2007","field_issuing_office_taxonomy":"Center for Devices and Radiological Health,Office of Product Evaluation and Quality,Office of In Vitro Diagnostics and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-24T15:00:28-04:00\u0022\u003E2020-03-24 15:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/exemption-reporting-and-recordkeeping-requirements-low-power-laser-products-laser-notice-54\u0022\u003EExemption from Reporting and Recordkeeping Requirements for Low Power Laser Products (Laser Notice 54): Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/74001\/download\u0022\u003EPDF (455.32 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (455.32 KB) of Exemption from Reporting and Recordkeeping Requirements for Low Power Laser Products (Laser Notice 54): Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/05\/2006","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-19T11:00:29-04:00\u0022\u003E2020-03-19 11:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/applicability-performance-standard-high-intensity-mercury-vapor-discharge-lamps-21-cfr-104030\u0022\u003EApplicability of the Performance Standard for High-Intensity Mercury Vapor Discharge Lamps (21 CFR 1040.30)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/74008\/download\u0022\u003EPDF (31.82 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (31.82 KB) of Applicability of the Performance Standard for High-Intensity Mercury Vapor Discharge Lamps (21 CFR 1040.30)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/05\/2005","field_issuing_office_taxonomy":"Center for Devices and Radiological Health,Office of Product Evaluation and Quality,Office of In Vitro Diagnostics and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-24T15:00:03-04:00\u0022\u003E2020-03-24 15:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/responsibilities-laser-light-show-projector-manufacturers-dealers-and-distributors-laser-notice-51\u0022\u003EResponsibilities of Laser Light Show Projector Manufacturers, Dealers, and Distributors; (Laser Notice 51)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/74032\/download\u0022\u003EPDF (211.08 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (211.08 KB) of Responsibilities of Laser Light Show Projector Manufacturers, Dealers, and Distributors; (Laser Notice 51)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/26\/2001","field_issuing_office_taxonomy":"Center for Devices and Radiological Health,Office of Product Evaluation and Quality,Office of In Vitro Diagnostics and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-24T15:23:07-04:00\u0022\u003E2020-03-24 15:23\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clarification-radiation-control-regulations-diagnostic-x-ray-equipment-fda-89-8221\u0022\u003EClarification of Radiation Control Regulations for Diagnostic X-Ray Equipment (FDA 89-8221)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1989","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"Radiology","field_topics":"","topics-product":"Radiology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222019-02-09T12:24:02-05:00\u0022\u003E2019-02-09 12:24\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-entity-compliance-guide-structurefunction-claims\u0022\u003ESmall Entity Compliance Guide on Structure\/Function Claims\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"01\/09\/2002","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1998-N-0071\u0022\u003EFDA-1998-N-0071\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Human Foods Program","field_regulated_product_field":"Dietary Supplements","changed":"\u003Ctime datetime=\u00222024-10-01T14:47:07-04:00\u0022\u003E2024-10-01 14:47\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/prospective-manufacturers-barrier-devices-used-during-oral-sex-std-protection\u0022\u003EProspective Manufacturers of Barrier Devices Used During Oral Sex for STD Protection\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/74267\/download\u0022\u003EPDF (79.74 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (79.74 KB) of Prospective Manufacturers of Barrier Devices Used During Oral Sex for STD Protection\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/30\/1996","field_issuing_office_taxonomy":"Center for Devices and Radiological Health,Office of Product Evaluation and Quality","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-24T15:40:15-04:00\u0022\u003E2020-03-24 15:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/variance-manufacturer-report-number-format-no-5\u0022\u003EVariance from Manufacturer Report Number Format - No. 5\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/11\/1996","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Postmarket","topics-product":"Postmarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222021-04-27T09:56:03-04:00\u0022\u003E2021-04-27 09:56\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/variance-manufacturer-report-number-format-mdr-letter\u0022\u003EVariance from Manufacturer Report Number Format [MDR letter]\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/15\/1996","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Adverse Event Reporting System (FAERS)","topics-product":"Adverse Event Reporting System (FAERS), ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222021-04-27T10:00:21-04:00\u0022\u003E2021-04-27 10:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-fumonisin-levels-human-foods-and-animal-feeds\u0022\u003EGuidance for Industry: Fumonisin Levels in Human Foods and Animal Feeds\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/09\/2001","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Animal \u0026amp; Veterinary, Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:00-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/inspection-and-field-testing-radiation-emitting-electronic-products-attachment\u0022\u003EInspection and Field Testing of Radiation-Emitting Electronic Products: Attachment A\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/30\/2007","field_issuing_office_taxonomy":"Center for Devices and Radiological Health,Office of Product Evaluation and Quality,Office of In Vitro Diagnostics and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Postmarket","topics-product":"Postmarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-24T12:15:06-04:00\u0022\u003E2020-03-24 12:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/inspection-and-field-testing-radiation-emitting-electronic-products-attachment-c-specific\u0022\u003EInspection and Field Testing of Radiation-Emitting Electronic Products: Attachment C: Specific Instructions for Sunlamp Product Inspections and Tests\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/30\/2007","field_issuing_office_taxonomy":"Center for Devices and Radiological Health,Office of Product Evaluation and Quality,Office of In Vitro Diagnostics and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-24T12:22:31-04:00\u0022\u003E2020-03-24 12:22\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-notice-growers-food-manufacturers-food-warehouse-managers-and-transporters-food\u0022\u003EGuidance for Industry: Notice to Growers, Food Manufacturers, Food Warehouse Managers, and Transporters of Food Products on Decontamination of Transport Vehicles\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/01\/2005","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Transportation","field_topics":"","topics-product":"Transportation","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2005-D-0337\u0022\u003EFDA-2005-D-0337\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:00-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-referral-program-food-and-drug-administration-national-oceanic-and-atmospheric\u0022\u003EGuidance for Industry: Referral Program from the Food and Drug Administration to the National Oceanic and Atmospheric Administration Seafood Inspection Program for the Certification of Fish and Fishery Products for Export to the European Union and the European Free Trade Association\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/11\/2009","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Export, Seafood\/Seafood Product","field_topics":"","topics-product":"Export, Seafood\/Seafood Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-D-0043\u0022\u003EFDA-2004-D-0043\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:02-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-seafood-list-fdas-guide-determine-acceptable-seafood-names\u0022\u003EGuidance for Industry: The Seafood List FDA\u2019s Guide to Determine Acceptable Seafood Names\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/171514\/download\u0022\u003EPDF (371.78 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (371.78 KB) of Guidance for Industry: The Seafood List FDA\u2019s Guide to Determine Acceptable Seafood Names\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/22\/2023","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Seafood\/Seafood Product","field_topics":"","topics-product":"Seafood\/Seafood Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1994-D-0221\u0022\u003EFDA-1994-D-0221\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222026-08-17T07:59:04-04:00\u0022\u003E2026-08-17 07:59\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-measures-address-risk-contamination-salmonella-species-food-containing-peanut\u0022\u003EGuidance for Industry: Measures to Address the Risk for Contamination by Salmonella Species in Food Containing a Peanut-Derived Product as an Ingredient\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/11\/2009","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Nuts \u0026amp; Nut Products, Salmonella","field_topics":"","topics-product":"Nuts \u0026amp; Nut Products, Salmonella","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0060\u0022\u003EFDA-2009-D-0060\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-11-04T11:13:31-05:00\u0022\u003E2024-11-04 11:13\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/chapter-1-general\u0022\u003EChapter 1 - General\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222019-02-09T12:04:43-05:00\u0022\u003E2019-02-09 12:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/chapter-2-biologics\u0022\u003EChapter 2 - Biologics\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"12\/13\/2019","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-24T14:51:46-04:00\u0022\u003E2024-10-24 14:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/chapter-3-devices\u0022\u003EChapter 3 - Devices\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222022-04-22T09:32:14-04:00\u0022\u003E2022-04-22 09:32\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-270100-final-container-labels-allergenic-extracts-containing-glycerin-reporting-changes\u0022\u003ECPG Sec. 270.100 Final Container Labels - Allergenic Extracts Containing Glycerin; Reporting Changes\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/31\/2000","field_issuing_office_taxonomy":"Office of Regulatory Affairs","field_health_topics":"","term_node_tid":"Allergenics","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Allergenics","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-10-24T14:52:32-04:00\u0022\u003E2024-10-24 14:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/chapter-4-human-drugs\u0022\u003EChapter 4 - Human Drugs\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222019-02-09T12:05:12-05:00\u0022\u003E2019-02-09 12:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-use-recycled-plastics-food-packaging-chemistry-considerations\u0022\u003EGuidance for Industry: Use of Recycled Plastics in Food Packaging (Chemistry Considerations)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/150792\/download\u0022\u003EPDF (338.92 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (338.92 KB) of Guidance for Industry: Use of Recycled Plastics in Food Packaging (Chemistry Considerations)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/15\/2021","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives, Food Contact Substances (FCS)","field_topics":"","topics-product":"Food \u0026amp; Color Additives, Food Contact Substances (FCS)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1456\u0022\u003EFDA-2020-D-1456\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T16:34:31-05:00\u0022\u003E2025-03-06 16:34\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/demonstration-comparability-human-biological-products-including-therapeutic-biotechnology-derived\u0022\u003EDemonstration of Comparability of Human Biological Products, Including Therapeutic Biotechnology-derived Products\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/31\/1996","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-06-04T06:05:11-04:00\u0022\u003E2019-06-04 06:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/development-new-stereoisomeric-drugs\u0022\u003EDevelopment of New Stereoisomeric Drugs\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"05\/01\/1992","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"","changed":"\u003Ctime datetime=\u00222020-04-28T13:10:07-04:00\u0022\u003E2020-04-28 13:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-1991-letter-seafood-manufacturers-regarding-fraudulent-practice-including-glaze\u0022\u003EGuidance for Industry: 1991 Letter to Seafood Manufacturers Regarding the Fraudulent Practice of Including Glaze (ice) as Part of the Weight of Frozen Seafood\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/18\/2009","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Seafood\/Seafood Product","field_topics":"","topics-product":"Seafood\/Seafood Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1923\u0022\u003EFDA-2020-D-1923\u003C\/a\u003E","field_communication_type":"Industry Letter","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:05-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/use-investigational-products-when-subjects-enter-second-institution\u0022\u003EUse of Investigational Products When Subjects Enter a Second Institution: Guidance for Institutional Review Boards and Clinical Investigators\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"01\/01\/1998","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP)","field_topics":"","topics-product":"Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Information Sheet","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222019-04-18T12:20:09-04:00\u0022\u003E2019-04-18 12:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/form-fda-3674-certifications-accompany-drug-biological-product-and-device-applicationssubmissions\u0022\u003EForm FDA 3674 - Certifications To Accompany Drug, Biological Product, and Device Applications\/Submissions: Guidance for Sponsors, Industry, Researchers, Investigators, and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/105405\/download\u0022\u003EPDF (51.64 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (51.64 KB) of Form FDA 3674 - Certifications To Accompany Drug, Biological Product, and Device Applications\/Submissions: Guidance for Sponsors, Industry, Researchers, Investigators, and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/07\/2017","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222026-07-20T09:37:46-04:00\u0022\u003E2026-07-20 09:37\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/emergency-use-investigational-drug-or-biologic\u0022\u003EEmergency Use of an Investigational Drug or Biologic: Guidance for Institutional Review Boards and Clinical Investigators\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"01\/01\/1998","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP)","field_topics":"","topics-product":"Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Information Sheet","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222025-02-03T15:21:12-05:00\u0022\u003E2025-02-03 15:21\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-205100-deleted-122198-obsolete\u0022\u003ECPG Sec. 205.100 Deleted 12\/21\/98, Obsolete\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"12\/20\/1998","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222018-12-01T10:01:16-05:00\u0022\u003E2018-12-01 10:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/evaluation-sex-differences-clinical-investigations\u0022\u003EEvaluation of Sex Differences in Clinical Investigations: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/185362\/download\u0022\u003EPDF (209.31 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (209.31 KB) of Evaluation of Sex Differences in Clinical Investigations: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/20\/2025","field_issuing_office_taxonomy":"Office of the Commissioner,Office of the Chief Medical Officer,Office of Clinical Policy","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP)","field_topics":"","topics-product":"Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-S-0610 \u0022\u003EFDA-2013-S-0610 \u003C\/a\u003E","field_communication_type":"Information Sheet","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222025-02-05T08:51:07-05:00\u0022\u003E2025-02-05 08:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/process-handling-referrals-fda-under-21-cfr-5054-additional-safeguards-children-clinical\u0022\u003EProcess for Handling Referrals to FDA Under 21 CFR 50.54 - Additional Safeguards for Children in Clinical Investigations: Guidance for Clinical Investigators, Institutional Review Boards and Sponsors\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/75222\/download\u0022\u003EPDF (115.95 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (115.95 KB) of Process for Handling Referrals to FDA Under 21 CFR 50.54 - Additional Safeguards for Children in Clinical Investigations: Guidance for Clinical Investigators, Institutional Review Boards and Sponsors\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/01\/2006","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Policy, Legislation, and International Affairs,Office of Policy","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP), Pediatric Product Development","field_topics":"","topics-product":"Good Clinical Practice (GCP), Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222024-08-09T22:18:55-04:00\u0022\u003E2024-08-09 22:18\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-210100-deleted-42699-outdated-and-obsolete\u0022\u003ECPG Sec. 210.100 Deleted 4\/26\/99, Outdated and Obsolete\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"04\/25\/1999","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222018-12-01T10:01:28-05:00\u0022\u003E2018-12-01 10:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-345300-menstrual-sponges\u0022\u003ECPG Sec. 345.300 Menstrual Sponges\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Physical Medicine","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Physical Medicine","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222021-05-05T14:11:09-04:00\u0022\u003E2021-05-05 14:11\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-370100-cytotoxic-testing-allergic-diseases\u0022\u003ECPG Sec. 370.100 Cytotoxic Testing for Allergic Diseases\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Clinical Chemistry \u0026amp; Clinical Toxicology ","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Clinical Chemistry \u0026amp; Clinical Toxicology ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222021-05-05T14:20:22-04:00\u0022\u003E2021-05-05 14:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/nonclinical-pharmacologytoxicology-development-topical-drugs-intended-prevent-transmission-sexually\u0022\u003ENonclinical Pharmacology\/Toxicology Development of Topical Drugs Intended to Prevent the Transmission of Sexually Transmitted Diseases (STD) and\/or for the Development of Drugs Intended to Act as Vaginal Contraceptives\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"06\/30\/2005","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"Pharmacology\/Toxicology","field_topics":"","topics-product":"Pharmacology\/Toxicology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"","changed":"\u003Ctime datetime=\u00222018-12-01T13:24:57-05:00\u0022\u003E2018-12-01 13:24\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/submission-and-resolution-formal-disputes-regarding-timeliness-premarket-review-combination-product\u0022\u003ESubmission and Resolution of Formal Disputes Regarding the Timeliness of Premarket Review of a Combination Product: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/76420\/download\u0022\u003EPDF (101.25 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (101.25 KB) of Submission and Resolution of Formal Disputes Regarding the Timeliness of Premarket Review of a Combination Product: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/03\/2004","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products","field_health_topics":"","term_node_tid":"Combination Products","field_topics":"","topics-product":"Combination Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-D-0502\u0022\u003EFDA-2004-D-0502\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222024-08-09T20:54:21-04:00\u0022\u003E2024-08-09 20:54\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/application-user-fees-combination-products\u0022\u003EApplication User Fees for Combination Products: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/76413\/download\u0022\u003EPDF (314.74 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (314.74 KB) of Application User Fees for Combination Products: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/16\/2024","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products","field_health_topics":"","term_node_tid":"Combination Products, Pediatric Product Development","field_topics":"User Fees","topics-product":"User Fees, Combination Products, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-D-0371\u0022\u003EFDA-2004-D-0371\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222024-07-16T08:44:31-04:00\u0022\u003E2024-07-16 08:44\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-and-fda-advisory-levels-deoxynivalenol-don-finished-wheat-products-human\u0022\u003EGuidance for Industry and FDA: Advisory Levels for Deoxynivalenol (DON) in Finished Wheat Products for Human Consumption and Grains and Grain By-Products used for Animal Feed\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/07\/2010","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Animal Feed, Grain\/Grain Product","field_topics":"","topics-product":"Animal Feed, Grain\/Grain Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Animal \u0026amp; Veterinary, Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:06-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/questions-and-answers-current-good-manufacturing-practice-questions-and-answers-current-good\u0022\u003EQuestions and Answers on Current Good Manufacturing Practice Questions and Answers on Current Good Manufacturing Practice Requirements | General Provisions\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"04\/30\/2009","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6821 \u0022\u003EFDA-2017-D-6821 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-11-16T13:57:11-05:00\u0022\u003E2022-11-16 13:57\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/early-development-considerations-innovative-combination-products\u0022\u003EEarly Development Considerations for Innovative Combination Products: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/75273\/download\u0022\u003EPDF (129.58 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (129.58 KB) of Early Development Considerations for Innovative Combination Products: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/01\/2006","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products","field_health_topics":"","term_node_tid":"Combination Products","field_topics":"","topics-product":"Combination Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1455\u0022\u003EFDA-2020-D-1455\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222021-05-13T16:05:12-04:00\u0022\u003E2021-05-13 16:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/devices-used-process-human-cells-tissues-and-cellular-and-tissue-based-products-hctps\u0022\u003EDevices Used to Process Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\/Ps): Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/148619\/download\u0022\u003EPDF (28.52 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (28.52 KB) of Devices Used to Process Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\/Ps): Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/01\/2007","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products","field_health_topics":"","term_node_tid":"Combination Products","field_topics":"","topics-product":"Combination Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1407\u0022\u003EFDA-2020-D-1407\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222021-05-13T10:26:03-04:00\u0022\u003E2021-05-13 10:26\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/how-write-request-designation-rfd\u0022\u003EHow to Write a Request for Designation (RFD): Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/80495\/download\u0022\u003EPDF (89.81 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (89.81 KB) of How to Write a Request for Designation (RFD): Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/14\/2011","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products","field_health_topics":"","term_node_tid":"Combination Products","field_topics":"","topics-product":"Combination Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0214\u0022\u003EFDA-2011-D-0214\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222021-05-13T15:46:18-04:00\u0022\u003E2021-05-13 15:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-dear-manufacturer-letter-regarding-front-package-symbols\u0022\u003EGuidance for Industry: Dear Manufacturer Letter Regarding Front-of-Package Symbols\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"12\/01\/2008","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1924\u0022\u003EFDA-2020-D-1924\u003C\/a\u003E","field_communication_type":"Industry Letter","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:06-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/standards-securing-drug-supply-chain-standardized-numerical-identification-prescription-drug\u0022\u003EStandards for Securing the Drug Supply Chain - Standardized Numerical Identification for Prescription Drug Packages: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/78317\/download\u0022\u003EPDF (60.67 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (60.67 KB) of Standards for Securing the Drug Supply Chain - Standardized Numerical Identification for Prescription Drug Packages: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/28\/2010","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222024-11-14T16:25:24-05:00\u0022\u003E2024-11-14 16:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/using-centralized-irb-review-process-multicenter-clinical-trials\u0022\u003EUsing a Centralized IRB Review Process in Multicenter Clinical Trials: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/75329\/download\u0022\u003EPDF (734.96 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (734.96 KB) of Using a Centralized IRB Review Process in Multicenter Clinical Trials: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/16\/2006","field_issuing_office_taxonomy":"Office of Regulatory Affairs\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Good Clinical Practice (GCP)","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Administrative \/ Procedural, Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2005-D-0443\u0022\u003EFDA-2005-D-0443\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222023-09-29T13:05:49-04:00\u0022\u003E2023-09-29 13:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-540650-uneviscerated-fish-products-are-salt-cured-dried-or-smoked-revised\u0022\u003ECPG Sec 540.650 Uneviscerated Fish Products that are Salt-cured, Dried, or Smoked (Revised)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Seeds","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Seeds","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:42:48-05:00\u0022\u003E2025-03-06 21:42\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/current-good-manufacturing-practice-requirements-combination-products\u0022\u003ECurrent Good Manufacturing Practice Requirements for Combination Products: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/90425\/download\u0022\u003EPDF (435.02 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (435.02 KB) of Current Good Manufacturing Practice Requirements for Combination Products: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/11\/2017","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Compounding, Pharmaceutical Quality, Current Good Manufacturing Practice (CGMP)","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Compounding, Pharmaceutical Quality, Current Good Manufacturing Practice (CGMP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"03\/30\/2015","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-0198\u0022\u003EFDA-2015-D-0198\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222024-11-14T16:25:47-05:00\u0022\u003E2024-11-14 16:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/supac-ir-questions-and-answers-about-supac-ir-guidance\u0022\u003ESUPAC-IR Questions and Answers about SUPAC-IR Guidance\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/18\/1997","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC)","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-05T11:45:13-04:00\u0022\u003E2020-05-05 11:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-recommendations-submission-chemical-and-technological-data-direct-food-additive\u0022\u003EGuidance for Industry: Recommendations for Submission of Chemical and Technological Data for Direct Food Additive Petitions\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/22\/2009","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1922\u0022\u003EFDA-2020-D-1922\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-03T13:36:08-04:00\u0022\u003E2024-10-03 13:36\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/establishment-and-operation-clinical-trial-data-monitoring-committees\u0022\u003EEstablishment and Operation of Clinical Trial Data Monitoring Committees: Guidance for Clinical Trial Sponsors\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/75398\/download\u0022\u003EPDF (395.28 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (395.28 KB) of Establishment and Operation of Clinical Trial Data Monitoring Committees: Guidance for Clinical Trial Sponsors\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/28\/2006","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Good Clinical Practice (GCP)","field_topics":"","topics-product":"Clinical - Medical, Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2001-D-0219\u0022\u003EFDA-2001-D-0219\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222021-12-03T12:16:04-05:00\u0022\u003E2021-12-03 12:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/part-11-electronic-records-electronic-signatures-scope-and-application\u0022\u003EPart 11, Electronic Records; Electronic Signatures - Scope and Application: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/75414\/download\u0022\u003EPDF (43.9 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (43.9 KB) of Part 11, Electronic Records; Electronic Signatures - Scope and Application: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/05\/2003","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003ECenter for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Current Good Manufacturing Practice (CGMP), Good Clinical Practice (GCP), Food \u0026amp; Color Additives","field_topics":"Postmarket, Compliance, Electronic Submissions, Investigation \u0026amp; Enforcement","topics-product":"Postmarket, Compliance, Electronic Submissions, Investigation \u0026amp; Enforcement, Administrative \/ Procedural, Current Good Manufacturing Practice (CGMP), Good Clinical Practice (GCP), Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2003-D-0143\u0022\u003EFDA-2003-D-0143\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:08-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/emergency-use-authorization-medical-products-and-related-authorities\u0022\u003EEmergency Use Authorization of Medical Products and Related Authorities: Guidance for Industry and Other Stakeholders\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/97321\/download\u0022\u003EPDF (364.64 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (364.64 KB) of Emergency Use Authorization of Medical Products and Related Authorities: Guidance for Industry and Other Stakeholders\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/13\/2017","field_issuing_office_taxonomy":"Office of the Commissioner,Office of the Chief Scientist,Office of Counterterrorism and Emerging Threats","field_health_topics":"","term_node_tid":"","field_topics":"Premarket, Emergencies","topics-product":"Premarket, Emergencies, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"06\/04\/2016","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-1025\u0022\u003EFDA-2016-D-1025\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222024-08-09T21:19:29-04:00\u0022\u003E2024-08-09 21:19\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/using-electronic-means-distribute-certain-product-information\u0022\u003EUsing Electronic Means to Distribute Certain Product Information: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/2006","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Policy, Legislation, and International Affairs,Office of Policy","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Food \u0026amp; Color Additives","field_topics":"","topics-product":"Administrative \/ Procedural, Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222024-08-09T20:22:46-04:00\u0022\u003E2024-08-09 20:22\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/direct-final-rule-procedures\u0022\u003EDirect Final Rule Procedures: Guidance for FDA and Industry\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/20\/1997","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Policy, Legislation, and International Affairs,Office of Policy","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222024-09-04T16:36:32-04:00\u0022\u003E2024-09-04 16:36\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/fda-export-certification\u0022\u003EFDA Export Certification: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/151701\/download\u0022\u003EPDF (344.56 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (344.56 KB) of FDA Export Certification: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/20\/2021","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program\u003Cbr\u003E\u003Cbr\u003ECenter for Veterinary Medicine","field_health_topics":"","term_node_tid":"Export, Import","field_topics":"","topics-product":"Export, Import","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Drugs, Food \u0026amp; Beverages, Medical Devices","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:09-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/institutional-review-boards-frequently-asked-questions\u0022\u003EInstitutional Review Boards Frequently Asked Questions: Guidance for Institutional Review Boards and Clinical Investigators\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/05\/2025","field_issuing_office_taxonomy":"Office of the Commissioner,Office of the Chief Medical Officer,Office of Clinical Policy","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP), Pediatric Product Development","field_topics":"","topics-product":"Good Clinical Practice (GCP), Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Information Sheet","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222025-02-05T11:35:16-05:00\u0022\u003E2025-02-05 11:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cooperative-research\u0022\u003ECooperative Research: Guidance for Institutional Review Boards and Clinical Investigators\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"01\/01\/1998","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP)","field_topics":"","topics-product":"Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Information Sheet","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222020-01-21T14:30:03-05:00\u0022\u003E2020-01-21 14:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/non-local-irb-review\u0022\u003ENon-local IRB Review : Guidance for Institutional Review Boards and Clinical Investigators\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"01\/01\/1998","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP)","field_topics":"","topics-product":"Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Information Sheet","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222020-01-21T14:30:40-05:00\u0022\u003E2020-01-21 14:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/sponsor-investigator-irb-interrelationship\u0022\u003ESponsor - Investigator - IRB Interrelationship: Guidance for Institutional Review Boards and Clinical Investigators\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"01\/01\/1998","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP)","field_topics":"","topics-product":"Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Information Sheet","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222019-04-18T12:05:02-04:00\u0022\u003E2019-04-18 12:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recruiting-study-subjects\u0022\u003ERecruiting Study Subjects: Guidance for Institutional Review Boards and Clinical Investigators\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"01\/01\/1998","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP)","field_topics":"","topics-product":"Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Information Sheet","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222019-04-18T11:55:05-04:00\u0022\u003E2019-04-18 11:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/payment-and-reimbursement-research-subjects\u0022\u003EPayment and Reimbursement to Research Subjects: Guidance for Institutional Review Boards and Clinical Investigators\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"01\/29\/2018","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP)","field_topics":"","topics-product":"Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Information Sheet","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222019-04-18T11:50:08-04:00\u0022\u003E2019-04-18 11:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/screening-tests-prior-study-enrollment\u0022\u003EScreening Tests Prior to Study Enrollment: Guidance for Institutional Review Boards and Clinical Investigators\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"01\/01\/1998","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP)","field_topics":"","topics-product":"Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Information Sheet","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222019-04-18T12:00:06-04:00\u0022\u003E2019-04-18 12:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/independent-consultants-biotechnology-clinical-trial-protocols\u0022\u003EIndependent Consultants for Biotechnology Clinical Trial Protocols: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/75135\/download\u0022\u003EPDF (39.87 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (39.87 KB) of Independent Consultants for Biotechnology Clinical Trial Protocols: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/19\/2004","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Good Clinical Practice (GCP)","field_topics":"","topics-product":"Administrative \/ Procedural, Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2003-D-0288\u0022\u003EFDA-2003-D-0288\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T13:40:20-04:00\u0022\u003E2020-04-24 13:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/ich-q3c-maintenance-procedures-guidance-industry-q3c-impurities-residual-solvents\u0022\u003EICH Q3C Maintenance Procedures for the Guidance for Industry Q3C Impurities: Residual Solvents\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/25\/2017","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-N-0327 (Cumene) FDA-2015-D-3474 (Triethylamine\/Methylisobutylketone) 4 Guidances listed under this Document:Triethylamine\/Methylisobutylketone - pdf on web Tetrahydrofuran (THF) - pdf ON web; Docket #2001B-0431 N-Methylpyrrolidone (NMP) - pdf ON\u0022\u003EFDA-2010-N-0327 (Cumene) FDA-2015-D-3474 (Triethylamine\/Methylisobutylketone) 4 Guidances listed under this Document:Triethylamine\/Methylisobutylketone - pdf on web Tetrahydrofuran (THF) - pdf ON web; Docket #2001B-0431 N-Methylpyrrolidone (NMP) - pdf ON\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-26T08:55:07-04:00\u0022\u003E2020-05-26 08:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q6a-specifications-test-procedures-and-acceptance-criteria-new-drug-substances-and-new-drug-products\u0022\u003EQ6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"12\/29\/2000","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1997-D-0005\u0022\u003EFDA-1997-D-0005\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-14T17:05:10-04:00\u0022\u003E2020-04-14 17:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-555320-listeria-monocytogenes\u0022\u003ECPG Sec 555.320 Listeria monocytogenes\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/01\/2008","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T15:40:17-04:00\u0022\u003E2025-03-17 15:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/information-disclosure-manufacturers-assemblers-diagnostic-x-ray-systems-guidance-industry-and-fda\u0022\u003EInformation Disclosure by Manufacturers to Assemblers for Diagnostic X-ray Systems - Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/76019\/download\u0022\u003EPDF (41.73 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (41.73 KB) of Information Disclosure by Manufacturers to Assemblers for Diagnostic X-ray Systems - Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/04\/2003","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Postmarket","topics-product":"Postmarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-19T10:15:05-04:00\u0022\u003E2020-03-19 10:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guideline-submitting-supporting-documentation-drug-applications-manufacture-drug-products\u0022\u003EGUIDELINE FOR SUBMITTING SUPPORTING DOCUMENTATION IN DRUG APPLICATIONS FOR THE MANUFACTURE OF DRUG PRODUCTS\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/131685\/download\u0022\u003EPDF (739.87 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (739.87 KB) of GUIDELINE FOR SUBMITTING SUPPORTING DOCUMENTATION IN DRUG APPLICATIONS FOR THE MANUFACTURE OF DRUG PRODUCTS\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/01\/1987","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1985-D-0033 \u0022\u003EFDA-1985-D-0033 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-10-16T14:07:52-04:00\u0022\u003E2019-10-16 14:07\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/complementary-and-alternative-medicine-products-and-their-regulation-food-and-drug-administration\u0022\u003EComplementary and Alternative Medicine Products and their Regulation by the Food and Drug Administration: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/76323\/download\u0022\u003EPDF (123.98 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (123.98 KB) of Complementary and Alternative Medicine Products and their Regulation by the Food and Drug Administration: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/27\/2007","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Food \u0026amp; Color Additives","field_topics":"Premarket","topics-product":"Premarket, Administrative \/ Procedural, Food \u0026amp; Color Additives","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"03\/01\/2006","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2006-D-0102 \u0022\u003EFDA-2006-D-0102 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:09-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/container-and-closure-system-integrity-testing-lieu-sterility-testing-component-stability-protocol\u0022\u003EContainer and Closure System Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/76338\/download\u0022\u003EPDF (64.2 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (64.2 KB) of Container and Closure System Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/25\/2008","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"Postmarket","topics-product":"Postmarket, Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0060\u0022\u003EFDA-2008-D-0060\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222020-05-06T14:00:26-04:00\u0022\u003E2020-05-06 14:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-entity-compliance-guide-bottled-water-and-residual-disinfectants-and-disinfection-byproducts\u0022\u003ESmall Entity Compliance Guide: Bottled Water and Residual Disinfectants and Disinfection Byproducts\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"06\/01\/2009","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Bottled Water ","field_topics":"","topics-product":"Bottled Water ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0224\u0022\u003EFDA-2009-D-0224\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:10-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-entity-compliance-guide-health-claims-calcium-and-osteoporosis-and-calcium-vitamin-d-and\u0022\u003ESmall Entity Compliance Guide: Health Claims on Calcium and Osteoporosis; and Calcium, Vitamin D, and Osteoporosis\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"05\/15\/2009","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0209\u0022\u003EFDA-2009-D-0209\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:11-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-110310-prior-notice-imported-food-under-public-health-security-and-bioterrorism-preparedness\u0022\u003ECPG Sec 110.310 Prior Notice of Imported Food Under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"05\/06\/2009","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Import","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Import","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2007-D-0487\u0022\u003EFDA-2007-D-0487\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Animal \u0026amp; Veterinary, Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T08:26:15-04:00\u0022\u003E2024-10-01 08:26\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-entity-compliance-guide-bottled-water-and-arsenic\u0022\u003ESmall Entity Compliance Guide: Bottled Water and Arsenic\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"04\/29\/2009","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Arsenic, Bottled Water ","field_topics":"","topics-product":"Arsenic, Bottled Water ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0196\u0022\u003EFDA-2009-D-0196\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:11-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-entity-compliance-guide-bottled-water-and-uranium\u0022\u003ESmall Entity Compliance Guide: Bottled Water and Uranium\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"04\/29\/2009","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Bottled Water ","field_topics":"","topics-product":"Bottled Water ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0195\u0022\u003EFDA-2009-D-0195\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:12-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-labeling-certain-beers-subject-labeling-jurisdiction-food-and-drug-administration\u0022\u003EGuidance for Industry: Labeling of Certain Beers Subject to the Labeling Jurisdiction of the Food and Drug Administration\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/90473\/download\u0022\u003EPDF (263.13 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (263.13 KB) of Guidance for Industry: Labeling of Certain Beers Subject to the Labeling Jurisdiction of the Food and Drug Administration\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/04\/2023","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0268\u0022\u003EFDA-2009-D-0268\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:13-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-questions-and-answers-regarding-adverse-event-reporting-and-recordkeeping-dietary\u0022\u003EGuidance for Industry: Questions and Answers Regarding Adverse Event Reporting and Recordkeeping for Dietary Supplements as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/87434\/download\u0022\u003EPDF (244.53 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (244.53 KB) of Guidance for Industry: Questions and Answers Regarding Adverse Event Reporting and Recordkeeping for Dietary Supplements as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/01\/2013","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Adverse Event Reporting","field_topics":"","topics-product":"Adverse Event Reporting","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2007-D-0372\u0022\u003EFDA-2007-D-0372\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Dietary Supplements","changed":"\u003Ctime datetime=\u00222025-02-05T17:35:06-05:00\u0022\u003E2025-02-05 17:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/questions-and-answers-about-emdr-electronic-medical-device-reporting-guidance-industry-user\u0022\u003EQuestions and Answers about eMDR - Electronic Medical Device Reporting - Guidance for Industry, User Facilities and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/76993\/download\u0022\u003EPDF (147.41 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (147.41 KB) of Questions and Answers about eMDR - Electronic Medical Device Reporting - Guidance for Industry, User Facilities and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/13\/2014","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Adverse Event Reporting","field_topics":"Adverse Event Reporting System (FAERS)","topics-product":"Adverse Event Reporting System (FAERS), Adverse Event Reporting","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-N-0393\u0022\u003EFDA-2008-N-0393\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-02T09:15:15-05:00\u0022\u003E2020-03-02 09:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-ingredients-declared-evaporated-cane-juice\u0022\u003EGuidance for Industry: Ingredients Declared as Evaporated Cane Juice\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/97827\/download\u0022\u003EPDF (102.88 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (102.88 KB) of Guidance for Industry: Ingredients Declared as Evaporated Cane Juice\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/26\/2016","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Juice, Labeling","field_topics":"","topics-product":"Juice, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0430\u0022\u003EFDA-2009-D-0430\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:13-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clinical-study-designs-surgical-ablation-devices-treatment-atrial-fibrillation-guidance-industry-and\u0022\u003EClinical Study Designs for Surgical Ablation Devices for Treatment of Atrial Fibrillation - Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/77365\/download\u0022\u003EPDF (169.08 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (169.08 KB) of Clinical Study Designs for Surgical Ablation Devices for Treatment of Atrial Fibrillation - Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/14\/2013","field_issuing_office_taxonomy":"Center for Devices and Radiological Health,Office of Product Evaluation and Quality","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0395\u0022\u003EFDA-2009-D-0395\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-02-28T14:10:03-05:00\u0022\u003E2020-02-28 14:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-questions-and-answers-regarding-reportable-food-registry-established-food-and-drug\u0022\u003EGuidance for Industry: Questions and Answers Regarding the Reportable Food Registry as Established by the Food and Drug Administration Amendments Act of 2007\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/09\/2009","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Reportable Food Registry","field_topics":"","topics-product":"Reportable Food Registry","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0260\u0022\u003EFDA-2009-D-0260\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:14-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-questions-and-answers-regarding-reportable-food-registry-established-food-and-drug-0\u0022\u003EGuidance for Industry: Questions and Answers Regarding the Reportable Food Registry as Established by the Food and Drug Adminstration Amendments Act of 2007 - Appendix\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/09\/2009","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Reportable Food Registry","field_topics":"","topics-product":"Reportable Food Registry","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0260\u0022\u003EFDA-2009-D-0260\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:14-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-questions-and-answers-regarding-labeling-dietary-supplements-required-dietary\u0022\u003EGuidance for Industry: Questions and Answers Regarding the Labeling of Dietary Supplements as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/01\/2009","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2007-D-0209\u0022\u003EFDA-2007-D-0209\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Dietary Supplements","changed":"\u003Ctime datetime=\u00222024-10-01T14:45:05-04:00\u0022\u003E2024-10-01 14:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-letter-regarding-point-purchase-food-labeling\u0022\u003EGuidance for Industry: Letter Regarding Point of Purchase Food Labeling\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/21\/2009","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling, Nutrition","field_topics":"","topics-product":"Labeling, Nutrition","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1921\u0022\u003EFDA-2020-D-1921\u003C\/a\u003E","field_communication_type":"Industry Letter","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:15-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/computer-assisted-detection-devices-applied-radiology-images-and-radiology-device-data-premarket\u0022\u003EComputer-Assisted Detection Devices Applied to Radiology Images and Radiology Device Data - Premarket Notification [510(k)] Submissions: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/77635\/download\u0022\u003EPDF (589.83 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (589.83 KB) of Computer-Assisted Detection Devices Applied to Radiology Images and Radiology Device Data - Premarket Notification [510(k)] Submissions: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/28\/2022","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Radiology","field_topics":"Premarket","topics-product":"Premarket, Radiology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0503\u0022\u003EFDA-2009-D-0503\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222022-09-27T17:13:31-04:00\u0022\u003E2022-09-27 17:13\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clinical-performance-assessment-considerations-computer-assisted-detection-devices-applied-radiology\u0022\u003EClinical Performance Assessment: Considerations for Computer-Assisted Detection Devices Applied to Radiology Images and Radiology Device Data in Premarket Notification (510(k)) Submissions: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/77642\/download\u0022\u003EPDF (499.67 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (499.67 KB) of Clinical Performance Assessment: Considerations for Computer-Assisted Detection Devices Applied to Radiology Images and Radiology Device Data in Premarket Notification (510(k)) Submissions: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/28\/2022","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Digital Health, Radiology, Labeling","field_topics":"Premarket","topics-product":"Premarket, 510(k), Digital Health, Radiology, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0503\u0022\u003EFDA-2009-D-0503\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222022-09-27T17:13:39-04:00\u0022\u003E2022-09-27 17:13\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/general-questions-and-answers-ban-cigarettes-contain-certain-characterizing-flavors-edition-2\u0022\u003EGeneral Questions and Answers on the Ban of Cigarettes that Contain Certain Characterizing Flavors (Edition 2): Guidance to Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/116681\/download\u0022\u003EPDF (30.93 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (30.93 KB) of General Questions and Answers on the Ban of Cigarettes that Contain Certain Characterizing Flavors (Edition 2): Guidance to Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/23\/2009","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"Cigarettes, Flavored","field_topics":"","topics-product":"Cigarettes, Flavored","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-N-0449\u0022\u003EFDA-2009-N-0449\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222020-07-28T11:05:38-04:00\u0022\u003E2020-07-28 11:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/scope-prohibition-against-marketing-tobacco-product-combination-another-article-or-product-regulated\u0022\u003EThe Scope of the Prohibition Against Marketing a Tobacco Product in Combination with Another Article or Product Regulated under the Federal Food, Drug, and Cosmetic Act: Draft Guidance for Manufacturers, Retailers, Importers and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/80592\/download\u0022\u003EPDF (30.08 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (30.08 KB) of The Scope of the Prohibition Against Marketing a Tobacco Product in Combination with Another Article or Product Regulated under the Federal Food, Drug, and Cosmetic Act: Draft Guidance for Manufacturers, Retailers, Importers and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/29\/2009","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"09\/30\/2009","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0470\u0022\u003EFDA-2009-D-0470\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222020-07-21T08:05:03-04:00\u0022\u003E2020-07-21 08:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/french-translation-guidance-industry-questions-and-answers-regarding-reportable-food-registry\u0022\u003EFrench Translation of Guidance for Industry: Questions and Answers Regarding the Reportable Food Registry (Questions et R\u00e9ponses relatives au Registre des aliments \u00e0 signaler)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/09\/2009","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Reportable Food Registry","field_topics":"","topics-product":"Reportable Food Registry","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0260\u0022\u003EFDA-2009-D-0260\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:16-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/preguntas-y-respuestas-sobre-el-registro-de-incidentes-sanitarios-en-productos-agroalimentarios\u0022\u003EPreguntas y respuestas sobre el Registro de incidentes sanitarios en productos agroalimentarios, seg\u00fan lo establecido por la Ley de Enmiendas de la Administraci\u00f3n de Medicamentos y Alimentos de 2007\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/09\/2009","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Reportable Food Registry","field_topics":"","topics-product":"Reportable Food Registry","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0260\u0022\u003EFDA-2009-D-0260\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:16-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/listing-ingredients-tobacco-products\u0022\u003EListing of Ingredients in Tobacco Products: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/101162\/download\u0022\u003EPDF (459.45 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (459.45 KB) of Listing of Ingredients in Tobacco Products: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/17\/2023","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"12\/01\/2009","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0524\u0022\u003EFDA-2009-D-0524\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222023-03-17T15:41:32-04:00\u0022\u003E2023-03-17 15:41\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/registration-and-product-listing-owners-and-operators-domestic-tobacco-product-establishments\u0022\u003ERegistration and Product Listing for Owners and Operators of Domestic Tobacco Product Establishments: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/78165\/download\u0022\u003EPDF (672.53 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (672.53 KB) of Registration and Product Listing for Owners and Operators of Domestic Tobacco Product Establishments: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/31\/2023","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"04\/07\/2014","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0508\u0022\u003EFDA-2009-D-0508\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222023-04-03T06:42:31-04:00\u0022\u003E2023-04-03 06:42\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q7a-good-manufacturing-practice-guidance-active-pharmaceutical-ingredients\u0022\u003EQ7A Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/01\/2001","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of the Commissioner","field_regulated_product_field":"","changed":"\u003Ctime datetime=\u00222024-10-24T14:52:42-04:00\u0022\u003E2024-10-24 14:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-and-other-stakeholders-redbook-2000\u0022\u003EGuidance for Industry and Other Stakeholders: Redbook 2000 : Toxicological Principles for the Safety Assessment of Food Ingredients\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/02\/2007","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives, Ingredients","field_topics":"","topics-product":"Food \u0026amp; Color Additives, Ingredients","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:17-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-food-labeling-guide\u0022\u003EGuidance for Industry: Food Labeling Guide\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/81606\/download\u0022\u003EPDF (8.53 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (8.53 MB) of Guidance for Industry: Food Labeling Guide\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/01\/2013","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling, Nutrition Label","field_topics":"","topics-product":"Labeling, Nutrition Label","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-01-15T18:46:17-05:00\u0022\u003E2025-01-15 18:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guia-para-la-industria-pruebas-de-disolucion-de-formas-de-dosificacion-oral-solidas-de-liberacion\u0022\u003EGu\u00eda para la Industria:\u00a0 Pruebas de disoluci\u00f3n de formas de dosificaci\u00f3n oral s\u00f3lidas de liberaci\u00f3n inmediata.\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"","changed":"\u003Ctime datetime=\u00222018-09-30T19:14:08-04:00\u0022\u003E2018-09-30 19:14\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guia-para-la-industria-formas-de-dosificacion-oral-de-liberacion-prolongada-elaboracion-evaluacion-y\u0022\u003EGu\u00eda para la Industria:\u00a0 Formas de dosificaci\u00f3n oral de liberaci\u00f3n prolongada: elaboraci\u00f3n, evaluaci\u00f3n y aplicaci\u00f3n de correlaciones in vitro\/in vivo\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"","changed":"\u003Ctime datetime=\u00222018-09-30T19:14:08-04:00\u0022\u003E2018-09-30 19:14\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/chinese-translation-guidance-industry-questions-and-answers-regarding-reportable-food-registry\u0022\u003EChinese Translation of the Guidance for Industry: Questions and Answers Regarding the Reportable Food Registry (\u5173\u4e8e\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u7ba1\u7406\u5c402007\u5e74\u4fee\u6b63\u6cd5\u6848\u89c4\u5b9a\u7684\u5e94\u901a\u62a5\u98df\u54c1\u6ce8\u518c\u7684\u95ee\u7b54)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/09\/2009","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Reportable Food Registry","field_topics":"","topics-product":"Reportable Food Registry","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0260\u0022\u003EFDA-2009-D-0260\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T08:26:18-04:00\u0022\u003E2024-10-01 08:26\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-entity-compliance-guide-bottled-water-and-total-coliform-and-e-coli\u0022\u003ESmall Entity Compliance Guide: Bottled Water and Total Coliform and E. coli\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/26\/2010","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Bottled Water , E. coli","field_topics":"","topics-product":"Bottled Water , E. coli","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0141\u0022\u003EFDA-2010-D-0141\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:18-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-sanitary-transportation-food\u0022\u003EGuidance for Industry: Sanitary Transportation of Food\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"04\/29\/2010","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Sanitation, Transportation","field_topics":"","topics-product":"Sanitation, Transportation","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1920\u0022\u003EFDA-2020-D-1920\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:19-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/draft-guidance-industry-providing-regulatory-submissions-electronic-or-paper-format-office-food\u0022\u003EDraft Guidance for Industry: Providing Regulatory Submissions in Electronic or Paper Format to the Office of Food Additive Safety\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/78268\/download\u0022\u003EPDF (813.15 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (813.15 KB) of Draft Guidance for Industry: Providing Regulatory Submissions in Electronic or Paper Format to the Office of Food Additive Safety\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/2010","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:20-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/formas-posologicas-orales-solidas-de-liberacion-inmediata-cambios-de-escala-y-posteriores-la\u0022\u003EFormas posol\u00f3gicas orales s\u00f3lidas de liberaci\u00f3n inmediata Cambios de escala y posteriores a la aprobaci\u00f3n: documentaci\u00f3n qu\u00edmica, de fabricaci\u00f3n y controles, de pruebas de disoluci\u00f3n in vitro y bioequivalencia in vivo.\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"","changed":"\u003Ctime datetime=\u00222019-02-08T22:04:34-05:00\u0022\u003E2019-02-08 22:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/french-translation-guidance-industry-submitting-report-multiple-facilities-reportable-food\u0022\u003EFrench Translation of Guidance for Industry: Submitting a Report for Multiple Facilities to the Reportable Food Electronic Portal (Soumission d\u2019un rapport concernant plusieurs usines aupr\u00e8s du portail \u00e9lectronique d\u2019enregistrement des denr\u00e9es alimentaires)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/25\/2010","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Reportable Food Registry","field_topics":"","topics-product":"Reportable Food Registry","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0260\u0022\u003EFDA-2009-D-0260\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:21-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/orientacion-preliminar-para-la-industria-presentacion-de-informe-para-multiples-instalaciones-al\u0022\u003EOrientaci\u00f3n preliminar para la industria: Presentaci\u00f3n de Informe para m\u00faltiples instalaciones al Portal electr\u00f3nico de incidentes\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/25\/2010","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Reportable Food Registry","field_topics":"","topics-product":"Reportable Food Registry","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0260\u0022\u003EFDA-2009-D-0260\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:21-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/chinese-translation-guidance-industry-submitting-report-multiple-facilities-reportable-food\u0022\u003EChinese Translation of Guidance for Industry: Submitting a Report for Multiple Facilities to the Reportable Food Electronic Portal (\u884c\u4e1a\u6307\u5357\uff1a\u5411\u7f8e\u56fd\u98df\u89c4\u5b9a\u7684\u5e94\u901a\u62a5\u98df\u54c1\u95e8\u6237\u7f51\u63d0\u4ea4\u591a\u4e2a\u673a\u6784\u7684\u62a5\u544a)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/2010","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Reportable Food Registry","field_topics":"","topics-product":"Reportable Food Registry","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0260\u0022\u003EFDA-2009-D-0260\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T08:27:16-04:00\u0022\u003E2024-10-01 08:27\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/tobacco-health-document-submission-revised\u0022\u003ETobacco Health Document Submission (Revised): Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/78616\/download\u0022\u003EPDF (329.55 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (329.55 KB) of Tobacco Health Document Submission (Revised): Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/31\/2023","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"Tobacco Health documents","field_topics":"","topics-product":"Tobacco Health documents","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"04\/20\/2010","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0600\u0022\u003EFDA-2009-D-0600\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222025-02-11T10:15:59-05:00\u0022\u003E2025-02-11 10:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/enforcement-policy-concerning-certain-regulations-restricting-sale-and-distribution-cigarettes-and\u0022\u003EEnforcement Policy Concerning Certain Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/78660\/download\u0022\u003EPDF (56.92 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (56.92 KB) of Enforcement Policy Concerning Certain Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/07\/2010","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"Cigarettes, Smokeless, Snuff, Chewing","field_topics":"","topics-product":"Cigarettes, Smokeless, Snuff, Chewing","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"05\/07\/2011","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0189\u0022\u003EFDA-2010-D-0189\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222020-07-28T11:05:31-04:00\u0022\u003E2020-07-28 11:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/acceptable-media-electronic-product-user-manuals\u0022\u003EAcceptable Media for Electronic Product User Manuals: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/78332\/download\u0022\u003EPDF (388.02 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (388.02 KB) of Acceptable Media for Electronic Product User Manuals: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/19\/2024","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222024-08-21T07:43:46-04:00\u0022\u003E2024-08-21 07:43\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-entity-compliance-guide-prevention-salmonella-enteritidis-shell-eggs-during-production\u0022\u003ESmall Entity Compliance Guide: Prevention of Salmonella Enteritidis in Shell Eggs During Production, Transportation, and Storage\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"04\/13\/2010","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Egg\/Egg Product, Transportation, Salmonella","field_topics":"","topics-product":"Egg\/Egg Product, Transportation, Salmonella","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0183\u0022\u003EFDA-2010-D-0183\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:23-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-use-water-food-manufacturers-areas-subject-boil-water-advisory\u0022\u003EGuidance for Industry: Use of Water by Food Manufacturers in Areas Subject to a Boil-Water Advisory\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"05\/13\/2010","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"Emergencies","topics-product":"Emergencies, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0236\u0022\u003EFDA-2010-D-0236\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:21:07-04:00\u0022\u003E2024-10-01 07:21\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-food-additive-petition-expedited-review\u0022\u003EGuidance for Industry: Food Additive Petition Expedited Review\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/30\/2010","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1918\u0022\u003EFDA-2020-D-1918\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:25-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/use-light-mild-low-or-similar-descriptors-label-labeling-or-advertising-tobacco-products\u0022\u003EUse of \u201cLight,\u201d \u201cMild,\u201d \u201cLow,\u201d or Similar Descriptors in the Label, Labeling, or Advertising of Tobacco Products: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/78927\/download\u0022\u003EPDF (161.55 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (161.55 KB) of Use of \u201cLight,\u201d \u201cMild,\u201d \u201cLow,\u201d or Similar Descriptors in the Label, Labeling, or Advertising of Tobacco Products: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/10\/2010","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"06\/10\/2010","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0282\u0022\u003EFDA-2010-D-0282\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222020-07-28T11:05:23-04:00\u0022\u003E2020-07-28 11:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/tobacco-retailer-training-programs\u0022\u003ETobacco Retailer Training Programs: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/79013\/download\u0022\u003EPDF (229.9 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (229.9 KB) of Tobacco Retailer Training Programs: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/09\/2018","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"","field_topics":"Training \u0026amp; Education","topics-product":"Training \u0026amp; Education, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"08\/16\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0350\u0022\u003EFDA-2010-D-0350\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222020-07-28T09:00:20-04:00\u0022\u003E2020-07-28 09:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-safety-imported-traditional-pottery-intended-use-food-and-use-term-lead-free\u0022\u003EGuidance for Industry: Safety of Imported Traditional Pottery Intended for Use with Food and the Use of the Term \u0026quot;Lead Free\u0026quot; in the Labeling of Pottery\/Proper Identification of Ornamental and Decorative Ceramicware\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/22\/2010","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Import, Labeling, Lead","field_topics":"","topics-product":"Import, Labeling, Lead","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0571\u0022\u003EFDA-2010-D-0571\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:27-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/draft-guidance-industry-questions-and-answers-regarding-reportable-food-registry-established-food\u0022\u003EDraft Guidance for Industry: Questions and Answers Regarding the Reportable Food Registry as Established by the Food and Drug Administration Amendments Act of 2007 (Edition 2)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/79130\/download\u0022\u003EPDF (171.3 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (171.3 KB) of Draft Guidance for Industry: Questions and Answers Regarding the Reportable Food Registry as Established by the Food and Drug Administration Amendments Act of 2007 (Edition 2)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/25\/2010","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Reportable Food Registry","field_topics":"","topics-product":"Reportable Food Registry","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"07\/26\/2010","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0260\u0022\u003EFDA-2009-D-0260\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Animal \u0026amp; Veterinary, Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:29-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/orientacion-preliminar-de-la-industria-preguntas-y-respuestas-sobre-el-registro-de-productos\u0022\u003EOrientaci\u00f3n preliminar de la industria: Preguntas y respuestas sobre el Registro de productos sanitarios en productos agroalimentarios, seg\u00fan establecido por la Ley de Enmiendas a la Alimentaci\u00f3n y Medicamentos (FDA), 2007 (Edici\u00f3n 2)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"05\/23\/2010","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Reportable Food Registry","field_topics":"","topics-product":"Reportable Food Registry","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"07\/26\/2010","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0260\u0022\u003EFDA-2009-D-0260\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:31-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/fdas-strategy-antimicrobial-resistance-questions-and-answers\u0022\u003EFDA\u0026#039;s Strategy on Antimicrobial Resistance - Questions and Answers\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"12\/10\/2013","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Antimicrobial Resistance","field_topics":"","topics-product":"Antimicrobial Resistance","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0094\u0022\u003EFDA-2010-D-0094\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:05:16-04:00\u0022\u003E2019-04-16 14:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/chinese-translation-draft-guidance-industry-questions-and-answers-regarding-reportable-food-registry\u0022\u003EChinese Translation of Draft Guidance for Industry: Questions and Answers Regarding the Reportable Food Registry Edition 2 (\u5173\u4e8e\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u7ba1\u7406\u5c402007\u5e74\u4fee\u6b63\u6cd5\u6848\u89c4\u5b9a\u7684\u5e94\u901a\u62a5\u98df\u54c1\u6ce8\u518c\u7684\u95ee\u7b54 2010\u5e745\u6708)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/172976\/download\u0022\u003EPDF (241.15 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (241.15 KB) of Chinese Translation of Draft Guidance for Industry: Questions and Answers Regarding the Reportable Food Registry Edition 2 (\u5173\u4e8e\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u7ba1\u7406\u5c402007\u5e74\u4fee\u6b63\u6cd5\u6848\u89c4\u5b9a\u7684\u5e94\u901a\u62a5\u98df\u54c1\u6ce8\u518c\u7684\u95ee\u7b54 2010\u5e745\u6708)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/23\/2010","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Reportable Food Registry","field_topics":"","topics-product":"Reportable Food Registry","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"07\/26\/2010","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0260\u0022\u003EFDA-2009-D-0260\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T08:27:35-04:00\u0022\u003E2024-10-01 08:27\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/addition-urls-electronic-product-labeling\u0022\u003EAddition of URLs to Electronic Product Labeling: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/79209\/download\u0022\u003EPDF (32.85 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (32.85 KB) of Addition of URLs to Electronic Product Labeling: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/29\/2010","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Labeling","field_topics":"Postmarket","topics-product":"Postmarket, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-24T09:10:02-04:00\u0022\u003E2020-03-24 09:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guide-pour-lindustrie-questions-et-reponses-concernant-le-registre-de-denrees-alimentaires-signaler\u0022\u003EGuide pour l\u2019industrie: Questions et r\u00e9ponses concernant le Registre de denr\u00e9es alimentaires \u00e0 signaler Reportable Food Registry (RFR) tel qu\u2019\u00e9tabli par le Food and Drug Administration Amendments Act de 2007 (FDAAA) (2\u00e8me \u00e9dition)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/79279\/download\u0022\u003EPDF (122.08 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (122.08 KB) of Guide pour l\u2019industrie: Questions et r\u00e9ponses concernant le Registre de denr\u00e9es alimentaires \u00e0 signaler Reportable Food Registry (RFR) tel qu\u2019\u00e9tabli par le Food and Drug Administration Amendments Act de 2007 (FDAAA) (2\u00e8me \u00e9dition)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/23\/2010","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Reportable Food Registry","field_topics":"","topics-product":"Reportable Food Registry","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"07\/26\/2010","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0260\u0022\u003EFDA-2009-D-0260\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:32-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-recommendations-submission-chemical-and-technological-data-food-additive-petitions\u0022\u003EGuidance for Industry: Recommendations for Submission of Chemical and Technological Data for Food Additive Petitions and GRAS Notices for Enzyme Preparations\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/79379\/download\u0022\u003EPDF (100.85 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (100.85 KB) of Guidance for Industry: Recommendations for Submission of Chemical and Technological Data for Food Additive Petitions and GRAS Notices for Enzyme Preparations\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/30\/2010","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives, GRAS","field_topics":"","topics-product":"Food \u0026amp; Color Additives, GRAS","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:33-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-microbiological-considerations-antimicrobial-agents-used-food-applications\u0022\u003EGuidance for Industry: Microbiological Considerations for Antimicrobial Agents Used in Food Applications\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/83078\/download\u0022\u003EPDF (378.85 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (378.85 KB) of Guidance for Industry: Microbiological Considerations for Antimicrobial Agents Used in Food Applications\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/01\/2021","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2007-D-0207\u0022\u003EFDA-2007-D-0207\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T16:01:51-05:00\u0022\u003E2025-03-06 16:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-entity-compliance-guide-current-good-manufacturing-practice-manufacturing-packaging-labeling\u0022\u003ESmall Entity Compliance Guide: Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"12\/16\/2010","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling, Packaging","field_topics":"","topics-product":"Labeling, Packaging","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0605\u0022\u003EFDA-2010-D-0605\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Human Foods Program","field_regulated_product_field":"Dietary Supplements, Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:35-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/blood-lancet-labeling-guidance-industry-and-food-and-drug-administration-staff\u0022\u003EBlood Lancet Labeling - Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/80085\/download\u0022\u003EPDF (39.59 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (39.59 KB) of Blood Lancet Labeling - Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/28\/2010","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0590\u0022\u003EFDA-2010-D-0590\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-02-28T13:52:46-05:00\u0022\u003E2020-02-28 13:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/harmful-and-potentially-harmful-constituents-tobacco-products-used-section-904e-federal-food-drug\u0022\u003E\u201cHarmful and Potentially Harmful Constituents\u201d in Tobacco Products as Used in Section 904(e) of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/80109\/download\u0022\u003EPDF (54.46 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (54.46 KB) of \u201cHarmful and Potentially Harmful Constituents\u201d in Tobacco Products as Used in Section 904(e) of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/01\/2016","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"09\/01\/2016","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0281\u0022\u003EFDA-2010-D-0281\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222020-07-28T10:25:03-04:00\u0022\u003E2020-07-28 10:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-questions-and-answers-about-food-additive-or-color-additive-petition-process\u0022\u003EGuidance for Industry: Questions and Answers About the Food Additive or Color Additive Petition Process\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/31\/2011","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1917\u0022\u003EFDA-2020-D-1917\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-26T09:32:16-04:00\u0022\u003E2025-03-26 09:32\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/classification-products-drugs-and-devices-and-additional-product-classification-issues\u0022\u003EClassification of Products as Drugs and Devices and Additional Product Classification Issues: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/80384\/download\u0022\u003EPDF (86.73 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (86.73 KB) of Classification of Products as Drugs and Devices and Additional Product Classification Issues: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/25\/2017","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products","field_health_topics":"","term_node_tid":"Combination Products","field_topics":"","topics-product":"Combination Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"09\/01\/2011","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0429\u0022\u003EFDA-2011-D-0429\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222021-05-13T15:45:17-04:00\u0022\u003E2021-05-13 15:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-letter-firms-grow-harvest-sort-pack-or-ship-fresh-cilantro\u0022\u003EGuidance for Industry: Letter to Firms that Grow, Harvest, Sort, Pack, or Ship Fresh Cilantro\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/01\/2011","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Vegetable Products, Produce","field_topics":"","topics-product":"Vegetable Products, Produce","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Industry Letter","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:37-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/draft-guidance-industry-new-dietary-ingredient-notifications-and-related-issues\u0022\u003EDraft Guidance for Industry: New Dietary Ingredient Notifications and Related Issues\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/99538\/download\u0022\u003EPDF (3.59 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (3.59 MB) of Draft Guidance for Industry: New Dietary Ingredient Notifications and Related Issues\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/19\/2026","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"12\/12\/2016","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0376\u0022\u003EFDA-2011-D-0376\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Dietary Supplements, Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222026-10-19T08:58:31-04:00\u0022\u003E2026-10-19 08:58\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/considering-whether-fda-regulated-product-involves-application-nanotechnology\u0022\u003EConsidering Whether an FDA-Regulated Product Involves the Application of Nanotechnology: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/88423\/download\u0022\u003EPDF (111.45 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (111.45 KB) of Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/23\/2014","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Policy, Legislation, and International Affairs,Office of Policy","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives, Records","field_topics":"Premarket","topics-product":"Premarket, Food \u0026amp; Color Additives, Records","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0530\u0022\u003EFDA-2010-D-0530\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222019-04-20T22:00:12-04:00\u0022\u003E2019-04-20 22:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/civil-money-penalties-and-no-tobacco-sale-orders-tobacco-retailers-responses-frequently-asked\u0022\u003ECivil Money Penalties and No-Tobacco-Sale Orders for Tobacco Retailers Responses to Frequently Asked Questions (*Revised): Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/92558\/download\u0022\u003EPDF (185.39 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (185.39 KB) of Civil Money Penalties and No-Tobacco-Sale Orders for Tobacco Retailers Responses to Frequently Asked Questions (*Revised): Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/16\/2016","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"No-tobacco-sale order (NTSO)","field_topics":"","topics-product":"No-tobacco-sale order (NTSO)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-1083\u0022\u003EFDA-2012-D-1083\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222020-07-28T09:12:52-04:00\u0022\u003E2020-07-28 09:12\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-and-food-and-drug-administration-staff-assemblers-guide-diagnostic-x-ray-equipment\u0022\u003EGuidance for Industry and Food and Drug Administration Staff - Assembler\u0026#039;s Guide to Diagnostic X-Ray Equipment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/80801\/download\u0022\u003EPDF (681.97 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (681.97 KB) of Guidance for Industry and Food and Drug Administration Staff - Assembler\u0026#039;s Guide to Diagnostic X-Ray Equipment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/21\/2023","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-4115\u0022\u003EFDA-2018-D-4115\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222023-02-21T12:18:46-05:00\u0022\u003E2023-02-21 12:18\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/submission-warning-plans-cigarettes-and-smokeless-tobacco-products\u0022\u003ESubmission of Warning Plans for Cigarettes and Smokeless Tobacco Products: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/81594\/download\u0022\u003EPDF (209.38 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (209.38 KB) of Submission of Warning Plans for Cigarettes and Smokeless Tobacco Products: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/09\/2011","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"Warning plans","field_topics":"","topics-product":"Warning plans","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"11\/08\/2011","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0480\u0022\u003EFDA-2011-D-0480\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222020-07-28T11:00:53-04:00\u0022\u003E2020-07-28 11:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-implementation-fee-provisions-section-107-fda-food-safety-modernization-act\u0022\u003EGuidance for Industry: Implementation of the Fee Provisions of Section 107 of the FDA Food Safety Modernization Act\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/06\/2011","field_issuing_office_taxonomy":"Office of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"User Fees","topics-product":"User Fees, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0721\u0022\u003EFDA-2011-D-0721\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-01-16T11:20:46-05:00\u0022\u003E2025-01-16 11:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/applications-premarket-review-new-tobacco-products\u0022\u003EApplications for Premarket Review of New Tobacco Products: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/81821\/download\u0022\u003EPDF (233.44 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (233.44 KB) of Applications for Premarket Review of New Tobacco Products: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/28\/2011","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"PreMarket","field_topics":"","topics-product":"PreMarket","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"09\/27\/2011","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0212\u0022\u003EFDA-2011-D-0212\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222020-07-28T11:00:33-04:00\u0022\u003E2020-07-28 11:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-measures-address-risk-contamination-salmonella-species-food-containing-pistachio\u0022\u003EGuidance for Industry: Measures to Address the Risk for Contamination by Salmonella Species in Food Containing a Pistachio-Derived Product as an Ingredient\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/81864\/download\u0022\u003EPDF (89 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (89 KB) of Guidance for Industry: Measures to Address the Risk for Contamination by Salmonella Species in Food Containing a Pistachio-Derived Product as an Ingredient\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/31\/2011","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Nuts \u0026amp; Nut Products, Salmonella","field_topics":"","topics-product":"Nuts \u0026amp; Nut Products, Salmonella","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0271\u0022\u003EFDA-2009-D-0271\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-26T09:16:03-04:00\u0022\u003E2025-03-26 09:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-letter-firms-grow-harvest-sort-pack-process-or-ship-fresh-cantaloupe\u0022\u003EGuidance for Industry: Letter to Firms that Grow, Harvest, Sort, Pack, Process, or Ship Fresh Cantaloupe\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/82249\/download\u0022\u003EPDF (1.43 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.43 MB) of Guidance for Industry: Letter to Firms that Grow, Harvest, Sort, Pack, Process, or Ship Fresh Cantaloupe\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/31\/2011","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Fruit\/Fruit Product ","field_topics":"","topics-product":"Fruit\/Fruit Product ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Industry Letter","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-25T13:46:47-04:00\u0022\u003E2025-03-25 13:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-evaluating-safety-flood-affected-food-crops-human-consumption\u0022\u003EGuidance for Industry: Evaluating the Safety of Flood-affected Food Crops for Human Consumption\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/24\/2011","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"Emergencies","topics-product":"Emergencies, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0733\u0022\u003EFDA-2011-D-0733\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:42-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-prevention-salmonella-enteritidis-shell-eggs-during-production-storage-and\u0022\u003EGuidance for Industry: Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/82653\/download\u0022\u003EPDF (853.05 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (853.05 KB) of Guidance for Industry: Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/28\/2011","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Egg\/Egg Product, Salmonella, Transportation","field_topics":"","topics-product":"Egg\/Egg Product, Salmonella, Transportation","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0313\u0022\u003EFDA-2010-D-0313\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-25T13:41:39-04:00\u0022\u003E2025-03-25 13:41\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/medical-device-classification-product-codes-guidance-industry-and-food-and-drug-administration-staff\u0022\u003EMedical Device Classification Product Codes - Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/82781\/download\u0022\u003EPDF (268.79 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (268.79 KB) of Medical Device Classification Product Codes - Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/10\/2013","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0916\u0022\u003EFDA-2011-D-0916\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222022-02-11T09:35:12-05:00\u0022\u003E2022-02-11 09:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-fda-records-access-authority-under-sections-414-and-704-federal-food-drug-cosmetic\u0022\u003EGuidance for Industry: FDA Records Access Authority Under Sections 414 and 704 of the Federal Food, Drug, \u0026amp; Cosmetic Act\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/83083\/download\u0022\u003EPDF (82.97 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (82.97 KB) of Guidance for Industry: FDA Records Access Authority Under Sections 414 and 704 of the Federal Food, Drug, \u0026amp; Cosmetic Act\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/04\/2014","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Records","field_topics":"","topics-product":"Records","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0674\u0022\u003EFDA-2011-D-0674\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Animal \u0026amp; Veterinary, Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:44-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-questions-and-answers-regarding-establishment-and-maintenance-records-persons-who\u0022\u003EGuidance for Industry: Questions and Answers Regarding Establishment and Maintenance of Records By Persons Who Manufacture, Process, Pack, Transport, Distribute, Receive, Hold, or Import Food (Edition 5)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/83073\/download\u0022\u003EPDF (334.4 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (334.4 KB) of Guidance for Industry: Questions and Answers Regarding Establishment and Maintenance of Records By Persons Who Manufacture, Process, Pack, Transport, Distribute, Receive, Hold, or Import Food (Edition 5)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/31\/2012","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Import, Packaging, Records, Transportation","field_topics":"","topics-product":"Import, Packaging, Records, Transportation","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0598\u0022\u003EFDA-2011-D-0598\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:45-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-testing-salmonella-species-human-foods-and-direct-human-contact-animal-foods\u0022\u003EGuidance for Industry: Testing for Salmonella Species in Human Foods and Direct-Human-Contact Animal Foods\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/83177\/download\u0022\u003EPDF (75.56 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (75.56 KB) of Guidance for Industry: Testing for Salmonella Species in Human Foods and Direct-Human-Contact Animal Foods\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/08\/2012","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Salmonella","field_topics":"","topics-product":"Salmonella","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0091\u0022\u003EFDA-2011-D-0091\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Animal \u0026amp; Veterinary, Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:45-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/further-amendments-general-regulations-food-and-drug-administration-incorporate-tobacco-products\u0022\u003EFurther Amendments to General Regulations of the Food and Drug Administration to Incorporate Tobacco Products - Small Entity Compliance Guide: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/83261\/download\u0022\u003EPDF (269.7 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (269.7 KB) of Further Amendments to General Regulations of the Food and Drug Administration to Incorporate Tobacco Products - Small Entity Compliance Guide: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/17\/2023","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"03\/28\/2012","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-N-0121\u0022\u003EFDA-2011-N-0121\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222023-03-17T15:41:36-04:00\u0022\u003E2023-03-17 15:41\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/modified-risk-tobacco-product-applications\u0022\u003EModified Risk Tobacco Product Applications: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/83300\/download\u0022\u003EPDF (977.02 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (977.02 KB) of Modified Risk Tobacco Product Applications: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/03\/2012","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"Modified Risk Tobacco Product (MRTP)","field_topics":"","topics-product":"Modified Risk Tobacco Product (MRTP)","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"06\/04\/2012","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-0071\u0022\u003EFDA-2012-D-0071\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222020-07-28T10:57:42-04:00\u0022\u003E2020-07-28 10:57\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/meetings-industry-and-investigators-research-and-development-tobacco-products-revised\u0022\u003EMeetings with Industry and Investigators on the Research and Development of Tobacco Products (Revised): Guidance for Industry and Investigators\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/83420\/download\u0022\u003EPDF (342.75 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (342.75 KB) of Meetings with Industry and Investigators on the Research and Development of Tobacco Products (Revised): Guidance for Industry and Investigators\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/07\/2022","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-0429\u0022\u003EFDA-2012-D-0429\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222026-07-17T09:42:48-04:00\u0022\u003E2026-07-17 09:42\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-questions-and-answers-regarding-final-rule-prevention-salmonella-enteritidis-shell\u0022\u003EGuidance for Industry: Questions and Answers Regarding the Final Rule, Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/83513\/download\u0022\u003EPDF (297.17 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (297.17 KB) of Guidance for Industry: Questions and Answers Regarding the Final Rule, Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/01\/2015","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Egg\/Egg Product, Transportation, Salmonella","field_topics":"","topics-product":"Egg\/Egg Product, Transportation, Salmonella","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0398\u0022\u003EFDA-2011-D-0398\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:46-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/s6r1-preclinical-safety-evaluation-biotechnology-derived-pharmaceuticals\u0022\u003ES6(R1) Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"05\/18\/2012","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Safety","field_topics":"","topics-product":"ICH-Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0573\u0022\u003EFDA-2009-D-0573\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-02-25T17:10:12-05:00\u0022\u003E2022-02-25 17:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-assessing-effects-significant-manufacturing-process-changes-including-emerging\u0022\u003EGuidance for Industry: Assessing the Effects of Significant Manufacturing Process Changes, Including Emerging Technologies, on the Safety and Regulatory Status of Food Ingredients and Food Contact Substances, Including Food Ingredients that Are Color Additives\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/115075\/download\u0022\u003EPDF (201.31 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (201.31 KB) of Guidance for Industry: Assessing the Effects of Significant Manufacturing Process Changes, Including Emerging Technologies, on the Safety and Regulatory Status of Food Ingredients and Food Contact Substances, Including Food Ingredients that Are Color Additives\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/27\/2014","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives, Ingredients, Food Contact Substances (FCS)","field_topics":"","topics-product":"Food \u0026amp; Color Additives, Ingredients, Food Contact Substances (FCS)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0490\u0022\u003EFDA-2011-D-0490\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:47-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-490200-parametric-release-parenteral-drug-products-terminally-sterilized-moist-heat\u0022\u003ECPG Sec. 490.200 Parametric Release of Parenteral Drug Products Terminally Sterilized by Moist Heat\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/01\/2012","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222020-04-16T10:00:19-04:00\u0022\u003E2020-04-16 10:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q8-q9-q10-questions-and-answers-appendix-qas-training-sessions-q8-q9-q10-points-consider\u0022\u003EQ8, Q9, \u0026amp; Q10 Questions and Answers -- Appendix: Q\u0026amp;As from Training Sessions (Q8, Q9, \u0026amp; Q10 Points to Consider)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/83904\/download\u0022\u003EPDF (262.52 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (262.52 KB) of Q8, Q9, \u0026amp; Q10 Questions and Answers -- Appendix: Q\u0026amp;As from Training Sessions (Q8, Q9, \u0026amp; Q10 Points to Consider)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/13\/2012","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-14T20:20:14-04:00\u0022\u003E2020-04-14 20:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-submitting-forms-food-canning-establishment-registration-and-food-process-filing\u0022\u003EGuidance for Industry: Submitting Forms for Food Canning Establishment Registration and Food Process Filing to FDA in Electronic or Paper Format\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/93770\/download\u0022\u003EPDF (122.72 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (122.72 KB) of Guidance for Industry: Submitting Forms for Food Canning Establishment Registration and Food Process Filing to FDA in Electronic or Paper Format\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/01\/2016","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Canned Foods","field_topics":"Registration","topics-product":"Registration, Canned Foods","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-1622\u0022\u003EFDA-2013-D-1622\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:48-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-suicidal-ideation-and-behavior-prospective-assessment-occurrence-clinical-trials\u0022\u003EGuidance for Industry: Suicidal Ideation and Behavior: Prospective Assessment of Occurrence in Clinical Trials\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/79482\/download\u0022\u003EPDF (421.53 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (421.53 KB) of Guidance for Industry: Suicidal Ideation and Behavior: Prospective Assessment of Occurrence in Clinical Trials\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/13\/2012","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-02-25T15:01:06-05:00\u0022\u003E2022-02-25 15:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-necessity-use-food-product-categories-food-facility-registrations-and-updates-food\u0022\u003EGuidance for Industry: Necessity of the Use of Food Product Categories in Food Facility Registrations and Updates to Food Product Categories (2016 Edition)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/84245\/download\u0022\u003EPDF (92.38 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (92.38 KB) of Guidance for Industry: Necessity of the Use of Food Product Categories in Food Facility Registrations and Updates to Food Product Categories (2016 Edition)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/01\/2016","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"Registration","topics-product":"Registration, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-0585\u0022\u003EFDA-2012-D-0585\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T14:31:14-04:00\u0022\u003E2024-10-01 14:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-acute-bacterial-otitis-media-developing-drugs-treatment\u0022\u003EGuidance for Industry: Acute Bacterial Otitis Media: Developing Drugs for Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71197\/download\u0022\u003EPDF (116.59 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (116.59 KB) of Guidance for Industry: Acute Bacterial Otitis Media: Developing Drugs for Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/30\/2012","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"","changed":"\u003Ctime datetime=\u00222022-02-25T14:50:15-05:00\u0022\u003E2022-02-25 14:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-entity-compliance-guide-establishing-allowable-level-di-2-ethylhexylphthalate-bottled-water\u0022\u003ESmall Entity Compliance Guide: Establishing an Allowable Level for di (2-ethylhexyl)phthalate in Bottled Water\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/84475\/download\u0022\u003EPDF (60.41 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (60.41 KB) of Small Entity Compliance Guide: Establishing an Allowable Level for di (2-ethylhexyl)phthalate in Bottled Water\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/01\/2012","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Bottled Water ","field_topics":"","topics-product":"Bottled Water ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-0316\u0022\u003EFDA-2012-D-0316\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-25T13:18:40-04:00\u0022\u003E2025-03-25 13:18\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-acute-bacterial-sinusitis-developing-drugs-treatment\u0022\u003EGuidance for Industry Acute Bacterial Sinusitis: Developing Drugs for Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71161\/download\u0022\u003EPDF (479.82 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (479.82 KB) of Guidance for Industry Acute Bacterial Sinusitis: Developing Drugs for Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/04\/2012","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pediatric Product Development","field_topics":"","topics-product":"Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-08-09T22:18:55-04:00\u0022\u003E2024-08-09 22:18\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/acute-bacterial-exacerbations-chronic-bronchitis-patients-chronic-obstructive-pulmonary-disease\u0022\u003EAcute Bacterial Exacerbations of Chronic Bronchitis in Patients With Chronic Obstructive Pulmonary Disease: Acute Bacterial Exacerbations of Chronic Bronchitis in Patients\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/27\/2012","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0419 \u0022\u003EFDA-2008-D-0419 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-10-17T14:20:46-04:00\u0022\u003E2019-10-17 14:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/labeling-bronchodilators-cold-cough-allergy-bronchodilator-and-antiasthmatic-drug-products-over\u0022\u003ELabeling for Bronchodilators: Cold, Cough, Allergy, Bronchodilator, And Antiasthmatic Drug Products for Over-the-Counter Human Use (Small Entity Compliance Guide): Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/15\/2012","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Over-the-Counter Drugs","field_topics":"","topics-product":"Over-the-Counter Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Small Entity Compliance Guide","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T01:43:02-04:00\u0022\u003E2020-04-24 01:43\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-entity-compliance-guide-registration-food-facilities\u0022\u003ESmall Entity Compliance Guide: Registration of Food Facilities\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/85098\/download\u0022\u003EPDF (361.57 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (361.57 KB) of Small Entity Compliance Guide: Registration of Food Facilities\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/29\/2018","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"Registration","topics-product":"Registration, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-1003\u0022\u003EFDA-2012-D-1003\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-12T10:32:53-04:00\u0022\u003E2025-03-12 10:32\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-questions-and-answers-regarding-food-facility-registration-seventh-edition\u0022\u003EGuidance for Industry: Questions and Answers Regarding Food Facility Registration (Seventh Edition)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/85043\/download\u0022\u003EPDF (463.59 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (463.59 KB) of Guidance for Industry: Questions and Answers Regarding Food Facility Registration (Seventh Edition)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/20\/2018","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"Registration","topics-product":"Registration, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-1002\u0022\u003EFDA-2012-D-1002\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-12T10:30:47-04:00\u0022\u003E2025-03-12 10:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-submitting-report-multiple-facilities-reportable-food-electronic-portal\u0022\u003EGuidance for Industry: Submitting a Report for Multiple Facilities to the Reportable Food Electronic Portal as Established by the Food and Drug Administration Amendments Act of 2007\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/25\/2010","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Reportable Food Registry","field_topics":"","topics-product":"Reportable Food Registry","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0260\u0022\u003EFDA-2009-D-0260\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:51-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pulse-oximeters-premarket-notification-submissions-510ks-guidance-industry-and-food-and-drug\u0022\u003EPulse Oximeters - Premarket Notification Submissions [510(k)s]: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72470\/download\u0022\u003EPDF (194.2 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (194.2 KB) of Pulse Oximeters - Premarket Notification Submissions [510(k)s]: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/03\/2013","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Pediatric Product Development","field_topics":"Premarket","topics-product":"Premarket, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2007-D-0205\u0022\u003EFDA-2007-D-0205\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222025-01-31T14:13:46-05:00\u0022\u003E2025-01-31 14:13\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/labeling-and-effectiveness-testing-sunscreen-drug-products-over-counter-human-use-small-entity\u0022\u003ELabeling and Effectiveness Testing: Sunscreen Drug Products for Over-The-Counter Human Use \u2014 Small Entity Compliance Guide: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"12\/06\/2012","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Over-the-Counter Drugs","field_topics":"","topics-product":"Over-the-Counter Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Small Entity Compliance Guide","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T01:35:02-04:00\u0022\u003E2020-04-24 01:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/limiting-use-certain-phthalates-excipients-cder-regulated-products\u0022\u003ELimiting the Use of Certain Phthalates as Excipients in CDER-Regulated Products: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"12\/06\/2012","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-1135\u0022\u003EFDA-2012-D-1135\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-02-25T16:30:17-05:00\u0022\u003E2022-02-25 16:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-entity-compliance-guide-what-you-need-know-about-administrative-detention-foods\u0022\u003ESmall Entity Compliance Guide: What You Need To Know About Administrative Detention of Foods\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/85381\/download\u0022\u003EPDF (80.88 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (80.88 KB) of Small Entity Compliance Guide: What You Need To Know About Administrative Detention of Foods\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/08\/2013","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0643\u0022\u003EFDA-2011-D-0643\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:51-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/establishing-performance-characteristics-in-vitro-diagnostic-devices-detection-antibodies-borrelia\u0022\u003EEstablishing the Performance Characteristics of In Vitro Diagnostic Devices for the Detection of Antibodies to Borrelia burgdorferi - Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/85572\/download\u0022\u003EPDF (177.73 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (177.73 KB) of Establishing the Performance Characteristics of In Vitro Diagnostic Devices for the Detection of Antibodies to Borrelia burgdorferi - Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/27\/2013","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Laboratory Tests","field_topics":"Premarket","topics-product":"Premarket, Laboratory Tests","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0095\u0022\u003EFDA-2008-D-0095\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-02-28T14:24:16-05:00\u0022\u003E2020-02-28 14:24\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/glass-syringes-delivering-drug-and-biological-products-technical-information-supplement\u0022\u003EGlass Syringes for Delivering Drug and Biological Products: Technical Information to Supplement International Organization for Standardization (ISO) Standard 11040-4: Draft Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/85748\/download\u0022\u003EPDF (178.04 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (178.04 KB) of Glass Syringes for Delivering Drug and Biological Products: Technical Information to Supplement International Organization for Standardization (ISO) Standard 11040-4: Draft Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/31\/2013","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products","field_health_topics":"","term_node_tid":"Combination Products","field_topics":"","topics-product":"Combination Products","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"07\/01\/2013","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0362\u0022\u003EFDA-2013-D-0362\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222026-03-24T08:01:47-04:00\u0022\u003E2026-03-24 08:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-510800-beverages-serving-size-labeling\u0022\u003ECPG Sec 510.800 Beverages-Serving Size Labeling\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"12\/01\/2010","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Beverage Bases\/Conc\/Nectar","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Beverage Bases\/Conc\/Nectar","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T14:40:47-05:00\u0022\u003E2025-03-05 14:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/annex-13-bulk-density-and-tapped-density-powders-general-chapter\u0022\u003EAnnex 13 Bulk Density and Tapped Density of Powders General Chapter\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/78958\/download\u0022\u003EPDF (93.51 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (93.51 KB) of Annex 13 Bulk Density and Tapped Density of Powders General Chapter\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/23\/2013","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"","changed":"\u003Ctime datetime=\u00222022-02-25T14:26:03-05:00\u0022\u003E2022-02-25 14:26\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-action-level-inorganic-arsenic-apple-juice\u0022\u003EGuidance for Industry: Action Level for Inorganic Arsenic in Apple Juice\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/86110\/download\u0022\u003EPDF (322.08 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (322.08 KB) of Guidance for Industry: Action Level for Inorganic Arsenic in Apple Juice\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/01\/2023","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Arsenic, Juice","field_topics":"","topics-product":"Arsenic, Juice","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-0322\u0022\u003EFDA-2012-D-0322\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:53-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-questions-and-answers-regarding-final-rule-prevention-salmonella-enteritidis-shell-0\u0022\u003EGuidance for Industry: Questions and Answers Regarding the Final Rule on Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation (Layers with Access to Areas Outside the Poultry House)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/86276\/download\u0022\u003EPDF (550.78 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (550.78 KB) of Guidance for Industry: Questions and Answers Regarding the Final Rule on Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation (Layers with Access to Areas Outside the Poultry House)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/10\/2022","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Egg\/Egg Product, Transportation","field_topics":"","topics-product":"Egg\/Egg Product, Transportation","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"09\/23\/2013","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2000-N-0190\u0022\u003EFDA-2000-N-0190\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:54-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/irb-responsibilities-reviewing-qualifications-investigators-adequacy-research-sites-and\u0022\u003EIRB Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of Research Sites, and the Determination of Whether an IND\/IDE is Needed: Guidance for IRBs, Clinical Investigators, and Sponsors\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/85294\/download\u0022\u003EPDF (47.44 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (47.44 KB) of IRB Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of Research Sites, and the Determination of Whether an IND\/IDE is Needed: Guidance for IRBs, Clinical Investigators, and Sponsors\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/27\/2013","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Good Clinical Practice (GCP)","field_topics":"","topics-product":"Administrative \/ Procedural, Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-0847\u0022\u003EFDA-2012-D-0847\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222021-07-22T11:01:04-04:00\u0022\u003E2021-07-22 11:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-acrylamide-foods\u0022\u003EGuidance for Industry: Acrylamide in Foods\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/87150\/download\u0022\u003EPDF (1.28 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.28 MB) of Guidance for Industry: Acrylamide in Foods\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/11\/2016","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0715\u0022\u003EFDA-2013-D-0715\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:55-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/regulatory-requirements-hearing-aid-devices-and-personal-sound-amplification-products\u0022\u003ERegulatory Requirements for Hearing Aid Devices and Personal Sound Amplification Products: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/87330\/download\u0022\u003EPDF (462.66 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (462.66 KB) of Regulatory Requirements for Hearing Aid Devices and Personal Sound Amplification Products: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/17\/2022","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1380\u0022\u003EFDA-2020-D-1380\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222022-10-17T13:16:24-04:00\u0022\u003E2022-10-17 13:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-distinguishing-liquid-dietary-supplements-beverages\u0022\u003EGuidance for Industry: Distinguishing Liquid Dietary Supplements from Beverages\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/87567\/download\u0022\u003EPDF (202.31 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (202.31 KB) of Guidance for Industry: Distinguishing Liquid Dietary Supplements from Beverages\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/14\/2014","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0542\u0022\u003EFDA-2009-D-0542\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Dietary Supplements, Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:57-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-dear-manufacturer-letter-regarding-changes-fdas-administration-process-filings\u0022\u003EGuidance for Industry: Dear Manufacturer Letter Regarding Changes to FDA\u0026#039;s Administration of Process Filings (Forms FDA 2541a and FDA 2541c) for Acidified Foods and Low-Acid Canned Foods\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/87625\/download\u0022\u003EPDF (104.95 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (104.95 KB) of Guidance for Industry: Dear Manufacturer Letter Regarding Changes to FDA\u0026#039;s Administration of Process Filings (Forms FDA 2541a and FDA 2541c) for Acidified Foods and Low-Acid Canned Foods\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/31\/2013","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Canned Foods","field_topics":"","topics-product":"Canned Foods","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Industry Letter","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:03:58-04:00\u0022\u003E2024-10-01 07:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-establishing-and-maintaining-list-us-milk-and-milk-product-seafood-infant-formula\u0022\u003EGuidance for Industry: Establishing and Maintaining a List of U.S. Milk and Milk Product, Seafood, Infant Formula, and Formula for Young Children Manufacturers\/Processors with Interest in Exporting to China\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/87676\/download\u0022\u003EPDF (52.84 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (52.84 KB) of Guidance for Industry: Establishing and Maintaining a List of U.S. Milk and Milk Product, Seafood, Infant Formula, and Formula for Young Children Manufacturers\/Processors with Interest in Exporting to China\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/27\/2018","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Export, Seafood\/Seafood Product, Milk\/Milk Product, Infant Formula \u0026amp; Foods","field_topics":"","topics-product":"Export, Seafood\/Seafood Product, Milk\/Milk Product, Infant Formula \u0026amp; Foods","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-4484\u0022\u003EFDA-2016-D-4484\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-10T15:09:16-04:00\u0022\u003E2025-03-10 15:09\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-considerations-regarding-substances-added-foods-including-beverages-and-dietary\u0022\u003EGuidance for Industry: Considerations Regarding Substances Added to Foods, Including Beverages and Dietary Supplements\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/87680\/download\u0022\u003EPDF (108.06 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (108.06 KB) of Guidance for Industry: Considerations Regarding Substances Added to Foods, Including Beverages and Dietary Supplements\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/14\/2014","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Ingredients","field_topics":"","topics-product":"Ingredients","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0542\u0022\u003EFDA-2009-D-0542\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Dietary Supplements, Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:04:02-04:00\u0022\u003E2024-10-01 07:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-proper-labeling-honey-and-honey-products\u0022\u003EGuidance for Industry: Proper Labeling of Honey and Honey Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/110846\/download\u0022\u003EPDF (70.21 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (70.21 KB) of Guidance for Industry: Proper Labeling of Honey and Honey Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/02\/2018","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling, Nutrition Label","field_topics":"","topics-product":"Labeling, Nutrition Label","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2006-P-0207\u0022\u003EFDA-2006-P-0207\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-18T13:46:31-04:00\u0022\u003E2025-03-18 13:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/enforcement-policy-certain-provisional-tobacco-products-fda-finds-not-substantially-equivalent\u0022\u003EEnforcement Policy for Certain (Provisional) Tobacco Products that FDA Finds Not Substantially Equivalent: Guidance for Industry and Tobacco Retailers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/87919\/download\u0022\u003EPDF (24.78 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (24.78 KB) of Enforcement Policy for Certain (Provisional) Tobacco Products that FDA Finds Not Substantially Equivalent: Guidance for Industry and Tobacco Retailers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/14\/2015","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-1600\u0022\u003EFDA-2013-D-1600\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222020-07-28T10:40:53-04:00\u0022\u003E2020-07-28 10:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/meaning-spouse-and-family-fdas-regulations-after-supreme-courts-ruling-united-states-v-windsor\u0022\u003EThe Meaning of \u0026quot;Spouse\u0026quot; and \u0026quot;Family\u0026quot; in FDA\u0026#039;s Regulations after the Supreme Court\u0026#039;s Ruling in United States v. Windsor: Questions and Answers: Guidance for Industry, Consumers, and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/88114\/download\u0022\u003EPDF (37.72 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (37.72 KB) of The Meaning of \u0026quot;Spouse\u0026quot; and \u0026quot;Family\u0026quot; in FDA\u0026#039;s Regulations after the Supreme Court\u0026#039;s Ruling in United States v. Windsor: Questions and Answers: Guidance for Industry, Consumers, and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/31\/2014","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Policy, Legislation, and International Affairs,Office of Policy","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Food \u0026amp; Color Additives","field_topics":"","topics-product":"Administrative \/ Procedural, Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0261\u0022\u003EFDA-2014-D-0261\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222019-04-20T22:40:04-04:00\u0022\u003E2019-04-20 22:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-exempt-infant-formula-production\u0022\u003EGuidance for Industry: Exempt Infant Formula Production\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/87996\/download\u0022\u003EPDF (255.08 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (255.08 KB) of Guidance for Industry: Exempt Infant Formula Production\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/15\/2016","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Infant Formula \u0026amp; Foods","field_topics":"","topics-product":"Infant Formula \u0026amp; Foods","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0044\u0022\u003EFDA-2014-D-0044\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:04:04-04:00\u0022\u003E2024-10-01 07:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/public-availability-advisory-committee-members-financial-interest-information-and-waivers\u0022\u003EPublic Availability of Advisory Committee Members\u0026#039; Financial Interest Information and Waivers: Guidance for the Public, FDA Advisory Committee Members, and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/83188\/download\u0022\u003EPDF (93.78 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (93.78 KB) of Public Availability of Advisory Committee Members\u0026#039; Financial Interest Information and Waivers: Guidance for the Public, FDA Advisory Committee Members, and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/28\/2014","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"Advisory Committees","topics-product":"Advisory Committees, Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222019-04-20T23:10:10-04:00\u0022\u003E2019-04-20 23:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-entity-compliance-guide-what-you-need-know-about-establishment-and-maintenance-records\u0022\u003ESmall Entity Compliance Guide: What You Need to Know About Establishment and Maintenance of Records\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/88292\/download\u0022\u003EPDF (90.59 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (90.59 KB) of Small Entity Compliance Guide: What You Need to Know About Establishment and Maintenance of Records\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/04\/2014","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Records","field_topics":"","topics-product":"Records","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-N-1421\u0022\u003EFDA-2013-N-1421\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Human Foods Program","field_regulated_product_field":"Animal \u0026amp; Veterinary, Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:04:06-04:00\u0022\u003E2024-10-01 07:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/surveying-leveling-and-alignment-laser-products\u0022\u003ESurveying, Leveling, and Alignment Laser Products: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/88325\/download\u0022\u003EPDF (618.11 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (618.11 KB) of Surveying, Leveling, and Alignment Laser Products: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/31\/2023","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Laser Notice, Radiological Health","field_topics":"","topics-product":"Laser Notice, Radiological Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0435\u0022\u003EFDA-2014-D-0435\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222023-01-30T09:10:46-05:00\u0022\u003E2023-01-30 09:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/live-case-presentations-during-investigational-device-exemption-ide-clinical-trials\u0022\u003ELive Case Presentations During Investigational Device Exemption (IDE) Clinical Trials: Guidance for Institutional Review Boards, Industry, Clinical Investigators, and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/88454\/download\u0022\u003EPDF (345.35 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (345.35 KB) of Live Case Presentations During Investigational Device Exemption (IDE) Clinical Trials: Guidance for Institutional Review Boards, Industry, Clinical Investigators, and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/11\/2019","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP), Pediatric Product Development, Investigational Device Exemption (IDE)","field_topics":"Premarket","topics-product":"Premarket, Good Clinical Practice (GCP), Pediatric Product Development, Investigational Device Exemption (IDE)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0331\u0022\u003EFDA-2014-D-0331\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222024-04-11T11:37:52-04:00\u0022\u003E2024-04-11 11:37\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-food-allergen-labeling-exemption-petitions-and-notifications\u0022\u003EGuidance for Industry: Food Allergen Labeling Exemption Petitions and Notifications\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/88332\/download\u0022\u003EPDF (653.6 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (653.6 KB) of Guidance for Industry: Food Allergen Labeling Exemption Petitions and Notifications\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/19\/2015","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Allergens, Labeling","field_topics":"","topics-product":"Allergens, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0052\u0022\u003EFDA-2014-D-0052\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:04:08-04:00\u0022\u003E2024-10-01 07:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-demonstration-quality-factor-requirements-under-21-cfr-10696i-eligible-infant\u0022\u003EGuidance for Industry: Demonstration of the Quality Factor Requirements Under 21 CFR 106.96(i) for \u0026quot;Eligible\u0026quot; Infant Formulas\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/88686\/download\u0022\u003EPDF (135.65 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (135.65 KB) of Guidance for Industry: Demonstration of the Quality Factor Requirements Under 21 CFR 106.96(i) for \u0026quot;Eligible\u0026quot; Infant Formulas\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/10\/2014","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Infant Formula \u0026amp; Foods","field_topics":"","topics-product":"Infant Formula \u0026amp; Foods","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0033\u0022\u003EFDA-2014-D-0033\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:04:09-04:00\u0022\u003E2024-10-01 07:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-dietary-supplement-labeling-guide\u0022\u003EGuidance for Industry: Dietary Supplement Labeling Guide\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/31\/2005","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-D-0544\u0022\u003EFDA-2004-D-0544\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Dietary Supplements, Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:04:11-04:00\u0022\u003E2024-10-01 07:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-entity-compliance-guide-gluten-free-labeling-foods\u0022\u003ESmall Entity Compliance Guide: Gluten-Free Labeling of Foods\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/88857\/download\u0022\u003EPDF (78.21 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (78.21 KB) of Small Entity Compliance Guide: Gluten-Free Labeling of Foods\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/26\/2014","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Allergens, Labeling","field_topics":"","topics-product":"Allergens, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2005-N-0404\u0022\u003EFDA-2005-N-0404\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:04:12-04:00\u0022\u003E2024-10-01 07:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/informed-consent\u0022\u003EInformed Consent: Guidance for IRBs, Clinical Investigators, and Sponsors\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/88915\/download\u0022\u003EPDF (747.35 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (747.35 KB) of Informed Consent: Guidance for IRBs, Clinical Investigators, and Sponsors\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/15\/2023","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP), Pediatric Product Development","field_topics":"","topics-product":"Good Clinical Practice (GCP), Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2006-D-0031\u0022\u003EFDA-2006-D-0031\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222024-04-11T11:28:01-04:00\u0022\u003E2024-04-11 11:28\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/establishing-tobacco-product-was-commercially-marketed-united-states-february-15-2007-revised\u0022\u003EEstablishing That a Tobacco Product Was Commercially Marketed in the United States as of February 15, 2007 (Revised): Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/173091\/download\u0022\u003EPDF (295.64 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (295.64 KB) of Establishing That a Tobacco Product Was Commercially Marketed in the United States as of February 15, 2007 (Revised): Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/18\/2023","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0125\u0022\u003EFDA-2011-D-0125\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222023-10-17T11:12:46-04:00\u0022\u003E2023-10-17 11:12\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/rare-pediatric-disease-priority-review-vouchers\u0022\u003ERare Pediatric Disease Priority Review Vouchers: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/90014\/download\u0022\u003EPDF (306.41 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (306.41 KB) of Rare Pediatric Disease Priority Review Vouchers: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/30\/2019","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Orphan Products Development","field_health_topics":"Rare Diseases","term_node_tid":"Administrative \/ Procedural, Pediatric Product Development","field_topics":"","topics-product":"Rare Diseases, Administrative \/ Procedural, Pediatric Product Development","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"09\/28\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-1461\u0022\u003EFDA-2014-D-1461\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T09:32:31-04:00\u0022\u003E2024-04-11 09:32\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/demonstrating-substantial-equivalence-new-tobacco-product-responses-frequently-asked-questions\u0022\u003EDemonstrating the Substantial Equivalence of a New Tobacco Product: Responses to Frequently Asked Questions (Revised): Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/173089\/download\u0022\u003EPDF (444.72 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (444.72 KB) of Demonstrating the Substantial Equivalence of a New Tobacco Product: Responses to Frequently Asked Questions (Revised): Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/18\/2023","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0147\u0022\u003EFDA-2011-D-0147\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222023-10-17T11:13:03-04:00\u0022\u003E2023-10-17 11:13\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-entity-compliance-guide-nutrition-labeling-standard-menu-items-restaurants-and-similar-retail\u0022\u003ESmall Entity Compliance Guide: Nutrition Labeling of Standard Menu Items in Restaurants and Similar Retail Food Establishments\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/91148\/download\u0022\u003EPDF (282.72 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (282.72 KB) of Small Entity Compliance Guide: Nutrition Labeling of Standard Menu Items in Restaurants and Similar Retail Food Establishments\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/13\/2015","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling, Nutrition","field_topics":"","topics-product":"Labeling, Nutrition","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-F-0172\u0022\u003EFDA-2011-F-0172\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:04:16-04:00\u0022\u003E2024-10-01 07:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-and-fda-staff-questions-and-answers-regarding-mandatory-food-recalls\u0022\u003EGuidance for Industry and FDA Staff: Questions and Answers Regarding Mandatory Food Recalls\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/117429\/download\u0022\u003EPDF (113.13 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (113.13 KB) of Guidance for Industry and FDA Staff: Questions and Answers Regarding Mandatory Food Recalls\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/06\/2018","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"Recalls","topics-product":"Recalls, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-0138\u0022\u003EFDA-2015-D-0138\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Animal \u0026amp; Veterinary, Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-10T15:33:27-04:00\u0022\u003E2025-03-10 15:33\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-fdas-voluntary-qualified-importer-program\u0022\u003EGuidance for Industry: FDA\u0026#039;s Voluntary Qualified Importer Program\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/92196\/download\u0022\u003EPDF (358.87 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (358.87 KB) of Guidance for Industry: FDA\u0026#039;s Voluntary Qualified Importer Program\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/14\/2024","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Import","field_topics":"","topics-product":"Import","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-N-0144\u0022\u003EFDA-2011-N-0144\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-11-14T08:51:35-05:00\u0022\u003E2024-11-14 08:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/determination-period-covered-no-tobacco-sale-order-and-compliance-order\u0022\u003EDetermination of the Period Covered by a No-Tobacco-Sale Order and Compliance With an Order: Guidance for Tobacco Retailers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/93328\/download\u0022\u003EPDF (268.96 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (268.96 KB) of Determination of the Period Covered by a No-Tobacco-Sale Order and Compliance With an Order: Guidance for Tobacco Retailers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/17\/2023","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"No-tobacco-sale order (NTSO)","field_topics":"","topics-product":"No-tobacco-sale order (NTSO)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-0404\u0022\u003EFDA-2015-D-0404\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222023-03-17T15:41:37-04:00\u0022\u003E2023-03-17 15:41\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/civil-money-penalties-and-no-tobacco-sale-orders-tobacco-retailers-revised\u0022\u003ECivil Money Penalties and No-Tobacco-Sale Orders For Tobacco Retailers (*Revised): Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/80888\/download\u0022\u003EPDF (547.39 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (547.39 KB) of Civil Money Penalties and No-Tobacco-Sale Orders For Tobacco Retailers (*Revised): Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/31\/2023","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"No-tobacco-sale order (NTSO)","field_topics":"","topics-product":"No-tobacco-sale order (NTSO)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0431\u0022\u003EFDA-2010-D-0431\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222023-08-31T13:43:35-04:00\u0022\u003E2023-08-31 13:43\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-and-fda-staff-model-accreditation-standards-third-party-certification-body\u0022\u003EGuidance for Industry and FDA Staff: Model Accreditation Standards for Third-Party Certification Body Accreditation for Food Safety Audits\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/92999\/download\u0022\u003EPDF (367.35 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (367.35 KB) of Guidance for Industry and FDA Staff: Model Accreditation Standards for Third-Party Certification Body Accreditation for Food Safety Audits\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/24\/2022","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Import","field_topics":"","topics-product":"Import","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-N-0146\u0022\u003EFDA-2011-N-0146\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:04:25-04:00\u0022\u003E2024-10-01 07:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-fdas-policy-declaring-small-amounts-nutrients-and-dietary-ingredients-nutrition\u0022\u003EGuidance for Industry: FDA\u0026#039;s Policy on Declaring Small Amounts of Nutrients and Dietary Ingredients on Nutrition Labels\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/98834\/download\u0022\u003EPDF (99.12 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (99.12 KB) of Guidance for Industry: FDA\u0026#039;s Policy on Declaring Small Amounts of Nutrients and Dietary Ingredients on Nutrition Labels\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/01\/2016","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling, Nutrition Label","field_topics":"","topics-product":"Labeling, Nutrition Label","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-1839\u0022\u003EFDA-2015-D-1839\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:04:27-04:00\u0022\u003E2024-10-01 07:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-labeling-guide-restaurants-and-retail-establishments-selling-away-home-foods-part-0\u0022\u003EGuidance for Industry: A Labeling Guide for Restaurants and Retail Establishments Selling Away-From-Home Foods - Part II \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/93414\/download\u0022\u003EPDF (349.16 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (349.16 KB) of Guidance for Industry: A Labeling Guide for Restaurants and Retail Establishments Selling Away-From-Home Foods - Part II \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/05\/2016","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-F-0172\u0022\u003EFDA-2011-F-0172\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:04:28-04:00\u0022\u003E2024-10-01 07:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/use-investigational-tobacco-products\u0022\u003EUse of Investigational Tobacco Products: Draft Guidance for Industry and Investigators\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/94052\/download\u0022\u003EPDF (734.03 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (734.03 KB) of Use of Investigational Tobacco Products: Draft Guidance for Industry and Investigators\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/20\/2019","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"04\/21\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-1939\u0022\u003EFDA-2014-D-1939\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222020-08-13T11:50:35-04:00\u0022\u003E2020-08-13 11:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/draft-guidance-industry-voluntary-labeling-indicating-whether-food-has-or-has-not-been-derived\u0022\u003EDraft Guidance for Industry: Voluntary Labeling Indicating Whether Food Has or Has Not Been Derived From Genetically Engineered Atlantic Salmon\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/120960\/download\u0022\u003EPDF (102.78 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (102.78 KB) of Draft Guidance for Industry: Voluntary Labeling Indicating Whether Food Has or Has Not Been Derived From Genetically Engineered Atlantic Salmon\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/11\/2019","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Bioengineering \/ GMOs, Labeling","field_topics":"","topics-product":"Bioengineering \/ GMOs, Labeling","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"01\/25\/2016","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-4272\u0022\u003EFDA-2015-D-4272\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Animal \u0026amp; Veterinary, Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-12T10:25:24-04:00\u0022\u003E2025-03-12 10:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-questions-and-answers-fdas-fortification-policy\u0022\u003EGuidance for Industry: Questions and Answers on FDA\u2019s Fortification Policy\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/94563\/download\u0022\u003EPDF (127.24 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (127.24 KB) of Guidance for Industry: Questions and Answers on FDA\u2019s Fortification Policy\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/05\/2015","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Nutrition","field_topics":"","topics-product":"Nutrition","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:04:31-04:00\u0022\u003E2024-10-01 07:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/national-environmental-policy-act-environmental-assessments-tobacco-products-categorical-exclusions\u0022\u003ENational Environmental Policy Act; Environmental Assessments for Tobacco Products; Categorical Exclusions \u2013 Small Entity Compliance Guide: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/94445\/download\u0022\u003EPDF (41.92 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (41.92 KB) of National Environmental Policy Act; Environmental Assessments for Tobacco Products; Categorical Exclusions \u2013 Small Entity Compliance Guide: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/26\/2015","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"Environmental Safety","field_topics":"","topics-product":"Environmental Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-N-1282\u0022\u003EFDA-2013-N-1282\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222020-07-28T10:31:15-04:00\u0022\u003E2020-07-28 10:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/minutes-institutional-review-board-irb-meetings\u0022\u003EMinutes of Institutional Review Board (IRB) Meetings: Guidance for Institutions and IRBs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/94686\/download\u0022\u003EPDF (117.59 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (117.59 KB) of Minutes of Institutional Review Board (IRB) Meetings: Guidance for Institutions and IRBs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/25\/2017","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP), Pediatric Product Development","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Good Clinical Practice (GCP), Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"01\/04\/2016","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-3638\u0022\u003EFDA-2015-D-3638\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222024-11-14T16:25:47-05:00\u0022\u003E2024-11-14 16:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-action-level-inorganic-arsenic-rice-cereals-infants\u0022\u003EGuidance for Industry: Action Level for Inorganic Arsenic in Rice Cereals for Infants\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/97234\/download\u0022\u003EPDF (124.11 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (124.11 KB) of Guidance for Industry: Action Level for Inorganic Arsenic in Rice Cereals for Infants\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/04\/2020","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Arsenic, Infant Formula \u0026amp; Foods","field_topics":"","topics-product":"Arsenic, Infant Formula \u0026amp; Foods","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-1099\u0022\u003EFDA-2016-D-1099\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-12T10:19:16-04:00\u0022\u003E2025-03-12 10:19\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-entity-compliance-guide-alpha-linolenic-acid-eicosapentaenoic-acid-and-docosahexaenoic-acid\u0022\u003ESmall Entity Compliance Guide: Alpha-Linolenic Acid, Eicosapentaenoic Acid, and Docosahexaenoic Acid Omega-3 Fatty Acids Nutrient Content Claims\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/95996\/download\u0022\u003EPDF (227.46 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (227.46 KB) of Small Entity Compliance Guide: Alpha-Linolenic Acid, Eicosapentaenoic Acid, and Docosahexaenoic Acid Omega-3 Fatty Acids Nutrient Content Claims\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/23\/2016","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-N-0585\u0022\u003EFDA-2016-N-0585\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:04:35-04:00\u0022\u003E2024-10-01 07:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-voluntary-sodium-reduction-goals\u0022\u003EGuidance for Industry: Voluntary Sodium Reduction Goals: Target Mean and Upper Bound Concentrations for Sodium in Commercially Processed, Packaged, and Prepared Foods\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/98264\/download\u0022\u003EPDF (35.76 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (35.76 KB) of Guidance for Industry: Voluntary Sodium Reduction Goals: Target Mean and Upper Bound Concentrations for Sodium in Commercially Processed, Packaged, and Prepared Foods\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/13\/2021","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Nutrition","field_topics":"","topics-product":"Nutrition","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0055\u0022\u003EFDA-2014-D-0055\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:04:36-04:00\u0022\u003E2024-10-01 07:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-determination-status-qualified-facility\u0022\u003EGuidance for Industry: Determination of Status as a Qualified Facility\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/125438\/download\u0022\u003EPDF (379.13 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (379.13 KB) of Guidance for Industry: Determination of Status as a Qualified Facility\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/17\/2018","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-1164\u0022\u003EFDA-2016-D-1164\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Animal \u0026amp; Veterinary, Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222026-09-28T10:20:03-04:00\u0022\u003E2026-09-28 10:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/tobacco-product-master-files\u0022\u003ETobacco Product Master Files: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/97632\/download\u0022\u003EPDF (153.37 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (153.37 KB) of Tobacco Product Master Files: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/10\/2016","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-2325\u0022\u003EFDA-2015-D-2325\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222020-07-28T10:30:53-04:00\u0022\u003E2020-07-28 10:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/premarket-tobacco-product-applications-electronic-nicotine-delivery-systems-ends\u0022\u003EPremarket Tobacco Product Applications for Electronic Nicotine Delivery Systems (ENDS): Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/127853\/download\u0022\u003EPDF (1.92 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.92 MB) of Premarket Tobacco Product Applications for Electronic Nicotine Delivery Systems (ENDS): Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/17\/2023","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"Electronic Nicotine Delivery Systems (ENDS), Product Application and Review","field_topics":"","topics-product":"Electronic Nicotine Delivery Systems (ENDS), Product Application and Review","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-2496\u0022\u003EFDA-2015-D-2496\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222025-02-11T10:15:52-05:00\u0022\u003E2025-02-11 10:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/fda-deems-certain-tobacco-products-subject-fda-authority-sales-and-distribution-restrictions-and\u0022\u003EFDA Deems Certain Tobacco Products Subject to FDA Authority, Sales and Distribution Restrictions, and Health Warning Requirements for Packages and Advertisements: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/143049\/download\u0022\u003EPDF (857.04 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (857.04 KB) of FDA Deems Certain Tobacco Products Subject to FDA Authority, Sales and Distribution Restrictions, and Health Warning Requirements for Packages and Advertisements: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/17\/2023","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-N-0189\u0022\u003EFDA-2014-N-0189\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222023-03-17T15:41:03-04:00\u0022\u003E2023-03-17 15:41\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/requirements-submission-data-needed-calculate-user-fees-domestic-manufacturers-and-importers-tobacco\u0022\u003ERequirements for the Submission of Data Needed to Calculate User Fees for Domestic Manufacturers and Importers of Tobacco Products: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/97683\/download\u0022\u003EPDF (93.03 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (93.03 KB) of Requirements for the Submission of Data Needed to Calculate User Fees for Domestic Manufacturers and Importers of Tobacco Products: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/10\/2016","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"User Fees","field_topics":"","topics-product":"User Fees","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0917\u0022\u003EFDA-2014-D-0917\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222023-05-02T10:48:16-04:00\u0022\u003E2023-05-02 10:48\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-standards-growing-harvesting-packing-and-holding-sprouts-human-consumption\u0022\u003EGuidance for Industry: Standards for the Growing, Harvesting, Packing, and Holding of Sprouts for Human Consumption \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/102430\/download\u0022\u003EPDF (3.89 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (3.89 MB) of Guidance for Industry: Standards for the Growing, Harvesting, Packing, and Holding of Sprouts for Human Consumption \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/28\/2023","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Produce","field_topics":"","topics-product":"Produce","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-0175\u0022\u003EFDA-2017-D-0175\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T14:32:32-04:00\u0022\u003E2025-03-17 14:32\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-entity-compliance-guide-calorie-labeling-articles-food-vending-machines\u0022\u003ESmall Entity Compliance Guide: Calorie Labeling of Articles of Food in Vending Machines\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/99885\/download\u0022\u003EPDF (447.85 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (447.85 KB) of Small Entity Compliance Guide: Calorie Labeling of Articles of Food in Vending Machines\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/16\/2016","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling, Nutrition Label","field_topics":"","topics-product":"Labeling, Nutrition Label","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-F-0171\u0022\u003EFDA-2011-F-0171\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:04:40-04:00\u0022\u003E2024-10-01 07:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/draft-guidance-industry-calorie-labeling-articles-food-vending-machines\u0022\u003EDraft Guidance for Industry: Calorie Labeling of Articles of Food in Vending Machines\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/99814\/download\u0022\u003EPDF (109.07 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (109.07 KB) of Draft Guidance for Industry: Calorie Labeling of Articles of Food in Vending Machines\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/16\/2016","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling, Nutrition Label","field_topics":"","topics-product":"Labeling, Nutrition Label","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"09\/30\/2016","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-F-0171\u0022\u003EFDA-2011-F-0171\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:04:40-04:00\u0022\u003E2024-10-01 07:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/gifts-fda-evaluation-and-acceptance\u0022\u003EGifts to FDA: Evaluation and Acceptance: Guidance for the Public and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/98917\/download\u0022\u003EPDF (95.02 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (95.02 KB) of Gifts to FDA: Evaluation and Acceptance: Guidance for the Public and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/16\/2016","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Policy, Legislation, and International Affairs,Office of Policy","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"09\/12\/2016","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-4361\u0022\u003EFDA-2015-D-4361\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"","changed":"\u003Ctime datetime=\u00222019-04-20T22:20:05-04:00\u0022\u003E2019-04-20 22:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/institutional-review-board-irb-written-procedures\u0022\u003EInstitutional Review Board (IRB) Written Procedures: Guidance for Institutions and IRBs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/185365\/download\u0022\u003EPDF (339.17 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (339.17 KB) of Institutional Review Board (IRB) Written Procedures: Guidance for Institutions and IRBs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/05\/2025","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of the Chief Medical Officer,Office of Clinical Policy","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP), Pediatric Product Development","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Good Clinical Practice (GCP), Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"09\/30\/2016","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-1605\u0022\u003EFDA-2016-D-1605\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222025-07-09T09:27:16-04:00\u0022\u003E2025-07-09 09:27\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/draft-guidance-industry-hazard-analysis-and-risk-based-preventive-controls-human-food\u0022\u003EDraft Guidance for Industry: Hazard Analysis and Risk-Based Preventive Controls for Human Food\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/100002\/download\u0022\u003EPDF (118 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (118 KB) of Draft Guidance for Industry: Hazard Analysis and Risk-Based Preventive Controls for Human Food\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/30\/2024","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"08\/02\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-2343\u0022\u003EFDA-2016-D-2343\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222026-10-22T11:43:05-04:00\u0022\u003E2026-10-22 11:43\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-labeling-infant-formula\u0022\u003EGuidance for Industry: Labeling of Infant Formula\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/99701\/download\u0022\u003EPDF (281.28 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (281.28 KB) of Guidance for Industry: Labeling of Infant Formula\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/06\/2023","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Infant Formula \u0026amp; Foods, Labeling","field_topics":"","topics-product":"Infant Formula \u0026amp; Foods, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-S-0610\u0022\u003EFDA-2013-S-0610\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T08:50:31-05:00\u0022\u003E2025-03-06 08:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/draft-guidance-industry-substantiation-structurefunction-claims-made-infant-formula-labels-and\u0022\u003EDraft Guidance for Industry: Substantiation for Structure\/Function Claims Made in Infant Formula Labels and Labeling\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/99691\/download\u0022\u003EPDF (130.07 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (130.07 KB) of Draft Guidance for Industry: Substantiation for Structure\/Function Claims Made in Infant Formula Labels and Labeling\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/09\/2016","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Infant Formula \u0026amp; Foods, Labeling","field_topics":"","topics-product":"Infant Formula \u0026amp; Foods, Labeling","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"02\/21\/2017","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-2241\u0022\u003EFDA-2016-D-2241\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:04:44-04:00\u0022\u003E2024-10-01 07:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/draft-guidance-industry-classification-activities-harvesting-packing-holding-or\u0022\u003EDraft Guidance for Industry: Classification of Activities as Harvesting, Packing, Holding, or Manufacturing\/Processing for Farms and Facilities\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/99911\/download\u0022\u003EPDF (256.75 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (256.75 KB) of Draft Guidance for Industry: Classification of Activities as Harvesting, Packing, Holding, or Manufacturing\/Processing for Farms and Facilities\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/25\/2016","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"02\/21\/2017","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-2373\u0022\u003EFDA-2016-D-2373\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:04:45-04:00\u0022\u003E2024-10-01 07:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/submission-warning-plans-cigars\u0022\u003ESubmission of Warning Plans for Cigars: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/102554\/download\u0022\u003EPDF (527.27 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (527.27 KB) of Submission of Warning Plans for Cigars: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/09\/2018","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"Cigars, Cigarillos, Little Filtered Cigars, Labeling","field_topics":"","topics-product":"Cigars, Cigarillos, Little Filtered Cigars, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-2495\u0022\u003EFDA-2016-D-2495\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222020-07-28T09:01:07-04:00\u0022\u003E2020-07-28 09:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/draft-guidance-industry-describing-hazard-needs-control-documents-accompanying-food-required-four\u0022\u003EDraft Guidance for Industry: Describing a Hazard That Needs Control in Documents Accompanying the Food, as Required by Four Rules Implementing FSMA\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/100907\/download\u0022\u003EPDF (60.3 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (60.3 KB) of Draft Guidance for Industry: Describing a Hazard That Needs Control in Documents Accompanying the Food, as Required by Four Rules Implementing FSMA\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/30\/2016","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"05\/01\/2017","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-2841\u0022\u003EFDA-2016-D-2841\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:04:47-04:00\u0022\u003E2024-10-01 07:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-use-term-healthy-labeling-human-food-products\u0022\u003EGuidance for Industry: Use of the Term \u201cHealthy\u201d in the Labeling of Human Food Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/100520\/download\u0022\u003EPDF (41.23 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (41.23 KB) of Guidance for Industry: Use of the Term \u201cHealthy\u201d in the Labeling of Human Food Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/28\/2016","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-2335\u0022\u003EFDA-2016-D-2335\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-14T15:13:01-04:00\u0022\u003E2025-03-14 15:13\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-preparation-food-contact-notifications-food-contact-substances-contact-infant\u0022\u003EGuidance for Industry: Preparation of Food Contact Notifications for Food Contact Substances in Contact with Infant Formula and\/or Human Milk\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/124714\/download\u0022\u003EPDF (371.8 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (371.8 KB) of Guidance for Industry: Preparation of Food Contact Notifications for Food Contact Substances in Contact with Infant Formula and\/or Human Milk\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/08\/2019","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Milk\/Milk Product, Food \u0026amp; Color Additives, Infant Formula \u0026amp; Foods","field_topics":"","topics-product":"Milk\/Milk Product, Food \u0026amp; Color Additives, Infant Formula \u0026amp; Foods","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-1814\u0022\u003EFDA-2016-D-1814\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:04:49-04:00\u0022\u003E2024-10-01 07:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-entity-compliance-guide-what-you-need-know-about-current-good-manufacturing-practice-hazard\u0022\u003ESmall Entity Compliance Guide: What You Need to Know About Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/100921\/download\u0022\u003EPDF (313.99 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (313.99 KB) of Small Entity Compliance Guide: What You Need to Know About Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/31\/2016","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-N-0920\u0022\u003EFDA-2011-N-0920\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:04:50-04:00\u0022\u003E2024-10-01 07:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-scientific-evaluation-evidence-beneficial-physiological-effects-isolated-or\u0022\u003EGuidance for Industry: Scientific Evaluation of the Evidence on the Beneficial Physiological Effects of Isolated or Synthetic Non-Digestible Carbohydrates Submitted as a Citizen Petition (21 CFR 10.30)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/101183\/download\u0022\u003EPDF (283.85 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (283.85 KB) of Guidance for Industry: Scientific Evaluation of the Evidence on the Beneficial Physiological Effects of Isolated or Synthetic Non-Digestible Carbohydrates Submitted as a Citizen Petition (21 CFR 10.30)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/02\/2018","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling, Nutrition Label","field_topics":"","topics-product":"Labeling, Nutrition Label","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-3401\u0022\u003EFDA-2016-D-3401\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-18T13:38:02-04:00\u0022\u003E2025-03-18 13:38\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/compliance-policy-required-warning-statements-small-packaged-cigars\u0022\u003ECompliance Policy for Required Warning Statements on Small-Packaged Cigars: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/102295\/download\u0022\u003EPDF (289.81 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (289.81 KB) of Compliance Policy for Required Warning Statements on Small-Packaged Cigars: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/09\/2018","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"Cigars, Cigarillos, Little Filtered Cigars, Labeling","field_topics":"","topics-product":"Cigars, Cigarillos, Little Filtered Cigars, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-0121\u0022\u003EFDA-2017-D-0121\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222020-10-06T10:05:42-04:00\u0022\u003E2020-10-06 10:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/interpretation-and-compliance-policy-certain-label-requirement-applicability-certain-federal-food\u0022\u003EInterpretation of and Compliance Policy for Certain Label Requirement; Applicability of Certain Federal Food, Drug, and Cosmetic Act Requirements to Vape Shops: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/102420\/download\u0022\u003EPDF (345.39 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (345.39 KB) of Interpretation of and Compliance Policy for Certain Label Requirement; Applicability of Certain Federal Food, Drug, and Cosmetic Act Requirements to Vape Shops: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/17\/2023","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-0120\u0022\u003EFDA-2017-D-0120\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222023-03-17T15:41:22-04:00\u0022\u003E2023-03-17 15:41\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/prohibition-distributing-free-samples-tobacco-products\u0022\u003EProhibition of Distributing Free Samples of Tobacco Products: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/118928\/download\u0022\u003EPDF (269.44 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (269.44 KB) of Prohibition of Distributing Free Samples of Tobacco Products: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/17\/2023","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"Free samples","field_topics":"","topics-product":"Free samples","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-0113\u0022\u003EFDA-2017-D-0113\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222023-03-17T15:41:25-04:00\u0022\u003E2023-03-17 15:41\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/how-prepare-pre-request-designation-pre-rfd\u0022\u003EHow to Prepare a Pre-Request for Designation (Pre-RFD): Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/189466\/download\u0022\u003EPDF (304.19 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (304.19 KB) of How to Prepare a Pre-Request for Designation (Pre-RFD): Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/06\/2025","field_issuing_office_taxonomy":"Office of the Commissioner,Office of the Chief Medical Officer,Office of Combination Products","field_health_topics":"","term_node_tid":"Combination Products","field_topics":"","topics-product":"Combination Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"04\/13\/2017","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-0040\u0022\u003EFDA-2017-D-0040\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222026-09-04T12:42:13-04:00\u0022\u003E2026-09-04 12:42\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-reference-amounts-customarily-consumed-list-products-each-product-category\u0022\u003EGuidance for Industry: Reference Amounts Customarily Consumed (List of Products for Each Product Category)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/102587\/download\u0022\u003EPDF (289.34 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (289.34 KB) of Guidance for Industry: Reference Amounts Customarily Consumed (List of Products for Each Product Category)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/02\/2018","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling, Nutrition Label","field_topics":"","topics-product":"Labeling, Nutrition Label","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-4098\u0022\u003EFDA-2016-D-4098\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-18T13:49:01-04:00\u0022\u003E2025-03-18 13:49\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-nutrition-and-supplement-facts-labels-questions-and-answers-related-compliance\u0022\u003EGuidance for Industry: Nutrition and Supplement Facts Labels Questions and Answers Related to the Compliance Date, Added Sugars, and Declaration of Quantitative Amounts of Vitamins and Minerals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/117402\/download\u0022\u003EPDF (179.14 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (179.14 KB) of Guidance for Industry: Nutrition and Supplement Facts Labels Questions and Answers Related to the Compliance Date, Added Sugars, and Declaration of Quantitative Amounts of Vitamins and Minerals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/16\/2019","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling, Nutrition Label","field_topics":"","topics-product":"Labeling, Nutrition Label","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-4414\u0022\u003EFDA-2016-D-4414\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:04:54-04:00\u0022\u003E2024-10-01 07:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-recognition-acceptable-unique-facility-identifier-ufi-foreign-supplier\u0022\u003EGuidance for Industry: Recognition of Acceptable Unique Facility Identifier (UFI) for the Foreign Supplier Verification Programs Regulation\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/104622\/download\u0022\u003EPDF (81.38 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (81.38 KB) of Guidance for Industry: Recognition of Acceptable Unique Facility Identifier (UFI) for the Foreign Supplier Verification Programs Regulation\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/13\/2017","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Import","field_topics":"","topics-product":"Import","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-N-0143\u0022\u003EFDA-2011-N-0143\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:04:55-04:00\u0022\u003E2024-10-01 07:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-compliance-providing-acceptable-unique-facility-identifier-foreign-supplier\u0022\u003EGuidance for Industry: Compliance with Providing an Acceptable Unique Facility Identifier for the Foreign Supplier Verification Programs for Food Importers Regulation\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/111885\/download\u0022\u003EPDF (264.54 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (264.54 KB) of Guidance for Industry: Compliance with Providing an Acceptable Unique Facility Identifier for the Foreign Supplier Verification Programs for Food Importers Regulation\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/27\/2022","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Import","field_topics":"","topics-product":"Import","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-N-0143\u0022\u003EFDA-2011-N-0143\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:04:56-04:00\u0022\u003E2024-10-01 07:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-entity-compliance-guide-mitigation-strategies-protect-food-against-intentional-adulteration\u0022\u003ESmall Entity Compliance Guide: Mitigation Strategies to Protect Food Against Intentional Adulteration\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/105742\/download\u0022\u003EPDF (128.82 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (128.82 KB) of Small Entity Compliance Guide: Mitigation Strategies to Protect Food Against Intentional Adulteration\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/25\/2017","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Defense \u0026amp; Security","field_topics":"","topics-product":"Defense \u0026amp; Security","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-N-1425\u0022\u003EFDA-2013-N-1425\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:04:58-04:00\u0022\u003E2024-10-01 07:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-juice-haccp-and-fda-food-safety-modernization-act\u0022\u003EGuidance for Industry: Juice HACCP and the FDA Food Safety Modernization Act\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/106711\/download\u0022\u003EPDF (432.99 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (432.99 KB) of Guidance for Industry: Juice HACCP and the FDA Food Safety Modernization Act\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/21\/2021","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"HACCP, Juice","field_topics":"","topics-product":"HACCP, Juice","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-3716\u0022\u003EFDA-2017-D-3716\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:04:58-04:00\u0022\u003E2024-10-01 07:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-low-acid-foods-packaged-hermetically-sealed-containers-lacf-regulation-and-fda\u0022\u003EGuidance for Industry: Low-Acid Foods Packaged in Hermetically Sealed Containers (LACF) Regulation and the FDA Food Safety Modernization Act\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/106721\/download\u0022\u003EPDF (329.54 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (329.54 KB) of Guidance for Industry: Low-Acid Foods Packaged in Hermetically Sealed Containers (LACF) Regulation and the FDA Food Safety Modernization Act\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/21\/2021","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Canned Foods","field_topics":"","topics-product":"Canned Foods","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-3716\u0022\u003EFDA-2017-D-3716\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:04:59-04:00\u0022\u003E2024-10-01 07:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-seafood-haccp-and-fda-food-safety-modernization-act\u0022\u003EGuidance for Industry: Seafood HACCP and the FDA Food Safety Modernization Act\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/106733\/download\u0022\u003EPDF (348.75 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (348.75 KB) of Guidance for Industry: Seafood HACCP and the FDA Food Safety Modernization Act\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/21\/2021","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"HACCP, Seafood\/Seafood Product","field_topics":"","topics-product":"HACCP, Seafood\/Seafood Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-3716\u0022\u003EFDA-2017-D-3716\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:05:01-04:00\u0022\u003E2024-10-01 07:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-ultrafiltered-milk-production-standardized-cheeses-and-related-cheese-products\u0022\u003EGuidance for Industry: Ultrafiltered Milk in the Production of Standardized Cheeses and Related Cheese Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/106876\/download\u0022\u003EPDF (38.08 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (38.08 KB) of Guidance for Industry: Ultrafiltered Milk in the Production of Standardized Cheeses and Related Cheese Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/14\/2017","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Cheese\/Cheese Product","field_topics":"","topics-product":"Cheese\/Cheese Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-4713\u0022\u003EFDA-2017-D-4713\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:05:02-04:00\u0022\u003E2024-10-01 07:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-clarification-food-establishment-waiver-requirements-sanitary-transportation-human\u0022\u003EGuidance for Industry: Clarification on Food Establishment Waiver from Requirements of the Sanitary Transportation of Human and Animal Food Rule\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/107146\/download\u0022\u003EPDF (37.42 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (37.42 KB) of Guidance for Industry: Clarification on Food Establishment Waiver from Requirements of the Sanitary Transportation of Human and Animal Food Rule\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/01\/2017","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Sanitation, Transportation","field_topics":"","topics-product":"Sanitation, Transportation","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-N-0013\u0022\u003EFDA-2013-N-0013\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:05:03-04:00\u0022\u003E2024-10-01 07:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-entity-compliance-guide-standards-growing-harvesting-packing-and-holding-produce-human\u0022\u003ESmall Entity Compliance Guide: Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/107298\/download\u0022\u003EPDF (475.82 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (475.82 KB) of Small Entity Compliance Guide: Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/25\/2024","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Produce","field_topics":"","topics-product":"Produce","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-N-0921\u0022\u003EFDA-2011-N-0921\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:05:05-04:00\u0022\u003E2024-10-01 07:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/draft-guidance-industry-application-solely-engaged-exemptions-parts-117-and-507\u0022\u003EDraft Guidance for Industry: Application of the \u201cSolely Engaged\u201d Exemptions in Parts 117 and 507\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/108360\/download\u0022\u003EPDF (97.61 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (97.61 KB) of Draft Guidance for Industry: Application of the \u201cSolely Engaged\u201d Exemptions in Parts 117 and 507\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/20\/2017","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"Registration","topics-product":"Registration, ","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"04\/18\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6133\u0022\u003EFDA-2017-D-6133\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Animal \u0026amp; Veterinary, Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T08:29:23-04:00\u0022\u003E2024-10-01 08:29\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-supply-chain-program-requirements-and-co-manufacturer-supplier-approval-and\u0022\u003EGuidance for Industry: Supply-Chain Program Requirements and Co-Manufacturer Supplier Approval and Verification for Human Food and Animal Food\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/108732\/download\u0022\u003EPDF (84.49 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (84.49 KB) of Guidance for Industry: Supply-Chain Program Requirements and Co-Manufacturer Supplier Approval and Verification for Human Food and Animal Food\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/06\/2017","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-5996\u0022\u003EFDA-2017-D-5996\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:05:06-04:00\u0022\u003E2024-10-01 07:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-menu-labeling-supplemental-guidance\u0022\u003EGuidance for Industry: Menu Labeling Supplemental Guidance\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/108737\/download\u0022\u003EPDF (3.62 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (3.62 MB) of Guidance for Industry: Menu Labeling Supplemental Guidance\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/01\/2018","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling, Nutrition","field_topics":"","topics-product":"Labeling, Nutrition","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-F-0172\u0022\u003EFDA-2011-F-0172\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-12T10:33:20-04:00\u0022\u003E2025-03-12 10:33\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-best-practices-convening-gras-panel\u0022\u003EGuidance for Industry: Best Practices for Convening a GRAS Panel\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/109006\/download\u0022\u003EPDF (665.74 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (665.74 KB) of Guidance for Industry: Best Practices for Convening a GRAS Panel\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/20\/2022","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"GRAS","field_topics":"","topics-product":"GRAS","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"05\/15\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-0085\u0022\u003EFDA-2017-D-0085\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:05:08-04:00\u0022\u003E2024-10-01 07:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-regulatory-framework-substances-intended-use-human-food-or-animal-food-basis\u0022\u003EGuidance for Industry: Regulatory Framework for Substances Intended for Use in Human Food or Animal Food on the Basis of the Generally Recognized as Safe (GRAS) Provision of the Federal Food, Drug, and Cosmetic Act\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/109117\/download\u0022\u003EPDF (176.65 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (176.65 KB) of Guidance for Industry: Regulatory Framework for Substances Intended for Use in Human Food or Animal Food on the Basis of the Generally Recognized as Safe (GRAS) Provision of the Federal Food, Drug, and Cosmetic Act\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/01\/2017","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"GRAS","field_topics":"","topics-product":"GRAS","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-4484\u0022\u003EFDA-2016-D-4484\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:05:09-04:00\u0022\u003E2024-10-01 07:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-entity-compliance-guide-sanitary-transportation-human-and-animal-food-what-you-need-know-about\u0022\u003ESmall Entity Compliance Guide: Sanitary Transportation of Human and Animal Food - What You Need to Know About the FDA Regulation\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/108944\/download\u0022\u003EPDF (131.42 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (131.42 KB) of Small Entity Compliance Guide: Sanitary Transportation of Human and Animal Food - What You Need to Know About the FDA Regulation\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/22\/2017","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Transportation","field_topics":"","topics-product":"Transportation","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-N-0013\u0022\u003EFDA-2013-N-0013\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:05:10-04:00\u0022\u003E2024-10-01 07:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-use-terms-brown-king-crab-and-golden-king-crab-labeling-human-food-products\u0022\u003EGuidance for Industry: Use of the Terms \u201cBrown King Crab\u201d and \u201cGolden King Crab\u201d in the Labeling of Human Food Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/109182\/download\u0022\u003EPDF (34.76 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (34.76 KB) of Guidance for Industry: Use of the Terms \u201cBrown King Crab\u201d and \u201cGolden King Crab\u201d in the Labeling of Human Food Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/15\/2017","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling, Seafood\/Seafood Product","field_topics":"","topics-product":"Labeling, Seafood\/Seafood Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:20:36-04:00\u0022\u003E2024-10-01 07:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-refusal-inspection-foreign-food-establishment-or-foreign-government\u0022\u003EGuidance for Industry: Refusal of Inspection by a Foreign Food Establishment or Foreign Government\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/109635\/download\u0022\u003EPDF (404.26 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (404.26 KB) of Guidance for Industry: Refusal of Inspection by a Foreign Food Establishment or Foreign Government\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/20\/2022","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"Inspection","topics-product":"Inspection, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6528\u0022\u003EFDA-2017-D-6528\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:05:12-04:00\u0022\u003E2024-10-01 07:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-policy-regarding-certain-entities-subject-current-good-manufacturing-practice-and\u0022\u003EGuidance for Industry: Policy Regarding Certain Entities Subject to the Current Good Manufacturing Practice and Preventive Controls, Produce Safety, and\/or Foreign Supplier Verification Programs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/110023\/download\u0022\u003EPDF (228.05 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (228.05 KB) of Guidance for Industry: Policy Regarding Certain Entities Subject to the Current Good Manufacturing Practice and Preventive Controls, Produce Safety, and\/or Foreign Supplier Verification Programs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/05\/2018","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-N-6908\u0022\u003EFDA-2017-N-6908\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-20T14:55:16-04:00\u0022\u003E2025-03-20 14:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-application-foreign-supplier-verification-program-regulation-importers-grain-raw\u0022\u003EGuidance for Industry: Application of the Foreign Supplier Verification Program Regulation to Importers of Grain Raw Agricultural Commodities\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/110302\/download\u0022\u003EPDF (72.31 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (72.31 KB) of Guidance for Industry: Application of the Foreign Supplier Verification Program Regulation to Importers of Grain Raw Agricultural Commodities\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/25\/2018","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Import","field_topics":"","topics-product":"Import","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6592\u0022\u003EFDA-2017-D-6592\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Animal \u0026amp; Veterinary, Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-18T13:57:31-04:00\u0022\u003E2025-03-18 13:57\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/withdrawn-guidances-biologics\u0022\u003EWithdrawn Guidances (Biologics)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/27\/2025","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222025-08-27T17:30:17-04:00\u0022\u003E2025-08-27 17:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-foreign-supplier-verification-programs-importers-food-humans-and-animals\u0022\u003EGuidance for Industry: Foreign Supplier Verification Programs for Importers of Food for Humans and Animals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/118241\/download\u0022\u003EPDF (1.19 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.19 MB) of Guidance for Industry: Foreign Supplier Verification Programs for Importers of Food for Humans and Animals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/10\/2023","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Import","field_topics":"","topics-product":"Import","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-5225\u0022\u003EFDA-2017-D-5225\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T11:45:47-05:00\u0022\u003E2025-03-05 11:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-entity-compliance-guide-foreign-supplier-verification-programs-importers-food-humans-and\u0022\u003ESmall Entity Compliance Guide: Foreign Supplier Verification Programs for Importers of Food for Humans and Animals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/110327\/download\u0022\u003EPDF (142.45 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (142.45 KB) of Small Entity Compliance Guide: Foreign Supplier Verification Programs for Importers of Food for Humans and Animals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/25\/2018","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Import","field_topics":"","topics-product":"Import","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-N-0143\u0022\u003EFDA-2011-N-0143\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:05:17-04:00\u0022\u003E2024-10-01 07:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/draft-guidance-industry-considerations-determining-whether-measure-provides-same-level-public-health\u0022\u003EDraft Guidance for Industry: Considerations for Determining Whether a Measure Provides the Same Level of Public Health Protection as the Corresponding Requirement in 21 CFR part 112 or the Preventive Controls Requirements in part 117 or 507\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/110317\/download\u0022\u003EPDF (112.96 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (112.96 KB) of Draft Guidance for Industry: Considerations for Determining Whether a Measure Provides the Same Level of Public Health Protection as the Corresponding Requirement in 21 CFR part 112 or the Preventive Controls Requirements in part 117 or 507\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/25\/2018","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"05\/25\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-0397\u0022\u003EFDA-2017-D-0397\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-18T14:04:46-04:00\u0022\u003E2025-03-18 14:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-serving-sizes-foods-can-reasonably-be-consumed-one-eating-occasion-dual-column\u0022\u003EGuidance for Industry: Serving Sizes of Foods That Can Reasonably Be Consumed At One Eating Occasion; Dual-Column Labeling; Updating, Modifying, and Establishing Certain Reference Amounts Customarily Consumed; Serving Size for Breath Mints\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/111144\/download\u0022\u003EPDF (762.08 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (762.08 KB) of Guidance for Industry: Serving Sizes of Foods That Can Reasonably Be Consumed At One Eating Occasion; Dual-Column Labeling; Updating, Modifying, and Establishing Certain Reference Amounts Customarily Consumed; Serving Size for Breath Mints\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/02\/2018","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling, Nutrition Label","field_topics":"","topics-product":"Labeling, Nutrition Label","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-N-0258\u0022\u003EFDA-2004-N-0258\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-18T13:52:16-04:00\u0022\u003E2025-03-18 13:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-declaration-added-sugars-honey-maple-syrup-other-single-ingredient-sugars-and\u0022\u003EGuidance for Industry: Declaration of Added Sugars on Honey, Maple Syrup, Other Single-Ingredient Sugars and Syrups, and Certain Cranberry Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/127928\/download\u0022\u003EPDF (408.53 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (408.53 KB) of Guidance for Industry: Declaration of Added Sugars on Honey, Maple Syrup, Other Single-Ingredient Sugars and Syrups, and Certain Cranberry Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/18\/2019","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling, Nutrition Label","field_topics":"","topics-product":"Labeling, Nutrition Label","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-0075\u0022\u003EFDA-2018-D-0075\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-10T16:18:04-04:00\u0022\u003E2025-03-10 16:18\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/postmarketing-safety-reporting-combination-products\u0022\u003EPostmarketing Safety Reporting for Combination Products: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/111788\/download\u0022\u003EPDF (620.95 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (620.95 KB) of Postmarketing Safety Reporting for Combination Products: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/22\/2019","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Combination Products","field_topics":"","topics-product":"Combination Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"06\/19\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-N-0424\u0022\u003EFDA-2008-N-0424\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222019-07-22T13:30:41-04:00\u0022\u003E2019-07-22 13:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/compliance-policy-combination-product-postmarketing-safety-reporting\u0022\u003ECompliance Policy for Combination Product Postmarketing Safety Reporting: Immediately in Effect Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/111795\/download\u0022\u003EPDF (57.6 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (57.6 KB) of Compliance Policy for Combination Product Postmarketing Safety Reporting: Immediately in Effect Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/20\/2019","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Combination Products","field_topics":"","topics-product":"Combination Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-N-0424\u0022\u003EFDA-2008-N-0424\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222020-05-07T15:15:19-04:00\u0022\u003E2020-05-07 15:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-determining-number-employees-purposes-small-business-definition-parts-117-and-507\u0022\u003EGuidance for Industry: Determining the Number of Employees for Purposes of the \u201cSmall Business\u201d Definition in Parts 117 and 507\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/111951\/download\u0022\u003EPDF (163.46 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (163.46 KB) of Guidance for Industry: Determining the Number of Employees for Purposes of the \u201cSmall Business\u201d Definition in Parts 117 and 507\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/19\/2019","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-0671\u0022\u003EFDA-2018-D-0671\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Animal \u0026amp; Veterinary, Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:05:22-04:00\u0022\u003E2024-10-01 07:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/providing-regulatory-submissions-electronic-format-orphan-drug-and-humanitarian-use-device\u0022\u003EProviding Regulatory Submissions in Electronic Format Orphan-Drug and Humanitarian Use Device Designation Requests and Related Submissions: Draft Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/111920\/download\u0022\u003EPDF (128.17 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (128.17 KB) of Providing Regulatory Submissions in Electronic Format Orphan-Drug and Humanitarian Use Device Designation Requests and Related Submissions: Draft Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/01\/2006","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Orphan Products Development","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2006-D-0159\u0022\u003EFDA-2006-D-0159\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222021-05-13T16:05:09-04:00\u0022\u003E2021-05-13 16:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/meetings-office-orphan-products-development\u0022\u003EMeetings with the Office of Orphan Products Development: Guidance for Industry, Researchers, Patient Groups, and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/111946\/download\u0022\u003EPDF (134.31 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (134.31 KB) of Meetings with the Office of Orphan Products Development: Guidance for Industry, Researchers, Patient Groups, and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/09\/2015","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Orphan Products Development","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Pediatric Product Development","field_topics":"","topics-product":"Administrative \/ Procedural, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0313\u0022\u003EFDA-2014-D-0313\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222024-04-11T11:04:31-04:00\u0022\u003E2024-04-11 11:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-application-foreign-supplier-verification-program-regulation-importation-live\u0022\u003EGuidance for Industry: Application of the Foreign Supplier Verification Program Regulation to the Importation of Live Animals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/112085\/download\u0022\u003EPDF (69.36 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (69.36 KB) of Guidance for Industry: Application of the Foreign Supplier Verification Program Regulation to the Importation of Live Animals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/22\/2018","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Import","field_topics":"","topics-product":"Import","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-0721\u0022\u003EFDA-2018-D-0721\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Animal \u0026amp; Veterinary, Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-18T11:28:47-04:00\u0022\u003E2025-03-18 11:28\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-highly-concentrated-caffeine-dietary-supplements\u0022\u003EGuidance for Industry: Highly Concentrated Caffeine in Dietary Supplements\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/112363\/download\u0022\u003EPDF (132.05 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (132.05 KB) of Guidance for Industry: Highly Concentrated Caffeine in Dietary Supplements\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/16\/2018","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1189\u0022\u003EFDA-2018-D-1189\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Dietary Supplements, Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-18T11:08:31-04:00\u0022\u003E2025-03-18 11:08\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-entity-compliance-guide-extension-and-clarification-compliance-dates-certain-provisions-four\u0022\u003ESmall Entity Compliance Guide: Extension and Clarification of Compliance Dates for Certain Provisions of Four Implementing Rules of the FDA Food Safety Modernization Act\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/112982\/download\u0022\u003EPDF (36.51 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (36.51 KB) of Small Entity Compliance Guide: Extension and Clarification of Compliance Dates for Certain Provisions of Four Implementing Rules of the FDA Food Safety Modernization Act\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/14\/2018","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1378\u0022\u003EFDA-2018-D-1378\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Human Foods Program","field_regulated_product_field":"Animal \u0026amp; Veterinary, Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-12T10:33:16-04:00\u0022\u003E2025-03-12 10:33\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/civil-money-penalties-relating-clinicaltrialsgov-data-bank\u0022\u003ECivil Money Penalties Relating to the ClinicalTrials.gov Data Bank: Guidance for Responsible Parties, Submitters of Certain Applications and Submissions to FDA, and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/113361\/download\u0022\u003EPDF (93.08 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (93.08 KB) of Civil Money Penalties Relating to the ClinicalTrials.gov Data Bank: Guidance for Responsible Parties, Submitters of Certain Applications and Submissions to FDA, and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/14\/2020","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP)","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-0787\u0022\u003EFDA-2018-D-0787\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222024-11-05T16:09:03-05:00\u0022\u003E2024-11-05 16:09\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-declaration-certain-isolated-or-synthetic-non-digestible-carbohydrates-dietary\u0022\u003EGuidance for Industry: The Declaration of Certain Isolated or Synthetic Non-Digestible Carbohydrates as Dietary Fiber on Nutrition and Supplement Facts Labels\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/113663\/download\u0022\u003EPDF (94.84 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (94.84 KB) of Guidance for Industry: The Declaration of Certain Isolated or Synthetic Non-Digestible Carbohydrates as Dietary Fiber on Nutrition and Supplement Facts Labels\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/15\/2018","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling, Nutrition Label","field_topics":"","topics-product":"Labeling, Nutrition Label","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1323\u0022\u003EFDA-2018-D-1323\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-12T10:32:47-04:00\u0022\u003E2025-03-12 10:32\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/draft-guidance-industry-mitigation-strategies-protect-food-against-intentional-adulteration\u0022\u003EDraft Guidance for Industry: Mitigation Strategies to Protect Food Against Intentional Adulteration\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/113684\/download\u0022\u003EPDF (995.91 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (995.91 KB) of Draft Guidance for Industry: Mitigation Strategies to Protect Food Against Intentional Adulteration\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/06\/2019","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"08\/14\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1398\u0022\u003EFDA-2018-D-1398\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-12T10:23:16-04:00\u0022\u003E2025-03-12 10:23\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/draft-guidance-industry-supplemental-questions-and-answers-regarding-food-facility-registration\u0022\u003EDraft Guidance for Industry: Supplemental Questions and Answers Regarding Food Facility Registration\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/115080\/download\u0022\u003EPDF (65.8 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (65.8 KB) of Draft Guidance for Industry: Supplemental Questions and Answers Regarding Food Facility Registration\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/20\/2018","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"Registration","topics-product":"Registration, ","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"10\/19\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-1002\u0022\u003EFDA-2012-D-1002\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-12T10:30:56-04:00\u0022\u003E2025-03-12 10:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/compliance-policy-certain-labeling-and-warning-statement-requirements-cigars-and-pipe-tobacco\u0022\u003ECompliance Policy for Certain Labeling and Warning Statement Requirements for Cigars and Pipe Tobacco: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/115103\/download\u0022\u003EPDF (122.48 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (122.48 KB) of Compliance Policy for Certain Labeling and Warning Statement Requirements for Cigars and Pipe Tobacco: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/09\/2018","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"Cigars, Cigarillos, Little Filtered Cigars, Pipe, Labeling","field_topics":"","topics-product":"Cigars, Cigarillos, Little Filtered Cigars, Pipe, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-3047\u0022\u003EFDA-2018-D-3047\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222020-10-06T10:05:35-04:00\u0022\u003E2020-10-06 10:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/real-world-data-real-world-evidence-rwdrwe\u0022\u003EReal World Data \/ Real World Evidence RWD\/RWE\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/18\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Real World Data \/ Real World Evidence (RWD\/RWE)","topics-product":"Real World Data \/ Real World Evidence (RWD\/RWE), ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-03-04T08:35:27-05:00\u0022\u003E2021-03-04 08:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/draft-guidance-industry-policy-regarding-quantitative-labeling-dietary-supplements-containing-live\u0022\u003EDraft Guidance for Industry: Policy Regarding Quantitative Labeling of Dietary Supplements Containing Live Microbials\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/115730\/download\u0022\u003EPDF (116.62 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (116.62 KB) of Draft Guidance for Industry: Policy Regarding Quantitative Labeling of Dietary Supplements Containing Live Microbials\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/07\/2018","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"11\/06\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0376\u0022\u003EFDA-2011-D-0376\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Dietary Supplements","changed":"\u003Ctime datetime=\u00222025-03-12T10:32:16-04:00\u0022\u003E2025-03-12 10:32\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/compliance-regulations-restricting-sale-and-distribution-cigarettes-and-smokeless-tobacco-protect\u0022\u003ECompliance with Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco To Protect Children and Adolescents: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/80572\/download\u0022\u003EPDF (288.44 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (288.44 KB) of Compliance with Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco To Protect Children and Adolescents: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/22\/2013","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"Cigarettes, Smokeless, Snuff, Chewing","field_topics":"","topics-product":"Cigarettes, Smokeless, Snuff, Chewing","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"08\/22\/2013","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0277\u0022\u003EFDA-2010-D-0277\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222020-07-28T10:45:14-04:00\u0022\u003E2020-07-28 10:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-179-use-animal-clones-and-clone-progeny-human-food-and-animal-feed\u0022\u003ECVM GFI #179 Use of Animal Clones and Clone Progeny for Human Food and Animal Feed\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/69900\/download\u0022\u003EPDF (51.58 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (51.58 KB) of CVM GFI #179 Use of Animal Clones and Clone Progeny for Human Food and Animal Feed\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/15\/2008","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"","field_topics":"Biotechnology","topics-product":"Biotechnology, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-N-0033\u0022\u003EFDA-2008-N-0033\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T13:45:21-04:00\u0022\u003E2019-04-16 13:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-178-recommended-design-and-evaluation-effectiveness-studies-swine-respiratory-disease-claims\u0022\u003ECVM GFI #178 Recommended Design and Evaluation of Effectiveness Studies for Swine Respiratory Disease Claims\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/69903\/download\u0022\u003EPDF (193.83 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (193.83 KB) of CVM GFI #178 Recommended Design and Evaluation of Effectiveness Studies for Swine Respiratory Disease Claims\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/01\/2007","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Feed","field_topics":"","topics-product":"Animal Feed","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2006-D-0479\u0022\u003EFDA-2006-D-0479\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:06:06-04:00\u0022\u003E2019-04-16 14:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-177-vich-gl40-test-proceduresacceptance-criteria-new-biotechnologicalbiological-veterinary\u0022\u003ECVM GFI #177 (VICH GL40) Test Procedures\/Acceptance Criteria for New Biotechnological\/Biological Veterinary Medicinal Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/69907\/download\u0022\u003EPDF (286.03 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (286.03 KB) of CVM GFI #177 (VICH GL40) Test Procedures\/Acceptance Criteria for New Biotechnological\/Biological Veterinary Medicinal Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/14\/2006","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"VICH","field_topics":"","topics-product":"VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2005-D-0028\u0022\u003EFDA-2005-D-0028\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T13:46:58-04:00\u0022\u003E2019-04-16 13:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-176-vich-gl39-specifications-test-procedures-and-acceptance-criteria-new-veterinary-drug\u0022\u003ECVM GFI #176 (VICH GL39) Specifications: Test Procedures and Acceptance Criteria for New Veterinary Drug Substances and New Medicinal Products: Chemical Substances\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/69909\/download\u0022\u003EPDF (277.27 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (277.27 KB) of CVM GFI #176 (VICH GL39) Specifications: Test Procedures and Acceptance Criteria for New Veterinary Drug Substances and New Medicinal Products: Chemical Substances\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/14\/2006","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), VICH","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2005-D-0336\u0022\u003EFDA-2005-D-0336\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T13:40:31-04:00\u0022\u003E2019-04-16 13:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-173-animal-drug-sponsor-fees-under-animal-drug-user-fee-act-adufa\u0022\u003ECVM GFI #173 Animal Drug Sponsor Fees Under the Animal Drug User Fee Act (ADUFA)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/69912\/download\u0022\u003EPDF (51.92 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (51.92 KB) of CVM GFI #173 Animal Drug Sponsor Fees Under the Animal Drug User Fee Act (ADUFA)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/07\/2005","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"","field_topics":"User Fees","topics-product":"User Fees, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-D-0181\u0022\u003EFDA-2004-D-0181\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T13:40:28-04:00\u0022\u003E2019-04-16 13:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-173-appendix-animal-drug-sponsor-fees-under-adufa\u0022\u003ECVM GFI #173 Appendix for the Animal Drug Sponsor Fees Under ADUFA\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/69915\/download\u0022\u003EPDF (43.8 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (43.8 KB) of CVM GFI #173 Appendix for the Animal Drug Sponsor Fees Under ADUFA\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/07\/2005","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"","field_topics":"User Fees","topics-product":"User Fees, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-D-0181\u0022\u003EFDA-2004-D-0181\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T13:40:30-04:00\u0022\u003E2019-04-16 13:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-170-animal-drug-user-fees-and-fee-waivers-and-reductions\u0022\u003ECVM GFI #170 Animal Drug User Fees and Fee Waivers and Reductions\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/69918\/download\u0022\u003EPDF (673.08 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (673.08 KB) of CVM GFI #170 Animal Drug User Fees and Fee Waivers and Reductions\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/13\/2023","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"","field_topics":"User Fees","topics-product":"User Fees, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"01\/03\/2017","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-D-0369\u0022\u003EFDA-2004-D-0369\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222023-04-13T10:44:01-04:00\u0022\u003E2023-04-13 10:44\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-169-drug-substance-chemistry-manufacturing-and-controls-information\u0022\u003ECVM GFI #169 Drug Substance Chemistry, Manufacturing, and Controls Information\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/69923\/download\u0022\u003EPDF (362.59 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (362.59 KB) of CVM GFI #169 Drug Substance Chemistry, Manufacturing, and Controls Information\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/06\/2010","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC)","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2003-D-0243\u0022\u003EFDA-2003-D-0243\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T13:40:44-04:00\u0022\u003E2019-04-16 13:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-166-vich-gl38-environmental-impact-assessments-eias-veterinary-medicinal-products-vmps-phase\u0022\u003ECVM GFI #166 (VICH GL38) Environmental Impact Assessments (EIA\u0026#039;s) for Veterinary Medicinal Products (VMP\u2019s) - Phase II\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/69927\/download\u0022\u003EPDF (427.09 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (427.09 KB) of CVM GFI #166 (VICH GL38) Environmental Impact Assessments (EIA\u0026#039;s) for Veterinary Medicinal Products (VMP\u2019s) - Phase II\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/09\/2006","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Environmental Safety, VICH","field_topics":"","topics-product":"Environmental Safety, VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-D-0273\u0022\u003EFDA-2004-D-0273\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T13:35:25-04:00\u0022\u003E2019-04-16 13:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-160-vich-gl37-studies-evaluate-safety-residues-veterinary-drugs-human-food-repeat-dose\u0022\u003ECVM GFI #160 (VICH GL37) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Repeat-Dose (Chronic) Toxicity Testing\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/69931\/download\u0022\u003EPDF (75.3 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (75.3 KB) of CVM GFI #160 (VICH GL37) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Repeat-Dose (Chronic) Toxicity Testing\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/27\/2006","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Human Food Safety, VICH","field_topics":"","topics-product":"Human Food Safety, VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2003-D-0372\u0022\u003EFDA-2003-D-0372\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T13:35:15-04:00\u0022\u003E2019-04-16 13:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-158-use-material-deer-and-elk-animal-feed\u0022\u003ECVM GFI #158 Use of Material from Deer and Elk in Animal Feed\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/69936\/download\u0022\u003EPDF (24.46 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (24.46 KB) of CVM GFI #158 Use of Material from Deer and Elk in Animal Feed\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/16\/2016","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"Bovine Spongiform Encephalopathy (BSE)","term_node_tid":"Animal Feed","field_topics":"","topics-product":"Bovine Spongiform Encephalopathy (BSE), Animal Feed","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2003-D-0432\u0022\u003EFDA-2003-D-0432\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T13:35:27-04:00\u0022\u003E2019-04-16 13:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-156-comparability-protocols-chemistry-manufacturing-and-controls-information-new-animal\u0022\u003ECVM GFI #156 Comparability Protocols - Chemistry, Manufacturing, and Controls Information for New Animal Drugs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/69943\/download\u0022\u003EPDF (110.64 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (110.64 KB) of CVM GFI #156 Comparability Protocols - Chemistry, Manufacturing, and Controls Information for New Animal Drugs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/04\/2016","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC)","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-0938\u0022\u003EFDA-2016-D-0938\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T13:35:13-04:00\u0022\u003E2019-04-16 13:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-152-evaluating-safety-antimicrobial-new-animal-drugs-regard-their-microbiological-effects\u0022\u003ECVM GFI #152 Evaluating the Safety of Antimicrobial New Animal Drugs with Regard to Their Microbiological Effects on Bacteria of Human Health Concern\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/69949\/download\u0022\u003EPDF (970.83 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (970.83 KB) of CVM GFI #152 Evaluating the Safety of Antimicrobial New Animal Drugs with Regard to Their Microbiological Effects on Bacteria of Human Health Concern\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/05\/2026","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Antimicrobial Resistance, Human Food Safety","field_topics":"","topics-product":"Antimicrobial Resistance, Human Food Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1998-D-0038\u0022\u003EFDA-1998-D-0038\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222026-08-05T08:49:32-04:00\u0022\u003E2026-08-05 08:49\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-150-concerns-related-use-clove-oil-anesthetic-fish\u0022\u003ECVM GFI #150 Concerns Related to the use of Clove Oil as an Anesthetic for Fish\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/69954\/download\u0022\u003EPDF (233.13 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (233.13 KB) of CVM GFI #150 Concerns Related to the use of Clove Oil as an Anesthetic for Fish\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/25\/2026","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Aquaculture","field_topics":"","topics-product":"Aquaculture","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1442\u0022\u003EFDA-2020-D-1442\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222026-08-25T13:59:02-04:00\u0022\u003E2026-08-25 13:59\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-5-drug-stability-guidelines\u0022\u003ECVM GFI #5 Drug Stability Guidelines\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/69957\/download\u0022\u003EPDF (384.72 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (384.72 KB) of CVM GFI #5 Drug Stability Guidelines\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/09\/2008","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC)","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1385\u0022\u003EFDA-2020-D-1385\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222021-07-08T10:40:20-04:00\u0022\u003E2021-07-08 10:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-149-vich-gl33-studies-evaluate-safety-residues-veterinary-drugs-human-food-general-approach\u0022\u003ECVM GFI #149 (VICH GL33) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: General Approach to Testing\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/69960\/download\u0022\u003EPDF (171.13 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (171.13 KB) of CVM GFI #149 (VICH GL33) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: General Approach to Testing\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/17\/2009","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Human Food Safety, VICH","field_topics":"","topics-product":"Human Food Safety, VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2002-D-0186\u0022\u003EFDA-2002-D-0186\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T13:31:22-04:00\u0022\u003E2019-04-16 13:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-148-vich-gl32-studies-evaluate-safety-residues-veterinary-drugs-human-food-developmental\u0022\u003ECVM GFI #148 (VICH GL32) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Developmental Toxicity Testing\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/69968\/download\u0022\u003EPDF (52.06 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (52.06 KB) of CVM GFI #148 (VICH GL32) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Developmental Toxicity Testing\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/27\/2006","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Human Food Safety, VICH","field_topics":"","topics-product":"Human Food Safety, VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2002-D-0090\u0022\u003EFDA-2002-D-0090\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T13:31:03-04:00\u0022\u003E2019-04-16 13:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-147-vich-gl31-studies-evaluate-safety-residues-veterinary-drugs-human-food-repeat-dose-90\u0022\u003ECVM GFI #147 (VICH GL31) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Repeat-Dose (90 Day) Toxicity Testing\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/69974\/download\u0022\u003EPDF (102.13 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (102.13 KB) of CVM GFI #147 (VICH GL31) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Repeat-Dose (90 Day) Toxicity Testing\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/27\/2006","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Human Food Safety, VICH","field_topics":"","topics-product":"Human Food Safety, VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2002-D-0091\u0022\u003EFDA-2002-D-0091\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T13:30:10-04:00\u0022\u003E2019-04-16 13:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-144-vich-gl27-pre-approval-information-registration-new-veterinary-medicinal-products-food\u0022\u003ECVM GFI #144 (VICH GL27) Pre-Approval Information for Registration of New Veterinary Medicinal Products for Food-Producing Animals with Respect to Antimicrobial Resistance\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/69981\/download\u0022\u003EPDF (179.67 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (179.67 KB) of CVM GFI #144 (VICH GL27) Pre-Approval Information for Registration of New Veterinary Medicinal Products for Food-Producing Animals with Respect to Antimicrobial Resistance\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/27\/2004","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Antimicrobial Resistance, VICH","field_topics":"","topics-product":"Antimicrobial Resistance, VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2003-D-0152\u0022\u003EFDA-2003-D-0152\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T13:25:37-04:00\u0022\u003E2019-04-16 13:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-143-vich-gl30-pharmacovigilance-veterinary-medicinal-products-controlled-list-terms\u0022\u003ECVM GFI #143 (VICH GL30) Pharmacovigilance of Veterinary Medicinal Products: Controlled List of Terms\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/69988\/download\u0022\u003EPDF (149.17 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (149.17 KB) of CVM GFI #143 (VICH GL30) Pharmacovigilance of Veterinary Medicinal Products: Controlled List of Terms\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/09\/2014","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Adverse Event Reporting, VICH","field_topics":"","topics-product":"Adverse Event Reporting, VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2002-D-0268\u0022\u003EFDA-2002-D-0268\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T13:25:06-04:00\u0022\u003E2019-04-16 13:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-141-vich-gl28-studies-evaluate-safety-residues-veterinary-drugs-human-food-carcinogenicity\u0022\u003ECVM GFI #141 (VICH GL28) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Carcinogenicity Testing\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/69996\/download\u0022\u003EPDF (82.76 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (82.76 KB) of CVM GFI #141 (VICH GL28) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Carcinogenicity Testing\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/27\/2006","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Human Food Safety, VICH","field_topics":"","topics-product":"Human Food Safety, VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2001-D-0101\u0022\u003EFDA-2001-D-0101\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T13:25:32-04:00\u0022\u003E2019-04-16 13:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-137-analytical-methods-description-type-c-medicated-feeds\u0022\u003ECVM GFI #137 Analytical Methods Description for Type C Medicated Feeds\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70003\/download\u0022\u003EPDF (94.14 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (94.14 KB) of CVM GFI #137 Analytical Methods Description for Type C Medicated Feeds\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/08\/2007","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Feed, Chemistry, Manufacturing, and Controls (CMC)","field_topics":"","topics-product":"Animal Feed, Chemistry, Manufacturing, and Controls (CMC)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2006-D-0231\u0022\u003EFDA-2006-D-0231\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T13:25:09-04:00\u0022\u003E2019-04-16 13:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-136-protocols-conduct-method-transfer-studies-type-c-medicated-feed-assay-methods\u0022\u003ECVM GFI #136 Protocols for the Conduct of Method Transfer Studies for Type C Medicated Feed Assay Methods\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70012\/download\u0022\u003EPDF (105.42 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (105.42 KB) of CVM GFI #136 Protocols for the Conduct of Method Transfer Studies for Type C Medicated Feed Assay Methods\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/26\/2007","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC)","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2006-D-0230\u0022\u003EFDA-2006-D-0230\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T13:21:44-04:00\u0022\u003E2019-04-16 13:21\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-135-validation-analytical-procedures-type-c-medicated-feeds\u0022\u003ECVM GFI #135 Validation of Analytical Procedures for Type C Medicated Feeds\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70019\/download\u0022\u003EPDF (106.96 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (106.96 KB) of CVM GFI #135 Validation of Analytical Procedures for Type C Medicated Feeds\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/07\/2005","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Feed, Chemistry, Manufacturing, and Controls (CMC)","field_topics":"","topics-product":"Animal Feed, Chemistry, Manufacturing, and Controls (CMC)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-D-0370\u0022\u003EFDA-2004-D-0370\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T13:20:47-04:00\u0022\u003E2019-04-16 13:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-3-general-principles-evaluating-human-food-safety-new-animal-drugs-used-food-producing\u0022\u003ECVM GFI #3 General Principles for Evaluating the Human Food Safety of New Animal Drugs Used In Food-Producing Animals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70028\/download\u0022\u003EPDF (639.65 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (639.65 KB) of CVM GFI #3 General Principles for Evaluating the Human Food Safety of New Animal Drugs Used In Food-Producing Animals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/10\/2022","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Human Food Safety","field_topics":"","topics-product":"Human Food Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"09\/19\/2016","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2005-D-0155\u0022\u003EFDA-2005-D-0155\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222022-05-10T13:05:10-04:00\u0022\u003E2022-05-10 13:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-132-administrative-applications-and-phased-review-process\u0022\u003ECVM GFI #132 Administrative Applications and the Phased Review Process\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70029\/download\u0022\u003EPDF (335.83 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (335.83 KB) of CVM GFI #132 Administrative Applications and the Phased Review Process\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/23\/2018","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"New Animal Drug Application (NADA)","field_topics":"","topics-product":"New Animal Drug Application (NADA)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2002-D-0147\u0022\u003EFDA-2002-D-0147\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T13:21:28-04:00\u0022\u003E2019-04-16 13:21\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-126-bacpac-i-intermediates-drug-substance-synthesis-bulk-actives-postapproval-changes\u0022\u003ECVM GFI #126 BACPAC I-Intermediates in Drug Substance Synthesis Bulk Actives Postapproval Changes: Chemistry, Manufacturing, and Controls Documentation\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70037\/download\u0022\u003EPDF (134.14 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (134.14 KB) of CVM GFI #126 BACPAC I-Intermediates in Drug Substance Synthesis Bulk Actives Postapproval Changes: Chemistry, Manufacturing, and Controls Documentation\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/01\/2006","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC)","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0610\u0022\u003EFDA-2021-D-0610\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222021-07-27T06:46:13-04:00\u0022\u003E2021-07-27 06:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-104-content-and-format-effectiveness-and-target-animal-safety-technical-sections-and-final\u0022\u003ECVM GFI #104 Content and Format of Effectiveness and Target Animal Safety Technical Sections and Final Study Reports For Submission\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70050\/download\u0022\u003EPDF (142.71 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (142.71 KB) of CVM GFI #104 Content and Format of Effectiveness and Target Animal Safety Technical Sections and Final Study Reports For Submission\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/10\/2001","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"New Animal Drug Application (NADA), Target Animal \u2013 Effectiveness, Target Animal \u2013 Safety, Investigational New Animal Drug (INAD)","field_topics":"","topics-product":"New Animal Drug Application (NADA), Target Animal \u2013 Effectiveness, Target Animal \u2013 Safety, Investigational New Animal Drug (INAD)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0619\u0022\u003EFDA-2021-D-0619\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222021-07-27T06:46:10-04:00\u0022\u003E2021-07-27 06:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-106-use-published-literature-support-new-animal-drug-approvals\u0022\u003ECVM GFI #106 The Use of Published Literature in Support of New Animal Drug Approvals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70056\/download\u0022\u003EPDF (620.52 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (620.52 KB) of CVM GFI #106 The Use of Published Literature in Support of New Animal Drug Approvals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/16\/2023","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Clinical - Antimicrobial, Clinical - Pharmacology, Safety - Issues, Errors, and Problems, Antimicrobial Resistance, New Animal Drug Application (NADA), Target Animal \u2013 Effectiveness, Target Animal \u2013 Safety, Investigational New Animal Drug (INAD), Minor Use\/ Minor Species (MUMS)","field_topics":"Premarket","topics-product":"Premarket, Chemistry, Manufacturing, and Controls (CMC), Clinical - Antimicrobial, Clinical - Pharmacology, Safety - Issues, Errors, and Problems, Antimicrobial Resistance, New Animal Drug Application (NADA), Target Animal \u2013 Effectiveness, Target Animal \u2013 Safety, Investigational New Animal Drug (INAD), Minor Use\/ Minor Species (MUMS)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"06\/21\/2022","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-1155\u0022\u003EFDA-2021-D-1155\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222023-03-15T08:48:16-04:00\u0022\u003E2023-03-15 08:48\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-108-registering-cvms-electronic-submission-system\u0022\u003ECVM GFI #108 Registering with CVM\u2019s Electronic Submission System\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70064\/download\u0022\u003EPDF (355.98 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (355.98 KB) of CVM GFI #108 Registering with CVM\u2019s Electronic Submission System\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/26\/2023","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"","field_topics":"Electronic Submissions","topics-product":"Electronic Submissions, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1992-S-0039\u0022\u003EFDA-1992-S-0039\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222025-04-14T08:03:01-04:00\u0022\u003E2025-04-14 08:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-109-vich-gl15-effectiveness-anthelmintics-specific-recommendations-equines\u0022\u003ECVM GFI #109 (VICH GL15) Effectiveness of Anthelmintics: Specific Recommendations for Equines\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70072\/download\u0022\u003EPDF (403.07 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (403.07 KB) of CVM GFI #109 (VICH GL15) Effectiveness of Anthelmintics: Specific Recommendations for Equines\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/23\/2026","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Anthelmintics, Target Animal \u2013 Effectiveness, VICH","field_topics":"","topics-product":"Anthelmintics, Target Animal \u2013 Effectiveness, VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-1494\u0022\u003EFDA-2022-D-1494\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222026-06-23T09:43:46-04:00\u0022\u003E2026-06-23 09:43\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-110-vich-gl16-effectiveness-anthelmintics-specific-recommendations-porcines\u0022\u003ECVM GFI #110 (VICH GL16) Effectiveness of Anthelmintics: Specific Recommendations for Porcines\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70080\/download\u0022\u003EPDF (402.16 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (402.16 KB) of CVM GFI #110 (VICH GL16) Effectiveness of Anthelmintics: Specific Recommendations for Porcines\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/23\/2026","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Anthelmintics, Target Animal \u2013 Effectiveness, VICH","field_topics":"","topics-product":"Anthelmintics, Target Animal \u2013 Effectiveness, VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-1494\u0022\u003EFDA-2022-D-1494\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222026-06-23T09:44:05-04:00\u0022\u003E2026-06-23 09:44\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-111-vich-gl19-effectiveness-anthelmintics-specific-recommendations-canines\u0022\u003ECVM GFI #111 (VICH GL19) Effectiveness of Anthelmintics: Specific Recommendations for Canines\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70091\/download\u0022\u003EPDF (397.05 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (397.05 KB) of CVM GFI #111 (VICH GL19) Effectiveness of Anthelmintics: Specific Recommendations for Canines\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/23\/2026","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Anthelmintics, Target Animal \u2013 Effectiveness, VICH","field_topics":"","topics-product":"Anthelmintics, Target Animal \u2013 Effectiveness, VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-1494\u0022\u003EFDA-2022-D-1494\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222026-06-23T09:44:31-04:00\u0022\u003E2026-06-23 09:44\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-113-vich-gl20-effectiveness-anthelmintics-specific-recommendations-felines\u0022\u003ECVM GFI #113 (VICH GL20) Effectiveness of Anthelmintics: Specific Recommendations for Felines\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70104\/download\u0022\u003EPDF (396.58 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (396.58 KB) of CVM GFI #113 (VICH GL20) Effectiveness of Anthelmintics: Specific Recommendations for Felines\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/23\/2026","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Anthelmintics, Target Animal \u2013 Effectiveness, VICH","field_topics":"","topics-product":"Anthelmintics, Target Animal \u2013 Effectiveness, VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-1494\u0022\u003EFDA-2022-D-1494\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222026-06-23T09:45:56-04:00\u0022\u003E2026-06-23 09:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-35-bioequivalence-guidance\u0022\u003ECVM GFI #35 Bioequivalence Guidance\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70115\/download\u0022\u003EPDF (193.31 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (193.31 KB) of CVM GFI #35 Bioequivalence Guidance\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/08\/2006","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Generic Animal Drugs, Generic Drugs","field_topics":"","topics-product":"Generic Animal Drugs, Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1994-D-0317\u0022\u003EFDA-1994-D-0317\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T11:36:08-04:00\u0022\u003E2019-04-16 11:36\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-114-vich-gl21-effectiveness-anthelmintics-specific-recommendations-chickens-gallus-gallus\u0022\u003ECVM GFI #114 (VICH GL21) Effectiveness of Anthelmintics: Specific Recommendations for Chickens Gallus gallus\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70118\/download\u0022\u003EPDF (421.41 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (421.41 KB) of CVM GFI #114 (VICH GL21) Effectiveness of Anthelmintics: Specific Recommendations for Chickens Gallus gallus\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/23\/2026","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Anthelmintics, Target Animal \u2013 Effectiveness","field_topics":"","topics-product":"Anthelmintics, Target Animal \u2013 Effectiveness","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-1494\u0022\u003EFDA-2022-D-1494\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222026-06-23T09:45:03-04:00\u0022\u003E2026-06-23 09:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-115-vich-gl22-studies-evaluate-safety-residues-veterinary-drugs-human-food-reproduction\u0022\u003ECVM GFI #115 (VICH GL22) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Reproduction Testing (Revision 1)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70128\/download\u0022\u003EPDF (388.11 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (388.11 KB) of CVM GFI #115 (VICH GL22) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Reproduction Testing (Revision 1)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/01\/2026","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Human Food Safety, VICH","field_topics":"","topics-product":"Human Food Safety, VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2000-D-0784\u0022\u003EFDA-2000-D-0784\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222026-09-01T14:19:46-04:00\u0022\u003E2026-09-01 14:19\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-116-vich-gl23-r2-studies-evaluate-safety-residues-veterinary-drugs-human-food-genotoxicity\u0022\u003ECVM GFI #116 (VICH GL23 (R2)) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Genotoxicity Testing (Revision 2)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70134\/download\u0022\u003EPDF (566.32 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (566.32 KB) of CVM GFI #116 (VICH GL23 (R2)) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Genotoxicity Testing (Revision 2)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/01\/2026","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Human Food Safety, VICH","field_topics":"","topics-product":"Human Food Safety, VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2000-D-0598\u0022\u003EFDA-2000-D-0598\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222026-09-01T14:19:50-04:00\u0022\u003E2026-09-01 14:19\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-56-protocol-development-guideline-clinical-effectiveness-and-target-animal-safety-trials\u0022\u003ECVM GFI #56 Protocol Development Guideline for Clinical Effectiveness and Target Animal Safety Trials\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70137\/download\u0022\u003EPDF (60.4 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (60.4 KB) of CVM GFI #56 Protocol Development Guideline for Clinical Effectiveness and Target Animal Safety Trials\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/10\/2001","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Environmental Safety, Target Animal \u2013 Effectiveness, Target Animal \u2013 Safety","field_topics":"","topics-product":"Environmental Safety, Target Animal \u2013 Effectiveness, Target Animal \u2013 Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0611\u0022\u003EFDA-2021-D-0611\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222021-07-27T06:35:16-04:00\u0022\u003E2021-07-27 06:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-117-vich-gl24-management-adverse-event-reports-aers\u0022\u003ECVM GFI #117 (VICH GL24) Management of Adverse Event Reports (AER\u0026#039;s)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70144\/download\u0022\u003EPDF (121.27 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (121.27 KB) of CVM GFI #117 (VICH GL24) Management of Adverse Event Reports (AER\u0026#039;s)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/01\/2006","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Adverse Event Reporting, VICH","field_topics":"","topics-product":"Adverse Event Reporting, VICH","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2000-D-0136\u0022\u003EFDA-2000-D-0136\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T13:11:11-04:00\u0022\u003E2019-04-16 13:11\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-57-preparation-and-submission-veterinary-master-files\u0022\u003ECVM GFI #57 Preparation and Submission of Veterinary Master Files\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70147\/download\u0022\u003EPDF (109.53 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (109.53 KB) of CVM GFI #57 Preparation and Submission of Veterinary Master Files\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/01\/1995","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC)","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0617\u0022\u003EFDA-2021-D-0617\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222021-07-27T06:50:04-04:00\u0022\u003E2021-07-27 06:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-118-mass-spectrometry-confirmation-identity-animal-drug-residues\u0022\u003ECVM GFI #118 Mass Spectrometry for Confirmation of Identity of Animal Drug Residues\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70154\/download\u0022\u003EPDF (112.22 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (112.22 KB) of CVM GFI #118 Mass Spectrometry for Confirmation of Identity of Animal Drug Residues\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/01\/2003","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Human Food Safety","field_topics":"","topics-product":"Human Food Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2001-D-0102\u0022\u003EFDA-2001-D-0102\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T13:10:36-04:00\u0022\u003E2019-04-16 13:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-61-special-considerations-incentives-and-programs-support-approval-new-animal-drugs-minor\u0022\u003ECVM GFI #61 Special Considerations, Incentives, and Programs to Support the Approval of New Animal Drugs for Minor Uses and for Minor Species \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70157\/download\u0022\u003EPDF (752.81 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (752.81 KB) of CVM GFI #61 Special Considerations, Incentives, and Programs to Support the Approval of New Animal Drugs for Minor Uses and for Minor Species \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/22\/2023","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Aquaculture, Investigational New Animal Drug (INAD)","field_topics":"Premarket","topics-product":"Premarket, Aquaculture, Investigational New Animal Drug (INAD)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"01\/11\/2021","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1997-D-0444\u0022\u003EFDA-1997-D-0444\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222023-12-21T09:01:01-05:00\u0022\u003E2023-12-21 09:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-119-how-cvm-intends-handle-deficient-submissions-filed-during-investigation-new-animal-drug\u0022\u003ECVM GFI #119 How CVM Intends to Handle Deficient Submissions Filed During the Investigation of a New Animal Drug\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70164\/download\u0022\u003EPDF (32.96 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (32.96 KB) of CVM GFI #119 How CVM Intends to Handle Deficient Submissions Filed During the Investigation of a New Animal Drug\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/29\/2002","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Investigational New Animal Drug (INAD)","field_topics":"","topics-product":"Investigational New Animal Drug (INAD)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2001-D-0011\u0022\u003EFDA-2001-D-0011\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T13:15:08-04:00\u0022\u003E2019-04-16 13:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-63-vich-gl1-validation-analytical-procedures-definition-and-terminology\u0022\u003ECVM GFI #63 (VICH GL1) Validation of Analytical Procedures: Definition and Terminology\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70168\/download\u0022\u003EPDF (373.12 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (373.12 KB) of CVM GFI #63 (VICH GL1) Validation of Analytical Procedures: Definition and Terminology\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/28\/2024","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), VICH","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0614\u0022\u003EFDA-2021-D-0614\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222024-08-28T12:16:39-04:00\u0022\u003E2024-08-28 12:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-120-veterinary-feed-directive-regulation-questions-and-answers\u0022\u003ECVM GFI #120 Veterinary Feed Directive Regulation Questions and Answers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70173\/download\u0022\u003EPDF (602.76 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (602.76 KB) of CVM GFI #120 Veterinary Feed Directive Regulation Questions and Answers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/29\/2024","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Feed","field_topics":"","topics-product":"Animal Feed","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"05\/28\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-N-0155\u0022\u003EFDA-2010-N-0155\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222024-04-26T08:51:27-04:00\u0022\u003E2024-04-26 08:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-122-manufacture-and-labeling-raw-meat-foods-companion-and-captive-noncompanion-carnivores\u0022\u003ECVM GFI #122 Manufacture and Labeling of Raw Meat Foods for Companion and Captive Noncompanion Carnivores and Omnivores\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70183\/download\u0022\u003EPDF (94.47 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (94.47 KB) of CVM GFI #122 Manufacture and Labeling of Raw Meat Foods for Companion and Captive Noncompanion Carnivores and Omnivores\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/09\/2004","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Feed","field_topics":"","topics-product":"Animal Feed","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2002-D-0148\u0022\u003EFDA-2002-D-0148\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T13:15:05-04:00\u0022\u003E2019-04-16 13:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-64-vich-gl2-validation-analytical-procedures-methodology\u0022\u003ECVM GFI #64 (VICH GL2) Validation of Analytical Procedures: Methodology\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70189\/download\u0022\u003EPDF (423.07 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (423.07 KB) of CVM GFI #64 (VICH GL2) Validation of Analytical Procedures: Methodology\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/28\/2024","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), VICH","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0616\u0022\u003EFDA-2021-D-0616\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222024-08-28T12:16:31-04:00\u0022\u003E2024-08-28 12:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-123-development-data-supporting-approval-nsaids-use-animals\u0022\u003ECVM GFI #123 Development of Data Supporting Approval of NSAIDS for Use in Animals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70191\/download\u0022\u003EPDF (52.46 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (52.46 KB) of CVM GFI #123 Development of Data Supporting Approval of NSAIDS for Use in Animals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/05\/2006","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Target Animal \u2013 Effectiveness, Target Animal \u2013 Safety","field_topics":"","topics-product":"Target Animal \u2013 Effectiveness, Target Animal \u2013 Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-D-0372\u0022\u003EFDA-2004-D-0372\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T13:15:21-04:00\u0022\u003E2019-04-16 13:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-67-small-entities-compliance-guide-renderers\u0022\u003ECVM GFI #67 Small Entities Compliance Guide for Renderers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70197\/download\u0022\u003EPDF (65.79 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (65.79 KB) of CVM GFI #67 Small Entities Compliance Guide for Renderers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/01\/1998","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"Bovine Spongiform Encephalopathy (BSE)","term_node_tid":"Current Good Manufacturing Practice (CGMP)","field_topics":"","topics-product":"Bovine Spongiform Encephalopathy (BSE), Current Good Manufacturing Practice (CGMP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Small Entity Compliance Guide","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T12:10:11-04:00\u0022\u003E2019-04-16 12:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-68-small-entities-compliance-guide-protein-blenders-feed-manufacturers-and-distributors\u0022\u003ECVM GFI #68 Small Entities Compliance Guide for Protein Blenders, Feed Manufacturers, and Distributors\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70205\/download\u0022\u003EPDF (65.92 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (65.92 KB) of CVM GFI #68 Small Entities Compliance Guide for Protein Blenders, Feed Manufacturers, and Distributors\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/01\/1998","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"Bovine Spongiform Encephalopathy (BSE)","term_node_tid":"Current Good Manufacturing Practice (CGMP)","field_topics":"","topics-product":"Bovine Spongiform Encephalopathy (BSE), Current Good Manufacturing Practice (CGMP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Small Entity Compliance Guide","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T12:10:14-04:00\u0022\u003E2019-04-16 12:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-69-small-entities-compliance-guide-feeders-ruminant-animals-farm-feed-mixing-operations\u0022\u003ECVM GFI #69 Small Entities Compliance Guide for Feeders of Ruminant Animals with On-Farm Feed Mixing Operations\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70214\/download\u0022\u003EPDF (62 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (62 KB) of CVM GFI #69 Small Entities Compliance Guide for Feeders of Ruminant Animals with On-Farm Feed Mixing Operations\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/01\/1998","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"Bovine Spongiform Encephalopathy (BSE)","term_node_tid":"Animal Feed","field_topics":"","topics-product":"Bovine Spongiform Encephalopathy (BSE), Animal Feed","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Small Entity Compliance Guide","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T12:10:13-04:00\u0022\u003E2019-04-16 12:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-70-small-entities-compliance-guide-feeders-ruminant-animals-without-farm-feed-mixing\u0022\u003ECVM GFI #70 Small Entities Compliance Guide for Feeders of Ruminant Animals Without On-Farm Feed Mixing Operations\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70227\/download\u0022\u003EPDF (58.73 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (58.73 KB) of CVM GFI #70 Small Entities Compliance Guide for Feeders of Ruminant Animals Without On-Farm Feed Mixing Operations\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/13\/2009","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"Bovine Spongiform Encephalopathy (BSE)","term_node_tid":"Animal Feed, Current Good Manufacturing Practice (CGMP)","field_topics":"","topics-product":"Bovine Spongiform Encephalopathy (BSE), Animal Feed, Current Good Manufacturing Practice (CGMP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Small Entity Compliance Guide","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T12:16:16-04:00\u0022\u003E2019-04-16 12:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-72-gmps-medicated-feed-manufacturers-not-required-register-and-be-licensed-fda\u0022\u003ECVM GFI #72 GMP\u0026#039;S For Medicated Feed Manufacturers Not Required to Register and be Licensed with FDA\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70235\/download\u0022\u003EPDF (56.67 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (56.67 KB) of CVM GFI #72 GMP\u0026#039;S For Medicated Feed Manufacturers Not Required to Register and be Licensed with FDA\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/01\/1998","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Feed, Current Good Manufacturing Practice (CGMP)","field_topics":"","topics-product":"Animal Feed, Current Good Manufacturing Practice (CGMP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T12:17:20-04:00\u0022\u003E2019-04-16 12:17\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-73-vich-gl3r-stability-testing-new-veterinary-drug-substances-and-medicinal-products\u0022\u003ECVM GFI #73 (VICH GL3(R)) Stability Testing of New Veterinary Drug Substances and Medicinal Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70241\/download\u0022\u003EPDF (227.8 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (227.8 KB) of CVM GFI #73 (VICH GL3(R)) Stability Testing of New Veterinary Drug Substances and Medicinal Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/21\/2007","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), VICH","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2006-D-0299\u0022\u003EFDA-2006-D-0299\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222023-09-29T12:20:16-04:00\u0022\u003E2023-09-29 12:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-74-vich-gl4-stability-testing-new-veterinary-dosage-forms\u0022\u003ECVM GFI #74 (VICH GL4 ) Stability Testing of New Veterinary Dosage Forms\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70255\/download\u0022\u003EPDF (78.51 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (78.51 KB) of CVM GFI #74 (VICH GL4 ) Stability Testing of New Veterinary Dosage Forms\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/01\/1999","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), VICH","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA -2006-D-0299\u0022\u003EFDA -2006-D-0299\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T12:25:22-04:00\u0022\u003E2019-04-16 12:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-75-vich-gl5-stability-testing-photostability-testing-new-veterinary-drug-substances-and\u0022\u003ECVM GFI #75 (VICH GL5) Stability Testing-Photostability Testing of New Veterinary Drug Substances and Medicinal Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70262\/download\u0022\u003EPDF (76.02 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (76.02 KB) of CVM GFI #75 (VICH GL5) Stability Testing-Photostability Testing of New Veterinary Drug Substances and Medicinal Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/01\/1999","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), VICH","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1998-D-1165\u0022\u003EFDA-1998-D-1165\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T12:25:55-04:00\u0022\u003E2019-04-16 12:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-76-questions-and-answers-bse-feed-regulations\u0022\u003ECVM GFI #76 Questions and Answers BSE Feed Regulations\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70270\/download\u0022\u003EPDF (152.28 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (152.28 KB) of CVM GFI #76 Questions and Answers BSE Feed Regulations\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/01\/1998","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"Bovine Spongiform Encephalopathy (BSE)","term_node_tid":"Current Good Manufacturing Practice (CGMP)","field_topics":"","topics-product":"Bovine Spongiform Encephalopathy (BSE), Current Good Manufacturing Practice (CGMP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Small Entity Compliance Guide","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T12:30:25-04:00\u0022\u003E2019-04-16 12:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-79-dispute-resolution-procedures-science-based-decisions-products-regulated-cvm\u0022\u003ECVM GFI #79 Dispute Resolution Procedures for Science-Based Decisions on Products Regulated by CVM\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70279\/download\u0022\u003EPDF (139.26 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (139.26 KB) of CVM GFI #79 Dispute Resolution Procedures for Science-Based Decisions on Products Regulated by CVM\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/29\/2014","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2003-D-0307\u0022\u003EFDA-2003-D-0307\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T12:30:10-04:00\u0022\u003E2019-04-16 12:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-80-evaluation-utility-anti-salmonella-chemical-food-additives\u0022\u003ECVM GFI #80 Evaluation the Utility of Anti-Salmonella Chemical Food Additives\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70304\/download\u0022\u003EPDF (78 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (78 KB) of CVM GFI #80 Evaluation the Utility of Anti-Salmonella Chemical Food Additives\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/21\/2002","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Food Additives","field_topics":"","topics-product":"Animal Food Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1994-D-0007\u0022\u003EFDA-1994-D-0007\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T12:30:45-04:00\u0022\u003E2019-04-16 12:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-82-development-supplemental-applications-approved-new-animal-drugs\u0022\u003ECVM GFI #82 Development of Supplemental Applications for Approved New Animal Drugs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70308\/download\u0022\u003EPDF (842.86 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (842.86 KB) of CVM GFI #82 Development of Supplemental Applications for Approved New Animal Drugs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/28\/2002","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"New Animal Drug Application (NADA)","field_topics":"","topics-product":"New Animal Drug Application (NADA)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1999-N-1881\u0022\u003EFDA-1999-N-1881\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T12:35:57-04:00\u0022\u003E2019-04-16 12:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-83-chemistry-manufacturing-and-controls-changes-approved-nadaanada\u0022\u003ECVM GFI #83 Chemistry, Manufacturing and Controls Changes to Approved NADA\/ANADA\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70323\/download\u0022\u003EPDF (162.29 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (162.29 KB) of CVM GFI #83 Chemistry, Manufacturing and Controls Changes to Approved NADA\/ANADA\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/30\/2007","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), New Animal Drug Application (NADA)","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), New Animal Drug Application (NADA)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1999-D-0011\u0022\u003EFDA-1999-D-0011\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T12:36:04-04:00\u0022\u003E2019-04-16 12:36\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-85-vich-gl9-good-clinical-practice\u0022\u003ECVM GFI #85 (VICH GL9) Good Clinical Practice\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70333\/download\u0022\u003EPDF (220.08 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (220.08 KB) of CVM GFI #85 (VICH GL9) Good Clinical Practice\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/09\/2001","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Target Animal \u2013 Effectiveness, Target Animal \u2013 Safety, VICH","field_topics":"","topics-product":"Target Animal \u2013 Effectiveness, Target Animal \u2013 Safety, VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1999-D-0754\u0022\u003EFDA-1999-D-0754\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T12:35:39-04:00\u0022\u003E2019-04-16 12:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-89-vich-gl6-eias-veterinary-medicinal-products-phase-i\u0022\u003ECVM GFI #89 (VICH GL6) EIAs for Veterinary Medicinal Products - Phase I\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70340\/download\u0022\u003EPDF (106.15 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (106.15 KB) of CVM GFI #89 (VICH GL6) EIAs for Veterinary Medicinal Products - Phase I\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/07\/2001","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Environmental Safety, VICH","field_topics":"","topics-product":"Environmental Safety, VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1999-D-3541\u0022\u003EFDA-1999-D-3541\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T12:36:12-04:00\u0022\u003E2019-04-16 12:36\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-90-vich-gl7-effectiveness-anthelmintics-general-recommendations\u0022\u003ECVM GFI #90 (VICH GL7) Effectiveness of Anthelmintics: General Recommendations\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70349\/download\u0022\u003EPDF (626.49 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (626.49 KB) of CVM GFI #90 (VICH GL7) Effectiveness of Anthelmintics: General Recommendations\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/23\/2026","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Anthelmintics, Target Animal \u2013 Effectiveness, VICH","field_topics":"","topics-product":"Anthelmintics, Target Animal \u2013 Effectiveness, VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-1494\u0022\u003EFDA-2022-D-1494\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222026-06-23T09:45:59-04:00\u0022\u003E2026-06-23 09:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-91-vich-gl8-r-stability-testing-medicated-premix-or-type-medicated-article-revision-1\u0022\u003ECVM GFI #91 (VICH GL8 (R)) Stability Testing for Medicated Premix (or Type A Medicated Article) (Revision 1)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/192057\/download\u0022\u003EPDF (358.97 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (358.97 KB) of CVM GFI #91 (VICH GL8 (R)) Stability Testing for Medicated Premix (or Type A Medicated Article) (Revision 1)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/21\/2026","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Feed, Chemistry, Manufacturing, and Controls (CMC), VICH","field_topics":"","topics-product":"Animal Feed, Chemistry, Manufacturing, and Controls (CMC), VICH","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"06\/15\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0613\u0022\u003EFDA-2021-D-0613\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222026-04-23T16:16:31-04:00\u0022\u003E2026-04-23 16:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-92-vich-gl10r-impurities-new-veterinary-drug-substances\u0022\u003ECVM GFI #92 (VICH GL10(R)) Impurities In New Veterinary Drug Substances\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70365\/download\u0022\u003EPDF (149.87 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (149.87 KB) of CVM GFI #92 (VICH GL10(R)) Impurities In New Veterinary Drug Substances\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/26\/2007","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), VICH","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1999-D-0064\u0022\u003EFDA-1999-D-0064\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T12:45:21-04:00\u0022\u003E2019-04-16 12:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-93-vich-gl11r-impurities-new-veterinary-medicinal-products\u0022\u003ECVM GFI #93 (VICH GL11(R)) Impurities in New Veterinary Medicinal Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70368\/download\u0022\u003EPDF (133.55 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (133.55 KB) of CVM GFI #93 (VICH GL11(R)) Impurities in New Veterinary Medicinal Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/21\/2007","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), VICH","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1999-D-0048\u0022\u003EFDA-1999-D-0048\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T12:50:19-04:00\u0022\u003E2019-04-16 12:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-142-vich-gl29-pharmacovigilance-veterinary-medicinal-products-management-periodic-summary\u0022\u003ECVM GFI #142 (VICH GL29) Pharmacovigilance of Veterinary Medicinal Products: Management of Periodic Summary Update Reports (PSUs)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70371\/download\u0022\u003EPDF (151.51 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (151.51 KB) of CVM GFI #142 (VICH GL29) Pharmacovigilance of Veterinary Medicinal Products: Management of Periodic Summary Update Reports (PSUs)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/06\/2001","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Adverse Event Reporting, VICH","field_topics":"","topics-product":"Adverse Event Reporting, VICH","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2001-D-0398\u0022\u003EFDA-2001-D-0398\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T13:25:17-04:00\u0022\u003E2019-04-16 13:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-95-vich-gl12-effectiveness-anthelmintics-specific-recommendations-bovines\u0022\u003ECVM GFI #95 (VICH GL12) Effectiveness of Anthelmintics: Specific Recommendations for Bovines\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70377\/download\u0022\u003EPDF (409.45 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (409.45 KB) of CVM GFI #95 (VICH GL12) Effectiveness of Anthelmintics: Specific Recommendations for Bovines\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/23\/2026","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Anthelmintics, Target Animal \u2013 Effectiveness, VICH","field_topics":"","topics-product":"Anthelmintics, Target Animal \u2013 Effectiveness, VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-1494\u0022\u003EFDA-2022-D-1494\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222026-06-23T09:43:02-04:00\u0022\u003E2026-06-23 09:43\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-96-vich-gl13-effectiveness-anthelmintics-specific-recommendations-ovines\u0022\u003ECVM GFI #96 (VICH GL13) Effectiveness of Anthelmintics: Specific Recommendations for Ovines\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70383\/download\u0022\u003EPDF (421.05 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (421.05 KB) of CVM GFI #96 (VICH GL13) Effectiveness of Anthelmintics: Specific Recommendations for Ovines\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/23\/2026","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Anthelmintics, Target Animal \u2013 Effectiveness, VICH","field_topics":"","topics-product":"Anthelmintics, Target Animal \u2013 Effectiveness, VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-1494\u0022\u003EFDA-2022-D-1494\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222026-06-23T09:46:04-04:00\u0022\u003E2026-06-23 09:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-97-vich-gl14-effectiveness-anthelmintics-specific-recommendations-caprines\u0022\u003ECVM GFI #97 (VICH GL14) Effectiveness of Anthelmintics: Specific Recommendations for Caprines\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70391\/download\u0022\u003EPDF (405.89 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (405.89 KB) of CVM GFI #97 (VICH GL14) Effectiveness of Anthelmintics: Specific Recommendations for Caprines\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/23\/2026","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Anthelmintics, Target Animal \u2013 Effectiveness, VICH","field_topics":"","topics-product":"Anthelmintics, Target Animal \u2013 Effectiveness, VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-1494\u0022\u003EFDA-2022-D-1494\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222026-06-23T09:46:06-04:00\u0022\u003E2026-06-23 09:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-98-dioxin-anti-caking-agents-animal-feed-and-feed-ingredients\u0022\u003ECVM GFI #98 Dioxin In Anti-Caking Agents In Animal Feed And Feed Ingredients\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70397\/download\u0022\u003EPDF (35.15 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (35.15 KB) of CVM GFI #98 Dioxin In Anti-Caking Agents In Animal Feed And Feed Ingredients\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/12\/2000","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Feed","field_topics":"","topics-product":"Animal Feed","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1999-D-2441\u0022\u003EFDA-1999-D-2441\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T12:55:05-04:00\u0022\u003E2019-04-16 12:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-99-vich-gl17-testing-new-biotechnologicalbiological-products\u0022\u003ECVM GFI #99 (VICH GL17) Testing of New Biotechnological\/Biological Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70404\/download\u0022\u003EPDF (118.25 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (118.25 KB) of CVM GFI #99 (VICH GL17) Testing of New Biotechnological\/Biological Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/26\/2001","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), VICH","field_topics":"Biotechnology","topics-product":"Biotechnology, Chemistry, Manufacturing, and Controls (CMC), VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0612\u0022\u003EFDA-2021-D-0612\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222021-07-27T06:46:04-04:00\u0022\u003E2021-07-27 06:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-100-vich-gl18-r2-impurities-residual-solvents-new-veterinary-medicinal-products-active\u0022\u003ECVM GFI #100 (VICH GL18 (R2)) Impurities: Residual Solvents in New Veterinary Medicinal Products, Active Substances and Excipients (Revision 2)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70410\/download\u0022\u003EPDF (569.79 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (569.79 KB) of CVM GFI #100 (VICH GL18 (R2)) Impurities: Residual Solvents in New Veterinary Medicinal Products, Active Substances and Excipients (Revision 2)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/25\/2024","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), VICH","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"09\/16\/2022","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1999-D-2955 \u0022\u003EFDA-1999-D-2955 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222024-07-24T08:49:01-04:00\u0022\u003E2024-07-24 08:49\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-195-small-entities-compliance-guide-renderers-substances-prohibited-use-animal-food-or-feed\u0022\u003ECVM GFI #195 Small Entities Compliance Guide For Renderers\u2014Substances Prohibited From Use In Animal Food Or Feed\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70417\/download\u0022\u003EPDF (250.9 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (250.9 KB) of CVM GFI #195 Small Entities Compliance Guide For Renderers\u2014Substances Prohibited From Use In Animal Food Or Feed\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/06\/2009","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"Bovine Spongiform Encephalopathy (BSE)","term_node_tid":"","field_topics":"","topics-product":"Bovine Spongiform Encephalopathy (BSE), ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0597\u0022\u003EFDA-2008-D-0597\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:00:38-04:00\u0022\u003E2019-04-16 14:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-191-changes-approved-nadas-new-nadas-vs-category-ii-supplemental-nadas\u0022\u003ECVM GFI #191 Changes to Approved NADAs - New NADAs vs. Category II Supplemental NADAs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70423\/download\u0022\u003EPDF (266.41 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (266.41 KB) of CVM GFI #191 Changes to Approved NADAs - New NADAs vs. Category II Supplemental NADAs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/27\/2020","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"New Animal Drug Application (NADA)","field_topics":"","topics-product":"New Animal Drug Application (NADA)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0614\u0022\u003EFDA-2008-D-0614\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222020-08-27T13:10:33-04:00\u0022\u003E2020-08-27 13:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-185-vich-gl43-target-animal-safety-veterinary-pharmaceutical-products\u0022\u003ECVM GFI #185 (VICH GL43) Target Animal Safety for Veterinary Pharmaceutical Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70438\/download\u0022\u003EPDF (395.36 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (395.36 KB) of CVM GFI #185 (VICH GL43) Target Animal Safety for Veterinary Pharmaceutical Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/24\/2009","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Target Animal \u2013 Safety, VICH","field_topics":"","topics-product":"Target Animal \u2013 Safety, VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2007-D-0430\u0022\u003EFDA-2007-D-0430\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:02:11-04:00\u0022\u003E2019-04-16 14:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-183-animal-drug-user-fees-fees-exceed-costs-waiverreduction\u0022\u003ECVM GFI #183 Animal Drug User Fees: Fees Exceed Costs Waiver\/Reduction\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70445\/download\u0022\u003EPDF (117.49 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (117.49 KB) of CVM GFI #183 Animal Drug User Fees: Fees Exceed Costs Waiver\/Reduction\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/09\/2007","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"","field_topics":"User Fees","topics-product":"User Fees, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2006-D-0361\u0022\u003EFDA-2006-D-0361\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T13:50:55-04:00\u0022\u003E2019-04-16 13:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-181-blue-bird-medicated-feed-labels\u0022\u003ECVM GFI #181 Blue Bird Medicated Feed Labels\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70452\/download\u0022\u003EPDF (146.78 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (146.78 KB) of CVM GFI #181 Blue Bird Medicated Feed Labels\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/23\/2019","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Feed, Labeling","field_topics":"","topics-product":"Animal Feed, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0165\u0022\u003EFDA-2008-D-0165\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-08-12T13:00:16-04:00\u0022\u003E2019-08-12 13:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/revised-recommendations-regarding-invalidation-test-results-licensed-and-510k-cleared-bloodborne\u0022\u003ERevised Recommendations Regarding Invalidation of Test Results of Licensed and 510(k) Cleared Bloodborne Pathogen Assays Used to Test Donors: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70633\/download\u0022\u003EPDF (32.91 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (32.91 KB) of Revised Recommendations Regarding Invalidation of Test Results of Licensed and 510(k) Cleared Bloodborne Pathogen Assays Used to Test Donors: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/11\/2001","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"Application \u0026amp; Approvals","topics-product":"Application \u0026amp; Approvals, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1999-D-0743\u0022\u003EFDA-1999-D-0743\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-06-21T10:31:03-04:00\u0022\u003E2024-06-21 10:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/use-sterile-connecting-devices-blood-bank-practices\u0022\u003EUse of Sterile Connecting Devices in Blood Bank Practices: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70656\/download\u0022\u003EPDF (38.25 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (38.25 KB) of Use of Sterile Connecting Devices in Blood Bank Practices: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/22\/2000","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"Application \u0026amp; Approvals","topics-product":"Application \u0026amp; Approvals, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0486\u0022\u003EFDA-2022-D-0486\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222022-04-28T15:14:34-04:00\u0022\u003E2022-04-28 15:14\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/notifying-fda-fatalities-related-blood-collection-or-transfusion\u0022\u003ENotifying FDA of Fatalities Related to Blood Collection or Transfusion: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70676\/download\u0022\u003EPDF (141.35 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (141.35 KB) of Notifying FDA of Fatalities Related to Blood Collection or Transfusion: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/20\/2021","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"Application \u0026amp; Approvals","topics-product":"Application \u0026amp; Approvals, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2002-D-0010\u0022\u003EFDA-2002-D-0010\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-04-18T08:46:01-04:00\u0022\u003E2024-04-18 08:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/informed-consent-recommendations-source-plasma-donors-participating-plasmapheresis-and-immunization\u0022\u003EInformed Consent Recommendations for Source Plasma Donors Participating in Plasmapheresis and Immunization Programs: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70685\/download\u0022\u003EPDF (56.11 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (56.11 KB) of Informed Consent Recommendations for Source Plasma Donors Participating in Plasmapheresis and Immunization Programs: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/01\/2007","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Blood","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2006-D-0350\u0022\u003EFDA-2006-D-0350\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-05-02T09:51:46-04:00\u0022\u003E2024-05-02 09:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/streamlining-donor-interview-process-recommendations-self-administered-questionnaires\u0022\u003EStreamlining the Donor Interview Process: Recommendations for Self-Administered Questionnaires: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70688\/download\u0022\u003EPDF (48.42 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (48.42 KB) of Streamlining the Donor Interview Process: Recommendations for Self-Administered Questionnaires: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/03\/2003","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"Application \u0026amp; Approvals","topics-product":"Application \u0026amp; Approvals, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2002-D-0524\u0022\u003EFDA-2002-D-0524\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-06-13T10:01:17-04:00\u0022\u003E2024-06-13 10:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/regulation-human-cells-tissues-and-cellular-and-tissue-based-products-hctps-small-entity-compliance\u0022\u003ERegulation of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\/Ps) - Small Entity Compliance Guide: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70689\/download\u0022\u003EPDF (354.33 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (354.33 KB) of Regulation of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\/Ps) - Small Entity Compliance Guide: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/01\/2022","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Tissue","field_topics":"","topics-product":"Tissue","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0563\u0022\u003EFDA-2022-D-0563\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222022-11-01T10:46:46-04:00\u0022\u003E2022-11-01 10:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/biological-product-deviation-reporting-blood-and-plasma-establishments\u0022\u003E Biological Product Deviation Reporting for Blood and Plasma Establishments: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70694\/download\u0022\u003EPDF (547.39 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (547.39 KB) of Biological Product Deviation Reporting for Blood and Plasma Establishments: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/12\/2020","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Blood","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2001-D-0007\u0022\u003EFDA-2001-D-0007\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222020-03-13T09:06:31-04:00\u0022\u003E2020-03-13 09:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/certain-human-cells-tissues-and-cellular-and-tissue-based-products-hctps-recovered-donors-who-were\u0022\u003ECertain Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\/Ps) Recovered from Donors Who Were Tested for Communicable Diseases Using Pooled Specimens or Diagnostic Tests: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70696\/download\u0022\u003EPDF (62.69 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (62.69 KB) of Certain Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\/Ps) Recovered from Donors Who Were Tested for Communicable Diseases Using Pooled Specimens or Diagnostic Tests: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/16\/2008","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Tissue","field_topics":"","topics-product":"Tissue","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2007-D-0070\u0022\u003EFDA-2007-D-0070\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-04-23T14:12:03-04:00\u0022\u003E2024-04-23 14:12\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/proposed-approach-regulation-cellular-and-tissue-based-products\u0022\u003EProposed Approach to Regulation of Cellular and Tissue-Based Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70704\/download\u0022\u003EPDF (452.22 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (452.22 KB) of Proposed Approach to Regulation of Cellular and Tissue-Based Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/28\/1997","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"04\/17\/1997","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1997-N-0207\u0022\u003EFDA-1997-N-0207\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-07-26T09:57:31-04:00\u0022\u003E2024-07-26 09:57\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cooperative-manufacturing-arrangements-licensed-biologics\u0022\u003ECooperative Manufacturing Arrangements for Licensed Biologics: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70712\/download\u0022\u003EPDF (74.63 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (74.63 KB) of Cooperative Manufacturing Arrangements for Licensed Biologics: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/28\/2008","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1999-D-0128\u0022\u003EFDA-1999-D-0128\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222020-10-20T12:34:24-04:00\u0022\u003E2020-10-20 12:34\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/premarket-notification-submissions-empty-containers-collection-and-processing-blood-and-blood\u0022\u003E Premarket Notification Submissions for Empty Containers for the Collection and Processing of Blood and Blood Components: Guidance for FDA Reviewers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70716\/download\u0022\u003EPDF (29.88 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (29.88 KB) of Premarket Notification Submissions for Empty Containers for the Collection and Processing of Blood and Blood Components: Guidance for FDA Reviewers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/19\/2001","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"Application \u0026amp; Approvals","topics-product":"Application \u0026amp; Approvals, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2007-D-0251\u0022\u003EFDA-2007-D-0251\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222022-04-28T14:55:05-04:00\u0022\u003E2022-04-28 14:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/collection-platelets-automated-methods\u0022\u003E Collection of Platelets by Automated Methods: Guidance for Industry and FDA Review Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70720\/download\u0022\u003EPDF (153.01 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (153.01 KB) of Collection of Platelets by Automated Methods: Guidance for Industry and FDA Review Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/01\/2007","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2005-D-0013\u0022\u003EFDA-2005-D-0013\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-04-23T14:14:46-04:00\u0022\u003E2024-04-23 14:14\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/premarket-notification-submissions-blood-and-plasma-warmers\u0022\u003EPremarket Notification Submissions for Blood and Plasma Warmers: Guidance for FDA Reviewers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70728\/download\u0022\u003EPDF (31.21 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (31.21 KB) of Premarket Notification Submissions for Blood and Plasma Warmers: Guidance for FDA Reviewers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/19\/2001","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"Application \u0026amp; Approvals","topics-product":"Application \u0026amp; Approvals, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0484\u0022\u003EFDA-2022-D-0484\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222022-04-28T15:07:04-04:00\u0022\u003E2022-04-28 15:07\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/premarket-notification-submissions-transfer-sets-excluding-sterile-connecting-devices\u0022\u003EPremarket Notification Submissions for Transfer Sets (Excluding Sterile Connecting Devices): Guidance for FDA Reviewers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70734\/download\u0022\u003EPDF (29.87 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (29.87 KB) of Premarket Notification Submissions for Transfer Sets (Excluding Sterile Connecting Devices): Guidance for FDA Reviewers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/19\/2001","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"Application \u0026amp; Approvals","topics-product":"Application \u0026amp; Approvals, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0485\u0022\u003EFDA-2022-D-0485\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222022-04-28T15:11:38-04:00\u0022\u003E2022-04-28 15:11\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommendations-assessment-donor-suitability-and-blood-and-blood-product-safety-cases-possible\u0022\u003ERecommendations for Assessment of Donor Suitability and Blood and Blood Product Safety in Cases of Possible Exposure to Anthrax: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70766\/download\u0022\u003EPDF (37.18 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (37.18 KB) of Recommendations for Assessment of Donor Suitability and Blood and Blood Product Safety in Cases of Possible Exposure to Anthrax: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/17\/2001","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"Application \u0026amp; Approvals","topics-product":"Application \u0026amp; Approvals, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2001-D-0488\u0022\u003EFDA-2001-D-0488\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-06-13T12:14:02-04:00\u0022\u003E2024-06-13 12:14\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/changes-approved-nda-or-anda-specifications-use-enforcement-discretion-compendial-changes\u0022\u003EChanges to an Approved NDA or ANDA; Specifications \u2013 Use of Enforcement Discretion for Compendial Changes: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70772\/download\u0022\u003EPDF (24.22 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (24.22 KB) of Changes to an Approved NDA or ANDA; Specifications \u2013 Use of Enforcement Discretion for Compendial Changes: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/22\/2004","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-D-0179\u0022\u003EFDA-2004-D-0179\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-04T14:35:19-04:00\u0022\u003E2020-05-04 14:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/container-closure-systems-packaging-human-drugs-and-biologics\u0022\u003EContainer Closure Systems for Packaging Human Drugs and Biologics: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70788\/download\u0022\u003EPDF (164.05 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (164.05 KB) of Container Closure Systems for Packaging Human Drugs and Biologics: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/07\/1999","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1997-D-0145\u0022\u003EFDA-1997-D-0145\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T14:05:07-04:00\u0022\u003E2020-05-06 14:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/container-closure-systems-packaging-human-drugs-and-biologics-questions-and-answers\u0022\u003EContainer Closure Systems for Packaging Human Drugs and Biologics -- Questions and Answers: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70794\/download\u0022\u003EPDF (34.31 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (34.31 KB) of Container Closure Systems for Packaging Human Drugs and Biologics -- Questions and Answers: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/01\/2002","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/None found\u0022\u003ENone found\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-02-25T14:35:05-05:00\u0022\u003E2022-02-25 14:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/drug-master-files-bulk-antibiotic-drug-substances\u0022\u003EDrug Master Files for Bulk Antibiotic Drug Substances: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70803\/download\u0022\u003EPDF (23.23 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (23.23 KB) of Drug Master Files for Bulk Antibiotic Drug Substances: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/1999","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1999-D-1314\u0022\u003EFDA-1999-D-1314\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-28T13:35:06-04:00\u0022\u003E2020-04-28 13:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/format-and-content-cmc-section-annual-report\u0022\u003EFormat and Content for the CMC Section of an Annual Report\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70816\/download\u0022\u003EPDF (29.3 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (29.3 KB) of Format and Content for the CMC Section of an Annual Report\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/01\/1994","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-06-04T06:06:41-04:00\u0022\u003E2019-06-04 06:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/inds-phase-2-and-phase-3-studies-chemistry-manufacturing-and-controls-information\u0022\u003EINDs for Phase 2 and Phase 3 Studies Chemistry, Manufacturing, and Controls Information: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70822\/download\u0022\u003EPDF (283.35 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (283.35 KB) of INDs for Phase 2 and Phase 3 Studies Chemistry, Manufacturing, and Controls Information: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/20\/2003","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Good Clinical Practice (GCP), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Good Clinical Practice (GCP), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1999-D-0030\u0022\u003EFDA-1999-D-0030\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T00:25:07-04:00\u0022\u003E2020-04-24 00:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/ind-meetings-human-drugs-and-biologics-chemistry-manufacturing-and-controls-information\u0022\u003EIND Meetings for Human Drugs and Biologics Chemistry, Manufacturing, and Controls Information: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70827\/download\u0022\u003EPDF (30.12 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (30.12 KB) of IND Meetings for Human Drugs and Biologics Chemistry, Manufacturing, and Controls Information: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/01\/2001","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-06-04T06:05:37-04:00\u0022\u003E2019-06-04 06:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/liposome-drug-products-chemistry-manufacturing-and-controls-human-pharmacokinetics-and\u0022\u003ELiposome Drug Products: Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70837\/download\u0022\u003EPDF (120.22 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (120.22 KB) of Liposome Drug Products: Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/05\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-2817\u0022\u003EFDA-2016-D-2817\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-10-04T10:25:30-04:00\u0022\u003E2021-10-04 10:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/monoclonal-antibodies-used-reagents-drug-manufacturing\u0022\u003EMonoclonal Antibodies Used as Reagents in Drug Manufacturing\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70845\/download\u0022\u003EPDF (28.78 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (28.78 KB) of Monoclonal Antibodies Used as Reagents in Drug Manufacturing\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/2001","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-06-04T06:07:44-04:00\u0022\u003E2019-06-04 06:07\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/metered-dose-inhaler-mdi-and-dry-powder-inhaler-dpi-drug-products-quality-considerations\u0022\u003EMetered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products--Quality Considerations\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70851\/download\u0022\u003EPDF (449.28 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (449.28 KB) of Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products--Quality Considerations\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/19\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1098\u0022\u003EFDA-2018-D-1098\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T13:35:29-04:00\u0022\u003E2020-04-24 13:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/nasal-spray-and-inhalation-solution-suspension-and-spray-drug-products-chemistry-manufacturing-and\u0022\u003ENasal Spray and Inhalation Solution, Suspension, and Spray Drug Products--Chemistry, Manufacturing, and Controls Documentation: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70857\/download\u0022\u003EPDF (436.38 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (436.38 KB) of Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products--Chemistry, Manufacturing, and Controls Documentation: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/05\/2002","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1999-D-0060\u0022\u003EFDA-1999-D-0060\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-14T10:15:25-04:00\u0022\u003E2020-05-14 10:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/bioanalytical-method-validation-guidance-industry\u0022\u003EBioanalytical Method Validation Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70858\/download\u0022\u003EPDF (385.62 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (385.62 KB) of Bioanalytical Method Validation Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/22\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Veterinary Medicine","field_health_topics":"","term_node_tid":"Biopharmaceutics","field_topics":"","topics-product":"Biopharmaceutics","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-1020\u0022\u003EFDA-2013-D-1020\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-29T16:25:05-04:00\u0022\u003E2020-04-29 16:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/bioavailability-and-bioequivalence-studies-nasal-aerosols-and-nasal-sprays-local-action\u0022\u003EBioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70867\/download\u0022\u003EPDF (727.41 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (727.41 KB) of Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/03\/2003","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Biopharmaceutics, Generic Drugs","field_topics":"","topics-product":"Biopharmaceutics, Generic Drugs","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1999-D-0050\u0022\u003EFDA-1999-D-0050\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-29T16:35:02-04:00\u0022\u003E2020-04-29 16:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/ndas-impurities-drug-substances\u0022\u003ENDAs: Impurities in Drug Substances\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70870\/download\u0022\u003EPDF (11.2 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (11.2 KB) of NDAs: Impurities in Drug Substances\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/01\/2000","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC)","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1998-D-0277\u0022\u003EFDA-1998-D-0277\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-04-28T10:20:05-04:00\u0022\u003E2022-04-28 10:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/orally-disintegrating-tablets\u0022\u003EOrally Disintegrating Tablets: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70877\/download\u0022\u003EPDF (51.6 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (51.6 KB) of Orally Disintegrating Tablets: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/16\/2008","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2007-D-0365\u0022\u003EFDA-2007-D-0365\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-15T01:08:03-04:00\u0022\u003E2020-05-15 01:08\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/statistical-information-june-1999-draft-guidance-and-statistical-information-in-vitro-bioequivalence\u0022\u003EStatistical Information from the June 1999 Draft Guidance and Statistical Information for In Vitro Bioequivalence Data Posted on August 18, 1999\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70878\/download\u0022\u003EPDF (190.76 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (190.76 KB) of Statistical Information from the June 1999 Draft Guidance and Statistical Information for In Vitro Bioequivalence Data Posted on August 18, 1999\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/11\/2003","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Biopharmaceutics, Generic Drugs","field_topics":"","topics-product":"Biopharmaceutics, Generic Drugs","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-29T14:15:13-04:00\u0022\u003E2020-04-29 14:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pac-atls-postapproval-changes-analytical-testing-laboratory-sites\u0022\u003EPAC-ATLS: Postapproval Changes - Analytical Testing Laboratory Sites: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70885\/download\u0022\u003EPDF (76.47 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (76.47 KB) of PAC-ATLS: Postapproval Changes - Analytical Testing Laboratory Sites: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/28\/1998","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1998-D-1157\u0022\u003EFDA-1998-D-1157\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-15T01:35:08-04:00\u0022\u003E2020-05-15 01:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/residual-solvents-drug-products-marketed-united-states\u0022\u003EResidual Solvents in Drug Products Marketed in the United States: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70928\/download\u0022\u003EPDF (51.82 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (51.82 KB) of Residual Solvents in Drug Products Marketed in the United States: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/25\/2009","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0413\u0022\u003EFDA-2008-D-0413\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-23T11:50:03-04:00\u0022\u003E2020-04-23 11:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/dissolution-testing-immediate-release-solid-oral-dosage-forms\u0022\u003EDissolution Testing of Immediate Release Solid Oral Dosage Forms\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70936\/download\u0022\u003EPDF (129.83 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (129.83 KB) of Dissolution Testing of Immediate Release Solid Oral Dosage Forms\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/25\/1997","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Biopharmaceutics","field_topics":"","topics-product":"Biopharmaceutics","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1997-D-0187\u0022\u003EFDA-1997-D-0187\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-10-17T08:36:04-04:00\u0022\u003E2019-10-17 08:36\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/extended-release-oral-dosage-forms-development-evaluation-and-application-vitroin-in-vivo-correlations\u0022\u003EExtended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro\/In Vivo Correlations\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70939\/download\u0022\u003EPDF (170.47 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (170.47 KB) of Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro\/In Vivo Correlations\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/01\/1997","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Biopharmaceutics","field_topics":"","topics-product":"Biopharmaceutics","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-03-08T15:00:04-05:00\u0022\u003E2019-03-08 15:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/food-effect-bioavailability-and-fed-bioequivalence-studies\u0022\u003EFood-Effect Bioavailability and Fed Bioequivalence Studies: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70945\/download\u0022\u003EPDF (216.55 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (216.55 KB) of Food-Effect Bioavailability and Fed Bioequivalence Studies: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/01\/2002","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Biopharmaceutics, Good Clinical Practice (GCP)","field_topics":"","topics-product":"Biopharmaceutics, Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2001-D-0040\u0022\u003EFDA-2001-D-0040\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-21T10:30:30-04:00\u0022\u003E2020-04-21 10:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/supac-ir-immediate-release-solid-oral-dosage-forms-scale-and-post-approval-changes-chemistry\u0022\u003ESUPAC-IR: Immediate-Release Solid Oral Dosage Forms: Scale-Up and Post-Approval Changes: Chemistry, Manufacturing and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70949\/download\u0022\u003EPDF (59.87 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (59.87 KB) of SUPAC-IR: Immediate-Release Solid Oral Dosage Forms: Scale-Up and Post-Approval Changes: Chemistry, Manufacturing and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/01\/1995","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-05T11:50:02-04:00\u0022\u003E2020-05-05 11:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/metaproterenol-sulfate-and-albuterol-metered-dose-inhalers-vitro\u0022\u003EMetaproterenol Sulfate and Albuterol Metered Dose Inhalers In Vitro\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70953\/download\u0022\u003EPDF (743.81 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (743.81 KB) of Metaproterenol Sulfate and Albuterol Metered Dose Inhalers In Vitro\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/27\/1989","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Biopharmaceutics","field_topics":"","topics-product":"Biopharmaceutics","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-01-23T10:13:14-05:00\u0022\u003E2019-01-23 10:13\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/supac-mr-modified-release-solid-oral-dosage-forms-scale-and-postapproval-changes-chemistry\u0022\u003ESUPAC-MR: Modified Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70956\/download\u0022\u003EPDF (214.71 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (214.71 KB) of SUPAC-MR: Modified Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/06\/1997","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1997-D-0507\u0022\u003EFDA-1997-D-0507\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-05T11:55:02-04:00\u0022\u003E2020-05-05 11:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/medical-gases-current-good-manufacturing-practice\u0022\u003EMedical Gases \u2014 Current Good Manufacturing Practice: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70973\/download\u0022\u003EPDF (418.59 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (418.59 KB) of Medical Gases \u2014 Current Good Manufacturing Practice: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/28\/2025","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_topics":"","topics-product":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"01\/30\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2003-D-0431 \u0022\u003EFDA-2003-D-0431 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-12-01T08:48:17-05:00\u0022\u003E2025-12-01 08:48\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/current-good-manufacturing-practice-phase-1-investigational-drugs\u0022\u003ECurrent Good Manufacturing Practice for Phase 1 Investigational Drugs: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70975\/download\u0022\u003EPDF (91.58 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (91.58 KB) of Current Good Manufacturing Practice for Phase 1 Investigational Drugs: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/14\/2008","field_issuing_office_taxonomy":"Office of Regulatory Affairs\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP), Good Clinical Practice (GCP), Pharmaceutical Quality","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Current Good Manufacturing Practice (CGMP), Good Clinical Practice (GCP), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2005-D-0157\u0022\u003EFDA-2005-D-0157\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222023-09-29T13:05:24-04:00\u0022\u003E2023-09-29 13:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/expiration-dating-and-stability-testing-solid-oral-dosage-form-drugs-containing-iron\u0022\u003EExpiration Dating and Stability Testing of Solid Oral Dosage Form Drugs Containing Iron: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70979\/download\u0022\u003EPDF (88.67 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (88.67 KB) of Expiration Dating and Stability Testing of Solid Oral Dosage Form Drugs Containing Iron: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/09\/1997","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_topics":"","topics-product":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1997-D-0489\u0022\u003EFDA-1997-D-0489\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-21T08:15:06-04:00\u0022\u003E2020-04-21 08:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/expiration-dating-unit-dose-repackaged-solid-oral-dosage-form-drug-products\u0022\u003EExpiration Dating of Unit-Dose Repackaged Solid Oral Dosage Form Drug Products: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70985\/download\u0022\u003EPDF (69.76 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (69.76 KB) of Expiration Dating of Unit-Dose Repackaged Solid Oral Dosage Form Drug Products: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/29\/2020","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_topics":"","topics-product":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-0829\u0022\u003EFDA-2017-D-0829\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-07-29T08:50:25-04:00\u0022\u003E2020-07-29 08:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/formal-dispute-resolution-scientific-and-technical-issues-related-pharmaceutical-cgmp\u0022\u003EFormal Dispute Resolution: Scientific and Technical Issues Related to Pharmaceutical CGMP\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/171562\/download\u0022\u003EPDF (266.83 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (266.83 KB) of Formal Dispute Resolution: Scientific and Technical Issues Related to Pharmaceutical CGMP\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/11\/2006","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2003-D-0369\u0022\u003EFDA-2003-D-0369\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-08-24T09:51:31-04:00\u0022\u003E2023-08-24 09:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/good-laboratory-practice-regulations-questions-and-answers\u0022\u003EGood Laboratory Practice Regulations Questions and Answers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70993\/download\u0022\u003EPDF (2.19 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (2.19 MB) of Good Laboratory Practice Regulations Questions and Answers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/02\/1998","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP)","field_topics":"Compliance","topics-product":"Compliance, Current Good Manufacturing Practice (CGMP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-02-01T11:40:22-05:00\u0022\u003E2021-02-01 11:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-hospitals-nursing-homes-and-other-health-care-facilities-fda-public-health-advisory\u0022\u003EGuidance for Hospitals, Nursing Homes, and Other Health Care Facilities - FDA Public Health Advisory: Guidance for Hospitals, Nursing Homes, and Other Health Care Facilities\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70999\/download\u0022\u003EPDF (18.7 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (18.7 KB) of Guidance for Hospitals, Nursing Homes, and Other Health Care Facilities - FDA Public Health Advisory: Guidance for Hospitals, Nursing Homes, and Other Health Care Facilities\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/05\/2001","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_topics":"","topics-product":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-06-05T09:37:46-04:00\u0022\u003E2019-06-05 09:37\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/investigating-out-specification-oos-test-results-pharmaceutical-production-level-2-revision\u0022\u003EInvestigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production - Level 2 revision: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/158416\/download\u0022\u003EPDF (268.95 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (268.95 KB) of Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production - Level 2 revision: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/16\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_topics":"","topics-product":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1998-D-0019\u0022\u003EFDA-1998-D-0019\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-08-01T14:27:16-04:00\u0022\u003E2024-08-01 14:27\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/nuclear-pharmacy-guideline-criteria-determining-when-register-drug-establishment\u0022\u003ENuclear Pharmacy Guideline Criteria for Determining When to Register as a Drug Establishment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71007\/download\u0022\u003EPDF (3.46 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (3.46 MB) of Nuclear Pharmacy Guideline Criteria for Determining When to Register as a Drug Establishment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/01\/1984","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Compliance","topics-product":"Compliance, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1975-N-0008\u0022\u003EFDA-1975-N-0008\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-27T09:00:25-04:00\u0022\u003E2020-04-27 09:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pat-framework-innovative-pharmaceutical-development-manufacturing-and-quality-assurance\u0022\u003EPAT \u2014 A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71012\/download\u0022\u003EPDF (210.76 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (210.76 KB) of PAT \u2014 A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/04\/2004","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2003-D-0032\u0022\u003EFDA-2003-D-0032\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-09-29T13:05:29-04:00\u0022\u003E2023-09-29 13:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pet-drug-products-current-good-manufacturing-practice-cgmp\u0022\u003EPET Drug Products - Current Good Manufacturing Practice (CGMP)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71013\/download\u0022\u003EPDF (399.04 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (399.04 KB) of PET Drug Products - Current Good Manufacturing Practice (CGMP)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/10\/2009","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_topics":"","topics-product":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1998-D-0025\u0022\u003EFDA-1998-D-0025\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-15T01:55:06-04:00\u0022\u003E2020-05-15 01:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/possible-dioxinpcb-contamination-drug-and-biological-products\u0022\u003EPossible Dioxin\/PCB Contamination of Drug and Biological Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71015\/download\u0022\u003EPDF (7.73 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (7.73 KB) of Possible Dioxin\/PCB Contamination of Drug and Biological Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/23\/1999","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Veterinary Medicine","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_topics":"","topics-product":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-01-28T13:15:10-05:00\u0022\u003E2020-01-28 13:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/preparation-investigational-new-drug-products-human-and-animal\u0022\u003EPreparation of Investigational New Drug Products (Human and Animal): Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71017\/download\u0022\u003EPDF (795.48 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (795.48 KB) of Preparation of Investigational New Drug Products (Human and Animal): Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/01\/1992","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_topics":"","topics-product":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-06-05T09:35:30-04:00\u0022\u003E2019-06-05 09:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/surveillance-and-detention-without-physical-examination-condoms\u0022\u003ESurveillance and Detention Without Physical Examination of Condoms: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71018\/download\u0022\u003EPDF (157.46 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (157.46 KB) of Surveillance and Detention Without Physical Examination of Condoms: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/11\/2008","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Postmarket","topics-product":"Postmarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2000-D-0137\u0022\u003EFDA-2000-D-0137\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-20T15:15:06-04:00\u0022\u003E2020-03-20 15:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/prescription-drug-marketing-act-donation-prescription-drug-samples-free-clinics\u0022\u003EPrescription Drug Marketing Act \u2014 Donation of Prescription Drug Samples to Free Clinics\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71019\/download\u0022\u003EPDF (37.79 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (37.79 KB) of Prescription Drug Marketing Act \u2014 Donation of Prescription Drug Samples to Free Clinics\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/14\/2006","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Compliance","topics-product":"Compliance, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2002-D-0092\u0022\u003EFDA-2002-D-0092\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-08T16:35:06-04:00\u0022\u003E2020-04-08 16:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/impact-resistant-lenses-questions-and-answers\u0022\u003EImpact-Resistant Lenses: Questions and Answers: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71020\/download\u0022\u003EPDF (135.12 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (135.12 KB) of Impact-Resistant Lenses: Questions and Answers: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/02\/2010","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2007-D-0367\u0022\u003EFDA-2007-D-0367\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-02-28T13:45:58-05:00\u0022\u003E2020-02-28 13:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/process-validation-general-principles-and-practices\u0022\u003EProcess Validation: General Principles and Practices: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71021\/download\u0022\u003EPDF (371.9 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (371.9 KB) of Process Validation: General Principles and Practices: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/25\/2011","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_topics":"","topics-product":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0559\u0022\u003EFDA-2008-D-0559\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-15T09:55:02-04:00\u0022\u003E2020-05-15 09:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/quality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations\u0022\u003EQuality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71023\/download\u0022\u003EPDF (362.89 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (362.89 KB) of Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/02\/2006","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-D-0300\u0022\u003EFDA-2004-D-0300\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-09-29T13:05:42-04:00\u0022\u003E2023-09-29 13:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/review-fdas-implementation-drug-export-amendments-1986\u0022\u003EReview of FDA\u0026#039;s Implementation of the Drug Export Amendments of 1986\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71025\/download\u0022\u003EPDF (2 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (2 MB) of Review of FDA\u0026#039;s Implementation of the Drug Export Amendments of 1986\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/01\/1989","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP)","field_topics":"Compliance","topics-product":"Compliance, Current Good Manufacturing Practice (CGMP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-02-01T11:20:34-05:00\u0022\u003E2021-02-01 11:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/sterile-drug-products-produced-aseptic-processing-current-good-manufacturing-practice\u0022\u003ESterile Drug Products Produced by Aseptic Processing \u2014 Current Good Manufacturing Practice: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71026\/download\u0022\u003EPDF (734.22 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (734.22 KB) of Sterile Drug Products Produced by Aseptic Processing \u2014 Current Good Manufacturing Practice: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/04\/2004","field_issuing_office_taxonomy":"Office of Regulatory Affairs\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2003-D-0145\u0022\u003EFDA-2003-D-0145\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222023-09-29T13:05:43-04:00\u0022\u003E2023-09-29 13:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/street-drug-alternatives\u0022\u003EStreet Drug Alternatives\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71027\/download\u0022\u003EPDF (10.51 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (10.51 KB) of Street Drug Alternatives\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/03\/2000","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Compliance","topics-product":"Compliance, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2000-D-0783\u0022\u003EFDA-2000-D-0783\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-01-26T10:15:48-05:00\u0022\u003E2021-01-26 10:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-medical-device-patient-labeling\u0022\u003EGuidance on Medical Device Patient Labeling: Final Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71030\/download\u0022\u003EPDF (378.23 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (378.23 KB) of Guidance on Medical Device Patient Labeling: Final Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/19\/2001","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2000-D-0067\u0022\u003EFDA-2000-D-0067\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-02-28T12:35:57-05:00\u0022\u003E2020-02-28 12:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/preparation-and-review-investigational-device-exemption-applications-ides-total-artificial-discs\u0022\u003EPreparation and Review of Investigational Device Exemption Applications (IDEs) for Total Artificial Discs: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71039\/download\u0022\u003EPDF (241.1 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (241.1 KB) of Preparation and Review of Investigational Device Exemption Applications (IDEs) for Total Artificial Discs: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/11\/2008","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Investigational Device Exemption (IDE), Orthopedic","field_topics":"Premarket","topics-product":"Premarket, Investigational Device Exemption (IDE), Orthopedic","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-20T15:06:52-04:00\u0022\u003E2020-03-20 15:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/role-hiv-drug-resistance-testing-antiretroviral-drug-development\u0022\u003ERole of HIV Drug Resistance Testing in Antiretroviral Drug Development\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71044\/download\u0022\u003EPDF (238.03 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (238.03 KB) of Role of HIV Drug Resistance Testing in Antiretroviral Drug Development\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/31\/2007","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-D-0242\u0022\u003EFDA-2004-D-0242\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-02-01T11:20:15-05:00\u0022\u003E2021-02-01 11:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/intravascular-administration-sets-premarket-notification-submissions-510k\u0022\u003EIntravascular Administration Sets Premarket Notification Submissions [510(k)]: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71046\/download\u0022\u003EPDF (317.03 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (317.03 KB) of Intravascular Administration Sets Premarket Notification Submissions [510(k)]: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/11\/2008","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k)","field_topics":"Premarket","topics-product":"Premarket, 510(k)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-20T15:15:08-04:00\u0022\u003E2020-03-20 15:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/smallpox-variola-virus-infection-developing-drugs-treatment-or-prevention-guidance-industry\u0022\u003ESmallpox (Variola Virus) Infection: Developing Drugs for Treatment or Prevention Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/132623\/download\u0022\u003EPDF (127.18 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (127.18 KB) of Smallpox (Variola Virus) Infection: Developing Drugs for Treatment or Prevention Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/18\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1835\u0022\u003EFDA-2018-D-1835\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-04T14:20:03-04:00\u0022\u003E2020-05-04 14:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/acute-bacterial-skin-and-skin-structure-infections-developing-drugs-treatment\u0022\u003EAcute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71052\/download\u0022\u003EPDF (266.74 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (266.74 KB) of Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/23\/2013","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-1181\u0022\u003EFDA-2013-D-1181\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-21T15:11:06-04:00\u0022\u003E2020-04-21 15:11\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/frequently-asked-questions-about-reprocessing-and-reuse-single-use-devices-third-party-and-hospital\u0022\u003EFrequently-Asked-Questions about the Reprocessing and Reuse of Single-Use Devices by Third-Party and Hospital Reprocessors: Final Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71057\/download\u0022\u003EPDF (287.92 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (287.92 KB) of Frequently-Asked-Questions about the Reprocessing and Reuse of Single-Use Devices by Third-Party and Hospital Reprocessors: Final Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/06\/2001","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-19T09:50:56-04:00\u0022\u003E2020-03-19 09:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/coronary-and-carotid-embolic-protection-devices-premarket-notification-510k-submissions\u0022\u003ECoronary and Carotid Embolic Protection Devices - Premarket Notification [510(k)] Submissions : Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71061\/download\u0022\u003EPDF (155.34 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (155.34 KB) of Coronary and Carotid Embolic Protection Devices - Premarket Notification [510(k)] Submissions : Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/15\/2008","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k)","field_topics":"Premarket","topics-product":"Premarket, 510(k)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-20T15:00:06-04:00\u0022\u003E2020-03-20 15:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/administrative-procedures-clia-categorization\u0022\u003EAdministrative Procedures for CLIA Categorization: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71065\/download\u0022\u003EPDF (124.22 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (124.22 KB) of Administrative Procedures for CLIA Categorization: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/02\/2017","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, CLIA (Clinical Laboratory Improvement Amendments)","field_topics":"User Fees","topics-product":"User Fees, Administrative \/ Procedural, CLIA (Clinical Laboratory Improvement Amendments)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0228\u0022\u003EFDA-2008-D-0228\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-02T10:00:26-05:00\u0022\u003E2020-03-02 10:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/integration-dose-counting-mechanisms-mdi-drug-products\u0022\u003EIntegration of Dose-Counting Mechanisms into MDI Drug Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71073\/download\u0022\u003EPDF (124.67 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (124.67 KB) of Integration of Dose-Counting Mechanisms into MDI Drug Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/13\/2003","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2003-D-0285\u0022\u003EFDA-2003-D-0285\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-02-25T16:25:15-05:00\u0022\u003E2022-02-25 16:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/in-vitro-diagnostic-ivd-device-studies-frequently-asked-questions\u0022\u003EIn Vitro Diagnostic (IVD) Device Studies - Frequently Asked Questions: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71075\/download\u0022\u003EPDF (352.1 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (352.1 KB) of In Vitro Diagnostic (IVD) Device Studies - Frequently Asked Questions: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/25\/2010","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP), Laboratory Tests, IVDs (In Vitro Diagnostic Devices)","field_topics":"Premarket","topics-product":"Premarket, Good Clinical Practice (GCP), Laboratory Tests, IVDs (In Vitro Diagnostic Devices)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2007-D-0076\u0022\u003EFDA-2007-D-0076\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222020-02-28T13:39:19-05:00\u0022\u003E2020-02-28 13:39\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/saline-silicone-gel-and-alternative-breast-implants\u0022\u003ESaline, Silicone Gel, and Alternative Breast Implants: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71081\/download\u0022\u003EPDF (452.04 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (452.04 KB) of Saline, Silicone Gel, and Alternative Breast Implants: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/29\/2020","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"General \u0026amp; Plastic Surgery , Labeling","field_topics":"Premarket","topics-product":"Premarket, General \u0026amp; Plastic Surgery , Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-D-0124\u0022\u003EFDA-2004-D-0124\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-09-28T09:01:12-04:00\u0022\u003E2020-09-28 09:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/quality-system-information-certain-premarket-application-reviews\u0022\u003EQuality System Information for Certain Premarket Application Reviews : Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71083\/download\u0022\u003EPDF (548 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (548 KB) of Quality System Information for Certain Premarket Application Reviews : Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/03\/2003","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Premarket Approval (PMA)","field_topics":"Premarket","topics-product":"Premarket, Premarket Approval (PMA)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-19T10:07:07-04:00\u0022\u003E2020-03-19 10:07\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/surveillance-and-detention-without-physical-examination-surgeons-andor-patient-examination-gloves\u0022\u003ESurveillance and Detention Without Physical Examination of Surgeons\u0026#039; and\/or Patient Examination Gloves: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71086\/download\u0022\u003EPDF (155.13 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (155.13 KB) of Surveillance and Detention Without Physical Examination of Surgeons\u0026#039; and\/or Patient Examination Gloves: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/11\/2008","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Postmarket","topics-product":"Postmarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2000-D-0186\u0022\u003EFDA-2000-D-0186\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-02-28T12:22:59-05:00\u0022\u003E2020-02-28 12:22\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/psychoactive-drugs-infants-and-children-clinical-evaluation\u0022\u003EPsychoactive Drugs in Infants and Children--Clinical Evaluation\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71089\/download\u0022\u003EPDF (17.9 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (17.9 MB) of Psychoactive Drugs in Infants and Children--Clinical Evaluation\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/02\/1998","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Pediatric Product Development","field_topics":"","topics-product":"Clinical - Medical, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T11:46:30-04:00\u0022\u003E2024-04-11 11:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/marketing-clearance-diagnostic-ultrasound-systems-and-transducers\u0022\u003EMarketing Clearance of Diagnostic Ultrasound Systems and Transducers : Guidance for Industry and Food and Drug Administration Staff \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71100\/download\u0022\u003EPDF (898.34 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (898.34 KB) of Marketing Clearance of Diagnostic Ultrasound Systems and Transducers : Guidance for Industry and Food and Drug Administration Staff \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/21\/2023","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Radiological Health, Radiology","field_topics":"Premarket","topics-product":"Premarket, 510(k), Radiological Health, Radiology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-5372\u0022\u003EFDA-2017-D-5372\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222023-02-21T11:07:31-05:00\u0022\u003E2023-02-21 11:07\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/study-and-evaluation-sex-differences-clinical-evaluation-drugs\u0022\u003EStudy and Evaluation of Sex Differences in the Clinical Evaluation of Drugs: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/22\/1993","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Good Clinical Practice (GCP)","field_topics":"","topics-product":"Clinical - Medical, Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1993-D-0184\u0022\u003EFDA-1993-D-0184\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-01-31T09:06:06-05:00\u0022\u003E2025-01-31 09:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/indexing-structured-product-labeling\u0022\u003EIndexing Structured Product Labeling\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71110\/download\u0022\u003EPDF (51.21 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (51.21 KB) of Indexing Structured Product Labeling\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/02\/2008","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Electronic Submissions","topics-product":"Electronic Submissions, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2007-D-0364\u0022\u003EFDA-2007-D-0364\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T00:20:09-04:00\u0022\u003E2020-04-24 00:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/study-drugs-likely-be-used-elderly\u0022\u003EStudy of Drugs Likely to be used in the Elderly\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71114\/download\u0022\u003EPDF (1.18 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.18 MB) of Study of Drugs Likely to be used in the Elderly\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/01\/1989","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-05T09:30:28-04:00\u0022\u003E2020-05-05 09:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clinical-study-designs-catheter-ablation-devices-treatment-atrial-flutter\u0022\u003EClinical Study Designs for Catheter Ablation Devices for Treatment of Atrial Flutter: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71116\/download\u0022\u003EPDF (86.12 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (86.12 KB) of Clinical Study Designs for Catheter Ablation Devices for Treatment of Atrial Flutter: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/05\/2008","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP)","field_topics":"Premarket","topics-product":"Premarket, Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-24T09:00:03-04:00\u0022\u003E2020-03-24 09:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-informed-consent-in-vitro-diagnostic-device-studies-using-leftover-human-specimens-are-not\u0022\u003EGuidance on Informed Consent for In Vitro Diagnostic Device Studies Using Leftover Human Specimens that are Not Individually Identifiable : Guidance for Sponsors, Institutional Review Boards, and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/122648\/download\u0022\u003EPDF (368.81 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (368.81 KB) of Guidance on Informed Consent for In Vitro Diagnostic Device Studies Using Leftover Human Specimens that are Not Individually Identifiable : Guidance for Sponsors, Institutional Review Boards, and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/25\/2006","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research,Office of Blood Research and Review","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP)","field_topics":"Premarket","topics-product":"Premarket, Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2006-D-0095\u0022\u003EFDA-2006-D-0095\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222026-05-04T19:49:46-04:00\u0022\u003E2026-05-04 19:49\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/chronic-obstructive-pulmonary-disease-use-st-georges-respiratory-questionnaire-pro-assessment-tool\u0022\u003EChronic Obstructive Pulmonary Disease: Use of the St. George\u2019s Respiratory Questionnaire as a PRO Assessment Tool Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71121\/download\u0022\u003EPDF (69.43 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (69.43 KB) of Chronic Obstructive Pulmonary Disease: Use of the St. George\u2019s Respiratory Questionnaire as a PRO Assessment Tool Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/26\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6821\u0022\u003EFDA-2017-D-6821\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-04T15:10:11-04:00\u0022\u003E2020-05-04 15:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/frequently-asked-questions-about-reprocessing-and-reuse-single-use-devices-third-party-and-hospital-0\u0022\u003EFrequently-Asked-Questions about the Reprocessing and Reuse of Single-Use Devices by Third-Party and Hospital Reprocessors - Three Additional Questions: Guidance for Industry, FDA Staff, Third-Party and Hospital Reprocessors\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71124\/download\u0022\u003EPDF (2.01 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (2.01 MB) of Frequently-Asked-Questions about the Reprocessing and Reuse of Single-Use Devices by Third-Party and Hospital Reprocessors - Three Additional Questions: Guidance for Industry, FDA Staff, Third-Party and Hospital Reprocessors\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/16\/2003","field_issuing_office_taxonomy":"Center for Devices and Radiological Health,Office of Communication, Information Disclosure, Training and Education","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222021-04-27T09:50:04-04:00\u0022\u003E2021-04-27 09:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/submission-abbreviated-reports-and-synopses-support-marketing-applications\u0022\u003ESubmission of Abbreviated Reports and Synopses in Support of Marketing Applications.\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71125\/download\u0022\u003EPDF (43.08 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (43.08 KB) of Submission of Abbreviated Reports and Synopses in Support of Marketing Applications.\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/13\/1999","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1998-D-0141\u0022\u003EFDA-1998-D-0141\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-27T08:45:35-04:00\u0022\u003E2020-05-27 08:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/providing-regulatory-submissions-electronic-format-content-labeling\u0022\u003EProviding Regulatory Submissions in Electronic Format \u2014 Content of Labeling\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71129\/download\u0022\u003EPDF (42.75 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (42.75 KB) of Providing Regulatory Submissions in Electronic Format \u2014 Content of Labeling\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/21\/2005","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Electronic Submissions","topics-product":"Electronic Submissions, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-15T10:10:08-04:00\u0022\u003E2020-05-15 10:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/osteoarthritis-structural-endpoints-development-drugs\u0022\u003EOsteoarthritis: Structural Endpoints for the Development of Drugs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71132\/download\u0022\u003EPDF (59.55 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (59.55 KB) of Osteoarthritis: Structural Endpoints for the Development of Drugs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/23\/2018","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"11\/22\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-2896\u0022\u003EFDA-2018-D-2896\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-15T01:15:30-04:00\u0022\u003E2020-05-15 01:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/biological-indicator-bi-premarket-notification-510k-submissions\u0022\u003EBiological Indicator (BI) Premarket Notification [510(k)] Submissions : Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71134\/download\u0022\u003EPDF (189.01 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (189.01 KB) of Biological Indicator (BI) Premarket Notification [510(k)] Submissions : Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/04\/2007","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k)","field_topics":"Premarket","topics-product":"Premarket, 510(k)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-19T13:37:53-04:00\u0022\u003E2020-03-19 13:37\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/user-labeling-devices-contain-natural-rubber-21-cfr-801437-small-entity-compliance-guide-guidance\u0022\u003EUser Labeling for Devices that Contain Natural Rubber (21 CFR 801.437); Small Entity Compliance Guide - Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71135\/download\u0022\u003EPDF (40.65 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (40.65 KB) of User Labeling for Devices that Contain Natural Rubber (21 CFR 801.437); Small Entity Compliance Guide - Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/01\/2003","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Radiological Health","field_topics":"","topics-product":"Radiological Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-19T10:05:59-04:00\u0022\u003E2020-03-19 10:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/decorative-non-corrective-contact-lenses\u0022\u003EDecorative, Non-corrective Contact Lenses: Guidance for Industry, FDA Staff, Eye Care Professionals, and Consumers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71138\/download\u0022\u003EPDF (119.8 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (119.8 KB) of Decorative, Non-corrective Contact Lenses: Guidance for Industry, FDA Staff, Eye Care Professionals, and Consumers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/24\/2006","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-19T13:09:59-04:00\u0022\u003E2020-03-19 13:09\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/summary-new-drug-and-antibiotic-applications-format-and-content-summary-new-drug-and-antibiotic\u0022\u003ESummary for New Drug and Antibiotic Applications--Format and Content of the Summary for New Drug and Antibiotic Applications\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71139\/download\u0022\u003EPDF (1.25 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.25 MB) of Summary for New Drug and Antibiotic Applications--Format and Content of the Summary for New Drug and Antibiotic Applications\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/01\/1987","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-05T11:15:26-04:00\u0022\u003E2020-05-05 11:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/supac-ss-nonsterile-semisolid-dosage-forms-scale-and-post-approval-changes-chemistry-manufacturing\u0022\u003ESUPAC-SS: Nonsterile Semisolid Dosage Forms; Scale-Up and Post-Approval Changes: Chemistry, Manufacturing and Controls; In Vitro Release Testing and In Vivo Bioequivalence Documentation: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71141\/download\u0022\u003EPDF (117.66 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (117.66 KB) of SUPAC-SS: Nonsterile Semisolid Dosage Forms; Scale-Up and Post-Approval Changes: Chemistry, Manufacturing and Controls; In Vitro Release Testing and In Vivo Bioequivalence Documentation: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/01\/1997","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1997-D-0380\u0022\u003EFDA-1997-D-0380\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-05T14:05:29-04:00\u0022\u003E2020-05-05 14:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clinical-development-programs-drugs-devices-and-biological-products-treatment-rheumatoid-arthritis\u0022\u003EClinical Development Programs for Drugs, Devices, and Biological Products for the Treatment of Rheumatoid Arthritis (RA)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71145\/download\u0022\u003EPDF (315.71 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (315.71 KB) of Clinical Development Programs for Drugs, Devices, and Biological Products for the Treatment of Rheumatoid Arthritis (RA)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/17\/1999","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1996-D-0004\u0022\u003EFDA-1996-D-0004\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-01-31T14:45:46-05:00\u0022\u003E2025-01-31 14:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/providing-regulatory-submissions-electronic-format-drug-establishment-registration-and-drug-listing\u0022\u003EProviding Regulatory Submissions in Electronic Format \u2013 Drug Establishment Registration and Drug Listing\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71146\/download\u0022\u003EPDF (103.33 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (103.33 KB) of Providing Regulatory Submissions in Electronic Format \u2013 Drug Establishment Registration and Drug Listing\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/01\/2009","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Veterinary Medicine","field_health_topics":"","term_node_tid":"","field_topics":"Electronic Submissions","topics-product":"Electronic Submissions, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2005-N-0464\u0022\u003EFDA-2005-N-0464\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-15T10:15:22-04:00\u0022\u003E2020-05-15 10:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/systemic-lupus-erythematosus-developing-medical-products-treatment\u0022\u003ESystemic Lupus Erythematosus --Developing Medical Products for Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71150\/download\u0022\u003EPDF (167.92 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (167.92 KB) of Systemic Lupus Erythematosus --Developing Medical Products for Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/22\/2010","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0249\u0022\u003EFDA-2010-D-0249\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-05T14:10:02-04:00\u0022\u003E2020-05-05 14:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/acute-bacterial-exacerbations-chronic-bronchitis-patients-chronic-obstructive-pulmonary-disease-0\u0022\u003EAcute Bacterial Exacerbations of Chronic Bronchitis in Patients with Chronic Obstructive Pulmonary Disease: Developing Antimicrobial Drugs for Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71151\/download\u0022\u003EPDF (143.52 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (143.52 KB) of Acute Bacterial Exacerbations of Chronic Bronchitis in Patients with Chronic Obstructive Pulmonary Disease: Developing Antimicrobial Drugs for Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/01\/2012","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0419\u0022\u003EFDA-2008-D-0419\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-01-26T09:43:06-05:00\u0022\u003E2021-01-26 09:43\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/acne-vulgaris-establishing-effectiveness-drugs-intended-treatment\u0022\u003EAcne Vulgaris: Establishing Effectiveness of Drugs Intended for Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71152\/download\u0022\u003EPDF (84.75 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (84.75 KB) of Acne Vulgaris: Establishing Effectiveness of Drugs Intended for Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/22\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2005-D-0461\u0022\u003EFDA-2005-D-0461\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-21T15:05:55-04:00\u0022\u003E2020-04-21 15:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/allergic-rhinitis-developing-drug-products-treatment-guidance-industry\u0022\u003EAllergic Rhinitis: Developing Drug Products for Treatment Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71158\/download\u0022\u003EPDF (120.43 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (120.43 KB) of Allergic Rhinitis: Developing Drug Products for Treatment Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/06\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Pediatric Product Development","field_topics":"","topics-product":"Clinical - Medical, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2000-D-0277\u0022\u003EFDA-2000-D-0277\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T11:43:16-04:00\u0022\u003E2024-04-11 11:43\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/acute-bacterial-sinusitis-developing-antimicrobial-drugs-treatment\u0022\u003EAcute Bacterial Sinusitis \u2014 Developing Antimicrobial Drugs for Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71161\/download\u0022\u003EPDF (479.82 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (479.82 KB) of Acute Bacterial Sinusitis \u2014 Developing Antimicrobial Drugs for Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/05\/2012","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-10-23T07:27:31-04:00\u0022\u003E2023-10-23 07:27\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clinical-evaluation-antiepileptic-drugs-adults-and-children\u0022\u003EClinical Evaluation of Antiepileptic Drugs (adults and children)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71165\/download\u0022\u003EPDF (1007.13 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1007.13 KB) of Clinical Evaluation of Antiepileptic Drugs (adults and children)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/01\/1981","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Pediatric Product Development","field_topics":"","topics-product":"Clinical - Medical, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T11:45:42-04:00\u0022\u003E2024-04-11 11:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clinical-evaluation-general-anesthetics\u0022\u003EClinical Evaluation of General Anesthetics\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"05\/01\/1982","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-02-28T09:45:30-05:00\u0022\u003E2020-02-28 09:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/providing-submissions-electronic-format-postmarketing-safety-reports\u0022\u003EProviding Submissions in Electronic Format \u2014 Postmarketing Safety Reports\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71176\/download\u0022\u003EPDF (327.01 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (327.01 KB) of Providing Submissions in Electronic Format \u2014 Postmarketing Safety Reports\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/27\/2022","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Electronic Submissions","topics-product":"Electronic Submissions, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2001-D-0067\u0022\u003EFDA-2001-D-0067\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-12-19T09:35:31-05:00\u0022\u003E2024-12-19 09:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e1a-extent-population-exposure-assess-clinical-safety-drugs-intended-long-term-treatment-non-life\u0022\u003EE1A The Extent of Population Exposure to Assess Clinical Safety: For Drugs Intended for Long-term Treatment of Non-Life-Threatening Conditions\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71180\/download\u0022\u003EPDF (17 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (17 KB) of E1A The Extent of Population Exposure to Assess Clinical Safety: For Drugs Intended for Long-term Treatment of Non-Life-Threatening Conditions\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Efficacy","field_topics":"","topics-product":"ICH-Efficacy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1994-D-0267\u0022\u003EFDA-1994-D-0267\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-29T16:40:13-04:00\u0022\u003E2020-04-29 16:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q3c-appendix-5\u0022\u003EQ3C: Appendix 5\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71186\/download\u0022\u003EPDF (216.11 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (216.11 KB) of Q3C: Appendix 5\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/18\/1998","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/None found\u0022\u003ENone found\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-08T11:50:03-04:00\u0022\u003E2020-04-08 11:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/compliance-section-301-medical-device-user-fee-and-modernization-act-2002-amended-prominent-and\u0022\u003ECompliance with Section 301 of the Medical Device User Fee and Modernization Act of 2002, as amended \u2013 Prominent and Conspicuous Mark of Manufacturers on Single-Use Devices: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71187\/download\u0022\u003EPDF (224.73 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (224.73 KB) of Compliance with Section 301 of the Medical Device User Fee and Modernization Act of 2002, as amended \u2013 Prominent and Conspicuous Mark of Manufacturers on Single-Use Devices: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/01\/2006","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Labeling","field_topics":"Postmarket, User Fees","topics-product":"Postmarket, User Fees, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2005-D-0156\u0022\u003EFDA-2005-D-0156\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-02-28T13:00:48-05:00\u0022\u003E2020-02-28 13:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/antidepressant-drugs-clinical-evaluation\u0022\u003EAntidepressant Drugs--Clinical Evaluation\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/01\/1977","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-02-28T09:45:21-05:00\u0022\u003E2020-02-28 09:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/providing-regulatory-submissions-electronic-format-receipt-date\u0022\u003EProviding Regulatory Submissions in Electronic Format--Receipt Date: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71190\/download\u0022\u003EPDF (218.46 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (218.46 KB) of Providing Regulatory Submissions in Electronic Format--Receipt Date: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/10\/2014","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Electronic Submissions","topics-product":"Electronic Submissions, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2007-D-0077\u0022\u003EFDA-2007-D-0077\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-07-21T09:36:09-04:00\u0022\u003E2021-07-21 09:36\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q3c-appendix-6\u0022\u003EQ3C: Appendix 6\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71194\/download\u0022\u003EPDF (127.67 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (127.67 KB) of Q3C: Appendix 6\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/18\/1998","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-02-25T17:01:04-05:00\u0022\u003E2022-02-25 17:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clinical-trial-endpoints-approval-cancer-drugs-and-biologics\u0022\u003EClinical Trial Endpoints for the Approval of Cancer Drugs and Biologics: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71195\/download\u0022\u003EPDF (145.97 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (145.97 KB) of Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/19\/2018","field_issuing_office_taxonomy":"Oncology Center of Excellence\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2005-D-0225\u0022\u003EFDA-2005-D-0225\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222021-01-25T11:20:04-05:00\u0022\u003E2021-01-25 11:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/providing-regulatory-submissions-electronic-format-general-considerations\u0022\u003EProviding Regulatory Submissions in Electronic Format; General Considerations\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71200\/download\u0022\u003EPDF (54.31 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (54.31 KB) of Providing Regulatory Submissions in Electronic Format; General Considerations\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/28\/1999","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Electronic Submissions","topics-product":"Electronic Submissions, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-15T10:15:16-04:00\u0022\u003E2020-05-15 10:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/content-and-format-investigational-new-drug-applications-inds-phase-1-studies-drugs-including-well\u0022\u003EContent and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-derived Products: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71203\/download\u0022\u003EPDF (42.07 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (42.07 KB) of Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-derived Products: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/01\/1995","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Pharmacology\/Toxicology, Investigational New Drug Application (INDA)","field_topics":"","topics-product":"Clinical - Medical, Pharmacology\/Toxicology, Investigational New Drug Application (INDA)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1995-D-0251\u0022\u003EFDA-1995-D-0251\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T14:10:14-04:00\u0022\u003E2020-05-06 14:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q4b-evaluation-and-recommendation-pharmacopoeial-texts-use-international-conference-harmonisation\u0022\u003EQ4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the International Conference on Harmonisation Regions\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71204\/download\u0022\u003EPDF (54.51 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (54.51 KB) of Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the International Conference on Harmonisation Regions\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/20\/2008","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0081\u0022\u003EFDA-2008-D-0081\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-13T15:00:15-04:00\u0022\u003E2020-04-13 15:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/medical-device-tracking\u0022\u003EMedical Device Tracking : Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71205\/download\u0022\u003EPDF (291.45 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (291.45 KB) of Medical Device Tracking : Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/27\/2014","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-24T09:15:06-04:00\u0022\u003E2020-03-24 09:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/writing-dear-doctor-letters-recalls-implantable-cardioverter-defibrillators-icds\u0022\u003EWriting Dear Doctor Letters for Recalls of Implantable Cardioverter Defibrillators (ICDs): Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71206\/download\u0022\u003EPDF (144.9 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (144.9 KB) of Writing Dear Doctor Letters for Recalls of Implantable Cardioverter Defibrillators (ICDs): Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/19\/2007","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Radiological Health","field_topics":"Postmarket","topics-product":"Postmarket, Radiological Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-19T13:30:14-04:00\u0022\u003E2020-03-19 13:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e2bm-data-elements-transmission-individual-case-safety-reports\u0022\u003EE2BM Data Elements for Transmission Of Individual Case Safety Reports\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71208\/download\u0022\u003EPDF (161.56 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (161.56 KB) of E2BM Data Elements for Transmission Of Individual Case Safety Reports\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/04\/2002","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Efficacy","field_topics":"","topics-product":"ICH-Efficacy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1996-D-0168\u0022\u003EFDA-1996-D-0168\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-20T11:30:33-04:00\u0022\u003E2020-04-20 11:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/spl-standard-content-labeling-technical-qs\u0022\u003ESPL Standard for Content of Labeling Technical Qs \u0026amp; As\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71211\/download\u0022\u003EPDF (57.92 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (57.92 KB) of SPL Standard for Content of Labeling Technical Qs \u0026amp; As\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/28\/2009","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Electronic Submissions","topics-product":"Electronic Submissions, ","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0355\u0022\u003EFDA-2009-D-0355\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222020-05-04T14:40:09-04:00\u0022\u003E2020-05-04 14:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/developing-medical-imaging-drug-and-biological-products-part-1-conducting-safety-assessments\u0022\u003EDeveloping Medical Imaging Drug and Biological Products Part 1: Conducting Safety Assessments\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71212\/download\u0022\u003EPDF (270.68 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (270.68 KB) of Developing Medical Imaging Drug and Biological Products Part 1: Conducting Safety Assessments\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/22\/2004","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1998-D-0035\u0022\u003EFDA-1998-D-0035\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-01-26T10:55:02-05:00\u0022\u003E2021-01-26 10:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q4b-annex-i-residue-ignitionsulphated-ash-general-chapter\u0022\u003EQ4B Annex I: Residue on Ignition\/Sulphated Ash General Chapter\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71214\/download\u0022\u003EPDF (58.33 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (58.33 KB) of Q4B Annex I: Residue on Ignition\/Sulphated Ash General Chapter\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/21\/2008","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0083\u0022\u003EFDA-2008-D-0083\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T13:50:28-04:00\u0022\u003E2020-05-06 13:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/antibacterial-drug-products-use-noninferiority-studies-support-approval\u0022\u003EAntibacterial Drug Products: Use of Noninferiority Studies to Support Approval\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71215\/download\u0022\u003EPDF (82.6 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (82.6 KB) of Antibacterial Drug Products: Use of Noninferiority Studies to Support Approval\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2010","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2007-D-0150\u0022\u003EFDA-2007-D-0150\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-22T16:15:25-04:00\u0022\u003E2020-04-22 16:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e2bm-questions-and-answers\u0022\u003EE2B(M) Questions and Answers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71218\/download\u0022\u003EPDF (61.07 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (61.07 KB) of E2B(M) Questions and Answers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/09\/2005","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Efficacy","field_topics":"","topics-product":"ICH-Efficacy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1996-D-0168\u0022\u003EFDA-1996-D-0168\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-11-28T08:46:15-05:00\u0022\u003E2023-11-28 08:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q4b-annex-2-test-extractable-volume-parenteral-preparations-general-chapter\u0022\u003EQ4B Annex 2: Test for Extractable Volume of Parenteral Preparations General Chapter\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71222\/download\u0022\u003EPDF (69.05 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (69.05 KB) of Q4B Annex 2: Test for Extractable Volume of Parenteral Preparations General Chapter\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/18\/2017","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0081\u0022\u003EFDA-2008-D-0081\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-08T15:00:39-04:00\u0022\u003E2020-04-08 15:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/antiviral-product-development-conducting-and-submitting-virology-studies-agency\u0022\u003EAntiviral Product Development--Conducting and Submitting Virology Studies to the Agency\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71223\/download\u0022\u003EPDF (100.47 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (100.47 KB) of Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/05\/2006","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2005-D-0282\u0022\u003EFDA-2005-D-0282\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T11:20:25-04:00\u0022\u003E2020-04-24 11:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/developing-medical-imaging-drug-and-biological-products-part-2-clinical-indications\u0022\u003EDeveloping Medical Imaging Drug and Biological Products Part 2: Clinical Indications\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71226\/download\u0022\u003EPDF (231.4 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (231.4 KB) of Developing Medical Imaging Drug and Biological Products Part 2: Clinical Indications\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/22\/2004","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1998-D-0035\u0022\u003EFDA-1998-D-0035\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-28T12:45:15-04:00\u0022\u003E2020-04-28 12:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q4b-annex-3-test-particulate-contamination-subvisible-particles-general-chapter\u0022\u003EQ4B Annex 3: Test for Particulate Contamination: Subvisible Particles General Chapter\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71231\/download\u0022\u003EPDF (992.85 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (992.85 KB) of Q4B Annex 3: Test for Particulate Contamination: Subvisible Particles General Chapter\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/09\/2009","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2007-D-0306\u0022\u003EFDA-2007-D-0306\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T11:35:02-04:00\u0022\u003E2020-05-06 11:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/antiviral-product-development-conducting-and-submitting-virology-studies-agency-guidance-submitting\u0022\u003EAntiviral Product Development--Conducting and Submitting Virology Studies to the Agency: Guidance for Submitting HIV Resistance Data\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71233\/download\u0022\u003EPDF (116.53 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (116.53 KB) of Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency: Guidance for Submitting HIV Resistance Data\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/02\/2006","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/None found\u0022\u003ENone found\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T11:25:14-04:00\u0022\u003E2020-04-24 11:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/developing-medical-imaging-drug-and-biological-products-part-3-design-analysis-and-interpretation\u0022\u003EDeveloping Medical Imaging Drug and Biological Products Part 3: Design, Analysis, and Interpretation of Clinical Studies\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71237\/download\u0022\u003EPDF (307.06 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (307.06 KB) of Developing Medical Imaging Drug and Biological Products Part 3: Design, Analysis, and Interpretation of Clinical Studies\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/22\/2004","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1998-D-0035\u0022\u003EFDA-1998-D-0035\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-28T12:50:04-04:00\u0022\u003E2020-04-28 12:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e2e-pharmacovigilance-planning\u0022\u003EE2E Pharmacovigilance Planning\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71238\/download\u0022\u003EPDF (305.26 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (305.26 KB) of E2E Pharmacovigilance Planning\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/01\/2005","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Efficacy","field_topics":"","topics-product":"ICH-Efficacy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-D-0245\u0022\u003EFDA-2004-D-0245\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-20T12:00:13-04:00\u0022\u003E2020-04-20 12:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q4b-annex-4a-microbiological-examination-non-sterile-products-microbial-enumeration-tests-general\u0022\u003EQ4B Annex 4A: Microbiological Examination of Non-Sterile Products: Microbial Enumeration Tests General Chapter\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71241\/download\u0022\u003EPDF (68.81 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (68.81 KB) of Q4B Annex 4A: Microbiological Examination of Non-Sterile Products: Microbial Enumeration Tests General Chapter\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/08\/2009","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0396\u0022\u003EFDA-2008-D-0396\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T11:40:06-04:00\u0022\u003E2020-05-06 11:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/antiviral-product-development-conducting-and-submitting-virology-studies-agency-guidance-submitting-0\u0022\u003EAntiviral Product Development--Conducting and Submitting Virology Studies to the Agency : Guidance for Submitting Influenza Resistance Data\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71250\/download\u0022\u003EPDF (107.75 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (107.75 KB) of Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency : Guidance for Submitting Influenza Resistance Data\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/02\/2006","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2005-D-0282\u0022\u003EFDA-2005-D-0282\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T11:25:06-04:00\u0022\u003E2020-04-24 11:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/obesity-and-overweight-developing-drugs-and-biological-products-weight-reduction\u0022\u003EObesity and Overweight: Developing Drugs and Biological Products for Weight Reduction\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71252\/download\u0022\u003EPDF (412.63 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (412.63 KB) of Obesity and Overweight: Developing Drugs and Biological Products for Weight Reduction\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/07\/2025","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pediatric Product Development","field_topics":"","topics-product":"Pediatric Product Development","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"04\/08\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2007-D-0435\u0022\u003EFDA-2007-D-0435\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222025-06-04T14:42:31-04:00\u0022\u003E2025-06-04 14:42\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e2f-development-safety-update-report\u0022\u003EE2F Development Safety Update Report\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71255\/download\u0022\u003EPDF (484.44 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (484.44 KB) of E2F Development Safety Update Report\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/23\/2011","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Efficacy","field_topics":"","topics-product":"ICH-Efficacy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0386\u0022\u003EFDA-2008-D-0386\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-02-04T14:31:31-05:00\u0022\u003E2025-02-04 14:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/calcium-dtpa-and-zinc-dtpa-drug-products-submitting-new-drug-application\u0022\u003ECalcium DTPA and Zinc DTPA Drug Products-Submitting a New Drug Application\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71258\/download\u0022\u003EPDF (168.17 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (168.17 KB) of Calcium DTPA and Zinc DTPA Drug Products-Submitting a New Drug Application\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/13\/2004","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/None found\u0022\u003ENone found\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-30T11:50:13-04:00\u0022\u003E2020-04-30 11:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q4b-annex-4b-microbiological-examination-non-sterile-products-tests-specified-micro-organisms\u0022\u003EQ4B Annex 4B: Microbiological Examination of Non-Sterile Products: Tests for Specified Micro-organisms General Chapter\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71267\/download\u0022\u003EPDF (69.05 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (69.05 KB) of Q4B Annex 4B: Microbiological Examination of Non-Sterile Products: Tests for Specified Micro-organisms General Chapter\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/08\/2009","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0398\u0022\u003EFDA-2008-D-0398\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T11:40:18-04:00\u0022\u003E2020-05-06 11:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/development-and-use-risk-minimization-action-plans\u0022\u003EDevelopment and Use of Risk Minimization Action Plans: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71268\/download\u0022\u003EPDF (128.07 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (128.07 KB) of Development and Use of Risk Minimization Action Plans: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/29\/2005","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Good Clinical Practice (GCP)","field_topics":"","topics-product":"Clinical - Medical, Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-D-0441\u0022\u003EFDA-2004-D-0441\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222020-04-15T08:35:03-04:00\u0022\u003E2020-04-15 08:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/antiviral-product-development-conducting-and-submitting-virology-studies-agency-guidance-submitting-1\u0022\u003EAntiviral Product Development--Conducting and Submitting Virology Studies to the Agency: Guidance for Submitting HCV Resistance Data\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71269\/download\u0022\u003EPDF (128.2 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (128.2 KB) of Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency: Guidance for Submitting HCV Resistance Data\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/02\/2006","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-09T12:05:07-04:00\u0022\u003E2020-04-09 12:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e3-structure-and-content-clinical-study-reports\u0022\u003EE3 Structure and Content of Clinical Study Reports\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71271\/download\u0022\u003EPDF (239.72 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (239.72 KB) of E3 Structure and Content of Clinical Study Reports\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/01\/1996","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Efficacy","field_topics":"","topics-product":"ICH-Efficacy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1995-D-0201\u0022\u003EFDA-1995-D-0201\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-29T16:50:21-04:00\u0022\u003E2020-04-29 16:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/chronic-cutaneous-ulcer-and-burn-wounds-developing-products-treatment\u0022\u003EChronic Cutaneous Ulcer and Burn Wounds -- Developing Products for Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71278\/download\u0022\u003EPDF (105.62 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (105.62 KB) of Chronic Cutaneous Ulcer and Burn Wounds -- Developing Products for Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/02\/2006","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2000-D-0037\u0022\u003EFDA-2000-D-0037\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-04T14:50:41-04:00\u0022\u003E2020-05-04 14:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/antiviral-product-development-conducting-and-submitting-virology-studies-agency-guidance-submitting-2\u0022\u003EAntiviral Product Development--Conducting and Submitting Virology Studies to the Agency: Guidance for Submitting HBV Resistance Data\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71283\/download\u0022\u003EPDF (84.75 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (84.75 KB) of Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency: Guidance for Submitting HBV Resistance Data\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/02\/2006","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2005-D-0183\u0022\u003EFDA-2005-D-0183\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-07T11:05:10-04:00\u0022\u003E2020-05-07 11:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/format-and-content-human-pharmacokinetics-and-bioavailability-section-application\u0022\u003EFormat and Content of the Human Pharmacokinetics and Bioavailability Section of an Application\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71286\/download\u0022\u003EPDF (519.21 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (519.21 KB) of Format and Content of the Human Pharmacokinetics and Bioavailability Section of an Application\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/01\/1987","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Pharmacology","field_topics":"","topics-product":"Clinical - Pharmacology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-21T11:40:02-04:00\u0022\u003E2020-04-21 11:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e5-ethnic-factors-acceptability-foreign-clinical-data\u0022\u003EE5 Ethnic Factors in the Acceptability of Foreign Clinical Data\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71287\/download\u0022\u003EPDF (79.19 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (79.19 KB) of E5 Ethnic Factors in the Acceptability of Foreign Clinical Data\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/10\/1998","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Efficacy","field_topics":"","topics-product":"ICH-Efficacy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1997-D-0360\u0022\u003EFDA-1997-D-0360\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-29T17:05:03-04:00\u0022\u003E2020-04-29 17:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q4b-annex-4c-microbiological-examination-non-sterile-products-acceptance-criteria-pharmaceutical\u0022\u003EQ4B Annex 4C: Microbiological Examination of Non-Sterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use General Chapter\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71291\/download\u0022\u003EPDF (57.38 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (57.38 KB) of Q4B Annex 4C: Microbiological Examination of Non-Sterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use General Chapter\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/08\/2009","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0400\u0022\u003EFDA-2008-D-0400\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T11:50:35-04:00\u0022\u003E2020-05-06 11:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clinical-development-and-labeling-anti-infective-drug-products\u0022\u003EClinical Development and Labeling of Anti-Infective Drug Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71295\/download\u0022\u003EPDF (5.11 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (5.11 MB) of Clinical Development and Labeling of Anti-Infective Drug Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/12\/2001","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/None found\u0022\u003ENone found\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T11:20:16-04:00\u0022\u003E2020-05-06 11:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/180-day-exclusivity-when-multiple-andas-are-submitted-same-day\u0022\u003E180-Day Exclusivity When Multiple ANDAs Are Submitted on the Same Day\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71304\/download\u0022\u003EPDF (138.08 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (138.08 KB) of 180-Day Exclusivity When Multiple ANDAs Are Submitted on the Same Day\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/01\/2003","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Generic Drugs","field_topics":"","topics-product":"Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/2003D-0325\u0022\u003E2003D-0325\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-02-27T14:50:12-05:00\u0022\u003E2019-02-27 14:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q4b-annex-5-disintegration-test-general-chapter\u0022\u003EQ4B Annex 5: Disintegration Test General Chapter\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71306\/download\u0022\u003EPDF (68.62 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (68.62 KB) of Q4B Annex 5: Disintegration Test General Chapter\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/23\/2009","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0399\u0022\u003EFDA-2008-D-0399\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T13:35:29-04:00\u0022\u003E2020-05-06 13:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pharmacokinetics-patients-impaired-hepatic-function-study-design-data-analysis-and-impact-dosing\u0022\u003EPharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71311\/download\u0022\u003EPDF (315.27 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (315.27 KB) of Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/02\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Pharmacology","field_topics":"","topics-product":"Clinical - Pharmacology","field_final_guidance_1":"Draft","open-comment":" Yes ","field_comment_close_date":"12\/01\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2026-D-8693\u0022\u003EFDA-2026-D-8693\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-10-07T14:14:31-04:00\u0022\u003E2026-10-07 14:14\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/complicated-urinary-tract-infections-developing-drugs-treatment\u0022\u003EComplicated Urinary Tract Infections: Developing Drugs for Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71313\/download\u0022\u003EPDF (380.96 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (380.96 KB) of Complicated Urinary Tract Infections: Developing Drugs for Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/01\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-0148\u0022\u003EFDA-2012-D-0148\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-07T17:35:18-04:00\u0022\u003E2020-05-07 17:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e7-studies-support-special-populations-geriatrics\u0022\u003EE7 Studies in Support of Special Populations: Geriatrics\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71317\/download\u0022\u003EPDF (24.71 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (24.71 KB) of E7 Studies in Support of Special Populations: Geriatrics\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/01\/1994","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Efficacy","field_topics":"","topics-product":"ICH-Efficacy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-29T17:35:16-04:00\u0022\u003E2020-04-29 17:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/anthrax-developing-drugs-prophylaxis-inhalational-anthrax-guidance-industry\u0022\u003EAnthrax: Developing Drugs for Prophylaxis of Inhalational Anthrax Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71320\/download\u0022\u003EPDF (116.35 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (116.35 KB) of Anthrax: Developing Drugs for Prophylaxis of Inhalational Anthrax Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/24\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-0412\u0022\u003EFDA-2016-D-0412\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-22T16:15:33-04:00\u0022\u003E2020-04-22 16:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/alternate-source-active-pharmaceutical-ingredient-pending-andas\u0022\u003EAlternate Source of the Active Pharmaceutical Ingredient in Pending ANDAs: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71321\/download\u0022\u003EPDF (14.36 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (14.36 KB) of Alternate Source of the Active Pharmaceutical Ingredient in Pending ANDAs: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/01\/2000","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Generic Drugs, Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Generic Drugs, Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/None found\u0022\u003ENone found\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-21T16:00:40-04:00\u0022\u003E2020-04-21 16:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-department-defense-exemption-fda-performance-standard-laser-products\u0022\u003EGuidance on the Department of Defense Exemption from the FDA Performance Standard for Laser Products: Guidance for Industry and FDA \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71322\/download\u0022\u003EPDF (318.25 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (318.25 KB) of Guidance on the Department of Defense Exemption from the FDA Performance Standard for Laser Products: Guidance for Industry and FDA \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/12\/2002","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-19T09:55:12-04:00\u0022\u003E2020-03-19 09:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e9-statistical-principles-clinical-trials\u0022\u003EE9 Statistical Principles for Clinical Trials\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71336\/download\u0022\u003EPDF (109.86 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (109.86 KB) of E9 Statistical Principles for Clinical Trials\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/16\/1998","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Efficacy","field_topics":"","topics-product":"ICH-Efficacy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1997-D-0508\u0022\u003EFDA-1997-D-0508\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-29T17:50:08-04:00\u0022\u003E2020-04-29 17:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/review-criteria-assessment-c-reactive-protein-crp-high-sensitivity-c-reactive-protein-hscrp-and\u0022\u003EReview Criteria for Assessment of C-Reactive Protein (CRP), High Sensitivity C-Reactive Protein (hsCRP) and Cardiac C-Reactive Assays: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71337\/download\u0022\u003EPDF (175.75 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (175.75 KB) of Review Criteria for Assessment of C-Reactive Protein (CRP), High Sensitivity C-Reactive Protein (hsCRP) and Cardiac C-Reactive Assays: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/22\/2005","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Cardiovascular ","field_topics":"Postmarket","topics-product":"Postmarket, Cardiovascular ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-19T10:52:42-04:00\u0022\u003E2020-03-19 10:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/quality-assurance-guidelines-hemodialysis-devices\u0022\u003EQuality Assurance Guidelines for Hemodialysis Devices\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71346\/download\u0022\u003EPDF (12.78 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (12.78 MB) of Quality Assurance Guidelines for Hemodialysis Devices\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/01\/1991","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Gastroenterology-Urology ","field_topics":"","topics-product":"Gastroenterology-Urology ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-17T10:40:10-04:00\u0022\u003E2020-03-17 10:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e10-choice-control-group-and-related-issues-clinical-trials\u0022\u003EE10 Choice of Control Group and Related Issues in Clinical Trials\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71349\/download\u0022\u003EPDF (93.22 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (93.22 KB) of E10 Choice of Control Group and Related Issues in Clinical Trials\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/14\/2001","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Efficacy","field_topics":"","topics-product":"ICH-Efficacy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1999-D-1874\u0022\u003EFDA-1999-D-1874\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-29T15:35:08-04:00\u0022\u003E2020-04-29 15:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/andas-impurities-drug-products\u0022\u003EANDAs: Impurities in Drug Products: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71351\/download\u0022\u003EPDF (154.52 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (154.52 KB) of ANDAs: Impurities in Drug Products: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2010","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0584\u0022\u003EFDA-2010-D-0584\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-22T11:21:16-04:00\u0022\u003E2020-04-22 11:21\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pharmacokinetics-pregnancy-study-design-data-analysis-and-impact-dosing-and-labeling\u0022\u003EPharmacokinetics in Pregnancy \u2014 Study Design, Data Analysis, and Impact on Dosing and Labeling\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71353\/download\u0022\u003EPDF (324.06 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (324.06 KB) of Pharmacokinetics in Pregnancy \u2014 Study Design, Data Analysis, and Impact on Dosing and Labeling\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/01\/2004","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Pharmacology","field_topics":"","topics-product":"Clinical - Pharmacology","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-D-0459\u0022\u003EFDA-2004-D-0459\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-27T10:20:03-04:00\u0022\u003E2020-04-27 10:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e11-clinical-investigation-medicinal-products-pediatric-population\u0022\u003EE11 Clinical Investigation of Medicinal Products in the Pediatric Population\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71355\/download\u0022\u003EPDF (60.38 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (60.38 KB) of E11 Clinical Investigation of Medicinal Products in the Pediatric Population\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/15\/2000","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Efficacy, Pediatric Product Development","field_topics":"","topics-product":"ICH-Efficacy, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2000-D-0942\u0022\u003EFDA-2000-D-0942\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T09:40:16-04:00\u0022\u003E2024-04-11 09:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/sterilized-convenience-kits-clinical-and-surgical-use\u0022\u003ESterilized Convenience Kits for Clinical and Surgical Use: Final Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71358\/download\u0022\u003EPDF (152.22 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (152.22 KB) of Sterilized Convenience Kits for Clinical and Surgical Use: Final Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/07\/2002","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Postmarket","topics-product":"Postmarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-19T09:55:20-04:00\u0022\u003E2020-03-19 09:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/estrogen-and-estrogenprogestin-drug-products-treat-vasomotor-symptoms-and-vulvar-and-vaginal-atrophy\u0022\u003EEstrogen and Estrogen\/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms \u2014 Recommendations for Clinical Evaluation\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71359\/download\u0022\u003EPDF (166 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (166 KB) of Estrogen and Estrogen\/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms \u2014 Recommendations for Clinical Evaluation\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/31\/2003","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-03-13T16:00:09-04:00\u0022\u003E2019-03-13 16:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e12a-principles-clinical-evaluation-new-antihypertensive-drugs\u0022\u003EE12A Principles for Clinical Evaluation of New Antihypertensive Drugs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71363\/download\u0022\u003EPDF (26.9 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (26.9 KB) of E12A Principles for Clinical Evaluation of New Antihypertensive Drugs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/09\/2000","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Efficacy","field_topics":"","topics-product":"ICH-Efficacy","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2000-D-0785\u0022\u003EFDA-2000-D-0785\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-20T08:15:32-04:00\u0022\u003E2020-04-20 08:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/population-pharmacokinetics\u0022\u003EPopulation Pharmacokinetics: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/128793\/download\u0022\u003EPDF (229.72 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (229.72 KB) of Population Pharmacokinetics: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/03\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Pharmacology","field_topics":"","topics-product":"Clinical - Pharmacology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-2398\u0022\u003EFDA-2019-D-2398\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222022-02-03T09:00:18-05:00\u0022\u003E2022-02-03 09:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/evaluating-risks-drug-exposure-human-pregnancies\u0022\u003EEvaluating the Risks of Drug Exposure in Human Pregnancies\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71368\/download\u0022\u003EPDF (3.08 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (3.08 MB) of Evaluating the Risks of Drug Exposure in Human Pregnancies\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/27\/2005","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-03-13T16:10:06-04:00\u0022\u003E2019-03-13 16:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e14-clinical-evaluation-qtqtc-interval-prolongation-and-proarrhythmic-potential-non-antiarrhythmic-0\u0022\u003EE14 Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71372\/download\u0022\u003EPDF (414.04 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (414.04 KB) of E14 Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/11\/2005","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Efficacy","field_topics":"","topics-product":"ICH-Efficacy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-D-0241\u0022\u003EFDA-2004-D-0241\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-10-30T08:51:05-04:00\u0022\u003E2026-10-30 08:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/andaspharmaceutical-solid-polymorphism-chemistry-manufacturing-and-controls-information\u0022\u003EANDAs:Pharmaceutical Solid Polymorphism: Chemistry, Manufacturing, and Controls Information: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71375\/download\u0022\u003EPDF (109.51 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (109.51 KB) of ANDAs:Pharmaceutical Solid Polymorphism: Chemistry, Manufacturing, and Controls Information: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/09\/2007","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Generic Drugs, Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Generic Drugs, Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-D-0182\u0022\u003EFDA-2004-D-0182\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-22T11:25:02-04:00\u0022\u003E2020-04-22 11:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/class-ii-special-controls-guidance-document-immunomagnetic-circulating-cancer-cell-selection-and\u0022\u003EClass II Special Controls Guidance Document: Immunomagnetic Circulating Cancer Cell Selection and Enumeration System (PDF version)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71378\/download\u0022\u003EPDF (64.19 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (64.19 KB) of Class II Special Controls Guidance Document: Immunomagnetic Circulating Cancer Cell Selection and Enumeration System (PDF version)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/11\/2004","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Special Controls Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222018-12-01T12:32:32-05:00\u0022\u003E2018-12-01 12:32\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e14-clinical-evaluation-qtqtc-interval-prolongation-and-proarrhythmic-potential-non-antiarrhythmic\u0022\u003EE14 Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs Questions and Answers (R3) Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71379\/download\u0022\u003EPDF (307.74 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (307.74 KB) of E14 Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs Questions and Answers (R3) Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/28\/2017","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Efficacy","field_topics":"","topics-product":"ICH-Efficacy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-D-0241\u0022\u003EFDA-2004-D-0241\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-02-03T16:30:55-05:00\u0022\u003E2025-02-03 16:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e15-pharmacogenomics-definitions-and-sample-coding\u0022\u003EE15 Pharmacogenomics Definitions and Sample Coding\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71389\/download\u0022\u003EPDF (53.27 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (53.27 KB) of E15 Pharmacogenomics Definitions and Sample Coding\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/08\/2008","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Efficacy","field_topics":"","topics-product":"ICH-Efficacy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0199 \u0022\u003EFDA-2008-D-0199 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-20T08:10:14-04:00\u0022\u003E2020-04-20 08:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/handling-and-retention-bioavailability-ba-and-bioequivalence-be-testing-samples\u0022\u003EHandling and Retention of Bioavailability BA and Bioequivalence BE Testing Samples: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71393\/download\u0022\u003EPDF (309.45 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (309.45 KB) of Handling and Retention of Bioavailability BA and Bioequivalence BE Testing Samples: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/27\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Generic Drugs, Good Clinical Practice (GCP)","field_topics":"","topics-product":"Generic Drugs, Good Clinical Practice (GCP)","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"05\/28\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2002-D-0176\u0022\u003EFDA-2002-D-0176\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-03-27T13:40:46-04:00\u0022\u003E2024-03-27 13:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/individual-product-bioequivalence-recommendations-specific-products\u0022\u003EIndividual Product Bioequivalence Recommendations for Specific Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71401\/download\u0022\u003EPDF (80 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (80 KB) of Individual Product Bioequivalence Recommendations for Specific Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/10\/2010","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Generic Drugs","field_topics":"","topics-product":"Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2007-D-0433\u0022\u003EFDA-2007-D-0433\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T14:25:06-04:00\u0022\u003E2020-04-24 14:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/labeling-recommendations-single-use-devices-reprocessed-third-parties-and-hospitals\u0022\u003ELabeling Recommendations for Single-Use Devices Reprocessed by Third Parties and Hospitals: Final Guidance for Industry and FDA \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71405\/download\u0022\u003EPDF (82.01 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (82.01 KB) of Labeling Recommendations for Single-Use Devices Reprocessed by Third Parties and Hospitals: Final Guidance for Industry and FDA \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/30\/2001","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-19T09:50:59-04:00\u0022\u003E2020-03-19 09:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pre-clinical-and-clinical-studies-neurothrombectomy-devices\u0022\u003EPre-Clinical and Clinical Studies for Neurothrombectomy Devices: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71411\/download\u0022\u003EPDF (118.87 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (118.87 KB) of Pre-Clinical and Clinical Studies for Neurothrombectomy Devices: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/18\/2007","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP)","field_topics":"Premarket","topics-product":"Premarket, Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-19T13:25:02-04:00\u0022\u003E2020-03-19 13:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q5b-quality-biotechnological-products-analysis-expression-construct-cells-used-production-r-dna\u0022\u003EQ5B Quality of Biotechnological Products: Analysis of the Expression Construct in Cells Used for Production of r-DNA Derived Protein Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71417\/download\u0022\u003EPDF (108.58 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (108.58 KB) of Q5B Quality of Biotechnological Products: Analysis of the Expression Construct in Cells Used for Production of r-DNA Derived Protein Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/23\/1996","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1995-D-0245\u0022\u003EFDA-1995-D-0245\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-14T10:25:05-04:00\u0022\u003E2020-04-14 10:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pharmacogenetic-tests-and-genetic-tests-heritable-markers\u0022\u003EPharmacogenetic Tests and Genetic Tests for Heritable Markers: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71422\/download\u0022\u003EPDF (92.43 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (92.43 KB) of Pharmacogenetic Tests and Genetic Tests for Heritable Markers: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/09\/2006","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2006-D-0232\u0022\u003EFDA-2006-D-0232\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222020-02-28T12:55:07-05:00\u0022\u003E2020-02-28 12:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/hemodialysis-blood-tubing-sets-premarket-notification-510k-submissions\u0022\u003EHemodialysis Blood Tubing Sets - Premarket Notification (510(k)) Submissions: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71429\/download\u0022\u003EPDF (602.02 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (602.02 KB) of Hemodialysis Blood Tubing Sets - Premarket Notification (510(k)) Submissions: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/23\/2026","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Gastroenterology-Urology ","field_topics":"Premarket","topics-product":"Premarket, 510(k), Gastroenterology-Urology ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2026-D-1877\u0022\u003EFDA-2026-D-1877\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222026-07-23T16:08:02-04:00\u0022\u003E2026-07-23 16:08\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/dental-handpieces-premarket-notification-510k-submissions\u0022\u003EDental Handpieces - Premarket Notification [510(k)] Submissions: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71432\/download\u0022\u003EPDF (115.81 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (115.81 KB) of Dental Handpieces - Premarket Notification [510(k)] Submissions: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/02\/2007","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-19T13:25:13-04:00\u0022\u003E2020-03-19 13:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/format-and-content-clinical-and-statistical-sections-application\u0022\u003EFormat and Content of the Clinical and Statistical Sections of an Application\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71436\/download\u0022\u003EPDF (1.09 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.09 MB) of Format and Content of the Clinical and Statistical Sections of an Application\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/01\/1988","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-21T11:30:19-04:00\u0022\u003E2020-04-21 11:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q5c-quality-biotechnological-products-stability-testing-biotechnologicalbiological-products\u0022\u003EQ5C Quality of Biotechnological Products: Stability Testing of Biotechnological\/Biological Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71441\/download\u0022\u003EPDF (70.17 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (70.17 KB) of Q5C Quality of Biotechnological Products: Stability Testing of Biotechnological\/Biological Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/01\/1996","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-04-08T17:25:04-04:00\u0022\u003E2019-04-08 17:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/submission-documentation-sterilization-process-validation-applications-human-and-veterinary-drug\u0022\u003ESubmission Documentation for Sterilization Process Validation in Applications for Human and Veterinary Drug Products: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71442\/download\u0022\u003EPDF (57.36 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (57.36 KB) of Submission Documentation for Sterilization Process Validation in Applications for Human and Veterinary Drug Products: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/01\/1994","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pharmaceutical Quality","field_topics":"Microbiology","topics-product":"Microbiology, Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Animal \u0026amp; Veterinary, Drugs","changed":"\u003Ctime datetime=\u00222020-05-05T10:05:12-04:00\u0022\u003E2020-05-05 10:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/hospital-bed-system-dimensional-and-assessment-guidance-reduce-entrapment\u0022\u003EHospital Bed System Dimensional and Assessment Guidance to Reduce Entrapment: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71460\/download\u0022\u003EPDF (978.13 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (978.13 KB) of Hospital Bed System Dimensional and Assessment Guidance to Reduce Entrapment: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/10\/2006","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Postmarket","topics-product":"Postmarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-D-0499\u0022\u003EFDA-2004-D-0499\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-02-28T13:00:53-05:00\u0022\u003E2020-02-28 13:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/submission-documentation-applications-parametric-release-human-and-veterinary-drug-products\u0022\u003ESubmission of Documentation in Applications for Parametric Release of Human and Veterinary Drug Products Terminally Sterilized by Moist Heat Processes: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71461\/download\u0022\u003EPDF (72.71 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (72.71 KB) of Submission of Documentation in Applications for Parametric Release of Human and Veterinary Drug Products Terminally Sterilized by Moist Heat Processes: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/26\/2010","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pharmaceutical Quality","field_topics":"Microbiology","topics-product":"Microbiology, Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0391\u0022\u003EFDA-2008-D-0391\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Animal \u0026amp; Veterinary, Drugs","changed":"\u003Ctime datetime=\u00222022-04-28T10:18:33-04:00\u0022\u003E2022-04-28 10:18\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q5d-quality-biotechnologicalbiological-products-derivation-and-characterization-cell-substrates-used\u0022\u003EQ5D Quality of Biotechnological\/Biological Products: Derivation and Characterization of Cell Substrates Used for Production of Biotechnological\/Biological Products; Availability\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71463\/download\u0022\u003EPDF (52.35 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (52.35 KB) of Q5D Quality of Biotechnological\/Biological Products: Derivation and Characterization of Cell Substrates Used for Production of Biotechnological\/Biological Products; Availability\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/21\/1998","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1997-D-0098\u0022\u003EFDA-1997-D-0098\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-14T16:50:06-04:00\u0022\u003E2020-04-14 16:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/medical-device-user-fee-and-modernization-act-2002-validation-data-premarket-notification\u0022\u003EMedical Device User Fee and Modernization Act of 2002, Validation Data in Premarket Notification Submissions (510(k)s) for Reprocessed Single-Use Medical Devices: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71482\/download\u0022\u003EPDF (133.23 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (133.23 KB) of Medical Device User Fee and Modernization Act of 2002, Validation Data in Premarket Notification Submissions (510(k)s) for Reprocessed Single-Use Medical Devices: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/02\/2004","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k)","field_topics":"User Fees","topics-product":"User Fees, 510(k)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2003-D-0309\u0022\u003EFDA-2003-D-0309\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-02-28T12:45:12-05:00\u0022\u003E2020-02-28 12:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/formatting-assembling-and-submitting-new-drug-and-antibiotic-applications\u0022\u003EFormatting, Assembling and Submitting New Drug and Antibiotic Applications*\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71485\/download\u0022\u003EPDF (1.7 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.7 MB) of Formatting, Assembling and Submitting New Drug and Antibiotic Applications*\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/01\/1987","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-03-20T15:45:04-04:00\u0022\u003E2019-03-20 15:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q5e-comparability-biotechnologicalbiological-products-subject-changes-their-manufacturing-process\u0022\u003EQ5E Comparability of Biotechnological\/Biological Products Subject to Changes in Their Manufacturing Process\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71489\/download\u0022\u003EPDF (58.1 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (58.1 KB) of Q5E Comparability of Biotechnological\/Biological Products Subject to Changes in Their Manufacturing Process\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/30\/2005","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-D-0440\u0022\u003EFDA-2004-D-0440\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-14T16:55:07-04:00\u0022\u003E2020-04-14 16:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/general-considerations-clinical-evaluation-drugs\u0022\u003EGeneral Considerations for the Clinical Evaluation of Drugs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71495\/download\u0022\u003EPDF (1.37 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.37 MB) of General Considerations for the Clinical Evaluation of Drugs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/01\/1997","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-03-20T15:55:05-04:00\u0022\u003E2019-03-20 15:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/variations-drug-products-may-be-included-single-anda\u0022\u003EVariations in Drug Products that May Be Included in a Single ANDA\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71497\/download\u0022\u003EPDF (106.73 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (106.73 KB) of Variations in Drug Products that May Be Included in a Single ANDA\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/01\/1998","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Generic Drugs","field_topics":"","topics-product":"Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0385\u0022\u003EFDA-2021-D-0385\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-04-13T15:05:03-04:00\u0022\u003E2021-04-13 15:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q6b-specifications-test-procedures-and-acceptance-criteria-biotechnologicalbiological-products\u0022\u003EQ6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological\/Biological Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71510\/download\u0022\u003EPDF (54 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (54 KB) of Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological\/Biological Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/18\/1999","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1998-D-0003\u0022\u003EFDA-1998-D-0003\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-14T17:05:03-04:00\u0022\u003E2020-04-14 17:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-use-bayesian-statistics-medical-device-clinical-trials-pdf-version\u0022\u003EGuidance for the Use of Bayesian Statistics in Medical Device Clinical Trials (PDF Version)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71512\/download\u0022\u003EPDF (341.52 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (341.52 KB) of Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials (PDF Version)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/05\/2010","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2006-D-0410\u0022\u003EFDA-2006-D-0410\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-02-28T13:30:02-05:00\u0022\u003E2020-02-28 13:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q7-good-manufacturing-practice-guidance-active-pharmaceutical-ingredients-guidance-industry\u0022\u003EQ7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71518\/download\u0022\u003EPDF (253.13 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (253.13 KB) of Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/30\/2016","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1995-D-0288\u0022\u003EFDA-1995-D-0288\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-05-27T12:55:46-04:00\u0022\u003E2026-05-27 12:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/class-ii-special-controls-guidance-document-serological-assays-detection-beta-glucan-pdf-version\u0022\u003EClass II Special Controls Guidance Document: Serological Assays for the Detection of Beta-Glucan (PDF version)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71529\/download\u0022\u003EPDF (55.39 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (55.39 KB) of Class II Special Controls Guidance Document: Serological Assays for the Detection of Beta-Glucan (PDF version)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/23\/2004","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Special Controls Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222018-12-01T12:33:02-05:00\u0022\u003E2018-12-01 12:33\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q8r2-pharmaceutical-development\u0022\u003EQ8(R2) Pharmaceutical Development\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71535\/download\u0022\u003EPDF (401.81 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (401.81 KB) of Q8(R2) Pharmaceutical Development\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/20\/2009","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2005-D-0154\u0022\u003EFDA-2005-D-0154\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-05-29T10:53:31-04:00\u0022\u003E2026-05-29 10:53\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/m3r2-nonclinical-safety-studies-conduct-human-clinical-trials-and-marketing-authorization\u0022\u003EM3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71542\/download\u0022\u003EPDF (439.88 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (439.88 KB) of M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/21\/2010","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Multidisciplinary","field_topics":"","topics-product":"ICH-Multidisciplinary","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0470 \u0022\u003EFDA-2008-D-0470 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-09-09T15:48:32-04:00\u0022\u003E2026-09-09 15:48\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/good-pharmacovigilance-practices-and-pharmacoepidemiologic-assessment\u0022\u003EGood Pharmacovigilance Practices and Pharmacoepidemiologic Assessment: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71546\/download\u0022\u003EPDF (368.42 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (368.42 KB) of Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/24\/2005","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Good Clinical Practice (GCP)","field_topics":"","topics-product":"Clinical - Medical, Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-D-0041\u0022\u003EFDA-2004-D-0041\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222020-04-22T09:55:02-04:00\u0022\u003E2020-04-22 09:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/m4-organization-common-technical-document-registration-pharmaceuticals-human-use-guidance-industry\u0022\u003EM4 Organization of the Common Technical Document for the Registration of Pharmaceuticals for Human Use Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71551\/download\u0022\u003EPDF (269.33 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (269.33 KB) of M4 Organization of the Common Technical Document for the Registration of Pharmaceuticals for Human Use Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/03\/2017","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Multidisciplinary","field_topics":"","topics-product":"ICH-Multidisciplinary","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-5139\u0022\u003EFDA-2017-D-5139\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T15:55:06-04:00\u0022\u003E2020-04-24 15:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q10-pharmaceutical-quality-system\u0022\u003EQ10 Pharmaceutical Quality System\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71553\/download\u0022\u003EPDF (273.92 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (273.92 KB) of Q10 Pharmaceutical Quality System\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/08\/2009","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2007-D-0370 \u0022\u003EFDA-2007-D-0370 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-05-29T10:53:37-04:00\u0022\u003E2026-05-29 10:53\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/investigational-device-exemptions-ides-devices-indicated-nocturnal-home-hemodialysis\u0022\u003EInvestigational Device Exemptions (IDEs) for Devices Indicated for Nocturnal Home Hemodialysis: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71554\/download\u0022\u003EPDF (196.53 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (196.53 KB) of Investigational Device Exemptions (IDEs) for Devices Indicated for Nocturnal Home Hemodialysis: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/15\/2008","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Investigational Device Exemption (IDE)","field_topics":"Premarket","topics-product":"Premarket, Investigational Device Exemption (IDE)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-20T15:08:30-04:00\u0022\u003E2020-03-20 15:08\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/m4-ctd-general-questions-and-answers\u0022\u003EM4: The CTD -- General Questions and Answers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71559\/download\u0022\u003EPDF (44.82 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (44.82 KB) of M4: The CTD -- General Questions and Answers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/22\/2004","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Multidisciplinary","field_topics":"","topics-product":"ICH-Multidisciplinary","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-04-05T13:30:09-04:00\u0022\u003E2019-04-05 13:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/keratome-and-replacement-keratome-blades-premarket-notification-510k-submissions\u0022\u003EKeratome and Replacement Keratome Blades Premarket Notification [510(k)] Submissions: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71574\/download\u0022\u003EPDF (113.6 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (113.6 KB) of Keratome and Replacement Keratome Blades Premarket Notification [510(k)] Submissions: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/18\/2006","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k)","field_topics":"Premarket","topics-product":"Premarket, 510(k)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-19T11:07:20-04:00\u0022\u003E2020-03-19 11:07\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/m4-ctd-quality\u0022\u003EM4: The CTD -- Quality\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71581\/download\u0022\u003EPDF (130.92 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (130.92 KB) of M4: The CTD -- Quality\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/01\/2001","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Multidisciplinary","field_topics":"","topics-product":"ICH-Multidisciplinary","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-04-05T13:35:03-04:00\u0022\u003E2019-04-05 13:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-development-vaginal-contraceptive-drugs-nda\u0022\u003EGuidance for the Development of Vaginal Contraceptive Drugs (NDA)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71584\/download\u0022\u003EPDF (465.1 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (465.1 KB) of Guidance for the Development of Vaginal Contraceptive Drugs (NDA)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/02\/1998","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-03-20T17:35:55-04:00\u0022\u003E2019-03-20 17:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/internal-radioactive-contamination-development-decorporation-agents\u0022\u003EInternal Radioactive Contamination \u2014Development of Decorporation Agents\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71589\/download\u0022\u003EPDF (395.13 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (395.13 KB) of Internal Radioactive Contamination \u2014Development of Decorporation Agents\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/02\/2006","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2005-D-0025\u0022\u003EFDA-2005-D-0025\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-14T14:05:08-04:00\u0022\u003E2020-05-14 14:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/levothyroxine-sodium-tablets-in-vivo-pharmacokinetic-and-bioavailability-studies-and-in-vitro-dissolution\u0022\u003ELevothyroxine Sodium Tablets - In Vivo Pharmacokinetic and Bioavailability Studies and In Vitro Dissolution Testing\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71591\/download\u0022\u003EPDF (27.48 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (27.48 KB) of Levothyroxine Sodium Tablets - In Vivo Pharmacokinetic and Bioavailability Studies and In Vitro Dissolution Testing\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/08\/2001","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1999-D-0010\u0022\u003EFDA-1999-D-0010\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T15:40:13-04:00\u0022\u003E2020-04-24 15:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/animal-models-essential-elements-address-efficacy-under-animal-rule-concept-paper\u0022\u003EAnimal Models \u2014 Essential Elements to Address Efficacy Under the Animal Rule - Concept Paper\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71592\/download\u0022\u003EPDF (28.21 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (28.21 KB) of Animal Models \u2014 Essential Elements to Address Efficacy Under the Animal Rule - Concept Paper\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/09\/2008","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pharmacology\/Toxicology","field_topics":"","topics-product":"Pharmacology\/Toxicology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/None found\u0022\u003ENone found\u003C\/a\u003E","field_communication_type":"Concept Paper","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-22T12:00:03-04:00\u0022\u003E2020-04-22 12:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/tonometers-premarket-notification-510k-submissions\u0022\u003ETonometers - Premarket Notification [510(k)] Submissions : Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71593\/download\u0022\u003EPDF (232.63 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (232.63 KB) of Tonometers - Premarket Notification [510(k)] Submissions : Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/27\/2006","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k)","field_topics":"Premarket","topics-product":"Premarket, 510(k)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-19T11:00:06-04:00\u0022\u003E2020-03-19 11:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/m4-ctd-quality-questions-and-answers-location-issues\u0022\u003EM4: The CTD -- Quality Questions and Answers \/Location Issues\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71599\/download\u0022\u003EPDF (85.61 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (85.61 KB) of M4: The CTD -- Quality Questions and Answers \/Location Issues\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/09\/2004","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Multidisciplinary","field_topics":"","topics-product":"ICH-Multidisciplinary","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2002-D-0261\u0022\u003EFDA-2002-D-0261\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T15:55:15-04:00\u0022\u003E2020-04-24 15:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/local-anesthetics-clinical-evaluation\u0022\u003ELocal Anesthetics--Clinical Evaluation\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/02\/1998","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-02-28T09:45:14-05:00\u0022\u003E2020-02-28 09:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/hypnotic-drugs-clinical-evaluation\u0022\u003EHypnotic Drugs--Clinical Evaluation\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71609\/download\u0022\u003EPDF (1.7 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.7 MB) of Hypnotic Drugs--Clinical Evaluation\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/01\/1977","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-01-29T13:40:18-05:00\u0022\u003E2020-01-29 13:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/m4-ctd-efficacy-questions-and-answers\u0022\u003EM4: The CTD -- Efficacy Questions and Answers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71616\/download\u0022\u003EPDF (165.46 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (165.46 KB) of M4: The CTD -- Efficacy Questions and Answers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/01\/2004","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Multidisciplinary","field_topics":"","topics-product":"ICH-Multidisciplinary","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-04-05T14:00:09-04:00\u0022\u003E2019-04-05 14:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/orally-inhaled-and-intranasal-corticosteroids-evaluation-effects-growth-children\u0022\u003EOrally Inhaled and Intranasal Corticosteroids: Evaluation of the Effects on Growth in Children\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71624\/download\u0022\u003EPDF (82.43 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (82.43 KB) of Orally Inhaled and Intranasal Corticosteroids: Evaluation of the Effects on Growth in Children\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/06\/2007","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Pediatric Product Development","field_topics":"","topics-product":"Clinical - Medical, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2001-D-0137\u0022\u003EFDA-2001-D-0137\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T11:47:04-04:00\u0022\u003E2024-04-11 11:47\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/ind-exemptions-studies-lawfully-marketed-drug-or-biological-products-treatment-cancer\u0022\u003EIND Exemptions for Studies of Lawfully Marketed Drug or Biological Products for the Treatment of Cancer: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71627\/download\u0022\u003EPDF (171.61 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (171.61 KB) of IND Exemptions for Studies of Lawfully Marketed Drug or Biological Products for the Treatment of Cancer: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/15\/2004","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Good Clinical Practice (GCP)","field_topics":"","topics-product":"Clinical - Medical, Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222019-04-19T17:50:14-04:00\u0022\u003E2019-04-19 17:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/m4s-ctd-safety\u0022\u003EM4S: The CTD -- Safety\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/185340\/download\u0022\u003EPDF (274.67 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (274.67 KB) of M4S: The CTD -- Safety\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/01\/2001","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Multidisciplinary","field_topics":"","topics-product":"ICH-Multidisciplinary","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-01-31T13:16:48-05:00\u0022\u003E2025-01-31 13:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pdufa-pilot-project-proprietary-name-review-concept-paper\u0022\u003EPDUFA Pilot Project: Proprietary Name Review - Concept Paper\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71630\/download\u0022\u003EPDF (186.4 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (186.4 KB) of PDUFA Pilot Project: Proprietary Name Review - Concept Paper\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/07\/2008","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-N-0281\u0022\u003EFDA-2008-N-0281\u003C\/a\u003E","field_communication_type":"Concept Paper","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-27T09:50:32-04:00\u0022\u003E2020-04-27 09:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/postmarketing-adverse-experience-reporting-human-drug-and-licensed-biological-products-clarification\u0022\u003EPostmarketing Adverse Experience Reporting for Human Drug and Licensed Biological Products: Clarification of What to Report\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71635\/download\u0022\u003EPDF (95.35 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (95.35 KB) of Postmarketing Adverse Experience Reporting for Human Drug and Licensed Biological Products: Clarification of What to Report\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/27\/1997","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1997-D-0445\u0022\u003EFDA-1997-D-0445\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-27T10:50:23-04:00\u0022\u003E2020-04-27 10:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/m4s-ctd-safety-appendices\u0022\u003EM4S: The CTD -- Safety Appendices\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71642\/download\u0022\u003EPDF (813.67 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (813.67 KB) of M4S: The CTD -- Safety Appendices\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/01\/2001","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Multidisciplinary","field_topics":"","topics-product":"ICH-Multidisciplinary","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-04-05T14:25:22-04:00\u0022\u003E2019-04-05 14:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/premarketing-risk-assessment\u0022\u003EPremarketing Risk Assessment: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71650\/download\u0022\u003EPDF (505.46 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (505.46 KB) of Premarketing Risk Assessment: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/29\/2005","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Good Clinical Practice (GCP)","field_topics":"","topics-product":"Clinical - Medical, Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-D-0121\u0022\u003EFDA-2004-D-0121\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222025-01-31T13:32:16-05:00\u0022\u003E2025-01-31 13:32\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/providing-clinical-evidence-effectiveness-human-drug-and-biological-products\u0022\u003EProviding Clinical Evidence of Effectiveness for Human Drug and Biological Products.\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71655\/download\u0022\u003EPDF (129.17 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (129.17 KB) of Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products.\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/15\/1998","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1997-D-0027\u0022\u003EFDA-1997-D-0027\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-27T08:40:29-04:00\u0022\u003E2020-05-27 08:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/preparing-notices-availability-investigational-medical-devices-and-recruiting-study-subjects\u0022\u003EPreparing Notices of Availability of Investigational Medical Devices and for Recruiting Study Subjects: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71657\/download\u0022\u003EPDF (25.84 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (25.84 KB) of Preparing Notices of Availability of Investigational Medical Devices and for Recruiting Study Subjects: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/19\/1999","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Investigational Device Exemption (IDE)","field_topics":"Premarket","topics-product":"Premarket, Investigational Device Exemption (IDE)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-18T14:52:22-04:00\u0022\u003E2020-03-18 14:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/m4-ctd-safety-questions-and-answers\u0022\u003EM4: The CTD -- Safety Questions and Answers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71658\/download\u0022\u003EPDF (27 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (27 KB) of M4: The CTD -- Safety Questions and Answers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/04\/2003","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Multidisciplinary","field_topics":"","topics-product":"ICH-Multidisciplinary","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-04-05T15:40:06-04:00\u0022\u003E2019-04-05 15:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/m5international-conference-harmonisation-draft-guidance-m5-data-elements-and-standards-drug\u0022\u003EM5International Conference on Harmonisation; Draft Guidance on M5 Data Elements and Standards for Drug Dictionaries\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71663\/download\u0022\u003EPDF (405.51 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (405.51 KB) of M5International Conference on Harmonisation; Draft Guidance on M5 Data Elements and Standards for Drug Dictionaries\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/06\/2005","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Multidisciplinary","field_topics":"","topics-product":"ICH-Multidisciplinary","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2005-D-0459\u0022\u003EFDA-2005-D-0459\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T16:05:23-04:00\u0022\u003E2020-04-24 16:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/submitting-marketing-applications-according-ichctd-format-general-considerations\u0022\u003ESubmitting Marketing Applications According to the ICH\/CTD Format: General Considerations\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71666\/download\u0022\u003EPDF (174.62 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (174.62 KB) of Submitting Marketing Applications According to the ICH\/CTD Format: General Considerations\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/01\/2001","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, ICH-Multidisciplinary","field_topics":"","topics-product":"Administrative \/ Procedural, ICH-Multidisciplinary","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-04-05T15:55:26-04:00\u0022\u003E2019-04-05 15:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q1ar2-stability-testing-new-drug-substances-and-products\u0022\u003EQ1A(R2) Stability Testing of New Drug Substances and Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71707\/download\u0022\u003EPDF (57.67 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (57.67 KB) of Q1A(R2) Stability Testing of New Drug Substances and Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/21\/2003","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2002-D-0222\u0022\u003EFDA-2002-D-0222\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-15T13:05:15-04:00\u0022\u003E2020-05-15 13:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q1b-photostability-testing-new-drug-substances-and-products\u0022\u003EQ1B Photostability Testing of New Drug Substances and Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71713\/download\u0022\u003EPDF (339.22 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (339.22 KB) of Q1B Photostability Testing of New Drug Substances and Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/07\/1996","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-15T13:25:02-04:00\u0022\u003E2020-05-15 13:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q1c-stability-testing-new-dosage-forms\u0022\u003EQ1C Stability Testing for New Dosage Forms\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71715\/download\u0022\u003EPDF (101.12 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (101.12 KB) of Q1C Stability Testing for New Dosage Forms\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/09\/1997","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-S-0610\u0022\u003EFDA-2013-S-0610\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-02-15T09:46:17-05:00\u0022\u003E2022-02-15 09:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q1d-bracketing-and-matrixing-designs-stability-testing-new-drug-substances-and-products\u0022\u003EQ1D Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71720\/download\u0022\u003EPDF (30.59 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (30.59 KB) of Q1D Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/16\/2003","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2001-D-0164\u0022\u003EFDA-2001-D-0164\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-15T14:20:27-04:00\u0022\u003E2020-05-15 14:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q1e-evaluation-stability-data\u0022\u003EQ1E Evaluation of Stability Data\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71722\/download\u0022\u003EPDF (220.51 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (220.51 KB) of Q1E Evaluation of Stability Data\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/08\/2004","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2002-D-0180\u0022\u003EFDA-2002-D-0180\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-15T15:00:14-04:00\u0022\u003E2020-05-15 15:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q2a-text-validation-analytical-procedures\u0022\u003EQ2A Text on Validation of Analytical Procedures\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71724\/download\u0022\u003EPDF (24.76 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (24.76 KB) of Q2A Text on Validation of Analytical Procedures\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1994-D-0401\u0022\u003EFDA-1994-D-0401\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-14T14:20:03-04:00\u0022\u003E2020-04-14 14:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q2b-validation-analytical-procedures-methodology\u0022\u003EQ2B Validation of Analytical Procedures: Methodology\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71725\/download\u0022\u003EPDF (132.18 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (132.18 KB) of Q2B Validation of Analytical Procedures: Methodology\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/19\/1997","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1996-D-0169\u0022\u003EFDA-1996-D-0169\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-14T14:25:02-04:00\u0022\u003E2020-04-14 14:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q3ar-impurities-new-drug-substances\u0022\u003EQ3A(R) Impurities in New Drug Substances\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71727\/download\u0022\u003EPDF (54.73 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (54.73 KB) of Q3A(R) Impurities in New Drug Substances\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/06\/2008","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-08T10:40:08-04:00\u0022\u003E2020-04-08 10:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q3br-impurities-new-drug-products-revision-3\u0022\u003EQ3B(R) Impurities in New Drug Products (Revision 3)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71733\/download\u0022\u003EPDF (133.64 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (133.64 KB) of Q3B(R) Impurities in New Drug Products (Revision 3)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/04\/2006","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1996-D-0048 (Revision 1) \u0022\u003EFDA-1996-D-0048 (Revision 1) \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-09-29T16:20:11-04:00\u0022\u003E2021-09-29 16:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/developing-and-responding-deficiencies-accordance-least-burdensome-provisions\u0022\u003EDeveloping and Responding to Deficiencies in Accordance with the Least Burdensome Provisions: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71735\/download\u0022\u003EPDF (426.19 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (426.19 KB) of Developing and Responding to Deficiencies in Accordance with the Least Burdensome Provisions: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/26\/2022","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Premarket Approval (PMA)","field_topics":"Premarket","topics-product":"Premarket, Premarket Approval (PMA)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-5711\u0022\u003EFDA-2017-D-5711\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222022-10-26T09:03:32-04:00\u0022\u003E2022-10-26 09:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q3c-impurities-residual-solvents_2011\u0022\u003EQ3C Impurities: Residual Solvents_2011\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71736\/download\u0022\u003EPDF (40.56 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (40.56 KB) of Q3C Impurities: Residual Solvents_2011\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/24\/1997","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1997-D-0381\u0022\u003EFDA-1997-D-0381\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-08T11:21:41-04:00\u0022\u003E2020-04-08 11:21\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q3c-tables-and-list-rev-4\u0022\u003EQ3C Tables and List Rev. 4\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/133650\/download\u0022\u003EPDF (255.6 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (255.6 KB) of Q3C Tables and List Rev. 4\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/01\/2018","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-02-25T17:05:05-05:00\u0022\u003E2022-02-25 17:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q3c-appendix-4\u0022\u003EQ3C: Appendix 4\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71738\/download\u0022\u003EPDF (120.43 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (120.43 KB) of Q3C: Appendix 4\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/18\/1998","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-04-08T15:55:12-04:00\u0022\u003E2019-04-08 15:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-230140-evaluation-and-processing-post-donation-information-reports-obsolete-and-was\u0022\u003ECPG Sec. 230.140 Evaluation and Processing Post Donation Information Reports is obsolete and was withdrawn on 7\/16\/2018.\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71746\/download\u0022\u003EPDF (131.44 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (131.44 KB) of CPG Sec. 230.140 Evaluation and Processing Post Donation Information Reports is obsolete and was withdrawn on 7\/16\/2018.\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/09\/1999","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222018-12-01T10:16:12-05:00\u0022\u003E2018-12-01 10:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-250500-plasma-brokers-registration-and-compliance-good-manufacturing-practices-obsolete-and\u0022\u003ECPG Sec. 250.500- Plasma Brokers - Registration and Compliance with Good Manufacturing Practices is obsolete and was withdrawn on 7\/16\/2018.\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71751\/download\u0022\u003EPDF (132.7 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (132.7 KB) of CPG Sec. 250.500- Plasma Brokers - Registration and Compliance with Good Manufacturing Practices is obsolete and was withdrawn on 7\/16\/2018.\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222018-12-01T10:16:15-05:00\u0022\u003E2018-12-01 10:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-490100-process-validation-requirements-drug-products-and-active-pharmaceutical-ingredients\u0022\u003ECPG Sec. 490.100 Process Validation Requirements for Drug Products and Active Pharmaceutical Ingredients Subject to Pre-Market Approval\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71756\/download\u0022\u003EPDF (124.71 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (124.71 KB) of CPG Sec. 490.100 Process Validation Requirements for Drug Products and Active Pharmaceutical Ingredients Subject to Pre-Market Approval\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/12\/2004","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222018-12-01T11:26:47-05:00\u0022\u003E2018-12-01 11:26\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-500500-guidance-levels-3-mcpd-3-chloro-12-propanediol-acid-hydrolyzed-protein-and-asian\u0022\u003ECPG Sec 500.500 Guidance Levels for 3-MCPD (3-chloro-1,2-propanediol) in Acid-Hydrolyzed Protein and Asian-Style Sauces\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71760\/download\u0022\u003EPDF (25.9 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (25.9 KB) of CPG Sec 500.500 Guidance Levels for 3-MCPD (3-chloro-1,2-propanediol) in Acid-Hydrolyzed Protein and Asian-Style Sauces\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/14\/2008","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Ingredients","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Ingredients","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T11:59:01-05:00\u0022\u003E2025-03-05 11:59\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-545400-pottery-ceramics-import-and-domestic-cadmium-contamination\u0022\u003ECPG Sec 545.400 Pottery (Ceramics); Import and Domestic - Cadmium Contamination\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71762\/download\u0022\u003EPDF (14.65 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (14.65 KB) of CPG Sec 545.400 Pottery (Ceramics); Import and Domestic - Cadmium Contamination\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:47:49-05:00\u0022\u003E2025-03-06 21:47\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-545450-pottery-ceramics-import-and-domestic-lead-contamination\u0022\u003ECPG Sec 545.450 Pottery (Ceramics); Import and Domestic - Lead Contamination\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71764\/download\u0022\u003EPDF (17.67 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (17.67 KB) of CPG Sec 545.450 Pottery (Ceramics); Import and Domestic - Lead Contamination\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:49:07-05:00\u0022\u003E2025-03-06 21:49\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-document-premarket-notification-submissions-nitric-oxide-delivery-apparatus-nitric-oxide\u0022\u003EGuidance Document for Premarket Notification Submissions for Nitric Oxide Delivery Apparatus, Nitric Oxide Analyzer and Nitrogen Dioxide Analyzer: Guidance for Industry and for FDA Reviewers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71766\/download\u0022\u003EPDF (1.57 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.57 MB) of Guidance Document for Premarket Notification Submissions for Nitric Oxide Delivery Apparatus, Nitric Oxide Analyzer and Nitrogen Dioxide Analyzer: Guidance for Industry and for FDA Reviewers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/24\/2000","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k)","field_topics":"Premarket","topics-product":"Premarket, 510(k)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1999-D-4090\u0022\u003EFDA-1999-D-4090\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-02-28T12:30:06-05:00\u0022\u003E2020-02-28 12:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-545500-silver-plated-hollowware-lead-contamination\u0022\u003ECPG Sec 545.500 Silver-Plated Hollowware - Lead Contamination\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71767\/download\u0022\u003EPDF (14.47 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (14.47 KB) of CPG Sec 545.500 Silver-Plated Hollowware - Lead Contamination\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:49:49-05:00\u0022\u003E2025-03-06 21:49\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-505500-macaroni-and-noodle-products-adulteration-involving-insect-fragments-and-rodent-hairs\u0022\u003ECPG Sec 505.500 Macaroni and Noodle Products - Adulteration Involving Insect Fragments and Rodent Hairs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71768\/download\u0022\u003EPDF (12 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (12 KB) of CPG Sec 505.500 Macaroni and Noodle Products - Adulteration Involving Insect Fragments and Rodent Hairs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/01\/1996","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Bakery Product\/Mix","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Bakery Product\/Mix","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T14:31:14-05:00\u0022\u003E2025-03-05 14:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-300500-reprocessing-single-use-devices\u0022\u003ECPG Sec. 300.500 *Reprocessing of Single Use* Devices\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71769\/download\u0022\u003EPDF (86.4 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (86.4 KB) of CPG Sec. 300.500 *Reprocessing of Single Use* Devices\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222018-12-01T12:03:28-05:00\u0022\u003E2018-12-01 12:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-545600-cinnamon-flavored-toothpicks\u0022\u003ECPG Sec 545.600 Cinnamon-Flavored Toothpicks\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71771\/download\u0022\u003EPDF (8.93 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (8.93 KB) of CPG Sec 545.600 Cinnamon-Flavored Toothpicks\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:50:36-05:00\u0022\u003E2025-03-06 21:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-550100-apple-butter-adulteration-mold-rodent-filth-insect\u0022\u003ECPG Sec 550.100 Apple Butter - Adulteration with Mold; Rodent Filth, Insect\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71774\/download\u0022\u003EPDF (10.52 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (10.52 KB) of CPG Sec 550.100 Apple Butter - Adulteration with Mold; Rodent Filth, Insect\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Fruit\/Fruit Product ","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Fruit\/Fruit Product ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-07T08:54:33-05:00\u0022\u003E2025-03-07 08:54\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-550150-apricots-canned-adulteration-insects\u0022\u003ECPG Sec 550.150 Apricots - Canned - Adulteration with Insects\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71775\/download\u0022\u003EPDF (9.54 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (9.54 KB) of CPG Sec 550.150 Apricots - Canned - Adulteration with Insects\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Fruit\/Fruit Product ","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Fruit\/Fruit Product ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-07T08:55:33-05:00\u0022\u003E2025-03-07 08:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-585150-asparagus-canned-or-frozen-adulteration-insect-filth\u0022\u003ECPG Sec 585.150 Asparagus, Canned or Frozen - Adulteration with Insect Filth\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71778\/download\u0022\u003EPDF (9.84 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (9.84 KB) of CPG Sec 585.150 Asparagus, Canned or Frozen - Adulteration with Insect Filth\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/08\/1988","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Vegetable Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Vegetable Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-24T11:59:31-04:00\u0022\u003E2025-03-24 11:59\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-550155-apricot-peach-and-pear-nectars-and-purees-adulteration-mold\u0022\u003ECPG Sec 550.155 Apricot, Peach and Pear Nectars and Purees - Adulteration with Mold\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71779\/download\u0022\u003EPDF (11.59 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (11.59 KB) of CPG Sec 550.155 Apricot, Peach and Pear Nectars and Purees - Adulteration with Mold\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-07T08:56:19-05:00\u0022\u003E2025-03-07 08:56\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-510500-green-coffee-beans-adulteration-insects-mold\u0022\u003ECPG Sec 510.500 Green Coffee Beans - Adulteration with Insects; Mold\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71780\/download\u0022\u003EPDF (12.51 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (12.51 KB) of CPG Sec 510.500 Green Coffee Beans - Adulteration with Insects; Mold\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Beverage Bases\/Conc\/Nectar","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Beverage Bases\/Conc\/Nectar","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T14:46:03-05:00\u0022\u003E2025-03-05 14:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-585200-beets-canned-adulteration-rot\u0022\u003ECPG Sec 585.200 Beets, Canned - Adulteration with Rot\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71782\/download\u0022\u003EPDF (8.87 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (8.87 KB) of CPG Sec 585.200 Beets, Canned - Adulteration with Rot\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Vegetable Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Vegetable Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-24T12:01:36-04:00\u0022\u003E2025-03-24 12:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-310210-blood-pressure-measurement-devices-sphygmomanometers-accuracy\u0022\u003ECPG Sec. 310.210 Blood Pressure Measurement Devices (Sphygmomanometers) - Accuracy\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71783\/download\u0022\u003EPDF (63.87 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (63.87 KB) of CPG Sec. 310.210 Blood Pressure Measurement Devices (Sphygmomanometers) - Accuracy\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/18\/2005","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2005-D-0029\u0022\u003EFDA-2005-D-0029\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222020-02-25T12:49:55-05:00\u0022\u003E2020-02-25 12:49\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-550200-drupelet-berries-blackberries-raspberries-etc-common-or-usual-names-varieties-canned\u0022\u003ECPG Sec 550.200 Drupelet Berries (Blackberries, Raspberries, Etc.) - Common or Usual Names of Varieties; Canned and Frozen - Adulteration with Rot and Insects\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71784\/download\u0022\u003EPDF (15.51 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (15.51 KB) of CPG Sec 550.200 Drupelet Berries (Blackberries, Raspberries, Etc.) - Common or Usual Names of Varieties; Canned and Frozen - Adulteration with Rot and Insects\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Fruit\/Fruit Product ","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Fruit\/Fruit Product ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-07T08:59:34-05:00\u0022\u003E2025-03-07 08:59\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-585225-black-eyed-peas-cow-peas-field-peas-dried-adulteration-lygus-bug-damage\u0022\u003ECPG Sec 585.225 Black-Eyed Peas (Cow Peas, Field Peas); Dried-Adulteration with Lygus Bug Damage\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71786\/download\u0022\u003EPDF (11.03 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (11.03 KB) of CPG Sec 585.225 Black-Eyed Peas (Cow Peas, Field Peas); Dried-Adulteration with Lygus Bug Damage\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Vegetable Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Vegetable Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-24T13:30:32-04:00\u0022\u003E2025-03-24 13:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-315100-illegal-interstate-commercial-shipment-dentures-cpg-retitled-and-revised-5192005\u0022\u003ECPG Sec. 315.100 Illegal Interstate Commercial Shipment of Dentures (CPG retitled and revised 5\/19\/2005)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71787\/download\u0022\u003EPDF (97.34 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (97.34 KB) of CPG Sec. 315.100 Illegal Interstate Commercial Shipment of Dentures (CPG retitled and revised 5\/19\/2005)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/19\/2005","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Dental ","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Dental ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222021-05-05T13:46:22-04:00\u0022\u003E2021-05-05 13:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-550225-cherries-brined-fresh-canned-and-frozen-adulteration-involving-rot-and-insect\u0022\u003ECPG Sec 550.225 Cherries Brined, Fresh, Canned and Frozen - Adulteration Involving Rot and Insect\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71788\/download\u0022\u003EPDF (9.65 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (9.65 KB) of CPG Sec 550.225 Cherries Brined, Fresh, Canned and Frozen - Adulteration Involving Rot and Insect\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Fruit\/Fruit Product ","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Fruit\/Fruit Product ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-07T10:03:33-05:00\u0022\u003E2025-03-07 10:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-515100-confectionery-use-non-nutritive-substances-ingredients\u0022\u003ECPG Sec 515.100 Confectionery - Use of Non-Nutritive Substances as Ingredients\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71790\/download\u0022\u003EPDF (16.2 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (16.2 KB) of CPG Sec 515.100 Confectionery - Use of Non-Nutritive Substances as Ingredients\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Candy\/Gum (without chocolate)","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Candy\/Gum (without chocolate)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T14:39:46-05:00\u0022\u003E2025-03-05 14:39\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-550230-cherries-canned-misbranding-involving-food-standards\u0022\u003ECPG Sec 550.230 Cherries, Canned - Misbranding Involving Food Standards\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71792\/download\u0022\u003EPDF (12.42 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (12.42 KB) of CPG Sec 550.230 Cherries, Canned - Misbranding Involving Food Standards\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Fruit\/Fruit Product ","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Fruit\/Fruit Product ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-07T10:04:33-05:00\u0022\u003E2025-03-07 10:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-585260-broccoli-frozen-adulteration-insects\u0022\u003ECPG Sec 585.260 Broccoli, Frozen - Adulteration with Insects\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71793\/download\u0022\u003EPDF (8.85 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (8.85 KB) of CPG Sec 585.260 Broccoli, Frozen - Adulteration with Insects\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/08\/1988","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Vegetable Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Vegetable Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-24T13:31:20-04:00\u0022\u003E2025-03-24 13:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/shelf-software-use-medical-devices\u0022\u003EOff-The-Shelf Software Use in Medical Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71794\/download\u0022\u003EPDF (524.43 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (524.43 KB) of Off-The-Shelf Software Use in Medical Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/11\/2023","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Digital Health","field_topics":"Premarket","topics-product":"Premarket, Digital Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-3598\u0022\u003EFDA-2019-D-3598\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222023-08-11T09:26:03-04:00\u0022\u003E2023-08-11 09:26\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-550235-cherry-jam-adulteration-mold\u0022\u003ECPG Sec 550.235 Cherry Jam - Adulteration with Mold\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71795\/download\u0022\u003EPDF (8.68 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (8.68 KB) of CPG Sec 550.235 Cherry Jam - Adulteration with Mold\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Fruit\/Fruit Product ","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Fruit\/Fruit Product ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-07T10:05:49-05:00\u0022\u003E2025-03-07 10:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-585275-brussels-sprouts-frozen-adulteration-insects\u0022\u003ECPG Sec 585.275 Brussels Sprouts, Frozen - Adulteration by Insects\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71797\/download\u0022\u003EPDF (9.37 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (9.37 KB) of CPG Sec 585.275 Brussels Sprouts, Frozen - Adulteration by Insects\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Vegetable Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Vegetable Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-24T13:32:16-04:00\u0022\u003E2025-03-24 13:32\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-submission-510ks-solid-state-x-ray-imaging-devices\u0022\u003EGuidance for the Submission of 510(k)s for Solid State X-ray Imaging Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71798\/download\u0022\u003EPDF (388.18 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (388.18 KB) of Guidance for the Submission of 510(k)s for Solid State X-ray Imaging Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/01\/2016","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Radiological Health, Radiology","field_topics":"Premarket","topics-product":"Premarket, 510(k), Radiological Health, Radiology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1997-N-0389\u0022\u003EFDA-1997-N-0389\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222019-05-13T13:35:23-04:00\u0022\u003E2019-05-13 13:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-550250-citrus-fruit-juices-canned-adulteration-fly-filth-and-mold\u0022\u003ECPG Sec 550.250 Citrus Fruit Juices, Canned - Adulteration with Fly Filth and Mold\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71799\/download\u0022\u003EPDF (10.23 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (10.23 KB) of CPG Sec 550.250 Citrus Fruit Juices, Canned - Adulteration with Fly Filth and Mold\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Fruit\/Fruit Product ","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Fruit\/Fruit Product ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T14:16:31-04:00\u0022\u003E2025-03-17 14:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-585300-corn-sweet-canned-adulteration-corn-ear-worms-corn-borers\u0022\u003ECPG Sec 585.300 Corn, Sweet; Canned - Adulteration by Corn Ear Worms, Corn Borers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71801\/download\u0022\u003EPDF (9.91 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (9.91 KB) of CPG Sec 585.300 Corn, Sweet; Canned - Adulteration by Corn Ear Worms, Corn Borers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Vegetable Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Vegetable Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-24T13:33:16-04:00\u0022\u003E2025-03-24 13:33\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-550260-cranberry-sauce-adulteration-mold\u0022\u003ECPG Sec 550.260 Cranberry Sauce - Adulteration with Mold\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71803\/download\u0022\u003EPDF (8.83 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (8.83 KB) of CPG Sec 550.260 Cranberry Sauce - Adulteration with Mold\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Fruit\/Fruit Product ","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Fruit\/Fruit Product ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T14:18:02-04:00\u0022\u003E2025-03-17 14:18\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-335800-clinical-thermometer-adulteration-misbranding-defects\u0022\u003ECPG Sec. 335.800 Clinical Thermometer - Adulteration; Misbranding Defects\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71806\/download\u0022\u003EPDF (64.91 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (64.91 KB) of CPG Sec. 335.800 Clinical Thermometer - Adulteration; Misbranding Defects\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/31\/1991","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222021-05-03T14:25:08-04:00\u0022\u003E2021-05-03 14:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-550270-currants-adulteration-involving-wormy-fruits\u0022\u003ECPG Sec 550.270 Currants - Adulteration Involving Wormy Fruits\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71808\/download\u0022\u003EPDF (8.77 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (8.77 KB) of CPG Sec 550.270 Currants - Adulteration Involving Wormy Fruits\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Fruit\/Fruit Product ","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Fruit\/Fruit Product ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T14:19:31-04:00\u0022\u003E2025-03-17 14:19\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-515700-chocolate-chocolate-liquor-adulteration-insect-and-rodent-filth\u0022\u003ECPG Sec 515.700 Chocolate \u0026amp; Chocolate Liquor - Adulteration with Insect and Rodent Filth\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71809\/download\u0022\u003EPDF (10.36 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (10.36 KB) of CPG Sec 515.700 Chocolate \u0026amp; Chocolate Liquor - Adulteration with Insect and Rodent Filth\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/01\/2000","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Chocolate\/Cocoa Product","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Chocolate\/Cocoa Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T14:50:39-05:00\u0022\u003E2025-03-05 14:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-585350-corn-husks-tamales-adulteration-filth\u0022\u003ECPG Sec 585.350 Corn Husks (for Tamales) - Adulteration with Filth\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71811\/download\u0022\u003EPDF (8.76 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (8.76 KB) of CPG Sec 585.350 Corn Husks (for Tamales) - Adulteration with Filth\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/08\/1988","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Vegetable Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Vegetable Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-24T13:36:31-04:00\u0022\u003E2025-03-24 13:36\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-345100-condoms-defects-criteria-direct-reference-seizure\u0022\u003ECPG Sec. 345.100 Condoms; Defects - Criteria for Direct Reference Seizure\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71812\/download\u0022\u003EPDF (73.78 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (73.78 KB) of CPG Sec. 345.100 Condoms; Defects - Criteria for Direct Reference Seizure\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222021-05-03T14:10:14-04:00\u0022\u003E2021-05-03 14:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-550300-dates-and-date-material-imported-and-domestic-adulteration-involving-mold-insect\u0022\u003ECPG Sec 550.300 Dates and Date Material; Imported and Domestic - Adulteration Involving Mold, Insect Excreta, Sour, Dirty, Worthless and Pits\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71813\/download\u0022\u003EPDF (22.01 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (22.01 KB) of CPG Sec 550.300 Dates and Date Material; Imported and Domestic - Adulteration Involving Mold, Insect Excreta, Sour, Dirty, Worthless and Pits\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Fruit\/Fruit Product ","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Fruit\/Fruit Product ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T14:20:46-04:00\u0022\u003E2025-03-17 14:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-515750-cocoa-beans-adulteration-mold-insect-infestation-and-mammalian-excreta\u0022\u003ECPG Sec 515.750 Cocoa Beans - Adulteration by Mold, Insect Infestation, and Mammalian Excreta\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71815\/download\u0022\u003EPDF (10.63 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (10.63 KB) of CPG Sec 515.750 Cocoa Beans - Adulteration by Mold, Insect Infestation, and Mammalian Excreta\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Chocolate\/Cocoa Product","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Chocolate\/Cocoa Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T14:51:24-05:00\u0022\u003E2025-03-05 14:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-585400-cowpeas-black-eyed-peas-canned-succulent-peas-adulteration-insects\u0022\u003ECPG Sec 585.400 Cowpeas (Black-Eyed Peas); Canned (Succulent Peas) - Adulteration by Insects\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71817\/download\u0022\u003EPDF (9.81 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (9.81 KB) of CPG Sec 585.400 Cowpeas (Black-Eyed Peas); Canned (Succulent Peas) - Adulteration by Insects\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Vegetable Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Vegetable Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-24T13:37:31-04:00\u0022\u003E2025-03-24 13:37\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-550350-figs-fig-paste-adulteration-involving-insect-infestation-mold-dirt\u0022\u003ECPG Sec 550.350 Figs; Fig Paste - Adulteration Involving Insect Infestation; Mold, Dirt\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71818\/download\u0022\u003EPDF (10.24 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (10.24 KB) of CPG Sec 550.350 Figs; Fig Paste - Adulteration Involving Insect Infestation; Mold, Dirt\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Fruit\/Fruit Product ","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Fruit\/Fruit Product ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T14:21:46-04:00\u0022\u003E2025-03-17 14:21\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-515775-cocoa-powder-press-cake-adulteration-insect-and-rodent-filth\u0022\u003ECPG Sec 515.775 Cocoa Powder, Press Cake - Adulteration with Insect and Rodent Filth\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Chocolate\/Cocoa Product","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Chocolate\/Cocoa Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T14:52:16-05:00\u0022\u003E2025-03-05 14:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-585450-greens-canned-adulteration-mildew\u0022\u003ECPG Sec 585.450 Greens, Canned - Adulteration by Mildew\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71823\/download\u0022\u003EPDF (8.82 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (8.82 KB) of CPG Sec 585.450 Greens, Canned - Adulteration by Mildew\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/08\/1988","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Spices, Flavors\u00a0\u0026amp; \u00a0Salts","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Spices, Flavors\u00a0\u0026amp; \u00a0Salts","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-24T13:38:46-04:00\u0022\u003E2025-03-24 13:38\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/hypertension-indication-drug-labeling-cardiovascular-outcome-claims\u0022\u003EHypertension Indication: Drug Labeling for Cardiovascular Outcome Claims\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/134777\/download\u0022\u003EPDF (229.31 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (229.31 KB) of Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/15\/2011","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0150\u0022\u003EFDA-2008-D-0150\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-01-12T12:55:01-05:00\u0022\u003E2023-01-12 12:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-355200-electrical-muscle-stimulators\u0022\u003ECPG Sec. 355.200 Electrical Muscle Stimulators\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71827\/download\u0022\u003EPDF (62.43 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (62.43 KB) of CPG Sec. 355.200 Electrical Muscle Stimulators\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222021-05-03T14:16:17-04:00\u0022\u003E2021-05-03 14:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-550450-jam-black-currant-adulteration-mold\u0022\u003ECPG Sec 550.450 Jam, Black Currant - Adulteration with Mold\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71829\/download\u0022\u003EPDF (8.77 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (8.77 KB) of CPG Sec 550.450 Jam, Black Currant - Adulteration with Mold\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Fruit\/Fruit Product ","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Fruit\/Fruit Product ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T14:24:01-04:00\u0022\u003E2025-03-17 14:24\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-585475-canned-green-beans-and-canned-wax-beans-misbranding-involving-food-standards\u0022\u003ECPG Sec 585.475 Canned Green Beans and Canned Wax Beans - Misbranding Involving Food Standards\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71830\/download\u0022\u003EPDF (16.69 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (16.69 KB) of CPG Sec 585.475 Canned Green Beans and Canned Wax Beans - Misbranding Involving Food Standards\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Vegetable Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Vegetable Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-24T13:39:31-04:00\u0022\u003E2025-03-24 13:39\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-550500-lingon-berries-canned-adulteration-insects\u0022\u003ECPG Sec 550.500 Lingon Berries, Canned - Adulteration by Insects\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71834\/download\u0022\u003EPDF (9.45 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (9.45 KB) of CPG Sec 550.500 Lingon Berries, Canned - Adulteration by Insects\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Fruit\/Fruit Product ","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Fruit\/Fruit Product ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T14:28:01-04:00\u0022\u003E2025-03-17 14:28\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/labeling-human-prescription-drug-and-biological-products-implementing-plr-content-and-format\u0022\u003ELabeling for Human Prescription Drug and Biological Products - Implementing the PLR Content and Format Requirements\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71836\/download\u0022\u003EPDF (526.69 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (526.69 KB) of Labeling for Human Prescription Drug and Biological Products - Implementing the PLR Content and Format Requirements\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/25\/2013","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2005-D-0153\u0022\u003EFDA-2005-D-0153\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T15:25:12-04:00\u0022\u003E2020-04-24 15:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-585575-peas-and-beans-dried-adulteration-involving-storage-insect-damage-rocks\u0022\u003ECPG Sec 585.575 Peas and Beans; Dried - Adulteration Involving Storage, Insect Damage, Rocks\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71838\/download\u0022\u003EPDF (14.46 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (14.46 KB) of CPG Sec 585.575 Peas and Beans; Dried - Adulteration Involving Storage, Insect Damage, Rocks\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Vegetable Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Vegetable Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-24T19:51:14-04:00\u0022\u003E2025-03-24 19:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-525150-bay-laurel-leaves-adulteration-insect-filth-mold-mammalian-excreta\u0022\u003ECPG Sec 525.150 Bay (Laurel) Leaves - Adulteration by Insect Filth; Mold; Mammalian Excreta\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71839\/download\u0022\u003EPDF (10.25 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (10.25 KB) of CPG Sec 525.150 Bay (Laurel) Leaves - Adulteration by Insect Filth; Mold; Mammalian Excreta\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Dressing\/Condiment","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Dressing\/Condiment","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T14:58:17-05:00\u0022\u003E2025-03-05 14:58\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-525200-capsicum-pods-ground-capsicums-excluding-paprika-ground-paprika-adulteration-insect\u0022\u003ECPG Sec 525.200 Capsicum Pods, Ground Capsicums Excluding Paprika, Ground Paprika - Adulteration with Insect and Rodent Filth, Mold, Mammalian Excreta\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71842\/download\u0022\u003EPDF (11.41 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (11.41 KB) of CPG Sec 525.200 Capsicum Pods, Ground Capsicums Excluding Paprika, Ground Paprika - Adulteration with Insect and Rodent Filth, Mold, Mammalian Excreta\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Dressing\/Condiment","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Dressing\/Condiment","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T14:59:01-05:00\u0022\u003E2025-03-05 14:59\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-550590-cloudberries-multer-berries-canned-adulteration-insects\u0022\u003ECPG Sec 550.590 Cloudberries (Multer Berries), Canned - Adulteration by Insects\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71843\/download\u0022\u003EPDF (8.89 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (8.89 KB) of CPG Sec 550.590 Cloudberries (Multer Berries), Canned - Adulteration by Insects\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Fruit\/Fruit Product ","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Fruit\/Fruit Product ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T14:34:46-04:00\u0022\u003E2025-03-17 14:34\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/changes-approved-nda-or-anda\u0022\u003EChanges to an Approved NDA or ANDA: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71846\/download\u0022\u003EPDF (173.43 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (173.43 KB) of Changes to an Approved NDA or ANDA: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/08\/2004","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1999-D-0049\u0022\u003EFDA-1999-D-0049\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-26T14:50:06-04:00\u0022\u003E2020-05-26 14:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-525225-whole-cassia-or-whole-cinnamon-ground-cinnamon-adulteration-insect-and-rodent-filth\u0022\u003ECPG Sec 525.225 - Whole Cassia or Whole Cinnamon, Ground Cinnamon - Adulteration by Insect and Rodent Filth; Mold; Mammalian Excreta\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71847\/download\u0022\u003EPDF (11.84 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (11.84 KB) of CPG Sec 525.225 - Whole Cassia or Whole Cinnamon, Ground Cinnamon - Adulteration by Insect and Rodent Filth; Mold; Mammalian Excreta\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/01\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Dressing\/Condiment","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Dressing\/Condiment","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T14:59:46-05:00\u0022\u003E2025-03-05 14:59\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/public-availability-labeling-changes-changes-being-effected-supplements\u0022\u003EPublic Availability of Labeling Changes in \u0026quot;Changes Being Effected\u0026quot; Supplements\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71848\/download\u0022\u003EPDF (25.91 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (25.91 KB) of Public Availability of Labeling Changes in \u0026quot;Changes Being Effected\u0026quot; Supplements\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/20\/2006","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2006-D-0038\u0022\u003EFDA-2006-D-0038\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-15T10:35:08-04:00\u0022\u003E2020-05-15 10:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-585675-popcorn-adulteration-rodent-filth-and-field-corn\u0022\u003ECPG Sec 585.675 Popcorn - Adulteration with Rodent Filth and Field Corn\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71849\/download\u0022\u003EPDF (10.94 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (10.94 KB) of CPG Sec 585.675 Popcorn - Adulteration with Rodent Filth and Field Corn\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/01\/1996","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Vegetable Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Vegetable Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-25T11:35:56-04:00\u0022\u003E2025-03-25 11:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-525250-cloves-adulteration-stems\u0022\u003ECPG Sec 525.250 Cloves - Adulteration with Stems\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71852\/download\u0022\u003EPDF (8.82 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (8.82 KB) of CPG Sec 525.250 Cloves - Adulteration with Stems\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Dressing\/Condiment","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Dressing\/Condiment","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T15:00:46-05:00\u0022\u003E2025-03-05 15:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-585700-potato-chips-adulteration-rot\u0022\u003ECPG Sec 585.700 Potato Chips - Adulteration with Rot\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71854\/download\u0022\u003EPDF (8.71 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (8.71 KB) of CPG Sec 585.700 Potato Chips - Adulteration with Rot\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/08\/1988","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Vegetable Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Vegetable Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-25T11:36:46-04:00\u0022\u003E2025-03-25 11:36\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-525300-condimental-seeds-other-fennel-seeds-and-sesame-seeds-adulteration-mammalian-excreta\u0022\u003ECPG Sec 525.300 Condimental Seeds Other than Fennel Seeds and Sesame Seeds - Adulteration by Mammalian Excreta\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71857\/download\u0022\u003EPDF (9.13 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (9.13 KB) of CPG Sec 525.300 Condimental Seeds Other than Fennel Seeds and Sesame Seeds - Adulteration by Mammalian Excreta\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Dressing\/Condiment","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Dressing\/Condiment","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T15:01:31-05:00\u0022\u003E2025-03-05 15:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-550600-olives-adulteration-involving-pits-rot-insect-infestation\u0022\u003ECPG Sec 550.600 Olives - Adulteration Involving Pits; Rot; Insect Infestation\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71862\/download\u0022\u003EPDF (14.61 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (14.61 KB) of CPG Sec 550.600 Olives - Adulteration Involving Pits; Rot; Insect Infestation\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Fruit\/Fruit Product ","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Fruit\/Fruit Product ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T14:43:31-04:00\u0022\u003E2025-03-17 14:43\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-525325-cumin-seed-adulteration-sand-and-grit\u0022\u003ECPG Sec 525.325 Cumin Seed - Adulteration with Sand and Grit\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71863\/download\u0022\u003EPDF (8.88 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (8.88 KB) of CPG Sec 525.325 Cumin Seed - Adulteration with Sand and Grit\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Dressing\/Condiment","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Dressing\/Condiment","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T15:16:13-05:00\u0022\u003E2025-03-05 15:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-585775-spinach-canned-or-frozen-adulteration-involving-insects-decomposition\u0022\u003ECPG Sec 585.775 Spinach, Canned or Frozen - Adulteration Involving Insects, Decomposition\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71867\/download\u0022\u003EPDF (11.95 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (11.95 KB) of CPG Sec 585.775 Spinach, Canned or Frozen - Adulteration Involving Insects, Decomposition\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Vegetable Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Vegetable Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-25T12:12:02-04:00\u0022\u003E2025-03-25 12:12\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-525330-curry-powder-adulteration-insect-and-rodent-filth\u0022\u003ECPG Sec 525.330 Curry Powder - Adulteration by Insect and Rodent Filth\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71870\/download\u0022\u003EPDF (9.43 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (9.43 KB) of CPG Sec 525.330 Curry Powder - Adulteration by Insect and Rodent Filth\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Dressing\/Condiment","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Dressing\/Condiment","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T15:03:16-05:00\u0022\u003E2025-03-05 15:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-585825-sweet-potatoes-dyeing-yellow-and-red-varieties\u0022\u003ECPG Sec 585.825 Sweet Potatoes - Dyeing of Yellow and Red Varieties\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71874\/download\u0022\u003EPDF (13.53 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (13.53 KB) of CPG Sec 585.825 Sweet Potatoes - Dyeing of Yellow and Red Varieties\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Vegetable Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Vegetable Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-25T13:04:46-04:00\u0022\u003E2025-03-25 13:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-525350-fennel-seed-adulteration-mammalian-excreta-insects\u0022\u003ECPG Sec 525.350 Fennel Seed - Adulteration by Mammalian Excreta; Insects\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71875\/download\u0022\u003EPDF (9.67 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (9.67 KB) of CPG Sec 525.350 Fennel Seed - Adulteration by Mammalian Excreta; Insects\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Dressing\/Condiment","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Dressing\/Condiment","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T15:04:02-05:00\u0022\u003E2025-03-05 15:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/format-and-content-microbiology-section-application\u0022\u003EFormat and Content of the Microbiology Section of an Application*: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71876\/download\u0022\u003EPDF (545.53 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (545.53 KB) of Format and Content of the Microbiology Section of an Application*: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/01\/1990","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pharmaceutical Quality","field_topics":"Microbiology","topics-product":"Microbiology, Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-06-05T09:37:34-04:00\u0022\u003E2019-06-05 09:37\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-550655-peaches-canned-misbranding-involving-food-standards\u0022\u003ECPG Sec 550.655 Peaches, Canned - Misbranding Involving Food Standards\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71880\/download\u0022\u003EPDF (13.61 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (13.61 KB) of CPG Sec 550.655 Peaches, Canned - Misbranding Involving Food Standards\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Fruit\/Fruit Product ","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Fruit\/Fruit Product ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T15:18:16-04:00\u0022\u003E2025-03-17 15:18\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-525375-whole-ginger-adulteration-insect-filth-mold-mammalian-excreta\u0022\u003ECPG Sec 525.375 Whole Ginger - Adulteration with Insect Filth; Mold; Mammalian Excreta\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71882\/download\u0022\u003EPDF (9.75 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (9.75 KB) of CPG Sec 525.375 Whole Ginger - Adulteration with Insect Filth; Mold; Mammalian Excreta\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Dressing\/Condiment","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Dressing\/Condiment","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T15:04:46-05:00\u0022\u003E2025-03-05 15:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-585875-tomatoes-canned-misbranding-involving-food-standards-peel\u0022\u003ECPG Sec 585.875 Tomatoes - Canned - Misbranding Involving Food Standards (Peel)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71886\/download\u0022\u003EPDF (10.64 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (10.64 KB) of CPG Sec 585.875 Tomatoes - Canned - Misbranding Involving Food Standards (Peel)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/25\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Vegetable Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Vegetable Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-25T13:06:31-04:00\u0022\u003E2025-03-25 13:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-550680-pineapple-canned-pineapple-juice-adulteration-mold\u0022\u003ECPG Sec 550.680 Pineapple, Canned; Pineapple Juice - Adulteration with Mold\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71889\/download\u0022\u003EPDF (9.34 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (9.34 KB) of CPG Sec 550.680 Pineapple, Canned; Pineapple Juice - Adulteration with Mold\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Fruit\/Fruit Product ","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Fruit\/Fruit Product ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T15:19:17-04:00\u0022\u003E2025-03-17 15:19\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-585890-tomato-products-adulteration-drosophila-fly-eggs-and-maggots\u0022\u003ECPG Sec 585.890 Tomato Products - Adulteration with Drosophila Fly Eggs and Maggots\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71892\/download\u0022\u003EPDF (11.29 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (11.29 KB) of CPG Sec 585.890 Tomato Products - Adulteration with Drosophila Fly Eggs and Maggots\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/25\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Vegetable Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Vegetable Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-25T13:07:21-04:00\u0022\u003E2025-03-25 13:07\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-525500-leafy-spices-other-bay-leaves-whole-oregano-leaves-whole-marjoram-whole-sage-leaves\u0022\u003ECPG Sec 525.500 Leafy Spices, Other than Bay Leaves - Whole Oregano Leaves, Whole Marjoram, Whole Sage Leaves and Whole Thyme Leaves - Adulteration with Insect Filth; Mold; Mammalian Excreta\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71893\/download\u0022\u003EPDF (10.7 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (10.7 KB) of CPG Sec 525.500 Leafy Spices, Other than Bay Leaves - Whole Oregano Leaves, Whole Marjoram, Whole Sage Leaves and Whole Thyme Leaves - Adulteration with Insect Filth; Mold; Mammalian Excreta\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Dressing\/Condiment","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Dressing\/Condiment","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T15:16:17-05:00\u0022\u003E2025-03-05 15:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-550685-pineapple-canned-imported-and-domestic-misbranding-involving-food-standards\u0022\u003ECPG Sec 550.685 Pineapple, Canned; Imported and Domestic - Misbranding Involving Food Standards\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71895\/download\u0022\u003EPDF (16.26 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (16.26 KB) of CPG Sec 550.685 Pineapple, Canned; Imported and Domestic - Misbranding Involving Food Standards\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Fruit\/Fruit Product ","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Fruit\/Fruit Product ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T15:20:16-04:00\u0022\u003E2025-03-17 15:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-585900-tomato-products-adulteration-mold\u0022\u003ECPG Sec 585.900 Tomato Products - Adulteration with Mold\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71898\/download\u0022\u003EPDF (20.94 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (20.94 KB) of CPG Sec 585.900 Tomato Products - Adulteration with Mold\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/25\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Vegetable Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Vegetable Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-25T13:08:03-04:00\u0022\u003E2025-03-25 13:08\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-525550-mace-adulteration-insect-filth-mold-foreign-matter-mammalian-excreta\u0022\u003ECPG Sec 525.550 Mace - Adulteration with Insect Filth; Mold; Foreign Matter; Mammalian Excreta\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71900\/download\u0022\u003EPDF (10.35 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (10.35 KB) of CPG Sec 525.550 Mace - Adulteration with Insect Filth; Mold; Foreign Matter; Mammalian Excreta\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Dressing\/Condiment","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Dressing\/Condiment","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T15:08:01-05:00\u0022\u003E2025-03-05 15:08\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-550690-plums-canned-adulteration-rot\u0022\u003ECPG Sec 550.690 Plums, Canned - Adulteration with Rot\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71903\/download\u0022\u003EPDF (9.43 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (9.43 KB) of CPG Sec 550.690 Plums, Canned - Adulteration with Rot\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Fruit\/Fruit Product ","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Fruit\/Fruit Product ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T15:21:46-04:00\u0022\u003E2025-03-17 15:21\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-525600-whole-and-ground-nutmeg-adulteration-insect-filth-mold-rodent-filth\u0022\u003ECPG Sec 525.600 Whole and Ground Nutmeg - Adulteration with Insect Filth; Mold; Rodent Filth\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71907\/download\u0022\u003EPDF (10.27 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (10.27 KB) of CPG Sec 525.600 Whole and Ground Nutmeg - Adulteration with Insect Filth; Mold; Rodent Filth\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Dressing\/Condiment","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Dressing\/Condiment","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T15:11:02-05:00\u0022\u003E2025-03-05 15:11\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-550700-dried-prunes-dehydrated-low-moisture-prunes-and-pitted-prunes-adulteration-involving\u0022\u003ECPG Sec 550.700 Dried Prunes, Dehydrated Low Moisture Prunes, and Pitted Prunes - Adulteration Involving Insects; Decomposition; Dirt; Pits; and Pit Fragments\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71909\/download\u0022\u003EPDF (11.29 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (11.29 KB) of CPG Sec 550.700 Dried Prunes, Dehydrated Low Moisture Prunes, and Pitted Prunes - Adulteration Involving Insects; Decomposition; Dirt; Pits; and Pit Fragments\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Fruit\/Fruit Product ","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Fruit\/Fruit Product ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T15:22:46-04:00\u0022\u003E2025-03-17 15:22\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/fda-animal-products-database-data-entry-form\u0022\u003EFDA Animal Products Database Data Entry Form\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71910\/download\u0022\u003EPDF (106.72 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (106.72 KB) of FDA Animal Products Database Data Entry Form\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/06\/1998","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-18T13:00:07-04:00\u0022\u003E2020-03-18 13:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-587300-color-additives\u0022\u003ECPG Sec 587.300 Color Additives\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71911\/download\u0022\u003EPDF (9.33 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (9.33 KB) of CPG Sec 587.300 Color Additives\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-25T13:10:31-04:00\u0022\u003E2025-03-25 13:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-525625-whole-and-ground-pepper-adulteration-insect-rodent-filth-mold-mammalian-excreta\u0022\u003ECPG Sec 525.625 Whole and Ground Pepper - Adulteration with Insect \u0026amp; Rodent Filth; Mold; Mammalian Excreta; Foreign Matter\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71915\/download\u0022\u003EPDF (11.26 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (11.26 KB) of CPG Sec 525.625 Whole and Ground Pepper - Adulteration with Insect \u0026amp; Rodent Filth; Mold; Mammalian Excreta; Foreign Matter\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Dressing\/Condiment","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Dressing\/Condiment","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T16:16:31-05:00\u0022\u003E2025-03-06 16:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-398350-regulatory-actions-against-assemblers-x-ray-equipment-fail-file-reports-assembly\u0022\u003ECPG Sec. 398.350 Regulatory Actions Against Assemblers of X-ray Equipment that Fail to File Reports of Assembly\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71917\/download\u0022\u003EPDF (67.05 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (67.05 KB) of CPG Sec. 398.350 Regulatory Actions Against Assemblers of X-ray Equipment that Fail to File Reports of Assembly\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"Radiology","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Radiology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222018-12-01T12:33:45-05:00\u0022\u003E2018-12-01 12:33\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-550750-raisins-adulteration-involving-mold-sand-grit-insects\u0022\u003ECPG Sec 550.750 Raisins - Adulteration Involving Mold, Sand, Grit, \u0026amp; Insects\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71918\/download\u0022\u003EPDF (9.93 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (9.93 KB) of CPG Sec 550.750 Raisins - Adulteration Involving Mold, Sand, Grit, \u0026amp; Insects\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Fruit\/Fruit Product ","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Fruit\/Fruit Product ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T15:23:31-04:00\u0022\u003E2025-03-17 15:23\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-590300-direct-reference-authority-pseudomonas-contamination-cosmetics-used-eye-area\u0022\u003ECPG Sec 590.300 Direct Reference Authority for Pseudomonas Contamination of Cosmetics Used in the Eye Area\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71920\/download\u0022\u003EPDF (9.57 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (9.57 KB) of CPG Sec 590.300 Direct Reference Authority for Pseudomonas Contamination of Cosmetics Used in the Eye Area\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Cosmetics","changed":"\u003Ctime datetime=\u00222025-03-25T13:11:16-04:00\u0022\u003E2025-03-25 13:11\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/s1a-need-long-term-rodent-carcinogenicity-studies-pharmaceuticals\u0022\u003ES1A The Need for Long-term Rodent Carcinogenicity Studies of Pharmaceuticals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71921\/download\u0022\u003EPDF (99.78 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (99.78 KB) of S1A The Need for Long-term Rodent Carcinogenicity Studies of Pharmaceuticals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/1996","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Safety","field_topics":"","topics-product":"ICH-Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1996-D-0010\u0022\u003EFDA-1996-D-0010\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-06-08T12:05:04-04:00\u0022\u003E2021-06-08 12:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-550800-standardized-canned-fruit-misbranding-involving-improper-declaration-packing-medium\u0022\u003ECPG Sec 550.800 Standardized Canned Fruit - Misbranding Involving Improper Declaration of Packing Medium\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71924\/download\u0022\u003EPDF (10.36 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (10.36 KB) of CPG Sec 550.800 Standardized Canned Fruit - Misbranding Involving Improper Declaration of Packing Medium\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Fruit\/Fruit Product ","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Fruit\/Fruit Product ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T15:27:01-04:00\u0022\u003E2025-03-17 15:27\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-590400-natural-bristle-brushes-ie-hair-brushes-shaving-brushes-nit-contamination\u0022\u003ECPG Sec 590.400 Natural Bristle Brushes (i.e., Hair Brushes, Shaving Brushes) - Nit Contamination\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71925\/download\u0022\u003EPDF (9.28 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (9.28 KB) of CPG Sec 590.400 Natural Bristle Brushes (i.e., Hair Brushes, Shaving Brushes) - Nit Contamination\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Cosmetics","changed":"\u003Ctime datetime=\u00222025-03-25T13:12:03-04:00\u0022\u003E2025-03-25 13:12\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-525700-sesame-seeds-adulteration-insect-filth-decomposition-mammalian-excreta-foreign-matter\u0022\u003ECPG Sec 525.700 Sesame Seeds - Adulteration with Insect Filth; Decomposition; Mammalian Excreta; Foreign Matter\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71926\/download\u0022\u003EPDF (10.59 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (10.59 KB) of CPG Sec 525.700 Sesame Seeds - Adulteration with Insect Filth; Decomposition; Mammalian Excreta; Foreign Matter\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Dressing\/Condiment","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Dressing\/Condiment","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T16:31:38-05:00\u0022\u003E2025-03-06 16:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-550850-strawberries-frozen-whole-or-sliced-adulteration-sand-mold\u0022\u003ECPG Sec 550.850 Strawberries; Frozen, Whole, or Sliced - Adulteration with Sand, Mold\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71930\/download\u0022\u003EPDF (10.12 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (10.12 KB) of CPG Sec 550.850 Strawberries; Frozen, Whole, or Sliced - Adulteration with Sand, Mold\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Fruit\/Fruit Product ","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Fruit\/Fruit Product ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T15:28:16-04:00\u0022\u003E2025-03-17 15:28\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/s1b-testing-carcinogenicity-pharmaceuticals\u0022\u003ES1B Testing for Carcinogenicity of Pharmaceuticals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71935\/download\u0022\u003EPDF (144.62 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (144.62 KB) of S1B Testing for Carcinogenicity of Pharmaceuticals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/23\/1998","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Safety","field_topics":"","topics-product":"ICH-Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1996-D-0010\u0022\u003EFDA-1996-D-0010\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-17T13:15:20-04:00\u0022\u003E2020-04-17 13:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-525825-vinegar-definitions-adulteration-vinegar-eels\u0022\u003ECPG Sec 525.825 Vinegar, Definitions - Adulteration with Vinegar Eels\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71937\/download\u0022\u003EPDF (15.1 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (15.1 KB) of CPG Sec 525.825 Vinegar, Definitions - Adulteration with Vinegar Eels\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Dressing\/Condiment","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Dressing\/Condiment","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T16:45:47-05:00\u0022\u003E2025-03-06 16:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-400100-drugs-human-failure-register\u0022\u003ECPG Sec. 400.100 Drugs, Human - Failure to Register\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71939\/download\u0022\u003EPDF (60.89 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (60.89 KB) of CPG Sec. 400.100 Drugs, Human - Failure to Register\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/None found\u0022\u003ENone found\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T15:25:22-04:00\u0022\u003E2020-05-06 15:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-555250-statement-policy-labeling-and-preventing-cross-contact-common-food-allergens\u0022\u003ECPG Sec 555.250 Statement of Policy for Labeling and Preventing Cross-contact of Common Food Allergens\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71940\/download\u0022\u003EPDF (24.45 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (24.45 KB) of CPG Sec 555.250 Statement of Policy for Labeling and Preventing Cross-contact of Common Food Allergens\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T08:37:47-04:00\u0022\u003E2024-10-01 08:37\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-525850-whole-plant-unprocessed-oregano-crushed-oregano-ground-oregano-adulteration-insect\u0022\u003ECPG Sec 525.850 Whole Plant (Unprocessed) Oregano, Crushed Oregano \u0026amp; Ground Oregano - Adulteration by Insect \u0026amp; Rodent Filth; Mold; Mammalian Excreta\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71942\/download\u0022\u003EPDF (11.82 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (11.82 KB) of CPG Sec 525.850 Whole Plant (Unprocessed) Oregano, Crushed Oregano \u0026amp; Ground Oregano - Adulteration by Insect \u0026amp; Rodent Filth; Mold; Mammalian Excreta\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Dressing\/Condiment","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Dressing\/Condiment","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T16:42:31-05:00\u0022\u003E2025-03-06 16:42\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/s1cr2-dose-selection-carcinogenicity-studies-pharmaceuticals\u0022\u003ES1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71944\/download\u0022\u003EPDF (184.53 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (184.53 KB) of S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/17\/2008","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Safety","field_topics":"","topics-product":"ICH-Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-23T14:55:02-04:00\u0022\u003E2020-04-23 14:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-555300-foods-except-dairy-products-adulteration-salmonella\u0022\u003ECPG Sec 555.300 Foods, Except Dairy Products - Adulteration with Salmonella\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71946\/download\u0022\u003EPDF (10.78 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (10.78 KB) of CPG Sec 555.300 Foods, Except Dairy Products - Adulteration with Salmonella\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T15:38:02-04:00\u0022\u003E2025-03-17 15:38\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-525900-whole-plant-unprocessed-marjoram-unground-processed-marjoram-ground-marjoram\u0022\u003ECPG Sec 525.900 Whole Plant (Unprocessed) Marjoram, Unground (Processed) Marjoram \u0026amp; Ground Marjoram - Adulteration by Insect \u0026amp; Rodent Filth; Mold; Mammalian Excreta\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71948\/download\u0022\u003EPDF (12.13 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (12.13 KB) of CPG Sec 525.900 Whole Plant (Unprocessed) Marjoram, Unground (Processed) Marjoram \u0026amp; Ground Marjoram - Adulteration by Insect \u0026amp; Rodent Filth; Mold; Mammalian Excreta\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Dressing\/Condiment","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Dressing\/Condiment","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T17:02:46-05:00\u0022\u003E2025-03-06 17:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-608500-illegal-sales-veterinary-prescription-drugs-direct-reference-authority-warning-letter\u0022\u003ECPG Sec. 608.500 Illegal Sales of Veterinary Prescription Drugs Direct Reference Authority for *Warning* Letter Issuance (Withdrawn 2\/20\/2020)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Drugs","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222020-02-20T09:50:18-05:00\u0022\u003E2020-02-20 09:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-555425-foods-adulteration-involving-hard-or-sharp-foreign-objects\u0022\u003ECPG Sec 555.425 Foods, Adulteration Involving hard or Sharp Foreign Objects\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71953\/download\u0022\u003EPDF (15.56 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (15.56 KB) of CPG Sec 555.425 Foods, Adulteration Involving hard or Sharp Foreign Objects\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/01\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T15:42:16-04:00\u0022\u003E2025-03-17 15:42\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-525925-whole-plant-unprocessed-thyme-unground-processed-thyme-ground-thyme-adulteration\u0022\u003ECPG Sec 525.925 Whole Plant (Unprocessed) Thyme, Unground (Processed) Thyme \u0026amp; Ground Thyme - Adulteration by Insect \u0026amp; Rodent Filth; Mold; Mammalian Excreta\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71956\/download\u0022\u003EPDF (12.21 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (12.21 KB) of CPG Sec 525.925 Whole Plant (Unprocessed) Thyme, Unground (Processed) Thyme \u0026amp; Ground Thyme - Adulteration by Insect \u0026amp; Rodent Filth; Mold; Mammalian Excreta\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Dressing\/Condiment","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Dressing\/Condiment","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T17:33:19-05:00\u0022\u003E2025-03-06 17:33\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-615115-extralabel-use-medicated-feeds-minor-species\u0022\u003ECPG Sec 615.115 Extralabel Use of Medicated Feeds for Minor Species\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71960\/download\u0022\u003EPDF (101.75 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (101.75 KB) of CPG Sec 615.115 Extralabel Use of Medicated Feeds for Minor Species\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/01\/2016","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Medicated Feed, Minor Use\/ Minor Species (MUMS)","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Medicated Feed, Minor Use\/ Minor Species (MUMS)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222024-11-14T16:25:45-05:00\u0022\u003E2024-11-14 16:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-525950-whole-plant-unprocessed-sage-and-ground-sage-adulteration-insect-and-rodent-filth\u0022\u003ECPG Sec 525.950 Whole Plant (Unprocessed) Sage, and Ground Sage - Adulteration by Insect and Rodent Filth; Mold; Mammalian Excreta\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71962\/download\u0022\u003EPDF (11.59 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (11.59 KB) of CPG Sec 525.950 Whole Plant (Unprocessed) Sage, and Ground Sage - Adulteration by Insect and Rodent Filth; Mold; Mammalian Excreta\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Dressing\/Condiment","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Dressing\/Condiment","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-07T17:46:29-05:00\u0022\u003E2025-03-07 17:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-555500-all-food-sanitation-including-bacteriological-inspections-classification\u0022\u003ECPG Sec 555.500 All Food Sanitation (Including Bacteriological) Inspections - Classification of Establishment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71965\/download\u0022\u003EPDF (10.31 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (10.31 KB) of CPG Sec 555.500 All Food Sanitation (Including Bacteriological) Inspections - Classification of Establishment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/01\/1980","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T15:46:17-04:00\u0022\u003E2025-03-17 15:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-527100-butter-adulteration-involving-insufficient-fat-content\u0022\u003ECPG Sec 527.100 Butter - Adulteration Involving Insufficient Fat Content\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71967\/download\u0022\u003EPDF (15.26 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (15.26 KB) of CPG Sec 527.100 Butter - Adulteration Involving Insufficient Fat Content\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Dairy","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Dairy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:09:49-05:00\u0022\u003E2025-03-06 21:09\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-555550-foods-standardized-enriched-or-fortified-adulteration-involving-misbranding-potency\u0022\u003ECPG Sec 555.550 Foods, Standardized; Enriched or Fortified - Adulteration Involving Misbranding - Potency\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71969\/download\u0022\u003EPDF (9.24 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (9.24 KB) of CPG Sec 555.550 Foods, Standardized; Enriched or Fortified - Adulteration Involving Misbranding - Potency\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/01\/1989","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T15:47:32-04:00\u0022\u003E2025-03-17 15:47\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/s2b-genotoxicity-standard-battery-genotoxicity-testing-pharmaceuticals\u0022\u003ES2B Genotoxicity: A Standard Battery for Genotoxicity Testing of Pharmaceuticals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71971\/download\u0022\u003EPDF (131.49 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (131.49 KB) of S2B Genotoxicity: A Standard Battery for Genotoxicity Testing of Pharmaceuticals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/21\/1997","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Safety","field_topics":"","topics-product":"ICH-Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1997-D-0199\u0022\u003EFDA-1997-D-0199\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T11:10:13-04:00\u0022\u003E2020-04-24 11:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-527200-cheese-cheese-products-adulteration-filth\u0022\u003ECPG Sec 527.200 Cheese \u0026amp; Cheese Products - Adulteration with Filth\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71972\/download\u0022\u003EPDF (12.21 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (12.21 KB) of CPG Sec 527.200 Cheese \u0026amp; Cheese Products - Adulteration with Filth\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/01\/1996","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Dairy","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Dairy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:10:49-05:00\u0022\u003E2025-03-06 21:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/radio-frequency-wireless-technology-medical-devices-guidance-industry-and-fda-staff\u0022\u003ERadio Frequency Wireless Technology in Medical Devices - Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71975\/download\u0022\u003EPDF (138.76 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (138.76 KB) of Radio Frequency Wireless Technology in Medical Devices - Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/14\/2013","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Digital Health","field_topics":"Premarket","topics-product":"Premarket, Digital Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2006-D-0300\u0022\u003EFDA-2006-D-0300\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-02-28T14:36:17-05:00\u0022\u003E2020-02-28 14:36\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-625300-unapproved-new-animal-drugs-follow-action-approved-warning-letter-direct-reference\u0022\u003ECPG Sec. 625.300 Unapproved New Animal Drugs - Follow-up Action to Approved Warning Letter - Direct Reference Seizure Authority (Withdrawn 2\/20\/2020)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Drugs, Unapproved Animal Drugs","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Drugs, Unapproved Animal Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222020-02-20T09:47:16-05:00\u0022\u003E2020-02-20 09:47\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-527225-cheese-misbranding-due-moisture-and-fat\u0022\u003ECPG Sec 527.225 Cheese - Misbranding Due to Moisture and Fat\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71978\/download\u0022\u003EPDF (11.48 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (11.48 KB) of CPG Sec 527.225 Cheese - Misbranding Due to Moisture and Fat\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Dairy","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Dairy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:13:29-05:00\u0022\u003E2025-03-06 21:13\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-420100-adulteration-drugs-under-section-501b-and-501c-act-direct-reference-seizure-authority\u0022\u003ECPG Sec. 420.100 Adulteration of Drugs Under Section 501(b) and 501(c) of the Act. *Direct Reference Seizure Authority for Adulterated Drugs Under Section 501(b)*\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71979\/download\u0022\u003EPDF (71.02 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (71.02 KB) of CPG Sec. 420.100 Adulteration of Drugs Under Section 501(b) and 501(c) of the Act. *Direct Reference Seizure Authority for Adulterated Drugs Under Section 501(b)*\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/01\/1992","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/None found\u0022\u003ENone found\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T15:40:05-04:00\u0022\u003E2020-05-06 15:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/s2r1-genotoxicity-testing-and-data-interpretation-pharmaceuticals-intended-human-use\u0022\u003ES2(R1) Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71980\/download\u0022\u003EPDF (427.35 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (427.35 KB) of S2(R1) Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/07\/2012","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Safety","field_topics":"","topics-product":"ICH-Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0178\u0022\u003EFDA-2008-D-0178\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T10:25:25-04:00\u0022\u003E2020-04-24 10:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/appropriate-use-voluntary-consensus-standards-premarket-submissions-medical-devices\u0022\u003EAppropriate Use of Voluntary Consensus Standards in Premarket Submissions for Medical Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71983\/download\u0022\u003EPDF (452.55 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (452.55 KB) of Appropriate Use of Voluntary Consensus Standards in Premarket Submissions for Medical Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/14\/2018","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"Postmarket, Premarket","topics-product":"Postmarket, Premarket, Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0456\u0022\u003EFDA-2014-D-0456\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-10-20T15:21:29-04:00\u0022\u003E2020-10-20 15:21\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-625500-failure-register-andor-drug-list-withdrawn-2202020\u0022\u003ECPG Sec. 625.500 Failure to Register *and\/or Drug List* (Withdrawn 2\/20\/2020)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Drugs","field_topics":"Registration, Investigation \u0026amp; Enforcement","topics-product":"Registration, Investigation \u0026amp; Enforcement, Animal Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222020-02-20T09:51:41-05:00\u0022\u003E2020-02-20 09:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-555850-water-damaged-food-products-screw-top-crimped-cap-and-similar-containers\u0022\u003ECPG Sec 555.850 Water Damaged Food Products in Screw-Top, Crimped-Cap and Similar Containers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71986\/download\u0022\u003EPDF (11.42 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (11.42 KB) of CPG Sec 555.850 Water Damaged Food Products in Screw-Top, Crimped-Cap and Similar Containers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/01\/1989","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T16:42:02-04:00\u0022\u003E2025-03-17 16:42\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/s3a-toxicokinetics-assessment-systemic-exposure-toxicity-studies\u0022\u003ES3A Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71990\/download\u0022\u003EPDF (45.65 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (45.65 KB) of S3A Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Safety","field_topics":"","topics-product":"ICH-Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T11:10:07-04:00\u0022\u003E2020-04-24 11:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/s3b-pharmacokinetics-guidance-repeated-dose-tissue-distribution-studies\u0022\u003ES3B Pharmacokinetics: Guidance for Repeated Dose Tissue Distribution Studies\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71993\/download\u0022\u003EPDF (13.92 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (13.92 KB) of S3B Pharmacokinetics: Guidance for Repeated Dose Tissue Distribution Studies\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Safety","field_topics":"","topics-product":"ICH-Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T11:15:11-04:00\u0022\u003E2020-04-24 11:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-560200-country-origin-labeling\u0022\u003ECPG Sec 560.200 Country of Origin Labeling\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71994\/download\u0022\u003EPDF (13.81 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (13.81 KB) of CPG Sec 560.200 Country of Origin Labeling\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Import","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Import","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T17:04:46-04:00\u0022\u003E2025-03-17 17:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-535100-oleomargarine-misbranding-due-insufficient-fat\u0022\u003ECPG Sec 535.100 Oleomargarine - Misbranding Due to Insufficient Fat\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71996\/download\u0022\u003EPDF (9.88 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (9.88 KB) of CPG Sec 535.100 Oleomargarine - Misbranding Due to Insufficient Fat\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Oils","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Oils","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:21:29-05:00\u0022\u003E2025-03-06 21:21\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/non-clinical-information-femoral-stem-prostheses\u0022\u003ENon-clinical Information for Femoral Stem Prostheses: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71998\/download\u0022\u003EPDF (156.85 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (156.85 KB) of Non-clinical Information for Femoral Stem Prostheses: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/17\/2007","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-19T13:37:50-04:00\u0022\u003E2020-03-19 13:37\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-537100-eggs-and-egg-products-frozen-adulteration-involving-decomposition\u0022\u003ECPG Sec 537.100 Eggs and Egg Products - Frozen - Adulteration Involving Decomposition\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72002\/download\u0022\u003EPDF (10.26 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (10.26 KB) of CPG Sec 537.100 Eggs and Egg Products - Frozen - Adulteration Involving Decomposition\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Egg\/Egg Product","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Egg\/Egg Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:22:19-05:00\u0022\u003E2025-03-06 21:22\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/s4a-duration-chronic-toxicity-testing-animals-rodent-and-nonrodent-toxicity-testing\u0022\u003ES4A Duration of Chronic Toxicity Testing in Animals (Rodent and Nonrodent Toxicity Testing)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72003\/download\u0022\u003EPDF (20.77 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (20.77 KB) of S4A Duration of Chronic Toxicity Testing in Animals (Rodent and Nonrodent Toxicity Testing)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/25\/1999","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Safety","field_topics":"","topics-product":"ICH-Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1997-D-0153\u0022\u003EFDA-1997-D-0153\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T13:55:18-04:00\u0022\u003E2020-05-06 13:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-560400-imported-milk-and-cream-federal-import-milk-act\u0022\u003ECPG Sec 560.400 Imported Milk and Cream - Federal Import Milk Act\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72004\/download\u0022\u003EPDF (23.28 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (23.28 KB) of CPG Sec 560.400 Imported Milk and Cream - Federal Import Milk Act\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/12\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Import","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Import","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T17:15:31-04:00\u0022\u003E2025-03-17 17:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-555880-guidance-levels-radionuclides-domestic-and-imported-foods\u0022\u003ECPG Sec 555.880 Guidance Levels for Radionuclides in Domestic and Imported Foods\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72014\/download\u0022\u003EPDF (26.41 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (26.41 KB) of CPG Sec 555.880 Guidance Levels for Radionuclides in Domestic and Imported Foods\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Import","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Import","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T16:44:16-04:00\u0022\u003E2025-03-17 16:44\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-654300-chloramphenicol-unapproved-new-animal-drug-direct-reference-seizure-authority\u0022\u003ECPG Sec. 654.300 Chloramphenicol as an Unapproved New Animal Drug - Direct Reference Seizure Authority (Withdrawn 2\/20\/2020)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/01\/1996","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Drugs, Unapproved Animal Drugs","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Drugs, Unapproved Animal Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222020-02-20T09:51:30-05:00\u0022\u003E2020-02-20 09:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-448100-reconditioning-new-drugs-which-do-not-have-approved-ndasandas\u0022\u003ECPG Sec. 448.100 Reconditioning of New Drugs Which Do Not Have Approved NDAs\/ANDAs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72017\/download\u0022\u003EPDF (70.36 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (70.36 KB) of CPG Sec. 448.100 Reconditioning of New Drugs Which Do Not Have Approved NDAs\/ANDAs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/None found\u0022\u003ENone found\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T16:25:05-04:00\u0022\u003E2020-05-06 16:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-450100-cgmp-enforcement-policy-otc-vs-rx-drugs\u0022\u003ECPG Sec. 450.100 CGMP Enforcement Policy - OTC vs Rx Drugs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72021\/download\u0022\u003EPDF (59.71 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (59.71 KB) of CPG Sec. 450.100 CGMP Enforcement Policy - OTC vs Rx Drugs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/01\/1982","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/None found\u0022\u003ENone found\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-08T10:15:49-04:00\u0022\u003E2020-05-08 10:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/s6-preclinical-safety-evaluation-biotechnology-derived-pharmaceuticals\u0022\u003ES6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72028\/download\u0022\u003EPDF (137.18 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (137.18 KB) of S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/18\/1997","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Safety","field_topics":"","topics-product":"ICH-Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1997-D-0265\u0022\u003EFDA-1997-D-0265\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T11:25:02-04:00\u0022\u003E2020-04-24 11:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/s7a-safety-pharmacology-studies-human-pharmaceuticals\u0022\u003ES7A Safety Pharmacology Studies for Human Pharmaceuticals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72033\/download\u0022\u003EPDF (121.59 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (121.59 KB) of S7A Safety Pharmacology Studies for Human Pharmaceuticals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/13\/2001","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Safety","field_topics":"","topics-product":"ICH-Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2000-D-0274\u0022\u003EFDA-2000-D-0274\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-01-31T15:59:31-05:00\u0022\u003E2025-01-31 15:59\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-540590-fish-fresh-and-frozen-listed-adulteration-parasites\u0022\u003ECPG Sec 540.590 Fish - Fresh and Frozen, as Listed - Adulteration by Parasites\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72041\/download\u0022\u003EPDF (11.85 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (11.85 KB) of CPG Sec 540.590 Fish - Fresh and Frozen, as Listed - Adulteration by Parasites\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Seafood\/Seafood Product","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Seafood\/Seafood Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:41:08-05:00\u0022\u003E2025-03-06 21:41\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/s8-immunotoxicity-studies-human-pharmaceuticals\u0022\u003ES8 Immunotoxicity Studies for Human Pharmaceuticals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72047\/download\u0022\u003EPDF (72.49 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (72.49 KB) of S8 Immunotoxicity Studies for Human Pharmaceuticals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/12\/2006","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Safety","field_topics":"","topics-product":"ICH-Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2005-D-0398\u0022\u003EFDA-2005-D-0398\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T14:05:27-04:00\u0022\u003E2020-05-06 14:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-570200-aflatoxins-brazil-nuts\u0022\u003ECPG Sec 570.200 Aflatoxins in Brazil Nuts\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72053\/download\u0022\u003EPDF (157.4 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (157.4 KB) of CPG Sec 570.200 Aflatoxins in Brazil Nuts\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/01\/2021","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Nuts \u0026amp; Nut Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Nuts \u0026amp; Nut Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0243\u0022\u003EFDA-2021-D-0243\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-21T16:38:16-04:00\u0022\u003E2025-03-21 16:38\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-545300-foods-rail-car-sanitation-adulteration\u0022\u003ECPG Sec 545.300 Foods, Rail Car Sanitation - Adulteration\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72054\/download\u0022\u003EPDF (12.92 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (12.92 KB) of CPG Sec 545.300 Foods, Rail Car Sanitation - Adulteration\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:46:49-05:00\u0022\u003E2025-03-06 21:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-470100-orders-post-approval-record-reviews\u0022\u003ECPG Sec. 470.100 Orders for Post-Approval Record Reviews\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72058\/download\u0022\u003EPDF (67.35 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (67.35 KB) of CPG Sec. 470.100 Orders for Post-Approval Record Reviews\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/24\/1992","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222018-12-01T11:27:31-05:00\u0022\u003E2018-12-01 11:27\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-570300-peanut-butter-adulteration-filth-grit\u0022\u003ECPG Sec 570.300 Peanut Butter - Adulteration with Filth; Grit\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72060\/download\u0022\u003EPDF (12.54 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (12.54 KB) of CPG Sec 570.300 Peanut Butter - Adulteration with Filth; Grit\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Nuts \u0026amp; Nut Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Nuts \u0026amp; Nut Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-21T16:40:16-04:00\u0022\u003E2025-03-21 16:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-480300-lack-expiration-date-stability-data\u0022\u003ECPG Sec. 480.300 Lack of Expiration Date of Stability Data\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72066\/download\u0022\u003EPDF (66.71 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (66.71 KB) of CPG Sec. 480.300 Lack of Expiration Date of Stability Data\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222018-12-01T11:27:33-05:00\u0022\u003E2018-12-01 11:27\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-570350-peanuts-shelled-and-unshelled-adulteration-filth-and-reject-nuts\u0022\u003ECPG Sec 570.350 Peanuts, Shelled and Unshelled - Adulteration with Filth and Reject Nuts\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72068\/download\u0022\u003EPDF (11.77 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (11.77 KB) of CPG Sec 570.350 Peanuts, Shelled and Unshelled - Adulteration with Filth and Reject Nuts\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Nuts \u0026amp; Nut Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Nuts \u0026amp; Nut Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-21T16:41:32-04:00\u0022\u003E2025-03-21 16:41\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-570375-aflatoxins-peanuts-and-peanut-products\u0022\u003ECPG Sec 570.375 Aflatoxins in Peanuts and Peanut Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72073\/download\u0022\u003EPDF (165.53 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (165.53 KB) of CPG Sec 570.375 Aflatoxins in Peanuts and Peanut Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/01\/2021","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Nuts \u0026amp; Nut Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Nuts \u0026amp; Nut Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0244\u0022\u003EFDA-2021-D-0244\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-21T16:42:16-04:00\u0022\u003E2025-03-21 16:42\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-570425-tree-nuts-adulteration-involving-rejects-insect-infestation-moldy-rancid-otherwise\u0022\u003ECPG Sec 570.425 Tree Nuts - Adulteration Involving Rejects (Insect Infestation, Moldy, Rancid, Otherwise Decomposed, Blanks, and Shriveled)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72078\/download\u0022\u003EPDF (17.86 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (17.86 KB) of CPG Sec 570.425 Tree Nuts - Adulteration Involving Rejects (Insect Infestation, Moldy, Rancid, Otherwise Decomposed, Blanks, and Shriveled)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Nuts \u0026amp; Nut Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Nuts \u0026amp; Nut Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-21T16:43:16-04:00\u0022\u003E2025-03-21 16:43\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-570450-tree-nuts-adulteration-filth-involving-presence-organism-escherichia-coli\u0022\u003ECPG Sec 570.450 Tree Nuts - Adulteration with Filth, Involving the Presence of the Organism Escherichia coli\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72081\/download\u0022\u003EPDF (13.08 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (13.08 KB) of CPG Sec 570.450 Tree Nuts - Adulteration with Filth, Involving the Presence of the Organism Escherichia coli\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Nuts \u0026amp; Nut Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Nuts \u0026amp; Nut Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-21T16:44:16-04:00\u0022\u003E2025-03-21 16:44\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-570500-aflatoxins-pistachio-nuts\u0022\u003ECPG Sec 570.500 Aflatoxins in Pistachio Nuts\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72084\/download\u0022\u003EPDF (156.26 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (156.26 KB) of CPG Sec 570.500 Aflatoxins in Pistachio Nuts\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/01\/2021","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Nuts \u0026amp; Nut Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Nuts \u0026amp; Nut Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0245\u0022\u003EFDA-2021-D-0245\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-21T16:45:47-04:00\u0022\u003E2025-03-21 16:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-578200-corn-meal-adulteration-insect-and-rodent-filth\u0022\u003ECPG Sec 578.200 Corn Meal - Adulteration by Insect and Rodent Filth\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72092\/download\u0022\u003EPDF (10.3 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (10.3 KB) of CPG Sec 578.200 Corn Meal - Adulteration by Insect and Rodent Filth\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/06\/1988","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Grain\/Grain Product","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Grain\/Grain Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-21T16:51:46-04:00\u0022\u003E2025-03-21 16:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-578300-wheat-adulteration-insect-and-rodent-filth\u0022\u003ECPG Sec 578.300 Wheat - Adulteration by Insect and Rodent filth\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72096\/download\u0022\u003EPDF (12.18 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (12.18 KB) of CPG Sec 578.300 Wheat - Adulteration by Insect and Rodent filth\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/06\/1988","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Grain\/Grain Product","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Grain\/Grain Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-21T16:53:02-04:00\u0022\u003E2025-03-21 16:53\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-578400-treated-grain-seed-mercury-residue\u0022\u003ECPG Sec 578.400 Treated Grain Seed - Mercury Residue\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72102\/download\u0022\u003EPDF (8.55 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (8.55 KB) of CPG Sec 578.400 Treated Grain Seed - Mercury Residue\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/01\/1980","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Grain\/Grain Product","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Grain\/Grain Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-24T11:51:56-04:00\u0022\u003E2025-03-24 11:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-578450-wheat-flour-adulteration-insect-fragments-and-rodent-hairs\u0022\u003ECPG Sec 578.450 Wheat Flour-Adulteration with Insect Fragments and Rodent Hairs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72104\/download\u0022\u003EPDF (10.09 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (10.09 KB) of CPG Sec 578.450 Wheat Flour-Adulteration with Insect Fragments and Rodent Hairs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/31\/1987","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Grain\/Grain Product","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Grain\/Grain Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-24T11:53:46-04:00\u0022\u003E2025-03-24 11:53\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/supplement-10111984-letter-about-policies-procedures-and-implementation-act-qa-format\u0022\u003ESupplement to 10\/11\/1984 letter about policies, procedures and implementation of the Act (Q\u0026amp;A format)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72106\/download\u0022\u003EPDF (740.37 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (740.37 KB) of Supplement to 10\/11\/1984 letter about policies, procedures and implementation of the Act (Q\u0026amp;A format)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/02\/1998","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Generic Drugs","field_topics":"","topics-product":"Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Industry Letter","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-03-09T07:20:10-05:00\u0022\u003E2021-03-09 07:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-580100-food-storage-and-warehousing-adulteration-filth-domestic-and-import\u0022\u003ECPG Sec 580.100 Food Storage and Warehousing-Adulteration-Filth (Domestic and Import)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72108\/download\u0022\u003EPDF (27.04 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (27.04 KB) of CPG Sec 580.100 Food Storage and Warehousing-Adulteration-Filth (Domestic and Import)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2005","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-24T11:57:02-04:00\u0022\u003E2025-03-24 11:57\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/letter-manufacturers-distributors-and-importers-condom-products-included-condom-packet-398\u0022\u003ELetter - Manufacturers, Distributors and Importers of Condom Products (included in Condom Packet 398) : Letter - Manufacturers, Distributors and Importers of Condom Products \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72114\/download\u0022\u003EPDF (74.51 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (74.51 KB) of Letter - Manufacturers, Distributors and Importers of Condom Products (included in Condom Packet 398) : Letter - Manufacturers, Distributors and Importers of Condom Products \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/23\/1994","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Postmarket, Premarket","topics-product":"Postmarket, Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-17T12:45:39-04:00\u0022\u003E2020-03-17 12:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommended-clinical-study-design-ventricular-tachycardia-ablation\u0022\u003ERecommended Clinical Study Design for Ventricular Tachycardia Ablation\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72128\/download\u0022\u003EPDF (1.14 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.14 MB) of Recommended Clinical Study Design for Ventricular Tachycardia Ablation\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/07\/1999","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-18T15:00:24-04:00\u0022\u003E2020-03-18 15:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/adverse-reactions-section-labeling-human-prescription-drug-and-biological-products-content-and\u0022\u003EAdverse Reactions Section of Labeling for Human Prescription Drug and Biological Products \u2014 Content and Format\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72139\/download\u0022\u003EPDF (225.94 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (225.94 KB) of Adverse Reactions Section of Labeling for Human Prescription Drug and Biological Products \u2014 Content and Format\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/24\/2006","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2005-D-0153\u0022\u003EFDA-2005-D-0153\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-21T15:50:04-04:00\u0022\u003E2020-04-21 15:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clinical-studies-section-labeling-human-prescription-drug-and-biological-products-content-and-format\u0022\u003EClinical Studies Section of Labeling for Human Prescription Drug and Biological Products \u2014 Content and Format: Guidance for Industry \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72140\/download\u0022\u003EPDF (279.55 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (279.55 KB) of Clinical Studies Section of Labeling for Human Prescription Drug and Biological Products \u2014 Content and Format: Guidance for Industry \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/24\/2006","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP), Labeling","field_topics":"","topics-product":"Good Clinical Practice (GCP), Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2000-D-0074\u0022\u003EFDA-2000-D-0074\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222025-01-31T14:50:06-05:00\u0022\u003E2025-01-31 14:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/dosage-and-administration-section-labeling-human-prescription-drug-and-biological-products-content\u0022\u003EDosage and Administration Section of Labeling for Human Prescription Drug and Biological Products \u2014 Content and Format\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72142\/download\u0022\u003EPDF (560.74 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (560.74 KB) of Dosage and Administration Section of Labeling for Human Prescription Drug and Biological Products \u2014 Content and Format\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/12\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"03\/14\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2007-D-0201 \u0022\u003EFDA-2007-D-0201 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-01-13T14:23:44-05:00\u0022\u003E2023-01-13 14:23\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/nucleic-acid-testing-reduce-possible-risk-parvovirus-b19-transmission-plasma-derived-products\u0022\u003E Nucleic Acid Testing to Reduce the Possible Risk of Parvovirus B19 Transmission by Plasma-Derived Products: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72156\/download\u0022\u003EPDF (57.38 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (57.38 KB) of Nucleic Acid Testing to Reduce the Possible Risk of Parvovirus B19 Transmission by Plasma-Derived Products: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/28\/2009","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0379\u0022\u003EFDA-2008-D-0379\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222019-05-15T12:20:20-04:00\u0022\u003E2019-05-15 12:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/safety-efficacy-and-pharmacokinetic-studies-support-marketing-immune-globulin-intravenous-human\u0022\u003ESafety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/124333\/download\u0022\u003EPDF (75.91 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (75.91 KB) of Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/01\/2008","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2005-D-0208\u0022\u003EFDA-2005-D-0208\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-04-22T09:09:46-04:00\u0022\u003E2024-04-22 09:09\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/all-us-condom-manufacturers-importers-and-repackagers\u0022\u003EAll U.S. Condom Manufacturers, Importers and Repackagers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72176\/download\u0022\u003EPDF (93.76 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (93.76 KB) of All U.S. Condom Manufacturers, Importers and Repackagers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/07\/1987","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Postmarket, Premarket","topics-product":"Postmarket, Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"","changed":"\u003Ctime datetime=\u00222021-04-27T10:05:11-04:00\u0022\u003E2021-04-27 10:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/content-and-format-chemistry-manufacturing-and-controls-information-and-establishment-description\u0022\u003EOn the Content and Format of Chemistry, Manufacturing and Controls Information and Establishment Description Information for an Allergenic Extract or Allergen Patch Test: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/124400\/download\u0022\u003EPDF (44.57 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (44.57 KB) of On the Content and Format of Chemistry, Manufacturing and Controls Information and Establishment Description Information for an Allergenic Extract or Allergen Patch Test: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/23\/1999","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Allergenics","field_topics":"","topics-product":"Allergenics","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1998-D-1277\u0022\u003EFDA-1998-D-1277\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-07-15T10:17:46-04:00\u0022\u003E2024-07-15 10:17\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/court-decisions-anda-approvals-and-180-day-exclusivity-under-hatch-waxman-amendments-federal-food\u0022\u003ECourt Decisions, ANDA Approvals, and 180-Day Exclusivity Under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72194\/download\u0022\u003EPDF (25.28 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (25.28 KB) of Court Decisions, ANDA Approvals, and 180-Day Exclusivity Under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/27\/2000","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"","changed":"\u003Ctime datetime=\u00222018-12-01T13:16:09-05:00\u0022\u003E2018-12-01 13:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/implementing-collection-program-source-plasma-containing-disease-associated-and-other-immunoglobulin\u0022\u003EImplementing a Collection Program for Source Plasma Containing Disease-Associated and Other Immunoglobulin (IgG) Antibodies: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72196\/download\u0022\u003EPDF (42.09 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (42.09 KB) of Implementing a Collection Program for Source Plasma Containing Disease-Associated and Other Immunoglobulin (IgG) Antibodies: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/08\/2006","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2005-D-0014\u0022\u003EFDA-2005-D-0014\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-05-08T10:06:20-04:00\u0022\u003E2024-05-08 10:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/disclosure-materials-provided-advisory-committees-connection-open-advisory-committee-meetings\u0022\u003EDisclosure of Materials Provided to Advisory Committees in Connection with Open Advisory Committee Meetings Convened by the Center for Drug Evaluation and Research Beginning on January 1, 2000\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72201\/download\u0022\u003EPDF (10.32 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (10.32 KB) of Disclosure of Materials Provided to Advisory Committees in Connection with Open Advisory Committee Meetings Convened by the Center for Drug Evaluation and Research Beginning on January 1, 2000\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/22\/1999","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-01-26T10:55:14-05:00\u0022\u003E2021-01-26 10:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/drug-products-containing-ensulizole-hypromellose-meradimate-octinoxate-and-octisalate-labeling\u0022\u003EDrug Products Containing Ensulizole, Hypromellose, Meradimate, Octinoxate, and Octisalate \u2014 Labeling Enforcement Policy\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72206\/download\u0022\u003EPDF (159.11 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (159.11 KB) of Drug Products Containing Ensulizole, Hypromellose, Meradimate, Octinoxate, and Octisalate \u2014 Labeling Enforcement Policy\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/03\/2003","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2003-D-0090\u0022\u003EFDA-2003-D-0090\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-28T13:50:07-04:00\u0022\u003E2020-04-28 13:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/labeling-otc-human-drug-products-using-column-format\u0022\u003ELabeling OTC Human Drug Products Using a Column Format\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72208\/download\u0022\u003EPDF (57 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (57 KB) of Labeling OTC Human Drug Products Using a Column Format\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/19\/2000","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Over-the-Counter Drugs","field_topics":"","topics-product":"Over-the-Counter Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1999-D-1300\u0022\u003EFDA-1999-D-1300\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-14T11:27:03-04:00\u0022\u003E2020-05-14 11:27\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/end-phase-2a-meetings\u0022\u003EEnd-of-Phase 2A Meetings\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72211\/download\u0022\u003EPDF (163.2 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (163.2 KB) of End-of-Phase 2A Meetings\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/18\/2009","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0514\u0022\u003EFDA-2008-D-0514\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-01T14:05:39-04:00\u0022\u003E2020-05-01 14:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/third-party-review-guidance-phacofragmentation-system-device-premarket-notification-510k\u0022\u003EThird Party Review Guidance for Phacofragmentation System Device Premarket Notification (510(k))\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72212\/download\u0022\u003EPDF (149.04 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (149.04 KB) of Third Party Review Guidance for Phacofragmentation System Device Premarket Notification (510(k))\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/31\/1997","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-18T10:42:27-04:00\u0022\u003E2020-03-18 10:42\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/time-and-extent-applications-nonprescription-drug-products\u0022\u003ETime and Extent Applications for Nonprescription Drug Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72219\/download\u0022\u003EPDF (241.46 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (241.46 KB) of Time and Extent Applications for Nonprescription Drug Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/29\/2011","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Over-the-Counter Drugs","field_topics":"","topics-product":"Over-the-Counter Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-D-0438\u0022\u003EFDA-2004-D-0438\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T08:20:03-04:00\u0022\u003E2020-05-06 08:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/upgrading-category-iii-antiperspirants-category-i-43-fr-46728-46731\u0022\u003EUpgrading Category III Antiperspirants to Category I (43 FR 46728-46731)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72221\/download\u0022\u003EPDF (582.91 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (582.91 KB) of Upgrading Category III Antiperspirants to Category I (43 FR 46728-46731)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/01\/1978","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Over-the-Counter Drugs","field_topics":"","topics-product":"Over-the-Counter Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T08:50:32-04:00\u0022\u003E2020-05-06 08:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/format-and-content-nonclinical-pharmacologytoxicology-section-application\u0022\u003EFormat and Content of the Nonclinical Pharmacology\/Toxicology Section of an Application*: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72223\/download\u0022\u003EPDF (1.27 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.27 MB) of Format and Content of the Nonclinical Pharmacology\/Toxicology Section of an Application*: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/01\/1987","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pharmacology\/Toxicology","field_topics":"","topics-product":"Pharmacology\/Toxicology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-21T11:45:18-04:00\u0022\u003E2020-04-21 11:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/nonclinical-evaluation-immunotoxic-potential-pharmaceuticals\u0022\u003ENonclinical Evaluation of the Immunotoxic Potential of Pharmaceuticals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/169117\/download\u0022\u003EPDF (288.98 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (288.98 KB) of Nonclinical Evaluation of the Immunotoxic Potential of Pharmaceuticals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/05\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pharmacology\/Toxicology","field_topics":"","topics-product":"Pharmacology\/Toxicology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-5607\u0022\u003EFDA-2019-D-5607\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-06-05T10:00:17-04:00\u0022\u003E2023-06-05 10:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/reproductive-and-developmental-toxicities-integrating-study-results-assess-concerns\u0022\u003EReproductive and Developmental Toxicities -- Integrating Study Results to Assess Concerns\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72231\/download\u0022\u003EPDF (391.57 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (391.57 KB) of Reproductive and Developmental Toxicities -- Integrating Study Results to Assess Concerns\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/23\/2011","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pharmacology\/Toxicology","field_topics":"","topics-product":"Pharmacology\/Toxicology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1999-N-0082 \u0022\u003EFDA-1999-N-0082 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-23T11:40:09-04:00\u0022\u003E2020-04-23 11:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/bone-anchors-premarket-notification-510k-submissions\u0022\u003EBone Anchors - Premarket Notification (510(k)) Submissions: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72235\/download\u0022\u003EPDF (503.42 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (503.42 KB) of Bone Anchors - Premarket Notification (510(k)) Submissions: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/03\/2020","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Orthopedic","field_topics":"Premarket","topics-product":"Premarket, 510(k), Orthopedic","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-4436\u0022\u003EFDA-2016-D-4436\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-02T08:30:09-05:00\u0022\u003E2020-03-02 08:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/nonclinical-evaluation-late-radiation-toxicity-therapeutic-radiopharmaceuticals\u0022\u003ENonclinical Evaluation of Late Radiation Toxicity of Therapeutic Radiopharmaceuticals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72237\/download\u0022\u003EPDF (137.2 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (137.2 KB) of Nonclinical Evaluation of Late Radiation Toxicity of Therapeutic Radiopharmaceuticals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/28\/2011","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pharmacology\/Toxicology","field_topics":"","topics-product":"Pharmacology\/Toxicology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-14T13:05:02-04:00\u0022\u003E2020-05-14 13:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommendations-reduce-risk-transfusion-transmitted-malaria\u0022\u003ERecommendations to Reduce the Risk of Transfusion-Transmitted Malaria: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/163737\/download\u0022\u003EPDF (311.41 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (311.41 KB) of Recommendations to Reduce the Risk of Transfusion-Transmitted Malaria: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/07\/2022","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Blood, Infectious Disease, Coronavirus","term_node_tid":"Blood Products","field_topics":"Laboratory Methods","topics-product":"Laboratory Methods, Blood, Infectious Disease, Coronavirus, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2000-D-0187\u0022\u003EFDA-2000-D-0187\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222022-12-09T11:04:18-05:00\u0022\u003E2022-12-09 11:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/nonclinical-safety-evaluation-reformulated-drug-products-and-products-intended-administration\u0022\u003ENonclinical Safety Evaluation of Reformulated Drug Products and Products Intended for Administration by an Alternate Route\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72246\/download\u0022\u003EPDF (153.48 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (153.48 KB) of Nonclinical Safety Evaluation of Reformulated Drug Products and Products Intended for Administration by an Alternate Route\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/28\/2015","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pharmacology\/Toxicology","field_topics":"","topics-product":"Pharmacology\/Toxicology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0142\u0022\u003EFDA-2008-D-0142\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-14T13:10:18-04:00\u0022\u003E2020-05-14 13:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/fixed-combinations-and-single-entity-versions-previously-approved-antiretrovirals-treatment-or\u0022\u003EFixed-Combinations and Single-Entity Versions of Previously Approved Antiretrovirals for the Treatment or Prevention of Human Immunodeficiency Virus-One Under the President\u2019s Emergency Plan for Acquired Immunodeficiency Syndrome Relief\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72248\/download\u0022\u003EPDF (385.65 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (385.65 KB) of Fixed-Combinations and Single-Entity Versions of Previously Approved Antiretrovirals for the Treatment or Prevention of Human Immunodeficiency Virus-One Under the President\u2019s Emergency Plan for Acquired Immunodeficiency Syndrome Relief\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/01\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"11\/01\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-D-0301\u0022\u003EFDA-2004-D-0301\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-08-02T10:24:30-04:00\u0022\u003E2023-08-02 10:24\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/national-uniformity-nonpresciption-drugs-ingredient-listing-otc-drugs\u0022\u003ENational Uniformity for Nonpresciption Drugs - Ingredient Listing for OTC Drugs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72250\/download\u0022\u003EPDF (73.83 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (73.83 KB) of National Uniformity for Nonpresciption Drugs - Ingredient Listing for OTC Drugs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/09\/1998","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1998-D-1007\u0022\u003EFDA-1998-D-1007\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-14T11:33:44-04:00\u0022\u003E2020-05-14 11:33\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/good-review-management-principles-and-practices-new-drug-applications-and-biologics-license\u0022\u003EGood Review Management Principles and Practices for New Drug Applications and Biologics License Applications: Draft Guidance for Industry and Review Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72259\/download\u0022\u003EPDF (98.25 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (98.25 KB) of Good Review Management Principles and Practices for New Drug Applications and Biologics License Applications: Draft Guidance for Industry and Review Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/25\/2018","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"11\/23\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-3103\u0022\u003EFDA-2018-D-3103\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-22T10:10:06-04:00\u0022\u003E2020-04-22 10:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/nonclinical-studies-safety-evaluation-pharmaceutical-excipients\u0022\u003ENonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72260\/download\u0022\u003EPDF (229.53 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (229.53 KB) of Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/19\/2005","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pharmacology\/Toxicology","field_topics":"","topics-product":"Pharmacology\/Toxicology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2002-D-0188\u0022\u003EFDA-2002-D-0188\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-14T13:15:19-04:00\u0022\u003E2020-05-14 13:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/hysteroscopes-and-gynecology-laparoscopes-submission-guidance-510k\u0022\u003EHysteroscopes and Gynecology Laparoscopes - Submission Guidance for a 510(k)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72262\/download\u0022\u003EPDF (1.15 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.15 MB) of Hysteroscopes and Gynecology Laparoscopes - Submission Guidance for a 510(k)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/07\/1996","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k)","field_topics":"Premarket","topics-product":"Premarket, 510(k)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-17T15:40:15-04:00\u0022\u003E2020-03-17 15:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/animal-models-essential-elements-address-efficacy-under-animal-rule_09\u0022\u003EAnimal Models \u2014 Essential Elements to Address Efficacy Under the Animal Rule_09\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72265\/download\u0022\u003EPDF (28.2 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (28.2 KB) of Animal Models \u2014 Essential Elements to Address Efficacy Under the Animal Rule_09\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/05\/2009","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pharmacology\/Toxicology","field_topics":"","topics-product":"Pharmacology\/Toxicology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/None found\u0022\u003ENone found\u003C\/a\u003E","field_communication_type":"Concept Paper","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-22T12:05:02-04:00\u0022\u003E2020-04-22 12:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommended-approaches-integration-genetic-toxicology-study-results\u0022\u003ERecommended Approaches to Integration of Genetic Toxicology Study Results\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72266\/download\u0022\u003EPDF (189.87 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (189.87 KB) of Recommended Approaches to Integration of Genetic Toxicology Study Results\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/04\/2006","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pharmacology\/Toxicology","field_topics":"","topics-product":"Pharmacology\/Toxicology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-D-0374\u0022\u003EFDA-2004-D-0374\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-16T15:06:55-04:00\u0022\u003E2020-04-16 15:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/assessing-donor-suitability-and-blood-and-blood-product-safety-cases-known-or-suspected-west-nile\u0022\u003EAssessing Donor Suitability and Blood and Blood Product Safety in Cases of Known or Suspected West Nile Virus Infection: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72269\/download\u0022\u003EPDF (39.62 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (39.62 KB) of Assessing Donor Suitability and Blood and Blood Product Safety in Cases of Known or Suspected West Nile Virus Infection: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/23\/2005","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2005-D-0139\u0022\u003EFDA-2005-D-0139\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-05-08T10:12:01-04:00\u0022\u003E2024-05-08 10:12\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/carcinogenicity-study-protocol-submissions\u0022\u003ECarcinogenicity Study Protocol Submissions\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72270\/download\u0022\u003EPDF (302.59 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (302.59 KB) of Carcinogenicity Study Protocol Submissions\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/23\/2002","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pharmacology\/Toxicology","field_topics":"","topics-product":"Pharmacology\/Toxicology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2000-D-1405\u0022\u003EFDA-2000-D-1405\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-02-01T11:20:22-05:00\u0022\u003E2021-02-01 11:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pet-drug-applications-content-and-format-ndas-and-andas_2011\u0022\u003EPET Drug Applications - Content and Format for NDAs and ANDAs_2011\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72271\/download\u0022\u003EPDF (429.23 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (429.23 KB) of PET Drug Applications - Content and Format for NDAs and ANDAs_2011\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/31\/2011","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-04-15T11:25:12-04:00\u0022\u003E2019-04-15 11:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/reference-guide-nonclinical-toxicity-studies-antivial-drugs-indicated-treatment-na-non-life\u0022\u003EReference Guide for the Nonclinical Toxicity Studies of Antivial Drugs Indicated for the Treatment of N\/A Non-Life Threatening Disease Evaluation of Drug Toxicity Prior to Phase I Clinical Studies\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72272\/download\u0022\u003EPDF (836.93 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (836.93 KB) of Reference Guide for the Nonclinical Toxicity Studies of Antivial Drugs Indicated for the Treatment of N\/A Non-Life Threatening Disease Evaluation of Drug Toxicity Prior to Phase I Clinical Studies\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/02\/1998","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pharmacology\/Toxicology","field_topics":"","topics-product":"Pharmacology\/Toxicology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-02-01T11:38:46-05:00\u0022\u003E2021-02-01 11:38\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/how-comply-pediatric-research-equity-act\u0022\u003EHow to Comply with the Pediatric Research Equity Act\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72274\/download\u0022\u003EPDF (115.53 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (115.53 KB) of How to Comply with the Pediatric Research Equity Act\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/07\/2005","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Pediatric Product Development","field_topics":"","topics-product":"Administrative \/ Procedural, Pediatric Product Development","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T09:39:31-04:00\u0022\u003E2024-04-11 09:39\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/checklist-mechanical-lithotripters-and-stone-dislodgers-used-gastroenterology-and-urology\u0022\u003EChecklist for Mechanical Lithotripters and Stone Dislodgers used in Gastroenterology and Urology\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72275\/download\u0022\u003EPDF (14.79 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (14.79 KB) of Checklist for Mechanical Lithotripters and Stone Dislodgers used in Gastroenterology and Urology\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/01\/1994","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-17T13:10:11-04:00\u0022\u003E2020-03-17 13:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pet-drug-applications-content-and-format-ndas-and-andas-attachment-i-sample-formats-chemistry\u0022\u003EPET Drug Applications - Content and Format for NDAs and ANDAs: Attachment I: Sample formats for chemistry, manufacturing, and controls (CMC) sections_2011\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72278\/download\u0022\u003EPDF (614.24 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (614.24 KB) of PET Drug Applications - Content and Format for NDAs and ANDAs: Attachment I: Sample formats for chemistry, manufacturing, and controls (CMC) sections_2011\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/01\/2011","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2000-D-1542\u0022\u003EFDA-2000-D-1542\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-15T01:51:31-04:00\u0022\u003E2020-05-15 01:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/safety-testing-drug-metabolites\u0022\u003ESafety Testing of Drug Metabolites\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72279\/download\u0022\u003EPDF (107.85 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (107.85 KB) of Safety Testing of Drug Metabolites\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/22\/2016","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Device \u0026amp; Drug Safety, Pharmacology\/Toxicology","field_topics":"","topics-product":"Device \u0026amp; Drug Safety, Pharmacology\/Toxicology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0065\u0022\u003EFDA-2008-D-0065\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-30T14:20:29-04:00\u0022\u003E2020-04-30 14:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/use-nucleic-acid-tests-pooled-and-individual-samples-donors-whole-blood-and-blood-components-0\u0022\u003E Use of Nucleic Acid Tests on Pooled and Individual Samples from Donors of Whole Blood and Blood Components (including Source Plasma and Source Leukocytes) to Adequately and Appropriately Reduce the Risk of Transmission of of HIV-1 and HCV: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/124349\/download\u0022\u003EPDF (54.21 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (54.21 KB) of Use of Nucleic Acid Tests on Pooled and Individual Samples from Donors of Whole Blood and Blood Components (including Source Plasma and Source Leukocytes) to Adequately and Appropriately Reduce the Risk of Transmission of of HIV-1 and HCV: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/21\/2004","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Blood","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2001-D-0095\u0022\u003EFDA-2001-D-0095\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-05-08T10:20:20-04:00\u0022\u003E2024-05-08 10:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/efficacy-studies-support-marketing-fibrin-sealant-products-manufactured-commercial-use\u0022\u003EEfficacy Studies to Support Marketing of Fibrin Sealant Products Manufactured for Commercial Use: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72283\/download\u0022\u003EPDF (12.05 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (12.05 KB) of Efficacy Studies to Support Marketing of Fibrin Sealant Products Manufactured for Commercial Use: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/20\/1999","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1997-D-0186\u0022\u003EFDA-1997-D-0186\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-06-21T10:31:30-04:00\u0022\u003E2024-06-21 10:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/content-and-format-inds-phase-1-studies-drugs-including-well-characterized-therapeutic-biotechnology\u0022\u003EContent and Format of INDs for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-Derived Products. Questions and Answers: Guidance for Industry Q\u0026amp;A\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72284\/download\u0022\u003EPDF (14.19 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (14.19 KB) of Content and Format of INDs for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-Derived Products. Questions and Answers: Guidance for Industry Q\u0026amp;A\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/01\/2000","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Pharmacology\/Toxicology, Investigational New Drug Application (INDA)","field_topics":"","topics-product":"Clinical - Medical, Pharmacology\/Toxicology, Investigational New Drug Application (INDA)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/None found\u0022\u003ENone found\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T14:10:21-04:00\u0022\u003E2020-05-06 14:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/single-dose-acute-toxicity-testing-pharmaceuticals\u0022\u003ESingle Dose Acute Toxicity Testing for Pharmaceuticals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72288\/download\u0022\u003EPDF (62.7 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (62.7 KB) of Single Dose Acute Toxicity Testing for Pharmaceuticals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/26\/1996","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pharmacology\/Toxicology","field_topics":"","topics-product":"Pharmacology\/Toxicology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1992-N-0026\u0022\u003EFDA-1992-N-0026\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T14:55:12-04:00\u0022\u003E2020-04-24 14:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/sample-formats-form-fda-356h_2011\u0022\u003ESample formats for Form FDA 356h_2011\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72293\/download\u0022\u003EPDF (601.16 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (601.16 KB) of Sample formats for Form FDA 356h_2011\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/02\/2011","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2000-D-1542\u0022\u003EFDA-2000-D-1542\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-05-17T15:25:07-04:00\u0022\u003E2021-05-17 15:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/statistical-aspects-design-analysis-and-interpretation-chronic-rodent-carcinogenicity-studies\u0022\u003EStatistical Aspects of the Design, Analysis, and Interpretation of Chronic Rodent Carcinogenicity Studies of Pharmaceuticals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72296\/download\u0022\u003EPDF (135.48 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (135.48 KB) of Statistical Aspects of the Design, Analysis, and Interpretation of Chronic Rodent Carcinogenicity Studies of Pharmaceuticals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/08\/2001","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pharmacology\/Toxicology","field_topics":"","topics-product":"Pharmacology\/Toxicology","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2001-D-0043\u0022\u003EFDA-2001-D-0043\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-01-26T10:50:10-05:00\u0022\u003E2021-01-26 10:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/implementation-section-120-food-and-drug-administration-modernization-act-1997-advisory-committees\u0022\u003EImplementation of Section 120 of the Food and Drug Administration Modernization Act of 1997-Advisory Committees\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72297\/download\u0022\u003EPDF (62.13 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (62.13 KB) of Implementation of Section 120 of the Food and Drug Administration Modernization Act of 1997-Advisory Committees\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/01\/1998","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-26T15:45:17-04:00\u0022\u003E2020-05-26 15:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/submission-chemistry-manufacturing-and-controls-and-establishment-description-information-human\u0022\u003E For the Submission of Chemistry, Manufacturing and Controls and Establishment Description Information for Human Blood and Blood Components Intended for Transfusion or for Further Manufacture and For the Completion of the Form FDA 356h: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/124371\/download\u0022\u003EPDF (94.13 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (94.13 KB) of For the Submission of Chemistry, Manufacturing and Controls and Establishment Description Information for Human Blood and Blood Components Intended for Transfusion or for Further Manufacture and For the Completion of the Form FDA 356h: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/10\/1999","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Blood","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"05\/10\/1999","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1998-D-0995\u0022\u003EFDA-1998-D-0995\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-07-15T10:20:03-04:00\u0022\u003E2024-07-15 10:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/sterility-requirement-aqueous-based-drug-products-oral-inhalation-small-entity-compliance-guide\u0022\u003ESterility Requirement for Aqueous-Based Drug Products for Oral Inhalation \u2014 Small Entity Compliance Guide: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72306\/download\u0022\u003EPDF (17.58 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (17.58 KB) of Sterility Requirement for Aqueous-Based Drug Products for Oral Inhalation \u2014 Small Entity Compliance Guide: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/07\/2001","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Small Entity Compliance Guide","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-04T15:00:23-04:00\u0022\u003E2020-05-04 15:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/estimating-maximum-safe-starting-dose-initial-clinical-trials-therapeutics-adult-healthy-volunteers\u0022\u003EEstimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72309\/download\u0022\u003EPDF (702.04 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (702.04 KB) of Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/28\/2005","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"Pharmacology\/Toxicology","field_topics":"","topics-product":"Pharmacology\/Toxicology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"","changed":"\u003Ctime datetime=\u00222018-12-01T13:25:41-05:00\u0022\u003E2018-12-01 13:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-recommendations-assessment-donor-suitability-and-blood-product-safety-cases\u0022\u003EGuidance for Industry: Recommendations for the Assessment of Donor Suitability and Blood Product Safety in Cases of Suspected Severe Acute Respiratory Syndrome (SARS) or Exposure to SARS\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72313\/download\u0022\u003EPDF (52.27 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (52.27 KB) of Guidance for Industry: Recommendations for the Assessment of Donor Suitability and Blood Product Safety in Cases of Suspected Severe Acute Respiratory Syndrome (SARS) or Exposure to SARS\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/17\/2003","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222019-06-15T12:26:03-04:00\u0022\u003E2019-06-15 12:26\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommendations-deferral-donors-and-quarantine-and-retrieval-blood-and-blood-products-recent\u0022\u003ERecommendations for Deferral of Donors and Quarantine and Retrieval of Blood and Blood Products in Recent Recipients of Smallpox Vaccine (Vaccinia Virus) and Certain Contacts of Smallpox Vaccine Recipients: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/124362\/download\u0022\u003EPDF (46.65 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (46.65 KB) of Recommendations for Deferral of Donors and Quarantine and Retrieval of Blood and Blood Products in Recent Recipients of Smallpox Vaccine (Vaccinia Virus) and Certain Contacts of Smallpox Vaccine Recipients: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/30\/2002","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2002-D-0013\u0022\u003EFDA-2002-D-0013\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-06-13T11:05:46-04:00\u0022\u003E2024-06-13 11:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/integrated-summary-effectiveness\u0022\u003EIntegrated Summary of Effectiveness\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72335\/download\u0022\u003EPDF (274.45 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (274.45 KB) of Integrated Summary of Effectiveness\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/08\/2015","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0449\u0022\u003EFDA-2008-D-0449\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-02-25T16:20:06-05:00\u0022\u003E2022-02-25 16:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/content-and-format-chemistry-manufacturing-and-controls-information-and-establishment-description-0\u0022\u003EContent and Format of Chemistry, Manufacturing and Controls Information and Establishment Description Information for a Biological In Vitro Diagnostic Product: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/124394\/download\u0022\u003EPDF (47.63 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (47.63 KB) of Content and Format of Chemistry, Manufacturing and Controls Information and Establishment Description Information for a Biological In Vitro Diagnostic Product: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/08\/1999","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1998-D-0689\u0022\u003EFDA-1998-D-0689\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-07-15T10:14:31-04:00\u0022\u003E2024-07-15 10:14\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/user-fee-waivers-reductions-and-refunds-drug-and-biological-products\u0022\u003EUser Fee Waivers, Reductions, and Refunds for Drug and Biological Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72340\/download\u0022\u003EPDF (152.59 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (152.59 KB) of User Fee Waivers, Reductions, and Refunds for Drug and Biological Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/27\/2011","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"User Fees","topics-product":"User Fees, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0108\u0022\u003EFDA-2011-D-0108\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T09:40:04-04:00\u0022\u003E2020-05-06 09:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/levothyroxine-sodium-products-enforcement-august-14-2001-compliance-date-and-submission-new\u0022\u003ELevothyroxine Sodium Products Enforcement of August 14, 2001 Compliance Date and Submission of New Applications\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72341\/download\u0022\u003EPDF (24.32 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (24.32 KB) of Levothyroxine Sodium Products Enforcement of August 14, 2001 Compliance Date and Submission of New Applications\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/13\/2001","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-02-01T11:10:03-05:00\u0022\u003E2021-02-01 11:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-premarket-notification-510k-submissions-automated-endoscope-washers-washerdisinfectors-and\u0022\u003EGuidance on Premarket Notification [510(k)] Submissions for Automated Endoscope Washers, Washer\/Disinfectors, and Disinfectors Intended for Use in Health Care Facilities\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72345\/download\u0022\u003EPDF (954.92 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (954.92 KB) of Guidance on Premarket Notification [510(k)] Submissions for Automated Endoscope Washers, Washer\/Disinfectors, and Disinfectors Intended for Use in Health Care Facilities\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/01\/1993","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k)","field_topics":"Premarket","topics-product":"Premarket, 510(k)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-17T12:35:59-04:00\u0022\u003E2020-03-17 12:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/fees-exceed-costs-waivers-under-prescription-drug-user-fee-act\u0022\u003EFees-Exceed-the-Costs Waivers Under the Prescription Drug User Fee Act\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72352\/download\u0022\u003EPDF (48.22 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (48.22 KB) of Fees-Exceed-the-Costs Waivers Under the Prescription Drug User Fee Act\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/01\/1999","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"User Fees","topics-product":"User Fees, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-03-15T11:20:16-04:00\u0022\u003E2019-03-15 11:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/submission-chemistry-manufacturing-and-controls-and-establishment-description-information-human-0\u0022\u003EFor the Submission of Chemistry, Manufacturing and Controls and Establishment Description Information for Human Plasma-Derived Biological Products, Animal Plasma or Serum-Derived Products: Guidance for Industry:\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/124397\/download\u0022\u003EPDF (39.77 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (39.77 KB) of For the Submission of Chemistry, Manufacturing and Controls and Establishment Description Information for Human Plasma-Derived Biological Products, Animal Plasma or Serum-Derived Products: Guidance for Industry:\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/17\/1999","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1998-D-0405\u0022\u003EFDA-1998-D-0405\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-07-15T10:06:31-04:00\u0022\u003E2024-07-15 10:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-premarket-notification-510k-submissions-surgical-gowns-and-surgical-drapes\u0022\u003EGuidance on Premarket Notification [510(k)] Submissions for Surgical Gowns and Surgical Drapes\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72369\/download\u0022\u003EPDF (635.1 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (635.1 KB) of Guidance on Premarket Notification [510(k)] Submissions for Surgical Gowns and Surgical Drapes\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/01\/1993","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k)","field_topics":"Premarket","topics-product":"Premarket, 510(k)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-17T12:30:06-04:00\u0022\u003E2020-03-17 12:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/submitting-separate-marketing-applications-and-clinical-data-purposes-assessing-user-fees\u0022\u003ESubmitting Separate Marketing Applications and Clinical Data for Purposes of Assessing User Fees: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72397\/download\u0022\u003EPDF (211.49 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (211.49 KB) of Submitting Separate Marketing Applications and Clinical Data for Purposes of Assessing User Fees: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/03\/2005","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"User Fees","topics-product":"User Fees, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2001-D-0134\u0022\u003EFDA-2001-D-0134\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222020-05-05T10:55:15-04:00\u0022\u003E2020-05-05 10:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-human-somatic-cell-therapy-and-gene-therapy\u0022\u003EGuidance for Human Somatic Cell Therapy and Gene Therapy: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72402\/download\u0022\u003EPDF (93.25 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (93.25 KB) of Guidance for Human Somatic Cell Therapy and Gene Therapy: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/1998","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Gene Therapy","field_topics":"Cellular \u0026amp; Gene Therapy","topics-product":"Cellular \u0026amp; Gene Therapy, Gene Therapy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0132-0016\u0022\u003EFDA-2009-D-0132-0016\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222021-04-21T10:46:03-04:00\u0022\u003E2021-04-21 10:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/user-fee-waivers-fdc-and-co-packaged-hiv-drugs-pepfar\u0022\u003EUser Fee Waivers for FDC and Co-Packaged HIV Drugs for PEPFAR\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72406\/download\u0022\u003EPDF (45.96 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (45.96 KB) of User Fee Waivers for FDC and Co-Packaged HIV Drugs for PEPFAR\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/08\/2007","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"User Fees","topics-product":"User Fees, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2005-D-0083\u0022\u003EFDA-2005-D-0083\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-05T17:05:10-04:00\u0022\u003E2020-05-05 17:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/180-day-generic-drug-exclusivity-under-hatch-waxman-amendments-federal-food-drug-and-cosmetic-act\u0022\u003E180-Day Generic Drug Exclusivity Under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72414\/download\u0022\u003EPDF (77.08 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (77.08 KB) of 180-Day Generic Drug Exclusivity Under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/01\/1998","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Generic Drugs","field_topics":"","topics-product":"Administrative \/ Procedural, Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1998-D-101c\u0022\u003EFDA-1998-D-101c\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-21T14:50:07-04:00\u0022\u003E2020-04-21 14:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/enforcement-policy-marketing-otc-combination-products-cpg-7132b16\u0022\u003EEnforcement Policy on Marketing OTC Combination Products (CPG 7132b.16).\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72417\/download\u0022\u003EPDF (293.59 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (293.59 KB) of Enforcement Policy on Marketing OTC Combination Products (CPG 7132b.16).\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/01\/1984","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Over-the-Counter Drugs","field_topics":"","topics-product":"Over-the-Counter Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-04-10T11:25:08-04:00\u0022\u003E2019-04-10 11:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/applications-covered-section-505b2\u0022\u003EApplications Covered by Section 505(b)(2)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72419\/download\u0022\u003EPDF (41.41 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (41.41 KB) of Applications Covered by Section 505(b)(2)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/08\/1999","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1999-D-0738\u0022\u003EFDA-1999-D-0738\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-02-01T11:05:03-05:00\u0022\u003E2021-02-01 11:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pharmacogenomic-data-submissions\u0022\u003EPharmacogenomic Data Submissions: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/122944\/download\u0022\u003EPDF (179.08 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (179.08 KB) of Pharmacogenomic Data Submissions: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/2005","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Good Clinical Practice (GCP)","field_topics":"","topics-product":"Administrative \/ Procedural, Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2003-D-0031\u0022\u003EFDA-2003-D-0031\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222020-04-27T10:01:01-04:00\u0022\u003E2020-04-27 10:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/general-guidelines-otc-combination-products\u0022\u003EGeneral Guidelines for OTC Combination Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72423\/download\u0022\u003EPDF (270.2 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (270.2 KB) of General Guidelines for OTC Combination Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/01\/1978","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Over-the-Counter Drugs","field_topics":"","topics-product":"Over-the-Counter Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-04-10T11:30:09-04:00\u0022\u003E2019-04-10 11:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pharmacogenomic-data-submissions-examples-voluntary-submissions-or-submissions-required-under-21-cfr\u0022\u003EPharmacogenomic Data Submissions; Examples of Voluntary Submissions or Submissions Required Under 21 CFR 312, 314, or 601\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72428\/download\u0022\u003EPDF (63.39 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (63.39 KB) of Pharmacogenomic Data Submissions; Examples of Voluntary Submissions or Submissions Required Under 21 CFR 312, 314, or 601\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/2005","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-06-15T12:33:39-04:00\u0022\u003E2019-06-15 12:33\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pharmacogenomic-data-submissions-companion-guidance\u0022\u003EPharmacogenomic Data Submissions \u2014 Companion Guidance\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72431\/download\u0022\u003EPDF (211.18 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (211.18 KB) of Pharmacogenomic Data Submissions \u2014 Companion Guidance\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/28\/2007","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2007-D-0136\u0022\u003EFDA-2007-D-0136\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-27T09:55:31-04:00\u0022\u003E2020-04-27 09:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/labeling-otc-human-drug-products-questions-and-answers\u0022\u003ELabeling OTC Human Drug Products -- Questions and Answers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72441\/download\u0022\u003EPDF (598.82 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (598.82 KB) of Labeling OTC Human Drug Products -- Questions and Answers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/05\/2009","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Over-the-Counter Drugs","field_topics":"","topics-product":"Over-the-Counter Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-D-0437\u0022\u003EFDA-2004-D-0437\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T01:50:22-04:00\u0022\u003E2020-04-24 01:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-premarket-notification-510k-sterilizers-intended-use-health-care-facilities\u0022\u003EGuidance on Premarket Notification 510(k) for Sterilizers Intended for Use in Health Care Facilities\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72458\/download\u0022\u003EPDF (843.41 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (843.41 KB) of Guidance on Premarket Notification 510(k) for Sterilizers Intended for Use in Health Care Facilities\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/1993","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k)","field_topics":"Premarket","topics-product":"Premarket, 510(k)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-17T11:22:27-04:00\u0022\u003E2020-03-17 11:22\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/review-guidelines-oxygen-generators-and-oxygen-equipment-emergency-use\u0022\u003EReview Guidelines for Oxygen Generators and Oxygen Equipment for Emergency Use\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"01\/01\/1977","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222021-04-27T10:05:08-04:00\u0022\u003E2021-04-27 10:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/shelf-life-medical-devices\u0022\u003EShelf Life of Medical Devices\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72487\/download\u0022\u003EPDF (1.75 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.75 MB) of Shelf Life of Medical Devices\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/01\/1991","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-17T10:45:32-04:00\u0022\u003E2020-03-17 10:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/postmarketing-adverse-event-reporting-medical-products-and-dietary-supplements-during-pandemic\u0022\u003EPostmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During a Pandemic\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72498\/download\u0022\u003EPDF (394.46 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (394.46 KB) of Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During a Pandemic\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/11\/2020","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Safety - Issues, Errors, and Problems","field_topics":"","topics-product":"Safety - Issues, Errors, and Problems","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0610\u0022\u003EFDA-2008-D-0610\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Dietary Supplements, Drugs","changed":"\u003Ctime datetime=\u00222024-12-17T15:58:01-05:00\u0022\u003E2024-12-17 15:58\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/potassium-iodide-thyroid-blocking-agent-radiation-emergencies\u0022\u003EPotassium Iodide as a Thyroid Blocking Agent in Radiation Emergencies\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72510\/download\u0022\u003EPDF (39.94 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (39.94 KB) of Potassium Iodide as a Thyroid Blocking Agent in Radiation Emergencies\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/11\/2001","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2000-D-1403\u0022\u003EFDA-2000-D-1403\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-07T22:20:09-04:00\u0022\u003E2020-04-07 22:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/potassium-iodide-ki-radiation-emergencies-questions-and-answers\u0022\u003E(Potassium Iodide) KI in Radiation Emergencies-Questions and Answers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72515\/download\u0022\u003EPDF (161.11 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (161.11 KB) of (Potassium Iodide) KI in Radiation Emergencies-Questions and Answers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/23\/2002","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/None found\u0022\u003ENone found\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-02-01T11:25:16-05:00\u0022\u003E2021-02-01 11:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/potassium-iodide-tablets-shelf-life-extension\u0022\u003EPotassium Iodide Tablets - Shelf Life Extension\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72521\/download\u0022\u003EPDF (191.25 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (191.25 KB) of Potassium Iodide Tablets - Shelf Life Extension\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/08\/2004","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2003-D-0029\u0022\u003EFDA-2003-D-0029\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-02-01T11:38:50-05:00\u0022\u003E2021-02-01 11:38\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-oxygen-conserving-device-510k-review-73-bzd-8685905-non-continuous-ventilator-class-ii\u0022\u003EGuidance for Oxygen Conserving Device 510(k) Review 73 BZD 868.5905 Non-continuous Ventilator Class II\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72527\/download\u0022\u003EPDF (99.57 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (99.57 KB) of Guidance for Oxygen Conserving Device 510(k) Review 73 BZD 868.5905 Non-continuous Ventilator Class II\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/01\/1989","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k)","field_topics":"Premarket","topics-product":"Premarket, 510(k)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-17T10:20:16-04:00\u0022\u003E2020-03-17 10:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/repeal-section-507-federal-food-drug-and-cosmetic-act-_1\u0022\u003ERepeal of Section 507 of the Federal Food, Drug and Cosmetic Act _1\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72530\/download\u0022\u003EPDF (84.7 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (84.7 KB) of Repeal of Section 507 of the Federal Food, Drug and Cosmetic Act _1\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/15\/1998","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1998-D-0864\u0022\u003EFDA-1998-D-0864\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-26T16:10:02-04:00\u0022\u003E2020-05-26 16:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/blood-establishment-computer-system-validation-users-facility\u0022\u003EBlood Establishment Computer System Validation in the User\u0026#039;s Facility: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72533\/download\u0022\u003EPDF (65.58 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (65.58 KB) of Blood Establishment Computer System Validation in the User\u0026#039;s Facility: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/01\/2013","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2007-D-0069\u0022\u003EFDA-2007-D-0069\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222019-05-15T11:40:04-04:00\u0022\u003E2019-05-15 11:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/reports-status-postmarketing-study-commitments-implementation-section-130-food-and-drug\u0022\u003EReports on the Status of Postmarketing Study Commitments \u2014 Implementation of Section 130 of the Food and Drug Administration Modernization Act of 1997\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72535\/download\u0022\u003EPDF (455.98 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (455.98 KB) of Reports on the Status of Postmarketing Study Commitments \u2014 Implementation of Section 130 of the Food and Drug Administration Modernization Act of 1997\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/16\/2006","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1999-N-0098\u0022\u003EFDA-1999-N-0098\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-02-01T11:30:24-05:00\u0022\u003E2021-02-01 11:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/master-files-part-iii-guidance-scientific-and-technical-information\u0022\u003EMaster Files Part III - Guidance on Scientific and Technical Information\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72543\/download\u0022\u003EPDF (317.65 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (317.65 KB) of Master Files Part III - Guidance on Scientific and Technical Information\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/01\/1987","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-17T09:54:32-04:00\u0022\u003E2020-03-17 09:54\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/submitting-and-reviewing-complete-responses-clinical-holds-revised\u0022\u003ESubmitting and Reviewing Complete Responses to Clinical Holds (Revised)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72548\/download\u0022\u003EPDF (25.51 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (25.51 KB) of Submitting and Reviewing Complete Responses to Clinical Holds (Revised)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/01\/2000","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Good Clinical Practice (GCP)","field_topics":"","topics-product":"Administrative \/ Procedural, Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1998-D-0279\u0022\u003EFDA-1998-D-0279\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222020-05-05T10:35:08-04:00\u0022\u003E2020-05-05 10:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/submitting-debarment-certification-statements\u0022\u003ESubmitting Debarment Certification Statements\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72557\/download\u0022\u003EPDF (143.85 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (143.85 KB) of Submitting Debarment Certification Statements\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/02\/1998","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Veterinary Medicine","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1998-D-0556\u0022\u003EFDA-1998-D-0556\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Drugs","changed":"\u003Ctime datetime=\u00222020-05-05T10:35:04-04:00\u0022\u003E2020-05-05 10:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/submitting-marketing-applications-according-ichctd-format-general-considerations-2001\u0022\u003ESubmitting Marketing Applications According to the ICH\/CTD Format: General Considerations 2001\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/05\/2001","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, ICH-Multidisciplinary","field_topics":"","topics-product":"Administrative \/ Procedural, ICH-Multidisciplinary","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2001-D-0061\u0022\u003EFDA-2001-D-0061\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-05T10:50:11-04:00\u0022\u003E2020-05-05 10:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/tropical-disease-priority-review-vouchers\u0022\u003ETropical Disease Priority Review Vouchers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72569\/download\u0022\u003EPDF (274.97 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (274.97 KB) of Tropical Disease Priority Review Vouchers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/06\/2016","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Over-the-Counter Drugs","field_topics":"","topics-product":"Administrative \/ Procedural, Over-the-Counter Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0530\u0022\u003EFDA-2008-D-0530\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222026-10-28T09:44:10-04:00\u0022\u003E2026-10-28 09:44\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/useful-written-consumer-medication-information-cmi\u0022\u003EUseful Written Consumer Medication Information (CMI)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72574\/download\u0022\u003EPDF (278.35 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (278.35 KB) of Useful Written Consumer Medication Information (CMI)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/18\/2006","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2005-D-0397\u0022\u003EFDA-2005-D-0397\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-01-26T09:42:52-05:00\u0022\u003E2021-01-26 09:42\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recognition-and-use-standard-uniform-blood-and-blood-component-container-labels\u0022\u003ERecognition and Use of a Standard for Uniform Blood and Blood Component Container Labels: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72586\/download\u0022\u003EPDF (206.79 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (206.79 KB) of Recognition and Use of a Standard for Uniform Blood and Blood Component Container Labels: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/30\/2024","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1998-D-0067\u0022\u003EFDA-1998-D-0067\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-05-21T11:31:13-04:00\u0022\u003E2024-05-21 11:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/labeling-otc-human-drug-products-updating-labeling-rlds-and-andas\u0022\u003ELabeling OTC Human Drug Products Updating Labeling in RLDs and ANDAs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72594\/download\u0022\u003EPDF (29.54 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (29.54 KB) of Labeling OTC Human Drug Products Updating Labeling in RLDs and ANDAs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/18\/2002","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Over-the-Counter Drugs","field_topics":"","topics-product":"Over-the-Counter Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2001-D-0135\u0022\u003EFDA-2001-D-0135\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T15:35:09-04:00\u0022\u003E2020-04-24 15:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/30-day-notices-135-day-premarket-approval-pma-supplements-and-75-day-humanitarian-device-exemption\u0022\u003E30-Day Notices, 135-Day Premarket Approval (PMA) Supplements and 75-Day Humanitarian Device Exemption (HDE) Supplements for Manufacturing Method or Process Changes: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72663\/download\u0022\u003EPDF (189.8 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (189.8 KB) of 30-Day Notices, 135-Day Premarket Approval (PMA) Supplements and 75-Day Humanitarian Device Exemption (HDE) Supplements for Manufacturing Method or Process Changes: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/16\/2019","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Device \u0026amp; Drug Safety, HUD\/HDE, Premarket Approval (PMA)","field_topics":"Premarket","topics-product":"Premarket, Administrative \/ Procedural, Device \u0026amp; Drug Safety, HUD\/HDE, Premarket Approval (PMA)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1998-D-0281\u0022\u003EFDA-1998-D-0281\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222021-01-26T10:35:15-05:00\u0022\u003E2021-01-26 10:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/de-novo-classification-process-evaluation-automatic-class-iii-designation\u0022\u003EDe Novo Classification Process (Evaluation of Automatic Class III Designation): Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72674\/download\u0022\u003EPDF (683.56 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (683.56 KB) of De Novo Classification Process (Evaluation of Automatic Class III Designation): Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/05\/2021","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"Premarket","topics-product":"Premarket, Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0689\u0022\u003EFDA-2011-D-0689\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222022-02-18T17:00:21-05:00\u0022\u003E2022-02-18 17:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-content-premarket-notifications-urine-drainage-bags\u0022\u003EGuidance for the Content of Premarket Notifications for Urine Drainage Bags\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72716\/download\u0022\u003EPDF (500.32 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (500.32 KB) of Guidance for the Content of Premarket Notifications for Urine Drainage Bags\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/07\/1994","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k)","field_topics":"Premarket","topics-product":"Premarket, 510(k)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-17T13:00:41-04:00\u0022\u003E2020-03-17 13:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/latex-condoms-men-information-510k-premarket-notifications-use-consensus-standards-abbreviated\u0022\u003ELatex Condoms for Men - Information for 510(k) Premarket Notifications: Use of Consensus Standards for Abbreviated Submissions: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72943\/download\u0022\u003EPDF (145.88 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (145.88 KB) of Latex Condoms for Men - Information for 510(k) Premarket Notifications: Use of Consensus Standards for Abbreviated Submissions: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/23\/1998","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k)","field_topics":"Premarket","topics-product":"Premarket, 510(k)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-18T12:30:19-04:00\u0022\u003E2020-03-18 12:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/eligibility-determination-donors-human-cells-tissues-and-cellular-and-tissue-based-products\u0022\u003EEligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73072\/download\u0022\u003EPDF (502.42 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (502.42 KB) of Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/08\/2007","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Gene Therapy","field_topics":"Cellular \u0026amp; Gene Therapy","topics-product":"Cellular \u0026amp; Gene Therapy, Gene Therapy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-D-0225\u0022\u003EFDA-2004-D-0225\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-05-02T09:42:16-04:00\u0022\u003E2024-05-02 09:42\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q4b-annex-6-uniformity-dosage-units-general-chapter\u0022\u003EQ4B Annex 6: Uniformity of Dosage Units General Chapter\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73112\/download\u0022\u003EPDF (53.18 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (53.18 KB) of Q4B Annex 6: Uniformity of Dosage Units General Chapter\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/16\/2014","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0011\u0022\u003EFDA-2009-D-0011\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T13:35:07-04:00\u0022\u003E2020-05-06 13:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommendations-obtaining-labeling-claim-communicable-disease-donor-screening-tests-using-cadaveric\u0022\u003ERecommendations for Obtaining a Labeling Claim for Communicable Disease Donor Screening Tests Using Cadaveric Blood Specimens from Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\/Ps): Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73121\/download\u0022\u003EPDF (33.12 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (33.12 KB) of Recommendations for Obtaining a Labeling Claim for Communicable Disease Donor Screening Tests Using Cadaveric Blood Specimens from Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\/Ps): Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/01\/2004","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling, Tissue","field_topics":"","topics-product":"Labeling, Tissue","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2005-D-0273\u0022\u003EFDA-2005-D-0273\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-05-08T10:15:02-04:00\u0022\u003E2024-05-08 10:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q4b-annex-7-r2-dissolution-test-general-chapter\u0022\u003EQ4B Annex 7 (R2): Dissolution Test General Chapter\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73122\/download\u0022\u003EPDF (101.62 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (101.62 KB) of Q4B Annex 7 (R2): Dissolution Test General Chapter\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/24\/2011","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0012\u0022\u003EFDA-2009-D-0012\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T13:40:27-04:00\u0022\u003E2020-05-06 13:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/real-time-premarket-approval-application-pma-supplements\u0022\u003EReal-Time Premarket Approval Application (PMA) Supplements: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73126\/download\u0022\u003EPDF (122.66 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (122.66 KB) of Real-Time Premarket Approval Application (PMA) Supplements: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/16\/2019","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Device \u0026amp; Drug Safety, Premarket Approval (PMA)","field_topics":"Premarket","topics-product":"Premarket, Administrative \/ Procedural, Device \u0026amp; Drug Safety, Premarket Approval (PMA)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-5971\u0022\u003EFDA-2017-D-5971\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-24T12:00:12-04:00\u0022\u003E2020-03-24 12:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q4b-annex-8-sterility-test-general-chapter\u0022\u003EQ4B Annex 8: Sterility Test General Chapter\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73134\/download\u0022\u003EPDF (68.49 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (68.49 KB) of Q4B Annex 8: Sterility Test General Chapter\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/22\/2009","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0013\u0022\u003EFDA-2009-D-0013\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T13:50:37-04:00\u0022\u003E2020-05-06 13:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/general-principles-software-validation\u0022\u003EGeneral Principles of Software Validation: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73141\/download\u0022\u003EPDF (239.78 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (239.78 KB) of General Principles of Software Validation: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/11\/2002","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Digital Health, Good Clinical Practice (GCP)","field_topics":"Premarket","topics-product":"Premarket, Digital Health, Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1997-D-0029\u0022\u003EFDA-1997-D-0029\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222025-09-23T09:25:46-04:00\u0022\u003E2025-09-23 09:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/s9-nonclinical-evaluation-anticancer-pharmaceuticals\u0022\u003ES9 Nonclinical Evaluation for Anticancer Pharmaceuticals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73161\/download\u0022\u003EPDF (169.33 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (169.33 KB) of S9 Nonclinical Evaluation for Anticancer Pharmaceuticals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/08\/2010","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Safety","field_topics":"","topics-product":"ICH-Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/ FDA-2009-D-0006\u0022\u003E FDA-2009-D-0006\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222020-04-30T14:15:35-04:00\u0022\u003E2020-04-30 14:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/least-burdensome-provisions-concept-and-principles\u0022\u003EThe Least Burdensome Provisions: Concept and Principles: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73188\/download\u0022\u003EPDF (483.29 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (483.29 KB) of The Least Burdensome Provisions: Concept and Principles: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/05\/2019","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6702\u0022\u003EFDA-2017-D-6702\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222020-10-20T15:21:08-04:00\u0022\u003E2020-10-20 15:21\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/validation-procedures-processing-human-tissues-intended-transplantation\u0022\u003EValidation of Procedures for Processing of Human Tissues Intended for Transplantation: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73242\/download\u0022\u003EPDF (16.71 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (16.71 KB) of Validation of Procedures for Processing of Human Tissues Intended for Transplantation: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/08\/2002","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Tissue","field_topics":"","topics-product":"Tissue","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2002-D-0181\u0022\u003EFDA-2002-D-0181\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-06-13T11:16:06-04:00\u0022\u003E2024-06-13 11:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/influenza-developing-drugs-treatment-andor-prophylaxis\u0022\u003EInfluenza: Developing Drugs for Treatment and\/or Prophylaxis\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73339\/download\u0022\u003EPDF (417.45 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (417.45 KB) of Influenza: Developing Drugs for Treatment and\/or Prophylaxis\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/13\/2011","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0044\u0022\u003EFDA-2009-D-0044\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-02-01T11:20:28-05:00\u0022\u003E2021-02-01 11:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/annual-reports-approved-premarket-approval-applications-pma\u0022\u003EAnnual Reports for Approved Premarket Approval Applications (PMA) : Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73391\/download\u0022\u003EPDF (214.25 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (214.25 KB) of Annual Reports for Approved Premarket Approval Applications (PMA) : Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/16\/2019","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Device \u0026amp; Drug Safety, Premarket Approval (PMA)","field_topics":"Premarket","topics-product":"Premarket, Administrative \/ Procedural, Device \u0026amp; Drug Safety, Premarket Approval (PMA)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2006-D-0039\u0022\u003EFDA-2006-D-0039\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-10-20T10:50:37-04:00\u0022\u003E2020-10-20 10:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/bundling-multiple-devices-or-multiple-indications-single-submission\u0022\u003EBundling Multiple Devices or Multiple Indications in a Single Submission: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73500\/download\u0022\u003EPDF (439.01 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (439.01 KB) of Bundling Multiple Devices or Multiple Indications in a Single Submission: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/22\/2007","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2003-D-0376\u0022\u003EFDA-2003-D-0376\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222020-02-28T13:15:17-05:00\u0022\u003E2020-02-28 13:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/fda-and-industry-actions-premarket-approval-applications-pmas-effect-fda-review-clock-and-goals\u0022\u003EFDA and Industry Actions on Premarket Approval Applications (PMAs): Effect on FDA Review Clock and Goals: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73504\/download\u0022\u003EPDF (471.95 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (471.95 KB) of FDA and Industry Actions on Premarket Approval Applications (PMAs): Effect on FDA Review Clock and Goals: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/03\/2022","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Premarket Approval (PMA)","field_topics":"Premarket","topics-product":"Premarket, Premarket Approval (PMA)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2003-D-0378\u0022\u003EFDA-2003-D-0378\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222022-10-06T06:26:16-04:00\u0022\u003E2022-10-06 06:26\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/fda-and-industry-actions-premarket-notification-510k-submissions-effect-fda-review-clock-and-goals\u0022\u003EFDA and Industry Actions on Premarket Notification (510(k)) Submissions: Effect on FDA Review Clock and Goals: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73507\/download\u0022\u003EPDF (516.34 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (516.34 KB) of FDA and Industry Actions on Premarket Notification (510(k)) Submissions: Effect on FDA Review Clock and Goals: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/03\/2022","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k)","field_topics":"Premarket","topics-product":"Premarket, 510(k)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2003-D-0033\u0022\u003EFDA-2003-D-0033\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222022-10-03T17:36:47-04:00\u0022\u003E2022-10-03 17:36\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/premarket-assessment-pediatric-medical-devices\u0022\u003EPremarket Assessment of Pediatric Medical Devices: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73510\/download\u0022\u003EPDF (213.07 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (213.07 KB) of Premarket Assessment of Pediatric Medical Devices: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/24\/2014","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Pediatric Product Development","field_topics":"Premarket","topics-product":"Premarket, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2003-D-0367\u0022\u003EFDA-2003-D-0367\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222024-04-11T09:29:04-04:00\u0022\u003E2024-04-11 09:29\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/premarket-approval-application-and-humanitarian-device-exemption-modular-review\u0022\u003EPremarket Approval Application and Humanitarian Device Exemption Modular Review: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73513\/download\u0022\u003EPDF (610.09 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (610.09 KB) of Premarket Approval Application and Humanitarian Device Exemption Modular Review: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/13\/2025","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-5332\u0022\u003EFDA-2024-D-5332\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222025-01-13T09:01:42-05:00\u0022\u003E2025-01-13 09:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/compliance-21-cfr-part-1271150c1-manufacturing-arrangements\u0022\u003ECompliance with 21 CFR Part 1271.150(c)(1) \u2013 Manufacturing Arrangements: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73522\/download\u0022\u003EPDF (45.62 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (45.62 KB) of Compliance with 21 CFR Part 1271.150(c)(1) \u2013 Manufacturing Arrangements: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/08\/2006","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Tissue","field_topics":"Compliance","topics-product":"Compliance, Tissue","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222019-05-17T11:20:12-04:00\u0022\u003E2019-05-17 11:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/fda-review-vaccine-labeling-requirements-warnings-use-instructions-and-precautionary-information\u0022\u003EFDA Review of Vaccine Labeling Requirements for Warnings, Use Instructions, and Precautionary Information: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73544\/download\u0022\u003EPDF (32.78 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (32.78 KB) of FDA Review of Vaccine Labeling Requirements for Warnings, Use Instructions, and Precautionary Information: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/01\/2004","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Pediatric Product Development, Vaccines","field_topics":"","topics-product":"Pediatric Product Development, Vaccines","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-D-0286\u0022\u003EFDA-2004-D-0286\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-06-13T09:39:02-04:00\u0022\u003E2024-06-13 09:39\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/postmarketing-safety-reporting-human-drug-and-biological-products-including-vaccines\u0022\u003EPostmarketing Safety Reporting for Human Drug and Biological Products Including Vaccines: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73593\/download\u0022\u003EPDF (380.54 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (380.54 KB) of Postmarketing Safety Reporting for Human Drug and Biological Products Including Vaccines: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/12\/2001","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Safety - Issues, Errors, and Problems, Vaccines","field_topics":"","topics-product":"Safety - Issues, Errors, and Problems, Vaccines","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/ FDA-2001-D-0506\u0022\u003E FDA-2001-D-0506\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222020-04-27T10:50:03-04:00\u0022\u003E2020-04-27 10:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/walk-workstations-laser-notice-37\u0022\u003EWalk-In Workstations (Laser Notice 37)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73615\/download\u0022\u003EPDF (85.64 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (85.64 KB) of Walk-In Workstations (Laser Notice 37)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/21\/1985","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-17T09:51:45-04:00\u0022\u003E2020-03-17 09:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/policy-warning-label-required-sunlamp-products\u0022\u003EPolicy on Warning Label Required on Sunlamp Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73620\/download\u0022\u003EPDF (71.19 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (71.19 KB) of Policy on Warning Label Required on Sunlamp Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/25\/1985","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-17T09:45:11-04:00\u0022\u003E2020-03-17 09:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/user-instruction-hazard-warnings-laser-notice-35\u0022\u003EUser Instruction Hazard Warnings (Laser Notice 35) \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73627\/download\u0022\u003EPDF (62.8 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (62.8 KB) of User Instruction Hazard Warnings (Laser Notice 35) \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/05\/1985","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Laser Notice","field_topics":"","topics-product":"Laser Notice","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222021-01-26T10:35:02-05:00\u0022\u003E2021-01-26 10:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/medical-laser-delivery-system-interlocks-laser-notice-34\u0022\u003EMedical Laser Delivery System Interlocks (Laser Notice 34) \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73634\/download\u0022\u003EPDF (90.27 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (90.27 KB) of Medical Laser Delivery System Interlocks (Laser Notice 34) \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/20\/1985","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-17T09:40:02-04:00\u0022\u003E2020-03-17 09:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/exemption-reporting-and-record-keeping-requirements-certain-sunlamp-product-manufacturers\u0022\u003EExemption from Reporting and Record keeping Requirements for Certain Sunlamp Product Manufacturers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73639\/download\u0022\u003EPDF (74.01 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (74.01 KB) of Exemption from Reporting and Record keeping Requirements for Certain Sunlamp Product Manufacturers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/16\/1981","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-17T09:30:14-04:00\u0022\u003E2020-03-17 09:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/investigational-medical-laser-significant-risk-device-laser-notice-31\u0022\u003EInvestigational Medical Laser Significant Risk Device (Laser Notice 31)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73645\/download\u0022\u003EPDF (116.98 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (116.98 KB) of Investigational Medical Laser Significant Risk Device (Laser Notice 31)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/18\/1981","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Laser Notice","field_topics":"","topics-product":"Laser Notice","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222021-01-26T10:35:09-05:00\u0022\u003E2021-01-26 10:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/alternate-wording-caution-statement-laser-notice-30\u0022\u003EAlternate Wording For Caution Statement (Laser Notice 30) \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73660\/download\u0022\u003EPDF (70.66 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (70.66 KB) of Alternate Wording For Caution Statement (Laser Notice 30) \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/25\/1980","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Radiology","field_topics":"","topics-product":"Radiology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-17T09:25:12-04:00\u0022\u003E2020-03-17 09:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/considerations-plasmid-dna-vaccines-infectious-disease-indications\u0022\u003EConsiderations for Plasmid DNA Vaccines for Infectious Disease Indications: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73667\/download\u0022\u003EPDF (87.65 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (87.65 KB) of Considerations for Plasmid DNA Vaccines for Infectious Disease Indications: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/01\/2007","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Vaccines","field_topics":"","topics-product":"Vaccines","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2005-D-0211\u0022\u003EFDA-2005-D-0211\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-04-23T15:45:17-04:00\u0022\u003E2024-04-23 15:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/assay-migration-studies-in-vitro-diagnostic-devices\u0022\u003EAssay Migration Studies for In Vitro Diagnostic Devices: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73669\/download\u0022\u003EPDF (1.21 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.21 MB) of Assay Migration Studies for In Vitro Diagnostic Devices: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/25\/2013","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Laboratory Tests, IVDs (In Vitro Diagnostic Devices)","field_topics":"Premarket","topics-product":"Premarket, Laboratory Tests, IVDs (In Vitro Diagnostic Devices)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0642\u0022\u003EFDA-2008-D-0642\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-02-28T14:30:12-05:00\u0022\u003E2020-02-28 14:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/exemption-certain-lasers-used-doe-noaa-and-us-dept-commerce-laser-notice-25\u0022\u003EExemption of Certain Lasers Used By DOE, NOAA and U.S. Dept. of Commerce (Laser Notice 25)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73678\/download\u0022\u003EPDF (116.62 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (116.62 KB) of Exemption of Certain Lasers Used By DOE, NOAA and U.S. Dept. of Commerce (Laser Notice 25)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/14\/1979","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Radiological Health","field_topics":"","topics-product":"Radiological Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Memorandum","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-17T09:15:08-04:00\u0022\u003E2020-03-17 09:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clinical-data-needed-support-licensure-pandemic-influenza-vaccines\u0022\u003EClinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73691\/download\u0022\u003EPDF (187.68 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (187.68 KB) of Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/31\/2007","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Vaccines","field_topics":"","topics-product":"Vaccines","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2006-D-0351\u0022\u003EFDA-2006-D-0351\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-05-02T10:15:31-04:00\u0022\u003E2024-05-02 10:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/laser-light-shows-subject-laser-product-performance-standard-laser-notice-22\u0022\u003ELaser Light Shows Subject to Laser Product Performance Standard (Laser Notice 22)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73704\/download\u0022\u003EPDF (154.43 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (154.43 KB) of Laser Light Shows Subject to Laser Product Performance Standard (Laser Notice 22)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/23\/1977","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-17T09:15:15-04:00\u0022\u003E2020-03-17 09:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clinical-data-needed-support-licensure-seasonal-inactivated-influenza-vaccines\u0022\u003EClinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73706\/download\u0022\u003EPDF (165.68 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (165.68 KB) of Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/31\/2007","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Vaccines","field_topics":"","topics-product":"Vaccines","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2006-D-0222\u0022\u003EFDA-2006-D-0222\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-05-02T10:18:17-04:00\u0022\u003E2024-05-02 10:18\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/warning-labels-dye-and-multiple-wavelength-lasers-laser-notice-16\u0022\u003EWarning Labels For Dye And Multiple Wavelength Lasers (Laser Notice 16)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73733\/download\u0022\u003EPDF (83.75 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (83.75 KB) of Warning Labels For Dye And Multiple Wavelength Lasers (Laser Notice 16)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/02\/1977","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Radiological Health","field_topics":"","topics-product":"Radiological Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-16T10:45:06-04:00\u0022\u003E2020-03-16 10:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/lasers-manufactured-and-used-house-laser-notice-14\u0022\u003ELasers Manufactured and Used In-House (Laser Notice 14) \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73740\/download\u0022\u003EPDF (54.95 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (54.95 KB) of Lasers Manufactured and Used In-House (Laser Notice 14) \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/23\/1976","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Laser Notice","field_topics":"","topics-product":"Laser Notice","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222021-01-26T10:35:28-05:00\u0022\u003E2021-01-26 10:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/manufacture-and-certification-laser-kits-laser-notice-13\u0022\u003EManufacture and Certification of Laser Kits (Laser Notice 13)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73749\/download\u0022\u003EPDF (85.79 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (85.79 KB) of Manufacture and Certification of Laser Kits (Laser Notice 13)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/14\/1976","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-16T10:45:03-04:00\u0022\u003E2020-03-16 10:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/remote-interlock-connectors-laser-notice-11\u0022\u003ERemote Interlock Connectors (Laser Notice 11)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73756\/download\u0022\u003EPDF (62.34 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (62.34 KB) of Remote Interlock Connectors (Laser Notice 11)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/07\/1976","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-16T10:30:03-04:00\u0022\u003E2020-03-16 10:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/certain-military-lasers-exempt-21-cfr-104010-11-laser-notice-9\u0022\u003ECertain Military Lasers Exempt From 21 CFR 1040.10 \u0026amp; .11 (Laser Notice 9)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73777\/download\u0022\u003EPDF (89.53 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (89.53 KB) of Certain Military Lasers Exempt From 21 CFR 1040.10 \u0026amp; .11 (Laser Notice 9)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/23\/1976","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Radiological Health","field_topics":"","topics-product":"Radiological Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Memorandum","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-16T10:25:11-04:00\u0022\u003E2020-03-16 10:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/viewing-optics-sighting-telescope-laser-notice-8\u0022\u003EViewing Optics - Sighting Telescope (Laser Notice 8)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73783\/download\u0022\u003EPDF (70.59 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (70.59 KB) of Viewing Optics - Sighting Telescope (Laser Notice 8)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/05\/1976","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-16T10:25:08-04:00\u0022\u003E2020-03-16 10:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/points-consider-cervical-cytology-devices\u0022\u003EPoints to Consider for Cervical Cytology Devices\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73795\/download\u0022\u003EPDF (660.62 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (660.62 KB) of Points to Consider for Cervical Cytology Devices\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/25\/1994","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-17T13:00:29-04:00\u0022\u003E2020-03-17 13:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/phs-guideline-infectious-disease-issues-xenotransplantation\u0022\u003EPHS Guideline on Infectious Disease Issues in Xenotransplantation: PHS Guideline\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73803\/download\u0022\u003EPDF (618.05 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (618.05 KB) of PHS Guideline on Infectious Disease Issues in Xenotransplantation: PHS Guideline\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/19\/2001","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Xenotransplantation","field_topics":"","topics-product":"Xenotransplantation","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1996-M-0140\u0022\u003EFDA-1996-M-0140\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-06-21T10:16:10-04:00\u0022\u003E2024-06-21 10:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-192-anesthetics-companion-animals\u0022\u003ECVM GFI #192 Anesthetics for Companion Animals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73814\/download\u0022\u003EPDF (379.47 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (379.47 KB) of CVM GFI #192 Anesthetics for Companion Animals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/25\/2010","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Target Animal \u2013 Safety","field_topics":"","topics-product":"Target Animal \u2013 Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0623\u0022\u003EFDA-2008-D-0623\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:01:44-04:00\u0022\u003E2019-04-16 14:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/laser-energy-source-laser-notice-2\u0022\u003ELaser Energy Source (Laser Notice 2)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73819\/download\u0022\u003EPDF (39.92 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (39.92 KB) of Laser Energy Source (Laser Notice 2)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/21\/1975","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-16T10:15:06-04:00\u0022\u003E2020-03-16 10:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/review-criteria-premarket-approval-in-vitro-diagnostic-devices-detection-antibodies-parvovirus-b19\u0022\u003EReview Criteria For Premarket Approval of In Vitro Diagnostic Devices for Detection of Antibodies to Parvovirus B19\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73831\/download\u0022\u003EPDF (636.84 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (636.84 KB) of Review Criteria For Premarket Approval of In Vitro Diagnostic Devices for Detection of Antibodies to Parvovirus B19\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/15\/1992","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Laboratory Tests, IVDs (In Vitro Diagnostic Devices)","field_topics":"Premarket","topics-product":"Premarket, Laboratory Tests, IVDs (In Vitro Diagnostic Devices)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-17T11:00:11-04:00\u0022\u003E2020-03-17 11:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/emitted-laser-beam-emission-indicator-class-ii-and-class-iiia-laser-products-laser-notice-49\u0022\u003EEmitted Laser Beam as Emission Indicator for Class II and Class IIIa Laser Products (Laser Notice 49)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73925\/download\u0022\u003EPDF (58.9 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (58.9 KB) of Emitted Laser Beam as Emission Indicator for Class II and Class IIIa Laser Products (Laser Notice 49)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/05\/1996","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-18T10:30:26-04:00\u0022\u003E2020-03-18 10:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/identification-labels-certain-class-i-laser-products-laser-notice-48\u0022\u003EIdentification Labels for Certain Class I Laser Products (Laser Notice 48)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73933\/download\u0022\u003EPDF (86.6 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (86.6 KB) of Identification Labels for Certain Class I Laser Products (Laser Notice 48)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/05\/1996","field_issuing_office_taxonomy":"Center for Devices and Radiological Health,Office of Product Evaluation and Quality,Office of In Vitro Diagnostics and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222021-04-27T09:55:03-04:00\u0022\u003E2021-04-27 09:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/effective-visual-control-laser-projections-laser-notice-47\u0022\u003EEffective Visual Control of Laser Projections (Laser Notice 47)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73939\/download\u0022\u003EPDF (147.45 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (147.45 KB) of Effective Visual Control of Laser Projections (Laser Notice 47)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/06\/1996","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Radiological Health","field_topics":"","topics-product":"Radiological Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-18T10:22:21-04:00\u0022\u003E2020-03-18 10:22\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/medical-device-reporting-user-facilities\u0022\u003EMedical Device Reporting for User Facilities\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73972\/download\u0022\u003EPDF (313.13 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (313.13 KB) of Medical Device Reporting for User Facilities\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/01\/1996","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Radiological Health","field_topics":"","topics-product":"Radiological Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-18T10:15:12-04:00\u0022\u003E2020-03-18 10:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/considerations-developmental-toxicity-studies-preventive-and-therapeutic-vaccines-infectious-disease\u0022\u003E Considerations for Developmental Toxicity Studies for Preventive and Therapeutic Vaccines for Infectious Disease Indications: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73986\/download\u0022\u003EPDF (53.02 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (53.02 KB) of Considerations for Developmental Toxicity Studies for Preventive and Therapeutic Vaccines for Infectious Disease Indications: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/01\/2006","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Pediatric Product Development, Vaccines","field_topics":"","topics-product":"Pediatric Product Development, Vaccines","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2000-D-0029\u0022\u003EFDA-2000-D-0029\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-05-08T10:08:47-04:00\u0022\u003E2024-05-08 10:08\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/user-instruction-medical-products-laser-notice-44\u0022\u003EUser Instruction for Medical Products (Laser Notice 44)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/74002\/download\u0022\u003EPDF (122.52 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (122.52 KB) of User Instruction for Medical Products (Laser Notice 44)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/11\/1995","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-17T15:30:41-04:00\u0022\u003E2020-03-17 15:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/beam-attenuators-and-emission-indicators-class-ii-and-iiia-laser-systems-laser-notice-43\u0022\u003EBeam Attenuators and Emission Indicators for Class II and IIIa Laser Systems (Laser Notice 43)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/74022\/download\u0022\u003EPDF (90.36 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (90.36 KB) of Beam Attenuators and Emission Indicators for Class II and IIIa Laser Systems (Laser Notice 43)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/07\/1993","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Radiological Health","field_topics":"","topics-product":"Radiological Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-17T11:30:18-04:00\u0022\u003E2020-03-17 11:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/compliance-guide-laser-products-fda-86-8260\u0022\u003ECompliance Guide for Laser Products (FDA 86-8260)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/74026\/download\u0022\u003EPDF (211.25 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (211.25 KB) of Compliance Guide for Laser Products (FDA 86-8260)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/01\/1992","field_issuing_office_taxonomy":"Center for Devices and Radiological Health,Office of Product Evaluation and Quality,Office of In Vitro Diagnostics and Radiological Health","field_health_topics":"","term_node_tid":"Radiological Health","field_topics":"","topics-product":"Radiological Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222023-02-21T11:08:44-05:00\u0022\u003E2023-02-21 11:08\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/labeling-regulatory-requirements-medical-devices-fda-89-4203\u0022\u003ELabeling - Regulatory Requirements for Medical Devices (FDA 89-4203)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/74034\/download\u0022\u003EPDF (2.98 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (2.98 MB) of Labeling - Regulatory Requirements for Medical Devices (FDA 89-4203)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/01\/1989","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-17T10:30:25-04:00\u0022\u003E2020-03-17 10:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clarification-radiation-control-regulations-diagnostic-x-ray-equipment-part-1\u0022\u003EClarification of Radiation Control Regulations for Diagnostic X-Ray Equipment (Part 1 )\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/74040\/download\u0022\u003EPDF (925.48 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (925.48 KB) of Clarification of Radiation Control Regulations for Diagnostic X-Ray Equipment (Part 1 )\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/1989","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Radiology","field_topics":"","topics-product":"Radiology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-4115\u0022\u003EFDA-2018-D-4115\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-02T11:53:42-05:00\u0022\u003E2020-03-02 11:53\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clarification-radiation-control-regulations-diagnostic-x-ray-equipment-part-2\u0022\u003EClarification of Radiation Control Regulations for Diagnostic X-Ray Equipment (Part 2)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/74044\/download\u0022\u003EPDF (1.08 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.08 MB) of Clarification of Radiation Control Regulations for Diagnostic X-Ray Equipment (Part 2)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/1989","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Radiology","field_topics":"","topics-product":"Radiology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-4115\u0022\u003EFDA-2018-D-4115\u003C\/a\u003E","field_communication_type":"Memorandum","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-02T12:00:58-05:00\u0022\u003E2020-03-02 12:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clarification-radiation-control-regulations-diagnostic-x-ray-equipment-part-3\u0022\u003EClarification of Radiation Control Regulations for Diagnostic X-Ray Equipment (Part 3)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/74048\/download\u0022\u003EPDF (1.08 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.08 MB) of Clarification of Radiation Control Regulations for Diagnostic X-Ray Equipment (Part 3)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/1989","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-4115\u0022\u003EFDA-2018-D-4115\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-02T12:01:53-05:00\u0022\u003E2020-03-02 12:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guide-establishing-and-maintaining-calibration-constancy-intercomparison-system-microwave-oven\u0022\u003EGuide for Establishing and Maintaining a Calibration Constancy Intercomparison System for Microwave Oven Compliance Survey Instruments (FDA 88-8264)] (PDF Only)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/74066\/download\u0022\u003EPDF (826.14 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (826.14 KB) of Guide for Establishing and Maintaining a Calibration Constancy Intercomparison System for Microwave Oven Compliance Survey Instruments (FDA 88-8264)] (PDF Only)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/1988","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"Radiological Health","field_topics":"","topics-product":"Radiological Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222018-12-01T12:38:45-05:00\u0022\u003E2018-12-01 12:38\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/user-instructions-multi-axis-workstations-laser-notice-39\u0022\u003EUser Instructions - Multi Axis Workstations (Laser Notice 39)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/74071\/download\u0022\u003EPDF (101.68 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (101.68 KB) of User Instructions - Multi Axis Workstations (Laser Notice 39)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/24\/1987","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-17T10:00:21-04:00\u0022\u003E2020-03-17 10:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/policy-lamp-compatibility-sunlamps\u0022\u003EPolicy on Lamp Compatibility (sunlamps)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/74075\/download\u0022\u003EPDF (65.83 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (65.83 KB) of Policy on Lamp Compatibility (sunlamps)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/02\/1986","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-17T09:51:32-04:00\u0022\u003E2020-03-17 09:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/testing-and-labeling-medical-devices-safety-magnetic-resonance-mr-environment\u0022\u003ETesting and Labeling Medical Devices for Safety in the Magnetic Resonance (MR) Environment: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/74201\/download\u0022\u003EPDF (1.02 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.02 MB) of Testing and Labeling Medical Devices for Safety in the Magnetic Resonance (MR) Environment: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/10\/2023","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Labeling, Safety - Issues, Errors, and Problems","field_topics":"Premarket","topics-product":"Premarket, Labeling, Safety - Issues, Errors, and Problems","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-2837\u0022\u003EFDA-2019-D-2837\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222023-10-10T11:04:57-04:00\u0022\u003E2023-10-10 11:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/dental-curing-lights-premarket-notification-510k-submissions\u0022\u003EDental Curing Lights - Premarket Notification (510(k)) Submissions: Guidance for Industry and Food and Drug Administration Staff\u00a0\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/74206\/download\u0022\u003EPDF (386.5 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (386.5 KB) of Dental Curing Lights - Premarket Notification (510(k)) Submissions: Guidance for Industry and Food and Drug Administration Staff\u00a0\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/02\/2026","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Dental ","field_topics":"Premarket","topics-product":"Premarket, 510(k), Dental ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-2512\u0022\u003EFDA-2024-D-2512\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222026-09-01T10:26:46-04:00\u0022\u003E2026-09-01 10:26\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/color-additive-petitions-medical-devices\u0022\u003EColor Additive Petitions - Medical Devices\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/74234\/download\u0022\u003EPDF (90.74 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (90.74 KB) of Color Additive Petitions - Medical Devices\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/01\/1987","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-17T10:00:03-04:00\u0022\u003E2020-03-17 10:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/letter-industry-powered-wheelchair-manufacturers-rmjohnson\u0022\u003ELetter to Industry, Powered Wheelchair Manufacturers from RMJohnson\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/74242\/download\u0022\u003EPDF (47.17 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (47.17 KB) of Letter to Industry, Powered Wheelchair Manufacturers from RMJohnson\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/10\/1993","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-17T11:30:49-04:00\u0022\u003E2020-03-17 11:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/humanitarian-device-exemption-hde-program\u0022\u003EHumanitarian Device Exemption (HDE) Program: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/74307\/download\u0022\u003EPDF (811.02 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (811.02 KB) of Humanitarian Device Exemption (HDE) Program: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/06\/2019","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP), HUD\/HDE, Premarket Approval (PMA)","field_topics":"Premarket","topics-product":"Premarket, Good Clinical Practice (GCP), HUD\/HDE, Premarket Approval (PMA)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0223\u0022\u003EFDA-2014-D-0223\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222019-09-05T09:06:55-04:00\u0022\u003E2019-09-05 09:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clinical-pharmacology-labeling-human-prescription-drug-and-biological-products-content-and-format\u0022\u003EClinical Pharmacology Labeling for Human Prescription Drug and Biological Products \u2014 Content and Format\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/74346\/download\u0022\u003EPDF (143.76 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (143.76 KB) of Clinical Pharmacology Labeling for Human Prescription Drug and Biological Products \u2014 Content and Format\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/05\/2016","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0095\u0022\u003EFDA-2009-D-0095\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-07T14:45:19-04:00\u0022\u003E2020-05-07 14:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/submission-and-review-sterility-information-premarket-notification-510k-submissions-devices-labeled\u0022\u003ESubmission and Review of Sterility Information in Premarket Notification (510(k)) Submissions for Devices Labeled as Sterile: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/74445\/download\u0022\u003EPDF (273.01 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (273.01 KB) of Submission and Review of Sterility Information in Premarket Notification (510(k)) Submissions for Devices Labeled as Sterile: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/08\/2024","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k)","field_topics":"Premarket","topics-product":"Premarket, 510(k)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0611\u0022\u003EFDA-2008-D-0611\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222024-01-08T09:10:47-05:00\u0022\u003E2024-01-08 09:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-187a-heritable-intentional-genomic-alterations-animals-risk-based-approach\u0022\u003ECVM GFI #187A Heritable Intentional Genomic Alterations in Animals: Risk-Based Approach\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/74614\/download\u0022\u003EPDF (392.06 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (392.06 KB) of CVM GFI #187A Heritable Intentional Genomic Alterations in Animals: Risk-Based Approach\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/02\/2024","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"","field_topics":"Biotechnology","topics-product":"Biotechnology, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"04\/19\/2017","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0394\u0022\u003EFDA-2008-D-0394\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222024-05-01T08:55:16-04:00\u0022\u003E2024-05-01 08:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/quality-control-guide-sunlamp-products-fda-88-8234\u0022\u003EQuality Control Guide for Sunlamp Products (FDA 88-8234)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/74980\/download\u0022\u003EPDF (4.17 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (4.17 MB) of Quality Control Guide for Sunlamp Products (FDA 88-8234)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/1988","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Tanning Lamps, Booths \u0026amp; Beds","field_topics":"","topics-product":"Tanning Lamps, Booths \u0026amp; Beds","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-17T10:05:38-04:00\u0022\u003E2020-03-17 10:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-230150-blood-donor-classification-statement-paid-or-volunteer-donor\u0022\u003ECPG Sec. 230.150 Blood Donor Classification Statement, Paid or Volunteer Donor\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/75039\/download\u0022\u003EPDF (72.09 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (72.09 KB) of CPG Sec. 230.150 Blood Donor Classification Statement, Paid or Volunteer Donor\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/01\/2019","field_issuing_office_taxonomy":"Office of Regulatory Affairs","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-10-24T14:52:35-04:00\u0022\u003E2024-10-24 14:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/changes-approved-nda-or-anda-questions-and-answers\u0022\u003EChanges to an Approved NDA or ANDA: Questions and Answers: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/75058\/download\u0022\u003EPDF (35.44 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (35.44 KB) of Changes to an Approved NDA or ANDA: Questions and Answers: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/01\/2001","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC)","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1999-D-0049\u0022\u003EFDA-1999-D-0049\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-01-26T10:50:16-05:00\u0022\u003E2021-01-26 10:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-197-documenting-electronic-data-files-and-statistical-analysis-programs\u0022\u003ECVM GFI #197 Documenting Electronic Data Files and Statistical Analysis Programs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/75077\/download\u0022\u003EPDF (130.84 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (130.84 KB) of CVM GFI #197 Documenting Electronic Data Files and Statistical Analysis Programs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/13\/2020","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Target Animal \u2013 Effectiveness, Target Animal \u2013 Safety, Investigational New Animal Drug (INAD)","field_topics":"","topics-product":"Target Animal \u2013 Effectiveness, Target Animal \u2013 Safety, Investigational New Animal Drug (INAD)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"07\/20\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0052\u0022\u003EFDA-2009-D-0052\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222021-01-20T15:45:47-05:00\u0022\u003E2021-01-20 15:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-300400-contamination-devices-labeled-sterile\u0022\u003ECPG Sec. 300.400 Contamination of Devices Labeled as Sterile\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/75112\/download\u0022\u003EPDF (62.53 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (62.53 KB) of CPG Sec. 300.400 Contamination of Devices Labeled as Sterile\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Office of Regulatory Affairs\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Labeling","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222021-05-03T14:10:10-04:00\u0022\u003E2021-05-03 14:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-525425-hops-adulteration-involving-aphid-infestation\u0022\u003ECPG Sec 525.425 Hops - Adulteration Involving Aphid Infestation\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/75127\/download\u0022\u003EPDF (8.77 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (8.77 KB) of CPG Sec 525.425 Hops - Adulteration Involving Aphid Infestation\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Dressing\/Condiment","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Dressing\/Condiment","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T15:16:18-05:00\u0022\u003E2025-03-05 15:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/data-retention-when-subjects-withdraw-fda-regulated-clinical-trials\u0022\u003EData Retention When Subjects Withdraw from FDA-Regulated Clinical Trials: Guidance for Sponsors, Clinical Investigators, and IRBs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/75138\/download\u0022\u003EPDF (74.79 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (74.79 KB) of Data Retention When Subjects Withdraw from FDA-Regulated Clinical Trials: Guidance for Sponsors, Clinical Investigators, and IRBs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/01\/2008","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP)","field_topics":"","topics-product":"Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0576\u0022\u003EFDA-2008-D-0576\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222021-07-21T11:06:03-04:00\u0022\u003E2021-07-21 11:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-540370-fish-and-fishery-products-decomposition\u0022\u003ECPG Sec 540.370 Fish and Fishery Products - Decomposition\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/75141\/download\u0022\u003EPDF (21.62 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (21.62 KB) of CPG Sec 540.370 Fish and Fishery Products - Decomposition\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/01\/2009","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Seafood\/Seafood Product","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Seafood\/Seafood Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:31:08-05:00\u0022\u003E2025-03-06 21:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/community-acquired-bacterial-pneumonia-developing-drugs-treatment\u0022\u003ECommunity-Acquired Bacterial Pneumonia: Developing Drugs for Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/75149\/download\u0022\u003EPDF (166.24 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (166.24 KB) of Community-Acquired Bacterial Pneumonia: Developing Drugs for Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/10\/2014","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0136\u0022\u003EFDA-2009-D-0136\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-06-24T09:00:35-04:00\u0022\u003E2020-06-24 09:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-575100-pesticide-residues-food-and-feed-enforcement-criteria\u0022\u003ECPG Sec 575.100 Pesticide Residues in Food and Feed - Enforcement Criteria\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/75151\/download\u0022\u003EPDF (68.52 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (68.52 KB) of CPG Sec 575.100 Pesticide Residues in Food and Feed - Enforcement Criteria\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Pesticide","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Pesticide","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T08:44:16-04:00\u0022\u003E2024-10-01 08:44\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/waiver-irb-requirements-drug-and-biological-product-studies\u0022\u003EWaiver of IRB Requirements for Drug and Biological Product Studies: Guidance For Sponsors, Clinical Investigators, and IRBs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/75152\/download\u0022\u003EPDF (87.28 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (87.28 KB) of Waiver of IRB Requirements for Drug and Biological Product Studies: Guidance For Sponsors, Clinical Investigators, and IRBs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/03\/2017","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP)","field_topics":"","topics-product":"Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Information Sheet","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222019-04-18T14:45:06-04:00\u0022\u003E2019-04-18 14:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-159-vich-gl36-studies-evaluate-safety-residues-veterinary-drugs-human-food-general-approach\u0022\u003ECVM GFI #159 (VICH GL36) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: General Approach to Establish a Microbiological ADI\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/75205\/download\u0022\u003EPDF (1.12 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.12 MB) of CVM GFI #159 (VICH GL36) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: General Approach to Establish a Microbiological ADI\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/21\/2022","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Human Food Safety, VICH","field_topics":"","topics-product":"Human Food Safety, VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2003-D-0433\u0022\u003EFDA-2003-D-0433\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222022-01-21T08:50:15-05:00\u0022\u003E2022-01-21 08:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/irb-review-stand-alone-hipaa-authorizations-under-fda-regulations\u0022\u003EIRB Review of Stand-Alone HIPAA Authorizations Under FDA Regulations: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/75279\/download\u0022\u003EPDF (613.57 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (613.57 KB) of IRB Review of Stand-Alone HIPAA Authorizations Under FDA Regulations: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/16\/2003","field_issuing_office_taxonomy":"Office of the Commissioner","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2003-D-0037\u0022\u003EFDA-2003-D-0037\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"","changed":"\u003Ctime datetime=\u00222021-07-21T09:40:09-04:00\u0022\u003E2021-07-21 09:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/use-clinical-holds-following-clinical-investigator-misconduct\u0022\u003EThe Use of Clinical Holds Following Clinical Investigator Misconduct: Guidance for Industry and Clinical Investigators\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/75301\/download\u0022\u003EPDF (37.48 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (37.48 KB) of The Use of Clinical Holds Following Clinical Investigator Misconduct: Guidance for Industry and Clinical Investigators\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/02\/2004","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Good Clinical Practice (GCP)","field_topics":"","topics-product":"Administrative \/ Procedural, Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2002-D-0053\u0022\u003EFDA-2002-D-0053\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T10:20:06-04:00\u0022\u003E2020-05-06 10:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/changes-approved-application-specified-biotechnology-and-specified-synthetic-biological-products\u0022\u003EChanges to an Approved Application for Specified Biotechnology and Specified Synthetic Biological Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/75318\/download\u0022\u003EPDF (32.75 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (32.75 KB) of Changes to an Approved Application for Specified Biotechnology and Specified Synthetic Biological Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/01\/1997","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1995-D-0101\u0022\u003EFDA-1995-D-0101\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-30T11:55:18-04:00\u0022\u003E2020-04-30 11:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/industry-supported-scientific-and-educational-activities\u0022\u003EIndustry Supported Scientific and Educational Activities: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/75334\/download\u0022\u003EPDF (428.5 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (428.5 KB) of Industry Supported Scientific and Educational Activities: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/01\/1997","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Policy, Legislation, and International Affairs,Office of Policy\u003Cbr\u003E\u003Cbr\u003ECenter for Veterinary Medicine","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1992-N-0007\u0022\u003EFDA-1992-N-0007\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222020-04-24T14:35:03-04:00\u0022\u003E2020-04-24 14:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/frequently-asked-questions-about-medical-devices\u0022\u003EFrequently Asked Questions About Medical Devices: Guidance For IRBs, Clinical Investigators, and Sponsors \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/75381\/download\u0022\u003EPDF (266.36 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (266.36 KB) of Frequently Asked Questions About Medical Devices: Guidance For IRBs, Clinical Investigators, and Sponsors \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/01\/2006","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP)","field_topics":"","topics-product":"Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2006-D-0031\u0022\u003EFDA-2006-D-0031\u003C\/a\u003E","field_communication_type":"Information Sheet","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222020-02-28T12:54:41-05:00\u0022\u003E2020-02-28 12:54\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/voting-procedures-advisory-committee-meetings\u0022\u003EVoting Procedures for Advisory Committee Meetings: Guidance for FDA Advisory Committee Members and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/75426\/download\u0022\u003EPDF (36.7 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (36.7 KB) of Voting Procedures for Advisory Committee Meetings: Guidance for FDA Advisory Committee Members and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/01\/2008","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"Advisory Committees","topics-product":"Advisory Committees, Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222019-04-20T23:15:05-04:00\u0022\u003E2019-04-20 23:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/preparation-and-public-availability-information-given-advisory-committee-members\u0022\u003EPreparation and Public Availability of Information Given to Advisory Committee Members: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/75436\/download\u0022\u003EPDF (169.24 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (169.24 KB) of Preparation and Public Availability of Information Given to Advisory Committee Members: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/01\/2008","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"Advisory Committees","topics-product":"Advisory Committees, Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222019-04-20T23:15:16-04:00\u0022\u003E2019-04-20 23:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/sample-who-certificate-quality-pharmaceutical-product\u0022\u003ESample WHO Certificate for Quality of a Pharmaceutical Product\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/75456\/download\u0022\u003EPDF (104.47 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (104.47 KB) of Sample WHO Certificate for Quality of a Pharmaceutical Product\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222018-12-01T12:08:30-05:00\u0022\u003E2018-12-01 12:08\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/significant-risk-and-nonsignificant-risk-medical-device-studies\u0022\u003ESignificant Risk and Nonsignificant Risk Medical Device Studies: Guidance For IRBs, Clinical Investigators, and Sponsors\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/75459\/download\u0022\u003EPDF (214.72 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (214.72 KB) of Significant Risk and Nonsignificant Risk Medical Device Studies: Guidance For IRBs, Clinical Investigators, and Sponsors\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/01\/2006","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP), Investigational Device Exemption (IDE)","field_topics":"","topics-product":"Good Clinical Practice (GCP), Investigational Device Exemption (IDE)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2006-D-0031\u0022\u003EFDA-2006-D-0031\u003C\/a\u003E","field_communication_type":"Information Sheet","field_center":"Office of the Commissioner","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222023-08-10T16:07:01-04:00\u0022\u003E2023-08-10 16:07\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/submission-summary-bioequivalence-data-abbreviated-new-drug-applications\u0022\u003ESubmission of Summary Bioequivalence Data for Abbreviated New Drug Applications\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/75535\/download\u0022\u003EPDF (137.06 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (137.06 KB) of Submission of Summary Bioequivalence Data for Abbreviated New Drug Applications\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/06\/2011","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Generic Drugs","field_topics":"","topics-product":"Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0126\u0022\u003EFDA-2009-D-0126\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-29T14:35:10-04:00\u0022\u003E2020-04-29 14:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/prescription-drug-marketing-act-pdma-requirements-questions-and-answers\u0022\u003EPrescription Drug Marketing Act (PDMA) Requirements- Questions and Answers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/75595\/download\u0022\u003EPDF (111.75 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (111.75 KB) of Prescription Drug Marketing Act (PDMA) Requirements- Questions and Answers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/15\/2006","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Compliance","topics-product":"Compliance, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1992-N-0056\u0022\u003EFDA-1992-N-0056\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-08T16:40:06-04:00\u0022\u003E2020-04-08 16:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/label-comprehension-studies-nonprescription-drug-products\u0022\u003ELabel Comprehension Studies for Nonprescription Drug Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/75626\/download\u0022\u003EPDF (147.74 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (147.74 KB) of Label Comprehension Studies for Nonprescription Drug Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/03\/2010","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Over-the-Counter Drugs","field_topics":"","topics-product":"Over-the-Counter Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0181\u0022\u003EFDA-2009-D-0181\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T01:35:23-04:00\u0022\u003E2020-04-24 01:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/integrated-summaries-effectiveness-and-safety-location-within-common-technical-document\u0022\u003EIntegrated Summaries of Effectiveness and Safety: Location Within the Common Technical Document\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/75783\/download\u0022\u003EPDF (97.96 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (97.96 KB) of Integrated Summaries of Effectiveness and Safety: Location Within the Common Technical Document\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/21\/2009","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2007-D-0031\u0022\u003EFDA-2007-D-0031\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T00:35:03-04:00\u0022\u003E2020-04-24 00:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/compliance-policy-guides-index\u0022\u003ECompliance Policy Guides Index\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/75894\/download\u0022\u003EPDF (396.94 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (396.94 KB) of Compliance Policy Guides Index\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/28\/2018","field_issuing_office_taxonomy":"Office of Regulatory Affairs","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222024-09-04T16:34:16-04:00\u0022\u003E2024-09-04 16:34\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/chapter-48-7348809-bioresearch-monitoring\u0022\u003ECHAPTER 48 - 7348.809 Bioresearch Monitoring\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/75909\/download\u0022\u003EPDF (410.87 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (410.87 KB) of CHAPTER 48 - 7348.809 Bioresearch Monitoring\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"","changed":"\u003Ctime datetime=\u00222018-12-01T01:55:10-05:00\u0022\u003E2018-12-01 01:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/radioactive-drug-research-committee-human-research-without-investigational-new-drug-application\u0022\u003ERadioactive Drug Research Committee: Human Research Without An Investigational New Drug Application\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/76286\/download\u0022\u003EPDF (429.19 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (429.19 KB) of Radioactive Drug Research Committee: Human Research Without An Investigational New Drug Application\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/02\/2010","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0125 \u0022\u003EFDA-2009-D-0125 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-01-31T13:25:11-05:00\u0022\u003E2023-01-31 13:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/biological-product-deviation-reporting-licensed-manufacturers-biological-products-other-blood-and\u0022\u003EBiological Product Deviation Reporting for Licensed Manufacturers of Biological Products Other than Blood and Blood Components\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/76309\/download\u0022\u003EPDF (115.19 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (115.19 KB) of Biological Product Deviation Reporting for Licensed Manufacturers of Biological Products Other than Blood and Blood Components\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/19\/2006","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC)","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2001-D-0008\u0022\u003EFDA-2001-D-0008\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222020-04-17T16:20:02-04:00\u0022\u003E2020-04-17 16:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/technical-considerations-pen-jet-and-related-injectors-intended-use-drugs-and-biological-products\u0022\u003ETechnical Considerations for Pen, Jet, and Related Injectors Intended for Use with Drugs and Biological Products: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/76403\/download\u0022\u003EPDF (179.56 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (179.56 KB) of Technical Considerations for Pen, Jet, and Related Injectors Intended for Use with Drugs and Biological Products: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/07\/2013","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Combination Products","field_topics":"","topics-product":"Administrative \/ Procedural, Combination Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0179\u0022\u003EFDA-2009-D-0179\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222020-05-05T14:20:20-04:00\u0022\u003E2020-05-05 14:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-providing-regulatory-submissions-cber-electronic-format-investigational-new-drug\u0022\u003EGuidance for Industry: Providing Regulatory Submissions to CBER in Electronic Format -- Investigational New Drug Applications (INDs) (PDF)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/76466\/download\u0022\u003EPDF (97.52 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (97.52 KB) of Guidance for Industry: Providing Regulatory Submissions to CBER in Electronic Format -- Investigational New Drug Applications (INDs) (PDF)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/2002","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222018-12-01T10:20:10-05:00\u0022\u003E2018-12-01 10:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/labeling-otc-human-drug-products-small-entity-compliance-guide\u0022\u003ELabeling OTC Human Drug Products; Small Entity Compliance Guide: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/76481\/download\u0022\u003EPDF (269.87 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (269.87 KB) of Labeling OTC Human Drug Products; Small Entity Compliance Guide: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/13\/2009","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Over-the-Counter Drugs","field_topics":"Compliance","topics-product":"Compliance, Over-the-Counter Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-D-0122\u0022\u003EFDA-2004-D-0122\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T01:55:49-04:00\u0022\u003E2020-04-24 01:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-199-animal-generic-drug-user-fees-and-fee-waivers-and-reductions\u0022\u003ECVM GFI #199 Animal Generic Drug User Fees and Fee Waivers and Reductions\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/76498\/download\u0022\u003EPDF (320.45 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (320.45 KB) of CVM GFI #199 Animal Generic Drug User Fees and Fee Waivers and Reductions\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/04\/2023","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"","field_topics":"User Fees","topics-product":"User Fees, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0189\u0022\u003EFDA-2009-D-0189\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222023-12-04T07:48:17-05:00\u0022\u003E2023-12-04 07:48\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cellular-therapy-cardiac-disease\u0022\u003E Cellular Therapy for Cardiac Disease: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/76587\/download\u0022\u003EPDF (199.9 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (199.9 KB) of Cellular Therapy for Cardiac Disease: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/01\/2010","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Gene Therapy","field_topics":"Cellular \u0026amp; Gene Therapy","topics-product":"Cellular \u0026amp; Gene Therapy, Gene Therapy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0132\u0022\u003EFDA-2009-D-0132\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222019-05-16T16:55:15-04:00\u0022\u003E2019-05-16 16:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/medication-guides-adding-toll-free-number-reporting-adverse-events\u0022\u003EMedication Guides \u2014 Adding a Toll-Free Number for Reporting Adverse Events\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/76667\/download\u0022\u003EPDF (66.81 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (66.81 KB) of Medication Guides \u2014 Adding a Toll-Free Number for Reporting Adverse Events\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/08\/2009","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Safety - Issues, Errors, and Problems","field_topics":"","topics-product":"Administrative \/ Procedural, Safety - Issues, Errors, and Problems","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0217 \u0022\u003EFDA-2009-D-0217 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T17:55:06-04:00\u0022\u003E2020-04-24 17:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q4b-annex-9-tablet-friability-general-chapter\u0022\u003EQ4B Annex 9: Tablet Friability General Chapter\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/77008\/download\u0022\u003EPDF (67.76 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (67.76 KB) of Q4B Annex 9: Tablet Friability General Chapter\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/05\/2010","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0343\u0022\u003EFDA-2009-D-0343\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T13:45:14-04:00\u0022\u003E2020-05-06 13:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q4b-annex-10-polyacrylamide-gel-electrophoresis-general-chapter\u0022\u003EQ4B Annex 10: Polyacrylamide Gel Electrophoresis General Chapter\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/77011\/download\u0022\u003EPDF (57.26 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (57.26 KB) of Q4B Annex 10: Polyacrylamide Gel Electrophoresis General Chapter\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/12\/2010","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0342\u0022\u003EFDA-2009-D-0342\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T11:25:02-04:00\u0022\u003E2020-05-06 11:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/fda-guidance-document-concerning-use-pilot-manufacturing-facilities-development-and-manufacture\u0022\u003EFDA Guidance Document Concerning Use of Pilot Manufacturing Facilities for the Development and Manufacture of Biological Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/77030\/download\u0022\u003EPDF (30.62 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (30.62 KB) of FDA Guidance Document Concerning Use of Pilot Manufacturing Facilities for the Development and Manufacture of Biological Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/11\/1995","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1995-D-0149\u0022\u003EFDA-1995-D-0149\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-07-26T09:48:46-04:00\u0022\u003E2024-07-26 09:48\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/frequently-asked-questions-irb-registration\u0022\u003EFrequently Asked Questions - IRB Registration: Guidance for Institutional Review Boards (IRBs) \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/77059\/download\u0022\u003EPDF (48.34 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (48.34 KB) of Frequently Asked Questions - IRB Registration: Guidance for Institutional Review Boards (IRBs) \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/09\/2009","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP)","field_topics":"","topics-product":"Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0312\u0022\u003EFDA-2009-D-0312\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222021-07-21T10:05:03-04:00\u0022\u003E2021-07-21 10:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-198-vich-gl45-bracketing-and-matrixing-designs-stability-testing-new-veterinary-drug\u0022\u003ECVM GFI #198 (VICH GL45) Bracketing and Matrixing Designs For Stability Testing of New Veterinary Drug Substances and Medicinal Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/77128\/download\u0022\u003EPDF (141.6 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (141.6 KB) of CVM GFI #198 (VICH GL45) Bracketing and Matrixing Designs For Stability Testing of New Veterinary Drug Substances and Medicinal Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/31\/2015","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"VICH","field_topics":"","topics-product":"VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0309\u0022\u003EFDA-2009-D-0309\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:01:26-04:00\u0022\u003E2019-04-16 14:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-evaluation-combination-vaccines-preventable-diseases-production-testing-and\u0022\u003EGuidance for Industry for the Evaluation of Combination Vaccines for Preventable Diseases: Production, Testing and Clinical Studies: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/77191\/download\u0022\u003EPDF (80.89 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (80.89 KB) of Guidance for Industry for the Evaluation of Combination Vaccines for Preventable Diseases: Production, Testing and Clinical Studies: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/10\/1997","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Vaccines","field_topics":"","topics-product":"Vaccines","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1997-N-0454\u0022\u003EFDA-1997-N-0454\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-07-26T10:01:07-04:00\u0022\u003E2024-07-26 10:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pharmaceutical-components-risk-melamine-contamination\u0022\u003EPharmaceutical Components at Risk for Melamine Contamination: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/77196\/download\u0022\u003EPDF (136.64 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (136.64 KB) of Pharmaceutical Components at Risk for Melamine Contamination: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/06\/2009","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_topics":"","topics-product":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0354\u0022\u003EFDA-2009-D-0354\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-15T02:05:29-04:00\u0022\u003E2020-05-15 02:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/interpreting-sameness-monoclonal-antibody-products-under-orphan-drug-regulations\u0022\u003EInterpreting Sameness of Monoclonal Antibody Products Under the Orphan Drug Regulations\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/77256\/download\u0022\u003EPDF (88.18 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (88.18 KB) of Interpreting Sameness of Monoclonal Antibody Products Under the Orphan Drug Regulations\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/01\/2014","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1999-D-0178\u0022\u003EFDA-1999-D-0178\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222018-12-01T09:23:35-05:00\u0022\u003E2018-12-01 09:23\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/andas-impurities-drug-substances\u0022\u003EANDAs: Impurities in Drug Substances: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/183885\/download\u0022\u003EPDF (48.11 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (48.11 KB) of ANDAs: Impurities in Drug Substances: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/15\/2009","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1998-D-0021\u0022\u003EFDA-1998-D-0021\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-05-04T19:46:13-04:00\u0022\u003E2026-05-04 19:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/information-request-and-discipline-review-letters-under-prescription-drug-user-fee-act\u0022\u003EInformation Request and Discipline Review Letters Under the Prescription Drug User Fee Act: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/77409\/download\u0022\u003EPDF (26.99 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (26.99 KB) of Information Request and Discipline Review Letters Under the Prescription Drug User Fee Act: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/21\/2001","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"User Fees","topics-product":"User Fees, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1999-D-1301\u0022\u003EFDA-1999-D-1301\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T00:30:40-04:00\u0022\u003E2020-04-24 00:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/labeling-nonprescription-human-drug-products-marketed-without-approved-application-required-dietary\u0022\u003ELabeling of Nonprescription Human Drug Products Marketed Without an Approved Application as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act: Questions and Answers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/77411\/download\u0022\u003EPDF (405.32 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (405.32 KB) of Labeling of Nonprescription Human Drug Products Marketed Without an Approved Application as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act: Questions and Answers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/01\/2009","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Over-the-Counter Drugs","field_topics":"","topics-product":"Over-the-Counter Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2007-D-0429\u0022\u003EFDA-2007-D-0429\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-01-19T18:06:16-05:00\u0022\u003E2023-01-19 18:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/microbiological-data-systemic-antibacterial-drug-products-development-analysis-and-presentation\u0022\u003EMicrobiological Data for Systemic Antibacterial Drug Products \u2014 Development, Analysis, and Presentation\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/77442\/download\u0022\u003EPDF (162.12 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (162.12 KB) of Microbiological Data for Systemic Antibacterial Drug Products \u2014 Development, Analysis, and Presentation\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/07\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0408\u0022\u003EFDA-2009-D-0408\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T13:35:02-04:00\u0022\u003E2020-04-24 13:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/considerations-allogeneic-pancreatic-islet-cell-products\u0022\u003EConsiderations for Allogeneic Pancreatic Islet Cell Products: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/77497\/download\u0022\u003EPDF (143.76 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (143.76 KB) of Considerations for Allogeneic Pancreatic Islet Cell Products: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/01\/2009","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Gene Therapy","field_topics":"Cellular \u0026amp; Gene Therapy","topics-product":"Cellular \u0026amp; Gene Therapy, Gene Therapy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0293\u0022\u003EFDA-2008-D-0293\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222019-05-16T16:55:03-04:00\u0022\u003E2019-05-16 16:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-submission-chemistry-manufacturing-and-controls-information-therapeutic\u0022\u003EGuidance for Industry for the Submission of Chemistry, Manufacturing, and Controls Information for a Therapeutic Recombinant DNA-Derived Product or a Monoclonal Antibody Product for In Vivo Use\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/77528\/download\u0022\u003EPDF (69.41 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (69.41 KB) of Guidance for Industry for the Submission of Chemistry, Manufacturing, and Controls Information for a Therapeutic Recombinant DNA-Derived Product or a Monoclonal Antibody Product for In Vivo Use\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/01\/1996","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1996-D-0071\u0022\u003EFDA-1996-D-0071\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-07-26T09:52:16-04:00\u0022\u003E2024-07-26 09:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/new-contrast-imaging-indication-considerations-devices-and-approved-drug-and-biological-products\u0022\u003ENew Contrast Imaging Indication Considerations for Devices and Approved Drug and Biological Products: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/77679\/download\u0022\u003EPDF (159.33 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (159.33 KB) of New Contrast Imaging Indication Considerations for Devices and Approved Drug and Biological Products: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/06\/2010","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Combination Products","field_topics":"","topics-product":"Combination Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0525\u0022\u003EFDA-2008-D-0525\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222020-05-14T12:40:07-04:00\u0022\u003E2020-05-14 12:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/planning-effects-high-absenteeism-ensure-availability-medically-necessary-drug-products\u0022\u003EPlanning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/14\/2011","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"","changed":"\u003Ctime datetime=\u00222018-12-01T13:17:41-05:00\u0022\u003E2018-12-01 13:17\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/investigator-responsibilities-protecting-rights-safety-and-welfare-study-subjects\u0022\u003EInvestigator Responsibilities \u2014 Protecting the Rights, Safety, and Welfare of Study Subjects: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/77765\/download\u0022\u003EPDF (163.4 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (163.4 KB) of Investigator Responsibilities \u2014 Protecting the Rights, Safety, and Welfare of Study Subjects: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/23\/2009","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Good Clinical Practice (GCP)","field_topics":"","topics-product":"Administrative \/ Procedural, Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222019-04-19T12:25:12-04:00\u0022\u003E2019-04-19 12:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/use-mechanical-calibration-dissolution-apparatus-1-and-2-current-good-manufacturing-practice-cgmp\u0022\u003EThe Use of Mechanical Calibration of Dissolution Apparatus 1 and 2 \u2013 Current Good Manufacturing Practice (CGMP): Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/77799\/download\u0022\u003EPDF (127.37 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (127.37 KB) of The Use of Mechanical Calibration of Dissolution Apparatus 1 and 2 \u2013 Current Good Manufacturing Practice (CGMP): Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/27\/2010","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP)","field_topics":"","topics-product":"Current Good Manufacturing Practice (CGMP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2007-D-0420\u0022\u003EFDA-2007-D-0420\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-01-26T09:50:23-05:00\u0022\u003E2021-01-26 09:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommendations-blood-establishments-training-back-personnel-assessment-blood-donor-suitability-and\u0022\u003ERecommendations for Blood Establishments: Training of Back-Up Personnel, Assessment of Blood Donor Suitability and Reporting Certain Changes to an Approved Application: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/124266\/download\u0022\u003EPDF (41.82 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (41.82 KB) of Recommendations for Blood Establishments: Training of Back-Up Personnel, Assessment of Blood Donor Suitability and Reporting Certain Changes to an Approved Application: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/01\/2010","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0533\u0022\u003EFDA-2009-D-0533\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222019-05-15T12:05:08-04:00\u0022\u003E2019-05-15 12:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims\u0022\u003EPatient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/77832\/download\u0022\u003EPDF (295 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (295 KB) of Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/09\/2009","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Good Clinical Practice (GCP)","field_topics":"","topics-product":"Clinical - Medical, Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2006-D-0362\u0022\u003EFDA-2006-D-0362\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222020-05-15T01:35:33-04:00\u0022\u003E2020-05-15 01:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/labeling-human-prescription-drug-and-biological-products-determining-established-pharmacologic-class\u0022\u003ELabeling for Human Prescription Drug and Biological Products \u2014 Determining Established Pharmacologic Class for Use in the Highlights of Prescribing Information\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/77834\/download\u0022\u003EPDF (65.5 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (65.5 KB) of Labeling for Human Prescription Drug and Biological Products \u2014 Determining Established Pharmacologic Class for Use in the Highlights of Prescribing Information\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/19\/2009","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2007-D-0302 \u0022\u003EFDA-2007-D-0302 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T01:47:03-04:00\u0022\u003E2020-04-24 01:47\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/format-and-content-rems-document-guidance-industry\u0022\u003EFormat and Content of a REMS Document Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/77846\/download\u0022\u003EPDF (331.56 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (331.56 KB) of Format and Content of a REMS Document Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/04\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Safety - Issues, Errors, and Problems","field_topics":"","topics-product":"Safety - Issues, Errors, and Problems","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"12\/11\/2017","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0461\u0022\u003EFDA-2009-D-0461\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-01-04T08:47:31-05:00\u0022\u003E2023-01-04 08:47\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/manufacturing-biological-intermediates-and-biological-drug-substances-using-spore-forming\u0022\u003EManufacturing Biological Intermediates and Biological Drug Substances Using Spore-Forming Microorganisms: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/77849\/download\u0022\u003EPDF (156.61 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (156.61 KB) of Manufacturing Biological Intermediates and Biological Drug Substances Using Spore-Forming Microorganisms: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/01\/2007","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2003-N-0096\u0022\u003EFDA-2003-N-0096\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-05-02T09:32:07-04:00\u0022\u003E2024-05-02 09:32\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-575100-draft-revision-pesticide-chemical-residues-food-enforcement-criteria\u0022\u003ECPG Sec 575.100 Draft Revision - Pesticide Chemical Residues in Food - Enforcement Criteria\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/77986\/download\u0022\u003EPDF (807.66 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (807.66 KB) of CPG Sec 575.100 Draft Revision - Pesticide Chemical Residues in Food - Enforcement Criteria\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/01\/2008","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-21T16:48:31-04:00\u0022\u003E2025-03-21 16:48\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/s6-r1-addendum-preclinical-safety-evaluation-biotechnology-derived-pharmaceuticals\u0022\u003ES6 (R1) Addendum: Preclinical Safety Evaluation of Biotechnology - Derived Pharmaceuticals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/78034\/download\u0022\u003EPDF (181.06 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (181.06 KB) of S6 (R1) Addendum: Preclinical Safety Evaluation of Biotechnology - Derived Pharmaceuticals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/15\/2012","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Safety","field_topics":"","topics-product":"ICH-Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-06-16T12:16:11-04:00\u0022\u003E2026-06-16 12:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q4b-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-annex-11-capillary\u0022\u003EQ4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions Annex 11: Capillary Electrophoresis General Chapter\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/78043\/download\u0022\u003EPDF (92.92 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (92.92 KB) of Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions Annex 11: Capillary Electrophoresis General Chapter\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/03\/2010","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0579\u0022\u003EFDA-2009-D-0579\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-13T14:50:09-04:00\u0022\u003E2020-04-13 14:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q4b-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-annex-12-analytical-sieving\u0022\u003EQ4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions Annex 12: Analytical Sieving General Chapter\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/78048\/download\u0022\u003EPDF (87.38 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (87.38 KB) of Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions Annex 12: Analytical Sieving General Chapter\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/02\/2010","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0579\u0022\u003EFDA-2009-D-0579\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-13T14:50:22-04:00\u0022\u003E2020-04-13 14:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/dosage-delivery-devices-orally-ingested-otc-liquid-drug-products\u0022\u003EDosage Delivery Devices for Orally Ingested OTC Liquid Drug Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/78087\/download\u0022\u003EPDF (594.59 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (594.59 KB) of Dosage Delivery Devices for Orally Ingested OTC Liquid Drug Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/05\/2011","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Over-the-Counter Drugs","field_topics":"","topics-product":"Over-the-Counter Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0322 \u0022\u003EFDA-2009-D-0322 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-28T13:25:06-04:00\u0022\u003E2020-04-28 13:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/helicobacter-pylori-associated-duodenal-ulcer-disease-adults-developing-drugs-treatment\u0022\u003EHelicobacter pylori-Associated Duodenal Ulcer Disease in Adults: Developing Drugs for Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/78115\/download\u0022\u003EPDF (147.7 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (147.7 KB) of Helicobacter pylori-Associated Duodenal Ulcer Disease in Adults: Developing Drugs for Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/05\/2009","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0447\u0022\u003EFDA-2009-D-0447\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-10-17T11:40:08-04:00\u0022\u003E2019-10-17 11:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/use-nucleic-acid-tests-reduce-risk-transmission-west-nile-virus-donors-whole-blood-and-blood\u0022\u003EUse of Nucleic Acid Tests to Reduce the Risk of Transmission of West Nile Virus from Donors of Whole Blood and Blood Components Intended for Transfusion: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/124300\/download\u0022\u003EPDF (52.46 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (52.46 KB) of Use of Nucleic Acid Tests to Reduce the Risk of Transmission of West Nile Virus from Donors of Whole Blood and Blood Components Intended for Transfusion: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/06\/2009","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0263\u0022\u003EFDA-2008-D-0263\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222022-05-26T10:33:37-04:00\u0022\u003E2022-05-26 10:33\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-205-vich-gl46-studies-evaluate-metabolism-and-residue-kinetics-veterinary-drugs-food\u0022\u003ECVM GFI #205 (VICH GL46) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Metabolism Study to Determine the Quantity and Identify the Nature of Residues (MRK)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/78339\/download\u0022\u003EPDF (209.51 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (209.51 KB) of CVM GFI #205 (VICH GL46) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Metabolism Study to Determine the Quantity and Identify the Nature of Residues (MRK)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/15\/2011","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Human Food Safety, VICH","field_topics":"","topics-product":"Human Food Safety, VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-8228\u0022\u003EFDA-2010-D-8228\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:05:46-04:00\u0022\u003E2019-04-16 14:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-206-vich-gl47-studies-evaluate-metabolism-and-residue-kinetics-veterinary-drugs-food\u0022\u003ECVM GFI #206 (VICH GL47) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Comparative Metabolism Studies in Laboratory Animals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/78347\/download\u0022\u003EPDF (153.13 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (153.13 KB) of CVM GFI #206 (VICH GL47) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Comparative Metabolism Studies in Laboratory Animals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/15\/2011","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Human Food Safety, VICH","field_topics":"","topics-product":"Human Food Safety, VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-8229\u0022\u003EFDA-2010-D-8229\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:06:10-04:00\u0022\u003E2019-04-16 14:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-207-vich-gl48-studies-evaluate-metabolism-and-residue-kinetics-veterinary-drugs-food\u0022\u003ECVM GFI #207 (VICH GL48) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs In Food-Producing Animals: Marker Residue Depletion Studies to Establish Product Withdrawal Periods\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/78351\/download\u0022\u003EPDF (303.03 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (303.03 KB) of CVM GFI #207 (VICH GL48) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs In Food-Producing Animals: Marker Residue Depletion Studies to Establish Product Withdrawal Periods\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/09\/2015","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Human Food Safety, VICH","field_topics":"","topics-product":"Human Food Safety, VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0166\u0022\u003EFDA-2010-D-0166\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:07:23-04:00\u0022\u003E2019-04-16 14:07\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-208-vich-gl49-studies-evaluate-metabolism-and-residue-kinetics-veterinary-drugs-food\u0022\u003ECVM GFI #208 (VICH GL49) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Validation of Analytical Methods Used in Residue Depletion Studies\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/78356\/download\u0022\u003EPDF (290.89 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (290.89 KB) of CVM GFI #208 (VICH GL49) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Validation of Analytical Methods Used in Residue Depletion Studies\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/09\/2015","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Human Food Safety, VICH","field_topics":"","topics-product":"Human Food Safety, VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0165\u0022\u003EFDA-2010-D-0165\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:05:15-04:00\u0022\u003E2019-04-16 14:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/infusion-pumps-total-product-life-cycle\u0022\u003EInfusion Pumps Total Product Life Cycle: Guidance for Industry and FDA Staff \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/78369\/download\u0022\u003EPDF (577.19 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (577.19 KB) of Infusion Pumps Total Product Life Cycle: Guidance for Industry and FDA Staff \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/02\/2014","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k)","field_topics":"Premarket","topics-product":"Premarket, 510(k)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0194\u0022\u003EFDA-2010-D-0194\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222019-02-09T15:29:24-05:00\u0022\u003E2019-02-09 15:29\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/fda-and-industry-procedures-section-513g-requests-information-under-federal-food-drug-and-cosmetic\u0022\u003EFDA and Industry Procedures for Section 513(g) Requests for Information under the Federal Food, Drug, and Cosmetic Act: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/78456\/download\u0022\u003EPDF (553.88 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (553.88 KB) of FDA and Industry Procedures for Section 513(g) Requests for Information under the Federal Food, Drug, and Cosmetic Act: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/23\/2024","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Labeling","field_topics":"Premarket","topics-product":"Premarket, Administrative \/ Procedural, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0153\u0022\u003EFDA-2010-D-0153\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222024-08-22T08:50:53-04:00\u0022\u003E2024-08-22 08:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/user-fees-513g-requests-information\u0022\u003EUser Fees for 513(g) Requests for Information: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/78463\/download\u0022\u003EPDF (322.37 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (322.37 KB) of User Fees for 513(g) Requests for Information: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/05\/2022","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Premarket, User Fees","topics-product":"Premarket, User Fees, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0144\u0022\u003EFDA-2010-D-0144\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222022-10-06T10:10:47-04:00\u0022\u003E2022-10-06 10:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/adaptive-design-clinical-trials-drugs-and-biologics-guidance-industry\u0022\u003EAdaptive Design Clinical Trials for Drugs and Biologics Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/78495\/download\u0022\u003EPDF (306.43 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (306.43 KB) of Adaptive Design Clinical Trials for Drugs and Biologics Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/02\/2019","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"Biostatistics","topics-product":"Biostatistics, Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-3124\u0022\u003EFDA-2018-D-3124\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222020-04-21T15:15:12-04:00\u0022\u003E2020-04-21 15:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/non-inferiority-clinical-trials\u0022\u003ENon-Inferiority Clinical Trials\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/78504\/download\u0022\u003EPDF (670.46 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (670.46 KB) of Non-Inferiority Clinical Trials\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/08\/2016","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0075\u0022\u003EFDA-2010-D-0075\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-27T08:50:02-04:00\u0022\u003E2020-04-27 08:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/nucleic-acid-testing-nat-human-immunodeficiency-virus-type-1-hiv-1-and-hepatitis-c-virus-hcv-testing\u0022\u003ENucleic Acid Testing (NAT) for Human Immunodeficiency Virus Type 1 (HIV-1) and Hepatitis C Virus (HCV): Testing, Product Disposition, and Donor Deferral and Reentry: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/124144\/download\u0022\u003EPDF (219.18 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (219.18 KB) of Nucleic Acid Testing (NAT) for Human Immunodeficiency Virus Type 1 (HIV-1) and Hepatitis C Virus (HCV): Testing, Product Disposition, and Donor Deferral and Reentry: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/28\/2017","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2005-D-0140\u0022\u003EFDA-2005-D-0140\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222023-01-23T08:35:13-05:00\u0022\u003E2023-01-23 08:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pharmacokinetics-patients-impaired-renal-function-study-design-data-analysis-and-impact-dosing\u0022\u003EPharmacokinetics in Patients with Impaired Renal Function \u2014 Study Design, Data Analysis, and Impact on Dosing\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/78573\/download\u0022\u003EPDF (364.42 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (364.42 KB) of Pharmacokinetics in Patients with Impaired Renal Function \u2014 Study Design, Data Analysis, and Impact on Dosing\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/15\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Pharmacology","field_topics":"","topics-product":"Clinical - Pharmacology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"12\/03\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0133 \u0022\u003EFDA-2010-D-0133 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-07-29T14:31:42-04:00\u0022\u003E2024-07-29 14:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/irritable-bowel-syndrome-clinical-evaluation-products-treatment\u0022\u003EIrritable Bowel Syndrome -- Clinical Evaluation of Products for Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/78622\/download\u0022\u003EPDF (317.13 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (317.13 KB) of Irritable Bowel Syndrome -- Clinical Evaluation of Products for Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/14\/2012","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0146\u0022\u003EFDA-2010-D-0146\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T01:35:25-04:00\u0022\u003E2020-04-24 01:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q8-q9-and-q10-questions-and-answers-r5\u0022\u003EQ8, Q9, and Q10 Questions and Answers (R5)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/78668\/download\u0022\u003EPDF (335.56 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (335.56 KB) of Q8, Q9, and Q10 Questions and Answers (R5)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/29\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6821\u0022\u003EFDA-2017-D-6821\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-05-29T10:50:01-04:00\u0022\u003E2026-05-29 10:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clinical-investigator-administrative-actions-disqualification\u0022\u003EClinical Investigator Administrative Actions - Disqualification: Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/164561\/download\u0022\u003EPDF (277.99 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (277.99 KB) of Clinical Investigator Administrative Actions - Disqualification: Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/01\/2022","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP)","field_topics":"","topics-product":"Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0265\u0022\u003EFDA-2010-D-0265\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222023-01-17T15:45:53-05:00\u0022\u003E2023-01-17 15:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommendations-premarket-notifications-lamotrigine-and-zonisamide-assays\u0022\u003ERecommendations for Premarket Notifications for Lamotrigine and Zonisamide Assays: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/78784\/download\u0022\u003EPDF (130.13 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (130.13 KB) of Recommendations for Premarket Notifications for Lamotrigine and Zonisamide Assays: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/09\/2016","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k)","field_topics":"Premarket","topics-product":"Premarket, 510(k)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0395\u0022\u003EFDA-2010-D-0395\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222019-03-14T11:27:38-04:00\u0022\u003E2019-03-14 11:27\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/frequently-asked-questions-statement-investigator-form-fda-1572\u0022\u003EFrequently Asked Questions \u2013 Statement of Investigator (Form FDA 1572): Guidance for Sponsors, Clinical Investigators, and IRBs \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/78830\/download\u0022\u003EPDF (105.19 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (105.19 KB) of Frequently Asked Questions \u2013 Statement of Investigator (Form FDA 1572): Guidance for Sponsors, Clinical Investigators, and IRBs \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/04\/2010","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Good Clinical Practice (GCP)","field_topics":"","topics-product":"Administrative \/ Procedural, Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0406\u0022\u003EFDA-2008-D-0406\u003C\/a\u003E","field_communication_type":"Information Sheet","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222020-04-21T11:45:16-04:00\u0022\u003E2020-04-21 11:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q4b-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-annex-13-bulk-density-and-tapped\u0022\u003EQ4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Annex 13: Bulk Density and Tapped Density of Powders General Chapter\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/78958\/download\u0022\u003EPDF (93.51 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (93.51 KB) of Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Annex 13: Bulk Density and Tapped Density of Powders General Chapter\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/28\/2013","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-08T14:55:09-04:00\u0022\u003E2020-04-08 14:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/organ-specific-warnings-internal-analgesic-antipyretic-and-antirheumatic-drug-products-over-counter\u0022\u003EOrgan-Specific Warnings: Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use \u2014 Small Entity Compliance Guide\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/79064\/download\u0022\u003EPDF (176.31 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (176.31 KB) of Organ-Specific Warnings: Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use \u2014 Small Entity Compliance Guide\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/17\/2010","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Over-the-Counter Drugs","field_topics":"","topics-product":"Over-the-Counter Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Small Entity Compliance Guide","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-15T01:10:03-04:00\u0022\u003E2020-05-15 01:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-188-data-elements-submission-veterinary-adverse-event-reports-center-veterinary-medicine\u0022\u003ECVM GFI #188 Data Elements for Submission of Veterinary Adverse Event Reports to the Center for Veterinary Medicine\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/79105\/download\u0022\u003EPDF (581.3 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (581.3 KB) of CVM GFI #188 Data Elements for Submission of Veterinary Adverse Event Reports to the Center for Veterinary Medicine\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/31\/2024","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Adverse Event Reporting","field_topics":"","topics-product":"Adverse Event Reporting","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0241\u0022\u003EFDA-2010-D-0241\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222024-02-01T12:47:17-05:00\u0022\u003E2024-02-01 12:47\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-209-judicious-use-medically-important-antimicrobial-drugs-food-producing-animals\u0022\u003ECVM GFI #209 The Judicious Use of Medically Important Antimicrobial Drugs in Food-Producing Animals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/79140\/download\u0022\u003EPDF (256.08 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (256.08 KB) of CVM GFI #209 The Judicious Use of Medically Important Antimicrobial Drugs in Food-Producing Animals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/13\/2012","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Antimicrobial Resistance","field_topics":"","topics-product":"Antimicrobial Resistance","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0094\u0022\u003EFDA-2010-D-0094\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:06:32-04:00\u0022\u003E2019-04-16 14:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cmc-postapproval-manufacturing-changes-be-documented-annual-reports\u0022\u003ECMC Postapproval Manufacturing Changes To Be Documented in Annual Reports\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/79182\/download\u0022\u003EPDF (298.36 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (298.36 KB) of CMC Postapproval Manufacturing Changes To Be Documented in Annual Reports\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/05\/2014","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0283\u0022\u003EFDA-2010-D-0283\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-02-15T15:17:18-05:00\u0022\u003E2024-02-15 15:17\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q4b-evaluation-and-recommendation-pharmacopoeial-texts-use-ich-regions-annex-14-bacterial-endotoxins\u0022\u003EQ4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions: Annex 14: Bacterial Endotoxins Test General Chapter\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/79183\/download\u0022\u003EPDF (96.23 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (96.23 KB) of Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions: Annex 14: Bacterial Endotoxins Test General Chapter\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/23\/2013","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0343\u0022\u003EFDA-2010-D-0343\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-13T14:50:02-04:00\u0022\u003E2020-04-13 14:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-200-secg-designation-new-animal-drugs-minor-uses-or-minor-species\u0022\u003ECVM GFI #200 SECG for Designation of New Animal Drugs for Minor Uses or Minor Species\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/79363\/download\u0022\u003EPDF (71.19 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (71.19 KB) of CVM GFI #200 SECG for Designation of New Animal Drugs for Minor Uses or Minor Species\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/29\/2014","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Minor Use\/ Minor Species (MUMS)","field_topics":"","topics-product":"Minor Use\/ Minor Species (MUMS)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0432\u0022\u003EFDA-2010-D-0432\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:06:29-04:00\u0022\u003E2019-04-16 14:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-201-secg-index-legally-marketed-unapproved-new-animal-drugs-minor-species\u0022\u003ECVM GFI #201 SECG for The Index of Legally Marketed Unapproved New Animal Drugs for Minor Species\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/79365\/download\u0022\u003EPDF (72.54 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (72.54 KB) of CVM GFI #201 SECG for The Index of Legally Marketed Unapproved New Animal Drugs for Minor Species\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/29\/2014","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Minor Use\/ Minor Species (MUMS)","field_topics":"","topics-product":"Minor Use\/ Minor Species (MUMS)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0435\u0022\u003EFDA-2010-D-0435\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:07:49-04:00\u0022\u003E2019-04-16 14:07\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/investigational-new-drug-applications-inds-determining-whether-human-research-studies-can-be\u0022\u003EInvestigational New Drug Applications (INDs) - Determining Whether Human Research Studies Can Be Conducted Without an IND: Guidance for Clinical Investigators, Sponsors, and IRBs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/79386\/download\u0022\u003EPDF (305.09 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (305.09 KB) of Investigational New Drug Applications (INDs) - Determining Whether Human Research Studies Can Be Conducted Without an IND: Guidance for Clinical Investigators, Sponsors, and IRBs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/10\/2013","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Good Clinical Practice (GCP)","field_topics":"","topics-product":"Clinical - Medical, Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0503\u0022\u003EFDA-2010-D-0503\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs, Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:05:31-04:00\u0022\u003E2024-10-01 07:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/non-clinical-and-clinical-investigation-devices-used-treatment-benign-prostatic-hyperplasia-bph\u0022\u003ENon-Clinical and Clinical Investigation of Devices Used for the Treatment of Benign Prostatic Hyperplasia (BPH): Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/79397\/download\u0022\u003EPDF (612.88 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (612.88 KB) of Non-Clinical and Clinical Investigation of Devices Used for the Treatment of Benign Prostatic Hyperplasia (BPH): Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/27\/2021","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Gastroenterology-Urology , Good Clinical Practice (GCP)","field_topics":"Premarket","topics-product":"Premarket, Gastroenterology-Urology , Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1118\u0022\u003EFDA-2020-D-1118\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222021-12-23T08:50:17-05:00\u0022\u003E2021-12-23 08:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/residual-drug-transdermal-and-related-drug-delivery-systems\u0022\u003EResidual Drug in Transdermal and Related Drug Delivery Systems: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/79401\/download\u0022\u003EPDF (43.68 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (43.68 KB) of Residual Drug in Transdermal and Related Drug Delivery Systems: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/17\/2011","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0246\u0022\u003EFDA-2010-D-0246\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-23T11:45:10-04:00\u0022\u003E2020-04-23 11:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/qualification-process-drug-development-tools-guidance-industry-and-fda-staff\u0022\u003EQualification Process for Drug Development Tools Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/133511\/download\u0022\u003EPDF (167.65 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (167.65 KB) of Qualification Process for Drug Development Tools Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/24\/2020","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Clinical - Medical, Drug Development Tools","field_topics":"","topics-product":"Administrative \/ Procedural, Clinical - Medical, Drug Development Tools","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0529\u0022\u003EFDA-2010-D-0529\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-11-24T08:55:03-05:00\u0022\u003E2020-11-24 08:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/chronic-hepatitis-c-virus-infection-developing-direct-acting-antiviral-drugs-treatment-guidance\u0022\u003EChronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Drugs for Treatment Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/79486\/download\u0022\u003EPDF (257.59 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (257.59 KB) of Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Drugs for Treatment Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/07\/2017","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-1170\u0022\u003EFDA-2013-D-1170\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-04T14:50:06-04:00\u0022\u003E2020-05-04 14:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/hospital-acquired-bacterial-pneumonia-and-ventilator-associated-bacterial-pneumonia-developing-drugs\u0022\u003EHospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Developing Drugs for Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/79516\/download\u0022\u003EPDF (293.52 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (293.52 KB) of Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Developing Drugs for Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/06\/2014","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0589\u0022\u003EFDA-2010-D-0589\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-02-04T17:10:32-05:00\u0022\u003E2025-02-04 17:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/size-beads-drug-products-labeled-sprinkle-rev1\u0022\u003ESize of Beads in Drug Products Labeled for Sprinkle Rev.1: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/79676\/download\u0022\u003EPDF (147.91 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (147.91 KB) of Size of Beads in Drug Products Labeled for Sprinkle Rev.1: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/16\/2012","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0021\u0022\u003EFDA-2011-D-0021\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T15:00:35-04:00\u0022\u003E2020-04-24 15:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-215-target-animal-safety-effectiveness-protocol-development-submission\u0022\u003ECVM GFI #215 Target Animal Safety \u0026amp; Effectiveness Protocol Development \u0026amp; Submission\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/79732\/download\u0022\u003EPDF (62.96 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (62.96 KB) of CVM GFI #215 Target Animal Safety \u0026amp; Effectiveness Protocol Development \u0026amp; Submission\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/29\/2011","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Target Animal \u2013 Effectiveness, Target Animal \u2013 Safety","field_topics":"","topics-product":"Target Animal \u2013 Effectiveness, Target Animal \u2013 Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0023\u0022\u003EFDA-2011-D-0023\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:10:12-04:00\u0022\u003E2019-04-16 14:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/chapter-48-7348809a-radioactive-drug-research-committee\u0022\u003EChapter 48 7348.809A Radioactive Drug Research Committee\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/79759\/download\u0022\u003EPDF (537.33 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (537.33 KB) of Chapter 48 7348.809A Radioactive Drug Research Committee\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"","changed":"\u003Ctime datetime=\u00222018-12-01T02:43:17-05:00\u0022\u003E2018-12-01 02:43\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/medication-guides-distribution-requirements-and-inclusion-risk-evaluation-and-mitigation-strategies\u0022\u003EMedication Guides \u2014 Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/79776\/download\u0022\u003EPDF (91.2 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (91.2 KB) of Medication Guides \u2014 Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/18\/2011","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Safety - Issues, Errors, and Problems","field_topics":"","topics-product":"Safety - Issues, Errors, and Problems","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-04-07T16:28:34-04:00\u0022\u003E2026-04-07 16:28\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-211-residual-solvents-animal-drug-products-questions-and-answers\u0022\u003ECVM GFI #211 Residual Solvents in Animal Drug Products Questions and Answers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/79782\/download\u0022\u003EPDF (75.83 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (75.83 KB) of CVM GFI #211 Residual Solvents in Animal Drug Products Questions and Answers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/03\/2015","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC)","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0566\u0022\u003EFDA-2010-D-0566\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:07:13-04:00\u0022\u003E2019-04-16 14:07\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/dear-health-care-provider-letters-improving-communication-important-safety-information\u0022\u003EDear Health Care Provider Letters: Improving Communication of Important Safety Information\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/79793\/download\u0022\u003EPDF (346.39 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (346.39 KB) of Dear Health Care Provider Letters: Improving Communication of Important Safety Information\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/02\/2014","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0319\u0022\u003EFDA-2010-D-0319\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-05-15T13:51:03-04:00\u0022\u003E2026-05-15 13:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/potency-tests-cellular-and-gene-therapy-products\u0022\u003EPotency Tests for Cellular and Gene Therapy Products: Final Guidance for Industry:\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/79856\/download\u0022\u003EPDF (121.48 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (121.48 KB) of Potency Tests for Cellular and Gene Therapy Products: Final Guidance for Industry:\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/01\/2011","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Gene Therapy","field_topics":"Cellular \u0026amp; Gene Therapy","topics-product":"Cellular \u0026amp; Gene Therapy, Gene Therapy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0520\u0022\u003EFDA-2008-D-0520\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222019-05-16T16:50:12-04:00\u0022\u003E2019-05-16 16:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-216-chemistry-manufacturing-and-controls-cmc-information-fermentation-derived-intermediates\u0022\u003ECVM GFI #216 Chemistry, Manufacturing, and Controls (CMC) Information - Fermentation-Derived Intermediates, Drug Substances, and Related Drug Products for Veterinary Medicinal Use\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/79873\/download\u0022\u003EPDF (78.44 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (78.44 KB) of CVM GFI #216 Chemistry, Manufacturing, and Controls (CMC) Information - Fermentation-Derived Intermediates, Drug Substances, and Related Drug Products for Veterinary Medicinal Use\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/08\/2012","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC)","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0112\u0022\u003EFDA-2011-D-0112\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:10:15-04:00\u0022\u003E2019-04-16 14:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/open-public-hearing-fda-advisory-committee-meetings\u0022\u003EThe Open Public Hearing at FDA Advisory Committee Meetings: Guidance for the Public, FDA Advisory Committee Members, and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/79874\/download\u0022\u003EPDF (68.71 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (68.71 KB) of The Open Public Hearing at FDA Advisory Committee Meetings: Guidance for the Public, FDA Advisory Committee Members, and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/15\/2013","field_issuing_office_taxonomy":"Office of the Commissioner","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"Advisory Committees","topics-product":"Advisory Committees, Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222019-04-20T23:10:06-04:00\u0022\u003E2019-04-20 23:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/non-penicillin-beta-lactam-drugs-cgmp-framework-preventing-cross-contamination\u0022\u003ENon-Penicillin Beta-Lactam Drugs: A CGMP Framework for Preventing Cross-Contamination: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/79971\/download\u0022\u003EPDF (70.18 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (70.18 KB) of Non-Penicillin Beta-Lactam Drugs: A CGMP Framework for Preventing Cross-Contamination: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/17\/2013","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_topics":"","topics-product":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0104\u0022\u003EFDA-2011-D-0104\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-14T13:25:05-04:00\u0022\u003E2020-05-14 13:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-527300-dairy-products-microbial-contaminants-alkaline-phosphatase-activity\u0022\u003ECPG Sec 527.300 Dairy Products - Microbial Contaminants \u0026amp; Alkaline Phosphatase Activity\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/80058\/download\u0022\u003EPDF (99.92 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (99.92 KB) of CPG Sec 527.300 Dairy Products - Microbial Contaminants \u0026amp; Alkaline Phosphatase Activity\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/01\/2010","field_issuing_office_taxonomy":"Office of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T08:44:23-04:00\u0022\u003E2024-10-01 08:44\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-527300-microbial-contaminants-alkaline-phosphatase-activity\u0022\u003ECPG Sec 527.300 Microbial Contaminants \u0026amp; Alkaline Phosphatase Activity\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/80074\/download\u0022\u003EPDF (103.81 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (103.81 KB) of CPG Sec 527.300 Microbial Contaminants \u0026amp; Alkaline Phosphatase Activity\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/23\/2010","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Dairy","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Dairy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"02\/21\/2010","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0466\u0022\u003EFDA-2009-D-0466\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:15:34-05:00\u0022\u003E2025-03-06 21:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/lookback-hepatitis-c-virus-hcv-product-quarantine-consignee-notification-further-testing-product\u0022\u003E\u201cLookback\u201d for Hepatitis C Virus (HCV): Product Quarantine, Consignee Notification, Further Testing, Product Disposition, and Notification of Transfusion Recipients Based on Donor Test Results Indicating Infection with HCV: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/124265\/download\u0022\u003EPDF (182.57 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (182.57 KB) of \u201cLookback\u201d for Hepatitis C Virus (HCV): Product Quarantine, Consignee Notification, Further Testing, Product Disposition, and Notification of Transfusion Recipients Based on Donor Test Results Indicating Infection with HCV: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/01\/2010","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1999-D-0002\u0022\u003EFDA-1999-D-0002\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-04-22T09:03:46-04:00\u0022\u003E2024-04-22 09:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/codevelopment-two-or-more-new-investigational-drugs-use-combination\u0022\u003ECodevelopment of Two or More New Investigational Drugs for Use in Combination\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/80100\/download\u0022\u003EPDF (91.31 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (91.31 KB) of Codevelopment of Two or More New Investigational Drugs for Use in Combination\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/14\/2013","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0616\u0022\u003EFDA-2010-D-0616\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T11:45:19-04:00\u0022\u003E2020-05-06 11:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/reprocessing-medical-devices-health-care-settings-validation-methods-and-labeling\u0022\u003EReprocessing Medical Devices in Health Care Settings: Validation Methods and Labeling : Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/80265\/download\u0022\u003EPDF (902.13 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (902.13 KB) of Reprocessing Medical Devices in Health Care Settings: Validation Methods and Labeling : Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/17\/2015","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Investigational Device Exemption (IDE), Premarket Approval (PMA)","field_topics":"Premarket","topics-product":"Premarket, 510(k), Investigational Device Exemption (IDE), Premarket Approval (PMA)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0293\u0022\u003EFDA-2011-D-0293\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222026-02-06T12:44:49-05:00\u0022\u003E2026-02-06 12:44\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/topical-acne-drug-products-over-counter-human-use-revision-labeling-and-classification-benzoyl\u0022\u003ETopical Acne Drug Products for Over-the-Counter Human Use--Revision of Labeling and Classification of Benzoyl Peroxide as Safe and Effective: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/80442\/download\u0022\u003EPDF (122.51 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (122.51 KB) of Topical Acne Drug Products for Over-the-Counter Human Use--Revision of Labeling and Classification of Benzoyl Peroxide as Safe and Effective: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/21\/2011","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling, Over-the-Counter Drugs","field_topics":"","topics-product":"Labeling, Over-the-Counter Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0404\u0022\u003EFDA-2011-D-0404\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-10-17T14:15:24-04:00\u0022\u003E2019-10-17 14:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/applying-human-factors-and-usability-engineering-medical-devices\u0022\u003EApplying Human Factors and Usability Engineering to Medical Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/80481\/download\u0022\u003EPDF (1.4 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.4 MB) of Applying Human Factors and Usability Engineering to Medical Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/03\/2026","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Safety - Issues, Errors, and Problems","field_topics":"Postmarket, Premarket","topics-product":"Postmarket, Premarket, Safety - Issues, Errors, and Problems","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0469\u0022\u003EFDA-2011-D-0469\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222026-08-03T09:45:06-04:00\u0022\u003E2026-08-03 09:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/content-investigational-device-exemption-ide-and-premarket-approval-pma-applications-artificial\u0022\u003EThe Content of Investigational Device Exemption (IDE) and Premarket Approval (PMA) Applications for Artificial Pancreas Device Systems: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/80644\/download\u0022\u003EPDF (688.74 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (688.74 KB) of The Content of Investigational Device Exemption (IDE) and Premarket Approval (PMA) Applications for Artificial Pancreas Device Systems: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/09\/2012","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Premarket Approval (PMA), Investigational Device Exemption (IDE)","field_topics":"Premarket","topics-product":"Premarket, Premarket Approval (PMA), Investigational Device Exemption (IDE)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0464\u0022\u003EFDA-2011-D-0464\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-02-28T14:07:20-05:00\u0022\u003E2020-02-28 14:07\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q3c-maintenance-procedures\u0022\u003EQ3C Maintenance Procedures\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/80680\/download\u0022\u003EPDF (94.02 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (94.02 KB) of Q3C Maintenance Procedures\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/24\/2017","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-10-23T07:42:31-04:00\u0022\u003E2023-10-23 07:42\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/donors-blood-and-blood-components-notification-donor-deferral-small-entity-compliance-guide\u0022\u003EDonors of Blood and Blood Components: Notification of Donor Deferral, Small Entity Compliance Guide: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/80682\/download\u0022\u003EPDF (44.98 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (44.98 KB) of Donors of Blood and Blood Components: Notification of Donor Deferral, Small Entity Compliance Guide: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/01\/2011","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1998-N-1016\u0022\u003EFDA-1998-N-1016\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222019-08-22T14:50:43-04:00\u0022\u003E2019-08-22 14:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/computer-crossmatch-computerized-analysis-compatibility-between-donors-cell-type-and-recipients\u0022\u003E\u0026quot;Computer Crossmatch\u0026quot; (Computerized Analysis of the Compatibility between the Donor\u0026#039;s Cell Type and the Recipient\u0026#039;s Serum or Plasma Type); : Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/80857\/download\u0022\u003EPDF (77.86 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (77.86 KB) of \u0026quot;Computer Crossmatch\u0026quot; (Computerized Analysis of the Compatibility between the Donor\u0026#039;s Cell Type and the Recipient\u0026#039;s Serum or Plasma Type); : Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/01\/2011","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2007-D-0019\u0022\u003EFDA-2007-D-0019\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222019-05-15T11:55:04-04:00\u0022\u003E2019-05-15 11:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-335700-surgeons-gloves-and-patient-examination-gloves-defects-criteria-direct-reference\u0022\u003ECPG Sec. 335.700 Surgeons\u0026#039; Gloves and Patient Examination Gloves; Defects - Criteria for Direct Reference Seizure\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/80870\/download\u0022\u003EPDF (17.19 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (17.19 KB) of CPG Sec. 335.700 Surgeons\u0026#039; Gloves and Patient Examination Gloves; Defects - Criteria for Direct Reference Seizure\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/2011","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-11-14T16:25:28-05:00\u0022\u003E2024-11-14 16:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q11-development-and-manufacture-drug-substances\u0022\u003EQ11 Development and Manufacture of Drug Substances\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/80909\/download\u0022\u003EPDF (708.32 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (708.32 KB) of Q11 Development and Manufacture of Drug Substances\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/20\/2012","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-05-27T12:55:31-04:00\u0022\u003E2026-05-27 12:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/policy-device-software-functions-and-mobile-medical-applications\u0022\u003EPolicy for Device Software Functions and Mobile Medical Applications: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/80958\/download\u0022\u003EPDF (844.39 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (844.39 KB) of Policy for Device Software Functions and Mobile Medical Applications: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/28\/2022","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Digital Health","field_topics":"Premarket","topics-product":"Premarket, Digital Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0530\u0022\u003EFDA-2011-D-0530\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222022-09-27T17:13:53-04:00\u0022\u003E2022-09-27 17:13\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/postmarket-surveillance-under-section-522-federal-food-drug-and-cosmetic-act\u0022\u003EPostmarket Surveillance Under Section 522 of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/81015\/download\u0022\u003EPDF (630.67 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (630.67 KB) of Postmarket Surveillance Under Section 522 of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/07\/2022","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0514\u0022\u003EFDA-2011-D-0514\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222022-10-17T13:47:47-04:00\u0022\u003E2022-10-17 13:47\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pet-drugs-current-good-manufacturing-practice-cgmp-small-entity-compliance-guide\u0022\u003EPET Drugs--Current Good Manufacturing Practice (CGMP); Small Entity Compliance Guide\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/81038\/download\u0022\u003EPDF (228.68 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (228.68 KB) of PET Drugs--Current Good Manufacturing Practice (CGMP); Small Entity Compliance Guide\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/05\/2011","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_topics":"","topics-product":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0541\u0022\u003EFDA-2011-D-0541\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-15T01:55:02-04:00\u0022\u003E2020-05-15 01:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-214-vich-gl35-pharmacovigilance-veterinary-medicinal-products-electronic-standards-transfer\u0022\u003ECVM GFI #214 (VICH GL35) Pharmacovigilance of Veterinary Medicinal Products Electronic Standards for Transfer of Data\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/81045\/download\u0022\u003EPDF (2.36 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (2.36 MB) of CVM GFI #214 (VICH GL35) Pharmacovigilance of Veterinary Medicinal Products Electronic Standards for Transfer of Data\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/31\/2024","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Adverse Event Reporting, VICH","field_topics":"","topics-product":"Adverse Event Reporting, VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0588\u0022\u003EFDA-2011-D-0588\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222024-02-01T07:04:39-05:00\u0022\u003E2024-02-01 07:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/self-selection-studies-nonprescription-drug-products\u0022\u003ESelf-Selection Studies for Nonprescription Drug Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/81141\/download\u0022\u003EPDF (159.78 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (159.78 KB) of Self-Selection Studies for Nonprescription Drug Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/11\/2013","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Over-the-Counter Drugs","field_topics":"","topics-product":"Over-the-Counter Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0620\u0022\u003EFDA-2011-D-0620\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T14:50:23-04:00\u0022\u003E2020-04-24 14:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clinical-trial-imaging-endpoint-process-standards-guidance-industry\u0022\u003EClinical Trial Imaging Endpoint Process Standards Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/81172\/download\u0022\u003EPDF (186.17 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (186.17 KB) of Clinical Trial Imaging Endpoint Process Standards Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/27\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0586\u0022\u003EFDA-2011-D-0586\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-12T09:05:04-04:00\u0022\u003E2020-05-12 09:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/availability-fdas-esubmitter-program-regulatory-submissions-licensed-blood-establishments\u0022\u003EAvailability of FDA\u2019s eSubmitter Program for Regulatory Submissions from Licensed Blood Establishments: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/81207\/download\u0022\u003EPDF (29.04 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (29.04 KB) of Availability of FDA\u2019s eSubmitter Program for Regulatory Submissions from Licensed Blood Establishments: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/01\/2011","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0579\u0022\u003EFDA-2011-D-0579\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222019-08-22T14:40:23-04:00\u0022\u003E2019-08-22 14:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/in-vitro-companion-diagnostic-devices\u0022\u003EIn Vitro Companion Diagnostic Devices: Guidance for Industry and Food and Drug Administration Staff \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/81309\/download\u0022\u003EPDF (159.23 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (159.23 KB) of In Vitro Companion Diagnostic Devices: Guidance for Industry and Food and Drug Administration Staff \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/06\/2014","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0215\u0022\u003EFDA-2011-D-0215\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-02T09:22:55-05:00\u0022\u003E2020-03-02 09:22\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e16-biomarkers-related-drug-or-biotechnology-product-development-context-structure-and-format\u0022\u003EE16 Biomarkers Related to Drug or Biotechnology Product Development: Context, Structure, and Format of Qualification Submissions\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/81311\/download\u0022\u003EPDF (111.49 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (111.49 KB) of E16 Biomarkers Related to Drug or Biotechnology Product Development: Context, Structure, and Format of Qualification Submissions\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/11\/2011","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Efficacy","field_topics":"","topics-product":"ICH-Efficacy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0324\u0022\u003EFDA-2009-D-0324\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-20T08:05:31-04:00\u0022\u003E2020-04-20 08:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/neglected-tropical-diseases-developing-world-developing-drugs-treatment-or-prevention\u0022\u003ENeglected Tropical Diseases of the Developing World: Developing Drugs for Treatment or Prevention\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/81312\/download\u0022\u003EPDF (364.01 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (364.01 KB) of Neglected Tropical Diseases of the Developing World: Developing Drugs for Treatment or Prevention\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/07\/2014","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0587\u0022\u003EFDA-2011-D-0587\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-14T11:34:57-04:00\u0022\u003E2020-05-14 11:34\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/modifications-devices-subject-premarket-approval-pma-pma-supplement-decision-making-process\u0022\u003EModifications to Devices Subject to Premarket Approval (PMA) - The PMA Supplement Decision-Making Process: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/81431\/download\u0022\u003EPDF (660.23 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (660.23 KB) of Modifications to Devices Subject to Premarket Approval (PMA) - The PMA Supplement Decision-Making Process: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/11\/2008","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Premarket Approval (PMA)","field_topics":"Premarket","topics-product":"Premarket, Premarket Approval (PMA)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2007-D-0025\u0022\u003EFDA-2007-D-0025\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222022-02-08T12:16:04-05:00\u0022\u003E2022-02-08 12:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/exculpatory-language-informed-consent\u0022\u003EExculpatory Language in Informed Consent\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/81521\/download\u0022\u003EPDF (112.4 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (112.4 KB) of Exculpatory Language in Informed Consent\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/19\/2011","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP)","field_topics":"","topics-product":"Good Clinical Practice (GCP)","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"11\/01\/2011","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/HHS-OPHS-2011-0014\u0022\u003EHHS-OPHS-2011-0014\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222021-07-21T10:01:07-04:00\u0022\u003E2021-07-21 10:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/tablet-scoringnomenclature-labeling-and-data-evaluation\u0022\u003ETablet Scoring:Nomenclature, Labeling, and Data for Evaluation\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/81626\/download\u0022\u003EPDF (55.61 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (55.61 KB) of Tablet Scoring:Nomenclature, Labeling, and Data for Evaluation\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/13\/2013","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0595\u0022\u003EFDA-2011-D-0595\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-05T14:20:23-04:00\u0022\u003E2020-05-05 14:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/investigational-device-exemptions-ides-early-feasibility-medical-device-clinical-studies-including\u0022\u003EInvestigational Device Exemptions (IDEs) for Early Feasibility Medical Device Clinical Studies, Including Certain First in Human (FIH) Studies: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/81784\/download\u0022\u003EPDF (1.44 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.44 MB) of Investigational Device Exemptions (IDEs) for Early Feasibility Medical Device Clinical Studies, Including Certain First in Human (FIH) Studies: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/01\/2013","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP), Investigational Device Exemption (IDE)","field_topics":"Premarket","topics-product":"Premarket, Good Clinical Practice (GCP), Investigational Device Exemption (IDE)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0787\u0022\u003EFDA-2011-D-0787\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-02-28T14:50:36-05:00\u0022\u003E2020-02-28 14:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/fda-decisions-investigational-device-exemption-clinical-investigations\u0022\u003EFDA Decisions for Investigational Device Exemption Clinical Investigations: Guidance for Sponsors, Clinical Investigators, Institutional Review Boards, and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/81792\/download\u0022\u003EPDF (630.79 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (630.79 KB) of FDA Decisions for Investigational Device Exemption Clinical Investigations: Guidance for Sponsors, Clinical Investigators, Institutional Review Boards, and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/19\/2014","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Investigational Device Exemption (IDE)","field_topics":"Premarket","topics-product":"Premarket, Investigational Device Exemption (IDE)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0790\u0022\u003EFDA-2011-D-0790\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222021-04-26T13:36:03-04:00\u0022\u003E2021-04-26 13:36\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/regulatory-classification-pharmaceutical-co-crystals\u0022\u003ERegulatory Classification of Pharmaceutical Co-Crystals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/81824\/download\u0022\u003EPDF (86.7 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (86.7 KB) of Regulatory Classification of Pharmaceutical Co-Crystals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/15\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0800\u0022\u003EFDA-2011-D-0800\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-17T14:45:12-04:00\u0022\u003E2020-04-17 14:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-217-evaluating-effectiveness-anticoccidial-drugs-food-producing-animals\u0022\u003ECVM GFI #217 Evaluating the Effectiveness of Anticoccidial Drugs in Food-Producing Animals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/81837\/download\u0022\u003EPDF (265.46 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (265.46 KB) of CVM GFI #217 Evaluating the Effectiveness of Anticoccidial Drugs in Food-Producing Animals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/20\/2012","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Target Animal \u2013 Effectiveness","field_topics":"","topics-product":"Target Animal \u2013 Effectiveness","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0784\u0022\u003EFDA-2011-D-0784\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:15:14-04:00\u0022\u003E2019-04-16 14:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/implementation-acceptable-full-length-and-abbreviated-donor-history-questionnaires-and-accompanying\u0022\u003EImplementation of Acceptable Full-Length and Abbreviated Donor History Questionnaires and Accompanying Materials for Use in Screening Donors of Blood and Blood Components: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/124193\/download\u0022\u003EPDF (248.04 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (248.04 KB) of Implementation of Acceptable Full-Length and Abbreviated Donor History Questionnaires and Accompanying Materials for Use in Screening Donors of Blood and Blood Components: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/11\/2023","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Blood","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-1342\u0022\u003EFDA-2016-D-1342\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222023-09-26T14:25:16-04:00\u0022\u003E2023-09-26 14:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/media-fills-validation-aseptic-preparations-positron-emission-tomography\u0022\u003EMedia Fills for Validation of Aseptic Preparations for Positron Emission Tomography\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/81974\/download\u0022\u003EPDF (155.82 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (155.82 KB) of Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/11\/2012","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_topics":"","topics-product":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0691\u0022\u003EFDA-2011-D-0691\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T13:30:24-04:00\u0022\u003E2020-04-24 13:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/evaluation-sex-specific-data-medical-device-clinical-studies-guidance-industry-and-food-and-drug\u0022\u003EEvaluation of Sex-Specific Data in Medical Device Clinical Studies - Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/82005\/download\u0022\u003EPDF (823.44 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (823.44 KB) of Evaluation of Sex-Specific Data in Medical Device Clinical Studies - Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/31\/2025","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP)","field_topics":"Premarket","topics-product":"Premarket, Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0817\u0022\u003EFDA-2011-D-0817\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222025-03-31T14:17:16-04:00\u0022\u003E2025-03-31 14:17\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/general-principles-development-vaccines-protect-against-global-infectious-diseases\u0022\u003E General Principles for the Development of Vaccines to Protect Against Global Infectious Diseases: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/82306\/download\u0022\u003EPDF (57.63 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (57.63 KB) of General Principles for the Development of Vaccines to Protect Against Global Infectious Diseases: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/01\/2011","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Vaccines","field_topics":"","topics-product":"Vaccines","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0855\u0022\u003EFDA-2011-D-0855\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222019-08-21T16:10:03-04:00\u0022\u003E2019-08-21 16:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clinical-considerations-therapeutic-cancer-vaccines\u0022\u003EClinical Considerations for Therapeutic Cancer Vaccines: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/82312\/download\u0022\u003EPDF (75.13 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (75.13 KB) of Clinical Considerations for Therapeutic Cancer Vaccines: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/01\/2011","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Gene Therapy, Vaccines, Good Clinical Practice (GCP)","field_topics":"Cellular \u0026amp; Gene Therapy","topics-product":"Cellular \u0026amp; Gene Therapy, Gene Therapy, Vaccines, Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0427\u0022\u003EFDA-2009-D-0427\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222019-08-21T15:55:04-04:00\u0022\u003E2019-08-21 15:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/510k-program-evaluating-substantial-equivalence-premarket-notifications-510k\u0022\u003EThe 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/82395\/download\u0022\u003EPDF (843.9 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (843.9 KB) of The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/28\/2014","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Administrative \/ Procedural","field_topics":"Premarket","topics-product":"Premarket, 510(k), Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0652\u0022\u003EFDA-2011-D-0652\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222019-03-28T15:20:09-04:00\u0022\u003E2019-03-28 15:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/preparation-ides-and-inds-products-intended-repair-or-replace-knee-cartilage\u0022\u003EPreparation of IDEs and INDs for Products Intended to Repair or Replace Knee Cartilage: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/82562\/download\u0022\u003EPDF (156.52 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (156.52 KB) of Preparation of IDEs and INDs for Products Intended to Repair or Replace Knee Cartilage: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/01\/2011","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Gene Therapy","field_topics":"Cellular \u0026amp; Gene Therapy","topics-product":"Cellular \u0026amp; Gene Therapy, Gene Therapy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2007-D-0020\u0022\u003EFDA-2007-D-0020\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222019-08-23T11:10:06-04:00\u0022\u003E2019-08-23 11:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/questions-and-answers-informed-consent-elements-21-cfr-ss-5025c\u0022\u003EQuestions and Answers on Informed Consent Elements, 21 CFR \u00a7 50.25(c): Guidance for Sponsors, Investigators, and Institutional Review Boards \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/82634\/download\u0022\u003EPDF (56.28 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (56.28 KB) of Questions and Answers on Informed Consent Elements, 21 CFR \u00a7 50.25(c): Guidance for Sponsors, Investigators, and Institutional Review Boards \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/01\/2012","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Policy, Legislation, and International Affairs,Office of Policy","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP)","field_topics":"","topics-product":"Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Small Entity Compliance Guide","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222019-04-19T14:45:11-04:00\u0022\u003E2019-04-19 14:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/development-therapeutic-protein-biosimilars-comparative-analytical-assessment-and-other-quality\u0022\u003EDevelopment of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/159261\/download\u0022\u003EPDF (432.23 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (432.23 KB) of Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/09\/2025","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Biosimilars","field_topics":"","topics-product":"Biosimilars","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-2102\u0022\u003EFDA-2019-D-2102\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-05-04T19:51:29-04:00\u0022\u003E2026-05-04 19:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/responding-unsolicited-requests-label-information-about-prescription-drugs-and-medical-devices\u0022\u003EResponding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/82660\/download\u0022\u003EPDF (302.29 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (302.29 KB) of Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/30\/2011","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Veterinary Medicine","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0868\u0022\u003EFDA-2011-D-0868\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-02-01T11:35:13-05:00\u0022\u003E2021-02-01 11:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/determining-extent-safety-data-collection-needed-late-stage-premarket-and-postapproval-clinical\u0022\u003EDetermining the Extent of Safety Data Collection Needed in Late Stage Premarket and Postapproval Clinical Investigations\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/82664\/download\u0022\u003EPDF (140.43 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (140.43 KB) of Determining the Extent of Safety Data Collection Needed in Late Stage Premarket and Postapproval Clinical Investigations\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/19\/2016","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-0096\u0022\u003EFDA-2012-D-0096\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-15T08:55:02-04:00\u0022\u003E2020-04-15 08:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/providing-regulatory-submissions-electronic-format-standardized-study-data\u0022\u003EProviding Regulatory Submissions in Electronic Format -- Standardized Study Data\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/82716\/download\u0022\u003EPDF (161.89 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (161.89 KB) of Providing Regulatory Submissions in Electronic Format -- Standardized Study Data\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/22\/2021","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Electronic Submissions","topics-product":"Electronic Submissions, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-0097\u0022\u003EFDA-2012-D-0097\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-01-03T11:01:11-05:00\u0022\u003E2022-01-03 11:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/current-good-tissue-practice-cgtp-and-additional-requirements-manufacturers-human-cells-tissues-and\u0022\u003ECurrent Good Tissue Practice (CGTP) and Additional Requirements for Manufacturers of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\/Ps): Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/82724\/download\u0022\u003EPDF (621.08 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (621.08 KB) of Current Good Tissue Practice (CGTP) and Additional Requirements for Manufacturers of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\/Ps): Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/01\/2011","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Tissue","field_topics":"","topics-product":"Tissue","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA\u20132008\u2013D\u20130659\u0022\u003EFDA\u20132008\u2013D\u20130659\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222023-08-16T10:33:46-04:00\u0022\u003E2023-08-16 10:33\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/m3r2nonclinical-safety-studies-conduct-human-clinical-trials-and-marketing-authorization\u0022\u003EM3(R2)Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals: Questions and Answers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/82725\/download\u0022\u003EPDF (311.38 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (311.38 KB) of M3(R2)Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals: Questions and Answers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/13\/2013","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Multidisciplinary","field_topics":"","topics-product":"ICH-Multidisciplinary","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0470\u0022\u003EFDA-2008-D-0470\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T15:50:33-04:00\u0022\u003E2020-04-24 15:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/considerations-use-histopathology-and-its-associated-methodologies-support-biomarker-qualification\u0022\u003EConsiderations for Use of Histopathology and Its Associated Methodologies to Support Biomarker Qualification Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/82768\/download\u0022\u003EPDF (125.91 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (125.91 KB) of Considerations for Use of Histopathology and Its Associated Methodologies to Support Biomarker Qualification Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/16\/2016","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Good Clinical Practice (GCP)","field_topics":"","topics-product":"Administrative \/ Procedural, Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0872\u0022\u003EFDA-2011-D-0872\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-07T18:20:19-04:00\u0022\u003E2020-05-07 18:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/fda-oversight-pet-drug-products-questions-and-answers\u0022\u003EFDA Oversight of PET Drug Products -- Questions and Answers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/82911\/download\u0022\u003EPDF (498.96 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (498.96 KB) of FDA Oversight of PET Drug Products -- Questions and Answers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/03\/2012","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-04-10T14:15:06-04:00\u0022\u003E2019-04-10 14:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/heparin-drug-and-medical-device-use-monitoring-crude-heparin-quality\u0022\u003EHeparin for Drug and Medical Device Use: Monitoring Crude Heparin for Quality: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/82924\/download\u0022\u003EPDF (66.18 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (66.18 KB) of Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Quality: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/25\/2013","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_topics":"","topics-product":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-0083\u0022\u003EFDA-2012-D-0083\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-02-28T14:30:31-05:00\u0022\u003E2020-02-28 14:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/early-clinical-trials-live-biotherapeutic-products-chemistry-manufacturing-and-control-information\u0022\u003EEarly Clinical Trials With Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/82945\/download\u0022\u003EPDF (174.31 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (174.31 KB) of Early Clinical Trials With Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/30\/2016","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP)","field_topics":"","topics-product":"Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0500\u0022\u003EFDA-2010-D-0500\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222021-07-22T11:05:04-04:00\u0022\u003E2021-07-22 11:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/investigational-new-drug-applications-positron-emission-tomography-pet-drugs\u0022\u003EInvestigational New Drug Applications for Positron Emission Tomography (PET) Drugs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/83077\/download\u0022\u003EPDF (368.85 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (368.85 KB) of Investigational New Drug Applications for Positron Emission Tomography (PET) Drugs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/03\/2012","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-0081\u0022\u003EFDA-2012-D-0081\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T01:20:25-04:00\u0022\u003E2020-04-24 01:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/irb-continuing-review-after-clinical-investigation-approval\u0022\u003EIRB Continuing Review After Clinical Investigation Approval: Guidance for IRBs, Clinical Investigators, and Sponsors\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/83121\/download\u0022\u003EPDF (144.99 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (144.99 KB) of IRB Continuing Review After Clinical Investigation Approval: Guidance for IRBs, Clinical Investigators, and Sponsors\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/27\/2012","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Good Clinical Practice (GCP)","field_topics":"","topics-product":"Administrative \/ Procedural, Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0605\u0022\u003EFDA-2009-D-0605\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222020-04-24T15:10:02-04:00\u0022\u003E2020-04-24 15:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pediatric-information-x-ray-imaging-device-premarket-notifications\u0022\u003EPediatric Information for X-ray Imaging Device Premarket Notifications: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/83281\/download\u0022\u003EPDF (671.92 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (671.92 KB) of Pediatric Information for X-ray Imaging Device Premarket Notifications: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/28\/2017","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Pediatric Product Development, Radiology","field_topics":"Premarket","topics-product":"Premarket, 510(k), Pediatric Product Development, Radiology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-0384\u0022\u003EFDA-2012-D-0384\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222024-04-08T11:33:16-04:00\u0022\u003E2024-04-08 11:33\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e2cr2-periodic-benefit-risk-evaluation-report-pbrer\u0022\u003EE2C(R2) Periodic Benefit-Risk Evaluation Report (PBRER)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/83371\/download\u0022\u003EPDF (461.54 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (461.54 KB) of E2C(R2) Periodic Benefit-Risk Evaluation Report (PBRER)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/18\/2016","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Efficacy","field_topics":"","topics-product":"ICH-Efficacy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-0315\u0022\u003EFDA-2012-D-0315\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-12-29T14:13:01-05:00\u0022\u003E2022-12-29 14:13\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/acceptance-and-filing-reviews-premarket-approval-applications-pmas\u0022\u003EAcceptance and Filing Reviews for Premarket Approval Applications (PMAs): Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/83408\/download\u0022\u003EPDF (777.39 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (777.39 KB) of Acceptance and Filing Reviews for Premarket Approval Applications (PMAs): Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/16\/2019","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Premarket Approval (PMA)","field_topics":"Premarket","topics-product":"Premarket, Administrative \/ Procedural, Premarket Approval (PMA)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-0524\u0022\u003EFDA-2012-D-0524\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-10-20T10:50:06-04:00\u0022\u003E2020-10-20 10:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/safety-considerations-mitigate-risks-misconnections-small-bore-connectors-intended-enteral\u0022\u003ESafety Considerations to Mitigate the Risks of Misconnections with Small-bore Connectors Intended for Enteral Applications: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/83412\/download\u0022\u003EPDF (141.95 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (141.95 KB) of Safety Considerations to Mitigate the Risks of Misconnections with Small-bore Connectors Intended for Enteral Applications: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/11\/2015","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k)","field_topics":"Premarket","topics-product":"Premarket, 510(k)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-0630\u0022\u003EFDA-2012-D-0630\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222019-03-18T19:45:06-04:00\u0022\u003E2019-03-18 19:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pyrogen-and-endotoxins-testing-questions-and-answers\u0022\u003EPyrogen and Endotoxins Testing: Questions and Answers: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/83477\/download\u0022\u003EPDF (352.11 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (352.11 KB) of Pyrogen and Endotoxins Testing: Questions and Answers: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/18\/2026","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-03-18T08:45:57-04:00\u0022\u003E2026-03-18 08:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-213-new-animal-drugs-and-new-animal-drug-combination-products-administered-or-medicated-feed\u0022\u003ECVM GFI #213 New Animal Drugs and New Animal Drug Combination Products Administered in or on Medicated Feed or Drinking Water of Food-Producing Animals: Recommendations for Drug Sponsors for Voluntarily Aligning Product Use Conditions with GFI #209\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/83488\/download\u0022\u003EPDF (115.35 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (115.35 KB) of CVM GFI #213 New Animal Drugs and New Animal Drug Combination Products Administered in or on Medicated Feed or Drinking Water of Food-Producing Animals: Recommendations for Drug Sponsors for Voluntarily Aligning Product Use Conditions with GFI #209\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/12\/2013","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Antimicrobial Resistance, New Animal Drug Application (NADA)","field_topics":"","topics-product":"Antimicrobial Resistance, New Animal Drug Application (NADA)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0889\u0022\u003EFDA-2011-D-0889\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:10:17-04:00\u0022\u003E2019-04-16 14:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pathological-complete-response-neoadjuvant-treatment-high-risk-early-stage-breast-cancer-use\u0022\u003EPathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/83507\/download\u0022\u003EPDF (241.24 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (241.24 KB) of Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/29\/2020","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-0432\u0022\u003EFDA-2012-D-0432\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-07-29T09:50:04-04:00\u0022\u003E2020-07-29 09:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/ecopy-program-medical-device-submissions\u0022\u003EeCopy Program for Medical Device Submissions: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/83522\/download\u0022\u003EPDF (752.89 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (752.89 KB) of eCopy Program for Medical Device Submissions: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/03\/2025","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Investigational Device Exemption (IDE)","field_topics":"Premarket, User Fees","topics-product":"Premarket, User Fees, Administrative \/ Procedural, Investigational Device Exemption (IDE)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-N-0628\u0022\u003EFDA-2018-N-0628\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222025-12-03T10:36:33-05:00\u0022\u003E2025-12-03 10:36\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-219-vich-gl51-statistical-evaluation-stability-data\u0022\u003ECVM GFI #219 (VICH GL51) Statistical Evaluation of Stability Data\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/83554\/download\u0022\u003EPDF (221.15 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (221.15 KB) of CVM GFI #219 (VICH GL51) Statistical Evaluation of Stability Data\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/13\/2014","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"VICH","field_topics":"","topics-product":"VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-0288\u0022\u003EFDA-2012-D-0288\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222023-07-28T08:39:16-04:00\u0022\u003E2023-07-28 08:39\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/organ-specific-warnings-internal-analgesic-antipyretic-and-antirheumatic-drug-products-over-counter-0\u0022\u003EOrgan-Specific Warnings: Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use \u2014: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/83588\/download\u0022\u003EPDF (173.4 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (173.4 KB) of Organ-Specific Warnings: Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use \u2014: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/17\/2015","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP), Over-the-Counter Drugs, Pharmaceutical Quality","field_topics":"Compliance","topics-product":"Compliance, Current Good Manufacturing Practice (CGMP), Over-the-Counter Drugs, Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-0529\u0022\u003EFDA-2012-D-0529\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-27T09:05:13-04:00\u0022\u003E2020-04-27 09:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/implanted-blood-access-devices-hemodialysis\u0022\u003EImplanted Blood Access Devices for Hemodialysis: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/83696\/download\u0022\u003EPDF (709.54 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (709.54 KB) of Implanted Blood Access Devices for Hemodialysis: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/21\/2016","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0749\u0022\u003EFDA-2013-D-0749\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222019-02-09T15:29:10-05:00\u0022\u003E2019-02-09 15:29\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-204-active-controls-studies-demonstrate-effectiveness-new-animal-drug-use-companion-animals\u0022\u003ECVM GFI #204 Active Controls in Studies to Demonstrate Effectiveness of a New Animal Drug for use in Companion Animals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/83724\/download\u0022\u003EPDF (180.96 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (180.96 KB) of CVM GFI #204 Active Controls in Studies to Demonstrate Effectiveness of a New Animal Drug for use in Companion Animals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/01\/2015","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Target Animal \u2013 Effectiveness","field_topics":"","topics-product":"Target Animal \u2013 Effectiveness","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-0419\u0022\u003EFDA-2012-D-0419\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:05:45-04:00\u0022\u003E2019-04-16 14:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/considerations-when-transferring-clinical-investigation-oversight-another-irb\u0022\u003EConsiderations When Transferring Clinical Investigation Oversight to Another IRB: Guidance for IRBs, Clinical Investigators, and Sponsors \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/83801\/download\u0022\u003EPDF (157.26 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (157.26 KB) of Considerations When Transferring Clinical Investigation Oversight to Another IRB: Guidance for IRBs, Clinical Investigators, and Sponsors \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/23\/2014","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP)","field_topics":"","topics-product":"Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0835\u0022\u003EFDA-2011-D-0835\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222020-05-07T18:20:34-04:00\u0022\u003E2020-05-07 18:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/refuse-accept-policy-510ks\u0022\u003ERefuse to Accept Policy for 510(k)s: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/83888\/download\u0022\u003EPDF (1.73 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.73 MB) of Refuse to Accept Policy for 510(k)s: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/21\/2022","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"510(k), Administrative \/ Procedural","field_topics":"Premarket","topics-product":"Premarket, 510(k), Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-0523\u0022\u003EFDA-2012-D-0523\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222022-04-25T09:05:10-04:00\u0022\u003E2022-04-25 09:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/self-identification-generic-drug-facilities-sites-and-organizations-guidance-industry\u0022\u003ESelf-Identification of Generic Drug Facilities, Sites, and Organizations; Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/83966\/download\u0022\u003EPDF (268.36 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (268.36 KB) of Self-Identification of Generic Drug Facilities, Sites, and Organizations; Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/23\/2016","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Generic Drugs","field_topics":"User Fees","topics-product":"User Fees, Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-0881\u0022\u003EFDA-2012-D-0881\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-29T14:00:36-04:00\u0022\u003E2020-04-29 14:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-335300-hypnotherapy-devices-self-hypnotic-tape-recordings\u0022\u003ECPG Sec. 335.300 Hypnotherapy Devices - Self-Hypnotic Tape Recordings\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/83980\/download\u0022\u003EPDF (89.52 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (89.52 KB) of CPG Sec. 335.300 Hypnotherapy Devices - Self-Hypnotic Tape Recordings\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/01\/1900","field_issuing_office_taxonomy":"Office of Regulatory Affairs\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222021-05-03T14:46:03-04:00\u0022\u003E2021-05-03 14:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-690150-labeling-and-marketing-dog-and-cat-food-diets-intended-diagnose-cure-mitigate-treat\u0022\u003ECPG Sec. 690.150 Labeling and Marketing of Dog and Cat Food Diets Intended to Diagnose, Cure, Mitigate, Treat, or Prevent Diseases\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/83998\/download\u0022\u003EPDF (91.21 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (91.21 KB) of CPG Sec. 690.150 Labeling and Marketing of Dog and Cat Food Diets Intended to Diagnose, Cure, Mitigate, Treat, or Prevent Diseases\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/01\/2016","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Labeling, Pet Food","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Labeling, Pet Food","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"11\/09\/2012","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-0755\u0022\u003EFDA-2012-D-0755\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222024-11-14T16:25:42-05:00\u0022\u003E2024-11-14 16:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/completeness-assessments-type-ii-api-dmfs-under-gdufa-guidance-industry\u0022\u003ECompleteness Assessments for Type II API DMFs Under GDUFA Guidance for Industry: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/84217\/download\u0022\u003EPDF (379.2 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (379.2 KB) of Completeness Assessments for Type II API DMFs Under GDUFA Guidance for Industry: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/11\/2017","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Generic Drugs, Pharmaceutical Quality","field_topics":"User Fees","topics-product":"User Fees, Chemistry, Manufacturing, and Controls (CMC), Generic Drugs, Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/None found\u0022\u003ENone found\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T13:40:04-04:00\u0022\u003E2020-05-06 13:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/andas-stability-testing-drug-substances-and-products\u0022\u003EANDAs: Stability Testing of Drug Substances and Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/84437\/download\u0022\u003EPDF (30.34 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (30.34 KB) of ANDAs: Stability Testing of Drug Substances and Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/20\/2013","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-0938\u0022\u003EFDA-2012-D-0938\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T15:05:07-04:00\u0022\u003E2020-05-06 15:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pre-storage-leukocyte-reduction-whole-blood-and-blood-components-intended-transfusion\u0022\u003EPre-Storage Leukocyte Reduction of Whole Blood and Blood Components Intended for Transfusion: Final Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/84460\/download\u0022\u003EPDF (226.54 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (226.54 KB) of Pre-Storage Leukocyte Reduction of Whole Blood and Blood Components Intended for Transfusion: Final Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/01\/2012","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2001-D-0254\u0022\u003EFDA-2001-D-0254\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222019-05-15T11:45:08-04:00\u0022\u003E2019-05-15 11:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/highly-multiplexed-microbiologicalmedical-countermeasure-in-vitro-nucleic-acid-based-diagnostic-devices\u0022\u003EHighly Multiplexed Microbiological\/Medical Countermeasure In Vitro Nucleic Acid Based Diagnostic Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/84491\/download\u0022\u003EPDF (849.17 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (849.17 KB) of Highly Multiplexed Microbiological\/Medical Countermeasure In Vitro Nucleic Acid Based Diagnostic Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/27\/2014","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Laboratory Tests, IVDs (In Vitro Diagnostic Devices)","field_topics":"","topics-product":"Laboratory Tests, IVDs (In Vitro Diagnostic Devices)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-1057\u0022\u003EFDA-2012-D-1057\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-02T09:20:33-05:00\u0022\u003E2020-03-02 09:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-550050-draft-canned-ackee-frozen-ackee-and-other-ackee-products-hypoglycin-toxin\u0022\u003ECPG Sec 550.050 (Draft) Canned Ackee, Frozen Ackee, and Other Ackee Products \u2013 Hypoglycin A Toxin\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/84578\/download\u0022\u003EPDF (22.47 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (22.47 KB) of CPG Sec 550.050 (Draft) Canned Ackee, Frozen Ackee, and Other Ackee Products \u2013 Hypoglycin A Toxin\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/01\/2012","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Fruit\/Fruit Product ","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Fruit\/Fruit Product ","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T08:44:27-04:00\u0022\u003E2024-10-01 08:44\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/complicated-intra-abdominal-infections-developing-drugs-treatment\u0022\u003EComplicated Intra-Abdominal Infections: Developing Drugs for Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/84691\/download\u0022\u003EPDF (129.97 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (129.97 KB) of Complicated Intra-Abdominal Infections: Developing Drugs for Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/01\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-0973\u0022\u003EFDA-2012-D-0973\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-07T17:35:08-04:00\u0022\u003E2020-05-07 17:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-420500-interference-compendial-tests-revised-11142012\u0022\u003ECPG Sec. 420.500 *Interference with Compendial Tests* (revised 11\/14\/2012)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/84697\/download\u0022\u003EPDF (90.51 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (90.51 KB) of CPG Sec. 420.500 *Interference with Compendial Tests* (revised 11\/14\/2012)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/01\/2012","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222020-04-09T15:45:19-04:00\u0022\u003E2020-04-09 15:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/generic-drug-user-fee-amendments-2012-questions-and-answers-related-user-fee-assessments\u0022\u003EGeneric Drug User Fee Amendments of 2012: Questions and Answers Related to User Fee Assessments: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/84730\/download\u0022\u003EPDF (221.68 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (221.68 KB) of Generic Drug User Fee Amendments of 2012: Questions and Answers Related to User Fee Assessments: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/22\/2016","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Generic Drugs","field_topics":"User Fees","topics-product":"User Fees, Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-0880\u0022\u003EFDA-2012-D-0880\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-22T09:40:23-04:00\u0022\u003E2020-04-22 09:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/abuse-deterrent-opioids-evaluation-and-labeling\u0022\u003EAbuse-Deterrent Opioids-Evaluation and Labeling\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/84819\/download\u0022\u003EPDF (226.28 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (226.28 KB) of Abuse-Deterrent Opioids-Evaluation and Labeling\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/02\/2015","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0045\u0022\u003EFDA-2013-D-0045\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-02-17T14:55:06-05:00\u0022\u003E2022-02-17 14:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-390100-definition-commerce-21-cfr-10003d-2\u0022\u003ECPG Sec 390.100 Definition of \u201cCommerce\u201d - 21 CFR 1000.3(d) 2\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/84821\/download\u0022\u003EPDF (16.41 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (16.41 KB) of CPG Sec 390.100 Definition of \u201cCommerce\u201d - 21 CFR 1000.3(d) 2\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/01\/1980","field_issuing_office_taxonomy":"Office of Regulatory Affairs\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222024-09-04T16:31:38-04:00\u0022\u003E2024-09-04 16:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/design-considerations-devices-intended-home-use\u0022\u003EDesign Considerations for Devices Intended for Home Use: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/84830\/download\u0022\u003EPDF (522.91 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (522.91 KB) of Design Considerations for Devices Intended for Home Use: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/24\/2014","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-1161\u0022\u003EFDA-2012-D-1161\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222019-02-19T15:11:53-05:00\u0022\u003E2019-02-19 15:11\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e3-structure-and-content-clinical-study-reports-questions-and-answers-r1\u0022\u003EE3 Structure and Content of Clinical Study Reports - Questions and Answers (R1)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/84857\/download\u0022\u003EPDF (141.13 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (141.13 KB) of E3 Structure and Content of Clinical Study Reports - Questions and Answers (R1)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/29\/2013","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Efficacy","field_topics":"","topics-product":"ICH-Efficacy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-29T16:50:18-04:00\u0022\u003E2020-04-29 16:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/safety-considerations-product-design-minimize-medication-errors-guidance-industry\u0022\u003ESafety Considerations for Product Design to Minimize Medication Errors Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/84903\/download\u0022\u003EPDF (211.98 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (211.98 KB) of Safety Considerations for Product Design to Minimize Medication Errors Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/12\/2016","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Safety - Issues, Errors, and Problems","field_topics":"","topics-product":"Safety - Issues, Errors, and Problems","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-1005\u0022\u003EFDA-2012-D-1005\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T13:25:20-04:00\u0022\u003E2020-04-24 13:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clinical-pharmacogenomics-premarket-evaluation-early-phase-clinical-studies-and-recommendations\u0022\u003EClinical Pharmacogenomics: Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/84923\/download\u0022\u003EPDF (272.95 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (272.95 KB) of Clinical Pharmacogenomics: Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/28\/2013","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Clinical - Pharmacology","field_topics":"","topics-product":"Clinical - Medical, Clinical - Pharmacology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0082\u0022\u003EFDA-2011-D-0082\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-01-31T14:19:46-05:00\u0022\u003E2025-01-31 14:19\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pediatric-information-incorporated-human-prescription-drug-and-biological-products-labeling-good\u0022\u003EPediatric Information Incorporated Into Human Prescription Drug and Biological Products Labeling Good Review Practice\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/84949\/download\u0022\u003EPDF (315.2 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (315.2 KB) of Pediatric Information Incorporated Into Human Prescription Drug and Biological Products Labeling Good Review Practice\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/28\/2019","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling, Pediatric Product Development","field_topics":"","topics-product":"Labeling, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0169\u0022\u003EFDA-2013-D-0169\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T11:05:11-04:00\u0022\u003E2024-04-11 11:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/immunogenicity-assessment-therapeutic-protein-products\u0022\u003EImmunogenicity Assessment for Therapeutic Protein Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/85017\/download\u0022\u003EPDF (241.55 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (241.55 KB) of Immunogenicity Assessment for Therapeutic Protein Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/14\/2014","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Clinical - Medical, Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Clinical - Medical, Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0092\u0022\u003EFDA-2013-D-0092\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T13:25:18-04:00\u0022\u003E2020-04-24 13:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/standardized-format-electronic-submission-nda-and-bla-content-planning-bioresearch-monitoring-bimo\u0022\u003EStandardized Format for Electronic Submission of NDA and BLA Content for the Planning of Bioresearch Monitoring (BIMO) Inspections for CDER Submissions Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/85056\/download\u0022\u003EPDF (275.84 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (275.84 KB) of Standardized Format for Electronic Submission of NDA and BLA Content for the Planning of Bioresearch Monitoring (BIMO) Inspections for CDER Submissions Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/06\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Electronic Submissions","topics-product":"Electronic Submissions, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-0481\u0022\u003EFDA-2018-D-0481\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222024-12-09T08:39:31-05:00\u0022\u003E2024-12-09 08:39\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/bioresearch-monitoring-technical-conformance-guide\u0022\u003EBioresearch Monitoring Technical Conformance Guide\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/85061\/download\u0022\u003EPDF (581.57 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (581.57 KB) of Bioresearch Monitoring Technical Conformance Guide\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/03\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Electronic Submissions","topics-product":"Electronic Submissions, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1216\u0022\u003EFDA-2018-D-1216\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-09-03T00:01:18-04:00\u0022\u003E2024-09-03 00:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/s10-photosafety-evaluation-pharmaceuticals\u0022\u003ES10 Photosafety Evaluation of Pharmaceuticals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/85076\/download\u0022\u003EPDF (255.89 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (255.89 KB) of S10 Photosafety Evaluation of Pharmaceuticals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/27\/2015","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Safety","field_topics":"","topics-product":"ICH-Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0068\u0022\u003EFDA-2013-D-0068\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-09T15:05:11-04:00\u0022\u003E2020-04-09 15:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/safety-reporting-requirements-inds-and-babe-studies\u0022\u003ESafety Reporting Requirements for INDs and BA\/BE Studies: Guidance for Industry and Investigators \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/85124\/download\u0022\u003EPDF (227.63 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (227.63 KB) of Safety Reporting Requirements for INDs and BA\/BE Studies: Guidance for Industry and Investigators \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/19\/2026","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Generic Drugs, Good Clinical Practice (GCP), Safety - Issues, Errors, and Problems","field_topics":"","topics-product":"Generic Drugs, Good Clinical Practice (GCP), Safety - Issues, Errors, and Problems","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0482\u0022\u003EFDA-2010-D-0482\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222026-10-19T12:26:31-04:00\u0022\u003E2026-10-19 12:26\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/antiviral-product-development-conducting-and-submitting-virology-studies-agency-guidance-submitting-3\u0022\u003EAntiviral Product Development \u2014 Conducting and Submitting Virology Studies to the Agency Guidance for Submitting HCV Resistance Data -Attachment to Guidance\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/85149\/download\u0022\u003EPDF (391.28 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (391.28 KB) of Antiviral Product Development \u2014 Conducting and Submitting Virology Studies to the Agency Guidance for Submitting HCV Resistance Data -Attachment to Guidance\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/25\/2013","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2005-D-0282\u0022\u003EFDA-2005-D-0282\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T11:20:08-04:00\u0022\u003E2020-04-24 11:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/electronic-source-data-clinical-investigations\u0022\u003EElectronic Source Data in Clinical Investigations: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/85183\/download\u0022\u003EPDF (190.31 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (190.31 KB) of Electronic Source Data in Clinical Investigations: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/18\/2013","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Good Clinical Practice (GCP)","field_topics":"","topics-product":"Administrative \/ Procedural, Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0643\u0022\u003EFDA-2010-D-0643\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222020-04-29T18:05:13-04:00\u0022\u003E2020-04-29 18:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/types-communication-during-review-medical-device-submissions\u0022\u003ETypes of Communication During the Review of Medical Device Submissions: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/85200\/download\u0022\u003EPDF (133.87 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (133.87 KB) of Types of Communication During the Review of Medical Device Submissions: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/04\/2014","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0147\u0022\u003EFDA-2013-D-0147\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-02T09:15:50-05:00\u0022\u003E2020-03-02 09:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/providing-information-about-pediatric-uses-medical-devices\u0022\u003EProviding Information about Pediatric Uses of Medical Devices: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/85233\/download\u0022\u003EPDF (370.53 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (370.53 KB) of Providing Information about Pediatric Uses of Medical Devices: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/01\/2014","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Pediatric Product Development","field_topics":"Premarket","topics-product":"Premarket, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0117\u0022\u003EFDA-2013-D-0117\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222024-04-08T11:35:02-04:00\u0022\u003E2024-04-08 11:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/submissions-postapproval-modifications-combination-product-approved-under-bla-nda-or-pma\u0022\u003ESubmissions for Postapproval Modifications to a Combination Product Approved Under a BLA, NDA, or PMA: Draft Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/85267\/download\u0022\u003EPDF (101.18 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (101.18 KB) of Submissions for Postapproval Modifications to a Combination Product Approved Under a BLA, NDA, or PMA: Draft Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/18\/2013","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products","field_health_topics":"","term_node_tid":"Combination Products","field_topics":"","topics-product":"Combination Products","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"04\/01\/2013","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-1240\u0022\u003EFDA-2012-D-1240\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222021-05-13T15:50:07-04:00\u0022\u003E2021-05-13 15:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/investigational-device-exemption-ide-guidance-retinal-prostheses\u0022\u003EInvestigational Device Exemption (IDE) Guidance for Retinal Prostheses: Guidance for Industry and FDA Staff \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/85270\/download\u0022\u003EPDF (168.79 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (168.79 KB) of Investigational Device Exemption (IDE) Guidance for Retinal Prostheses: Guidance for Industry and FDA Staff \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/06\/2013","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Investigational Device Exemption (IDE), Ophthalmic","field_topics":"","topics-product":"Investigational Device Exemption (IDE), Ophthalmic","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0010\u0022\u003EFDA-2009-D-0010\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-02-28T14:15:22-05:00\u0022\u003E2020-02-28 14:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommendations-screening-testing-and-management-blood-donors-and-blood-and-blood-components-based\u0022\u003ERecommendations for Screening, Testing, and Management of Blood Donors and Blood and Blood Components Based on Screening Tests for Syphilis: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/85283\/download\u0022\u003EPDF (1.07 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.07 MB) of Recommendations for Screening, Testing, and Management of Blood Donors and Blood and Blood Components Based on Screening Tests for Syphilis: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/02\/2020","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2003-D-0128\u0022\u003EFDA-2003-D-0128\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222021-01-20T15:30:05-05:00\u0022\u003E2021-01-20 15:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/financial-disclosure-clinical-investigators\u0022\u003EFinancial Disclosure by Clinical Investigators: Guidance for Clinical Investigators, Industry,and FDA Staff \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/85293\/download\u0022\u003EPDF (165.38 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (165.38 KB) of Financial Disclosure by Clinical Investigators: Guidance for Clinical Investigators, Industry,and FDA Staff \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/01\/2013","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP), Investigational Device Exemption (IDE)","field_topics":"","topics-product":"Good Clinical Practice (GCP), Investigational Device Exemption (IDE)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1999-D-0742\u0022\u003EFDA-1999-D-0742\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222023-08-10T16:02:46-04:00\u0022\u003E2023-08-10 16:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/compliance-policy-guide-sec-390200-determination-secretary-product-fails-comply-or-has-defect-21-cfr\u0022\u003ECompliance Policy Guide Sec. 390.200 Determination by Secretary that Product Fails to Comply or has Defect - 21 CFR 1003.11\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/85319\/download\u0022\u003EPDF (44.63 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (44.63 KB) of Compliance Policy Guide Sec. 390.200 Determination by Secretary that Product Fails to Comply or has Defect - 21 CFR 1003.11\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/01\/2012","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222024-11-14T16:25:33-05:00\u0022\u003E2024-11-14 16:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/implementation-acceptable-full-length-and-abbreviated-donor-history-questionnaires-and-accompanying-0\u0022\u003EImplementation of Acceptable Full-Length and Abbreviated Donor History Questionnaires and Accompanying Materials for Use in Screening Donors of Source Plasma: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/124172\/download\u0022\u003EPDF (230.2 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (230.2 KB) of Implementation of Acceptable Full-Length and Abbreviated Donor History Questionnaires and Accompanying Materials for Use in Screening Donors of Source Plasma: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/14\/2023","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Blood","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-1342\u0022\u003EFDA-2016-D-1342\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222023-06-14T09:10:32-04:00\u0022\u003E2023-06-14 09:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/humanitarian-use-device-hud-designations\u0022\u003EHumanitarian Use Device (HUD) Designations : Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/130442\/download\u0022\u003EPDF (349.8 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (349.8 KB) of Humanitarian Use Device (HUD) Designations : Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/05\/2019","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP)","field_topics":"Premarket","topics-product":"Premarket, Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0223\u0022\u003EFDA-2014-D-0223\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222021-05-13T15:46:05-04:00\u0022\u003E2021-05-13 15:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommendations-labeling-medical-products-inform-users-product-or-product-container-not-made-natural\u0022\u003ERecommendations for Labeling Medical Products to Inform Users that the Product or Product Container is not Made with Natural Rubber Latex: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/85473\/download\u0022\u003EPDF (75.67 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (75.67 KB) of Recommendations for Labeling Medical Products to Inform Users that the Product or Product Container is not Made with Natural Rubber Latex: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/02\/2014","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0168\u0022\u003EFDA-2013-D-0168\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222019-03-14T11:15:22-04:00\u0022\u003E2019-03-14 11:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/molecular-diagnostic-instruments-combined-functions\u0022\u003EMolecular Diagnostic Instruments with Combined Functions: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/85513\/download\u0022\u003EPDF (424.7 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (424.7 KB) of Molecular Diagnostic Instruments with Combined Functions: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/12\/2014","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0258\u0022\u003EFDA-2013-D-0258\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-02T09:30:10-05:00\u0022\u003E2020-03-02 09:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/providing-postmarket-periodic-safety-reports-ich-e2cr2-format-periodic-benefit-risk-evaluation\u0022\u003EProviding Postmarket Periodic Safety Reports in the ICH E2C(R2) Format (Periodic Benefit-Risk Evaluation Report)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/85520\/download\u0022\u003EPDF (300.03 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (300.03 KB) of Providing Postmarket Periodic Safety Reports in the ICH E2C(R2) Format (Periodic Benefit-Risk Evaluation Report)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2016","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Safety - Issues, Errors, and Problems","field_topics":"","topics-product":"Safety - Issues, Errors, and Problems","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0349\u0022\u003EFDA-2013-D-0349\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-12-19T08:02:16-05:00\u0022\u003E2024-12-19 08:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/user-fees-and-refunds-premarket-notification-submissions-510ks\u0022\u003EUser Fees and Refunds for Premarket Notification Submissions (510(k)s): Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/85591\/download\u0022\u003EPDF (523.75 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (523.75 KB) of User Fees and Refunds for Premarket Notification Submissions (510(k)s): Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/05\/2022","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k)","field_topics":"Premarket, User Fees","topics-product":"Premarket, User Fees, 510(k)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2003-D-0198\u0022\u003EFDA-2003-D-0198\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222022-10-06T10:05:31-04:00\u0022\u003E2022-10-06 10:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/formal-dispute-resolution-sponsor-appeals-above-division-level-guidance-industry-and-review-staff\u0022\u003EFormal Dispute Resolution: Sponsor Appeals Above the Division Level Guidance for Industry and Review Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/126910\/download\u0022\u003EPDF (297.56 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (297.56 KB) of Formal Dispute Resolution: Sponsor Appeals Above the Division Level Guidance for Industry and Review Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/30\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0221\u0022\u003EFDA-2013-D-0221\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-04-28T08:45:33-04:00\u0022\u003E2022-04-28 08:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/supac-manufacturing-equipment-addendum\u0022\u003ESUPAC: Manufacturing Equipment Addendum\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/85681\/download\u0022\u003EPDF (212.88 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (212.88 KB) of SUPAC: Manufacturing Equipment Addendum\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/02\/2014","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0295\u0022\u003EFDA-2013-D-0295\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-05T11:45:24-04:00\u0022\u003E2020-05-05 11:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/user-fees-and-refunds-premarket-approval-applications-and-device-biologics-license-applications\u0022\u003EUser Fees and Refunds for Premarket Approval Applications and Device Biologics License Applications: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/85712\/download\u0022\u003EPDF (417.84 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (417.84 KB) of User Fees and Refunds for Premarket Approval Applications and Device Biologics License Applications: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/05\/2022","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Premarket, User Fees","topics-product":"Premarket, User Fees, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0051\u0022\u003EFDA-2009-D-0051\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222022-10-19T14:59:46-04:00\u0022\u003E2022-10-19 14:59\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/use-international-standard-iso-10993-1-biological-evaluation-medical-devices-part-1-evaluation-and\u0022\u003EUse of International Standard ISO 10993-1, \u0026quot;Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process\u0026quot; : Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/142959\/download\u0022\u003EPDF (1.25 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.25 MB) of Use of International Standard ISO 10993-1, \u0026quot;Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process\u0026quot; : Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/08\/2023","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"510(k), Premarket Approval (PMA), Investigational Device Exemption (IDE), HUD\/HDE, Safety - Issues, Errors, and Problems","field_topics":"Premarket","topics-product":"Premarket, 510(k), Premarket Approval (PMA), Investigational Device Exemption (IDE), HUD\/HDE, Safety - Issues, Errors, and Problems","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0350\u0022\u003EFDA-2013-D-0350\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222024-09-05T00:00:32-04:00\u0022\u003E2024-09-05 00:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/safety-considerations-container-labels-and-carton-labeling-design-minimize-medication-errors\u0022\u003ESafety Considerations for Container Labels and Carton Labeling Design to Minimize Medication Errors\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/158522\/download\u0022\u003EPDF (570.23 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (570.23 KB) of Safety Considerations for Container Labels and Carton Labeling Design to Minimize Medication Errors\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/18\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Safety - Issues, Errors, and Problems","field_topics":"","topics-product":"Safety - Issues, Errors, and Problems","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0401\u0022\u003EFDA-2013-D-0401\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-05-18T13:00:41-04:00\u0022\u003E2022-05-18 13:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-m7r2-assessment-and-control-dna-reactive-mutagenic-impurities-pharmaceuticals\u0022\u003EGuidance for Industry | M7(R2) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals To Limit Potential Carcinogenic Risk\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/170461\/download\u0022\u003EPDF (515.37 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (515.37 KB) of Guidance for Industry | M7(R2) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals To Limit Potential Carcinogenic Risk\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/25\/2023","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Multidisciplinary","field_topics":"","topics-product":"ICH-Multidisciplinary","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0055\u0022\u003EFDA-2022-D-0055\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-05-27T12:55:49-04:00\u0022\u003E2026-05-27 12:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/rheumatoid-arthritis-developing-drug-products-treatment\u0022\u003ERheumatoid Arthritis: Developing Drug Products for Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/86066\/download\u0022\u003EPDF (176.46 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (176.46 KB) of Rheumatoid Arthritis: Developing Drug Products for Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/31\/2013","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0571\u0022\u003EFDA-2013-D-0571\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-23T14:50:30-04:00\u0022\u003E2020-04-23 14:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/changes-approved-application-biological-products-human-blood-and-blood-components-intended\u0022\u003EChanges to an Approved Application: Biological Products: Human Blood and Blood Components Intended for Transfusion or for Further Manufacture: Final Guidance\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/86137\/download\u0022\u003EPDF (390.87 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (390.87 KB) of Changes to an Approved Application: Biological Products: Human Blood and Blood Components Intended for Transfusion or for Further Manufacture: Final Guidance\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/01\/2014","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1999-D-3528\u0022\u003EFDA-1999-D-3528\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222019-08-22T14:35:58-04:00\u0022\u003E2019-08-22 14:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/contract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry\u0022\u003EContract Manufacturing Arrangements for Drugs: Quality Agreements Guidance for Industry: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/86193\/download\u0022\u003EPDF (122.79 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (122.79 KB) of Contract Manufacturing Arrangements for Drugs: Quality Agreements Guidance for Industry: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/23\/2016","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_topics":"Compliance","topics-product":"Compliance, Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0558\u0022\u003EFDA-2013-D-0558\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-07T18:40:10-04:00\u0022\u003E2020-05-07 18:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/providing-submissions-electronic-format-postmarket-non-expedited-icsrs-technical-questions-and\u0022\u003EProviding Submissions in Electronic Format \u2013 Postmarket Non-Expedited ICSRs Technical Questions and Answers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/86236\/download\u0022\u003EPDF (103.51 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (103.51 KB) of Providing Submissions in Electronic Format \u2013 Postmarket Non-Expedited ICSRs Technical Questions and Answers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/24\/2013","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Electronic Submissions","topics-product":"Electronic Submissions, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0755\u0022\u003EFDA-2013-D-0755\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-14T14:05:24-04:00\u0022\u003E2020-04-14 14:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-690800-compliance-policy-guide-salmonella-food-animals\u0022\u003ECPG Sec 690.800 Compliance Policy Guide Salmonella in Food for Animals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/86240\/download\u0022\u003EPDF (42.07 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (42.07 KB) of CPG Sec 690.800 Compliance Policy Guide Salmonella in Food for Animals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/01\/2013","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Feed","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Feed","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0378\u0022\u003EFDA-2010-D-0378\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222024-11-14T16:25:36-05:00\u0022\u003E2024-11-14 16:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pre-launch-activities-importation-requests-plair\u0022\u003EPre-Launch Activities Importation Requests (PLAIR): Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/86243\/download\u0022\u003EPDF (226.44 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (226.44 KB) of Pre-Launch Activities Importation Requests (PLAIR): Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/2022","field_issuing_office_taxonomy":"Office of the Commissioner\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Biosimilars","field_topics":"","topics-product":"Administrative \/ Procedural, Biosimilars","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0836\u0022\u003EFDA-2013-D-0836\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-03-02T09:01:21-05:00\u0022\u003E2022-03-02 09:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/antibacterial-therapies-patients-unmet-medical-need-treatment-serious-bacterial-diseases\u0022\u003EAntibacterial Therapies for Patients With an Unmet Medical Need for the Treatment of Serious Bacterial Diseases\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/86250\/download\u0022\u003EPDF (148.81 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (148.81 KB) of Antibacterial Therapies for Patients With an Unmet Medical Need for the Treatment of Serious Bacterial Diseases\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/02\/2017","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0744\u0022\u003EFDA-2013-D-0744\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T11:20:22-04:00\u0022\u003E2020-04-24 11:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/human-immunodeficiency-virus-1-infection-developing-antiretroviral-drugs-treatment\u0022\u003EHuman Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/86284\/download\u0022\u003EPDF (609.36 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (609.36 KB) of Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/02\/2015","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-03-12T14:50:06-04:00\u0022\u003E2019-03-12 14:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/circumstances-constitute-delaying-denying-limiting-or-refusing-drug-or-device-inspection\u0022\u003ECircumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug or Device Inspection: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/86328\/download\u0022\u003EPDF (341.74 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (341.74 KB) of Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug or Device Inspection: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/20\/2024","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Postmarket, Investigation \u0026amp; Enforcement","topics-product":"Postmarket, Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0710\u0022\u003EFDA-2013-D-0710\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222024-11-05T16:09:22-05:00\u0022\u003E2024-11-05 16:09\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pediatric-study-plans-content-and-process-submitting-initial-pediatric-study-plans-and-amended\u0022\u003EPediatric Study Plans: Content of and Process for Submitting Initial Pediatric Study Plans and Amended Initial Pediatric Study Plans\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/86340\/download\u0022\u003EPDF (369.14 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (369.14 KB) of Pediatric Study Plans: Content of and Process for Submitting Initial Pediatric Study Plans and Amended Initial Pediatric Study Plans\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/31\/2020","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Pediatric Product Development","field_topics":"","topics-product":"Administrative \/ Procedural, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0814\u0022\u003EFDA-2013-D-0814\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T09:38:16-04:00\u0022\u003E2024-04-11 09:38\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/expedited-programs-serious-conditions-drugs-and-biologics\u0022\u003EExpedited Programs for Serious Conditions | Drugs and Biologics\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/86377\/download\u0022\u003EPDF (494.14 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (494.14 KB) of Expedited Programs for Serious Conditions | Drugs and Biologics\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/30\/2014","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0575\u0022\u003EFDA-2013-D-0575\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-12-14T16:20:47-05:00\u0022\u003E2023-12-14 16:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/bla-minimally-manipulated-unrelated-allogeneic-placentalumbilical-cord-blood-intended-hematopoietic\u0022\u003EBLA for Minimally Manipulated, Unrelated Allogeneic Placental\/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/86387\/download\u0022\u003EPDF (378.54 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (378.54 KB) of BLA for Minimally Manipulated, Unrelated Allogeneic Placental\/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/2014","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Gene Therapy","field_topics":"Cellular \u0026amp; Gene Therapy","topics-product":"Cellular \u0026amp; Gene Therapy, Gene Therapy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2006-D-0157\u0022\u003EFDA-2006-D-0157\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222019-05-16T16:45:20-04:00\u0022\u003E2019-05-16 16:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/medical-device-reporting-manufacturers\u0022\u003EMedical Device Reporting for Manufacturers : Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/86420\/download\u0022\u003EPDF (423.83 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (423.83 KB) of Medical Device Reporting for Manufacturers : Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/08\/2016","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Adverse Event Reporting","field_topics":"Postmarket, Adverse Event Reporting System (FAERS)","topics-product":"Postmarket, Adverse Event Reporting System (FAERS), Adverse Event Reporting","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0743\u0022\u003EFDA-2013-D-0743\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222019-02-09T15:41:24-05:00\u0022\u003E2019-02-09 15:41\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/enforcement-policy-regarding-investigational-new-drug-requirements-use-fecal-microbiota\u0022\u003EEnforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/86440\/download\u0022\u003EPDF (224.27 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (224.27 KB) of Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/28\/2022","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Vaccines","field_topics":"","topics-product":"Vaccines","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0811\u0022\u003EFDA-2013-D-0811\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222022-11-29T09:59:25-05:00\u0022\u003E2022-11-29 09:59\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/minimizing-risk-childrens-toy-laser-products\u0022\u003EMinimizing Risk for Children\u0026#039;s Toy Laser Products: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/86481\/download\u0022\u003EPDF (58.93 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (58.93 KB) of Minimizing Risk for Children\u0026#039;s Toy Laser Products: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/19\/2014","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Radiological Health","field_topics":"","topics-product":"Radiological Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-1092\u0022\u003EFDA-2012-D-1092\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-24T11:24:17-04:00\u0022\u003E2020-03-24 11:24\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/global-unique-device-identification-database-gudid\u0022\u003EGlobal Unique Device Identification Database (GUDID): Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/86569\/download\u0022\u003EPDF (2.55 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (2.55 MB) of Global Unique Device Identification Database (GUDID): Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/17\/2024","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"GUDID, Labeling, UDI","field_topics":"","topics-product":"GUDID, Labeling, UDI","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0636\u0022\u003EFDA-2013-D-0636\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222024-12-17T08:41:32-05:00\u0022\u003E2024-12-17 08:41\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/anda-submissions-refuse-receive-standards-rev2\u0022\u003EANDA Submissions -- Refuse-to-Receive Standards Rev.2\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/86660\/download\u0022\u003EPDF (198.75 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (198.75 KB) of ANDA Submissions -- Refuse-to-Receive Standards Rev.2\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/28\/2016","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Generic Drugs","field_topics":"User Fees","topics-product":"User Fees, Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-1120\u0022\u003EFDA-2013-D-1120\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-21T16:25:02-04:00\u0022\u003E2020-04-21 16:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/patient-counseling-information-section-labeling-human-prescription-drug-and-biological-products\u0022\u003EPatient Counseling Information Section of Labeling for Human Prescription Drug and Biological Products \u2014 Content and Format\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/86734\/download\u0022\u003EPDF (91.12 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (91.12 KB) of Patient Counseling Information Section of Labeling for Human Prescription Drug and Biological Products \u2014 Content and Format\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/10\/2014","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-1067\u0022\u003EFDA-2013-D-1067\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-27T09:10:12-04:00\u0022\u003E2020-04-27 09:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-223-small-entity-compliance-guide-declaring-color-additives-animal-foods\u0022\u003ECVM GFI #223 Small Entity Compliance Guide Declaring Color Additives in Animal Foods\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/86896\/download\u0022\u003EPDF (47.67 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (47.67 KB) of CVM GFI #223 Small Entity Compliance Guide Declaring Color Additives in Animal Foods\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/27\/2013","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Feed","field_topics":"","topics-product":"Animal Feed","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-1088\u0022\u003EFDA-2013-D-1088\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:15:07-04:00\u0022\u003E2019-04-16 14:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/acceptable-circular-information-use-human-blood-and-blood-components\u0022\u003EAn Acceptable Circular of Information for the Use of Human Blood and Blood Components: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/86898\/download\u0022\u003EPDF (226.66 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (226.66 KB) of An Acceptable Circular of Information for the Use of Human Blood and Blood Components: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/25\/2024","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Blood","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2002-D-0223\u0022\u003EFDA-2002-D-0223\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-09-25T09:57:16-04:00\u0022\u003E2024-09-25 09:57\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-221-recommendations-preparation-and-submission-animal-food-additive-petitions\u0022\u003ECVM GFI #221 Recommendations for Preparation and Submission of Animal Food Additive Petitions\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/86905\/download\u0022\u003EPDF (121.79 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (121.79 KB) of CVM GFI #221 Recommendations for Preparation and Submission of Animal Food Additive Petitions\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/12\/2015","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Food Additives","field_topics":"","topics-product":"Animal Food Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0928\u0022\u003EFDA-2013-D-0928\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:16:30-04:00\u0022\u003E2019-04-16 14:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/nonclinical-evaluation-endocrine-related-drug-toxicity\u0022\u003ENonclinical Evaluation of Endocrine-Related Drug Toxicity\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/86996\/download\u0022\u003EPDF (129.18 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (129.18 KB) of Nonclinical Evaluation of Endocrine-Related Drug Toxicity\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/09\/2015","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pharmacology\/Toxicology","field_topics":"","topics-product":"Pharmacology\/Toxicology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-14T12:55:02-04:00\u0022\u003E2020-05-14 12:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/use-nucleic-acid-tests-reduce-risk-transmission-west-nile-virus-living-donors-human-cells-tissues\u0022\u003EUse of Nucleic Acid Tests to Reduce the Risk of Transmission of West Nile Virus from Living Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\/Ps): Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/87050\/download\u0022\u003EPDF (101.63 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (101.63 KB) of Use of Nucleic Acid Tests to Reduce the Risk of Transmission of West Nile Virus from Living Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\/Ps): Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/08\/2016","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Tissue","field_topics":"Policy Making","topics-product":"Policy Making, Tissue","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-1143\u0022\u003EFDA-2013-D-1143\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222019-05-17T10:55:34-04:00\u0022\u003E2019-05-17 10:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/andas-stability-testing-drug-substances-and-products-questions-and-answers\u0022\u003EANDAs: Stability Testing of Drug Substances and Products, Questions and Answers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/87051\/download\u0022\u003EPDF (124.21 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (124.21 KB) of ANDAs: Stability Testing of Drug Substances and Products, Questions and Answers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/15\/2014","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0547\u0022\u003EFDA-2014-D-0547\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-22T11:19:21-04:00\u0022\u003E2020-04-22 11:19\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/qualification-medical-device-development-tools\u0022\u003EQualification of Medical Device Development Tools: Guidance for Industry, Tool Developers, and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/87134\/download\u0022\u003EPDF (386.33 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (386.33 KB) of Qualification of Medical Device Development Tools: Guidance for Industry, Tool Developers, and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/17\/2023","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Digital Health","field_topics":"Premarket","topics-product":"Premarket, Administrative \/ Procedural, Digital Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-1279\u0022\u003EFDA-2013-D-1279\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222023-07-17T12:05:16-04:00\u0022\u003E2023-07-17 12:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/use-donor-screening-tests-test-donors-human-cells-tissues-and-cellular-and-tissue-based-products\u0022\u003EUse of Donor Screening Tests to Test Donors of Human Cells, Tissues and Cellular and Tissue-Based Products for Infection with Treponema pallidum (Syphilis): Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/87143\/download\u0022\u003EPDF (175.47 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (175.47 KB) of Use of Donor Screening Tests to Test Donors of Human Cells, Tissues and Cellular and Tissue-Based Products for Infection with Treponema pallidum (Syphilis): Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/09\/2015","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Tissue","field_topics":"","topics-product":"Tissue","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-1213\u0022\u003EFDA-2013-D-1213\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222019-05-17T11:00:32-04:00\u0022\u003E2019-05-17 11:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pulmonary-tuberculosis-developing-drugs-treatment\u0022\u003EPulmonary Tuberculosis: Developing Drugs for Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/87194\/download\u0022\u003EPDF (385.76 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (385.76 KB) of Pulmonary Tuberculosis: Developing Drugs for Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/08\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial, Pediatric Product Development","field_topics":"","topics-product":"Clinical - Antimicrobial, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-1319\u0022\u003EFDA-2013-D-1319\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-06-03T08:15:50-04:00\u0022\u003E2026-06-03 08:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommendations-premarket-notification-510k-submissions-nucleic-acid-based-human-leukocyte-antigen\u0022\u003ERecommendations for Premarket Notification (510(k)) Submissions for Nucleic Acid-Based Human Leukocyte Antigen (HLA) Test Kits Used for Matching of Donors and Recipients in Transfusion and Transplantation: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/87197\/download\u0022\u003EPDF (75.4 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (75.4 KB) of Recommendations for Premarket Notification (510(k)) Submissions for Nucleic Acid-Based Human Leukocyte Antigen (HLA) Test Kits Used for Matching of Donors and Recipients in Transfusion and Transplantation: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/31\/2015","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Blood","term_node_tid":"Blood Products","field_topics":"Premarket","topics-product":"Premarket, Blood, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-1358\u0022\u003EFDA-2013-D-1358\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222021-04-21T09:25:03-04:00\u0022\u003E2021-04-21 09:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/bioequivalence-studies-pharmacokinetic-endpoints-drugs-submitted-under-abbreviated-new-drug\u0022\u003EBioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an Abbreviated New Drug Application\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/192774\/download\u0022\u003EPDF (332.68 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (332.68 KB) of Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an Abbreviated New Drug Application\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/29\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Biopharmaceutics, Generic Drugs","field_topics":"","topics-product":"Biopharmaceutics, Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-1464\u0022\u003EFDA-2013-D-1464\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-05-28T09:22:48-04:00\u0022\u003E2026-05-28 09:22\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/naming-drug-products-containing-salt-drug-substances\u0022\u003ENaming of Drug Products Containing Salt Drug Substances\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/87247\/download\u0022\u003EPDF (209.94 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (209.94 KB) of Naming of Drug Products Containing Salt Drug Substances\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/17\/2015","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-1566\u0022\u003EFDA-2013-D-1566\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-14T11:27:10-04:00\u0022\u003E2020-05-14 11:27\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/size-shape-and-other-physical-attributes-generic-tablets-and-capsules\u0022\u003ESize, Shape, and Other Physical Attributes of Generic Tablets and Capsules\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/161902\/download\u0022\u003EPDF (303.31 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (303.31 KB) of Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/03\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-N-1434\u0022\u003EFDA-2013-N-1434\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-10-03T12:45:47-04:00\u0022\u003E2022-10-03 12:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/design-considerations-pivotal-clinical-investigations-medical-devices\u0022\u003EDesign Considerations for Pivotal Clinical Investigations for Medical Devices: Guidance for Industry, Clinical Investigators, Institutional Review Boards and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/87363\/download\u0022\u003EPDF (402.07 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (402.07 KB) of Design Considerations for Pivotal Clinical Investigations for Medical Devices: Guidance for Industry, Clinical Investigators, Institutional Review Boards and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/07\/2013","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP), Investigational Device Exemption (IDE)","field_topics":"Premarket","topics-product":"Premarket, Good Clinical Practice (GCP), Investigational Device Exemption (IDE)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0567\u0022\u003EFDA-2011-D-0567\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222023-08-10T16:08:01-04:00\u0022\u003E2023-08-10 16:08\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/distribution-in-vitro-diagnostic-products-labeled-research-use-only-or-investigational-use-only\u0022\u003EDistribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/87374\/download\u0022\u003EPDF (195.23 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (195.23 KB) of Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/25\/2013","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP), Investigational Device Exemption (IDE), Laboratory Tests, IVDs (In Vitro Diagnostic Devices)","field_topics":"Premarket","topics-product":"Premarket, Good Clinical Practice (GCP), Investigational Device Exemption (IDE), Laboratory Tests, IVDs (In Vitro Diagnostic Devices)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0305\u0022\u003EFDA-2011-D-0305\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-02T09:05:55-05:00\u0022\u003E2020-03-02 09:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/attachement-qualification-process-drug-development-tools-qualification-exacerbations-chronic\u0022\u003EAttachement - Qualification Process for Drug Development Tools: Qualification of Exacerbations of Chronic Pulmonary Disease Tool for Measurement of Symptoms of Acute Bacterial Exacerbation of Chronic Bronchitis in Patients With Chronic Obstructive Pulmonary Disease\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/87409\/download\u0022\u003EPDF (79.89 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (79.89 KB) of Attachement - Qualification Process for Drug Development Tools: Qualification of Exacerbations of Chronic Pulmonary Disease Tool for Measurement of Symptoms of Acute Bacterial Exacerbation of Chronic Bronchitis in Patients With Chronic Obstructive Pulmonary Disease\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/10\/2014","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-1630\u0022\u003EFDA-2013-D-1630\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-29T16:10:05-04:00\u0022\u003E2020-04-29 16:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/registration-human-drug-compounding-outsourcing-facilities-under-section-503b-federal-food-drug-and\u0022\u003ERegistration for Human Drug Compounding Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/87570\/download\u0022\u003EPDF (71.02 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (71.02 KB) of Registration for Human Drug Compounding Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/24\/2014","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Compounding","field_topics":"","topics-product":"Administrative \/ Procedural, Compounding","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-N-1429\u0022\u003EFDA-2013-N-1429\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-17T14:45:14-04:00\u0022\u003E2020-04-17 14:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/reporting-computational-modeling-studies-medical-device-submissions\u0022\u003EReporting of Computational Modeling Studies in Medical Device Submissions: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/87586\/download\u0022\u003EPDF (771.67 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (771.67 KB) of Reporting of Computational Modeling Studies in Medical Device Submissions: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/21\/2016","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Premarket Approval (PMA), Investigational Device Exemption (IDE)","field_topics":"Premarket","topics-product":"Premarket, 510(k), Premarket Approval (PMA), Investigational Device Exemption (IDE)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-1530\u0022\u003EFDA-2013-D-1530\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222019-03-17T17:20:05-04:00\u0022\u003E2019-03-17 17:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/self-monitoring-blood-glucose-test-systems-over-counter-use\u0022\u003ESelf-Monitoring Blood Glucose Test Systems for Over-the-Counter Use: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/87721\/download\u0022\u003EPDF (867.93 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (867.93 KB) of Self-Monitoring Blood Glucose Test Systems for Over-the-Counter Use: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/29\/2020","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Clinical Chemistry \u0026amp; Clinical Toxicology , Over-the-Counter Drugs","field_topics":"Premarket","topics-product":"Premarket, 510(k), Clinical Chemistry \u0026amp; Clinical Toxicology , Over-the-Counter Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-1446\u0022\u003EFDA-2013-D-1446\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222021-06-25T14:01:10-04:00\u0022\u003E2021-06-25 14:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/analytical-procedures-and-methods-validation-drugs-and-biologics\u0022\u003EAnalytical Procedures and Methods Validation for Drugs and Biologics\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/87801\/download\u0022\u003EPDF (133.79 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (133.79 KB) of Analytical Procedures and Methods Validation for Drugs and Biologics\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/27\/2015","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-N-0007\u0022\u003EFDA-2015-N-0007\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-21T16:10:06-04:00\u0022\u003E2020-04-21 16:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/chronic-fatigue-syndromemyalgic-encephalomyelitis-developing-drug-products-treatment\u0022\u003EChronic Fatigue Syndrome\/Myalgic Encephalomyelitis: Developing Drug Products for Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/87875\/download\u0022\u003EPDF (337.45 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (337.45 KB) of Chronic Fatigue Syndrome\/Myalgic Encephalomyelitis: Developing Drug Products for Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/11\/2014","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0264 \u0022\u003EFDA-2014-D-0264 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-01-26T10:35:22-05:00\u0022\u003E2021-01-26 10:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/new-chemical-entity-exclusivity-determinations-certain-fixed-combination-drug-products\u0022\u003ENew Chemical Entity Exclusivity Determinations for Certain Fixed-Combination Drug Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/87932\/download\u0022\u003EPDF (351.45 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (351.45 KB) of New Chemical Entity Exclusivity Determinations for Certain Fixed-Combination Drug Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/16\/2014","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-1675\u0022\u003EFDA-2013-D-1675\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-14T12:35:08-04:00\u0022\u003E2020-05-14 12:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/premarket-notification-510k-submissions-bipolar-electrosurgical-vessel-sealers-general-surgery\u0022\u003EPremarket Notification (510(k)) Submissions for Bipolar Electrosurgical Vessel Sealers for General Surgery: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/87987\/download\u0022\u003EPDF (450.4 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (450.4 KB) of Premarket Notification (510(k)) Submissions for Bipolar Electrosurgical Vessel Sealers for General Surgery: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/15\/2016","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Clinical - Medical, Good Clinical Practice (GCP), Labeling, General \u0026amp; Plastic Surgery ","field_topics":"Premarket","topics-product":"Premarket, 510(k), Clinical - Medical, Good Clinical Practice (GCP), Labeling, General \u0026amp; Plastic Surgery ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0218\u0022\u003EFDA-2014-D-0218\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-02T09:45:02-05:00\u0022\u003E2020-03-02 09:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/premarket-notification-510k-submissions-electrosurgical-devices-general-surgery\u0022\u003EPremarket Notification (510(k)) Submissions for Electrosurgical Devices for General Surgery: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/87995\/download\u0022\u003EPDF (638.17 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (638.17 KB) of Premarket Notification (510(k)) Submissions for Electrosurgical Devices for General Surgery: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/09\/2020","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Clinical - Medical, Good Clinical Practice (GCP), Labeling, General \u0026amp; Plastic Surgery ","field_topics":"Premarket","topics-product":"Premarket, 510(k), Clinical - Medical, Good Clinical Practice (GCP), Labeling, General \u0026amp; Plastic Surgery ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0217\u0022\u003EFDA-2014-D-0217\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-09T09:23:10-04:00\u0022\u003E2020-03-09 09:23\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/labeling-human-prescription-drug-and-biological-products-approved-under-accelerated-approval\u0022\u003ELabeling for Human Prescription Drug and Biological Products Approved Under the Accelerated Approval Regulatory Pathway\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/119755\/download\u0022\u003EPDF (84.95 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (84.95 KB) of Labeling for Human Prescription Drug and Biological Products Approved Under the Accelerated Approval Regulatory Pathway\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/04\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0250\u0022\u003EFDA-2014-D-0250\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T01:46:41-04:00\u0022\u003E2020-04-24 01:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/allowable-excess-volume-and-labeled-vial-fill-size-injectable-drug-and-biological-products\u0022\u003EAllowable Excess Volume and Labeled Vial Fill Size in Injectable Drug and Biological Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/88138\/download\u0022\u003EPDF (76.58 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (76.58 KB) of Allowable Excess Volume and Labeled Vial Fill Size in Injectable Drug and Biological Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/25\/2015","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0248\u0022\u003EFDA-2014-D-0248\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T14:55:13-04:00\u0022\u003E2020-05-06 14:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/fees-human-drug-compounding-outsourcing-facilities-under-sections-503b-and-744k-fdc-act\u0022\u003EFees for Human Drug Compounding Outsourcing Facilities Under Sections 503B and 744K of the FD\u0026amp;C Act\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/136683\/download\u0022\u003EPDF (172.27 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (172.27 KB) of Fees for Human Drug Compounding Outsourcing Facilities Under Sections 503B and 744K of the FD\u0026amp;C Act\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/03\/2020","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Compounding","field_topics":"User Fees","topics-product":"User Fees, Compounding","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0329\u0022\u003EFDA-2014-D-0329\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-03T16:55:48-04:00\u0022\u003E2020-04-03 16:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/immunogenicity-related-considerations-low-molecular-weight-heparin-guidance-industry\u0022\u003EImmunogenicity-Related Considerations for Low Molecular Weight Heparin Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/88253\/download\u0022\u003EPDF (136.19 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (136.19 KB) of Immunogenicity-Related Considerations for Low Molecular Weight Heparin Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/18\/2016","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-05-31T11:30:20-04:00\u0022\u003E2019-05-31 11:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/bioavailability-and-bioequivalence-studies-submitted-ndas-or-inds-general-considerations\u0022\u003EBioavailability and Bioequivalence Studies Submitted in NDAs or INDs \u2014 General Considerations\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/88254\/download\u0022\u003EPDF (804.84 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (804.84 KB) of Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs \u2014 General Considerations\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/18\/2014","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Biopharmaceutics","field_topics":"","topics-product":"Biopharmaceutics","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0204\u0022\u003EFDA-2014-D-0204\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-29T16:35:06-04:00\u0022\u003E2020-04-29 16:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/antiviral-product-development-conducting-and-submitting-virology-studies-agency-guidance-submitting-4\u0022\u003EAntiviral Product Development \u2014 Conducting and Submitting Virology Studies to the Agency: Guidance for Submitting HIV-1 Resistance Data: Attachment to the Guidance: Draft Draft Guidance: This draft guidance updates the final guidance posted 6\/2\/06\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/88255\/download\u0022\u003EPDF (166.83 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (166.83 KB) of Antiviral Product Development \u2014 Conducting and Submitting Virology Studies to the Agency: Guidance for Submitting HIV-1 Resistance Data: Attachment to the Guidance: Draft Draft Guidance: This draft guidance updates the final guidance posted 6\/2\/06\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/28\/2014","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0180\u0022\u003EFDA-2014-D-0180\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-01-26T09:43:13-05:00\u0022\u003E2021-01-26 09:43\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/balancing-premarket-and-postmarket-data-collection-devices-subject-premarket-approval\u0022\u003EBalancing Premarket and Postmarket Data Collection for Devices Subject to Premarket Approval: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/88381\/download\u0022\u003EPDF (500.14 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (500.14 KB) of Balancing Premarket and Postmarket Data Collection for Devices Subject to Premarket Approval: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/13\/2015","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Premarket Approval (PMA)","field_topics":"Postmarket, Premarket","topics-product":"Postmarket, Premarket, Premarket Approval (PMA)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0090\u0022\u003EFDA-2014-D-0090\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222020-10-20T15:30:32-04:00\u0022\u003E2020-10-20 15:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/best-practices-developing-proprietary-names-human-prescription-drug-products-guidance-industry\u0022\u003EBest Practices in Developing Proprietary Names for Human Prescription Drug Products; Guidance for Industry: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/88496\/download\u0022\u003EPDF (346.09 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (346.09 KB) of Best Practices in Developing Proprietary Names for Human Prescription Drug Products; Guidance for Industry: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/08\/2020","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Safety - Issues, Errors, and Problems","field_topics":"","topics-product":"Safety - Issues, Errors, and Problems","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0622\u0022\u003EFDA-2014-D-0622\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-12-09T15:05:05-05:00\u0022\u003E2020-12-09 15:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-550050-canned-ackee-frozen-ackee-and-other-ackee-products-hypoglycin-toxin\u0022\u003ECPG Sec 550.050 Canned Ackee, Frozen Ackee, and Other Ackee Products- Hypoglycin A Toxin\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/88521\/download\u0022\u003EPDF (17.18 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (17.18 KB) of CPG Sec 550.050 Canned Ackee, Frozen Ackee, and Other Ackee Products- Hypoglycin A Toxin\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/01\/2014","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Fruit\/Fruit Product ","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Fruit\/Fruit Product ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-07T08:53:07-05:00\u0022\u003E2025-03-07 08:53\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/medical-device-data-systems-medical-image-storage-devices-and-medical-image-communications-devices\u0022\u003EMedical Device Data Systems, Medical Image Storage Devices, and Medical Image Communications Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/88572\/download\u0022\u003EPDF (371.78 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (371.78 KB) of Medical Device Data Systems, Medical Image Storage Devices, and Medical Image Communications Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/28\/2022","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Digital Health","field_topics":"","topics-product":"Digital Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0798\u0022\u003EFDA-2014-D-0798\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222022-09-27T17:13:50-04:00\u0022\u003E2022-09-27 17:13\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/endotoxin-testing-recommendations-single-use-intraocular-ophthalmic-devices\u0022\u003EEndotoxin Testing Recommendations for Single-Use Intraocular Ophthalmic Devices\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/88615\/download\u0022\u003EPDF (418.97 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (418.97 KB) of Endotoxin Testing Recommendations for Single-Use Intraocular Ophthalmic Devices\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/17\/2015","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Ophthalmic","field_topics":"Premarket","topics-product":"Premarket, Ophthalmic","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0332\u0022\u003EFDA-2014-D-0332\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222019-03-04T09:40:04-05:00\u0022\u003E2019-03-04 09:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clinical-pharmacology-data-support-demonstration-biosimilarity-reference-product\u0022\u003EClinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/88622\/download\u0022\u003EPDF (149.89 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (149.89 KB) of Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/29\/2016","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Biosimilars, Clinical - Pharmacology","field_topics":"","topics-product":"Biosimilars, Clinical - Pharmacology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0234\u0022\u003EFDA-2014-D-0234\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T11:40:30-04:00\u0022\u003E2020-05-06 11:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/product-development-under-animal-rule\u0022\u003EProduct Development Under the Animal Rule\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/88625\/download\u0022\u003EPDF (573.6 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (573.6 KB) of Product Development Under the Animal Rule\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/02\/2015","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Animal Rule","field_topics":"","topics-product":"Animal Rule","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0007\u0022\u003EFDA-2009-D-0007\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222024-04-02T13:03:01-04:00\u0022\u003E2024-04-02 13:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/newrevisedwithdrawn-guidances-2014\u0022\u003ENew\/Revised\/Withdrawn Guidances 2014\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/88642\/download\u0022\u003EPDF (46.79 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (46.79 KB) of New\/Revised\/Withdrawn Guidances 2014\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"","changed":"\u003Ctime datetime=\u00222018-12-01T03:27:33-05:00\u0022\u003E2018-12-01 03:27\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/distributing-scientific-and-medical-publications-risk-information-approved-prescription-drugs-and\u0022\u003EDistributing Scientific and Medical Publications on Risk Information for Approved Prescription Drugs and Biological Products\u2014Recommended Practices\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/88674\/download\u0022\u003EPDF (94.88 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (94.88 KB) of Distributing Scientific and Medical Publications on Risk Information for Approved Prescription Drugs and Biological Products\u2014Recommended Practices\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/11\/2014","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0758\u0022\u003EFDA-2014-D-0758\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-16T12:30:17-04:00\u0022\u003E2020-04-16 12:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-100250-food-facility-registration-human-and-animal-food\u0022\u003ECPG Sec 100.250 Food Facility Registration (Human and Animal Food)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/88691\/download\u0022\u003EPDF (98.12 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (98.12 KB) of CPG Sec 100.250 Food Facility Registration (Human and Animal Food)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/01\/2014","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0126\u0022\u003EFDA-2013-D-0126\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Animal \u0026amp; Veterinary, Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T08:44:33-04:00\u0022\u003E2024-10-01 08:44\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/drug-supply-chain-security-act-implementation-identification-suspect-product-and-notification\u0022\u003EDrug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/88790\/download\u0022\u003EPDF (369.21 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (369.21 KB) of Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/03\/2021","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0609\u0022\u003EFDA-2014-D-0609\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222024-11-05T16:09:09-05:00\u0022\u003E2024-11-05 16:09\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-220-use-nanomaterials-food-animals\u0022\u003ECVM GFI #220 Use of Nanomaterials in Food for Animals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/88828\/download\u0022\u003EPDF (86.3 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (86.3 KB) of CVM GFI #220 Use of Nanomaterials in Food for Animals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/05\/2015","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Food Additives","field_topics":"Nanotechnology","topics-product":"Nanotechnology, Animal Food Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"09\/10\/2014","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-1009\u0022\u003EFDA-2013-D-1009\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:16:08-04:00\u0022\u003E2019-04-16 14:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/anda-submissions-content-and-format-abbreviated-new-drug-applications\u0022\u003EANDA Submissions \u2014 Content and Format of Abbreviated New Drug Applications: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/128127\/download\u0022\u003EPDF (308.01 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (308.01 KB) of ANDA Submissions \u2014 Content and Format of Abbreviated New Drug Applications: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/20\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Generic Drugs","field_topics":"User Fees","topics-product":"User Fees, Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0725\u0022\u003EFDA-2014-D-0725\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-21T16:15:25-04:00\u0022\u003E2020-04-21 16:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/uncomplicated-gonorrhea-developing-drugs-treatment\u0022\u003EUncomplicated Gonorrhea: Developing Drugs for Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/88904\/download\u0022\u003EPDF (222.06 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (222.06 KB) of Uncomplicated Gonorrhea: Developing Drugs for Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/18\/2015","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0640\u0022\u003EFDA-2014-D-0640\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T08:50:27-04:00\u0022\u003E2020-05-06 08:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/reporting-drug-sample-information-under-section-6004-affordable-care-act\u0022\u003EReporting Drug Sample Information Under Section 6004 of the Affordable Care Act\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/88910\/download\u0022\u003EPDF (113.9 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (113.9 KB) of Reporting Drug Sample Information Under Section 6004 of the Affordable Care Act\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/11\/2014","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Electronic Submissions","topics-product":"Electronic Submissions, ","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0829\u0022\u003EFDA-2014-D-0829\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-22T11:22:24-04:00\u0022\u003E2020-04-22 11:22\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-218-cell-based-products-animal-use\u0022\u003ECVM GFI #218 Cell-Based Products for Animal Use\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/88925\/download\u0022\u003EPDF (161.91 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (161.91 KB) of CVM GFI #218 Cell-Based Products for Animal Use\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/12\/2015","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Investigational New Animal Drug (INAD)","field_topics":"Cellular \u0026amp; Gene Therapy","topics-product":"Cellular \u0026amp; Gene Therapy, Investigational New Animal Drug (INAD)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"09\/30\/2014","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0634\u0022\u003EFDA-2014-D-0634\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:16:35-04:00\u0022\u003E2019-04-16 14:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/benefit-risk-factors-consider-when-determining-substantial-equivalence-premarket-notifications-510k\u0022\u003EBenefit-Risk Factors to Consider When Determining Substantial Equivalence in Premarket Notifications (510(k)) with Different Technological Characteristics: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/89019\/download\u0022\u003EPDF (537.58 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (537.58 KB) of Benefit-Risk Factors to Consider When Determining Substantial Equivalence in Premarket Notifications (510(k)) with Different Technological Characteristics: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/25\/2018","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"510(k)","field_topics":"","topics-product":"510(k)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0900\u0022\u003EFDA-2014-D-0900\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222020-10-20T15:21:15-04:00\u0022\u003E2020-10-20 15:21\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/design-and-analysis-shedding-studies-virus-or-bacteria-based-gene-therapy-and-oncolytic-products\u0022\u003EDesign and Analysis of Shedding Studies for Virus or Bacteria-Based Gene Therapy and Oncolytic Products: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/89036\/download\u0022\u003EPDF (120.35 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (120.35 KB) of Design and Analysis of Shedding Studies for Virus or Bacteria-Based Gene Therapy and Oncolytic Products: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/27\/2015","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Gene Therapy","field_topics":"Cellular \u0026amp; Gene Therapy","topics-product":"Cellular \u0026amp; Gene Therapy, Gene Therapy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0852\u0022\u003EFDA-2014-D-0852\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222019-05-16T16:30:11-04:00\u0022\u003E2019-05-16 16:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/reference-product-exclusivity-biological-products-filed-under-section-351a-phs-act\u0022\u003EReference Product Exclusivity for Biological Products Filed Under Section 351(a) of the PHS Act\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/89049\/download\u0022\u003EPDF (99.35 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (99.35 KB) of Reference Product Exclusivity for Biological Products Filed Under Section 351(a) of the PHS Act\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/04\/2014","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Biosimilars","field_topics":"","topics-product":"Administrative \/ Procedural, Biosimilars","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-1165\u0022\u003EFDA-2013-D-1165\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-15T17:10:20-04:00\u0022\u003E2020-04-15 17:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/upper-facial-lines-developing-botulinum-toxin-drug-products\u0022\u003EUpper Facial Lines: Developing Botulinum Toxin Drug Products\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/06\/2014","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0968\u0022\u003EFDA-2014-D-0968\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-01-22T16:11:18-05:00\u0022\u003E2025-01-22 16:11\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/unique-device-identification-system-small-entity-compliance-guide\u0022\u003EUnique Device Identification System: Small Entity Compliance Guide: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/89222\/download\u0022\u003EPDF (490.26 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (490.26 KB) of Unique Device Identification System: Small Entity Compliance Guide: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/13\/2014","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0790\u0022\u003EFDA-2011-D-0790\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-24T09:30:14-04:00\u0022\u003E2020-03-24 09:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/intent-exempt-certain-unclassified-medical-devices-premarket-notification-requirements\u0022\u003EIntent to Exempt Certain Unclassified Medical Devices from Premarket Notification Requirements: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/89238\/download\u0022\u003EPDF (260.95 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (260.95 KB) of Intent to Exempt Certain Unclassified Medical Devices from Premarket Notification Requirements: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/05\/2026","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k)","field_topics":"Premarket","topics-product":"Premarket, 510(k)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0967\u0022\u003EFDA-2014-D-0967\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222026-06-04T09:30:06-04:00\u0022\u003E2026-06-04 09:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/anda-submissions-amendments-abbreviated-new-drug-applications-under-gdufa\u0022\u003EANDA Submissions | Amendments to Abbreviated New Drug Applications Under GDUFA: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/89258\/download\u0022\u003EPDF (400.85 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (400.85 KB) of ANDA Submissions | Amendments to Abbreviated New Drug Applications Under GDUFA: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/11\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Drug Competition Action Plan, Generic Drugs","field_topics":"User Fees","topics-product":"User Fees, Drug Competition Action Plan, Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-5670\u0022\u003EFDA-2017-D-5670\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-09-16T11:22:04-04:00\u0022\u003E2024-09-16 11:22\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/anda-submissions-prior-approval-supplements-under-gdufa\u0022\u003EANDA Submissions \u2013 Prior Approval Supplements Under GDUFA: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/89263\/download\u0022\u003EPDF (347 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (347 KB) of ANDA Submissions \u2013 Prior Approval Supplements Under GDUFA: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/14\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Drug Competition Action Plan, Generic Drugs","field_topics":"User Fees","topics-product":"User Fees, Drug Competition Action Plan, Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0901\u0022\u003EFDA-2014-D-0901\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-01-11T16:03:46-05:00\u0022\u003E2023-01-11 16:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/unique-device-identifier-system-frequently-asked-questions-vol-1\u0022\u003EUnique Device Identifier System: Frequently Asked Questions, Vol. 1 : Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/89275\/download\u0022\u003EPDF (462.01 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (462.01 KB) of Unique Device Identifier System: Frequently Asked Questions, Vol. 1 : Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/20\/2014","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling, UDI","field_topics":"","topics-product":"Labeling, UDI","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222021-07-15T12:35:07-04:00\u0022\u003E2021-07-15 12:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/ind-applications-minimally-manipulated-unrelated-allogeneic-placentalumbilical-cord-blood-intended\u0022\u003EIND Applications for Minimally Manipulated, Unrelated Allogeneic Placental\/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/89441\/download\u0022\u003EPDF (119.68 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (119.68 KB) of IND Applications for Minimally Manipulated, Unrelated Allogeneic Placental\/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/2014","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Gene Therapy","field_topics":"Cellular \u0026amp; Gene Therapy","topics-product":"Cellular \u0026amp; Gene Therapy, Gene Therapy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0490\u0022\u003EFDA-2009-D-0490\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222019-05-16T16:45:24-04:00\u0022\u003E2019-05-16 16:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-225-vich-gl53-electronic-exchange-documents-file-format-recommendations\u0022\u003ECVM GFI #225 (VICH GL53) Electronic Exchange of Documents: File Format Recommendations\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/89444\/download\u0022\u003EPDF (113.45 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (113.45 KB) of CVM GFI #225 (VICH GL53) Electronic Exchange of Documents: File Format Recommendations\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/01\/2015","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"New Animal Drug Application (NADA), VICH","field_topics":"Electronic Submissions","topics-product":"Electronic Submissions, New Animal Drug Application (NADA), VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"10\/27\/2014","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-1177\u0022\u003EFDA-2014-D-1177\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:25:28-04:00\u0022\u003E2019-04-16 14:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/over-counter-pediatric-oral-liquid-drug-products-containing-acetaminophen\u0022\u003EOver-the-Counter Pediatric Oral Liquid Drug Products Containing Acetaminophen\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/89475\/download\u0022\u003EPDF (81.71 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (81.71 KB) of Over-the-Counter Pediatric Oral Liquid Drug Products Containing Acetaminophen\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/05\/2015","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Over-the-Counter Drugs, Safety - Issues, Errors, and Problems, Administrative \/ Procedural, Combination Products","field_topics":"","topics-product":"Over-the-Counter Drugs, Safety - Issues, Errors, and Problems, Administrative \/ Procedural, Combination Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-1473\u0022\u003EFDA-2014-D-1473\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-15T01:20:28-04:00\u0022\u003E2020-05-15 01:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/critical-path-innovation-meetings\u0022\u003ECritical Path Innovation Meetings\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/89497\/download\u0022\u003EPDF (68.37 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (68.37 KB) of Critical Path Innovation Meetings\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/30\/2015","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222018-12-01T11:33:04-05:00\u0022\u003E2018-12-01 11:33\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/qualification-biomarker-galactomannan-studies-treatments-invasive\u0022\u003EQualification of Biomarker \u2014 Galactomannan in studies of treatments of invasive\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/89512\/download\u0022\u003EPDF (162.39 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (162.39 KB) of Qualification of Biomarker \u2014 Galactomannan in studies of treatments of invasive\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/13\/2015","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Drug Development Tools","field_topics":"","topics-product":"Drug Development Tools","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-1630\u0022\u003EFDA-2013-D-1630\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-14T20:25:06-04:00\u0022\u003E2020-04-14 20:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-227-chemistry-manufacturing-and-controls-cmc-technical-section-filing-strategies\u0022\u003ECVM GFI #227 Chemistry, Manufacturing, and Controls (CMC) Technical Section Filing Strategies\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/89527\/download\u0022\u003EPDF (311.11 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (311.11 KB) of CVM GFI #227 Chemistry, Manufacturing, and Controls (CMC) Technical Section Filing Strategies\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/17\/2024","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Drugs, Chemistry, Manufacturing, and Controls (CMC), Investigational New Animal Drug (INAD), New Animal Drug Application (NADA)","field_topics":"Premarket","topics-product":"Premarket, Animal Drugs, Chemistry, Manufacturing, and Controls (CMC), Investigational New Animal Drug (INAD), New Animal Drug Application (NADA)","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"11\/18\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-1492\u0022\u003EFDA-2014-D-1492\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222024-09-16T08:50:04-04:00\u0022\u003E2024-09-16 08:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/content-and-format-abbreviated-510ks-early-growth-response-1-egr1-gene-fluorescence-situ\u0022\u003EContent and Format for Abbreviated 510(k)s for Early Growth Response 1 (EGR1) Gene Fluorescence In-Situ Hybridization (FISH) Test System for Specimen Characterization Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/89551\/download\u0022\u003EPDF (330.31 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (330.31 KB) of Content and Format for Abbreviated 510(k)s for Early Growth Response 1 (EGR1) Gene Fluorescence In-Situ Hybridization (FISH) Test System for Specimen Characterization Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/17\/2015","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Labeling, Laboratory Tests, IVDs (In Vitro Diagnostic Devices), Molecular and Clinical Genetics, Immunology \u0026amp; Microbiology ","field_topics":"Premarket","topics-product":"Premarket, 510(k), Labeling, Laboratory Tests, IVDs (In Vitro Diagnostic Devices), Molecular and Clinical Genetics, Immunology \u0026amp; Microbiology ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-1242\u0022\u003EFDA-2014-D-1242\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222019-04-11T17:40:04-04:00\u0022\u003E2019-04-11 17:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/electronic-submission-lot-distribution-reports\u0022\u003EElectronic Submission of Lot Distribution Reports: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/89610\/download\u0022\u003EPDF (64.97 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (64.97 KB) of Electronic Submission of Lot Distribution Reports: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/23\/2015","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Electronic Submissions","topics-product":"Electronic Submissions, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-1288\u0022\u003EFDA-2014-D-1288\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222020-04-29T18:20:14-04:00\u0022\u003E2020-04-29 18:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/migraine-developing-drugs-acute-treatment\u0022\u003EMigraine: Developing Drugs for Acute Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/89829\/download\u0022\u003EPDF (115.42 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (115.42 KB) of Migraine: Developing Drugs for Acute Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/16\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-1540\u0022\u003EFDA-2014-D-1540\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T13:40:02-04:00\u0022\u003E2020-04-24 13:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-224-vich-gl52-bioequivalence-blood-level-bioequivalence-study\u0022\u003ECVM GFI #224 (VICH GL52) Bioequivalence: Blood Level Bioequivalence Study\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/89840\/download\u0022\u003EPDF (333.75 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (333.75 KB) of CVM GFI #224 (VICH GL52) Bioequivalence: Blood Level Bioequivalence Study\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/16\/2016","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Generic Animal Drugs, Generic Drugs, New Animal Drug Application (NADA), VICH","field_topics":"","topics-product":"Generic Animal Drugs, Generic Drugs, New Animal Drug Application (NADA), VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"11\/24\/2014","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-1352\u0022\u003EFDA-2014-D-1352\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:20:11-04:00\u0022\u003E2019-04-16 14:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-224-supplement-vich-gl52-supplemental-examples-illustrating-statistical-concepts-described\u0022\u003ECVM GFI #224 (Supplement to VICH GL52) Supplemental Examples For Illustrating Statistical Concepts Described in the VICH In Vivo Bioequivalence Guidance GL52\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/89845\/download\u0022\u003EPDF (131.25 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (131.25 KB) of CVM GFI #224 (Supplement to VICH GL52) Supplemental Examples For Illustrating Statistical Concepts Described in the VICH In Vivo Bioequivalence Guidance GL52\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/24\/2014","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Generic Animal Drugs, Generic Drugs, New Animal Drug Application (NADA), VICH","field_topics":"","topics-product":"Generic Animal Drugs, Generic Drugs, New Animal Drug Application (NADA), VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"11\/24\/2014","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-1352\u0022\u003EFDA-2014-D-1352\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:20:08-04:00\u0022\u003E2019-04-16 14:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/custom-device-exemption\u0022\u003ECustom Device Exemption: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/89897\/download\u0022\u003EPDF (601.52 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (601.52 KB) of Custom Device Exemption: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/24\/2014","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-1601\u0022\u003EFDA-2013-D-1601\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222019-02-21T15:27:32-05:00\u0022\u003E2019-02-21 15:27\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/distinguishing-medical-device-recalls-medical-device-enhancements\u0022\u003EDistinguishing Medical Device Recalls from Medical Device Enhancements: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/89909\/download\u0022\u003EPDF (440.4 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (440.4 KB) of Distinguishing Medical Device Recalls from Medical Device Enhancements: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/15\/2014","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Postmarket","topics-product":"Postmarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0114\u0022\u003EFDA-2013-D-0114\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222019-02-26T08:35:04-05:00\u0022\u003E2019-02-26 08:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/policy-clarification-certain-fluoroscopic-equipment-requirements\u0022\u003EPolicy Clarification for Certain Fluoroscopic Equipment Requirements: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/89919\/download\u0022\u003EPDF (336.85 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (336.85 KB) of Policy Clarification for Certain Fluoroscopic Equipment Requirements: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/08\/2019","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Radiological Health","field_topics":"","topics-product":"Radiological Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-1344\u0022\u003EFDA-2014-D-1344\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222019-05-07T08:50:27-04:00\u0022\u003E2019-05-07 08:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/same-surgical-procedure-exception-under-21-cfr-127115b-questions-and-answers-regarding-scope\u0022\u003ESame Surgical Procedure Exception under 21 CFR 1271.15(b):\u00a0Questions and Answers Regarding the Scope of the Exception\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/89920\/download\u0022\u003EPDF (79.29 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (79.29 KB) of Same Surgical Procedure Exception under 21 CFR 1271.15(b):\u00a0Questions and Answers Regarding the Scope of the Exception\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/16\/2017","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Tissue","field_topics":"Cellular \u0026amp; Gene Therapy","topics-product":"Cellular \u0026amp; Gene Therapy, Tissue","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-1584\u0022\u003EFDA-2014-D-1584\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222019-05-16T16:20:11-04:00\u0022\u003E2019-05-16 16:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/specification-unique-facility-identifier-ufi-system-drug-establishment\u0022\u003ESpecification of the Unique Facility Identifier (UFI) System for Drug Establishment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/89926\/download\u0022\u003EPDF (61.12 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (61.12 KB) of Specification of the Unique Facility Identifier (UFI) System for Drug Establishment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/06\/2014","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0984\u0022\u003EFDA-2013-D-0984\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-04T14:35:38-04:00\u0022\u003E2020-05-04 14:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/anda-submissions-refuse-receive-lack-justification-impurity-limits\u0022\u003EANDA Submissions \u2014 Refuse to Receive for Lack of Justification of Impurity Limits: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/89932\/download\u0022\u003EPDF (325.96 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (325.96 KB) of ANDA Submissions \u2014 Refuse to Receive for Lack of Justification of Impurity Limits: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/14\/2016","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Generic Drugs","field_topics":"User Fees","topics-product":"User Fees, Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-1292\u0022\u003EFDA-2014-D-1292\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-21T16:25:10-04:00\u0022\u003E2020-04-21 16:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/drug-product-tracing-effect-section-585-fdc-act\u0022\u003EDrug Product Tracing: The Effect of Section 585 of the FD\u0026amp;C Act\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/89954\/download\u0022\u003EPDF (144.3 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (144.3 KB) of Drug Product Tracing: The Effect of Section 585 of the FD\u0026amp;C Act\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/03\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-1411\u0022\u003EFDA-2014-D-1411\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222024-11-05T16:09:11-05:00\u0022\u003E2024-11-05 16:09\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/product-labeling-laparoscopic-power-morcellators\u0022\u003EProduct Labeling for Laparoscopic Power Morcellators: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/90012\/download\u0022\u003EPDF (325.39 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (325.39 KB) of Product Labeling for Laparoscopic Power Morcellators: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/30\/2020","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Labeling, Safety - Issues, Errors, and Problems, Obstetrical \u0026amp; Gynecological, General \u0026amp; Plastic Surgery ","field_topics":"Postmarket, Premarket","topics-product":"Postmarket, Premarket, 510(k), Labeling, Safety - Issues, Errors, and Problems, Obstetrical \u0026amp; Gynecological, General \u0026amp; Plastic Surgery ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-1804\u0022\u003EFDA-2014-D-1804\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-12-29T08:50:24-05:00\u0022\u003E2020-12-29 08:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/mitigating-risk-cross-contamination-valves-and-accessories-used-irrigation-through-flexible\u0022\u003EMitigating the Risk of Cross-Contamination from Valves and Accessories Used for Irrigation Through Flexible Gastrointestinal Endoscopes: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/90148\/download\u0022\u003EPDF (445.11 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (445.11 KB) of Mitigating the Risk of Cross-Contamination from Valves and Accessories Used for Irrigation Through Flexible Gastrointestinal Endoscopes: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/29\/2016","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Gastroenterology-Urology ","field_topics":"Premarket","topics-product":"Premarket, Gastroenterology-Urology ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-2153\u0022\u003EFDA-2014-D-2153\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222019-03-05T12:20:08-05:00\u0022\u003E2019-03-05 12:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pregnancy-lactation-and-reproductive-potential-labeling-human-prescription-drug-and-biological\u0022\u003EPregnancy, Lactation, and Reproductive Potential: Labeling for Human Prescription Drug and Biological Products-Content and Format: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/90160\/download\u0022\u003EPDF (410.23 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (410.23 KB) of Pregnancy, Lactation, and Reproductive Potential: Labeling for Human Prescription Drug and Biological Products-Content and Format: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/29\/2020","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"09\/29\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-1551\u0022\u003EFDA-2014-D-1551\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-07-29T08:55:02-04:00\u0022\u003E2020-07-29 08:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/electronic-drug-product-reporting-human-drug-compounding-outsourcing-facilities-under-section-503b\u0022\u003EElectronic Drug Product Reporting for Human Drug Compounding Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act.\u201d\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/90173\/download\u0022\u003EPDF (190.66 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (190.66 KB) of Electronic Drug Product Reporting for Human Drug Compounding Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act.\u201d\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/03\/2017","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Compounding","field_topics":"","topics-product":"Administrative \/ Procedural, Compounding","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-N-1428\u0022\u003EFDA-2013-N-1428\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-04-28T10:15:42-04:00\u0022\u003E2022-04-28 10:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-540700-labeling-processed-and-blended-seafood-products-made-primarily-fish-protein\u0022\u003ECPG Sec 540.700 Labeling of Processed and Blended Seafood Products Made Primarily with Fish Protein\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/90259\/download\u0022\u003EPDF (17.8 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (17.8 KB) of CPG Sec 540.700 Labeling of Processed and Blended Seafood Products Made Primarily with Fish Protein\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/01\/2014","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Seafood\/Seafood Product","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Seafood\/Seafood Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:43:49-05:00\u0022\u003E2025-03-06 21:43\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-540275-draft-crabmeat-fresh-and-frozen-adulteration-filth-involving-presence-escherichia\u0022\u003ECPG Sec 540.275 (Draft) Crabmeat - Fresh and Frozen - Adulteration with Filth, Involving the Presence of Escherichia coli\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/90349\/download\u0022\u003EPDF (53.66 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (53.66 KB) of CPG Sec 540.275 (Draft) Crabmeat - Fresh and Frozen - Adulteration with Filth, Involving the Presence of Escherichia coli\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/16\/2014","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Seafood\/Seafood Product","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Seafood\/Seafood Product","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-1842\u0022\u003EFDA-2014-D-1842\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T08:44:35-04:00\u0022\u003E2024-10-01 08:44\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/general-clinical-pharmacology-considerations-pediatric-studies-drugs-including-biological-products\u0022\u003EGeneral Clinical Pharmacology Considerations for Pediatric Studies of Drugs, Including Biological Products \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/90358\/download\u0022\u003EPDF (426.03 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (426.03 KB) of General Clinical Pharmacology Considerations for Pediatric Studies of Drugs, Including Biological Products \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/07\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Pharmacology, Pediatric Product Development","field_topics":"","topics-product":"Clinical - Pharmacology, Pediatric Product Development","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"12\/07\/2022","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-1275\u0022\u003EFDA-2013-D-1275\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T09:41:02-04:00\u0022\u003E2024-04-11 09:41\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/radiation-biodosimetry-medical-countermeasure-devices\u0022\u003ERadiation Biodosimetry Medical Countermeasure Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/90385\/download\u0022\u003EPDF (692.86 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (692.86 KB) of Radiation Biodosimetry Medical Countermeasure Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/18\/2016","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Laboratory Tests, IVDs (In Vitro Diagnostic Devices), Radiological Health","field_topics":"Premarket, Emergencies","topics-product":"Premarket, Emergencies, Laboratory Tests, IVDs (In Vitro Diagnostic Devices), Radiological Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"03\/30\/2015","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-2065\u0022\u003EFDA-2014-D-2065\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222019-03-14T10:55:04-04:00\u0022\u003E2019-03-14 10:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/dscsa-implementation-product-tracing-requirements-compliance-policy\u0022\u003EDSCSA Implementation: Product Tracing Requirements \u2014 Compliance Policy\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/90397\/download\u0022\u003EPDF (55.76 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (55.76 KB) of DSCSA Implementation: Product Tracing Requirements \u2014 Compliance Policy\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/31\/2014","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-2254\u0022\u003EFDA-2014-D-2254\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-01T14:06:26-04:00\u0022\u003E2020-05-01 14:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/dscsa-implementation-annual-reporting-prescription-drug-wholesale-distributors-and-third-party\u0022\u003EDSCSA Implementation: Annual Reporting by Prescription Drug Wholesale Distributors and Third-Party Logistics Providers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/90442\/download\u0022\u003EPDF (94.17 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (94.17 KB) of DSCSA Implementation: Annual Reporting by Prescription Drug Wholesale Distributors and Third-Party Logistics Providers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/09\/2014","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-2083\u0022\u003EFDA-2014-D-2083\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-28T15:15:12-04:00\u0022\u003E2020-04-28 15:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/dscsa-standards-interoperable-exchange-information-tracing-certain-human-finished-prescription-drugs\u0022\u003EDSCSA Standards for the Interoperable Exchange of Information for Tracing of Certain Human, Finished, Prescription Drugs Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/171796\/download\u0022\u003EPDF (237.14 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (237.14 KB) of DSCSA Standards for the Interoperable Exchange of Information for Tracing of Certain Human, Finished, Prescription Drugs Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/06\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-1981\u0022\u003EFDA-2014-D-1981\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-11-05T16:09:19-05:00\u0022\u003E2024-11-05 16:09\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommended-warning-over-counter-acetaminophen-containing-drug-products-and-labeling-statements\u0022\u003ERecommended Warning for Over-the-Counter Acetaminophen-Containing Drug Products and Labeling Statements Regarding Serious Skin Reactions\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/90572\/download\u0022\u003EPDF (89.49 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (89.49 KB) of Recommended Warning for Over-the-Counter Acetaminophen-Containing Drug Products and Labeling Statements Regarding Serious Skin Reactions\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/11\/2017","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP), Over-the-Counter Drugs","field_topics":"Compliance","topics-product":"Compliance, Current Good Manufacturing Practice (CGMP), Over-the-Counter Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-1862\u0022\u003EFDA-2014-D-1862\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-02-01T11:35:07-05:00\u0022\u003E2021-02-01 11:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/medical-glove-guidance-manual\u0022\u003EMedical Glove Guidance Manual: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/90612\/download\u0022\u003EPDF (782.41 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (782.41 KB) of Medical Glove Guidance Manual: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/22\/2008","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k)","field_topics":"Premarket","topics-product":"Premarket, 510(k)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222026-02-03T15:51:03-05:00\u0022\u003E2026-02-03 15:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/medical-device-accessories-describing-accessories-and-classification-pathways\u0022\u003EMedical Device Accessories - Describing Accessories and Classification Pathways: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/90647\/download\u0022\u003EPDF (442.1 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (442.1 KB) of Medical Device Accessories - Describing Accessories and Classification Pathways: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/20\/2017","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Digital Health","field_topics":"Premarket","topics-product":"Premarket, Administrative \/ Procedural, Digital Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"04\/10\/2015","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-0025\u0022\u003EFDA-2015-D-0025\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222026-03-19T14:10:05-04:00\u0022\u003E2026-03-19 14:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/general-wellness-policy-low-risk-devices\u0022\u003EGeneral Wellness: Policy for Low Risk Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/90652\/download\u0022\u003EPDF (304.87 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (304.87 KB) of General Wellness: Policy for Low Risk Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/06\/2026","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Digital Health","field_topics":"Premarket","topics-product":"Premarket, Digital Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-N-1039\u0022\u003EFDA-2014-N-1039\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222026-01-06T12:00:15-05:00\u0022\u003E2026-01-06 12:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/evaluating-drug-effects-ability-operate-motor-vehicle\u0022\u003EEvaluating Drug Effects on the Ability to Operate a Motor Vehicle\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/90670\/download\u0022\u003EPDF (104.38 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (104.38 KB) of Evaluating Drug Effects on the Ability to Operate a Motor Vehicle\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/08\/2017","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-03-25T15:30:05-04:00\u0022\u003E2019-03-25 15:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/technical-performance-assessment-digital-pathology-whole-slide-imaging-devices\u0022\u003ETechnical Performance Assessment of Digital Pathology Whole Slide Imaging Devices : Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/90791\/download\u0022\u003EPDF (579.46 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (579.46 KB) of Technical Performance Assessment of Digital Pathology Whole Slide Imaging Devices : Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/20\/2016","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Labeling, Laboratory Tests, IVDs (In Vitro Diagnostic Devices)","field_topics":"Premarket","topics-product":"Premarket, 510(k), Labeling, Laboratory Tests, IVDs (In Vitro Diagnostic Devices)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-0230\u0022\u003EFDA-2015-D-0230\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222019-03-28T15:15:05-04:00\u0022\u003E2019-03-28 15:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/classification-and-requirements-laser-illuminated-projectors-lips-laser-notice-no-57\u0022\u003EClassification and Requirements for Laser Illuminated Projectors (LIPs) (Laser Notice No. 57): Guidance for Industry and Food and Drug Administration\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/90796\/download\u0022\u003EPDF (368.73 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (368.73 KB) of Classification and Requirements for Laser Illuminated Projectors (LIPs) (Laser Notice No. 57): Guidance for Industry and Food and Drug Administration\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/08\/2019","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Radiological Health","field_topics":"","topics-product":"Radiological Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-2245\u0022\u003EFDA-2014-D-2245\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222019-05-07T08:55:37-04:00\u0022\u003E2019-05-07 08:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/medical-devices-and-clinical-trial-design-treatment-or-improvement-appearance-fungally-infected\u0022\u003EMedical Devices and Clinical Trial Design for the Treatment or Improvement in the Appearance of Fungally-Infected Nails: Guidance for Industry and Food and Drug Administration Staff \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/90831\/download\u0022\u003EPDF (419.95 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (419.95 KB) of Medical Devices and Clinical Trial Design for the Treatment or Improvement in the Appearance of Fungally-Infected Nails: Guidance for Industry and Food and Drug Administration Staff \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/07\/2016","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Premarket Approval (PMA), Investigational Device Exemption (IDE), HUD\/HDE, General \u0026amp; Plastic Surgery , Good Clinical Practice (GCP), Labeling","field_topics":"Premarket","topics-product":"Premarket, 510(k), Premarket Approval (PMA), Investigational Device Exemption (IDE), HUD\/HDE, General \u0026amp; Plastic Surgery , Good Clinical Practice (GCP), Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-1849\u0022\u003EFDA-2014-D-1849\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222019-02-09T15:41:42-05:00\u0022\u003E2019-02-09 15:41\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/premarket-studies-implantable-minimally-invasive-glaucoma-surgical-migs-devices\u0022\u003EPremarket Studies of Implantable Minimally Invasive Glaucoma Surgical (MIGS) Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/90950\/download\u0022\u003EPDF (691.59 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (691.59 KB) of Premarket Studies of Implantable Minimally Invasive Glaucoma Surgical (MIGS) Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/15\/2015","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Ophthalmic, Premarket Approval (PMA)","field_topics":"Premarket","topics-product":"Premarket, Ophthalmic, Premarket Approval (PMA)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"05\/12\/2015","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-0288\u0022\u003EFDA-2015-D-0288\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-02T09:40:16-05:00\u0022\u003E2020-03-02 09:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-entities-considering-whether-register-outsourcing-facilities-under-section-503b-federal\u0022\u003EGuidance For Entities Considering Whether to Register As Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/90971\/download\u0022\u003EPDF (74.03 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (74.03 KB) of Guidance For Entities Considering Whether to Register As Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/11\/2015","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Compounding","field_topics":"","topics-product":"Administrative \/ Procedural, Compounding","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"05\/17\/2015","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-03-28T14:10:39-04:00\u0022\u003E2019-03-28 14:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/repackaging-certain-human-drug-products-pharmacies-and-outsourcing-facilities\u0022\u003ERepackaging of Certain Human Drug Products by Pharmacies and Outsourcing Facilities: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/90978\/download\u0022\u003EPDF (645.92 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (645.92 KB) of Repackaging of Certain Human Drug Products by Pharmacies and Outsourcing Facilities: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/13\/2017","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Compounding, Pharmaceutical Quality, Current Good Manufacturing Practice (CGMP)","field_topics":"Compliance","topics-product":"Compliance, Compounding, Pharmaceutical Quality, Current Good Manufacturing Practice (CGMP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-1524\u0022\u003EFDA-2014-D-1524\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-17T14:50:13-04:00\u0022\u003E2020-04-17 14:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/mixing-diluting-or-repackaging-biological-products-outside-scope-approved-biologics-license\u0022\u003EMixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/90986\/download\u0022\u003EPDF (555.69 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (555.69 KB) of Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/18\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Compounding, Pharmaceutical Quality, Current Good Manufacturing Practice (CGMP)","field_topics":"","topics-product":"Compounding, Pharmaceutical Quality, Current Good Manufacturing Practice (CGMP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"03\/13\/2017","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-06-05T09:38:22-04:00\u0022\u003E2019-06-05 09:38\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/adverse-event-reporting-outsourcing-facilities-under-section-503b-federal-food-drug-and-cosmetic-act\u0022\u003EAdverse Event Reporting for Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/90997\/download\u0022\u003EPDF (247.62 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (247.62 KB) of Adverse Event Reporting for Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/08\/2015","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Compounding, Safety - Issues, Errors, and Problems","field_topics":"","topics-product":"Compounding, Safety - Issues, Errors, and Problems","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"05\/17\/2015","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-2138\u0022\u003EFDA-2014-D-2138\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-21T15:45:07-04:00\u0022\u003E2020-04-21 15:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-203-ensuring-safety-animal-feed-maintained-and-fed-farm\u0022\u003ECVM GFI #203 Ensuring Safety of Animal Feed Maintained and Fed On-Farm\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/91080\/download\u0022\u003EPDF (107.8 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (107.8 KB) of CVM GFI #203 Ensuring Safety of Animal Feed Maintained and Fed On-Farm\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/09\/2016","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Feed","field_topics":"","topics-product":"Animal Feed","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"06\/03\/2015","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-1180\u0022\u003EFDA-2014-D-1180\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:05:54-04:00\u0022\u003E2019-04-16 14:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/individual-patient-expanded-access-applications-form-fda-3926\u0022\u003EIndividual Patient Expanded Access Applications: Form FDA 3926\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/91160\/download\u0022\u003EPDF (271.83 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (271.83 KB) of Individual Patient Expanded Access Applications: Form FDA 3926\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/03\/2017","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-0268\u0022\u003EFDA-2015-D-0268\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-01-29T08:45:05-05:00\u0022\u003E2024-01-29 08:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/alcoholism-developing-drugs-treatment\u0022\u003EAlcoholism: Developing Drugs for Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/91222\/download\u0022\u003EPDF (350.4 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (350.4 KB) of Alcoholism: Developing Drugs for Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/12\/2015","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-0152\u0022\u003EFDA-2015-D-0152\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-21T15:50:13-04:00\u0022\u003E2020-04-21 15:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-229-evaluating-effectiveness-new-animal-drugs-reduction-pathogenic-shiga-toxin-producing-e\u0022\u003ECVM GFI #229 Evaluating the Effectiveness of New Animal Drugs for the Reduction of Pathogenic Shiga Toxin-Producing E. coli in Cattle\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/91229\/download\u0022\u003EPDF (128.2 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (128.2 KB) of CVM GFI #229 Evaluating the Effectiveness of New Animal Drugs for the Reduction of Pathogenic Shiga Toxin-Producing E. coli in Cattle\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/19\/2015","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Target Animal \u2013 Effectiveness","field_topics":"","topics-product":"Target Animal \u2013 Effectiveness","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"04\/27\/2015","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-0235\u0022\u003EFDA-2015-D-0235\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:25:22-04:00\u0022\u003E2019-04-16 14:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/development-and-submission-near-infrared-analytical-procedures\u0022\u003EDevelopment and Submission of Near Infrared Analytical Procedures\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/91343\/download\u0022\u003EPDF (236.73 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (236.73 KB) of Development and Submission of Near Infrared Analytical Procedures\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/06\/2021","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-0868\u0022\u003EFDA-2015-D-0868\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-08-06T08:56:04-04:00\u0022\u003E2021-08-06 08:56\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-226-target-animal-safety-data-presentation-and-statistical-analysis\u0022\u003ECVM GFI #226 Target Animal Safety Data Presentation and Statistical Analysis\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/91376\/download\u0022\u003EPDF (560.62 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (560.62 KB) of CVM GFI #226 Target Animal Safety Data Presentation and Statistical Analysis\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/21\/2016","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Target Animal \u2013 Safety, Investigational New Animal Drug (INAD)","field_topics":"","topics-product":"Target Animal \u2013 Safety, Investigational New Animal Drug (INAD)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"06\/01\/2015","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-0839\u0022\u003EFDA-2015-D-0839\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:25:25-04:00\u0022\u003E2019-04-16 14:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/determining-need-and-content-environmental-assessments-gene-therapies-vectored-vaccines-and-related\u0022\u003EDetermining the Need for and Content of Environmental Assessments for Gene Therapies, Vectored Vaccines, and Related Recombinant Viral or Microbial Products: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/91425\/download\u0022\u003EPDF (103.71 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (103.71 KB) of Determining the Need for and Content of Environmental Assessments for Gene Therapies, Vectored Vaccines, and Related Recombinant Viral or Microbial Products: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/2015","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Gene Therapy","field_topics":"","topics-product":"Gene Therapy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0663\u0022\u003EFDA-2014-D-0663\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222019-05-16T16:40:04-04:00\u0022\u003E2019-05-16 16:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/procedures-meetings-medical-devices-advisory-committee\u0022\u003EProcedures for Meetings of the Medical Devices Advisory Committee: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/91429\/download\u0022\u003EPDF (443.17 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (443.17 KB) of Procedures for Meetings of the Medical Devices Advisory Committee: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/01\/2017","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Premarket Approval (PMA), HUD\/HDE, Administrative \/ Procedural, Labeling, Safety - Issues, Errors, and Problems, Anesthesiology , Laboratory Tests, IVDs (In Vitro Diagnostic Devices), Physical Medicine, Orthopedic, Ophthalmic, Obstetrical \u0026amp; Gynecological, Neurological, Molecular and Clinical Genetics, Immunology \u0026amp; Microbiology , Cardiovascular , Hematology \u0026amp; Pathology , General Hospital \u0026amp; Personal Use , General \u0026amp; Plastic Surgery , Gastroenterology-Urology , Ear, Nose \u0026amp; Throat , Dental , Clinical Chemistry \u0026amp; Clinical Toxicology , Radiology, Laser Notice","field_topics":"Premarket, Advisory Committees","topics-product":"Premarket, Advisory Committees, 510(k), Premarket Approval (PMA), HUD\/HDE, Administrative \/ Procedural, Labeling, Safety - Issues, Errors, and Problems, Anesthesiology , Laboratory Tests, IVDs (In Vitro Diagnostic Devices), Physical Medicine, Orthopedic, Ophthalmic, Obstetrical \u0026amp; Gynecological, Neurological, Molecular and Clinical Genetics, Immunology \u0026amp; Microbiology , Cardiovascular , Hematology \u0026amp; Pathology , General Hospital \u0026amp; Personal Use , General \u0026amp; Plastic Surgery , Gastroenterology-Urology , Ear, Nose \u0026amp; Throat , Dental , Clinical Chemistry \u0026amp; Clinical Toxicology , Radiology, Laser Notice","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"05\/29\/2015","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-0838\u0022\u003EFDA-2015-D-0838\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222019-03-12T14:15:04-04:00\u0022\u003E2019-03-12 14:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/providing-regulatory-submissions-electronic-and-non-electronic-format-promotional-labeling-and\u0022\u003EProviding Regulatory Submissions in Electronic and Non-Electronic Format\u2014Promotional Labeling and Advertising Materials for Human Prescription Drugs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/128163\/download\u0022\u003EPDF (463.59 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (463.59 KB) of Providing Regulatory Submissions in Electronic and Non-Electronic Format\u2014Promotional Labeling and Advertising Materials for Human Prescription Drugs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/11\/2022","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Electronic Submissions","topics-product":"Electronic Submissions, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-1163\u0022\u003EFDA-2015-D-1163\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-04-11T16:00:17-04:00\u0022\u003E2022-04-11 16:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/leveraging-existing-clinical-data-extrapolation-pediatric-uses-medical-devices\u0022\u003ELeveraging Existing Clinical Data for Extrapolation to Pediatric Uses of Medical Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/91889\/download\u0022\u003EPDF (367.42 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (367.42 KB) of Leveraging Existing Clinical Data for Extrapolation to Pediatric Uses of Medical Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/21\/2016","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP), Pediatric Product Development, Premarket Approval (PMA), HUD\/HDE","field_topics":"Premarket","topics-product":"Premarket, Good Clinical Practice (GCP), Pediatric Product Development, Premarket Approval (PMA), HUD\/HDE","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"09\/19\/2016","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-1376\u0022\u003EFDA-2015-D-1376\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222024-04-08T11:34:04-04:00\u0022\u003E2024-04-08 11:34\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/environmental-assessment-questions-and-answers-regarding-drugs-estrogenic-androgenic-or-thyroid\u0022\u003EEnvironmental Assessment: Questions and Answers Regarding Drugs With Estrogenic, Androgenic, or Thyroid Activity\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/91941\/download\u0022\u003EPDF (68.67 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (68.67 KB) of Environmental Assessment: Questions and Answers Regarding Drugs With Estrogenic, Androgenic, or Thyroid Activity\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/04\/2016","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-06-03T09:40:13-04:00\u0022\u003E2019-06-03 09:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-232-vich-gl54-studies-evaluate-safety-residues-veterinary-drugs-human-food-general-approach\u0022\u003ECVM GFI #232 (VICH GL54) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: General Approach to Establish an Acute Reference Dose (ARfD)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/92063\/download\u0022\u003EPDF (99.89 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (99.89 KB) of CVM GFI #232 (VICH GL54) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: General Approach to Establish an Acute Reference Dose (ARfD)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/23\/2017","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Human Food Safety, VICH","field_topics":"","topics-product":"Human Food Safety, VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"07\/31\/2015","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-1804\u0022\u003EFDA-2015-D-1804\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:30:27-04:00\u0022\u003E2019-04-16 14:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/unique-device-identification-direct-marking-devices\u0022\u003EUnique Device Identification: Direct Marking of Devices : Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/92100\/download\u0022\u003EPDF (586.68 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (586.68 KB) of Unique Device Identification: Direct Marking of Devices : Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/17\/2017","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling, UDI","field_topics":"","topics-product":"Labeling, UDI","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"09\/24\/2015","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-2245\u0022\u003EFDA-2015-D-2245\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222021-07-15T12:31:14-04:00\u0022\u003E2021-07-15 12:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/premarket-notification-requirements-concerning-gowns-intended-use-health-care-settings\u0022\u003EPremarket Notification Requirements Concerning Gowns Intended for Use in Health Care Settings: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/92146\/download\u0022\u003EPDF (318.85 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (318.85 KB) of Premarket Notification Requirements Concerning Gowns Intended for Use in Health Care Settings: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/09\/2015","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"Ebola","term_node_tid":"","field_topics":"","topics-product":"Ebola, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"08\/29\/2015","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-2261\u0022\u003EFDA-2015-D-2261\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222019-08-28T16:50:16-04:00\u0022\u003E2019-08-28 16:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/duchenne-muscular-dystrophy-and-related-dystrophinopathies-developing-drugs-treatment-guidance\u0022\u003EDuchenne Muscular Dystrophy and Related Dystrophinopathies: Developing Drugs for Treatment Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/92233\/download\u0022\u003EPDF (118.81 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (118.81 KB) of Duchenne Muscular Dystrophy and Related Dystrophinopathies: Developing Drugs for Treatment Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/16\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-1884\u0022\u003EFDA-2015-D-1884\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-17T11:35:11-04:00\u0022\u003E2020-04-17 11:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/factors-consider-when-making-benefit-risk-determinations-medical-device-investigational-device\u0022\u003EFactors to Consider When Making Benefit-Risk Determinations for Medical Device Investigational Device Exemptions: Guidance for Investigational Device Exemption Sponsors, Sponsor-Investigators and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/92427\/download\u0022\u003EPDF (796.71 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (796.71 KB) of Factors to Consider When Making Benefit-Risk Determinations for Medical Device Investigational Device Exemptions: Guidance for Investigational Device Exemption Sponsors, Sponsor-Investigators and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/13\/2017","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Investigational Device Exemption (IDE)","field_topics":"Premarket","topics-product":"Premarket, Clinical - Medical, Investigational Device Exemption (IDE)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"09\/16\/2015","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-1777\u0022\u003EFDA-2015-D-1777\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222020-10-20T15:25:51-04:00\u0022\u003E2020-10-20 15:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/assessment-radiofrequency-induced-heating-magnetic-resonance-mr-environment-multi-configuration\u0022\u003EAssessment of Radiofrequency-Induced Heating in the Magnetic Resonance (MR) Environment for Multi-Configuration Passive Medical Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/92447\/download\u0022\u003EPDF (393.81 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (393.81 KB) of Assessment of Radiofrequency-Induced Heating in the Magnetic Resonance (MR) Environment for Multi-Configuration Passive Medical Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/22\/2016","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Premarket Approval (PMA), Investigational Device Exemption (IDE), Anesthesiology , Physical Medicine, Orthopedic, Ophthalmic, Obstetrical \u0026amp; Gynecological, Neurological, Cardiovascular , General Hospital \u0026amp; Personal Use , General \u0026amp; Plastic Surgery , Gastroenterology-Urology , Ear, Nose \u0026amp; Throat , Dental , Radiology, Labeling, Safety - Issues, Errors, and Problems","field_topics":"Premarket","topics-product":"Premarket, 510(k), Premarket Approval (PMA), Investigational Device Exemption (IDE), Anesthesiology , Physical Medicine, Orthopedic, Ophthalmic, Obstetrical \u0026amp; Gynecological, Neurological, Cardiovascular , General Hospital \u0026amp; Personal Use , General \u0026amp; Plastic Surgery , Gastroenterology-Urology , Ear, Nose \u0026amp; Throat , Dental , Radiology, Labeling, Safety - Issues, Errors, and Problems","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"08\/28\/2015","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-2104\u0022\u003EFDA-2015-D-2104\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222019-02-09T15:35:03-05:00\u0022\u003E2019-02-09 15:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/investigational-enzyme-replacement-therapy-products-nonclinical-assessment\u0022\u003EInvestigational Enzyme Replacement Therapy Products: Nonclinical Assessment: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/131295\/download\u0022\u003EPDF (95.62 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (95.62 KB) of Investigational Enzyme Replacement Therapy Products: Nonclinical Assessment: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/03\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pharmacology\/Toxicology","field_topics":"","topics-product":"Pharmacology\/Toxicology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"01\/02\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-1246\u0022\u003EFDA-2015-D-1246\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T01:15:15-04:00\u0022\u003E2020-04-24 01:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pregnancy-lactation-and-reproductive-potential-labeling-human-prescription-drug-and-biological-0\u0022\u003EPregnancy, Lactation, and Reproductive Potential: Labeling for Human Prescription Drug and Biological Products \u2014 Content and Format Guidance for Industry (Small Entity Compliance Guide)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/92565\/download\u0022\u003EPDF (164.53 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (164.53 KB) of Pregnancy, Lactation, and Reproductive Potential: Labeling for Human Prescription Drug and Biological Products \u2014 Content and Format Guidance for Industry (Small Entity Compliance Guide)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/10\/2015","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Small Entity Compliance Guide","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-07T22:25:02-04:00\u0022\u003E2020-04-07 22:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/incorporating-voluntary-patient-preference-information-over-total-product-life-cycle\u0022\u003EIncorporating Voluntary Patient Preference Information over the Total Product Life Cycle: Guidance for Industry, Food and Drug Administration Staff, and Other Interested Parties\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/92593\/download\u0022\u003EPDF (501.45 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (501.45 KB) of Incorporating Voluntary Patient Preference Information over the Total Product Life Cycle: Guidance for Industry, Food and Drug Administration Staff, and Other Interested Parties\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/30\/2026","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-1580\u0022\u003EFDA-2015-D-1580\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222026-03-27T09:43:17-04:00\u0022\u003E2026-03-27 09:43\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/investigational-new-drug-applications-prepared-and-submitted-sponsor-investigators\u0022\u003EInvestigational New Drug Applications Prepared and Submitted by Sponsor-Investigators\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/92604\/download\u0022\u003EPDF (430.73 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (430.73 KB) of Investigational New Drug Applications Prepared and Submitted by Sponsor-Investigators\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/15\/2015","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-1484\u0022\u003EFDA-2015-D-1484\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-14T10:09:53-04:00\u0022\u003E2020-05-14 10:09\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/dscsa-implementation-product-tracing-requirements-dispensers-compliance-policy-revised-guidance\u0022\u003EDSCSA Implementation: Product Tracing Requirements for Dispensers \u2014 Compliance Policy (Revised) Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/92650\/download\u0022\u003EPDF (54.76 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (54.76 KB) of DSCSA Implementation: Product Tracing Requirements for Dispensers \u2014 Compliance Policy (Revised) Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/02\/2015","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-2270\u0022\u003EFDA-2015-D-2270\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-29T15:25:06-04:00\u0022\u003E2020-04-29 15:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/adaptive-designs-medical-device-clinical-studies\u0022\u003EAdaptive Designs for Medical Device Clinical Studies: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/92671\/download\u0022\u003EPDF (587.38 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (587.38 KB) of Adaptive Designs for Medical Device Clinical Studies: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/27\/2016","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP), Premarket Approval (PMA), Investigational Device Exemption (IDE), HUD\/HDE","field_topics":"Premarket","topics-product":"Premarket, Good Clinical Practice (GCP), Premarket Approval (PMA), Investigational Device Exemption (IDE), HUD\/HDE","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-1439\u0022\u003EFDA-2015-D-1439\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222020-10-20T15:35:38-04:00\u0022\u003E2020-10-20 15:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/qualification-biomarker-plasma-fibrinogen-studies-examining-exacerbations-andor-all-cause-mortality\u0022\u003EQualification of Biomarker Plasma Fibrinogen in Studies Examining Exacerbations and\/or All-Cause Mortality in Patients With Chronic Obstructive Pulmonary Disease Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/92782\/download\u0022\u003EPDF (38.52 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (38.52 KB) of Qualification of Biomarker Plasma Fibrinogen in Studies Examining Exacerbations and\/or All-Cause Mortality in Patients With Chronic Obstructive Pulmonary Disease Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/13\/2016","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Drug Development Tools","field_topics":"","topics-product":"Drug Development Tools","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-2244\u0022\u003EFDA-2015-D-2244\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-15T16:15:12-04:00\u0022\u003E2020-04-15 16:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/submission-premarket-notifications-magnetic-resonance-diagnostic-devices\u0022\u003ESubmission of Premarket Notifications for Magnetic Resonance Diagnostic Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/92921\/download\u0022\u003EPDF (506.83 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (506.83 KB) of Submission of Premarket Notifications for Magnetic Resonance Diagnostic Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/10\/2023","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Radiological Health, Radiology","field_topics":"Premarket","topics-product":"Premarket, 510(k), Radiological Health, Radiology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-2148\u0022\u003EFDA-2015-D-2148\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222023-10-10T11:05:01-04:00\u0022\u003E2023-10-10 11:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/establishing-performance-characteristics-in-vitro-diagnostic-devices-detection-or-detection-and-0\u0022\u003EEstablishing the Performance Characteristics of In Vitro Diagnostic Devices for the Detection or Detection and Differentiation of Human Papillomaviruses: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/92930\/download\u0022\u003EPDF (785.66 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (785.66 KB) of Establishing the Performance Characteristics of In Vitro Diagnostic Devices for the Detection or Detection and Differentiation of Human Papillomaviruses: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/15\/2017","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Laboratory Tests, IVDs (In Vitro Diagnostic Devices), Premarket Approval (PMA)","field_topics":"Premarket, Microbiology","topics-product":"Premarket, Microbiology, Laboratory Tests, IVDs (In Vitro Diagnostic Devices), Premarket Approval (PMA)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"11\/12\/2015","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0386\u0022\u003EFDA-2009-D-0386\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222019-04-11T17:55:06-04:00\u0022\u003E2019-04-11 17:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/dissolution-testing-and-acceptance-criteria-immediate-release-solid-oral-dosage-form-drug-products\u0022\u003EDissolution Testing and Acceptance Criteria for Immediate-Release Solid Oral Dosage Form Drug Products Containing High Solubility Drug Substances Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/92988\/download\u0022\u003EPDF (103.25 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (103.25 KB) of Dissolution Testing and Acceptance Criteria for Immediate-Release Solid Oral Dosage Form Drug Products Containing High Solubility Drug Substances Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/09\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Biopharmaceutics","field_topics":"","topics-product":"Biopharmaceutics","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-2614\u0022\u003EFDA-2018-D-2614\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-16T10:25:09-04:00\u0022\u003E2020-04-16 10:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/submission-quality-metrics-data-guidance-industry\u0022\u003ESubmission of Quality Metrics Data Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/93012\/download\u0022\u003EPDF (339.64 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (339.64 KB) of Submission of Quality Metrics Data Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/25\/2016","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"01\/23\/2017","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-2537\u0022\u003EFDA-2015-D-2537\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-05T10:30:20-04:00\u0022\u003E2020-05-05 10:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/qualification-biomarker-total-kidney-volume-studies-treatment-autosomal-dominant-polycystic-kidney\u0022\u003EQualification of Biomarker Total Kidney Volume in Studies for Treatment of Autosomal Dominant Polycystic Kidney Disease Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/93105\/download\u0022\u003EPDF (32.23 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (32.23 KB) of Qualification of Biomarker Total Kidney Volume in Studies for Treatment of Autosomal Dominant Polycystic Kidney Disease Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/16\/2016","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Drug Development Tools","field_topics":"","topics-product":"Drug Development Tools","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-2843\u0022\u003EFDA-2015-D-2843\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-15T16:20:03-04:00\u0022\u003E2020-04-15 16:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/botanical-drug-development-guidance-industry\u0022\u003EBotanical Drug Development: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/93113\/download\u0022\u003EPDF (221.35 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (221.35 KB) of Botanical Drug Development: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/29\/2016","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2000-D-0103\u0022\u003EFDA-2000-D-0103\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-07T14:16:39-04:00\u0022\u003E2020-05-07 14:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/select-updates-non-clinical-engineering-tests-and-recommended-labeling-intravascular-stents-and\u0022\u003ESelect Updates for Non-Clinical Engineering Tests and Recommended Labeling for Intravascular Stents and Associated Delivery Systems: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/93134\/download\u0022\u003EPDF (410.18 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (410.18 KB) of Select Updates for Non-Clinical Engineering Tests and Recommended Labeling for Intravascular Stents and Associated Delivery Systems: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/18\/2015","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0920\u0022\u003EFDA-2013-D-0920\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222019-03-18T20:00:06-04:00\u0022\u003E2019-03-18 20:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/heparin-containing-medical-devices-and-combination-products-recommendations-labeling-and-safety\u0022\u003EHeparin-Containing Medical Devices and Combination Products: Recommendations for Labeling and Safety Testing: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/93196\/download\u0022\u003EPDF (345.46 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (345.46 KB) of Heparin-Containing Medical Devices and Combination Products: Recommendations for Labeling and Safety Testing: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/20\/2018","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Premarket Approval (PMA), HUD\/HDE, Combination Products","field_topics":"Premarket","topics-product":"Premarket, 510(k), Premarket Approval (PMA), HUD\/HDE, Combination Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-2167\u0022\u003EFDA-2015-D-2167\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222019-04-12T09:20:20-04:00\u0022\u003E2019-04-12 09:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/nonproprietary-naming-biological-products-guidance-industry\u0022\u003ENonproprietary Naming of Biological Products Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/93218\/download\u0022\u003EPDF (114.73 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (114.73 KB) of Nonproprietary Naming of Biological Products Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/12\/2017","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-1543\u0022\u003EFDA-2013-D-1543\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-27T08:55:14-04:00\u0022\u003E2020-04-27 08:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/providing-submissions-electronic-format-postmarketing-safety-reports-vaccines\u0022\u003EProviding Submissions in Electronic Format \u2014 Postmarketing Safety Reports for Vaccines: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/93233\/download\u0022\u003EPDF (77.06 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (77.06 KB) of Providing Submissions in Electronic Format \u2014 Postmarketing Safety Reports for Vaccines: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/18\/2015","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Safety - Issues, Errors, and Problems, Vaccines","field_topics":"Postmarket, Electronic Submissions","topics-product":"Postmarket, Electronic Submissions, Safety - Issues, Errors, and Problems, Vaccines","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0903\u0022\u003EFDA-2014-D-0903\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222019-05-17T14:20:18-04:00\u0022\u003E2019-05-17 14:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-231-distributor-labeling-new-animal-drugs\u0022\u003ECVM GFI #231 Distributor Labeling for New Animal Drugs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/93540\/download\u0022\u003EPDF (84.76 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (84.76 KB) of CVM GFI #231 Distributor Labeling for New Animal Drugs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/20\/2016","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Advertising, Labeling, New Animal Drug Application (NADA)","field_topics":"","topics-product":"Administrative \/ Procedural, Advertising, Labeling, New Animal Drug Application (NADA)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"11\/09\/2015","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-3056\u0022\u003EFDA-2015-D-3056\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:30:46-04:00\u0022\u003E2019-04-16 14:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/m4er2-ctd-efficacy\u0022\u003EM4E(R2): The CTD \u2013 Efficacy\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/93569\/download\u0022\u003EPDF (679.97 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (679.97 KB) of M4E(R2): The CTD \u2013 Efficacy\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/24\/2017","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Multidisciplinary","field_topics":"","topics-product":"ICH-Multidisciplinary","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-3235\u0022\u003EFDA-2015-D-3235\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-02-03T08:49:46-05:00\u0022\u003E2025-02-03 08:49\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/general-considerations-animal-studies-intended-evaluate-medical-devices\u0022\u003EGeneral Considerations for Animal Studies Intended to Evaluate Medical Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/93963\/download\u0022\u003EPDF (684.66 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (684.66 KB) of General Considerations for Animal Studies Intended to Evaluate Medical Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/28\/2023","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Premarket Approval (PMA), Investigational Device Exemption (IDE), HUD\/HDE","field_topics":"Premarket","topics-product":"Premarket, 510(k), Premarket Approval (PMA), Investigational Device Exemption (IDE), HUD\/HDE","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-3419\u0022\u003EFDA-2015-D-3419\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222023-03-27T09:06:45-04:00\u0022\u003E2023-03-27 09:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/acceptability-draft-labeling-support-abbreviated-new-drug-application-approval-guidance-industry\u0022\u003EAcceptability of Draft Labeling to Support Abbreviated New Drug Application Approval; Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/93971\/download\u0022\u003EPDF (52.58 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (52.58 KB) of Acceptability of Draft Labeling to Support Abbreviated New Drug Application Approval; Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/07\/2015","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Generic Drugs","field_topics":"","topics-product":"Generic Drugs","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-3378\u0022\u003EFDA-2015-D-3378\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-21T15:05:57-04:00\u0022\u003E2020-04-21 15:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-100101-crotalaria-spp-seeds-grains\u0022\u003ECPG Sec 100.101 Crotalaria spp. Seeds in Grains\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/94048\/download\u0022\u003EPDF (221.83 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (221.83 KB) of CPG Sec 100.101 Crotalaria spp. Seeds in Grains\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/21\/2015","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-2994\u0022\u003EFDA-2015-D-2994\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Animal \u0026amp; Veterinary, Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T08:44:37-04:00\u0022\u003E2024-10-01 08:44\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommendations-microbial-vectors-used-gene-therapy\u0022\u003ERecommendations for Microbial Vectors Used for Gene Therapy: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/94200\/download\u0022\u003EPDF (161.34 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (161.34 KB) of Recommendations for Microbial Vectors Used for Gene Therapy: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/16\/2016","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Gene Therapy","field_topics":"Cellular \u0026amp; Gene Therapy","topics-product":"Cellular \u0026amp; Gene Therapy, Gene Therapy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-3399\u0022\u003EFDA-2015-D-3399\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222019-05-16T16:25:05-04:00\u0022\u003E2019-05-16 16:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/sunscreen-innovation-act-section-586cc-advisory-committee-process\u0022\u003ESunscreen Innovation Act: Section 586C(c) Advisory Committee Process\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/94237\/download\u0022\u003EPDF (102.97 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (102.97 KB) of Sunscreen Innovation Act: Section 586C(c) Advisory Committee Process\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/11\/2016","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Over-the-Counter Drugs","field_topics":"","topics-product":"Over-the-Counter Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-3990\u0022\u003EFDA-2015-D-3990\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-05T11:15:19-04:00\u0022\u003E2020-05-05 11:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/nonprescription-sunscreen-drug-products-format-and-content-data-submissions\u0022\u003ENonprescription Sunscreen Drug Products \u2013 Format and Content of Data Submissions\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/94249\/download\u0022\u003EPDF (116.77 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (116.77 KB) of Nonprescription Sunscreen Drug Products \u2013 Format and Content of Data Submissions\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/23\/2016","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Over-the-Counter Drugs","field_topics":"","topics-product":"Over-the-Counter Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-4033\u0022\u003EFDA-2015-D-4033\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-27T08:55:07-04:00\u0022\u003E2020-04-27 08:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pdes-triethylamine-and-methylisobutylketone\u0022\u003EPDEs for Triethylamine and for Methylisobutylketone\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/94385\/download\u0022\u003EPDF (129.02 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (129.02 KB) of PDEs for Triethylamine and for Methylisobutylketone\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/25\/2017","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Efficacy","field_topics":"","topics-product":"ICH-Efficacy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-15T01:35:05-04:00\u0022\u003E2020-05-15 01:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pharmacy-compounding-human-drug-products-under-section-503a-federal-food-drug-and-cosmetic-act\u0022\u003EPharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/94393\/download\u0022\u003EPDF (84.64 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (84.64 KB) of Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/02\/2014","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Compounding","field_topics":"","topics-product":"Administrative \/ Procedural, Compounding","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-1444\u0022\u003EFDA-2013-D-1444\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-15T02:02:17-04:00\u0022\u003E2020-05-15 02:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/interim-policy-compounding-using-bulk-drug-substances-under-section-503b-federal-food-drug-and\u0022\u003EInterim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/94402\/download\u0022\u003EPDF (301.2 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (301.2 KB) of Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/06\/2025","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Compounding","field_topics":"","topics-product":"Administrative \/ Procedural, Compounding","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-3539\u0022\u003EFDA-2015-D-3539\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-01-07T10:03:46-05:00\u0022\u003E2025-01-07 10:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/nepa_final_guidance\u0022\u003ENEPA_Final_Guidance\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/94445\/download\u0022\u003EPDF (41.92 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (41.92 KB) of NEPA_Final_Guidance\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"","field_center":"Center for Tobacco Products","field_regulated_product_field":"","changed":"\u003Ctime datetime=\u00222018-12-01T03:56:58-05:00\u0022\u003E2018-12-01 03:56\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/nonprescription-sunscreen-drug-products-safety-and-effectiveness-data\u0022\u003ENonprescription Sunscreen Drug Products \u2013 Safety and Effectiveness Data\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/94513\/download\u0022\u003EPDF (140.4 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (140.4 KB) of Nonprescription Sunscreen Drug Products \u2013 Safety and Effectiveness Data\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/22\/2016","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Over-the-Counter Drugs","field_topics":"","topics-product":"Over-the-Counter Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-4021\u0022\u003EFDA-2015-D-4021\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-14T13:35:02-04:00\u0022\u003E2020-05-14 13:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/sunscreen-innovation-act-withdrawal-586a-request-or-pending-request-guidance-industry\u0022\u003ESunscreen Innovation Act: Withdrawal of a 586A Request or Pending Request Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/94523\/download\u0022\u003EPDF (105.1 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (105.1 KB) of Sunscreen Innovation Act: Withdrawal of a 586A Request or Pending Request Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/11\/2016","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Over-the-Counter Drugs","field_topics":"","topics-product":"Over-the-Counter Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-4012\u0022\u003EFDA-2015-D-4012\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-05T11:40:07-04:00\u0022\u003E2020-05-05 11:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-233-veterinary-feed-directive-common-format-questions-and-answers\u0022\u003ECVM GFI #233 Veterinary Feed Directive Common Format Questions and Answers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/94752\/download\u0022\u003EPDF (834.27 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (834.27 KB) of CVM GFI #233 Veterinary Feed Directive Common Format Questions and Answers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/22\/2016","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Antimicrobial Resistance, Labeling, New Animal Drug Application (NADA)","field_topics":"","topics-product":"Antimicrobial Resistance, Labeling, New Animal Drug Application (NADA)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"02\/01\/2016","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-N-0155\u0022\u003EFDA-2010-N-0155\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:30:19-04:00\u0022\u003E2019-04-16 14:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/electromagnetic-compatibility-emc-medical-devices\u0022\u003EElectromagnetic Compatibility (EMC) of Medical Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/94758\/download\u0022\u003EPDF (532.25 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (532.25 KB) of Electromagnetic Compatibility (EMC) of Medical Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/06\/2022","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Investigational Device Exemption (IDE), Radiological Health, Radiology, Safety - Issues, Errors, and Problems","field_topics":"","topics-product":"Investigational Device Exemption (IDE), Radiological Health, Radiology, Safety - Issues, Errors, and Problems","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-3787\u0022\u003EFDA-2015-D-3787\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222022-06-03T09:14:36-04:00\u0022\u003E2022-06-03 09:14\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/best-practices-communication-between-ind-sponsors-and-fda-during-drug-development\u0022\u003EBest Practices for Communication Between IND Sponsors and FDA During Drug Development\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/94850\/download\u0022\u003EPDF (191.28 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (191.28 KB) of Best Practices for Communication Between IND Sponsors and FDA During Drug Development\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/29\/2017","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6564\u0022\u003EFDA-2017-D-6564\u003C\/a\u003E","field_communication_type":"Good Review Practices","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-29T16:17:12-04:00\u0022\u003E2020-04-29 16:17\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommendations-assessment-blood-donor-eligibility-donor-deferral-and-blood-product-management\u0022\u003ERecommendations for Assessment of Blood Donor Eligibility, Donor Deferral and Blood Product Management in Response to Ebola Virus: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/94902\/download\u0022\u003EPDF (286.85 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (286.85 KB) of Recommendations for Assessment of Blood Donor Eligibility, Donor Deferral and Blood Product Management in Response to Ebola Virus: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/29\/2026","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Blood, Ebola","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood, Ebola, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-2175\u0022\u003EFDA-2014-D-2175\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222026-06-29T11:56:05-04:00\u0022\u003E2026-06-29 11:56\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/head-lice-infestation-developing-drugs-topical-treatment-guidance-industry\u0022\u003EHead Lice Infestation: Developing Drugs for Topical Treatment Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/05\/2016","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-01-22T16:11:20-05:00\u0022\u003E2025-01-22 16:11\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/unique-device-identification-convenience-kits\u0022\u003EUnique Device Identification: Convenience Kits : Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/95120\/download\u0022\u003EPDF (364.59 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (364.59 KB) of Unique Device Identification: Convenience Kits : Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/26\/2019","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Labeling, UDI","field_topics":"","topics-product":"Labeling, UDI","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"04\/05\/2016","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-4048\u0022\u003EFDA-2015-D-4048\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222021-07-15T12:31:11-04:00\u0022\u003E2021-07-15 12:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/public-notification-emerging-postmarket-medical-device-signals-emerging-signals\u0022\u003EPublic Notification of Emerging Postmarket Medical Device Signals (\u0026quot;Emerging Signals\u0026quot;): Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/95125\/download\u0022\u003EPDF (127.96 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (127.96 KB) of Public Notification of Emerging Postmarket Medical Device Signals (\u0026quot;Emerging Signals\u0026quot;): Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/14\/2016","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Safety - Issues, Errors, and Problems","field_topics":"Postmarket","topics-product":"Postmarket, Safety - Issues, Errors, and Problems","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-4803\u0022\u003EFDA-2015-D-4803\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222019-03-12T14:45:23-04:00\u0022\u003E2019-03-12 14:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-238-modified-release-veterinary-parenteral-dosage-forms-development-evaluation-and\u0022\u003ECVM GFI #238 Modified Release Veterinary Parenteral Dosage Forms: Development, Evaluation, and Establishment of Specifications\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/95426\/download\u0022\u003EPDF (164.17 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (164.17 KB) of CVM GFI #238 Modified Release Veterinary Parenteral Dosage Forms: Development, Evaluation, and Establishment of Specifications\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/17\/2016","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC)","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"03\/21\/2016","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-N-4563\u0022\u003EFDA-2015-N-4563\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:35:30-04:00\u0022\u003E2019-04-16 14:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/advancement-emerging-technology-applications-pharmaceutical-innovation-and-modernization-guidance\u0022\u003EAdvancement of Emerging Technology Applications for Pharmaceutical Innovation and Modernization Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/95444\/download\u0022\u003EPDF (71.22 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (71.22 KB) of Advancement of Emerging Technology Applications for Pharmaceutical Innovation and Modernization Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/29\/2017","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-4644\u0022\u003EFDA-2015-D-4644\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-21T15:40:09-04:00\u0022\u003E2020-04-21 15:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/display-devices-diagnostic-radiology\u0022\u003EDisplay Devices for Diagnostic Radiology: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/95527\/download\u0022\u003EPDF (449.06 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (449.06 KB) of Display Devices for Diagnostic Radiology: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/28\/2022","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Labeling, Radiological Health, Radiology","field_topics":"Premarket","topics-product":"Premarket, 510(k), Labeling, Radiological Health, Radiology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-0270\u0022\u003EFDA-2016-D-0270\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222022-09-27T17:13:47-04:00\u0022\u003E2022-09-27 17:13\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/design-considerations-and-pre-market-submission-recommendations-interoperable-medical-devices\u0022\u003EDesign Considerations and Pre-market Submission Recommendations for Interoperable Medical Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/95636\/download\u0022\u003EPDF (421.33 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (421.33 KB) of Design Considerations and Pre-market Submission Recommendations for Interoperable Medical Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/06\/2017","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Anesthesiology , Neurological, Cardiovascular , General Hospital \u0026amp; Personal Use , Digital Health, Dental , Radiological Health","field_topics":"","topics-product":"510(k), Anesthesiology , Neurological, Cardiovascular , General Hospital \u0026amp; Personal Use , Digital Health, Dental , Radiological Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"04\/28\/2016","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-4852\u0022\u003EFDA-2015-D-4852\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222019-02-19T15:02:56-05:00\u0022\u003E2019-02-19 15:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/characterization-ultrahigh-molecular-weight-polyethylene-uhmwpe-used-orthopedic-devices\u0022\u003ECharacterization of Ultrahigh Molecular Weight Polyethylene (UHMWPE) Used in Orthopedic Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/95791\/download\u0022\u003EPDF (519.76 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (519.76 KB) of Characterization of Ultrahigh Molecular Weight Polyethylene (UHMWPE) Used in Orthopedic Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/26\/2019","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Premarket Approval (PMA), Investigational Device Exemption (IDE), Orthopedic","field_topics":"","topics-product":"510(k), Premarket Approval (PMA), Investigational Device Exemption (IDE), Orthopedic","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"05\/12\/2016","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-0363\u0022\u003EFDA-2016-D-0363\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222019-04-24T09:45:31-04:00\u0022\u003E2019-04-24 09:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/postmarket-management-cybersecurity-medical-devices\u0022\u003EPostmarket Management of Cybersecurity in Medical Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/95862\/download\u0022\u003EPDF (1.32 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.32 MB) of Postmarket Management of Cybersecurity in Medical Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/28\/2016","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Premarket Approval (PMA), Digital Health, Labeling, Safety - Issues, Errors, and Problems","field_topics":"Postmarket, Premarket","topics-product":"Postmarket, Premarket, 510(k), Premarket Approval (PMA), Digital Health, Labeling, Safety - Issues, Errors, and Problems","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-5105\u0022\u003EFDA-2015-D-5105\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222019-03-07T09:50:10-05:00\u0022\u003E2019-03-07 09:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/nonallergic-rhinitis-developing-drug-products-treatment\u0022\u003ENonallergic Rhinitis: Developing Drug Products for Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/95943\/download\u0022\u003EPDF (75.16 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (75.16 KB) of Nonallergic Rhinitis: Developing Drug Products for Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/06\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Pediatric Product Development","field_topics":"","topics-product":"Clinical - Medical, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-0236\u0022\u003EFDA-2016-D-0236\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T11:42:30-04:00\u0022\u003E2024-04-11 11:42\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/application-human-factors-engineering-principles-combination-products-questions-and-answers\u0022\u003EApplication of Human Factors Engineering Principles for Combination Products: Questions and Answers: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/171855\/download\u0022\u003EPDF (417.71 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (417.71 KB) of Application of Human Factors Engineering Principles for Combination Products: Questions and Answers: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/07\/2023","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products","field_health_topics":"","term_node_tid":"Combination Products","field_topics":"","topics-product":"Combination Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"05\/03\/2016","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-4848\u0022\u003EFDA-2015-D-4848\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222023-09-07T09:02:01-04:00\u0022\u003E2023-09-07 09:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clinical-considerations-investigational-device-exemptions-ides-neurological-devices-targeting\u0022\u003EClinical Considerations for Investigational Device Exemptions (IDEs) for Neurological Devices Targeting Disease Progression and Clinical Outcomes: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/96228\/download\u0022\u003EPDF (176.87 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (176.87 KB) of Clinical Considerations for Investigational Device Exemptions (IDEs) for Neurological Devices Targeting Disease Progression and Clinical Outcomes: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/07\/2016","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Premarket Approval (PMA), HUD\/HDE, Clinical - Medical, Good Clinical Practice (GCP), Labeling, Safety - Issues, Errors, and Problems, Laser Notice, Neurological","field_topics":"Premarket, Advisory Committees","topics-product":"Premarket, Advisory Committees, 510(k), Premarket Approval (PMA), HUD\/HDE, Clinical - Medical, Good Clinical Practice (GCP), Labeling, Safety - Issues, Errors, and Problems, Laser Notice, Neurological","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"06\/05\/2016","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-0539\u0022\u003EFDA-2016-D-0539\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222019-02-14T14:44:24-05:00\u0022\u003E2019-02-14 14:44\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/evaluating-respiratory-symptoms-chronic-obstructive-pulmonary-disease-patient-reported-outcome\u0022\u003EEvaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease, a Patient-Reported Outcome Instrument for the Measurement of Severity of Respiratory Symptoms in Stable Chronic Obstructive Pulmonary Disease: Qualification for Exploratory Use \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/96271\/download\u0022\u003EPDF (50.04 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (50.04 KB) of Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease, a Patient-Reported Outcome Instrument for the Measurement of Severity of Respiratory Symptoms in Stable Chronic Obstructive Pulmonary Disease: Qualification for Exploratory Use \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/2016","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-06-15T15:32:27-04:00\u0022\u003E2019-06-15 15:32\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/labeling-permanent-hysteroscopically-placed-tubal-implants-intended-sterilization\u0022\u003ELabeling for Permanent Hysteroscopically-Placed Tubal Implants Intended for Sterilization: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/96315\/download\u0022\u003EPDF (384.46 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (384.46 KB) of Labeling for Permanent Hysteroscopically-Placed Tubal Implants Intended for Sterilization: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/31\/2016","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Adverse Event Reporting, Labeling, Gastroenterology-Urology ","field_topics":"Postmarket, Biostatistics, Adverse Event Reporting System (FAERS)","topics-product":"Postmarket, Biostatistics, Adverse Event Reporting System (FAERS), 510(k), Adverse Event Reporting, Labeling, Gastroenterology-Urology ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"04\/29\/2016","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-0435\u0022\u003EFDA-2016-D-0435\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222019-02-09T15:29:47-05:00\u0022\u003E2019-02-09 15:29\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/requirements-transactions-first-responders-under-section-582-federal-food-drug-and-cosmetic-act\u0022\u003ERequirements for Transactions with First Responders under Section 582 of the Federal Food, Drug, and Cosmetic Act\u2014 Compliance Policy Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/96584\/download\u0022\u003EPDF (88.52 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (88.52 KB) of Requirements for Transactions with First Responders under Section 582 of the Federal Food, Drug, and Cosmetic Act\u2014 Compliance Policy Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/29\/2016","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-0631\u0022\u003EFDA-2016-D-0631\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-17T11:40:09-04:00\u0022\u003E2020-04-17 11:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/general-principles-evaluating-abuse-deterrence-generic-solid-oral-opioid-drug-products-guidance\u0022\u003EGeneral Principles for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/96643\/download\u0022\u003EPDF (520.34 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (520.34 KB) of General Principles for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/21\/2017","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Drug Competition Action Plan, Generic Drugs","field_topics":"","topics-product":"Drug Competition Action Plan, Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-0785\u0022\u003EFDA-2016-D-0785\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-21T12:35:08-04:00\u0022\u003E2020-04-21 12:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-234-question-based-review-chemistry-manufacturing-and-controls-technical-section-animal-drug\u0022\u003ECVM GFI #234 Question-Based Review for the Chemistry, Manufacturing, and Controls Technical Section of Animal Drug Applications\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/96718\/download\u0022\u003EPDF (614.22 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (614.22 KB) of CVM GFI #234 Question-Based Review for the Chemistry, Manufacturing, and Controls Technical Section of Animal Drug Applications\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/20\/2016","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC)","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"05\/17\/2016","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-0620\u0022\u003EFDA-2016-D-0620\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:30:56-04:00\u0022\u003E2019-04-16 14:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/labeling-biosimilar-products-guidance-industry\u0022\u003ELabeling for Biosimilar Products Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/96894\/download\u0022\u003EPDF (284.71 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (284.71 KB) of Labeling for Biosimilar Products Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/18\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"10\/18\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-0643\u0022\u003EFDA-2016-D-0643\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T15:20:36-04:00\u0022\u003E2020-04-24 15:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/comparability-protocols-postapproval-changes-chemistry-manufacturing-and-controls-information-nda\u0022\u003EComparability Protocols for Postapproval Changes to the Chemistry, Manufacturing, and Controls Information in an NDA, ANDA, or BLA\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/162263\/download\u0022\u003EPDF (459.7 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (459.7 KB) of Comparability Protocols for Postapproval Changes to the Chemistry, Manufacturing, and Controls Information in an NDA, ANDA, or BLA\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/13\/2022","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-0973\u0022\u003EFDA-2016-D-0973\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-10-14T15:29:31-04:00\u0022\u003E2022-10-14 15:29\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/prescription-requirement-under-section-503a-federal-food-drug-and-cosmetic-act-guidance-industry\u0022\u003EPrescription Requirement Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/97347\/download\u0022\u003EPDF (348.92 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (348.92 KB) of Prescription Requirement Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/29\/2016","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Compounding","field_topics":"","topics-product":"Compounding","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-0269\u0022\u003EFDA-2016-D-0269\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-15T02:25:07-04:00\u0022\u003E2020-05-15 02:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/hospital-and-health-system-compounding-under-section-503a-federal-food-drug-and-cosmetic-act\u0022\u003EHospital and Health System Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/97353\/download\u0022\u003EPDF (122.11 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (122.11 KB) of Hospital and Health System Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/06\/2021","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Compounding","field_topics":"","topics-product":"Compounding","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-0271\u0022\u003EFDA-2016-D-0271\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-10-06T09:11:03-04:00\u0022\u003E2021-10-06 09:11\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/facility-definition-under-section-503b-federal-food-drug-and-cosmetic-act\u0022\u003EFacility Definition Under Section 503B of the Federal Food, Drug, and Cosmetic Act\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/97359\/download\u0022\u003EPDF (86.66 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (86.66 KB) of Facility Definition Under Section 503B of the Federal Food, Drug, and Cosmetic Act\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/10\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Compounding","field_topics":"","topics-product":"Compounding","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-04-01T11:55:06-04:00\u0022\u003E2019-04-01 11:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-540275-crabmeat-fresh-and-frozen-adulteration-filth-involving-presence-escherichia-coli\u0022\u003ECPG Sec 540.275 Crabmeat \u2013 Fresh and Frozen \u2013 Adulteration with Filth, Involving the Presence of Escherichia coli\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/97455\/download\u0022\u003EPDF (19.11 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (19.11 KB) of CPG Sec 540.275 Crabmeat \u2013 Fresh and Frozen \u2013 Adulteration with Filth, Involving the Presence of Escherichia coli\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/30\/2016","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Seafood\/Seafood Product","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Seafood\/Seafood Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-1842\u0022\u003EFDA-2014-D-1842\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T21:26:49-05:00\u0022\u003E2025-03-06 21:26\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-235-current-good-manufacturing-practice-requirements-food-animals\u0022\u003ECVM GFI #235 Current Good Manufacturing Practice Requirements for Food for Animals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/97464\/download\u0022\u003EPDF (361.86 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (361.86 KB) of CVM GFI #235 Current Good Manufacturing Practice Requirements for Food for Animals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/20\/2017","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Feed, Current Good Manufacturing Practice (CGMP)","field_topics":"","topics-product":"Animal Feed, Current Good Manufacturing Practice (CGMP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"11\/23\/2016","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-1229\u0022\u003EFDA-2016-D-1229\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:30:07-04:00\u0022\u003E2019-04-16 14:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-239-human-food-products-use-animal-food\u0022\u003ECVM GFI #239 Human Food By-Products For Use As Animal Food\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/97467\/download\u0022\u003EPDF (145.58 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (145.58 KB) of CVM GFI #239 Human Food By-Products For Use As Animal Food\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/25\/2016","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Feed, Current Good Manufacturing Practice (CGMP)","field_topics":"","topics-product":"Animal Feed, Current Good Manufacturing Practice (CGMP)","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"11\/23\/2016","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-1220\u0022\u003EFDA-2016-D-1220\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:35:17-04:00\u0022\u003E2019-04-16 14:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-241-small-entity-compliance-guide-what-you-need-know-about-fda-regulation-current-good\u0022\u003ECVM GFI #241 Small Entity Compliance Guide \u2013 What You Need to Know About the FDA Regulation: Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Food for Animals (21 CFR Part 507)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/97470\/download\u0022\u003EPDF (237.57 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (237.57 KB) of CVM GFI #241 Small Entity Compliance Guide \u2013 What You Need to Know About the FDA Regulation: Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Food for Animals (21 CFR Part 507)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/01\/2016","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Feed","field_topics":"","topics-product":"Animal Feed","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-N-0922\u0022\u003EFDA-2011-N-0922\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:35:09-04:00\u0022\u003E2019-04-16 14:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/use-electronic-health-record-data-clinical-investigations-guidance-industry\u0022\u003EUse of Electronic Health Record Data in Clinical Investigations Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/97567\/download\u0022\u003EPDF (327.2 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (327.2 KB) of Use of Electronic Health Record Data in Clinical Investigations Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/19\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-1224\u0022\u003EFDA-2016-D-1224\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-08T13:20:12-04:00\u0022\u003E2020-05-08 13:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/special-protocol-assessment-guidance-industry\u0022\u003ESpecial Protocol Assessment Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/97618\/download\u0022\u003EPDF (371.64 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (371.64 KB) of Special Protocol Assessment Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/16\/2018","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-1174\u0022\u003EFDA-2016-D-1174\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222023-04-06T15:14:31-04:00\u0022\u003E2023-04-06 15:14\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/technical-considerations-additive-manufactured-medical-devices\u0022\u003ETechnical Considerations for Additive Manufactured Medical Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/97633\/download\u0022\u003EPDF (926.41 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (926.41 KB) of Technical Considerations for Additive Manufactured Medical Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/05\/2017","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Premarket Approval (PMA), Investigational Device Exemption (IDE), HUD\/HDE, Orthopedic, Tissue","field_topics":"Premarket, Biotechnology","topics-product":"Premarket, Biotechnology, 510(k), Premarket Approval (PMA), Investigational Device Exemption (IDE), HUD\/HDE, Orthopedic, Tissue","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"08\/08\/2016","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-1210\u0022\u003EFDA-2016-D-1210\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-02T10:15:02-05:00\u0022\u003E2020-03-02 10:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/osteoporosis-nonclinical-evaluation-drugs-intended-treatment-guidance-industry\u0022\u003EOsteoporosis: Nonclinical Evaluation of Drugs Intended for Treatment Guidance for Industry: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/129899\/download\u0022\u003EPDF (94.69 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (94.69 KB) of Osteoporosis: Nonclinical Evaluation of Drugs Intended for Treatment Guidance for Industry: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/15\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Pharmacology\/Toxicology","field_topics":"","topics-product":"Clinical - Medical, Pharmacology\/Toxicology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-1273\u0022\u003EFDA-2016-D-1273\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-15T01:17:29-04:00\u0022\u003E2020-05-15 01:17\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-237-oncology-drugs-companion-animals\u0022\u003ECVM GFI #237 Oncology Drugs for Companion Animals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/98399\/download\u0022\u003EPDF (198.25 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (198.25 KB) of CVM GFI #237 Oncology Drugs for Companion Animals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/23\/2017","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Investigational New Animal Drug (INAD)","field_topics":"","topics-product":"Investigational New Animal Drug (INAD)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"08\/09\/2016","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-1248\u0022\u003EFDA-2016-D-1248\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:30:16-04:00\u0022\u003E2019-04-16 14:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/manufacturers-sharing-patient-specific-information-medical-devices-patients-upon-request\u0022\u003EManufacturers Sharing Patient-Specific Information from Medical Devices with Patients Upon Request: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/98519\/download\u0022\u003EPDF (268.93 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (268.93 KB) of Manufacturers Sharing Patient-Specific Information from Medical Devices with Patients Upon Request: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/30\/2017","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Postmarket","topics-product":"Postmarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"08\/09\/2016","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-1264\u0022\u003EFDA-2016-D-1264\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222019-02-09T15:40:55-05:00\u0022\u003E2019-02-09 15:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/fda-categorization-investigational-device-exemption-ide-devices-assist-centers-medicare-and-medicaid\u0022\u003EFDA Categorization of Investigational Device Exemption (IDE) Devices to Assist the Centers for Medicare and Medicaid Services (CMS) with Coverage Decisions: Guidance for Sponsors, Clinical Investigators, Industry, Institutional Review Boards, and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/98578\/download\u0022\u003EPDF (572.88 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (572.88 KB) of FDA Categorization of Investigational Device Exemption (IDE) Devices to Assist the Centers for Medicare and Medicaid Services (CMS) with Coverage Decisions: Guidance for Sponsors, Clinical Investigators, Industry, Institutional Review Boards, and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/05\/2017","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Investigational Device Exemption (IDE)","field_topics":"","topics-product":"Investigational Device Exemption (IDE)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-1159\u0022\u003EFDA-2016-D-1159\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222020-10-20T15:25:10-04:00\u0022\u003E2020-10-20 15:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e18-genomic-sampling-and-management-genomic-data-guidance-industry\u0022\u003EE18 Genomic Sampling and Management of Genomic Data Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/98596\/download\u0022\u003EPDF (97.94 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (97.94 KB) of E18 Genomic Sampling and Management of Genomic Data Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/02\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Efficacy","field_topics":"","topics-product":"ICH-Efficacy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-1255\u0022\u003EFDA-2016-D-1255\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-29T16:35:08-04:00\u0022\u003E2020-04-29 16:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/quality-attribute-considerations-chewable-tablets-guidance-industry\u0022\u003EQuality Attribute Considerations for Chewable Tablets Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/98598\/download\u0022\u003EPDF (169.2 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (169.2 KB) of Quality Attribute Considerations for Chewable Tablets Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/21\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-1490\u0022\u003EFDA-2016-D-1490\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-14T11:25:13-04:00\u0022\u003E2020-04-14 11:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/assessing-adhesion-transdermal-and-topical-delivery-systems-andas\u0022\u003EAssessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/167043\/download\u0022\u003EPDF (222.36 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (222.36 KB) of Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/31\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Drug Competition Action Plan, Generic Drugs","field_topics":"","topics-product":"Drug Competition Action Plan, Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-1254\u0022\u003EFDA-2016-D-1254\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-08-03T09:50:47-04:00\u0022\u003E2026-08-03 09:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/factors-consider-regarding-benefit-risk-medical-device-product-availability-compliance-and\u0022\u003EFactors to Consider Regarding Benefit-Risk in Medical Device Product Availability, Compliance, and Enforcement Decisions: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/98657\/download\u0022\u003EPDF (870.11 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (870.11 KB) of Factors to Consider Regarding Benefit-Risk in Medical Device Product Availability, Compliance, and Enforcement Decisions: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/27\/2016","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Premarket Approval (PMA), Investigational Device Exemption (IDE), HUD\/HDE, Adverse Event Reporting, Combination Products, Safety - Issues, Errors, and Problems, Laser Notice","field_topics":"Postmarket, Recalls, Adverse Event Reporting System (FAERS)","topics-product":"Postmarket, Recalls, Adverse Event Reporting System (FAERS), 510(k), Premarket Approval (PMA), Investigational Device Exemption (IDE), HUD\/HDE, Adverse Event Reporting, Combination Products, Safety - Issues, Errors, and Problems, Laser Notice","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"09\/14\/2016","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-1495\u0022\u003EFDA-2016-D-1495\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222019-03-04T10:45:10-05:00\u0022\u003E2019-03-04 10:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/evaluation-and-reporting-age-race-and-ethnicity-specific-data-medical-device-clinical-studies\u0022\u003EEvaluation and Reporting of Age-, Race-, and Ethnicity-Specific Data in Medical Device Clinical Studies: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/98686\/download\u0022\u003EPDF (1.16 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.16 MB) of Evaluation and Reporting of Age-, Race-, and Ethnicity-Specific Data in Medical Device Clinical Studies: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/12\/2017","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"510(k), Premarket Approval (PMA), Investigational Device Exemption (IDE), HUD\/HDE, Clinical - Medical, Good Clinical Practice (GCP), Labeling, Pediatric Product Development, Laboratory Tests, IVDs (In Vitro Diagnostic Devices), Physical Medicine, Orthopedic, Ophthalmic, Obstetrical \u0026amp; Gynecological, Neurological, Molecular and Clinical Genetics, Immunology \u0026amp; Microbiology , Cardiovascular , Hematology \u0026amp; Pathology , General Hospital \u0026amp; Personal Use , General \u0026amp; Plastic Surgery , Gastroenterology-Urology , Ear, Nose \u0026amp; Throat , Dental , Clinical Chemistry \u0026amp; Clinical Toxicology , Radiology, Radiological Health","field_topics":"Premarket","topics-product":"Premarket, 510(k), Premarket Approval (PMA), Investigational Device Exemption (IDE), HUD\/HDE, Clinical - Medical, Good Clinical Practice (GCP), Labeling, Pediatric Product Development, Laboratory Tests, IVDs (In Vitro Diagnostic Devices), Physical Medicine, Orthopedic, Ophthalmic, Obstetrical \u0026amp; Gynecological, Neurological, Molecular and Clinical Genetics, Immunology \u0026amp; Microbiology , Cardiovascular , Hematology \u0026amp; Pathology , General Hospital \u0026amp; Personal Use , General \u0026amp; Plastic Surgery , Gastroenterology-Urology , Ear, Nose \u0026amp; Throat , Dental , Clinical Chemistry \u0026amp; Clinical Toxicology , Radiology, Radiological Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"09\/18\/2016","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-0734\u0022\u003EFDA-2016-D-0734\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222024-04-08T11:37:46-04:00\u0022\u003E2024-04-08 11:37\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/elemental-impurities-drug-products-guidance-industry\u0022\u003EElemental Impurities in Drug Products Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/98847\/download\u0022\u003EPDF (91.65 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (91.65 KB) of Elemental Impurities in Drug Products Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/08\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-1692\u0022\u003EFDA-2016-D-1692\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222020-04-29T18:20:11-04:00\u0022\u003E2020-04-29 18:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/procedures-evaluating-appearance-issues-and-granting-authorizations-participation-fda-advisory\u0022\u003EProcedures for Evaluating Appearance Issues and Granting Authorizations for Participation in FDA Advisory Committees: Draft Guidance for the Public, FDA Advisory Committee Members, and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/98852\/download\u0022\u003EPDF (946.76 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (946.76 KB) of Procedures for Evaluating Appearance Issues and Granting Authorizations for Participation in FDA Advisory Committees: Draft Guidance for the Public, FDA Advisory Committee Members, and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/29\/2016","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Tobacco Products\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of the Chief Scientist,National Center for Toxicological Research\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy","field_health_topics":"","term_node_tid":"","field_topics":"Advisory Committees","topics-product":"Advisory Committees, ","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"06\/29\/2016","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-1399\u0022\u003EFDA-2016-D-1399\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222024-10-01T07:05:33-04:00\u0022\u003E2024-10-01 07:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/compounded-drug-products-are-essentially-copies-approved-drug-products-under-section-503b-federal\u0022\u003ECompounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503B of the Federal Food, Drug, and Cosmetic Act Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/98964\/download\u0022\u003EPDF (468.33 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (468.33 KB) of Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503B of the Federal Food, Drug, and Cosmetic Act Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/19\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Compounding","field_topics":"","topics-product":"Compounding","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-1267\u0022\u003EFDA-2016-D-1267\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-07T17:55:07-04:00\u0022\u003E2020-05-07 17:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/compounded-drug-products-are-essentially-copies-commercially-available-drug-product-under-section\u0022\u003ECompounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/98973\/download\u0022\u003EPDF (552.95 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (552.95 KB) of Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/19\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Compounding","field_topics":"","topics-product":"Compounding","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-1309\u0022\u003EFDA-2016-D-1309\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T13:45:16-04:00\u0022\u003E2020-05-06 13:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/principles-codevelopment-in-vitro-companion-diagnostic-device-therapeutic-product\u0022\u003EPrinciples for Codevelopment of an In Vitro Companion Diagnostic Device with a Therapeutic Product: Draft Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/99030\/download\u0022\u003EPDF (1.1 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.1 MB) of Principles for Codevelopment of an In Vitro Companion Diagnostic Device with a Therapeutic Product: Draft Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/15\/2016","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Premarket Approval (PMA), Laboratory Tests, IVDs (In Vitro Diagnostic Devices)","field_topics":"Premarket","topics-product":"Premarket, 510(k), Premarket Approval (PMA), Laboratory Tests, IVDs (In Vitro Diagnostic Devices)","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"10\/13\/2016","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-1703\u0022\u003EFDA-2016-D-1703\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222019-05-14T09:24:38-04:00\u0022\u003E2019-05-14 09:24\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/updating-anda-labeling-after-marketing-application-reference-listed-drug-has-been-withdrawn-guidance\u0022\u003EUpdating ANDA Labeling After the Marketing Application for the Reference Listed Drug Has Been Withdrawn Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/99041\/download\u0022\u003EPDF (94.11 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (94.11 KB) of Updating ANDA Labeling After the Marketing Application for the Reference Listed Drug Has Been Withdrawn Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/11\/2016","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Generic Drugs","field_topics":"","topics-product":"Generic Drugs","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-1673\u0022\u003EFDA-2016-D-1673\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-08T13:20:08-04:00\u0022\u003E2020-05-08 13:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/use-public-human-genetic-variant-databases-support-clinical-validity-genetic-and-genomic-based-vitro\u0022\u003EUse of Public Human Genetic Variant Databases to Support Clinical Validity for Genetic and Genomic-Based In Vitro Diagnostics : Guidance for Stakeholders and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/99200\/download\u0022\u003EPDF (593.15 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (593.15 KB) of Use of Public Human Genetic Variant Databases to Support Clinical Validity for Genetic and Genomic-Based In Vitro Diagnostics : Guidance for Stakeholders and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/13\/2018","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Laboratory Tests, IVDs (In Vitro Diagnostic Devices), Molecular and Clinical Genetics","field_topics":"Premarket","topics-product":"Premarket, Laboratory Tests, IVDs (In Vitro Diagnostic Devices), Molecular and Clinical Genetics","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-1233\u0022\u003EFDA-2016-D-1233\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222019-04-09T10:35:05-04:00\u0022\u003E2019-04-09 10:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/considerations-design-development-and-analytical-validation-next-generation-sequencing-ngs-based\u0022\u003EConsiderations for Design, Development, and Analytical Validation of Next Generation Sequencing (NGS) - Based In Vitro Diagnostics (IVDs) Intended to Aid in the Diagnosis of Suspected Germline Diseases: Guidance for Stakeholders and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/99208\/download\u0022\u003EPDF (868.7 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (868.7 KB) of Considerations for Design, Development, and Analytical Validation of Next Generation Sequencing (NGS) - Based In Vitro Diagnostics (IVDs) Intended to Aid in the Diagnosis of Suspected Germline Diseases: Guidance for Stakeholders and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/13\/2018","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-1270\u0022\u003EFDA-2016-D-1270\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-02T10:30:13-05:00\u0022\u003E2020-03-02 10:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e2cr2-periodic-benefit-risk-evaluation-report-questions-and-answers\u0022\u003EE2C(R2) Periodic Benefit-Risk Evaluation Report \u2013 Questions and Answers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/99228\/download\u0022\u003EPDF (153.4 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (153.4 KB) of E2C(R2) Periodic Benefit-Risk Evaluation Report \u2013 Questions and Answers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/19\/2016","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Efficacy","field_topics":"","topics-product":"ICH-Efficacy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-0315\u0022\u003EFDA-2012-D-0315\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-12-29T14:18:48-05:00\u0022\u003E2022-12-29 14:18\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/bacterial-vaginosis-developing-drugs-treatment-guidance-industry\u0022\u003EBacterial Vaginosis: Developing Drugs for Treatment Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/129530\/download\u0022\u003EPDF (269.89 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (269.89 KB) of Bacterial Vaginosis: Developing Drugs for Treatment Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/01\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-1659\u0022\u003EFDA-2016-D-1659\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-29T16:10:08-04:00\u0022\u003E2020-04-29 16:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recurrent-herpes-labialis-developing-drugs-treatment-and-prevention\u0022\u003ERecurrent Herpes Labialis: Developing Drugs for Treatment and Prevention\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/99233\/download\u0022\u003EPDF (153.47 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (153.47 KB) of Recurrent Herpes Labialis: Developing Drugs for Treatment and Prevention\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/08\/2017","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-1504\u0022\u003EFDA-2016-D-1504\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-17T13:40:06-04:00\u0022\u003E2020-04-17 13:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/vulvovaginal-candidiasis-developing-drugs-treatment\u0022\u003EVulvovaginal Candidiasis: Developing Drugs for Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/129537\/download\u0022\u003EPDF (91.37 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (91.37 KB) of Vulvovaginal Candidiasis: Developing Drugs for Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/01\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-1662\u0022\u003EFDA-2016-D-1662\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T09:55:28-04:00\u0022\u003E2020-05-06 09:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/determining-donor-eligibility-autologous-donors-blood-and-blood-components-intended-solely\u0022\u003EDetermining Donor Eligibility for Autologous Donors of Blood and Blood Components Intended Solely for Autologous Use - Compliance Policy: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/99325\/download\u0022\u003EPDF (85.63 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (85.63 KB) of Determining Donor Eligibility for Autologous Donors of Blood and Blood Components Intended Solely for Autologous Use - Compliance Policy: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/01\/2016","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-2071\u0022\u003EFDA-2016-D-2071\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222019-03-14T15:45:05-04:00\u0022\u003E2019-03-14 15:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/use-real-world-evidence-support-regulatory-decision-making-medical-devices\u0022\u003EUse of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/190201\/download\u0022\u003EPDF (852.29 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (852.29 KB) of Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/18\/2025","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Postmarket, Premarket, Real World Data \/ Real World Evidence (RWD\/RWE)","topics-product":"Postmarket, Premarket, Real World Data \/ Real World Evidence (RWD\/RWE), ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-4395\u0022\u003EFDA-2023-D-4395\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222026-02-17T12:40:32-05:00\u0022\u003E2026-02-17 12:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/medical-x-ray-imaging-devices-conformance-iec-standards\u0022\u003EMedical X-Ray Imaging Devices Conformance with IEC Standards: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/99466\/download\u0022\u003EPDF (535.82 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (535.82 KB) of Medical X-Ray Imaging Devices Conformance with IEC Standards: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/21\/2023","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Radiological Health, Radiology","field_topics":"Premarket","topics-product":"Premarket, 510(k), Radiological Health, Radiology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-2049\u0022\u003EFDA-2016-D-2049\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222023-02-21T11:06:11-05:00\u0022\u003E2023-02-21 11:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/ulcerative-colitis-developing-drugs-treatment\u0022\u003EUlcerative Colitis: Developing Drugs for Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/158016\/download\u0022\u003EPDF (321.54 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (321.54 KB) of Ulcerative Colitis: Developing Drugs for Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/28\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"06\/28\/2022","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0140\u0022\u003EFDA-2022-D-0140\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-10-31T17:37:46-04:00\u0022\u003E2022-10-31 17:37\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/use-nucleic-acid-tests-reduce-risk-transmission-hepatitis-b-virus-donors-human-cells-tissues-and\u0022\u003EUse of Nucleic Acid Tests to Reduce the Risk of Transmission of Hepatitis B Virus from Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/99642\/download\u0022\u003EPDF (66.85 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (66.85 KB) of Use of Nucleic Acid Tests to Reduce the Risk of Transmission of Hepatitis B Virus from Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/01\/2016","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Tissue","field_topics":"","topics-product":"Tissue","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-5073\u0022\u003EFDA-2015-D-5073\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222019-05-17T10:55:30-04:00\u0022\u003E2019-05-17 10:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/insanitary-conditions-compounding-facilities-guidance-industry\u0022\u003EInsanitary Conditions at Compounding Facilities Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/124948\/download\u0022\u003EPDF (123.19 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (123.19 KB) of Insanitary Conditions at Compounding Facilities Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/06\/2020","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Compounding","field_topics":"","topics-product":"Administrative \/ Procedural, Compounding","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-2268\u0022\u003EFDA-2016-D-2268\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-11-06T08:55:13-05:00\u0022\u003E2020-11-06 08:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/factors-consider-when-making-benefit-risk-determinations-medical-device-premarket-approval-and-de\u0022\u003EFactors to Consider When Making Benefit-Risk Determinations in Medical Device Premarket Approval and De Novo Classifications: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/99769\/download\u0022\u003EPDF (675.17 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (675.17 KB) of Factors to Consider When Making Benefit-Risk Determinations in Medical Device Premarket Approval and De Novo Classifications: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/30\/2019","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Premarket Approval (PMA)","field_topics":"Premarket","topics-product":"Premarket, Premarket Approval (PMA)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0577\u0022\u003EFDA-2011-D-0577\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222020-10-20T15:20:46-04:00\u0022\u003E2020-10-20 15:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/deciding-when-submit-510k-software-change-existing-device\u0022\u003EDeciding When to Submit a 510(k) for a Software Change to an Existing Device: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/99785\/download\u0022\u003EPDF (666.29 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (666.29 KB) of Deciding When to Submit a 510(k) for a Software Change to an Existing Device: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/25\/2017","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Labeling, Laboratory Tests, IVDs (In Vitro Diagnostic Devices), Digital Health","field_topics":"Premarket","topics-product":"Premarket, 510(k), Labeling, Laboratory Tests, IVDs (In Vitro Diagnostic Devices), Digital Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"11\/06\/2016","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-2021\u0022\u003EFDA-2016-D-2021\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-02T10:10:06-05:00\u0022\u003E2020-03-02 10:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/deciding-when-submit-510k-change-existing-device\u0022\u003EDeciding When to Submit a 510(k) for a Change to an Existing Device: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/99812\/download\u0022\u003EPDF (757.57 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (757.57 KB) of Deciding When to Submit a 510(k) for a Change to an Existing Device: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/25\/2017","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Labeling, Laboratory Tests, IVDs (In Vitro Diagnostic Devices)","field_topics":"Premarket","topics-product":"Premarket, 510(k), Labeling, Laboratory Tests, IVDs (In Vitro Diagnostic Devices)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"11\/06\/2016","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0453\u0022\u003EFDA-2011-D-0453\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-02T10:05:02-05:00\u0022\u003E2020-03-02 10:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e17-general-principles-planning-and-design-multi-regional-clinical-trials\u0022\u003EE17 General Principles for Planning and Design of Multi-Regional Clinical Trials\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/99974\/download\u0022\u003EPDF (403.56 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (403.56 KB) of E17 General Principles for Planning and Design of Multi-Regional Clinical Trials\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/19\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Efficacy","field_topics":"","topics-product":"ICH-Efficacy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"11\/08\/2016","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/2018-15395\u0022\u003E2018-15395\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-29T16:10:25-04:00\u0022\u003E2020-04-29 16:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/s3a-guidance-note-guidance-toxicokinetics-assessment-systemic-exposure-toxicity-studies-focus\u0022\u003ES3A Guidance: Note for Guidance on Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies: Focus on Microsampling\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/100027\/download\u0022\u003EPDF (148.76 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (148.76 KB) of S3A Guidance: Note for Guidance on Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies: Focus on Microsampling\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/09\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Safety","field_topics":"","topics-product":"ICH-Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-2513\u0022\u003EFDA-2016-D-2513\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-17T13:20:13-04:00\u0022\u003E2020-04-17 13:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-150200-compliance-review-private-laboratory-analytical-packages-plaps\u0022\u003ECPG Sec. 150.200 Compliance Review of Private Laboratory Analytical Packages (PLAPs)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/100067\/download\u0022\u003EPDF (34.49 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (34.49 KB) of CPG Sec. 150.200 Compliance Review of Private Laboratory Analytical Packages (PLAPs)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/01\/2016","field_issuing_office_taxonomy":"Office of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-11-14T16:25:43-05:00\u0022\u003E2024-11-14 16:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/fdas-application-statutory-factors-determining-when-rems-necessary\u0022\u003EFDA\u2019s Application of Statutory Factors in Determining When a REMS Is Necessary \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/100307\/download\u0022\u003EPDF (110.01 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (110.01 KB) of FDA\u2019s Application of Statutory Factors in Determining When a REMS Is Necessary \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/04\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Safety - Issues, Errors, and Problems","field_topics":"","topics-product":"Safety - Issues, Errors, and Problems","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-2730\u0022\u003EFDA-2016-D-2730\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-04-05T11:50:13-04:00\u0022\u003E2019-04-05 11:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/s9-nonclinical-evaluation-anticancer-pharmaceuticals-questions-and-answers\u0022\u003ES9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/100344\/download\u0022\u003EPDF (536.49 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (536.49 KB) of S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/08\/2010","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Safety","field_topics":"","topics-product":"ICH-Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"11\/16\/2016","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0006\u0022\u003EFDA-2009-D-0006\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-06-11T15:15:56-04:00\u0022\u003E2026-06-11 15:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-101100-fda-considerations-recommending-charges-causing-introduction-violative-products\u0022\u003ECPG Sec. 101.100 FDA Considerations for Recommending Charges for Causing the Introduction of Violative Products into Interstate Commerce\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/100824\/download\u0022\u003EPDF (27.22 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (27.22 KB) of CPG Sec. 101.100 FDA Considerations for Recommending Charges for Causing the Introduction of Violative Products into Interstate Commerce\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/17\/2016","field_issuing_office_taxonomy":"Office of Regulatory Affairs","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-24T14:52:29-04:00\u0022\u003E2024-10-24 14:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/low-sexual-interest-desire-andor-arousal-women-developing-drugs-treatment-guidance-industry\u0022\u003ELow Sexual Interest, Desire, and\/or Arousal in Women: Developing Drugs for Treatment Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/100833\/download\u0022\u003EPDF (298.14 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (298.14 KB) of Low Sexual Interest, Desire, and\/or Arousal in Women: Developing Drugs for Treatment Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/25\/2016","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"12\/25\/2016","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-2817\u0022\u003EFDA-2016-D-2817\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T10:05:21-04:00\u0022\u003E2020-04-24 10:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/product-labeling-certain-ultrasonic-surgical-aspirator-devices\u0022\u003EProduct Labeling for Certain Ultrasonic Surgical Aspirator Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/100882\/download\u0022\u003EPDF (273 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (273 KB) of Product Labeling for Certain Ultrasonic Surgical Aspirator Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/30\/2017","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Labeling, Safety - Issues, Errors, and Problems, Obstetrical \u0026amp; Gynecological, General \u0026amp; Plastic Surgery ","field_topics":"Premarket","topics-product":"Premarket, 510(k), Labeling, Safety - Issues, Errors, and Problems, Obstetrical \u0026amp; Gynecological, General \u0026amp; Plastic Surgery ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"01\/09\/2017","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-3275\u0022\u003EFDA-2016-D-3275\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222019-03-12T14:26:20-04:00\u0022\u003E2019-03-12 14:26\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/use-serological-tests-reduce-risk-transmission-trypanosoma-cruzi-infection-blood-and-blood\u0022\u003EUse of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Blood and Blood Components: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/101270\/download\u0022\u003EPDF (159.72 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (159.72 KB) of Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Blood and Blood Components: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/05\/2017","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Blood","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"12\/06\/2017","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0137\u0022\u003EFDA-2009-D-0137\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222020-10-22T12:51:06-04:00\u0022\u003E2020-10-22 12:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e11r1-addendum-clinical-investigation-medicinal-products-pediatric-population\u0022\u003EE11(R1) Addendum: Clinical Investigation of Medicinal Products in the Pediatric Population\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/101398\/download\u0022\u003EPDF (354.33 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (354.33 KB) of E11(R1) Addendum: Clinical Investigation of Medicinal Products in the Pediatric Population\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/11\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Efficacy, Pediatric Product Development","field_topics":"","topics-product":"ICH-Efficacy, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-3848\u0022\u003EFDA-2016-D-3848\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T11:05:42-04:00\u0022\u003E2024-04-11 11:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/revised-recommendations-determining-eligibility-donors-human-cells-tissues-and-cellular-and-tissue\u0022\u003ERevised Recommendations for Determining Eligibility of Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products Who Have Received Human-Derived Clotting Factor Concentrates: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/101401\/download\u0022\u003EPDF (55.24 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (55.24 KB) of Revised Recommendations for Determining Eligibility of Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products Who Have Received Human-Derived Clotting Factor Concentrates: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/01\/2016","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Tissue","field_topics":"","topics-product":"Tissue","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-3750\u0022\u003EFDA-2016-D-3750\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222019-05-17T10:55:38-04:00\u0022\u003E2019-05-17 10:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/bacillus-calmette-guerin-unresponsive-nonmuscle-invasive-bladder-cancer-developing-drugs-and\u0022\u003EBacillus Calmette-Gu\u00e9rin-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biological Products for Treatment : Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/101468\/download\u0022\u003EPDF (326.5 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (326.5 KB) of Bacillus Calmette-Gu\u00e9rin-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biological Products for Treatment : Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/08\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-0342 \u0022\u003EFDA-2018-D-0342 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-08-09T09:23:17-04:00\u0022\u003E2024-08-09 09:23\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/physiologically-based-pharmacokinetic-analyses-format-and-content-guidance-industry\u0022\u003EPhysiologically Based Pharmacokinetic Analyses \u2014 Format and Content Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/101469\/download\u0022\u003EPDF (87.1 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (87.1 KB) of Physiologically Based Pharmacokinetic Analyses \u2014 Format and Content Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/04\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Pharmacology","field_topics":"","topics-product":"Clinical - Pharmacology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-3969\u0022\u003EFDA-2016-D-3969\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-01-26T09:32:28-05:00\u0022\u003E2021-01-26 09:32\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/source-animal-product-preclinical-and-clinical-issues-concerning-use-xenotransplantation-products\u0022\u003ESource Animal, Product, Preclinical, and Clinical Issues Concerning the Use of Xenotransplantation Products in Humans: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/102126\/download\u0022\u003EPDF (294.51 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (294.51 KB) of Source Animal, Product, Preclinical, and Clinical Issues Concerning the Use of Xenotransplantation Products in Humans: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/13\/2016","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Xenotransplantation","field_topics":"","topics-product":"Xenotransplantation","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2000-D-0129\u0022\u003EFDA-2000-D-0129\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-04-22T08:29:31-04:00\u0022\u003E2024-04-22 08:29\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-236-clarification-fda-and-epa-jurisdiction-over-mosquito-related-products\u0022\u003ECVM GFI #236 Clarification of FDA and EPA Jurisdiction Over Mosquito-Related Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/102158\/download\u0022\u003EPDF (322.3 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (322.3 KB) of CVM GFI #236 Clarification of FDA and EPA Jurisdiction Over Mosquito-Related Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/27\/2025","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"New Animal Drug Application (NADA)","field_topics":"","topics-product":"New Animal Drug Application (NADA)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"02\/21\/2017","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-4482\u0022\u003EFDA-2016-D-4482\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222025-08-27T15:04:46-04:00\u0022\u003E2025-08-27 15:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/labeling-red-blood-cell-units-historical-antigen-typing-results\u0022\u003ELabeling of Red Blood Cell Units with Historical Antigen Typing Results: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/119376\/download\u0022\u003EPDF (135.21 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (135.21 KB) of Labeling of Red Blood Cell Units with Historical Antigen Typing Results: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/20\/2018","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-4308\u0022\u003EFDA-2016-D-4308\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222019-11-27T14:00:03-05:00\u0022\u003E2019-11-27 14:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/comparative-analyses-and-related-comparative-use-human-factors-studies-drug-device-combination\u0022\u003EComparative Analyses and Related Comparative Use Human Factors Studies for a Drug-Device Combination Product Submitted in an ANDA: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/102349\/download\u0022\u003EPDF (199.81 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (199.81 KB) of Comparative Analyses and Related Comparative Use Human Factors Studies for a Drug-Device Combination Product Submitted in an ANDA: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/17\/2017","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Generic Drugs","field_topics":"","topics-product":"Generic Drugs","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"03\/13\/2017","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-4412 \u0022\u003EFDA-2016-D-4412 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T11:55:09-04:00\u0022\u003E2020-05-06 11:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/referencing-approved-drug-products-anda-submissions-guidance-industry\u0022\u003EReferencing Approved Drug Products in ANDA Submissions Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/102360\/download\u0022\u003EPDF (154.94 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (154.94 KB) of Referencing Approved Drug Products in ANDA Submissions Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/27\/2020","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Generic Drugs","field_topics":"","topics-product":"Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-0114\u0022\u003EFDA-2017-D-0114\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-10-27T09:44:08-04:00\u0022\u003E2020-10-27 09:44\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-242-use-stability-studies-and-associated-labeling-statements-multiple-dose-injectable-animal\u0022\u003ECVM GFI #242 In-Use Stability Studies and Associated Labeling Statements for Multiple-Dose Injectable Animal Drug Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/102469\/download\u0022\u003EPDF (141.27 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (141.27 KB) of CVM GFI #242 In-Use Stability Studies and Associated Labeling Statements for Multiple-Dose Injectable Animal Drug Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/27\/2020","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), New Animal Drug Application (NADA), Investigational New Animal Drug (INAD)","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), New Animal Drug Application (NADA), Investigational New Animal Drug (INAD)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"03\/06\/2017","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-4437\u0022\u003EFDA-2016-D-4437\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222021-01-20T15:40:10-05:00\u0022\u003E2021-01-20 15:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommended-statement-over-counter-aspirin-containing-drug-products-labeled-cardiovascular-related\u0022\u003ERecommended Statement for Over-the-Counter Aspirin-Containing Drug Products Labeled With Cardiovascular Related Imagery Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/102479\/download\u0022\u003EPDF (192.74 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (192.74 KB) of Recommended Statement for Over-the-Counter Aspirin-Containing Drug Products Labeled With Cardiovascular Related Imagery Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/07\/2017","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Compliance","topics-product":"Compliance, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-0529\u0022\u003EFDA-2012-D-0529\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-15T17:00:17-04:00\u0022\u003E2020-04-15 17:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-243-vich-gl56-studies-evaluate-metabolism-and-residue-kinetics-veterinary-drugs-food\u0022\u003ECVM GFI #243 (VICH GL56) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Species: Study Design Recommendations for Residue Studies in Honey for Establishing Maximum Residue Limits and Withdrawal Periods\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/102492\/download\u0022\u003EPDF (202.44 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (202.44 KB) of CVM GFI #243 (VICH GL56) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Species: Study Design Recommendations for Residue Studies in Honey for Establishing Maximum Residue Limits and Withdrawal Periods\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/14\/2018","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Human Food Safety, VICH","field_topics":"","topics-product":"Human Food Safety, VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"03\/06\/2017","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-4461\u0022\u003EFDA-2016-D-4461\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:41:43-04:00\u0022\u003E2019-04-16 14:41\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/medical-product-communications-are-consistent-fda-required-labeling-questions-and-answers\u0022\u003EMedical Product Communications That Are Consistent With the FDA-Required Labeling \u2014 Questions and Answers : Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/133619\/download\u0022\u003EPDF (353.14 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (353.14 KB) of Medical Product Communications That Are Consistent With the FDA-Required Labeling \u2014 Questions and Answers : Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/13\/2018","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-2285\u0022\u003EFDA-2016-D-2285\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222026-06-26T06:50:33-04:00\u0022\u003E2026-06-26 06:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/considerations-demonstrating-interchangeability-reference-product-guidance-industry\u0022\u003EConsiderations in Demonstrating Interchangeability With a Reference Product Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/124907\/download\u0022\u003EPDF (448.98 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (448.98 KB) of Considerations in Demonstrating Interchangeability With a Reference Product Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/14\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Biosimilars","field_topics":"","topics-product":"Biosimilars","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-0154\u0022\u003EFDA-2017-D-0154\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-06-20T09:46:20-04:00\u0022\u003E2024-06-20 09:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/compounding-and-repackaging-radiopharmaceuticals-state-licensed-nuclear-pharmacies-and-federal\u0022\u003ECompounding and Repackaging of Radiopharmaceuticals by State-Licensed Nuclear Pharmacies and Federal Facilities Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/102615\/download\u0022\u003EPDF (306.64 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (306.64 KB) of Compounding and Repackaging of Radiopharmaceuticals by State-Licensed Nuclear Pharmacies and Federal Facilities Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/26\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Compounding","field_topics":"","topics-product":"Compounding","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-4318\u0022\u003EFDA-2016-D-4318\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-07T18:05:03-04:00\u0022\u003E2020-05-07 18:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/compounding-and-repackaging-radiopharmaceuticals-outsourcing-facilities-guidance-industry\u0022\u003ECompounding and Repackaging of Radiopharmaceuticals By Outsourcing Facilities Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/102637\/download\u0022\u003EPDF (324.37 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (324.37 KB) of Compounding and Repackaging of Radiopharmaceuticals By Outsourcing Facilities Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/26\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Compounding","field_topics":"","topics-product":"Compounding","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-4317\u0022\u003EFDA-2016-D-4317\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-07T17:55:03-04:00\u0022\u003E2020-05-07 17:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/2016-medical-gas-container-closure-rule-questions-and-answers-guidance-industry\u0022\u003E2016 Medical Gas Container-Closure Rule Questions and Answers Guidance for Industry: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/102638\/download\u0022\u003EPDF (81.54 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (81.54 KB) of 2016 Medical Gas Container-Closure Rule Questions and Answers Guidance for Industry: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/17\/2017","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP), Labeling","field_topics":"","topics-product":"Current Good Manufacturing Practice (CGMP), Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Small Entity Compliance Guide","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T14:40:15-04:00\u0022\u003E2020-05-06 14:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/annual-reporting-prescription-drug-wholesale-distributors-and-third-party-logistics-providers\u0022\u003EAnnual Reporting by Prescription Drug Wholesale Distributors and Third-Party Logistics Providers: Questions and Answers Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/102639\/download\u0022\u003EPDF (111.44 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (111.44 KB) of Annual Reporting by Prescription Drug Wholesale Distributors and Third-Party Logistics Providers: Questions and Answers Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/10\/2017","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-4646\u0022\u003EFDA-2016-D-4646\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-22T16:10:02-04:00\u0022\u003E2020-04-22 16:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-180-day-exclusivity-questions-and-answers\u0022\u003EGuidance for Industry 180-Day Exclusivity: Questions and Answers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/102650\/download\u0022\u003EPDF (239.52 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (239.52 KB) of Guidance for Industry 180-Day Exclusivity: Questions and Answers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/12\/2017","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Generic Drugs","field_topics":"","topics-product":"Generic Drugs","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"03\/12\/2017","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-4645\u0022\u003EFDA-2016-D-4645\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-22T10:20:05-04:00\u0022\u003E2020-04-22 10:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/multiple-endpoints-clinical-trials\u0022\u003EMultiple Endpoints in Clinical Trials: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/162416\/download\u0022\u003EPDF (317.1 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (317.1 KB) of Multiple Endpoints in Clinical Trials: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/21\/2022","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-4460\u0022\u003EFDA-2016-D-4460\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-04-17T11:32:01-04:00\u0022\u003E2024-04-17 11:32\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/drug-and-device-manufacturer-communications-payors-formulary-committees-and-similar-entities\u0022\u003EDrug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities \u2013 Questions and Answers: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/133620\/download\u0022\u003EPDF (397.7 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (397.7 KB) of Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities \u2013 Questions and Answers: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/02\/2026","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"08\/03\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-1307\u0022\u003EFDA-2016-D-1307\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222026-06-02T08:52:47-04:00\u0022\u003E2026-06-02 08:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q11-development-and-manufacture-drug-substances-questions-and-answers-chemical-entities-and\u0022\u003EQ11 Development and Manufacture of Drug Substances--Questions and Answers (Chemical Entities and Biotechnological\/Biological Entities)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/103162\/download\u0022\u003EPDF (843.18 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (843.18 KB) of Q11 Development and Manufacture of Drug Substances--Questions and Answers (Chemical Entities and Biotechnological\/Biological Entities)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/26\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0436\u0022\u003EFDA-2011-D-0436\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-15T10:40:13-04:00\u0022\u003E2020-05-15 10:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/product-identifier-requirements-under-drug-supply-chain-security-act-compliance-policy-guidance\u0022\u003EProduct Identifier Requirements Under the Drug Supply Chain Security Act \u2013 Compliance Policy Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/106198\/download\u0022\u003EPDF (249.15 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (249.15 KB) of Product Identifier Requirements Under the Drug Supply Chain Security Act \u2013 Compliance Policy Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/20\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-15T09:55:09-04:00\u0022\u003E2020-05-15 09:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/considerations-design-early-phase-clinical-trials-cellular-and-gene-therapy-products\u0022\u003EConsiderations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/106369\/download\u0022\u003EPDF (312.74 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (312.74 KB) of Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/27\/2015","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Gene Therapy","field_topics":"","topics-product":"Gene Therapy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0576\u0022\u003EFDA-2013-D-0576\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222020-02-10T14:07:11-05:00\u0022\u003E2020-02-10 14:07\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/consumer-antiseptic-wash-final-rule-questions-and-answers\u0022\u003EConsumer Antiseptic Wash Final Rule Questions and Answers: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/106652\/download\u0022\u003EPDF (91.76 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (91.76 KB) of Consumer Antiseptic Wash Final Rule Questions and Answers: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/26\/2017","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Over-the-Counter Drugs","field_topics":"","topics-product":"Over-the-Counter Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-3906\u0022\u003EFDA-2017-D-3906\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-07T18:35:05-04:00\u0022\u003E2020-05-07 18:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cmc-postapproval-manufacturing-changes-specified-biological-products-be-documented-annual-reports\u0022\u003ECMC Postapproval Manufacturing Changes for Specified Biological Products To Be Documented in Annual Reports\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/106935\/download\u0022\u003EPDF (96.67 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (96.67 KB) of CMC Postapproval Manufacturing Changes for Specified Biological Products To Be Documented in Annual Reports\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/09\/2021","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-2802\u0022\u003EFDA-2017-D-2802\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-12-09T09:01:11-05:00\u0022\u003E2021-12-09 09:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/identifying-trading-partners-under-drug-supply-chain-security-act-guidance-industry\u0022\u003EIdentifying Trading Partners Under the Drug Supply Chain Security Act Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/106961\/download\u0022\u003EPDF (180.61 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (180.61 KB) of Identifying Trading Partners Under the Drug Supply Chain Security Act Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/18\/2017","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"10\/18\/2017","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222018-12-01T11:36:39-05:00\u0022\u003E2018-12-01 11:36\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/policy-clarification-and-premarket-notification-510k-submissions-ultrasonic-diathermy-devices\u0022\u003EPolicy Clarification and Premarket Notification [510(k)] Submissions for Ultrasonic Diathermy Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/107094\/download\u0022\u003EPDF (545.39 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (545.39 KB) of Policy Clarification and Premarket Notification [510(k)] Submissions for Ultrasonic Diathermy Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/21\/2023","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Physical Medicine","field_topics":"Premarket","topics-product":"Premarket, 510(k), Physical Medicine","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"10\/30\/2017","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-4764\u0022\u003EFDA-2017-D-4764\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222023-02-21T11:06:41-05:00\u0022\u003E2023-02-21 11:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/providing-regulatory-submissions-electronic-format-content-risk-evaluation-and-mitigation-strategies\u0022\u003EProviding Regulatory Submissions in Electronic Format --Content of the Risk Evaluation and Mitigation Strategies Document Using Structured Product Labeling: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/107302\/download\u0022\u003EPDF (144.06 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (144.06 KB) of Providing Regulatory Submissions in Electronic Format --Content of the Risk Evaluation and Mitigation Strategies Document Using Structured Product Labeling: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/23\/2020","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Generic Drugs","field_topics":"Electronic Submissions","topics-product":"Electronic Submissions, Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-4303\u0022\u003EFDA-2017-D-4303\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-12-23T08:50:10-05:00\u0022\u003E2020-12-23 08:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/requalification-donors-previously-deferred-history-viral-hepatitis-after-11th-birthday\u0022\u003ERequalification of Donors Previously Deferred for a History of Viral Hepatitis after the 11th Birthday: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/107384\/download\u0022\u003EPDF (77.49 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (77.49 KB) of Requalification of Donors Previously Deferred for a History of Viral Hepatitis after the 11th Birthday: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/01\/2017","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Blood","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-5152\u0022\u003EFDA-2017-D-5152\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222019-08-22T14:26:21-04:00\u0022\u003E2019-08-22 14:26\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/formal-meetings-between-fda-and-anda-applicants-complex-products-under-gdufa-guidance-industry\u0022\u003EFormal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/107626\/download\u0022\u003EPDF (489.27 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (489.27 KB) of Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/05\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Drug Competition Action Plan, Generic Drugs","field_topics":"User Fees","topics-product":"User Fees, Drug Competition Action Plan, Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-5739\u0022\u003EFDA-2017-D-5739\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-01-11T16:27:46-05:00\u0022\u003E2023-01-11 16:27\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/anda-submissions-refuse-receive-standards-questions-and-answers-guidance-industry\u0022\u003EANDA Submissions - Refuse-to-Receive Standards: Questions and Answers Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/107637\/download\u0022\u003EPDF (153.07 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (153.07 KB) of ANDA Submissions - Refuse-to-Receive Standards: Questions and Answers Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/03\/2017","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Generic Drugs","field_topics":"User Fees","topics-product":"User Fees, Generic Drugs","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"01\/02\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-5846\u0022\u003EFDA-2017-D-5846\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-21T16:35:08-04:00\u0022\u003E2020-04-21 16:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/microdose-radiopharmaceutical-diagnostic-drugs-nonclinical-study-recommendations\u0022\u003EMicrodose Radiopharmaceutical Diagnostic Drugs: Nonclinical Study Recommendations: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/107641\/download\u0022\u003EPDF (83.23 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (83.23 KB) of Microdose Radiopharmaceutical Diagnostic Drugs: Nonclinical Study Recommendations: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/21\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pharmacology\/Toxicology","field_topics":"","topics-product":"Pharmacology\/Toxicology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-5297\u0022\u003EFDA-2017-D-5297\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-27T08:00:39-04:00\u0022\u003E2020-04-27 08:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/fda-and-industry-actions-de-novo-classification-requests-effect-fda-review-clock-and-goals\u0022\u003EFDA and Industry Actions on De Novo Classification Requests: Effect on FDA Review Clock and Goals: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/107652\/download\u0022\u003EPDF (436.19 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (436.19 KB) of FDA and Industry Actions on De Novo Classification Requests: Effect on FDA Review Clock and Goals: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/03\/2022","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"Premarket","topics-product":"Premarket, Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-5712\u0022\u003EFDA-2017-D-5712\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222022-10-03T17:35:31-04:00\u0022\u003E2022-10-03 17:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/user-fees-and-refunds-de-novo-classification-requests\u0022\u003EUser Fees and Refunds for De Novo Classification Requests : Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/107658\/download\u0022\u003EPDF (498.87 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (498.87 KB) of User Fees and Refunds for De Novo Classification Requests : Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/05\/2022","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"Premarket, User Fees","topics-product":"Premarket, User Fees, Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-5713\u0022\u003EFDA-2017-D-5713\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222022-10-06T10:08:16-04:00\u0022\u003E2022-10-06 10:08\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/utilizing-animal-studies-evaluate-organ-preservation-devices\u0022\u003EUtilizing Animal Studies to Evaluate Organ Preservation Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/107701\/download\u0022\u003EPDF (175.89 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (175.89 KB) of Utilizing Animal Studies to Evaluate Organ Preservation Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/08\/2019","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Gastroenterology-Urology ","field_topics":"Premarket","topics-product":"Premarket, 510(k), Gastroenterology-Urology ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-4886\u0022\u003EFDA-2017-D-4886\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222019-05-07T14:50:34-04:00\u0022\u003E2019-05-07 14:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/deviation-reporting-human-cells-tissues-and-cellular-and-tissue-based-products-regulated-solely\u0022\u003EDeviation Reporting for Human Cells, Tissues, and Cellular and Tissue-Based Products Regulated Solely Under Section 361 of the Public Health Service Act and 21 CFR Part 1271: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/107703\/download\u0022\u003EPDF (157.07 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (157.07 KB) of Deviation Reporting for Human Cells, Tissues, and Cellular and Tissue-Based Products Regulated Solely Under Section 361 of the Public Health Service Act and 21 CFR Part 1271: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/06\/2017","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Tissue","field_topics":"Cellular \u0026amp; Gene Therapy","topics-product":"Cellular \u0026amp; Gene Therapy, Tissue","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-4386\u0022\u003EFDA-2015-D-4386\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222019-05-16T16:25:19-04:00\u0022\u003E2019-05-16 16:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/regulatory-considerations-microneedling-products\u0022\u003ERegulatory Considerations for Microneedling Products: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/107708\/download\u0022\u003EPDF (380.45 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (380.45 KB) of Regulatory Considerations for Microneedling Products: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/10\/2020","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"General \u0026amp; Plastic Surgery ","field_topics":"Premarket","topics-product":"Premarket, General \u0026amp; Plastic Surgery ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-4792\u0022\u003EFDA-2017-D-4792\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-11-09T12:56:15-05:00\u0022\u003E2020-11-09 12:56\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/oncology-pharmaceuticals-reproductive-toxicity-testing-and-labeling-recommendations-guidance\u0022\u003EOncology Pharmaceuticals: Reproductive Toxicity Testing and Labeling Recommendations Guidance for Industry: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/124829\/download\u0022\u003EPDF (118.32 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (118.32 KB) of Oncology Pharmaceuticals: Reproductive Toxicity Testing and Labeling Recommendations Guidance for Industry: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/10\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pharmacology\/Toxicology","field_topics":"","topics-product":"Pharmacology\/Toxicology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-2165\u0022\u003EFDA-2017-D-2165\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-14T13:35:15-04:00\u0022\u003E2020-05-14 13:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/assessing-user-fees-under-prescription-drug-user-fee-amendments-2017-guidance-industry\u0022\u003EAssessing User Fees Under the Prescription Drug User Fee Amendments of 2017 Guidance for Industry: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/108233\/download\u0022\u003EPDF (224.28 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (224.28 KB) of Assessing User Fees Under the Prescription Drug User Fee Amendments of 2017 Guidance for Industry: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/09\/2020","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"User Fees","topics-product":"User Fees, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-5913 \u0022\u003EFDA-2017-D-5913 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222020-11-09T08:51:42-05:00\u0022\u003E2020-11-09 08:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/requests-reconsideration-division-level-under-gdufa\u0022\u003ERequests for Reconsideration at the Division Level Under GDUFA\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/108398\/download\u0022\u003EPDF (259.37 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (259.37 KB) of Requests for Reconsideration at the Division Level Under GDUFA\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/16\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Generic Drugs","field_topics":"User Fees","topics-product":"User Fees, Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"03\/11\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-5868\u0022\u003EFDA-2017-D-5868\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-10-17T08:57:16-04:00\u0022\u003E2024-10-17 08:57\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/respiratory-syncytial-virus-infection-developing-antiviral-drugs-prophylaxis-and-treatment-guidance\u0022\u003ERespiratory Syncytial Virus Infection: Developing Antiviral Drugs for Prophylaxis and Treatment Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/108437\/download\u0022\u003EPDF (179.49 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (179.49 KB) of Respiratory Syncytial Virus Infection: Developing Antiviral Drugs for Prophylaxis and Treatment Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/11\/2017","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial, Pediatric Product Development","field_topics":"","topics-product":"Clinical - Antimicrobial, Pediatric Product Development","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"12\/11\/2017","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T11:39:30-04:00\u0022\u003E2024-04-11 11:39\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pediatric-gastroesophageal-reflux-disease-developing-drugs-treatment-guidance-industry\u0022\u003EPediatric Gastroesophageal Reflux Disease: Developing Drugs for Treatment Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/108594\/download\u0022\u003EPDF (310.68 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (310.68 KB) of Pediatric Gastroesophageal Reflux Disease: Developing Drugs for Treatment Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/26\/2017","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Pediatric Product Development","field_topics":"","topics-product":"Clinical - Medical, Pediatric Product Development","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"01\/26\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-5912\u0022\u003EFDA-2017-D-5912\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T11:05:37-04:00\u0022\u003E2024-04-11 11:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e9r1-statistical-principles-clinical-trials-addendum-estimands-and-sensitivity-analysis-clinical\u0022\u003EE9(R1) Statistical Principles for Clinical Trials: Addendum: Estimands and Sensitivity Analysis in Clinical Trials: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/148473\/download\u0022\u003EPDF (235.63 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (235.63 KB) of E9(R1) Statistical Principles for Clinical Trials: Addendum: Estimands and Sensitivity Analysis in Clinical Trials: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/11\/2021","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Efficacy","field_topics":"","topics-product":"ICH-Efficacy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6113\u0022\u003EFDA-2017-D-6113\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222021-05-11T11:06:03-04:00\u0022\u003E2021-05-11 11:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/s5r3-detection-reproductive-and-developmental-toxicity-human-pharmaceuticals\u0022\u003ES5(R3) Detection of Reproductive and Developmental Toxicity for Human Pharmaceuticals : Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/148475\/download\u0022\u003EPDF (817.76 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (817.76 KB) of S5(R3) Detection of Reproductive and Developmental Toxicity for Human Pharmaceuticals : Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/11\/2021","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Safety","field_topics":"","topics-product":"ICH-Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-5138\u0022\u003EFDA-2017-D-5138\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222021-05-11T11:10:03-04:00\u0022\u003E2021-05-11 11:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/assessing-user-fees-under-biosimilar-user-fee-amendments-2022\u0022\u003EAssessing User Fees Under the Biosimilar User Fee Amendments of 2022: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/170634\/download\u0022\u003EPDF (366.77 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (366.77 KB) of Assessing User Fees Under the Biosimilar User Fee Amendments of 2022: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/31\/2023","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"User Fees","topics-product":"User Fees, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6209\u0022\u003EFDA-2017-D-6209\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-07-27T15:21:01-04:00\u0022\u003E2023-07-27 15:21\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/use-drug-master-file-shared-system-rems-submissions-guidance-industry\u0022\u003EUse of a Drug Master File for Shared System REMS Submissions Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/109124\/download\u0022\u003EPDF (102.63 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (102.63 KB) of Use of a Drug Master File for Shared System REMS Submissions Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/09\/2017","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Drug Competition Action Plan","field_topics":"","topics-product":"Administrative \/ Procedural, Drug Competition Action Plan","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6231\u0022\u003EFDA-2017-D-6231\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-08T13:20:15-04:00\u0022\u003E2020-05-08 13:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/regulatory-considerations-human-cells-tissues-and-cellular-and-tissue-based-products-minimal\u0022\u003ERegulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/109176\/download\u0022\u003EPDF (225.48 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (225.48 KB) of Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/20\/2020","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Tissue","field_topics":"Cellular \u0026amp; Gene Therapy","topics-product":"Cellular \u0026amp; Gene Therapy, Tissue","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6146\u0022\u003EFDA-2017-D-6146\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222020-07-21T10:10:03-04:00\u0022\u003E2020-07-21 10:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/expedited-programs-regenerative-medicine-therapies-serious-conditions\u0022\u003EExpedited Programs for Regenerative Medicine Therapies for Serious Conditions: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/120267\/download\u0022\u003EPDF (219.2 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (219.2 KB) of Expedited Programs for Regenerative Medicine Therapies for Serious Conditions: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/15\/2019","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Gene Therapy","field_topics":"Cellular \u0026amp; Gene Therapy","topics-product":"Cellular \u0026amp; Gene Therapy, Gene Therapy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"02\/15\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6159\u0022\u003EFDA-2017-D-6159\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222019-05-16T16:05:15-04:00\u0022\u003E2019-05-16 16:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/evaluation-devices-used-regenerative-medicine-advanced-therapies\u0022\u003EEvaluation of Devices Used with Regenerative Medicine Advanced Therapies: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/120266\/download\u0022\u003EPDF (193.57 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (193.57 KB) of Evaluation of Devices Used with Regenerative Medicine Advanced Therapies: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/15\/2019","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products","field_health_topics":"","term_node_tid":"Combination Products, Gene Therapy","field_topics":"","topics-product":"Combination Products, Gene Therapy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"02\/15\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6154\u0022\u003EFDA-2017-D-6154\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222019-07-29T15:20:07-04:00\u0022\u003E2019-07-29 15:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/investigational-ivds-used-clinical-investigations-therapeutic-products\u0022\u003EInvestigational IVDs Used in Clinical Investigations of Therapeutic Products: Draft Guidance for Industry, Food and Drug Administration Staff, Sponsors, and Institutional Review Boards \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/109464\/download\u0022\u003EPDF (730.53 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (730.53 KB) of Investigational IVDs Used in Clinical Investigations of Therapeutic Products: Draft Guidance for Industry, Food and Drug Administration Staff, Sponsors, and Institutional Review Boards \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/18\/2017","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP), Labeling, Investigational Device Exemption (IDE), Investigational New Drug Application (INDA), Laboratory Tests, IVDs (In Vitro Diagnostic Devices)","field_topics":"","topics-product":"Good Clinical Practice (GCP), Labeling, Investigational Device Exemption (IDE), Investigational New Drug Application (INDA), Laboratory Tests, IVDs (In Vitro Diagnostic Devices)","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"03\/19\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-N-6356\u0022\u003EFDA-2017-N-6356\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-02T10:20:13-05:00\u0022\u003E2020-03-02 10:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pediatric-rare-diseases-collaborative-approach-drug-development-using-gaucher-disease-model-draft\u0022\u003EPediatric Rare Diseases--A Collaborative Approach for Drug Development Using Gaucher Disease as a Model; Draft Guidance for Industry: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/109465\/download\u0022\u003EPDF (262.2 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (262.2 KB) of Pediatric Rare Diseases--A Collaborative Approach for Drug Development Using Gaucher Disease as a Model; Draft Guidance for Industry: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/07\/2017","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"Rare Diseases","term_node_tid":"Pediatric Product Development","field_topics":"","topics-product":"Rare Diseases, Pediatric Product Development","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"03\/06\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-N-6476\u0022\u003EFDA-2017-N-6476\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T11:05:31-04:00\u0022\u003E2024-04-11 11:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clarification-orphan-designation-drugs-and-biologics-pediatric-subpopulations-common-diseases\u0022\u003EClarification of Orphan Designation of Drugs and Biologics for Pediatric Subpopulations of Common Diseases: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/109496\/download\u0022\u003EPDF (81.03 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (81.03 KB) of Clarification of Orphan Designation of Drugs and Biologics for Pediatric Subpopulations of Common Diseases: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/19\/2017","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Orphan Products Development","field_health_topics":"","term_node_tid":"Pediatric Product Development","field_topics":"Premarket","topics-product":"Premarket, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"07\/27\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6380.\u0022\u003EFDA-2017-D-6380.\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T09:30:02-04:00\u0022\u003E2024-04-11 09:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommendations-reduce-possible-risk-transmission-creutzfeldt-jakob-disease-and-variant-creutzfeldt\u0022\u003ERecommendations to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Components: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/124156\/download\u0022\u003EPDF (284.19 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (284.19 KB) of Recommendations to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Components: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/23\/2022","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Blood","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-0307\u0022\u003EFDA-2012-D-0307\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222022-05-24T14:12:20-04:00\u0022\u003E2022-05-24 14:12\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommendations-dual-510k-and-clia-waiver-application-studies\u0022\u003ERecommendations for Dual 510(k) and CLIA Waiver by Application Studies: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/109574\/download\u0022\u003EPDF (392.56 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (392.56 KB) of Recommendations for Dual 510(k) and CLIA Waiver by Application Studies: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/26\/2020","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"CLIA (Clinical Laboratory Improvement Amendments), 510(k)","field_topics":"Premarket, Postmarket","topics-product":"Premarket, Postmarket, CLIA (Clinical Laboratory Improvement Amendments), 510(k)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-5625\u0022\u003EFDA-2017-D-5625\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222021-01-26T10:40:31-05:00\u0022\u003E2021-01-26 10:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommendations-clinical-laboratory-improvement-amendments-1988-clia-waiver-applications\u0022\u003ERecommendations for Clinical Laboratory Improvement Amendments of 1988 (CLIA) Waiver Applications for Manufacturers of In Vitro Diagnostic Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/109582\/download\u0022\u003EPDF (596.03 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (596.03 KB) of Recommendations for Clinical Laboratory Improvement Amendments of 1988 (CLIA) Waiver Applications for Manufacturers of In Vitro Diagnostic Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/26\/2020","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"CLIA (Clinical Laboratory Improvement Amendments)","field_topics":"","topics-product":"CLIA (Clinical Laboratory Improvement Amendments)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-5570\u0022\u003EFDA-2017-D-5570\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222024-08-09T20:35:06-04:00\u0022\u003E2024-08-09 20:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/grandfathering-policy-packages-and-homogenous-cases-product-without-product-identifier\u0022\u003EGrandfathering Policy for Packages and Homogenous Cases of Product Without a Product Identifier\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/109591\/download\u0022\u003EPDF (319.01 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (319.01 KB) of Grandfathering Policy for Packages and Homogenous Cases of Product Without a Product Identifier\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/19\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222018-12-01T11:37:44-05:00\u0022\u003E2018-12-01 11:37\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/chemistry-manufacturing-and-controls-changes-approved-application-certain-biological-products\u0022\u003EChemistry, Manufacturing, and Controls Changes to an Approved Application: Certain Biological Products: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/109615\/download\u0022\u003EPDF (480.03 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (480.03 KB) of Chemistry, Manufacturing, and Controls Changes to an Approved Application: Certain Biological Products: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/21\/2021","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1995-D-0288\u0022\u003EFDA-1995-D-0288\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"","changed":"\u003Ctime datetime=\u00222021-08-27T09:00:41-04:00\u0022\u003E2021-08-27 09:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/changes-existing-medical-software-policies-resulting-section-3060-21st-century-cures-act\u0022\u003EChanges to Existing Medical Software Policies Resulting from Section 3060 of the 21st Century Cures Act: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/109622\/download\u0022\u003EPDF (660.31 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (660.31 KB) of Changes to Existing Medical Software Policies Resulting from Section 3060 of the 21st Century Cures Act: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/27\/2019","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Digital Health","field_topics":"Postmarket, Premarket","topics-product":"Postmarket, Premarket, Digital Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6294\u0022\u003EFDA-2017-D-6294\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222019-09-30T09:45:33-04:00\u0022\u003E2019-09-30 09:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/refuse-file-nda-and-bla-submissions-cder-guidance-industry\u0022\u003ERefuse to File: NDA and BLA Submissions to CDER Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/109758\/download\u0022\u003EPDF (109.48 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (109.48 KB) of Refuse to File: NDA and BLA Submissions to CDER Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/13\/2017","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"03\/12\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6554\u0022\u003EFDA-2017-D-6554\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-17T14:35:19-04:00\u0022\u003E2020-04-17 14:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/homeopathic-drug-products-guidance-fda-staff-and-industry\u0022\u003EHomeopathic Drug Products Guidance for FDA Staff and Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/163755\/download\u0022\u003EPDF (283.97 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (283.97 KB) of Homeopathic Drug Products Guidance for FDA Staff and Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/07\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"Compliance","topics-product":"Compliance, Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6580\u0022\u003EFDA-2017-D-6580\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-11-03T15:09:31-04:00\u0022\u003E2023-11-03 15:09\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/systemic-antibacterial-and-antifungal-drugs-susceptibility-test-interpretive-criteria-labeling-ndas\u0022\u003ESystemic Antibacterial and Antifungal Drugs: Susceptibility Test Interpretive Criteria Labeling for NDAs and ANDAs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/109839\/download\u0022\u003EPDF (92 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (92 KB) of Systemic Antibacterial and Antifungal Drugs: Susceptibility Test Interpretive Criteria Labeling for NDAs and ANDAs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/13\/2017","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-N-5925\u0022\u003EFDA-2017-N-5925\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-05T14:05:07-04:00\u0022\u003E2020-05-05 14:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/drug-products-including-biological-products-contain-nanomaterials-guidance-industry\u0022\u003EDrug Products, Including Biological Products, that Contain Nanomaterials - Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/157812\/download\u0022\u003EPDF (458.28 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (458.28 KB) of Drug Products, Including Biological Products, that Contain Nanomaterials - Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/21\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"03\/13\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-0759\u0022\u003EFDA-2017-D-0759\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-04-21T11:55:03-04:00\u0022\u003E2022-04-21 11:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/information-requests-and-discipline-review-letters-under-generic-drug-user-fee-amendments\u0022\u003EInformation Requests and Discipline Review Letters Under the Generic Drug User Fee Amendments: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/109915\/download\u0022\u003EPDF (253.33 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (253.33 KB) of Information Requests and Discipline Review Letters Under the Generic Drug User Fee Amendments: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/05\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Generic Drugs","field_topics":"User Fees","topics-product":"User Fees, Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6752\u0022\u003EFDA-2017-D-6752\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-01-11T16:26:01-05:00\u0022\u003E2023-01-11 16:26\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/formal-meetings-between-fda-and-sponsors-or-applicants-pdufa-products\u0022\u003EFormal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/172311\/download\u0022\u003EPDF (374.21 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (374.21 KB) of Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/12\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6530\u0022\u003EFDA-2017-D-6530\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-08-13T08:34:46-04:00\u0022\u003E2026-08-13 08:34\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/establishing-effectiveness-drugs-intended-treat-male-hypogonadotropic-hypogonadism-attributed\u0022\u003EEstablishing Effectiveness for Drugs Intended to Treat Male Hypogonadotropic Hypogonadism Attributed to Nonstructural Disorders Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/110004\/download\u0022\u003EPDF (65.97 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (65.97 KB) of Establishing Effectiveness for Drugs Intended to Treat Male Hypogonadotropic Hypogonadism Attributed to Nonstructural Disorders Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/18\/2018","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222018-12-01T11:38:06-05:00\u0022\u003E2018-12-01 11:38\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/labeling-combined-hormonal-contraceptives-guidance-industry\u0022\u003ELabeling for Combined Hormonal Contraceptives Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/110050\/download\u0022\u003EPDF (436.92 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (436.92 KB) of Labeling for Combined Hormonal Contraceptives Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/02\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"02\/28\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-1846\u0022\u003EFDA-2017-D-1846\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T01:40:03-04:00\u0022\u003E2020-04-24 01:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/laser-products-conformance-iec-60825-1-ed-3-and-iec-60601-2-22-ed-31-laser-notice-no-56\u0022\u003ELaser Products - Conformance with IEC 60825-1 Ed. 3 and IEC 60601-2-22 Ed. 3.1 (Laser Notice No. 56): Guidance for Industry and Food and Drug Administration Staff \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/110120\/download\u0022\u003EPDF (379.78 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (379.78 KB) of Laser Products - Conformance with IEC 60825-1 Ed. 3 and IEC 60601-2-22 Ed. 3.1 (Laser Notice No. 56): Guidance for Industry and Food and Drug Administration Staff \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/21\/2023","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Export, Import, Laser Notice, Radiological Health, Radiology","field_topics":"","topics-product":"Export, Import, Laser Notice, Radiological Health, Radiology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-7011\u0022\u003EFDA-2017-D-7011\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222023-02-21T11:05:46-05:00\u0022\u003E2023-02-21 11:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/material-threat-medical-countermeasure-priority-review-vouchers-draft-guidance-industry\u0022\u003EMaterial Threat Medical Countermeasure Priority Review Vouchers - Draft Guidance for Industry: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/110193\/download\u0022\u003EPDF (148.16 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (148.16 KB) of Material Threat Medical Countermeasure Priority Review Vouchers - Draft Guidance for Industry: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/19\/2018","field_issuing_office_taxonomy":"Office of the Commissioner,Office of the Chief Scientist,Office of Counterterrorism and Emerging Threats","field_health_topics":"","term_node_tid":"","field_topics":"Emergencies","topics-product":"Emergencies, ","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"03\/20\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6880\u0022\u003EFDA-2017-D-6880\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-04-20T22:40:07-04:00\u0022\u003E2019-04-20 22:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/assessing-user-fees-under-generic-drug-user-fee-amendments-2017-guidance-industry\u0022\u003EAssessing User Fees Under the Generic Drug User Fee Amendments of 2017 Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/30\/2017","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Generic Drugs","field_topics":"User Fees","topics-product":"User Fees, Generic Drugs","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-0880\u0022\u003EFDA-2012-D-0880\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-05-16T17:40:47-04:00\u0022\u003E2022-05-16 17:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/product-title-and-initial-us-approval-highlights-prescribing-information-human-prescription-drug-and\u0022\u003EProduct Title and Initial U.S. Approval in the Highlights of Prescribing Information for Human Prescription Drug and Biological Products \u2014 Content and Format Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/110453\/download\u0022\u003EPDF (679.86 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (679.86 KB) of Product Title and Initial U.S. Approval in the Highlights of Prescribing Information for Human Prescription Drug and Biological Products \u2014 Content and Format Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/19\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"03\/19\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6969\u0022\u003EFDA-2017-D-6969\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-14T13:35:22-04:00\u0022\u003E2020-04-14 13:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/public-warning-notification-recalls-under-21-cfr-part-7-subpart-c\u0022\u003EPublic Warning-Notification of Recalls Under 21 CFR Part 7, Subpart C : Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/110457\/download\u0022\u003EPDF (441.33 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (441.33 KB) of Public Warning-Notification of Recalls Under 21 CFR Part 7, Subpart C : Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/08\/2019","field_issuing_office_taxonomy":"Office of Regulatory Affairs\u003Cbr\u003E\u003Cbr\u003ECenter for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Tobacco Products","field_health_topics":"","term_node_tid":"","field_topics":"Recalls, Investigation \u0026amp; Enforcement","topics-product":"Recalls, Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"02\/08\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-3548\u0022\u003EFDA-2016-D-3548\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Drugs, Food \u0026amp; Beverages, Medical Devices, Tobacco","changed":"\u003Ctime datetime=\u00222023-09-29T13:05:32-04:00\u0022\u003E2023-09-29 13:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-245-hazard-analysis-and-risk-based-preventive-controls-food-animals\u0022\u003ECVM GFI #245 Hazard Analysis and Risk-Based Preventive Controls for Food for Animals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/110477\/download\u0022\u003EPDF (1.04 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.04 MB) of CVM GFI #245 Hazard Analysis and Risk-Based Preventive Controls for Food for Animals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/08\/2022","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Feed","field_topics":"","topics-product":"Animal Feed","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"07\/23\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-0388\u0022\u003EFDA-2018-D-0388\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222022-07-06T08:51:32-04:00\u0022\u003E2022-07-06 08:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/unique-device-identification-policy-regarding-compliance-dates-class-i-and-unclassified-devices\u0022\u003EUnique Device Identification: Policy Regarding Compliance Dates for Class I and Unclassified Devices, Direct Marking, and Global Unique Device Identification Database Requirements for Certain Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/110564\/download\u0022\u003EPDF (558.76 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (558.76 KB) of Unique Device Identification: Policy Regarding Compliance Dates for Class I and Unclassified Devices, Direct Marking, and Global Unique Device Identification Database Requirements for Certain Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/25\/2022","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Labeling, UDI","field_topics":"","topics-product":"Labeling, UDI","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6841\u0022\u003EFDA-2017-D-6841\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222022-07-22T08:47:16-04:00\u0022\u003E2022-07-22 08:47\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/good-anda-submission-practices-guidance-industry\u0022\u003EGood ANDA Submission Practices Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/110689\/download\u0022\u003EPDF (247.39 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (247.39 KB) of Good ANDA Submission Practices Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/26\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Drug Competition Action Plan, Generic Drugs","field_topics":"","topics-product":"Drug Competition Action Plan, Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6854\u0022\u003EFDA-2017-D-6854\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-04-01T14:22:06-04:00\u0022\u003E2022-04-01 14:22\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/amyotrophic-lateral-sclerosis-developing-drugs-treatment-guidance-industry\u0022\u003EAmyotrophic Lateral Sclerosis: Developing Drugs for Treatment Guidance for Industry: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/130964\/download\u0022\u003EPDF (228.24 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (228.24 KB) of Amyotrophic Lateral Sclerosis: Developing Drugs for Treatment Guidance for Industry: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/24\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-N-0035\u0022\u003EFDA-2013-N-0035\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-21T16:05:05-04:00\u0022\u003E2020-04-21 16:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/early-alzheimers-disease-developing-drugs-treatment\u0022\u003EEarly Alzheimer\u2019s Disease: Developing Drugs for Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/110903\/download\u0022\u003EPDF (260.09 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (260.09 KB) of Early Alzheimer\u2019s Disease: Developing Drugs for Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/12\/2024","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"06\/10\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0077\u0022\u003EFDA-2013-D-0077\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-03-12T09:14:04-04:00\u0022\u003E2024-03-12 09:14\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/drugs-treatment-partial-onset-seizures-extrapolation-efficacy-adults-pediatric-patients-1-month-age\u0022\u003EDrugs for the Treatment of Partial Onset Seizures: Extrapolation of Efficacy from Adults to Pediatric Patients 1 Month of Age and Older\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/130449\/download\u0022\u003EPDF (200.85 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (200.85 KB) of Drugs for the Treatment of Partial Onset Seizures: Extrapolation of Efficacy from Adults to Pediatric Patients 1 Month of Age and Older\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/15\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Pharmacology, Pediatric Product Development","field_topics":"","topics-product":"Clinical - Pharmacology, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-0178 \u0022\u003EFDA-2018-D-0178 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-07-15T13:13:46-04:00\u0022\u003E2024-07-15 13:13\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/qualified-infectious-disease-product-designation-questions-and-answers\u0022\u003EQualified Infectious Disease Product Designation Questions and Answers: Guidance for Industy\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/148480\/download\u0022\u003EPDF (122.83 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (122.83 KB) of Qualified Infectious Disease Product Designation Questions and Answers: Guidance for Industy\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/11\/2021","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-7001\u0022\u003EFDA-2017-D-7001\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-05-11T11:11:03-04:00\u0022\u003E2021-05-11 11:11\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/replacement-reagent-and-instrument-family-policy-in-vitro-diagnostic-devices\u0022\u003EReplacement Reagent and Instrument Family Policy for In Vitro Diagnostic Devices: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/111186\/download\u0022\u003EPDF (1.11 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.11 MB) of Replacement Reagent and Instrument Family Policy for In Vitro Diagnostic Devices: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/17\/2022","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Laboratory Tests","field_topics":"","topics-product":"Laboratory Tests","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6765\u0022\u003EFDA-2017-D-6765\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222022-08-16T09:05:31-04:00\u0022\u003E2022-08-16 09:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/acceptance-clinical-data-support-medical-device-applications-and-submissions-frequently-asked\u0022\u003EAcceptance of Clinical Data to Support Medical Device Applications and Submissions: Frequently Asked Questions: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/111346\/download\u0022\u003EPDF (484.51 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (484.51 KB) of Acceptance of Clinical Data to Support Medical Device Applications and Submissions: Frequently Asked Questions: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/21\/2018","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP), Investigational Device Exemption (IDE)","field_topics":"Premarket","topics-product":"Premarket, Good Clinical Practice (GCP), Investigational Device Exemption (IDE)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-N-0080\u0022\u003EFDA-2013-N-0080\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222023-08-10T15:42:31-04:00\u0022\u003E2023-08-10 15:42\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/standardization-data-and-documentation-practices-product-tracing-guidance-industry\u0022\u003EStandardization of Data and Documentation Practices for Product Tracing Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/111451\/download\u0022\u003EPDF (170.08 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (170.08 KB) of Standardization of Data and Documentation Practices for Product Tracing Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/02\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"05\/01\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-0688\u0022\u003EFDA-2018-D-0688\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222020-05-04T14:50:18-04:00\u0022\u003E2020-05-04 14:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/definitions-suspect-product-and-illegitimate-product-verification-obligations-under-drug-supply\u0022\u003EDefinitions of Suspect Product and Illegitimate Product for Verification Obligations Under the Drug Supply Chain Security Act Guidance for Industry: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/111468\/download\u0022\u003EPDF (240.02 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (240.02 KB) of Definitions of Suspect Product and Illegitimate Product for Verification Obligations Under the Drug Supply Chain Security Act Guidance for Industry: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/16\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-0338\u0022\u003EFDA-2018-D-0338\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222023-03-16T10:24:01-04:00\u0022\u003E2023-03-16 10:24\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-240-proprietary-names-new-animal-drugs\u0022\u003ECVM GFI #240 Proprietary Names for New Animal Drugs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/111947\/download\u0022\u003EPDF (175.72 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (175.72 KB) of CVM GFI #240 Proprietary Names for New Animal Drugs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/01\/2020","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Advertising, Labeling, New Animal Drug Application (NADA)","field_topics":"","topics-product":"Administrative \/ Procedural, Advertising, Labeling, New Animal Drug Application (NADA)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"05\/11\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-0626\u0022\u003EFDA-2018-D-0626\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222020-05-29T08:50:59-04:00\u0022\u003E2020-05-29 08:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-255-elemental-impurities-animal-drug-products-questions-and-answers\u0022\u003ECVM GFI #255 Elemental Impurities in Animal Drug Products Questions and Answers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/111953\/download\u0022\u003EPDF (152.19 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (152.19 KB) of CVM GFI #255 Elemental Impurities in Animal Drug Products Questions and Answers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/23\/2020","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC)","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"05\/29\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-0943\u0022\u003EFDA-2018-D-0943\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222021-01-20T15:41:41-05:00\u0022\u003E2021-01-20 15:41\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pregnant-women-scientific-and-ethical-considerations-inclusion-clinical-trials\u0022\u003EPregnant Women: Scientific and Ethical Considerations for Inclusion in Clinical Trials\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/112195\/download\u0022\u003EPDF (116.6 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (116.6 KB) of Pregnant Women: Scientific and Ethical Considerations for Inclusion in Clinical Trials\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/09\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1201\u0022\u003EFDA-2018-D-1201\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-15T02:20:10-04:00\u0022\u003E2020-05-15 02:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q7-good-manufacturing-practice-guidance-active-pharmaceutical-ingredients-questions-and-answers\u0022\u003EQ7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients Questions and Answers Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/112426\/download\u0022\u003EPDF (218.22 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (218.22 KB) of Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients Questions and Answers Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/20\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1176\u0022\u003EFDA-2018-D-1176\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-14T10:40:21-04:00\u0022\u003E2020-04-14 10:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/final-in-vivo-bioavailability-bioequivalence-studies-analytical\u0022\u003EFinal In Vivo Bioavailability-Bioequivalence Studies- Analytical\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/112533\/download\u0022\u003EPDF (664.54 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (664.54 KB) of Final In Vivo Bioavailability-Bioequivalence Studies- Analytical\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"","field_issuing_office_taxonomy":"","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"","changed":"\u003Ctime datetime=\u00222018-12-01T04:40:19-05:00\u0022\u003E2018-12-01 04:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/submitting-study-datasets-vaccines-office-vaccines-research-and-review\u0022\u003ESubmitting Study Datasets for Vaccines to the Office of Vaccines Research and Review: Guidance for Industry; Technical Specifications Document\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/112581\/download\u0022\u003EPDF (259.57 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (259.57 KB) of Submitting Study Datasets for Vaccines to the Office of Vaccines Research and Review: Guidance for Industry; Technical Specifications Document\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/20\/2019","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"Electronic Submissions","topics-product":"Electronic Submissions, Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1216\u0022\u003EFDA-2018-D-1216\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222019-12-20T11:08:25-05:00\u0022\u003E2019-12-20 11:08\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/investigational-in-vitro-diagnostics-oncology-trials-streamlined-submission-process-study-risk\u0022\u003EInvestigational In Vitro Diagnostics in Oncology Trials: Streamlined Submission Process for Study Risk Determination Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/112605\/download\u0022\u003EPDF (83.67 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (83.67 KB) of Investigational In Vitro Diagnostics in Oncology Trials: Streamlined Submission Process for Study Risk Determination Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/10\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-0944\u0022\u003EFDA-2018-D-0944\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T01:20:53-04:00\u0022\u003E2020-04-24 01:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/multiple-function-device-products-policy-and-considerations\u0022\u003EMultiple Function Device Products: Policy and Considerations: Guidance for Industry and Food and Drug Administration\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/112671\/download\u0022\u003EPDF (748.91 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (748.91 KB) of Multiple Function Device Products: Policy and Considerations: Guidance for Industry and Food and Drug Administration\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/29\/2020","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Combination Products, Digital Health","field_topics":"Postmarket, Premarket","topics-product":"Postmarket, Premarket, Combination Products, Digital Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1339\u0022\u003EFDA-2018-D-1339\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222020-07-29T10:10:29-04:00\u0022\u003E2020-07-29 10:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/safety-and-performance-based-pathway\u0022\u003ESafety and Performance Based Pathway: Guidance for Industry and Food and Drug Administration\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/112691\/download\u0022\u003EPDF (358.91 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (358.91 KB) of Safety and Performance Based Pathway: Guidance for Industry and Food and Drug Administration\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/20\/2019","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"510(k)","field_topics":"Premarket","topics-product":"Premarket, 510(k)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1387\u0022\u003EFDA-2018-D-1387\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222019-09-19T08:35:15-04:00\u0022\u003E2019-09-19 08:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/severely-debilitating-or-life-threatening-hematologic-disorders-nonclinical-development\u0022\u003ESeverely Debilitating or Life-Threatening Hematologic Disorders: Nonclinical Development of Pharmaceuticals Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/112750\/download\u0022\u003EPDF (121.8 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (121.8 KB) of Severely Debilitating or Life-Threatening Hematologic Disorders: Nonclinical Development of Pharmaceuticals Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/15\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pharmacology\/Toxicology","field_topics":"","topics-product":"Pharmacology\/Toxicology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1328\u0022\u003EFDA-2018-D-1328\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T14:55:09-04:00\u0022\u003E2020-04-24 14:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cytomegalovirus-transplantation-developing-drugs-treat-or-prevent-disease\u0022\u003ECytomegalovirus in Transplantation: Developing Drugs to Treat or Prevent Disease\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/112942\/download\u0022\u003EPDF (219.48 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (219.48 KB) of Cytomegalovirus in Transplantation: Developing Drugs to Treat or Prevent Disease\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/21\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"07\/17\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1711\u0022\u003EFDA-2018-D-1711\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-07T08:50:31-04:00\u0022\u003E2020-05-07 08:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/uncomplicated-urinary-tract-infections-developing-drugs-treatment-guidance-industry\u0022\u003EUncomplicated Urinary Tract Infections: Developing Drugs for Treatment Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/129531\/download\u0022\u003EPDF (301.3 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (301.3 KB) of Uncomplicated Urinary Tract Infections: Developing Drugs for Treatment Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/01\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1562\u0022\u003EFDA-2018-D-1562\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T08:50:21-04:00\u0022\u003E2020-05-06 08:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/maximal-usage-trials-topically-applied-active-ingredients-being-considered-inclusion-over-counter\u0022\u003EMaximal Usage Trials for Topically Applied Active Ingredients Being Considered for Inclusion in an Over-The-Counter Monograph: Study Elements and Considerations\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/125080\/download\u0022\u003EPDF (156 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (156 KB) of Maximal Usage Trials for Topically Applied Active Ingredients Being Considered for Inclusion in an Over-The-Counter Monograph: Study Elements and Considerations\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/10\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Pharmacology, Pediatric Product Development, Over-the-Counter Drugs","field_topics":"","topics-product":"Clinical - Pharmacology, Pediatric Product Development, Over-the-Counter Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1456\u0022\u003EFDA-2018-D-1456\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T11:03:31-04:00\u0022\u003E2024-04-11 11:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommended-content-and-format-non-clinical-bench-performance-testing-information-premarket\u0022\u003ERecommended Content and Format of Non-Clinical Bench Performance Testing Information in Premarket Submissions: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/113230\/download\u0022\u003EPDF (383.76 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (383.76 KB) of Recommended Content and Format of Non-Clinical Bench Performance Testing Information in Premarket Submissions: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/20\/2019","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1329\u0022\u003EFDA-2018-D-1329\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-10-20T10:45:19-04:00\u0022\u003E2020-10-20 10:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pediatric-hiv-infection-drug-development-treatment\u0022\u003EPediatric HIV Infection: Drug Development for Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/113319\/download\u0022\u003EPDF (70.68 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (70.68 KB) of Pediatric HIV Infection: Drug Development for Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/20\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Pediatric Product Development","field_topics":"","topics-product":"Clinical - Medical, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1638\u0022\u003EFDA-2018-D-1638\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T09:38:47-04:00\u0022\u003E2024-04-11 09:38\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/waivers-exceptions-and-exemptions-requirements-section-582-federal-food-drug-and-cosmetic-act\u0022\u003EWaivers, Exceptions, and Exemptions from the Requirements of Section 582 of the Federal Food, Drug, and Cosmetic Act\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/113342\/download\u0022\u003EPDF (296.22 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (296.22 KB) of Waivers, Exceptions, and Exemptions from the Requirements of Section 582 of the Federal Food, Drug, and Cosmetic Act\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/04\/2023","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1434\u0022\u003EFDA-2018-D-1434\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222023-08-04T07:26:16-04:00\u0022\u003E2023-08-04 07:26\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/assessment-pressor-effects-drugs-guidance-industry\u0022\u003EAssessment of Pressor Effects of Drugs Guidance for Industry: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/113477\/download\u0022\u003EPDF (183.44 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (183.44 KB) of Assessment of Pressor Effects of Drugs Guidance for Industry: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/03\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1636\u0022\u003EFDA-2018-D-1636\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-02-03T09:00:27-05:00\u0022\u003E2022-02-03 09:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q12-technical-and-regulatory-considerations-pharmaceutical-product-lifecycle-management-guidance\u0022\u003EQ12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management Guidance for Industry: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/148476\/download\u0022\u003EPDF (359.57 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (359.57 KB) of Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management Guidance for Industry: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/11\/2021","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1609\u0022\u003EFDA-2018-D-1609\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222021-05-13T14:16:03-04:00\u0022\u003E2021-05-13 14:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/considerations-inclusion-adolescent-patients-adult-oncology-clinical-trials\u0022\u003EConsiderations for the Inclusion of Adolescent Patients in Adult Oncology Clinical Trials\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/113499\/download\u0022\u003EPDF (87.34 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (87.34 KB) of Considerations for the Inclusion of Adolescent Patients in Adult Oncology Clinical Trials\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/13\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner","field_health_topics":"","term_node_tid":"Clinical - Medical, Pediatric Product Development","field_topics":"","topics-product":"Clinical - Medical, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1540\u0022\u003EFDA-2018-D-1540\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T11:30:16-04:00\u0022\u003E2024-04-11 11:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-collecting-comprehensive-and-representative-input\u0022\u003EPatient-Focused Drug Development: Collecting Comprehensive and Representative Input\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/139088\/download\u0022\u003EPDF (908.94 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (908.94 KB) of Patient-Focused Drug Development: Collecting Comprehensive and Representative Input\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/13\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"09\/12\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1893\u0022\u003EFDA-2018-D-1893\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-01-26T09:32:00-05:00\u0022\u003E2021-01-26 09:32\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/limited-population-pathway-antibacterial-and-antifungal-drugs-guidance-industry\u0022\u003ELimited Population Pathway for Antibacterial and Antifungal Drugs Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/113729\/download\u0022\u003EPDF (285.08 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (285.08 KB) of Limited Population Pathway for Antibacterial and Antifungal Drugs Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/05\/2020","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-2032\u0022\u003EFDA-2018-D-2032\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222020-08-05T09:35:05-04:00\u0022\u003E2020-08-05 09:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/chemistry-manufacturing-and-control-cmc-information-human-gene-therapy-investigational-new-drug\u0022\u003EChemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs): Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/113760\/download\u0022\u003EPDF (466.7 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (466.7 KB) of Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs): Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/28\/2020","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Gene Therapy","field_topics":"Cellular \u0026amp; Gene Therapy","topics-product":"Cellular \u0026amp; Gene Therapy, Gene Therapy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"10\/10\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/2008-D-0205\u0022\u003E2008-D-0205\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222020-01-31T13:30:03-05:00\u0022\u003E2020-01-31 13:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/long-term-follow-after-administration-human-gene-therapy-products\u0022\u003ELong Term Follow-up After Administration of Human Gene Therapy Products: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/113768\/download\u0022\u003EPDF (508.09 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (508.09 KB) of Long Term Follow-up After Administration of Human Gene Therapy Products: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/28\/2020","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Cellular \u0026amp; Gene Therapy","topics-product":"Cellular \u0026amp; Gene Therapy, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"10\/10\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-2173\u0022\u003EFDA-2018-D-2173\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222020-01-30T14:30:19-05:00\u0022\u003E2020-01-30 14:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/testing-retroviral-vector-based-human-gene-therapy-products-replication-competent-retrovirus-during\u0022\u003ETesting of Retroviral Vector-Based Human Gene Therapy Products for Replication Competent Retrovirus During Product Manufacture and Patient Follow-up: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/113790\/download\u0022\u003EPDF (227.35 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (227.35 KB) of Testing of Retroviral Vector-Based Human Gene Therapy Products for Replication Competent Retrovirus During Product Manufacture and Patient Follow-up: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/28\/2020","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Gene Therapy","field_topics":"Cellular \u0026amp; Gene Therapy","topics-product":"Cellular \u0026amp; Gene Therapy, Gene Therapy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"10\/10\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1999-D-0081\u0022\u003EFDA-1999-D-0081\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222020-01-31T13:25:02-05:00\u0022\u003E2020-01-31 13:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/human-gene-therapy-hemophilia\u0022\u003EHuman Gene Therapy for Hemophilia: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/113799\/download\u0022\u003EPDF (283.85 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (283.85 KB) of Human Gene Therapy for Hemophilia: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/28\/2020","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Gene Therapy","field_topics":"Cellular \u0026amp; Gene Therapy","topics-product":"Cellular \u0026amp; Gene Therapy, Gene Therapy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"10\/18\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA 2018-D-2238\u0022\u003EFDA 2018-D-2238\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222025-01-31T16:16:31-05:00\u0022\u003E2025-01-31 16:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/human-gene-therapy-rare-diseases\u0022\u003EHuman Gene Therapy for Rare Diseases: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/113807\/download\u0022\u003EPDF (240.96 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (240.96 KB) of Human Gene Therapy for Rare Diseases: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/28\/2020","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Gene Therapy, Pediatric Product Development","field_topics":"Cellular \u0026amp; Gene Therapy","topics-product":"Cellular \u0026amp; Gene Therapy, Gene Therapy, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"10\/10\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-2258\u0022\u003EFDA-2018-D-2258\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-04-11T11:03:34-04:00\u0022\u003E2024-04-11 11:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/human-gene-therapy-retinal-disorders\u0022\u003EHuman Gene Therapy for Retinal Disorders: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/124641\/download\u0022\u003EPDF (107.86 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (107.86 KB) of Human Gene Therapy for Retinal Disorders: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/28\/2020","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Gene Therapy, Pediatric Product Development","field_topics":"Cellular \u0026amp; Gene Therapy","topics-product":"Cellular \u0026amp; Gene Therapy, Gene Therapy, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"10\/10\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-2236\u0022\u003EFDA-2018-D-2236\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-04-11T11:03:46-04:00\u0022\u003E2024-04-11 11:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/development-shared-system-rems-guidance-industry\u0022\u003EDevelopment of a Shared System REMS Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/113869\/download\u0022\u003EPDF (98.62 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (98.62 KB) of Development of a Shared System REMS Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/01\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Drug Competition Action Plan, Safety - Issues, Errors, and Problems","field_topics":"","topics-product":"Drug Competition Action Plan, Safety - Issues, Errors, and Problems","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"07\/31\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1041\u0022\u003EFDA-2018-D-1041\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-16T10:05:08-04:00\u0022\u003E2020-04-16 10:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/prescription-drug-user-fee-act-waivers-reductions-and-refunds-drug-and-biological-products-guidance\u0022\u003EPrescription Drug User Fee Act Waivers, Reductions, and Refunds for Drug and Biological Products Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/131797\/download\u0022\u003EPDF (514.8 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (514.8 KB) of Prescription Drug User Fee Act Waivers, Reductions, and Refunds for Drug and Biological Products Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/17\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"User Fees","topics-product":"User Fees, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/2019-22690 \u0022\u003E2019-22690 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222020-05-15T02:20:20-04:00\u0022\u003E2020-05-15 02:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q12-technical-and-regulatory-considerations-pharmaceutical-product-lifecycle-management-annex\u0022\u003EQ12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management Annex\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/148477\/download\u0022\u003EPDF (237.14 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (237.14 KB) of Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management Annex\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/11\/2021","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1609\u0022\u003EFDA-2018-D-1609\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222021-10-28T17:31:09-04:00\u0022\u003E2021-10-28 17:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/formal-meetings-between-fda-and-sponsors-or-applicants-bsufa-products-guidance-industry\u0022\u003EFormal Meetings Between the FDA and Sponsors or Applicants of BsUFA Products Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/113913\/download\u0022\u003EPDF (358.01 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (358.01 KB) of Formal Meetings Between the FDA and Sponsors or Applicants of BsUFA Products Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/18\/2025","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Biosimilars","field_topics":"","topics-product":"Administrative \/ Procedural, Biosimilars","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1922\u0022\u003EFDA-2018-D-1922\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-07-18T08:58:46-04:00\u0022\u003E2025-07-18 08:58\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-246-hazard-analysis-and-risk-based-preventive-controls-food-animals-supply-chain-program\u0022\u003ECVM GFI #246 Hazard Analysis and Risk-Based Preventive Controls for Food for Animals: Supply-Chain Program\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/113923\/download\u0022\u003EPDF (301.2 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (301.2 KB) of CVM GFI #246 Hazard Analysis and Risk-Based Preventive Controls for Food for Animals: Supply-Chain Program\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/15\/2018","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Animal Feed","field_topics":"","topics-product":"Administrative \/ Procedural, Animal Feed","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"12\/12\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1861\u0022\u003EFDA-2018-D-1861\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:41:09-04:00\u0022\u003E2019-04-16 14:41\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/human-immunodeficiency-virus-1-infection-developing-systemic-drug-products-pre-exposure-prophylaxis\u0022\u003EHuman Immunodeficiency Virus-1 Infection: Developing Systemic Drug Products for Pre-Exposure Prophylaxis\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/113940\/download\u0022\u003EPDF (90.91 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (90.91 KB) of Human Immunodeficiency Virus-1 Infection: Developing Systemic Drug Products for Pre-Exposure Prophylaxis\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/18\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1918\u0022\u003EFDA-2018-D-1918\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-10-29T10:06:18-04:00\u0022\u003E2019-10-29 10:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/intravascular-catheters-wires-and-delivery-systems-lubricious-coatings-labeling-considerations\u0022\u003EIntravascular Catheters, Wires, and Delivery Systems with Lubricious Coatings - Labeling Considerations: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/113951\/download\u0022\u003EPDF (371.46 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (371.46 KB) of Intravascular Catheters, Wires, and Delivery Systems with Lubricious Coatings - Labeling Considerations: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/10\/2019","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Premarket Approval (PMA), Labeling, Neurological, Cardiovascular ","field_topics":"","topics-product":"510(k), Premarket Approval (PMA), Labeling, Neurological, Cardiovascular ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1788\u0022\u003EFDA-2018-D-1788\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222019-10-09T08:36:58-04:00\u0022\u003E2019-10-09 08:36\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/coronary-peripheral-and-neurovascular-guidewires-performance-tests-and-recommended-labeling\u0022\u003ECoronary, Peripheral, and Neurovascular Guidewires - Performance Tests and Recommended Labeling: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/113959\/download\u0022\u003EPDF (527.16 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (527.16 KB) of Coronary, Peripheral, and Neurovascular Guidewires - Performance Tests and Recommended Labeling: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/10\/2019","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Cardiovascular , Neurological","field_topics":"Premarket","topics-product":"Premarket, 510(k), Cardiovascular , Neurological","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1775\u0022\u003EFDA-2018-D-1775\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222019-10-09T08:50:02-04:00\u0022\u003E2019-10-09 08:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/logical-observation-identifiers-names-and-codes-in-vitro-diagnostic-tests\u0022\u003ELogical Observation Identifiers Names and Codes for In Vitro Diagnostic Tests : Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/113967\/download\u0022\u003EPDF (322.78 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (322.78 KB) of Logical Observation Identifiers Names and Codes for In Vitro Diagnostic Tests : Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/15\/2018","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Labeling, Laboratory Tests, IVDs (In Vitro Diagnostic Devices), Digital Health","field_topics":"","topics-product":"Labeling, Laboratory Tests, IVDs (In Vitro Diagnostic Devices), Digital Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6982\u0022\u003EFDA-2017-D-6982\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222019-02-09T15:40:35-05:00\u0022\u003E2019-02-09 15:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/major-depressive-disorder-developing-drugs-treatment\u0022\u003EMajor Depressive Disorder: Developing Drugs for Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/113988\/download\u0022\u003EPDF (291.28 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (291.28 KB) of Major Depressive Disorder: Developing Drugs for Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/21\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"09\/20\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1919\u0022\u003EFDA-2018-D-1919\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T10:55:02-04:00\u0022\u003E2020-04-24 10:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/epidermolysis-bullosa-developing-drugs-treatment-cutaneous-manifestations-guidance-industry\u0022\u003EEpidermolysis Bullosa: Developing Drugs for Treatment of Cutaneous Manifestations; Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/128419\/download\u0022\u003EPDF (259.75 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (259.75 KB) of Epidermolysis Bullosa: Developing Drugs for Treatment of Cutaneous Manifestations; Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/28\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-2016\u0022\u003EFDA-2018-D-2016\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-10-25T09:30:16-04:00\u0022\u003E2019-10-25 09:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/requests-feedback-and-meetings-medical-device-submissions-q-submission-program\u0022\u003ERequests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program: - Final Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/114034\/download\u0022\u003EPDF (572.34 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (572.34 KB) of Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program: - Final Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/29\/2025","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Investigational Device Exemption (IDE)","field_topics":"","topics-product":"Administrative \/ Procedural, Investigational Device Exemption (IDE)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1774\u0022\u003EFDA-2018-D-1774\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222025-05-28T10:40:22-04:00\u0022\u003E2025-05-28 10:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/prescription-drug-user-fee-act-waivers-fixed-combination-antiretroviral-drugs-presidents-emergency\u0022\u003EPrescription Drug User Fee Act Waivers for Fixed-Combination Antiretroviral Drugs for the President\u2019s Emergency Plan for AIDS Relief: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/114038\/download\u0022\u003EPDF (331.85 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (331.85 KB) of Prescription Drug User Fee Act Waivers for Fixed-Combination Antiretroviral Drugs for the President\u2019s Emergency Plan for AIDS Relief: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/07\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"User Fees","topics-product":"User Fees, ","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"08\/06\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1635\u0022\u003EFDA-2018-D-1635\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-14T13:22:53-04:00\u0022\u003E2020-04-14 13:22\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-252-small-entity-compliance-guide-antimicrobial-animal-drug-sales-and-distribution-reporting\u0022\u003ECVM GFI #252 Small Entity Compliance Guide Antimicrobial Animal Drug Sales and Distribution Reporting\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/114144\/download\u0022\u003EPDF (34.08 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (34.08 KB) of CVM GFI #252 Small Entity Compliance Guide Antimicrobial Animal Drug Sales and Distribution Reporting\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/29\/2018","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Antimicrobial Resistance","field_topics":"","topics-product":"Administrative \/ Procedural, Antimicrobial Resistance","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-N-0447\u0022\u003EFDA-2012-N-0447\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-04-16T14:40:53-04:00\u0022\u003E2019-04-16 14:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/oncology-therapeutic-radiopharmaceuticals-nonclinical-studies-and-labeling-recommendations-guidance\u0022\u003EOncology Therapeutic Radiopharmaceuticals: Nonclinical Studies and Labeling Recommendations Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/129547\/download\u0022\u003EPDF (167.51 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (167.51 KB) of Oncology Therapeutic Radiopharmaceuticals: Nonclinical Studies and Labeling Recommendations Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/02\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pharmacology\/Toxicology","field_topics":"","topics-product":"Pharmacology\/Toxicology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1772\u0022\u003EFDA-2018-D-1772\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-15T00:55:15-04:00\u0022\u003E2020-05-15 00:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/innovative-approaches-nonprescription-drug-products\u0022\u003EInnovative Approaches for Nonprescription Drug Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/114328\/download\u0022\u003EPDF (246.74 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (246.74 KB) of Innovative Approaches for Nonprescription Drug Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/18\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Over-the-Counter Drugs","field_topics":"","topics-product":"Over-the-Counter Drugs","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"10\/17\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/ FDA-2018-D-2281\u0022\u003E FDA-2018-D-2281\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T14:50:25-04:00\u0022\u003E2020-04-24 14:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/indications-and-usage-section-labeling-human-prescription-drug-and-biological-products-content-and\u0022\u003EIndications and Usage Section of Labeling for Human Prescription Drug and Biological Products \u2014 Content and Format Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/114443\/download\u0022\u003EPDF (480.52 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (480.52 KB) of Indications and Usage Section of Labeling for Human Prescription Drug and Biological Products \u2014 Content and Format Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/06\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"10\/05\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1895\u0022\u003EFDA-2018-D-1895\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-10-18T14:45:20-04:00\u0022\u003E2019-10-18 14:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/field-alert-report-submission-questions-and-answers-guidance-industry\u0022\u003EField Alert Report Submission: Questions and Answers Guidance for Industry: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/114549\/download\u0022\u003EPDF (113.59 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (113.59 KB) of Field Alert Report Submission: Questions and Answers Guidance for Industry: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/22\/2021","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Chemistry, Manufacturing, and Controls (CMC), Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-2326\u0022\u003EFDA-2018-D-2326\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222024-11-05T16:09:09-05:00\u0022\u003E2024-11-05 16:09\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/hypertension-conducting-studies-drugs-treat-patients-background-multiple-antihypertensive-drugs\u0022\u003EHypertension: Conducting Studies of Drugs to Treat Patients on a Background of Multiple Antihypertensive Drugs Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/114731\/download\u0022\u003EPDF (56.96 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (56.96 KB) of Hypertension: Conducting Studies of Drugs to Treat Patients on a Background of Multiple Antihypertensive Drugs Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/13\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"10\/12\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/ FDA-2018-D-2515\u0022\u003E FDA-2018-D-2515\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-10-18T14:50:15-04:00\u0022\u003E2019-10-18 14:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-257-vich-gl57-studies-evaluate-metabolism-and-residue-kinetics-veterinary-drugs-food\u0022\u003ECVM GFI #257 (VICH GL57) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Species: Marker Residue Depletion Studies to Establish Product Withdrawal Periods in Aquatic Species\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/114760\/download\u0022\u003EPDF (152.79 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (152.79 KB) of CVM GFI #257 (VICH GL57) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Species: Marker Residue Depletion Studies to Establish Product Withdrawal Periods in Aquatic Species\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/19\/2019","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Human Food Safety, VICH, Minor Use\/ Minor Species (MUMS)","field_topics":"","topics-product":"Human Food Safety, VICH, Minor Use\/ Minor Species (MUMS)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"09\/24\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-2354\u0022\u003EFDA-2018-D-2354\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-08-16T08:50:23-04:00\u0022\u003E2019-08-16 08:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/inborn-errors-metabolism-use-dietary-management-considerations-optimizing-and-standardizing-diet\u0022\u003EInborn Errors of Metabolism That Use Dietary Management: Considerations for Optimizing and Standardizing Diet in Clinical Trials for Drug Product Development: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/114764\/download\u0022\u003EPDF (248.13 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (248.13 KB) of Inborn Errors of Metabolism That Use Dietary Management: Considerations for Optimizing and Standardizing Diet in Clinical Trials for Drug Product Development: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/12\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Pediatric Product Development","field_topics":"","topics-product":"Clinical - Medical, Pediatric Product Development","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"09\/11\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-2647\u0022\u003EFDA-2018-D-2647\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T11:30:32-04:00\u0022\u003E2024-04-11 11:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommendations-reducing-risk-transfusion-transmitted-babesiosis\u0022\u003ERecommendations for Reducing the Risk of Transfusion-Transmitted Babesiosis: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/114847\/download\u0022\u003EPDF (115.46 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (115.46 KB) of Recommendations for Reducing the Risk of Transfusion-Transmitted Babesiosis: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/09\/2019","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Blood","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-2478\u0022\u003EFDA-2018-D-2478\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222019-05-14T14:45:07-04:00\u0022\u003E2019-05-14 14:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/peripheral-vascular-atherectomy-devices-premarket-notification-510k-submissions\u0022\u003EPeripheral Vascular Atherectomy Devices - Premarket Notification [510(k)] Submissions: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/114852\/download\u0022\u003EPDF (698.62 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (698.62 KB) of Peripheral Vascular Atherectomy Devices - Premarket Notification [510(k)] Submissions: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/20\/2021","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Cardiovascular , Labeling","field_topics":"Premarket","topics-product":"Premarket, 510(k), Cardiovascular , Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-2494\u0022\u003EFDA-2018-D-2494\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222021-05-19T09:00:29-04:00\u0022\u003E2021-05-19 09:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/use-liquids-andor-soft-foods-vehicles-drug-administration-general-considerations-selection-and-vitro\u0022\u003EUse of Liquids and\/or Soft Foods as Vehicles for Drug Administration: General Considerations for Selection and In Vitro Methods for Product Quality Assessments\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/114872\/download\u0022\u003EPDF (410.15 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (410.15 KB) of Use of Liquids and\/or Soft Foods as Vehicles for Drug Administration: General Considerations for Selection and In Vitro Methods for Product Quality Assessments\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/25\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"10\/24\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-2544\u0022\u003EFDA-2018-D-2544\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T08:55:06-04:00\u0022\u003E2020-05-06 08:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/opioid-use-disorder-endpoints-demonstrating-effectiveness-drugs-treatment-guidance-industry\u0022\u003EOpioid Use Disorder: Endpoints for Demonstrating Effectiveness of Drugs for Treatment Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/114948\/download\u0022\u003EPDF (53.23 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (53.23 KB) of Opioid Use Disorder: Endpoints for Demonstrating Effectiveness of Drugs for Treatment Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/01\/2020","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-2382\u0022\u003EFDA-2018-D-2382\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-10-05T09:55:14-04:00\u0022\u003E2020-10-05 09:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/nonclinical-testing-orally-inhaled-nicotine-containing-drug-products-guidance-industry\u0022\u003ENonclinical Testing of Orally Inhaled Nicotine-Containing Drug Products Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/115150\/download\u0022\u003EPDF (117.92 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (117.92 KB) of Nonclinical Testing of Orally Inhaled Nicotine-Containing Drug Products Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/28\/2020","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pharmacology\/Toxicology","field_topics":"","topics-product":"Pharmacology\/Toxicology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-2583\u0022\u003EFDA-2018-D-2583\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-10-28T09:10:02-04:00\u0022\u003E2020-10-28 09:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/expansion-cohorts-use-first-human-clinical-trials-expedite-development-oncology-drugs-and-biologics\u0022\u003EExpansion Cohorts: Use in First-In-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics Guidance for Industry: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/115172\/download\u0022\u003EPDF (146.86 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (146.86 KB) of Expansion Cohorts: Use in First-In-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics Guidance for Industry: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOncology Center of Excellence","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Biosimilars","field_topics":"","topics-product":"Administrative \/ Procedural, Biosimilars","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-2777\u0022\u003EFDA-2018-D-2777\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-03-02T09:01:06-05:00\u0022\u003E2022-03-02 09:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/slowly-progressive-low-prevalence-rare-diseases-substrate-deposition-results-single-enzyme-defects\u0022\u003ESlowly Progressive, Low-Prevalence Rare Diseases with Substrate Deposition That Results from Single Enzyme Defects: Providing Evidence of Effectiveness for Replacement or Corrective Therapies Guidance for Industry: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/136058\/download\u0022\u003EPDF (116.37 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (116.37 KB) of Slowly Progressive, Low-Prevalence Rare Diseases with Substrate Deposition That Results from Single Enzyme Defects: Providing Evidence of Effectiveness for Replacement or Corrective Therapies Guidance for Industry: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/27\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"Rare Diseases","term_node_tid":"Pediatric Product Development","field_topics":"","topics-product":"Rare Diseases, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-2456\u0022\u003EFDA-2018-D-2456\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T11:29:57-04:00\u0022\u003E2024-04-11 11:29\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/process-request-review-fdas-decision-not-issue-certain-export-certificates-devices\u0022\u003EProcess to Request a Review of FDA\u0026#039;s Decision Not to Issue Certain Export Certificates for Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/115432\/download\u0022\u003EPDF (494.44 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (494.44 KB) of Process to Request a Review of FDA\u0026#039;s Decision Not to Issue Certain Export Certificates for Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/03\/2023","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Export, Import","field_topics":"Postmarket","topics-product":"Postmarket, Export, Import","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-2310\u0022\u003EFDA-2018-D-2310\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222023-11-03T09:38:30-04:00\u0022\u003E2023-11-03 09:38\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/consideration-uncertainty-making-benefit-risk-determinations-medical-device-premarket-approvals-de\u0022\u003EConsideration of Uncertainty in Making Benefit-Risk Determinations in Medical Device Premarket Approvals, De Novo Classifications, and Humanitarian Device Exemptions: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/115672\/download\u0022\u003EPDF (510.27 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (510.27 KB) of Consideration of Uncertainty in Making Benefit-Risk Determinations in Medical Device Premarket Approvals, De Novo Classifications, and Humanitarian Device Exemptions: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/30\/2019","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Premarket Approval (PMA), HUD\/HDE","field_topics":"Postmarket","topics-product":"Postmarket, Premarket Approval (PMA), HUD\/HDE","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-3130\u0022\u003EFDA-2018-D-3130\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222019-08-29T08:51:42-04:00\u0022\u003E2019-08-29 08:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/placebos-and-blinding-randomized-controlled-cancer-clinical-trials-drug-and-biological-products\u0022\u003EPlacebos and Blinding in Randomized Controlled Cancer Clinical Trials for Drug and Biological Products Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/130326\/download\u0022\u003EPDF (69.75 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (69.75 KB) of Placebos and Blinding in Randomized Controlled Cancer Clinical Trials for Drug and Biological Products Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/29\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-3092\u0022\u003EFDA-2018-D-3092\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222020-05-15T02:05:05-04:00\u0022\u003E2020-05-15 02:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/use-serological-tests-reduce-risk-transfusion-transmitted-human-t-lymphotropic-virus-types-i-and-ii\u0022\u003EUse of Serological Tests to Reduce the Risk of Transfusion-Transmitted Human T-Lymphotropic Virus Types I and II (HTLV-I\/II): Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/124062\/download\u0022\u003EPDF (781.67 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (781.67 KB) of Use of Serological Tests to Reduce the Risk of Transfusion-Transmitted Human T-Lymphotropic Virus Types I and II (HTLV-I\/II): Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/05\/2020","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-3324\u0022\u003EFDA-2018-D-3324\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222020-02-06T09:40:27-05:00\u0022\u003E2020-02-06 09:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/product-identifiers-under-drug-supply-chain-security-act-questions-and-answers\u0022\u003EProduct Identifiers under the Drug Supply Chain Security Act - Questions and Answers: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/116304\/download\u0022\u003EPDF (216.35 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (216.35 KB) of Product Identifiers under the Drug Supply Chain Security Act - Questions and Answers: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/03\/2021","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-3175\u0022\u003EFDA-2018-D-3175\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222021-06-03T08:55:09-04:00\u0022\u003E2021-06-03 08:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/further-testing-donations-are-reactive-licensed-donor-screening-test-antibodies-hepatitis-c-virus\u0022\u003EFurther Testing of Donations that are Reactive on a Licensed Donor Screening Test for Antibodies to Hepatitis C Virus: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/116353\/download\u0022\u003EPDF (109.92 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (109.92 KB) of Further Testing of Donations that are Reactive on a Licensed Donor Screening Test for Antibodies to Hepatitis C Virus: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/02\/2019","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Blood","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"12\/24\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-3197\u0022\u003EFDA-2018-D-3197\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222020-07-16T08:15:11-04:00\u0022\u003E2020-07-16 08:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/public-availability-lists-retail-consignees-effectuate-certain-human-and-animal-food-recalls\u0022\u003EPublic Availability of Lists of Retail Consignees to Effectuate Certain Human and Animal Food Recalls: Guidance for Industry and FDA Staff \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/116401\/download\u0022\u003EPDF (54.69 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (54.69 KB) of Public Availability of Lists of Retail Consignees to Effectuate Certain Human and Animal Food Recalls: Guidance for Industry and FDA Staff \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/20\/2020","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Retail Food Protection","field_topics":"Recalls","topics-product":"Recalls, Retail Food Protection","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"11\/26\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1752\u0022\u003EFDA-2018-D-1752\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Animal \u0026amp; Veterinary, Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:05:33-04:00\u0022\u003E2024-10-01 07:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/special-510k-program\u0022\u003EThe Special 510(k) Program: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/116418\/download\u0022\u003EPDF (736.16 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (736.16 KB) of The Special 510(k) Program: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/13\/2019","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"510(k), Administrative \/ Procedural","field_topics":"Premarket","topics-product":"Premarket, 510(k), Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-3304\u0022\u003EFDA-2018-D-3304\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222019-09-12T08:36:05-04:00\u0022\u003E2019-09-12 08:36\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/third-series-letters-regarding-implementation-act\u0022\u003EThird of a series of letters regarding the implementation of the Act\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/116580\/download\u0022\u003EPDF (393.27 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (393.27 KB) of Third of a series of letters regarding the implementation of the Act\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/02\/1998","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Generic Drugs","field_topics":"","topics-product":"Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0595\u0022\u003EFDA-2011-D-0595\u003C\/a\u003E","field_communication_type":"Industry Letter","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-03-09T07:20:03-05:00\u0022\u003E2021-03-09 07:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/safety-labeling-changes-implementation-section-505o4-federal-food-drug-and-cosmetic-act\u0022\u003ESafety Labeling Changes -- Implementation of Section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/116594\/download\u0022\u003EPDF (117.89 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (117.89 KB) of Safety Labeling Changes -- Implementation of Section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/30\/2013","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Device \u0026amp; Drug Safety","field_topics":"","topics-product":"Device \u0026amp; Drug Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0164\u0022\u003EFDA-2011-D-0164\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222021-01-26T10:40:18-05:00\u0022\u003E2021-01-26 10:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/toll-free-number-labeling-and-related-requirements-over-counter-and-prescription-drugs-marketed\u0022\u003E\u0026quot;Toll-Free Number Labeling and Related Requirements for Over-the-Counter and Prescription Drugs Marketed With Approved Applications\u0026quot;\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/131807\/download\u0022\u003EPDF (118.75 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (118.75 KB) of \u0026quot;Toll-Free Number Labeling and Related Requirements for Over-the-Counter and Prescription Drugs Marketed With Approved Applications\u0026quot;\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/15\/2012","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-0544\u0022\u003EFDA-2012-D-0544\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-05-04T19:49:43-04:00\u0022\u003E2026-05-04 19:49\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/incorporation-physical-chemical-identifiers-solid-oral-dosage-form-drug-products-anticounterfeiting\u0022\u003EIncorporation of Physical-Chemical Identifiers into Solid Oral Dosage Form Drug Products for Anticounterfeiting: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/116720\/download\u0022\u003EPDF (73.65 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (73.65 KB) of Incorporation of Physical-Chemical Identifiers into Solid Oral Dosage Form Drug Products for Anticounterfeiting: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/11\/2011","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0212\u0022\u003EFDA-2009-D-0212\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T13:30:27-04:00\u0022\u003E2020-04-24 13:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/drug-induced-liver-injury-premarketing-clinical-evaluation\u0022\u003EDrug-Induced Liver Injury: Premarketing Clinical Evaluation\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/116737\/download\u0022\u003EPDF (205.82 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (205.82 KB) of Drug-Induced Liver Injury: Premarketing Clinical Evaluation\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/29\/2009","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Safety - Issues, Errors, and Problems","field_topics":"","topics-product":"Safety - Issues, Errors, and Problems","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0128\u0022\u003EFDA-2008-D-0128\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-10-17T11:35:14-04:00\u0022\u003E2019-10-17 11:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/oversight-clinical-investigations-risk-based-approach-monitoring\u0022\u003EOversight of Clinical Investigations \u2014 A Risk-Based Approach to Monitoring: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/116754\/download\u0022\u003EPDF (382.77 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (382.77 KB) of Oversight of Clinical Investigations \u2014 A Risk-Based Approach to Monitoring: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/07\/2013","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Good Clinical Practice (GCP)","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Administrative \/ Procedural, Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0597\u0022\u003EFDA-2011-D-0597\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222024-11-14T16:25:40-05:00\u0022\u003E2024-11-14 16:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/use-electronic-informed-consent-clinical-investigations-questions-and-answers\u0022\u003EUse of Electronic Informed Consent in Clinical Investigations \u2013 Questions and Answers: Guidance for Institutional Review Boards, Investigators, and Sponsors\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/116850\/download\u0022\u003EPDF (230.82 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (230.82 KB) of Use of Electronic Informed Consent in Clinical Investigations \u2013 Questions and Answers: Guidance for Institutional Review Boards, Investigators, and Sponsors\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/15\/2016","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-0390\u0022\u003EFDA-2015-D-0390\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222021-01-26T09:50:06-05:00\u0022\u003E2021-01-26 09:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clinical-trial-endpoints-approval-non-small-cell-lung-cancer-drugs-and-biologics\u0022\u003EClinical Trial Endpoints for the Approval of Non-Small Cell Lung Cancer Drugs and Biologics\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/116860\/download\u0022\u003EPDF (343 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (343 KB) of Clinical Trial Endpoints for the Approval of Non-Small Cell Lung Cancer Drugs and Biologics\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/22\/2015","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0432\u0022\u003EFDA-2011-D-0432\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-07T14:55:33-04:00\u0022\u003E2020-05-07 14:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/acceptance-review-de-novo-classification-requests\u0022\u003EAcceptance Review for De Novo Classification Requests: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/152657\/download\u0022\u003EPDF (893.39 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (893.39 KB) of Acceptance Review for De Novo Classification Requests: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/05\/2021","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6069\u0022\u003EFDA-2017-D-6069\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222022-02-18T17:00:25-05:00\u0022\u003E2022-02-18 17:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/gluten-drug-products-and-associated-labeling-recommendations-draft-guidance-industry\u0022\u003EGluten in Drug Products and Associated Labeling Recommendations; Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/116958\/download\u0022\u003EPDF (135.93 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (135.93 KB) of Gluten in Drug Products and Associated Labeling Recommendations; Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/12\/2017","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"03\/12\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6352\u0022\u003EFDA-2017-D-6352\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-22T09:40:29-04:00\u0022\u003E2020-04-22 09:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/rare-diseases-early-drug-development-and-role-pre-ind-meetings\u0022\u003ERare Diseases: Early Drug Development and the Role of Pre-IND Meetings : Draft Guidance for Industry \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/117322\/download\u0022\u003EPDF (131.81 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (131.81 KB) of Rare Diseases: Early Drug Development and the Role of Pre-IND Meetings : Draft Guidance for Industry \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/16\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"Rare Diseases","term_node_tid":"Pediatric Product Development","field_topics":"","topics-product":"Rare Diseases, Pediatric Product Development","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"12\/17\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-3268\u0022\u003EFDA-2018-D-3268\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T11:28:56-04:00\u0022\u003E2024-04-11 11:28\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/statement-policy-foods-derived-new-plant-varieties\u0022\u003EStatement of Policy - Foods Derived from New Plant Varieties\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"05\/29\/1992","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Bioengineering \/ GMOs","field_topics":"","topics-product":"Bioengineering \/ GMOs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:05:35-04:00\u0022\u003E2024-10-01 07:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/considerations-development-dried-plasma-products-intended-transfusion\u0022\u003EConsiderations for the Development of Dried Plasma Products Intended for Transfusion: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/124148\/download\u0022\u003EPDF (119.37 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (119.37 KB) of Considerations for the Development of Dried Plasma Products Intended for Transfusion: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/19\/2019","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Blood","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"01\/28\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-3759\u0022\u003EFDA-2018-D-3759\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222019-12-20T16:29:04-05:00\u0022\u003E2019-12-20 16:29\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-entity-compliance-guide-declaration-name-label-all-foods-and-cosmetic-products-contain\u0022\u003ESmall Entity Compliance Guide: Declaration by Name on the Label of All Foods and Cosmetic Products that Contain Cochineal Extract and Carmine\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"04\/30\/2009","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives, Labeling","field_topics":"","topics-product":"Food \u0026amp; Color Additives, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0198\u0022\u003EFDA-2009-D-0198\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Human Foods Program","field_regulated_product_field":"Cosmetics, Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:05:35-04:00\u0022\u003E2024-10-01 07:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-colored-sea-salt\u0022\u003EGuidance for Industry: Colored Sea Salt\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/94036\/download\u0022\u003EPDF (173.3 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (173.3 KB) of Guidance for Industry: Colored Sea Salt\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/01\/2015","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:05:37-04:00\u0022\u003E2024-10-01 07:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-color-additive-petitions-fda-recommendations-submission-chemical-and-technological\u0022\u003EGuidance for Industry: Color Additive Petitions - FDA Recommendations for Submission of Chemical and Technological Data on Color Additives for Food, Drugs, Cosmetics, or Medical Devices\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/01\/2009","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Cosmetics, Drugs, Food \u0026amp; Beverages, Medical Devices","changed":"\u003Ctime datetime=\u00222024-10-01T07:05:37-04:00\u0022\u003E2024-10-01 07:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-preparing-color-additive-petition-submission-center-food-safety-and-applied\u0022\u003EGuidance for Industry: Preparing a Color Additive Petition for Submission to the Center for Food Safety and Applied Nutrition for Color Additives Used in or on Contact Lenses\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"05\/01\/2006","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives","field_topics":"","topics-product":"Food \u0026amp; Color Additives","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages, Medical Devices","changed":"\u003Ctime datetime=\u00222024-10-01T07:05:39-04:00\u0022\u003E2024-10-01 07:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-serving-sizes-foods-can-reasonably-be-consumed-one-eating-occasion-reference\u0022\u003EGuidance for Industry: Serving Sizes of Foods That Can Reasonably Be Consumed At One Eating Occasion, Reference Amounts Customarily Consumed, Serving Size-Related Issues, Dual-Column Labeling, and Miscellaneous Topics\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/133699\/download\u0022\u003EPDF (327.33 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (327.33 KB) of Guidance for Industry: Serving Sizes of Foods That Can Reasonably Be Consumed At One Eating Occasion, Reference Amounts Customarily Consumed, Serving Size-Related Issues, Dual-Column Labeling, and Miscellaneous Topics\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/30\/2019","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling, Nutrition Label","field_topics":"","topics-product":"Labeling, Nutrition Label","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1459\u0022\u003EFDA-2018-D-1459\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-10T16:26:16-04:00\u0022\u003E2025-03-10 16:26\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-questions-and-answers-haccp-regulation-fish-and-fishery-products\u0022\u003EGuidance for Industry: Questions and Answers on HACCP Regulation for Fish and Fishery Products\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"01\/01\/1999","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"HACCP, Seafood\/Seafood Product","field_topics":"","topics-product":"HACCP, Seafood\/Seafood Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1960\u0022\u003EFDA-2020-D-1960\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:05:41-04:00\u0022\u003E2024-10-01 07:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-bulk-transport-juice-concentrates-and-certain-shelf-stable-juices\u0022\u003EGuidance for Industry: Bulk Transport of Juice Concentrates and Certain Shelf-Stable Juices\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"04\/24\/2003","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Juice, Transportation","field_topics":"","topics-product":"Juice, Transportation","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2002-P-0302\u0022\u003EFDA-2002-P-0302\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:05:41-04:00\u0022\u003E2024-10-01 07:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-entity-compliance-guide-juice-haccp\u0022\u003ESmall Entity Compliance Guide: Juice HACCP\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"04\/04\/2003","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"HACCP, Juice","field_topics":"","topics-product":"HACCP, Juice","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2003-D-0283\u0022\u003EFDA-2003-D-0283\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:05:43-04:00\u0022\u003E2024-10-01 07:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-prior-notice-imported-food-contingency-plan-system-outages\u0022\u003EGuidance for Industry: Prior Notice of Imported Food Contingency Plan for System Outages\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/143799\/download\u0022\u003EPDF (84.82 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (84.82 KB) of Guidance for Industry: Prior Notice of Imported Food Contingency Plan for System Outages\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/01\/2020","field_issuing_office_taxonomy":"Office of Inspections and Investigations","field_health_topics":"","term_node_tid":"Import","field_topics":"","topics-product":"Import","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-D-0042\u0022\u003EFDA-2004-D-0042\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-07T09:39:07-05:00\u0022\u003E2025-03-07 09:39\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-guide-minimize-biological-hazards-ready-eat-fresh-cut-produce\u0022\u003EGuidance for Industry: Guide to Minimize Biological Hazards in Ready-to-Eat Fresh-Cut Produce\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/117526\/download\u0022\u003EPDF (762.01 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (762.01 KB) of Guidance for Industry: Guide to Minimize Biological Hazards in Ready-to-Eat Fresh-Cut Produce\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/11\/2026","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Fruit\/Fruit Product , Vegetable Products","field_topics":"","topics-product":"Fruit\/Fruit Product , Vegetable Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-3583\u0022\u003EFDA-2018-D-3583\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222026-08-11T09:29:52-04:00\u0022\u003E2026-08-11 09:29\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/assessing-irritation-and-sensitization-potential-transdermal-and-topical-delivery-systems-andas\u0022\u003EAssessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/167073\/download\u0022\u003EPDF (254.89 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (254.89 KB) of Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/31\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Drug Competition Action Plan, Generic Drugs","field_topics":"","topics-product":"Drug Competition Action Plan, Generic Drugs","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"10\/02\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-3546\u0022\u003EFDA-2018-D-3546\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-08-03T09:52:32-04:00\u0022\u003E2026-08-03 09:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/atopic-dermatitis-timing-pediatric-studies-during-development-systemic-drugs\u0022\u003EAtopic Dermatitis: Timing of Pediatric Studies During Development of Systemic Drugs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/117570\/download\u0022\u003EPDF (70.95 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (70.95 KB) of Atopic Dermatitis: Timing of Pediatric Studies During Development of Systemic Drugs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/03\/2018","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Pediatric Product Development","field_topics":"","topics-product":"Clinical - Medical, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1175\u0022\u003EFDA-2018-D-1175\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T09:34:01-04:00\u0022\u003E2024-04-11 09:34\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-business-nutrition-labeling-exemption-guidance\u0022\u003ESmall Business Nutrition Labeling Exemption Guidance\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"05\/07\/2007","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:01:05-04:00\u0022\u003E2024-10-01 07:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-what-you-need-know-about-prior-notice-imported-food-shipments\u0022\u003EGuidance for Industry: What You Need to Know About Prior Notice of Imported Food Shipments\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/15\/2011","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Import","field_topics":"","topics-product":"Import","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-N-0179\u0022\u003EFDA-2011-N-0179\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-12-05T17:22:46-05:00\u0022\u003E2024-12-05 17:22\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/nonmetastatic-castration-resistant-prostate-cancer-considerations-metastasis-free-survival-endpoint\u0022\u003ENonmetastatic Castration-Resistant Prostate Cancer: Considerations for Metastasis-Free Survival Endpoint in Clinical Trials\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/117792\/download\u0022\u003EPDF (73.73 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (73.73 KB) of Nonmetastatic Castration-Resistant Prostate Cancer: Considerations for Metastasis-Free Survival Endpoint in Clinical Trials\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/06\/2021","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-3931\u0022\u003EFDA-2018-D-3931\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-08-06T08:51:03-04:00\u0022\u003E2021-08-06 08:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-labeling-cosmetics-containing-alpha-hydroxy-acids\u0022\u003EGuidance for Industry: Labeling for Cosmetics Containing Alpha Hydroxy Acids\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"01\/10\/2005","field_issuing_office_taxonomy":"Office of the Commissioner,Office of the Chief Scientist","field_health_topics":"","term_node_tid":"Ingredients, Labeling","field_topics":"","topics-product":"Ingredients, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2000-P-0063\u0022\u003EFDA-2000-P-0063\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Cosmetics","changed":"\u003Ctime datetime=\u00222024-08-23T12:40:32-04:00\u0022\u003E2024-08-23 12:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-safety-nanomaterials-cosmetic-products\u0022\u003EGuidance for Industry: Safety of Nanomaterials in Cosmetic Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/83957\/download\u0022\u003EPDF (130.65 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (130.65 KB) of Guidance for Industry: Safety of Nanomaterials in Cosmetic Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/24\/2014","field_issuing_office_taxonomy":"Office of the Commissioner,Office of the Chief Scientist","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0489\u0022\u003EFDA-2011-D-0489\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Cosmetics","changed":"\u003Ctime datetime=\u00222024-10-01T14:30:32-04:00\u0022\u003E2024-10-01 14:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/draft-guidance-industry-cosmetic-good-manufacturing-practices\u0022\u003EDraft Guidance for Industry: Cosmetic Good Manufacturing Practices\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/86366\/download\u0022\u003EPDF (77.92 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (77.92 KB) of Draft Guidance for Industry: Cosmetic Good Manufacturing Practices\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/01\/2013","field_issuing_office_taxonomy":"Office of the Commissioner,Office of the Chief Scientist","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP)","field_topics":"","topics-product":"Current Good Manufacturing Practice (CGMP)","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Cosmetics","changed":"\u003Ctime datetime=\u00222024-09-04T16:58:32-04:00\u0022\u003E2024-09-04 16:58\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/draft-guidance-industry-lead-cosmetic-lip-products-and-externally-applied-cosmetics-recommended\u0022\u003EDraft Guidance for Industry: Lead in Cosmetic Lip Products and Externally Applied Cosmetics: Recommended Maximum Level\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/99866\/download\u0022\u003EPDF (115.52 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (115.52 KB) of Draft Guidance for Industry: Lead in Cosmetic Lip Products and Externally Applied Cosmetics: Recommended Maximum Level\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/22\/2016","field_issuing_office_taxonomy":"Office of the Commissioner,Office of the Chief Scientist","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"02\/21\/2017","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-2275\u0022\u003EFDA-2014-D-2275\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Cosmetics","changed":"\u003Ctime datetime=\u00222024-09-04T16:59:46-04:00\u0022\u003E2024-09-04 16:59\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/selection-appropriate-package-type-terms-and-recommendations-labeling-injectable-medical-products\u0022\u003ESelection of the Appropriate Package Type Terms and Recommendations for Labeling Injectable Medical Products Packaged in Multiple-Dose, Single-Dose, and Single-Patient-Use Containers for Human Use: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/117883\/download\u0022\u003EPDF (166.88 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (166.88 KB) of Selection of the Appropriate Package Type Terms and Recommendations for Labeling Injectable Medical Products Packaged in Multiple-Dose, Single-Dose, and Single-Patient-Use Containers for Human Use: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/03\/2018","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Combination Products, Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Combination Products, Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-3438\u0022\u003EFDA-2015-D-3438\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222019-05-31T11:32:26-04:00\u0022\u003E2019-05-31 11:32\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/citizen-petitions-and-petitions-stay-action-subject-section-505q-federal-food-drug-and-cosmetic-act\u0022\u003ECitizen Petitions and Petitions for Stay of Action Subject to Section 505(q) of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/130878\/download\u0022\u003EPDF (364.83 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (364.83 KB) of Citizen Petitions and Petitions for Stay of Action Subject to Section 505(q) of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/19\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Drug Competition Action Plan","field_topics":"","topics-product":"Administrative \/ Procedural, Drug Competition Action Plan","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0008\u0022\u003EFDA-2009-D-0008\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-07T14:35:19-04:00\u0022\u003E2020-05-07 14:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/testicular-toxicity-evaluation-during-drug-development\u0022\u003ETesticular Toxicity: Evaluation During Drug Development\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/117948\/download\u0022\u003EPDF (180.41 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (180.41 KB) of Testicular Toxicity: Evaluation During Drug Development\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/25\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Pharmacology\/Toxicology","field_topics":"","topics-product":"Clinical - Medical, Pharmacology\/Toxicology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-2306\u0022\u003EFDA-2015-D-2306\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-05T14:20:07-04:00\u0022\u003E2020-05-05 14:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/verification-systems-under-drug-supply-chain-security-act-certain-prescription-drugs\u0022\u003EVerification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/117950\/download\u0022\u003EPDF (354.14 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (354.14 KB) of Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/07\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research,Office of Regulatory Policy","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-3462\u0022\u003EFDA-2018-D-3462\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222023-12-07T14:02:31-05:00\u0022\u003E2023-12-07 14:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/m9-biopharmaceutics-classification-system-based-biowaivers\u0022\u003EM9 Biopharmaceutics Classification System-Based Biowaivers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/148472\/download\u0022\u003EPDF (288.16 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (288.16 KB) of M9 Biopharmaceutics Classification System-Based Biowaivers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/11\/2021","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Multidisciplinary","field_topics":"","topics-product":"ICH-Multidisciplinary","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-3614\u0022\u003EFDA-2018-D-3614\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-05-02T17:23:34-04:00\u0022\u003E2023-05-02 17:23\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/hypertension-developing-fixed-dose-combination-drugs-treatment\u0022\u003EHypertension: Developing Fixed-Dose Combination Drugs for Treatment \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/117975\/download\u0022\u003EPDF (95.73 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (95.73 KB) of Hypertension: Developing Fixed-Dose Combination Drugs for Treatment \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/07\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"01\/26\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-3860\u0022\u003EFDA-2018-D-3860\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-05-08T14:25:08-04:00\u0022\u003E2019-05-08 14:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/meta-analyses-randomized-controlled-clinical-trials-evaluate-safety-human-drugs-or-biological\u0022\u003EMeta-Analyses of Randomized Controlled Clinical Trials to Evaluate the Safety of Human Drugs or Biological Products \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/117976\/download\u0022\u003EPDF (227.44 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (227.44 KB) of Meta-Analyses of Randomized Controlled Clinical Trials to Evaluate the Safety of Human Drugs or Biological Products \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/07\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Device \u0026amp; Drug Safety","field_topics":"","topics-product":"Clinical - Medical, Device \u0026amp; Drug Safety","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"01\/07\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-3710\u0022\u003EFDA-2018-D-3710\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-27T07:55:06-04:00\u0022\u003E2020-04-27 07:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/chronic-hepatitis-b-virus-infection-developing-drugs-treatment\u0022\u003EChronic Hepatitis B Virus Infection: Developing Drugs for Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/117977\/download\u0022\u003EPDF (464.57 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (464.57 KB) of Chronic Hepatitis B Virus Infection: Developing Drugs for Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/07\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-3903\u0022\u003EFDA-2018-D-3903\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-10-27T10:52:21-04:00\u0022\u003E2022-10-27 10:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/draft-guidance-industry-standards-growing-harvesting-packing-and-holding-produce-human-consumption\u0022\u003EDraft Guidance for Industry: Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/117414\/download\u0022\u003EPDF (1.72 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.72 MB) of Draft Guidance for Industry: Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/22\/2018","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Fruit\/Fruit Product , Vegetable Products","field_topics":"","topics-product":"Fruit\/Fruit Product , Vegetable Products","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"04\/22\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-3631\u0022\u003EFDA-2018-D-3631\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:05:46-04:00\u0022\u003E2024-10-01 07:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/noncirrhotic-nonalcoholic-steatohepatitis-liver-fibrosis-developing-drugs-treatment\u0022\u003ENoncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/119044\/download\u0022\u003EPDF (97.63 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (97.63 KB) of Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/04\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"02\/04\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-3632\u0022\u003EFDA-2018-D-3632\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-14T12:50:25-04:00\u0022\u003E2020-05-14 12:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/post-complete-response-letter-clarification-teleconferences-between-fda-and-anda-applicants-under\u0022\u003EPost-Complete Response Letter Clarification Teleconferences Between FDA and ANDA Applicants Under GDUFA Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/108337\/download\u0022\u003EPDF (321.03 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (321.03 KB) of Post-Complete Response Letter Clarification Teleconferences Between FDA and ANDA Applicants Under GDUFA Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/05\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Generic Drugs","field_topics":"User Fees","topics-product":"User Fees, Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-5928\u0022\u003EFDA-2017-D-5928\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-01-11T16:31:46-05:00\u0022\u003E2023-01-11 16:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/current-good-manufacturing-practice-guidance-human-drug-compounding-outsourcing-facilities-under\u0022\u003ECurrent Good Manufacturing Practice\u2014Guidance for Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD\u0026amp;C Act Guidance for Industry: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/88905\/download\u0022\u003EPDF (484.69 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (484.69 KB) of Current Good Manufacturing Practice\u2014Guidance for Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD\u0026amp;C Act Guidance for Industry: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/22\/2020","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Compounding, Pharmaceutical Quality, Current Good Manufacturing Practice (CGMP)","field_topics":"","topics-product":"Compounding, Pharmaceutical Quality, Current Good Manufacturing Practice (CGMP)","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"02\/11\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0779\u0022\u003EFDA-2014-D-0779\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-05-04T19:50:41-04:00\u0022\u003E2026-05-04 19:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/questions-and-answers-biosimilar-development-and-bpci-act\u0022\u003EQuestions and Answers on Biosimilar Development and the BPCI Act: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/119258\/download\u0022\u003EPDF (335.66 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (335.66 KB) of Questions and Answers on Biosimilar Development and the BPCI Act: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/09\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Biosimilars","field_topics":"","topics-product":"Biosimilars","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0611\u0022\u003EFDA-2011-D-0611\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-10-09T09:20:32-04:00\u0022\u003E2026-10-09 09:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/data-integrity-and-compliance-drug-cgmp-questions-and-answers\u0022\u003EData Integrity and Compliance With Drug CGMP: Questions and Answers: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/119267\/download\u0022\u003EPDF (127.11 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (127.11 KB) of Data Integrity and Compliance With Drug CGMP: Questions and Answers: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/13\/2018","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research,Office of Regulatory Policy","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_topics":"","topics-product":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-3984\u0022\u003EFDA-2018-D-3984\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-12-28T07:28:31-05:00\u0022\u003E2022-12-28 07:28\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/biomarker-qualification-evidentiary-framework\u0022\u003EBiomarker Qualification: Evidentiary Framework: Draft Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/122319\/download\u0022\u003EPDF (346.05 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (346.05 KB) of Biomarker Qualification: Evidentiary Framework: Draft Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/12\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Drug Development Tools","field_topics":"","topics-product":"Drug Development Tools","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"02\/11\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-4267\u0022\u003EFDA-2018-D-4267\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-07T11:35:08-04:00\u0022\u003E2020-05-07 11:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/deemed-be-license-provision-bpci-act-questions-and-answers\u0022\u003EThe \u201cDeemed to be a License\u201d Provision of the BPCI Act: Questions and Answers : Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/135838\/download\u0022\u003EPDF (319.91 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (319.91 KB) of The \u201cDeemed to be a License\u201d Provision of the BPCI Act: Questions and Answers : Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/04\/2020","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research,Office of Regulatory Policy\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-4750. \u0022\u003EFDA-2015-D-4750. \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222020-03-04T09:00:38-05:00\u0022\u003E2020-03-04 09:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/interpretation-deemed-be-license-provision-biologics-price-competition-and-innovation-act-2009\u0022\u003EInterpretation of the \u201cDeemed to be a License\u201d Provision of the Biologics Price Competition and Innovation Act of 2009 : Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/119272\/download\u0022\u003EPDF (410.32 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (410.32 KB) of Interpretation of the \u201cDeemed to be a License\u201d Provision of the Biologics Price Competition and Innovation Act of 2009 : Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/12\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-4750\u0022\u003EFDA-2015-D-4750\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T01:05:59-04:00\u0022\u003E2020-04-24 01:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/new-and-revised-draft-qas-biosimilar-development-and-bpci-act-revision-4\u0022\u003ENew and Revised Draft Q\u0026amp;As on Biosimilar Development and the BPCI Act (Revision 4): Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/119278\/download\u0022\u003EPDF (306.95 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (306.95 KB) of New and Revised Draft Q\u0026amp;As on Biosimilar Development and the BPCI Act (Revision 4): Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/09\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Biosimilars","field_topics":"","topics-product":"Biosimilars","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0611\u0022\u003EFDA-2011-D-0611\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-04-08T16:16:46-04:00\u0022\u003E2026-04-08 16:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/principles-premarket-pathways-combination-products\u0022\u003EPrinciples of Premarket Pathways for Combination Products: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/119958\/download\u0022\u003EPDF (397.22 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (397.22 KB) of Principles of Premarket Pathways for Combination Products: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/26\/2022","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products","field_health_topics":"","term_node_tid":"Combination Products","field_topics":"","topics-product":"Combination Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"05\/07\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-0078\u0022\u003EFDA-2019-D-0078\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222022-01-28T12:21:04-05:00\u0022\u003E2022-01-28 12:21\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/addressing-misinformation-about-medical-devices-and-prescription-drugs-questions-and-answers\u0022\u003EAddressing Misinformation About Medical Devices and Prescription Drugs: Questions and Answers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/179827\/download\u0022\u003EPDF (374.75 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (374.75 KB) of Addressing Misinformation About Medical Devices and Prescription Drugs: Questions and Answers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/08\/2024","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Advertising","field_topics":"","topics-product":"Advertising","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0447\u0022\u003EFDA-2014-D-0447\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-07-08T09:53:01-04:00\u0022\u003E2024-07-08 09:53\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clarification-radiation-control-regulations-manufacturers-diagnostic-x-ray-equipment\u0022\u003EClarification of Radiation Control Regulations For Manufacturers of Diagnostic X-Ray Equipment: Guidance for Industry and Food and Drug Administration Staff \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/119827\/download\u0022\u003EPDF (922.48 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (922.48 KB) of Clarification of Radiation Control Regulations For Manufacturers of Diagnostic X-Ray Equipment: Guidance for Industry and Food and Drug Administration Staff \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/27\/2024","field_issuing_office_taxonomy":"Center for Devices and Radiological Health,Office of Product Evaluation and Quality,Office of In Vitro Diagnostics and Radiological Health","field_health_topics":"","term_node_tid":"Export, Import, Labeling, Radiology","field_topics":"","topics-product":"Export, Import, Labeling, Radiology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-4115\u0022\u003EFDA-2018-D-4115\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222024-09-27T09:02:31-04:00\u0022\u003E2024-09-27 09:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/opioid-use-disorder-developing-depot-buprenorphine-products-treatment\u0022\u003EOpioid Use Disorder: Developing Depot Buprenorphine Products for Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/120090\/download\u0022\u003EPDF (262.09 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (262.09 KB) of Opioid Use Disorder: Developing Depot Buprenorphine Products for Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/07\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1334\u0022\u003EFDA-2018-D-1334\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-01-17T08:45:23-05:00\u0022\u003E2020-01-17 08:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/fulfilling-regulatory-requirements-postmarketing-submissions-interactive-promotional-media\u0022\u003EFulfilling Regulatory Requirements for Postmarketing Submissions of Interactive Promotional Media for Prescription Human and Animal Drugs and Biologics\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/87685\/download\u0022\u003EPDF (117.65 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (117.65 KB) of Fulfilling Regulatory Requirements for Postmarketing Submissions of Interactive Promotional Media for Prescription Human and Animal Drugs and Biologics\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/14\/2014","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Antimicrobial Resistance","field_topics":"","topics-product":"Antimicrobial Resistance","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-N-1430\u0022\u003EFDA-2013-N-1430\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-02-08T21:48:45-05:00\u0022\u003E2019-02-08 21:48\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-259-vich-gl58-stability-testing-new-veterinary-drug-substances-and-medicinal-products\u0022\u003ECVM GFI #259 (VICH GL58) Stability Testing of New Veterinary Drug Substances and Medicinal Products in Climatic Zones III and IV\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/119840\/download\u0022\u003EPDF (200.75 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (200.75 KB) of CVM GFI #259 (VICH GL58) Stability Testing of New Veterinary Drug Substances and Medicinal Products in Climatic Zones III and IV\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/14\/2020","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), VICH","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), VICH","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"02\/26\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-4662\u0022\u003EFDA-2018-D-4662\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222020-04-13T08:55:21-04:00\u0022\u003E2020-04-13 08:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/internetsocial-media-platforms-character-space-limitations-presenting-risk-and-benefit-information\u0022\u003EInternet\/Social Media Platforms with Character Space Limitations\u2014 Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"06\/18\/2014","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Advertising","field_topics":"","topics-product":"Advertising","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0397\u0022\u003EFDA-2014-D-0397\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-02-08T21:49:43-05:00\u0022\u003E2019-02-08 21:49\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/planning-effects-high-absenteeism-ensure-availability-medically-necessary-drug-products-0\u0022\u003EPlanning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/120092\/download\u0022\u003EPDF (234.89 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (234.89 KB) of Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/15\/2011","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"05\/31\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0568\u0022\u003EFDA-2009-D-0568\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-10-27T08:45:04-04:00\u0022\u003E2022-10-27 08:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/blood-glucose-monitoring-test-systems-prescription-point-care-use\u0022\u003EBlood Glucose Monitoring Test Systems for Prescription Point-of-Care Use: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/119829\/download\u0022\u003EPDF (899.61 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (899.61 KB) of Blood Glucose Monitoring Test Systems for Prescription Point-of-Care Use: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/29\/2020","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"CLIA (Clinical Laboratory Improvement Amendments), IVDs (In Vitro Diagnostic Devices), General Hospital \u0026amp; Personal Use , Clinical Chemistry \u0026amp; Clinical Toxicology ","field_topics":"Premarket","topics-product":"Premarket, CLIA (Clinical Laboratory Improvement Amendments), IVDs (In Vitro Diagnostic Devices), General Hospital \u0026amp; Personal Use , Clinical Chemistry \u0026amp; Clinical Toxicology ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-1445\u0022\u003EFDA-2013-D-1445\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222021-01-26T10:40:11-05:00\u0022\u003E2021-01-26 10:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/presenting-risk-information-prescription-drug-and-medical-device-promotion\u0022\u003EPresenting Risk Information in Prescription Drug and Medical Device Promotion\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/76269\/download\u0022\u003EPDF (932.59 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (932.59 KB) of Presenting Risk Information in Prescription Drug and Medical Device Promotion\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/27\/2009","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Advertising","field_topics":"","topics-product":"Advertising","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0253\u0022\u003EFDA-2008-D-0253\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-02-08T21:51:44-05:00\u0022\u003E2019-02-08 21:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/marketing-status-notifications-under-section-506i-federal-food-drug-and-cosmetic-act\u0022\u003EMarketing Status Notifications Under Section 506I of the Federal Food, Drug, and Cosmetic Act\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/120095\/download\u0022\u003EPDF (84.56 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (84.56 KB) of Marketing Status Notifications Under Section 506I of the Federal Food, Drug, and Cosmetic Act\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/10\/2020","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-4615\u0022\u003EFDA-2018-D-4615\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-08-10T10:55:49-04:00\u0022\u003E2020-08-10 10:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/eosinophilic-esophagitis-developing-drugs-treatment-guidance-industry\u0022\u003EEosinophilic Esophagitis: Developing Drugs for Treatment Guidance for Industry \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/120089\/download\u0022\u003EPDF (271.07 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (271.07 KB) of Eosinophilic Esophagitis: Developing Drugs for Treatment Guidance for Industry \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/15\/2020","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Pediatric Product Development","field_topics":"","topics-product":"Clinical - Medical, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-0177\u0022\u003EFDA-2019-D-0177\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T11:04:22-04:00\u0022\u003E2024-04-11 11:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/nonclinical-safety-evaluation-pediatric-drug-products\u0022\u003ENonclinical Safety Evaluation of Pediatric Drug Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/119658\/download\u0022\u003EPDF (478.84 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (478.84 KB) of Nonclinical Safety Evaluation of Pediatric Drug Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/15\/2006","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pediatric Product Development, Pharmacology\/Toxicology","field_topics":"","topics-product":"Pediatric Product Development, Pharmacology\/Toxicology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/2003D-0001\u0022\u003E2003D-0001\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T09:31:01-04:00\u0022\u003E2024-04-11 09:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/industry-supported-scientific-and-educational-activites\u0022\u003EIndustry-Supported Scientific and Educational Activites\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70844\/download\u0022\u003EPDF (428.5 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (428.5 KB) of Industry-Supported Scientific and Educational Activites\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/03\/1997","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Policy, Legislation, and International Affairs,Office of Policy","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Advertising","field_topics":"","topics-product":"Administrative \/ Procedural, Advertising","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/92N-0434\u0022\u003E92N-0434\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222019-04-17T12:40:16-04:00\u0022\u003E2019-04-17 12:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/nonclinical-safety-evaluation-drug-or-biologic-combinations\u0022\u003ENonclinical Safety Evaluation of Drug or Biologic Combinations\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/119657\/download\u0022\u003EPDF (99.71 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (99.71 KB) of Nonclinical Safety Evaluation of Drug or Biologic Combinations\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/15\/2006","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pharmacology\/Toxicology","field_topics":"","topics-product":"Pharmacology\/Toxicology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/2005D-0004\u0022\u003E2005D-0004\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-02-08T22:19:03-05:00\u0022\u003E2019-02-08 22:19\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/brief-summary-and-adequate-directions-use-disclosing-risk-information-consumer-directed-print\u0022\u003EBrief Summary and Adequate Directions for Use: Disclosing Risk Information in Consumer-Directed Print Advertisements and Promotional Labeling for Prescription Drugs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70768\/download\u0022\u003EPDF (303.33 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (303.33 KB) of Brief Summary and Adequate Directions for Use: Disclosing Risk Information in Consumer-Directed Print Advertisements and Promotional Labeling for Prescription Drugs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/06\/2015","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research,Office of Regulatory Policy\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Advertising","field_topics":"","topics-product":"Advertising","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"10\/05\/2015","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-D-0500\u0022\u003EFDA-2004-D-0500\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-02-08T22:18:10-05:00\u0022\u003E2019-02-08 22:18\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/nonbinding-feedback-after-certain-fda-inspections-device-establishments\u0022\u003ENonbinding Feedback After Certain FDA Inspections of Device Establishments: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/120260\/download\u0022\u003EPDF (338.73 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (338.73 KB) of Nonbinding Feedback After Certain FDA Inspections of Device Establishments: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/22\/2020","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Postmarket","topics-product":"Postmarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"04\/20\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-4711\u0022\u003EFDA-2018-D-4711\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-04-21T08:30:12-04:00\u0022\u003E2020-04-21 08:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/developing-and-labeling-in-vitro-companion-diagnostic-devices-specific-group-oncology-therapeutic\u0022\u003EDeveloping and Labeling In vitro Companion Diagnostic Devices for a Specific Group of Oncology Therapeutic Products: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/120340\/download\u0022\u003EPDF (323.18 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (323.18 KB) of Developing and Labeling In vitro Companion Diagnostic Devices for a Specific Group of Oncology Therapeutic Products: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/13\/2020","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOncology Center of Excellence","field_health_topics":"","term_node_tid":"Labeling","field_topics":"Premarket","topics-product":"Premarket, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"02\/05\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-3380\u0022\u003EFDA-2018-D-3380\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222020-04-13T11:05:23-04:00\u0022\u003E2020-04-13 11:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/implanted-brain-computer-interface-bci-devices-patients-paralysis-or-amputation-non-clinical-testing\u0022\u003EImplanted Brain-Computer Interface (BCI) Devices for Patients with Paralysis or Amputation - Non-clinical Testing and Clinical Considerations: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/120362\/download\u0022\u003EPDF (687.1 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (687.1 KB) of Implanted Brain-Computer Interface (BCI) Devices for Patients with Paralysis or Amputation - Non-clinical Testing and Clinical Considerations: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/20\/2021","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Investigational Device Exemption (IDE), Neurological","field_topics":"Premarket","topics-product":"Premarket, Investigational Device Exemption (IDE), Neurological","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-N-1130\u0022\u003EFDA-2014-N-1130\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222021-05-19T09:00:17-04:00\u0022\u003E2021-05-19 09:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/providing-lot-release-protocol-submissions-center-biologics-evaluation-and-research-cber-electronic\u0022\u003EProviding Lot Release Protocol Submissions to the Center for Biologics Evaluation and Research (CBER) in Electronic Format: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/120438\/download\u0022\u003EPDF (220.05 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (220.05 KB) of Providing Lot Release Protocol Submissions to the Center for Biologics Evaluation and Research (CBER) in Electronic Format: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/22\/2019","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"Premarket","topics-product":"Premarket, Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1998-D-0095\u0022\u003EFDA-1998-D-0095\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-04-19T10:19:46-04:00\u0022\u003E2024-04-19 10:19\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/master-protocols-efficient-clinical-trial-design-strategies-expedite-development-oncology-drugs-and\u0022\u003EMaster Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics Guidance for Industry: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/120721\/download\u0022\u003EPDF (518.2 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (518.2 KB) of Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics Guidance for Industry: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/2022","field_issuing_office_taxonomy":"Oncology Center of Excellence\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Pediatric Product Development, Biosimilars","field_topics":"","topics-product":"Administrative \/ Procedural, Pediatric Product Development, Biosimilars","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"11\/30\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-3292\u0022\u003EFDA-2018-D-3292\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T11:04:16-04:00\u0022\u003E2024-04-11 11:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/enforcement-policy-certain-marketed-tobacco-products\u0022\u003EEnforcement Policy for Certain Marketed Tobacco Products: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/120808\/download\u0022\u003EPDF (74.91 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (74.91 KB) of Enforcement Policy for Certain Marketed Tobacco Products: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/28\/2019","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"04\/30\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-3244\u0022\u003EFDA-2018-D-3244\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222020-02-14T13:36:04-05:00\u0022\u003E2020-02-14 13:36\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/bacterial-risk-control-strategies-blood-collection-establishments-and-transfusion-services-enhance\u0022\u003EBacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/123448\/download\u0022\u003EPDF (371.3 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (371.3 KB) of Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/17\/2020","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-1814\u0022\u003EFDA-2014-D-1814\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222022-05-25T12:47:07-04:00\u0022\u003E2022-05-25 12:47\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/developing-and-submitting-proposed-draft-guidance-relating-patient-experience-data\u0022\u003EDeveloping and Submitting Proposed Draft Guidance Relating to Patient Experience Data\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/119542\/download\u0022\u003EPDF (137.82 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (137.82 KB) of Developing and Submitting Proposed Draft Guidance Relating to Patient Experience Data\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/21\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research,Office of Regulatory Policy\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Generic Drugs","field_topics":"","topics-product":"Administrative \/ Procedural, Generic Drugs","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"03\/21\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-4455\u0022\u003EFDA-2018-D-4455\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-23T14:50:07-04:00\u0022\u003E2020-04-23 14:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/anda-submissions-amendments-and-requests-final-approval-tentatively-approved-andas\u0022\u003EANDA Submissions \u2013 Amendments and Requests for Final Approval to Tentatively Approved ANDAs: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/119718\/download\u0022\u003EPDF (330.67 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (330.67 KB) of ANDA Submissions \u2013 Amendments and Requests for Final Approval to Tentatively Approved ANDAs: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/16\/2025","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Drug Competition Action Plan, Generic Drugs","field_topics":"","topics-product":"Drug Competition Action Plan, Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-4726\u0022\u003EFDA-2018-D-4726\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-12-16T13:05:49-05:00\u0022\u003E2025-12-16 13:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/s11-nonclinical-safety-testing-support-development-pediatric-pharmaceuticals\u0022\u003ES11 Nonclinical Safety Testing In Support of Development of Pediatric Pharmaceuticals : International Council for Harmonisation; Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/148478\/download\u0022\u003EPDF (502.03 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (502.03 KB) of S11 Nonclinical Safety Testing In Support of Development of Pediatric Pharmaceuticals : International Council for Harmonisation; Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/11\/2021","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Safety, Pediatric Product Development","field_topics":"","topics-product":"ICH-Safety, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-4524\u0022\u003EFDA-2018-D-4524\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T09:35:02-04:00\u0022\u003E2024-04-11 09:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/immunogenicity-testing-therapeutic-protein-products-developing-and-validating-assays-anti-drug\u0022\u003EImmunogenicity Testing of Therapeutic Protein Products \u2014Developing and Validating Assays for Anti-Drug Antibody Detection\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/119788\/download\u0022\u003EPDF (725.73 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (725.73 KB) of Immunogenicity Testing of Therapeutic Protein Products \u2014Developing and Validating Assays for Anti-Drug Antibody Detection\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/01\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0539\u0022\u003EFDA-2009-D-0539\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T13:35:31-04:00\u0022\u003E2020-04-24 13:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/rems-assessment-planning-and-reporting\u0022\u003EREMS Assessment: Planning and Reporting\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/119790\/download\u0022\u003EPDF (590.24 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (590.24 KB) of REMS Assessment: Planning and Reporting\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/01\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"04\/02\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-4628\u0022\u003EFDA-2018-D-4628\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-17T11:30:47-04:00\u0022\u003E2020-04-17 11:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cders-program-recognition-voluntary-consensus-standards-related-pharmaceutical-quality\u0022\u003ECDER\u2019s Program for the Recognition of Voluntary Consensus Standards Related to Pharmaceutical Quality\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/121305\/download\u0022\u003EPDF (273.53 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (273.53 KB) of CDER\u2019s Program for the Recognition of Voluntary Consensus Standards Related to Pharmaceutical Quality\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/26\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Drug Competition Action Plan","field_topics":"","topics-product":"Administrative \/ Procedural, Drug Competition Action Plan","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-4417\u0022\u003EFDA-2018-D-4417\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-07-26T09:23:46-04:00\u0022\u003E2023-07-26 09:23\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/competitive-generic-therapies\u0022\u003ECompetitive Generic Therapies\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/136063\/download\u0022\u003EPDF (396.05 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (396.05 KB) of Competitive Generic Therapies\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/05\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Drug Competition Action Plan, Generic Drugs","field_topics":"","topics-product":"Drug Competition Action Plan, Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-0065\u0022\u003EFDA-2019-D-0065\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-01-11T16:30:01-05:00\u0022\u003E2023-01-11 16:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/smoking-cessation-and-related-indications-developing-nicotine-replacement-therapy-drug-products\u0022\u003ESmoking Cessation and Related Indications: Developing Nicotine Replacement Therapy Drug Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/167599\/download\u0022\u003EPDF (353.58 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (353.58 KB) of Smoking Cessation and Related Indications: Developing Nicotine Replacement Therapy Drug Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/01\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Pediatric Product Development","field_topics":"","topics-product":"Clinical - Medical, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-0297\u0022\u003EFDA-2019-D-0297\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T11:29:28-04:00\u0022\u003E2024-04-11 11:29\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/bioavailability-studies-submitted-ndas-or-inds-general-considerations\u0022\u003EBioavailability Studies Submitted in NDAs or INDs \u2013 General Considerations\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/121311\/download\u0022\u003EPDF (472.59 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (472.59 KB) of Bioavailability Studies Submitted in NDAs or INDs \u2013 General Considerations\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/15\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Pharmacology","field_topics":"","topics-product":"Clinical - Pharmacology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"05\/28\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-4367\u0022\u003EFDA-2018-D-4367\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-04-12T10:54:38-04:00\u0022\u003E2024-04-12 10:54\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/assessing-effects-food-drugs-inds-and-ndas-clinical-pharmacology-considerations\u0022\u003EAssessing the Effects of Food on Drugs in INDs and NDAs \u2013 Clinical Pharmacology Considerations\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/121313\/download\u0022\u003EPDF (345.08 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (345.08 KB) of Assessing the Effects of Food on Drugs in INDs and NDAs \u2013 Clinical Pharmacology Considerations\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/20\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Pharmacology","field_topics":"","topics-product":"Clinical - Pharmacology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-4368\u0022\u003EFDA-2018-D-4368\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-05-29T13:49:47-04:00\u0022\u003E2026-05-29 13:49\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/evaluation-bulk-drug-substances-nominated-use-compounding-under-section-503b-federal-food-drug-and\u0022\u003EEvaluation of Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/121315\/download\u0022\u003EPDF (323.4 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (323.4 KB) of Evaluation of Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/13\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Compounding","field_topics":"","topics-product":"Compounding","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1067\u0022\u003EFDA-2018-D-1067\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-06-17T10:15:21-04:00\u0022\u003E2019-06-17 10:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/nonproprietary-naming-biological-products-update-guidance-industry\u0022\u003ENonproprietary Naming of Biological Products: Update Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/121316\/download\u0022\u003EPDF (322.39 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (322.39 KB) of Nonproprietary Naming of Biological Products: Update Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/08\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"05\/07\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-1543\u0022\u003EFDA-2013-D-1543\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-27T09:00:22-04:00\u0022\u003E2020-04-27 09:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cancer-clinical-trial-eligibility-criteria-brain-metastases\u0022\u003ECancer Clinical Trial Eligibility Criteria: Brain Metastases\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/121317\/download\u0022\u003EPDF (117.81 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (117.81 KB) of Cancer Clinical Trial Eligibility Criteria: Brain Metastases\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/10\/2020","field_issuing_office_taxonomy":"Oncology Center of Excellence\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-0357\u0022\u003EFDA-2019-D-0357\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-07-10T14:35:06-04:00\u0022\u003E2020-07-10 14:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cancer-clinical-trial-eligibility-criteria-minimum-age-considerations-inclusion-pediatric-patients\u0022\u003ECancer Clinical Trial Eligibility Criteria: Minimum Age Considerations for Inclusion of Pediatric Patients\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/121318\/download\u0022\u003EPDF (133.3 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (133.3 KB) of Cancer Clinical Trial Eligibility Criteria: Minimum Age Considerations for Inclusion of Pediatric Patients\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/10\/2020","field_issuing_office_taxonomy":"Oncology Center of Excellence\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Pediatric Product Development","field_topics":"","topics-product":"Clinical - Medical, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-0358\u0022\u003EFDA-2019-D-0358\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T09:36:01-04:00\u0022\u003E2024-04-11 09:36\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cancer-clinical-trial-eligibility-criteria-patients-hiv-hepatitis-b-virus-or-hepatitis-c-virus\u0022\u003ECancer Clinical Trial Eligibility Criteria: Patients with HIV, Hepatitis B Virus, or Hepatitis C Virus Infections\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/121319\/download\u0022\u003EPDF (185.88 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (185.88 KB) of Cancer Clinical Trial Eligibility Criteria: Patients with HIV, Hepatitis B Virus, or Hepatitis C Virus Infections\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/10\/2020","field_issuing_office_taxonomy":"Oncology Center of Excellence\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-0363\u0022\u003EFDA-2019-D-0363\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222020-07-10T11:50:07-04:00\u0022\u003E2020-07-10 11:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/enrichment-strategies-clinical-trials-support-approval-human-drugs-and-biological-products\u0022\u003EEnrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/121320\/download\u0022\u003EPDF (576.03 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (576.03 KB) of Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/15\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Good Clinical Practice (GCP)","field_topics":"","topics-product":"Clinical - Medical, Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-1145\u0022\u003EFDA-2012-D-1145\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222019-04-20T14:15:03-04:00\u0022\u003E2019-04-20 14:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/enforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\u0022\u003EEnforcement Priorities for Electronic Nicotine Delivery System (ENDS) and Other Deemed Products on the Market Without Premarket Authorization: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/133880\/download\u0022\u003EPDF (872.13 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (872.13 KB) of Enforcement Priorities for Electronic Nicotine Delivery System (ENDS) and Other Deemed Products on the Market Without Premarket Authorization: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/29\/2020","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"Electronic Nicotine Delivery Systems (ENDS), Product Application and Review","field_topics":"","topics-product":"Electronic Nicotine Delivery Systems (ENDS), Product Application and Review","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"04\/15\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-0661\u0022\u003EFDA-2019-D-0661\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222020-08-18T09:50:31-04:00\u0022\u003E2020-08-18 09:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/risk-based-approach-monitoring-clinical-investigations-questions-and-answers\u0022\u003EA Risk-Based Approach to Monitoring of Clinical Investigations Questions and Answers: Guidance for Industry \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/121479\/download\u0022\u003EPDF (265.71 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (265.71 KB) of A Risk-Based Approach to Monitoring of Clinical Investigations Questions and Answers: Guidance for Industry \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/12\/2023","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-0362\u0022\u003EFDA-2019-D-0362\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222024-11-05T16:09:13-05:00\u0022\u003E2024-11-05 16:09\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/prussian-blue-drug-products-submitting-new-drug-application\u0022\u003EPrussian Blue Drug Products \u2014 Submitting a New Drug Application\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71071\/download\u0022\u003EPDF (158.67 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (158.67 KB) of Prussian Blue Drug Products \u2014 Submitting a New Drug Application\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/04\/2003","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2003-D-0727\u0022\u003EFDA-2003-D-0727\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-15T10:35:28-04:00\u0022\u003E2020-05-15 10:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/standards-development-and-use-standards-regulatory-submissions-reviewed-center-biologics-evaluation\u0022\u003EStandards Development and the Use of Standards in Regulatory Submissions Reviewed in the Center for Biologics Evaluation and Research: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/124694\/download\u0022\u003EPDF (133.3 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (133.3 KB) of Standards Development and the Use of Standards in Regulatory Submissions Reviewed in the Center for Biologics Evaluation and Research: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/25\/2019","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"Compliance","topics-product":"Compliance, Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6535\u0022\u003EFDA-2017-D-6535\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222023-03-10T11:47:16-05:00\u0022\u003E2023-03-10 11:47\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/rare-diseases-natural-history-studies-drug-development\u0022\u003ERare Diseases: Natural History Studies for Drug Development: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/122425\/download\u0022\u003EPDF (354.85 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (354.85 KB) of Rare Diseases: Natural History Studies for Drug Development: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/25\/2019","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Orphan Products Development\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"Diseases \u0026amp; Conditions, Rare Diseases","term_node_tid":"","field_topics":"","topics-product":"Diseases \u0026amp; Conditions, Rare Diseases, ","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"05\/24\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-0481\u0022\u003EFDA-2019-D-0481\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"","changed":"\u003Ctime datetime=\u00222020-04-15T16:25:05-04:00\u0022\u003E2020-04-15 16:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/providing-regulatory-submissions-electronic-format-submissions-under-section-745aa-federal-food-drug\u0022\u003EProviding Regulatory Submissions in Electronic Format \u2014 Submissions Under Section 745A(a) of the Federal Food, Drug, and Cosmetic Act\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/88120\/download\u0022\u003EPDF (81.47 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (81.47 KB) of Providing Regulatory Submissions in Electronic Format \u2014 Submissions Under Section 745A(a) of the Federal Food, Drug, and Cosmetic Act\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/18\/2014","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Electronic Submissions","topics-product":"Electronic Submissions, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-1953\u0022\u003EFDA-2014-D-1953\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-14T13:55:07-04:00\u0022\u003E2020-04-14 13:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/determining-whether-submit-anda-or-505b2-application\u0022\u003EDetermining Whether to Submit an ANDA or a 505(b)(2) Application\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/124848\/download\u0022\u003EPDF (149.99 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (149.99 KB) of Determining Whether to Submit an ANDA or a 505(b)(2) Application\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/10\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Drug Competition Action Plan, Generic Drugs","field_topics":"","topics-product":"Drug Competition Action Plan, Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-5974\u0022\u003EFDA-2017-D-5974\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-08-17T10:29:47-04:00\u0022\u003E2026-08-17 10:29\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/unique-device-identification-system-form-and-content-unique-device-identifier-udi\u0022\u003EUnique Device Identification System: Form and Content of the Unique Device Identifier (UDI): Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/99084\/download\u0022\u003EPDF (478.28 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (478.28 KB) of Unique Device Identification System: Form and Content of the Unique Device Identifier (UDI): Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/07\/2021","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Labeling, UDI","field_topics":"","topics-product":"Labeling, UDI","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-1853\u0022\u003EFDA-2016-D-1853\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222021-07-15T12:29:14-04:00\u0022\u003E2021-07-15 12:29\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/class-ii-and-iiia-laser-light-show-projectors-and-shows-laser-notice-40\u0022\u003EClass II and IIIA Laser Light Show Projectors and Shows (Laser Notice 40)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/77188\/download\u0022\u003EPDF (194.21 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (194.21 KB) of Class II and IIIA Laser Light Show Projectors and Shows (Laser Notice 40)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/29\/1987","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Laser Notice, Laser Notice","field_topics":"","topics-product":"Laser Notice, Laser Notice","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-17T10:05:12-04:00\u0022\u003E2020-03-17 10:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/policy-maximum-timer-interval-and-exposure-schedule-sunlamp-products\u0022\u003EPolicy On Maximum Timer Interval and Exposure Schedule For Sunlamp Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/77779\/download\u0022\u003EPDF (182.17 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (182.17 KB) of Policy On Maximum Timer Interval and Exposure Schedule For Sunlamp Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/21\/1985","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Tanning Lamps, Booths \u0026amp; Beds","field_topics":"","topics-product":"Tanning Lamps, Booths \u0026amp; Beds","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-17T09:45:08-04:00\u0022\u003E2020-03-17 09:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/quality-control-practices-compliance-federal-laser-performance-standard\u0022\u003EQuality Control Practices for Compliance with the Federal Laser Performance Standard \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/75913\/download\u0022\u003EPDF (1.07 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.07 MB) of Quality Control Practices for Compliance with the Federal Laser Performance Standard \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/1976","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-03-16T10:21:54-04:00\u0022\u003E2020-03-16 10:21\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-enforcement-policy-entities-growing-harvesting-packing-or-holding-hops-wine-grapes\u0022\u003EGuidance for Industry: Enforcement Policy for Entities Growing, Harvesting, Packing, or Holding Hops, Wine Grapes, Pulse Crops, and Almonds\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/122904\/download\u0022\u003EPDF (95.49 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (95.49 KB) of Guidance for Industry: Enforcement Policy for Entities Growing, Harvesting, Packing, or Holding Hops, Wine Grapes, Pulse Crops, and Almonds\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/27\/2019","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-1266\u0022\u003EFDA-2019-D-1266\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:05:49-04:00\u0022\u003E2024-10-01 07:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/contents-complete-submission-threshold-analyses-and-human-factors-submissions-drug-and-biologic\u0022\u003EContents of a Complete Submission for Threshold Analyses and Human Factors Submissions to Drug and Biologic Applications\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/122971\/download\u0022\u003EPDF (457.33 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (457.33 KB) of Contents of a Complete Submission for Threshold Analyses and Human Factors Submissions to Drug and Biologic Applications\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/01\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-3275\u0022\u003EFDA-2018-D-3275\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T14:20:03-04:00\u0022\u003E2020-05-06 14:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/release-ora-laboratory-analytical-results-responsible-party\u0022\u003ERelease of ORA Laboratory Analytical Results to the Responsible Party: Guidance for Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/123137\/download\u0022\u003EPDF (69.02 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (69.02 KB) of Release of ORA Laboratory Analytical Results to the Responsible Party: Guidance for Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/2019","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Tobacco Products","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-1163\u0022\u003EFDA-2019-D-1163\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222024-10-01T07:05:49-04:00\u0022\u003E2024-10-01 07:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/technical-considerations-non-clinical-assessment-medical-devices-containing-nitinol\u0022\u003ETechnical Considerations for Non-Clinical Assessment of Medical Devices Containing Nitinol: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/123272\/download\u0022\u003EPDF (560.51 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (560.51 KB) of Technical Considerations for Non-Clinical Assessment of Medical Devices Containing Nitinol: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/09\/2021","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Animal Cell-Based Products","field_topics":"Premarket","topics-product":"Premarket, Animal Cell-Based Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-1261\u0022\u003EFDA-2019-D-1261\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Animal \u0026amp; Veterinary, Medical Devices","changed":"\u003Ctime datetime=\u00222021-08-09T12:50:04-04:00\u0022\u003E2021-08-09 12:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/technical-performance-assessment-quantitative-imaging-radiological-device-premarket-submissions\u0022\u003ETechnical Performance Assessment of Quantitative Imaging in Radiological Device Premarket Submissions: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/123271\/download\u0022\u003EPDF (618.82 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (618.82 KB) of Technical Performance Assessment of Quantitative Imaging in Radiological Device Premarket Submissions: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/16\/2022","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Radiological Health","field_topics":"Premarket","topics-product":"Premarket, Radiological Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-1470\u0022\u003EFDA-2019-D-1470\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222022-06-15T08:48:16-04:00\u0022\u003E2022-06-15 08:48\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/impact-certain-provisions-revised-common-rule-fda-regulated-clinical-investigations\u0022\u003EImpact of Certain Provisions of the Revised Common Rule on FDA-Regulated Clinical Investigations: Guidance for Sponsors, Investigators, and Institutional Review Boards\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/117042\/download\u0022\u003EPDF (135.4 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (135.4 KB) of Impact of Certain Provisions of the Revised Common Rule on FDA-Regulated Clinical Investigations: Guidance for Sponsors, Investigators, and Institutional Review Boards\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/11\/2018","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP)","field_topics":"","topics-product":"Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-3551\u0022\u003EFDA-2018-D-3551\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222019-07-18T14:50:22-04:00\u0022\u003E2019-07-18 14:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recognition-and-withdrawal-voluntary-consensus-standards\u0022\u003ERecognition and Withdrawal of Voluntary Consensus Standards: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71995\/download\u0022\u003EPDF (559.96 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (559.96 KB) of Recognition and Withdrawal of Voluntary Consensus Standards: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/15\/2020","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-2936\u0022\u003EFDA-2018-D-2936\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-09-14T08:50:26-04:00\u0022\u003E2020-09-14 08:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/bispecific-antibody-development-programs-guidance-industry\u0022\u003EBispecific Antibody Development Programs Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/123313\/download\u0022\u003EPDF (83.98 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (83.98 KB) of Bispecific Antibody Development Programs Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/24\/2021","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-0621\u0022\u003EFDA-2019-D-0621\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222021-05-24T09:00:16-04:00\u0022\u003E2021-05-24 09:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-declaration-allulose-and-calories-allulose-nutrition-and-supplement-facts-labels\u0022\u003EGuidance for Industry: The Declaration of Allulose and Calories from Allulose on Nutrition and Supplement Facts Labels\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/123342\/download\u0022\u003EPDF (108.49 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (108.49 KB) of Guidance for Industry: The Declaration of Allulose and Calories from Allulose on Nutrition and Supplement Facts Labels\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/16\/2020","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling, Nutrition Label","field_topics":"","topics-product":"Labeling, Nutrition Label","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-0725\u0022\u003EFDA-2019-D-0725\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-12T10:18:46-04:00\u0022\u003E2025-03-12 10:18\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/developing-targeted-therapies-low-frequency-molecular-subsets-disease\u0022\u003EDeveloping Targeted Therapies in Low-Frequency Molecular Subsets of a Disease\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/117173\/download\u0022\u003EPDF (90.9 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (90.9 KB) of Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/16\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Pharmacology","field_topics":"","topics-product":"Clinical - Pharmacology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6617\u0022\u003EFDA-2017-D-6617\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-04-09T09:02:01-04:00\u0022\u003E2024-04-09 09:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/hematologic-malignancies-regulatory-considerations-use-minimal-residual-disease-development-drug-and\u0022\u003EHematologic Malignancies: Regulatory Considerations for Use of Minimal Residual Disease in Development of Drug and Biological Products for Treatment: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/134605\/download\u0022\u003EPDF (153.92 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (153.92 KB) of Hematologic Malignancies: Regulatory Considerations for Use of Minimal Residual Disease in Development of Drug and Biological Products for Treatment: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/24\/2020","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-3090\u0022\u003EFDA-2018-D-3090\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222020-01-24T08:52:12-05:00\u0022\u003E2020-01-24 08:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/surgical-staplers-and-staples-internal-use-labeling-recommendations\u0022\u003ESurgical Staplers and Staples for Internal Use - Labeling Recommendations: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/123572\/download\u0022\u003EPDF (345.34 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (345.34 KB) of Surgical Staplers and Staples for Internal Use - Labeling Recommendations: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/08\/2021","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Device \u0026amp; Drug Safety, General \u0026amp; Plastic Surgery , Labeling, Device \u0026amp; Drug Safety","field_topics":"","topics-product":"Device \u0026amp; Drug Safety, General \u0026amp; Plastic Surgery , Labeling, Device \u0026amp; Drug Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-1262\u0022\u003EFDA-2019-D-1262\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222021-10-07T10:10:11-04:00\u0022\u003E2021-10-07 10:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/initiation-voluntary-recalls-under-21-cfr-part-7-subpart-c\u0022\u003EInitiation of Voluntary Recalls Under 21 CFR Part 7, Subpart C: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/123664\/download\u0022\u003EPDF (355.26 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (355.26 KB) of Initiation of Voluntary Recalls Under 21 CFR Part 7, Subpart C: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/04\/2022","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Tobacco Products","field_health_topics":"","term_node_tid":"","field_topics":"Recalls, Investigation \u0026amp; Enforcement","topics-product":"Recalls, Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-2074\u0022\u003EFDA-2018-D-2074\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"","changed":"\u003Ctime datetime=\u00222024-10-01T14:30:02-04:00\u0022\u003E2024-10-01 14:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cancer-clinical-trial-eligibility-criteria-patients-organ-dysfunction-or-prior-or-concurrent\u0022\u003ECancer Clinical Trial Eligibility Criteria: Patients with Organ Dysfunction or Prior or Concurrent Malignancies\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/123745\/download\u0022\u003EPDF (154.93 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (154.93 KB) of Cancer Clinical Trial Eligibility Criteria: Patients with Organ Dysfunction or Prior or Concurrent Malignancies\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/10\/2020","field_issuing_office_taxonomy":"Oncology Center of Excellence\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-0359\u0022\u003EFDA-2019-D-0359\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222020-07-10T11:50:29-04:00\u0022\u003E2020-07-10 11:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/extending-expiration-dates-doxycycline-tablets-and-capsules-strategic-stockpiles\u0022\u003EExtending Expiration Dates of Doxycycline Tablets and Capsules in Strategic Stockpiles : Guidance for Government Public Health and Emergency Response Stakeholders\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/123805\/download\u0022\u003EPDF (209.17 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (209.17 KB) of Extending Expiration Dates of Doxycycline Tablets and Capsules in Strategic Stockpiles : Guidance for Government Public Health and Emergency Response Stakeholders\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/24\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/2019-08349 \u0022\u003E2019-08349 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-06-11T13:46:37-04:00\u0022\u003E2019-06-11 13:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/coordinated-development-antimicrobial-drugs-and-antimicrobial-susceptibility-test-devices\u0022\u003ECoordinated Development of Antimicrobial Drugs and Antimicrobial Susceptibility Test Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/124382\/download\u0022\u003EPDF (580.43 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (580.43 KB) of Coordinated Development of Antimicrobial Drugs and Antimicrobial Susceptibility Test Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/01\/2019","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"IVDs (In Vitro Diagnostic Devices), Premarket Approval (PMA), Testing","field_topics":"","topics-product":"IVDs (In Vitro Diagnostic Devices), Premarket Approval (PMA), Testing","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-2561\u0022\u003EFDA-2016-D-2561\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222019-05-02T09:00:05-04:00\u0022\u003E2019-05-02 09:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/manufacturing-site-change-supplements-content-and-submission\u0022\u003EManufacturing Site Change Supplements: Content and Submission: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/124387\/download\u0022\u003EPDF (243.25 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (243.25 KB) of Manufacturing Site Change Supplements: Content and Submission: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/17\/2018","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Premarket Approval (PMA)","field_topics":"Postmarket","topics-product":"Postmarket, Premarket Approval (PMA)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-N-3454\u0022\u003EFDA-2015-N-3454\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222020-10-22T15:40:03-04:00\u0022\u003E2020-10-22 15:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/attention-deficit-hyperactivity-disorder-developing-stimulant-drugs-treatment-guidance-industry\u0022\u003EAttention Deficit Hyperactivity Disorder: Developing Stimulant Drugs for Treatment Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/124334\/download\u0022\u003EPDF (247.83 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (247.83 KB) of Attention Deficit Hyperactivity Disorder: Developing Stimulant Drugs for Treatment Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/06\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Pediatric Product Development, Over-the-Counter Drugs","field_topics":"","topics-product":"Clinical - Medical, Pediatric Product Development, Over-the-Counter Drugs","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"07\/03\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-0849\u0022\u003EFDA-2019-D-0849\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T11:04:01-04:00\u0022\u003E2024-04-11 11:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-683100-action-levels-aflatoxins-animal-feeds\u0022\u003ECPG Sec. 683.100 Action Levels for Aflatoxins in Animal Feeds\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/121202\/download\u0022\u003EPDF (38.81 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (38.81 KB) of CPG Sec. 683.100 Action Levels for Aflatoxins in Animal Feeds\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/2019","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Feed","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Feed","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222019-05-07T10:35:20-04:00\u0022\u003E2019-05-07 10:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/postapproval-pregnancy-safety-studies\u0022\u003EPostapproval Pregnancy Safety Studies\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/124746\/download\u0022\u003EPDF (435.54 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (435.54 KB) of Postapproval Pregnancy Safety Studies\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/08\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-4693\u0022\u003EFDA-2018-D-4693\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222026-05-11T15:32:47-04:00\u0022\u003E2026-05-11 15:32\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/submitting-documents-using-real-world-data-and-real-world-evidence-fda-drug-and-biological-products\u0022\u003ESubmitting Documents Using Real-World Data and Real-World Evidence to FDA for Drug and Biological Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/124795\/download\u0022\u003EPDF (244.63 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (244.63 KB) of Submitting Documents Using Real-World Data and Real-World Evidence to FDA for Drug and Biological Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/09\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"Real World Data \/ Real World Evidence (RWD\/RWE)","topics-product":"Real World Data \/ Real World Evidence (RWD\/RWE), Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-1263\u0022\u003EFDA-2019-D-1263\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-03-15T13:46:45-04:00\u0022\u003E2023-03-15 13:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clinical-lactation-studies-considerations-study-design\u0022\u003EClinical Lactation Studies: Considerations for Study Design \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/124749\/download\u0022\u003EPDF (329.81 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (329.81 KB) of Clinical Lactation Studies: Considerations for Study Design \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/09\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Clinical - Pharmacology","field_topics":"","topics-product":"Clinical - Medical, Clinical - Pharmacology","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-4525. \u0022\u003EFDA-2018-D-4525. \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T11:35:39-04:00\u0022\u003E2020-05-06 11:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/rare-diseases-considerations-development-drugs-and-biological-products\u0022\u003ERare Diseases: Considerations for the Development of Drugs and Biological Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/119757\/download\u0022\u003EPDF (409.38 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (409.38 KB) of Rare Diseases: Considerations for the Development of Drugs and Biological Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/26\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"Rare Diseases","term_node_tid":"Pediatric Product Development","field_topics":"","topics-product":"Rare Diseases, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-2818\u0022\u003EFDA-2015-D-2818\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T11:29:01-04:00\u0022\u003E2024-04-11 11:29\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-use-alternate-name-potassium-chloride-food-labeling\u0022\u003EGuidance for Industry: The Use of an Alternate Name for Potassium Chloride in Food Labeling\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/125081\/download\u0022\u003EPDF (75.25 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (75.25 KB) of Guidance for Industry: The Use of an Alternate Name for Potassium Chloride in Food Labeling\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/17\/2020","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-0892\u0022\u003EFDA-2019-D-0892\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-07T09:28:19-05:00\u0022\u003E2025-03-07 09:28\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/section-503a-bulks-list-final-rule-questions-and-answers-small-entity-compliance-guide\u0022\u003ESection 503A Bulks List Final Rule Questions and Answers; Small Entity Compliance Guide;: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/126110\/download\u0022\u003EPDF (68.34 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (68.34 KB) of Section 503A Bulks List Final Rule Questions and Answers; Small Entity Compliance Guide;: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/24\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Compounding","field_topics":"","topics-product":"Administrative \/ Procedural, Compounding","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-2011\u0022\u003EFDA-2019-D-2011\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T14:50:20-04:00\u0022\u003E2020-04-24 14:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/draft-guidance-industry-evaluating-alternate-curricula-standards-growing-harvesting-packing-and\u0022\u003EDraft Guidance for Industry: Evaluating Alternate Curricula for the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/126868\/download\u0022\u003EPDF (398.38 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (398.38 KB) of Draft Guidance for Industry: Evaluating Alternate Curricula for the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/03\/2019","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Produce","field_topics":"","topics-product":"Produce","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"10\/02\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-2131\u0022\u003EFDA-2019-D-2131\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-10T15:57:16-04:00\u0022\u003E2025-03-10 15:57\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/nonalcoholic-steatohepatitis-compensated-cirrhosis-developing-drugs-treatment-guidance-industry\u0022\u003ENonalcoholic Steatohepatitis with Compensated Cirrhosis: Developing Drugs for Treatment Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/127738\/download\u0022\u003EPDF (231 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (231 KB) of Nonalcoholic Steatohepatitis with Compensated Cirrhosis: Developing Drugs for Treatment Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/07\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"08\/06\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-1516\u0022\u003EFDA-2019-D-1516\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-14T12:50:03-04:00\u0022\u003E2020-05-14 12:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/mouse-embryo-assay-assisted-reproduction-technology-devices\u0022\u003EMouse Embryo Assay for Assisted Reproduction Technology Devices\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/127874\/download\u0022\u003EPDF (325.49 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (325.49 KB) of Mouse Embryo Assay for Assisted Reproduction Technology Devices\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/05\/2021","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Premarket Approval (PMA), Investigational Device Exemption (IDE), Obstetrical \u0026amp; Gynecological","field_topics":"Premarket","topics-product":"Premarket, 510(k), Premarket Approval (PMA), Investigational Device Exemption (IDE), Obstetrical \u0026amp; Gynecological","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-2105\u0022\u003EFDA-2019-D-2105\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222021-01-04T08:51:08-05:00\u0022\u003E2021-01-04 08:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/testing-biotin-interference-in-vitro-diagnostic-devices\u0022\u003ETesting for Biotin Interference in In Vitro Diagnostic Devices: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/127915\/download\u0022\u003EPDF (90.06 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (90.06 KB) of Testing for Biotin Interference in In Vitro Diagnostic Devices: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/16\/2020","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"Blood","term_node_tid":"Blood Products, IVDs (In Vitro Diagnostic Devices)","field_topics":"","topics-product":"Blood, Blood Products, IVDs (In Vitro Diagnostic Devices)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-1876\u0022\u003EFDA-2019-D-1876\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222021-06-11T11:01:05-04:00\u0022\u003E2021-06-11 11:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/opioid-analgesic-drugs-considerations-benefit-risk-assessment-framework\u0022\u003EOpioid Analgesic Drugs: Considerations for Benefit-Risk Assessment Framework\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/128150\/download\u0022\u003EPDF (288.29 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (288.29 KB) of Opioid Analgesic Drugs: Considerations for Benefit-Risk Assessment Framework\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/13\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-1536\u0022\u003EFDA-2019-D-1536\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-05-13T13:01:34-04:00\u0022\u003E2026-05-13 13:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-reducing-microbial-food-safety-hazards-production-seed-sprouting\u0022\u003EGuidance for Industry: Reducing Microbial Food Safety Hazards in the Production of Seed for Sprouting\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/127972\/download\u0022\u003EPDF (283.7 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (283.7 KB) of Guidance for Industry: Reducing Microbial Food Safety Hazards in the Production of Seed for Sprouting\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/13\/2022","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Produce","field_topics":"","topics-product":"Produce","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"08\/26\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-4534\u0022\u003EFDA-2018-D-4534\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T09:08:20-05:00\u0022\u003E2025-03-06 09:08\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clinical-investigations-prostate-tissue-ablation-devices\u0022\u003EClinical Investigations for Prostate Tissue Ablation Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/128263\/download\u0022\u003EPDF (352.13 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (352.13 KB) of Clinical Investigations for Prostate Tissue Ablation Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/15\/2020","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Investigational Device Exemption (IDE), Gastroenterology-Urology , Good Clinical Practice (GCP)","field_topics":"Premarket","topics-product":"Premarket, 510(k), Investigational Device Exemption (IDE), Gastroenterology-Urology , Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-2223\u0022\u003EFDA-2019-D-2223\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-07-14T09:03:39-04:00\u0022\u003E2020-07-14 09:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e19-optimisation-safety-data-collection\u0022\u003EE19 OPTIMISATION OF SAFETY DATA COLLECTION\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/128313\/download\u0022\u003EPDF (188.94 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (188.94 KB) of E19 OPTIMISATION OF SAFETY DATA COLLECTION\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/27\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Efficacy","field_topics":"","topics-product":"ICH-Efficacy","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"08\/26\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-1828\u0022\u003EFDA-2019-D-1828\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-20T08:25:14-04:00\u0022\u003E2020-04-20 08:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/m10-bioanalytical-method-validation\u0022\u003EM10 BIOANALYTICAL METHOD VALIDATION\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/128343\/download\u0022\u003EPDF (620.74 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (620.74 KB) of M10 BIOANALYTICAL METHOD VALIDATION\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/26\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, ICH-Multidisciplinary","field_topics":"","topics-product":"Clinical - Medical, ICH-Multidisciplinary","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"08\/26\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-1469\u0022\u003EFDA-2019-D-1469\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T10:10:11-04:00\u0022\u003E2020-04-24 10:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/treatment-heart-failure-endpoints-drug-development-guidance-industry\u0022\u003ETreatment for Heart Failure: Endpoints for Drug Development Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/128372\/download\u0022\u003EPDF (86.02 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (86.02 KB) of Treatment for Heart Failure: Endpoints for Drug Development Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/28\/2019","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"08\/27\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-2314\u0022\u003EFDA-2019-D-2314\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T08:25:16-04:00\u0022\u003E2020-05-06 08:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/drug-abuse-and-dependence-section-labeling-human-prescription-drug-and-biological-products-content\u0022\u003EDrug Abuse and Dependence Section of Labeling for Human Prescription Drug and Biological Products \u2014 Content and Format Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/128443\/download\u0022\u003EPDF (130.14 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (130.14 KB) of Drug Abuse and Dependence Section of Labeling for Human Prescription Drug and Biological Products \u2014 Content and Format Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/01\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"09\/02\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-1917\u0022\u003EFDA-2019-D-1917\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222019-10-25T09:21:24-04:00\u0022\u003E2019-10-25 09:21\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/instructions-use-patient-labeling-human-prescription-drug-and-biological-products-content-and-format\u0022\u003EInstructions for Use \u2014 Patient Labeling for Human Prescription Drug and Biological Products \u2014 Content and Format\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/128446\/download\u0022\u003EPDF (392.19 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (392.19 KB) of Instructions for Use \u2014 Patient Labeling for Human Prescription Drug and Biological Products \u2014 Content and Format\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/15\/2022","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of the Chief Medical Officer,Office of Combination Products","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-1615\u0022\u003EFDA-2019-D-1615\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222025-03-07T15:22:51-05:00\u0022\u003E2025-03-07 15:22\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/center-devices-and-radiological-health-cdrh-appeals-processes-questions-and-answers-about-517a\u0022\u003ECenter for Devices and Radiological Health (CDRH) Appeals Processes: Questions and Answers About 517A: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/128447\/download\u0022\u003EPDF (267.03 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (267.03 KB) of Center for Devices and Radiological Health (CDRH) Appeals Processes: Questions and Answers About 517A: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/27\/2020","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Premarket Approval (PMA), Administrative \/ Procedural","field_topics":"","topics-product":"510(k), Premarket Approval (PMA), Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0501\u0022\u003EFDA-2013-D-0501\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222025-11-19T12:17:28-05:00\u0022\u003E2025-11-19 12:17\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/center-devices-and-radiological-health-cdrh-appeals-processes\u0022\u003ECenter for Devices and Radiological Health (CDRH) Appeals Processes: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/128444\/download\u0022\u003EPDF (613.99 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (613.99 KB) of Center for Devices and Radiological Health (CDRH) Appeals Processes: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/02\/2022","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0893\u0022\u003EFDA-2011-D-0893\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222025-11-19T12:17:17-05:00\u0022\u003E2025-11-19 12:17\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/compliance-policy-certain-compounding-oral-oxitriptan-5-htp-drug-products-patients\u0022\u003ECompliance Policy for Certain Compounding of Oral Oxitriptan (5-HTP) Drug Products for Patients With Tetrahydrobiopterin (BH4) Deficiency Immediately in Effect Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/128603\/download\u0022\u003EPDF (77.61 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (77.61 KB) of Compliance Policy for Certain Compounding of Oral Oxitriptan (5-HTP) Drug Products for Patients With Tetrahydrobiopterin (BH4) Deficiency Immediately in Effect Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/08\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Compounding","field_topics":"","topics-product":"Compounding","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-2733\u0022\u003EFDA-2019-D-2733\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T13:45:19-04:00\u0022\u003E2020-05-06 13:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/risk-evaluation-and-mitigation-strategies-modifications-and-revisions-guidance-industry\u0022\u003ERisk Evaluation and Mitigation Strategies: Modifications and Revisions Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/128651\/download\u0022\u003EPDF (371.97 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (371.97 KB) of Risk Evaluation and Mitigation Strategies: Modifications and Revisions Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/09\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Device \u0026amp; Drug Safety","field_topics":"","topics-product":"Device \u0026amp; Drug Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-1747\u0022\u003EFDA-2014-D-1747\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222020-06-29T09:30:32-04:00\u0022\u003E2020-06-29 09:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/harmonizing-compendial-standards-drug-application-approval-using-usp-pending-monograph-process\u0022\u003EHarmonizing Compendial Standards With Drug Application Approval Using the USP Pending Monograph Process Guidance for Industry \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/128689\/download\u0022\u003EPDF (176.07 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (176.07 KB) of Harmonizing Compendial Standards With Drug Application Approval Using the USP Pending Monograph Process Guidance for Industry \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/10\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Veterinary Medicine","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality, Drug Competition Action Plan","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality, Drug Competition Action Plan","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"09\/10\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-1768 \u0022\u003EFDA-2019-D-1768 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-01-28T13:25:19-05:00\u0022\u003E2020-01-28 13:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/using-inactive-ingredient-database-guidance-industry\u0022\u003EUsing the Inactive Ingredient Database Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/128687\/download\u0022\u003EPDF (121.68 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (121.68 KB) of Using the Inactive Ingredient Database Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/11\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Drug Competition Action Plan, Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Drug Competition Action Plan, Pharmaceutical Quality","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"10\/09\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-2397\u0022\u003EFDA-2019-D-2397\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T09:50:10-04:00\u0022\u003E2020-05-06 09:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/establishing-effectiveness-and-safety-hormonal-drug-products-intended-prevent-pregnancy-guidance\u0022\u003EEstablishing Effectiveness and Safety for Hormonal Drug Products Intended to Prevent Pregnancy Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/128792\/download\u0022\u003EPDF (133.02 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (133.02 KB) of Establishing Effectiveness and Safety for Hormonal Drug Products Intended to Prevent Pregnancy Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/12\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"09\/11\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-2153\u0022\u003EFDA-2019-D-2153\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222020-04-21T07:40:02-04:00\u0022\u003E2020-04-21 07:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/providing-regulatory-submissions-electronic-format-certain-human-pharmaceutical-product-applications\u0022\u003EProviding Regulatory Submissions in Electronic Format \u2014 Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/135373\/download\u0022\u003EPDF (362.91 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (362.91 KB) of Providing Regulatory Submissions in Electronic Format \u2014 Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/13\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Electronic Submissions","topics-product":"Electronic Submissions, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-N-1006\u0022\u003EFDA-2014-N-1006\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222024-09-11T15:42:46-04:00\u0022\u003E2024-09-11 15:42\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/advanced-prostate-cancer-developing-gonadotropin-releasing-hormone-analogues-guidance-industry\u0022\u003EAdvanced Prostate Cancer: Developing Gonadotropin-Releasing Hormone Analogues Guidance for Industry: Clinical\/Medical\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/129027\/download\u0022\u003EPDF (271.21 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (271.21 KB) of Advanced Prostate Cancer: Developing Gonadotropin-Releasing Hormone Analogues Guidance for Industry: Clinical\/Medical\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/27\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-2808\u0022\u003EFDA-2019-D-2808\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-05-26T08:45:12-04:00\u0022\u003E2022-05-26 08:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/submitting-next-generation-sequencing-data-division-antiviral-products\u0022\u003ESubmitting Next-Generation Sequencing Data to the Division of Antiviral Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/129126\/download\u0022\u003EPDF (313.51 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (313.51 KB) of Submitting Next-Generation Sequencing Data to the Division of Antiviral Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/01\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Technical Specifications","field_topics":"","topics-product":"Technical Specifications","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6821\u0022\u003EFDA-2017-D-6821\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222026-07-01T10:53:02-04:00\u0022\u003E2026-07-01 10:53\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/providing-regulatory-submissions-electronic-format-submission-manufacturing-establishment\u0022\u003EProviding Regulatory Submissions in Electronic Format--Submission of Manufacturing Establishment Information Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/23\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-08-07T14:55:32-04:00\u0022\u003E2019-08-07 14:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/delayed-graft-function-kidney-transplantation-developing-drugs-prevention-guidance-industry\u0022\u003EDelayed Graft Function in Kidney Transplantation: Developing Drugs for Prevention Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/129320\/download\u0022\u003EPDF (277.36 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (277.36 KB) of Delayed Graft Function in Kidney Transplantation: Developing Drugs for Prevention Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/29\/2019","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-0198\u0022\u003EFDA-2017-D-0198\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-23T14:35:28-04:00\u0022\u003E2020-04-23 14:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/general-clinical-pharmacology-considerations-neonatal-studies-drugs-and-biological-products-guidance\u0022\u003EGeneral Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/129532\/download\u0022\u003EPDF (385.7 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (385.7 KB) of General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/27\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Pharmacology, Pediatric Product Development","field_topics":"","topics-product":"Clinical - Pharmacology, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-3132\u0022\u003EFDA-2019-D-3132\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222024-04-15T11:00:46-04:00\u0022\u003E2024-04-15 11:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pathology-peer-review-nonclinical-toxicology-studies-questions-and-answers\u0022\u003EPathology Peer Review in Nonclinical Toxicology Studies: Questions and Answers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/129533\/download\u0022\u003EPDF (193.76 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (193.76 KB) of Pathology Peer Review in Nonclinical Toxicology Studies: Questions and Answers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/27\/2021","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pharmacology\/Toxicology","field_topics":"","topics-product":"Pharmacology\/Toxicology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-2330\u0022\u003EFDA-2019-D-2330\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Drugs, Food \u0026amp; Beverages, Medical Devices, Tobacco","changed":"\u003Ctime datetime=\u00222024-10-01T07:05:57-04:00\u0022\u003E2024-10-01 07:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/fabry-disease-developing-drugs-treatment-guidance-industry\u0022\u003EFabry Disease: Developing Drugs for Treatment Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/129690\/download\u0022\u003EPDF (285.28 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (285.28 KB) of Fabry Disease: Developing Drugs for Treatment Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/07\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"11\/06\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-2973\u0022\u003EFDA-2019-D-2973\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-10-23T11:40:11-04:00\u0022\u003E2019-10-23 11:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/gastroparesis-clinical-evaluation-drugs-treatment-guidance-industry\u0022\u003EGastroparesis: Clinical Evaluation of Drugs for Treatment Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/129880\/download\u0022\u003EPDF (99.88 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (99.88 KB) of Gastroparesis: Clinical Evaluation of Drugs for Treatment Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/13\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"10\/14\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-2479\u0022\u003EFDA-2015-D-2479\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-10-23T11:40:02-04:00\u0022\u003E2019-10-23 11:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/child-resistant-packaging-statements-drug-product-labeling-guidance-industry\u0022\u003EChild-Resistant Packaging Statements in Drug Product Labeling Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/129881\/download\u0022\u003EPDF (97.52 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (97.52 KB) of Child-Resistant Packaging Statements in Drug Product Labeling Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/13\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-2163\u0022\u003EFDA-2017-D-2163\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-10-04T11:55:09-04:00\u0022\u003E2021-10-04 11:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-converting-units-measure-folate-niacin-and-vitamins-d-and-e-nutrition-and\u0022\u003EGuidance for Industry: Converting Units of Measure for Folate, Niacin, and Vitamins A, D, and E on the Nutrition and Supplement Facts Labels\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/129863\/download\u0022\u003EPDF (247.1 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (247.1 KB) of Guidance for Industry: Converting Units of Measure for Folate, Niacin, and Vitamins A, D, and E on the Nutrition and Supplement Facts Labels\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/15\/2019","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling, Nutrition Label","field_topics":"","topics-product":"Labeling, Nutrition Label","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-4484\u0022\u003EFDA-2016-D-4484\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:05:57-04:00\u0022\u003E2024-10-01 07:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/male-breast-cancer-developing-drugs-treatment\u0022\u003EMale Breast Cancer: Developing Drugs for Treatment: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/130061\/download\u0022\u003EPDF (59.99 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (59.99 KB) of Male Breast Cancer: Developing Drugs for Treatment: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/12\/2020","field_issuing_office_taxonomy":"Oncology Center of Excellence\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"10\/28\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-2966\u0022\u003EFDA-2019-D-2966\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222020-08-17T09:50:46-04:00\u0022\u003E2020-08-17 09:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-policy-related-cranberry-products-added-flavorings\u0022\u003EGuidance for Industry: Policy Related to Cranberry Products with Added Flavorings\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/130373\/download\u0022\u003EPDF (291.77 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (291.77 KB) of Guidance for Industry: Policy Related to Cranberry Products with Added Flavorings\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/30\/2019","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling, Nutrition Label","field_topics":"","topics-product":"Labeling, Nutrition Label","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-0075\u0022\u003EFDA-2018-D-0075\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-10T16:22:52-04:00\u0022\u003E2025-03-10 16:22\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/evaluation-internal-standard-responses-during-chromatographic-bioanalysis-questions-and-answers\u0022\u003EEvaluation of Internal Standard Responses During Chromatographic Bioanalysis: Questions and Answers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/130451\/download\u0022\u003EPDF (117.32 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (117.32 KB) of Evaluation of Internal Standard Responses During Chromatographic Bioanalysis: Questions and Answers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/04\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Biopharmaceutics","field_topics":"","topics-product":"Biopharmaceutics","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0008\u0022\u003EFDA-2009-D-0008\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-10-23T11:22:41-04:00\u0022\u003E2019-10-23 11:22\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-reconditioning-fish-and-fishery-products-segregation\u0022\u003EGuidance for Industry: Reconditioning of Fish and Fishery Products by Segregation\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/130658\/download\u0022\u003EPDF (313.35 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (313.35 KB) of Guidance for Industry: Reconditioning of Fish and Fishery Products by Segregation\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/13\/2022","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Seafood\/Seafood Product","field_topics":"","topics-product":"Seafood\/Seafood Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-3324\u0022\u003EFDA-2019-D-3324\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T12:49:31-05:00\u0022\u003E2025-03-06 12:49\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/safer-technologies-program-medical-devices\u0022\u003ESafer Technologies Program for Medical Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/130815\/download\u0022\u003EPDF (314.29 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (314.29 KB) of Safer Technologies Program for Medical Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/06\/2021","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"510(k), Premarket Approval (PMA)","field_topics":"Premarket","topics-product":"Premarket, 510(k), Premarket Approval (PMA)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-4048\u0022\u003EFDA-2019-D-4048\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222021-01-07T15:00:15-05:00\u0022\u003E2021-01-07 15:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cutaneous-electrodes-recording-purposes-performance-criteria-safety-and-performance-based-pathway\u0022\u003ECutaneous Electrodes for Recording Purposes - Performance Criteria for Safety and Performance Based Pathway: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/130864\/download\u0022\u003EPDF (79.43 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (79.43 KB) of Cutaneous Electrodes for Recording Purposes - Performance Criteria for Safety and Performance Based Pathway: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/14\/2020","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Neurological","field_topics":"Premarket","topics-product":"Premarket, 510(k), Neurological","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-1649\u0022\u003EFDA-2019-D-1649\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-08-13T09:00:49-04:00\u0022\u003E2020-08-13 09:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/orthopedic-non-spinal-metallic-bone-screws-and-washers-performance-criteria-safety-and-performance\u0022\u003EOrthopedic Non-Spinal Metallic Bone Screws and Washers - Performance Criteria for Safety and Performance Based Pathway: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/130866\/download\u0022\u003EPDF (441.49 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (441.49 KB) of Orthopedic Non-Spinal Metallic Bone Screws and Washers - Performance Criteria for Safety and Performance Based Pathway: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/22\/2024","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Orthopedic","field_topics":"Premarket","topics-product":"Premarket, 510(k), Orthopedic","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-1652\u0022\u003EFDA-2019-D-1652\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222024-11-21T09:06:31-05:00\u0022\u003E2024-11-21 09:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/spinal-plating-systems-performance-criteria-safety-and-performance-based-pathway\u0022\u003ESpinal Plating Systems - Performance Criteria for Safety and Performance Based Pathway: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/130867\/download\u0022\u003EPDF (463.16 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (463.16 KB) of Spinal Plating Systems - Performance Criteria for Safety and Performance Based Pathway: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/11\/2020","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Orthopedic","field_topics":"Premarket","topics-product":"Premarket, 510(k), Orthopedic","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-1647\u0022\u003EFDA-2019-D-1647\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-12-10T09:06:15-05:00\u0022\u003E2020-12-10 09:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/conventional-foley-catheters-performance-criteria-safety-and-performance-based-pathway\u0022\u003EConventional Foley Catheters - Performance Criteria for Safety and Performance Based Pathway: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/130865\/download\u0022\u003EPDF (94.14 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (94.14 KB) of Conventional Foley Catheters - Performance Criteria for Safety and Performance Based Pathway: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/14\/2020","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Gastroenterology-Urology ","field_topics":"Premarket","topics-product":"Premarket, 510(k), Gastroenterology-Urology ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-1651\u0022\u003EFDA-2019-D-1651\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-08-13T09:00:56-04:00\u0022\u003E2020-08-13 09:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/accreditation-scheme-conformity-assessment-asca-pilot-program\u0022\u003EThe Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program: Guidance for Industry, Accreditation Bodies, Testing Laboratories, and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/130901\/download\u0022\u003EPDF (867.5 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (867.5 KB) of The Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program: Guidance for Industry, Accreditation Bodies, Testing Laboratories, and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/25\/2020","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-3805\u0022\u003EFDA-2019-D-3805\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222024-08-09T21:46:57-04:00\u0022\u003E2024-08-09 21:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/interacting-fda-complex-innovative-trial-designs-drugs-and-biological-products\u0022\u003EInteracting with the FDA on Complex Innovative Trial Designs for Drugs and Biological Products: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/130897\/download\u0022\u003EPDF (126.2 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (126.2 KB) of Interacting with the FDA on Complex Innovative Trial Designs for Drugs and Biological Products: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/16\/2020","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-3679\u0022\u003EFDA-2019-D-3679\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222024-04-09T09:01:06-04:00\u0022\u003E2024-04-09 09:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/patient-engagement-design-and-conduct-medical-device-clinical-studies\u0022\u003EPatient Engagement in the Design and Conduct of Medical Device Clinical Studies: Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/130917\/download\u0022\u003EPDF (308.26 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (308.26 KB) of Patient Engagement in the Design and Conduct of Medical Device Clinical Studies: Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/26\/2022","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP)","field_topics":"Premarket","topics-product":"Premarket, Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-3846\u0022\u003EFDA-2019-D-3846\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222022-01-25T08:50:48-05:00\u0022\u003E2022-01-25 08:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/wholesale-distributor-verification-requirement-saleable-returned-drug-product-and-dispenser\u0022\u003EWholesale Distributor Verification Requirement for Saleable Returned Drug Product and Dispenser Verification Requirements When Investigating a Suspect or Illegitimate Product\u2014Compliance Policies\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/131005\/download\u0022\u003EPDF (237 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (237 KB) of Wholesale Distributor Verification Requirement for Saleable Returned Drug Product and Dispenser Verification Requirements When Investigating a Suspect or Illegitimate Product\u2014Compliance Policies\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/22\/2020","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-4212.\u0022\u003EFDA-2019-D-4212.\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222024-11-05T16:09:05-05:00\u0022\u003E2024-11-05 16:09\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-263-recommendations-sponsors-medically-important-antimicrobial-drugs-approved-use-animals\u0022\u003ECVM GFI #263 Recommendations for Sponsors of Medically Important Antimicrobial Drugs Approved for Use in Animals to Voluntarily Bring Under Veterinary Oversight All Products That Continue to be Available Over-the-Counter \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/130610\/download\u0022\u003EPDF (310.55 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (310.55 KB) of CVM GFI #263 Recommendations for Sponsors of Medically Important Antimicrobial Drugs Approved for Use in Animals to Voluntarily Bring Under Veterinary Oversight All Products That Continue to be Available Over-the-Counter \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/11\/2021","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Antimicrobial Resistance, Labeling, New Animal Drug Application (NADA)","field_topics":"Premarket","topics-product":"Premarket, Antimicrobial Resistance, Labeling, New Animal Drug Application (NADA)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"12\/24\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-3614\u0022\u003EFDA-2019-D-3614\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222021-06-10T08:51:04-04:00\u0022\u003E2021-06-10 08:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/providing-regulatory-submissions-medical-devices-electronic-format-submissions-under-section-745ab\u0022\u003EProviding Regulatory Submissions for Medical Devices in Electronic Format - Submissions Under Section 745A(b) of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/131064\/download\u0022\u003EPDF (385.46 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (385.46 KB) of Providing Regulatory Submissions for Medical Devices in Electronic Format - Submissions Under Section 745A(b) of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/15\/2020","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Electronic Submissions","topics-product":"Electronic Submissions, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-3769\u0022\u003EFDA-2019-D-3769\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222020-07-14T10:20:26-04:00\u0022\u003E2020-07-14 10:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-261-eligibility-criteria-expanded-conditional-approval-new-animal-drugs\u0022\u003ECVM GFI #261 - Eligibility Criteria for Expanded Conditional Approval of New Animal Drugs \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/130706\/download\u0022\u003EPDF (266.69 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (266.69 KB) of CVM GFI #261 - Eligibility Criteria for Expanded Conditional Approval of New Animal Drugs \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/14\/2021","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Antimicrobial Resistance, New Animal Drug Application (NADA), Target Animal \u2013 Effectiveness","field_topics":"Premarket, User Fees","topics-product":"Premarket, User Fees, Antimicrobial Resistance, New Animal Drug Application (NADA), Target Animal \u2013 Effectiveness","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"01\/28\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-3361\u0022\u003EFDA-2019-D-3361\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222021-07-13T08:55:02-04:00\u0022\u003E2021-07-13 08:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-171-demonstrating-bioequivalence-soluble-powder-oral-dosage-form-products-and-type-medicated\u0022\u003ECVM GFI #171 - Demonstrating Bioequivalence for Soluble Powder Oral Dosage Form Products and Type A Medicated Articles Containing Active Pharmaceutical Ingredients Considered to Be Soluble in Aqueous Media\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/131173\/download\u0022\u003EPDF (419.64 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (419.64 KB) of CVM GFI #171 - Demonstrating Bioequivalence for Soluble Powder Oral Dosage Form Products and Type A Medicated Articles Containing Active Pharmaceutical Ingredients Considered to Be Soluble in Aqueous Media\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/16\/2023","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Aquaculture, Generic Animal Drugs, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA)","field_topics":"Premarket","topics-product":"Premarket, Aquaculture, Generic Animal Drugs, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"11\/29\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-3764\u0022\u003EFDA-2019-D-3764\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222023-06-16T10:28:31-04:00\u0022\u003E2023-06-16 10:28\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-methods-identify-what-important-patients\u0022\u003EPatient-Focused Drug Development: Methods to Identify What Is Important to Patients: Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/131230\/download\u0022\u003EPDF (528.3 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (528.3 KB) of Patient-Focused Drug Development: Methods to Identify What Is Important to Patients: Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/25\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"12\/30\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-4247 \u0022\u003EFDA-2019-D-4247 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222025-01-31T14:58:46-05:00\u0022\u003E2025-01-31 14:58\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/reporting-harmful-and-potentially-harmful-constituents-tobacco-products-and-tobacco-smoke-under\u0022\u003EReporting Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke Under Section 904(a)(3) of the Federal Food, Drug, and Cosmetic Act: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/83375\/download\u0022\u003EPDF (313.12 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (313.12 KB) of Reporting Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke Under Section 904(a)(3) of the Federal Food, Drug, and Cosmetic Act: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/03\/2012","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"04\/03\/2012","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-0049\u0022\u003EFDA-2012-D-0049\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222020-07-28T10:57:35-04:00\u0022\u003E2020-07-28 10:57\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/drug-master-files-guidance-industry\u0022\u003EDrug Master Files Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/131861\/download\u0022\u003EPDF (195.14 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (195.14 KB) of Drug Master Files Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/15\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"12\/20\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-3989\u0022\u003EFDA-2019-D-3989\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-18T11:35:11-04:00\u0022\u003E2020-05-18 11:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/identification-manufacturing-establishments-applications-submitted-cber-and-cder-questions-and\u0022\u003EIdentification of Manufacturing Establishments in Applications Submitted to CBER and CDER Questions and Answers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/131911\/download\u0022\u003EPDF (279 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (279 KB) of Identification of Manufacturing Establishments in Applications Submitted to CBER and CDER Questions and Answers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/22\/2019","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6821\u0022\u003EFDA-2017-D-6821\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-09-20T16:58:32-04:00\u0022\u003E2024-09-20 16:58\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/breast-implants-certain-labeling-recommendations-improve-patient-communication\u0022\u003EBreast Implants - Certain Labeling Recommendations to Improve Patient Communication: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/131885\/download\u0022\u003EPDF (459.48 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (459.48 KB) of Breast Implants - Certain Labeling Recommendations to Improve Patient Communication: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/29\/2020","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"General \u0026amp; Plastic Surgery , Labeling","field_topics":"Premarket","topics-product":"Premarket, General \u0026amp; Plastic Surgery , Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"12\/23\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-4467\u0022\u003EFDA-2019-D-4467\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-09-28T12:00:17-04:00\u0022\u003E2020-09-28 12:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/type-v-dmfs-cder-led-combination-products-using-device-constituent-parts-electronics-or-software\u0022\u003EType V DMFs for CDER-Led Combination Products Using Device Constituent Parts With Electronics or Software Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/132043\/download\u0022\u003EPDF (145.25 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (145.25 KB) of Type V DMFs for CDER-Led Combination Products Using Device Constituent Parts With Electronics or Software Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/29\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"12\/30\/2019","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-4258\u0022\u003EFDA-2019-D-4258\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T08:35:07-04:00\u0022\u003E2020-05-06 08:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/providing-regulatory-submissions-electronic-format-ind-safety-reports-guidance-industry\u0022\u003EProviding Regulatory Submissions in Electronic Format: IND Safety Reports Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/132079\/download\u0022\u003EPDF (251.48 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (251.48 KB) of Providing Regulatory Submissions in Electronic Format: IND Safety Reports Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/01\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOncology Center of Excellence","field_health_topics":"","term_node_tid":"","field_topics":"Electronic Submissions","topics-product":"Electronic Submissions, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-3953\u0022\u003EFDA-2019-D-3953\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-04-01T10:14:46-04:00\u0022\u003E2024-04-01 10:14\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/electronic-submission-ind-safety-reports-technical-conformance-guide\u0022\u003EElectronic Submission of IND Safety Reports Technical Conformance Guide : Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/132078\/download\u0022\u003EPDF (326.93 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (326.93 KB) of Electronic Submission of IND Safety Reports Technical Conformance Guide : Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/29\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOncology Center of Excellence\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Electronic Submissions","topics-product":"Electronic Submissions, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1216\u0022\u003EFDA-2018-D-1216\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-05-02T10:56:33-04:00\u0022\u003E2022-05-02 10:56\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/chronic-hepatitis-d-virus-infection-developing-drugs-treatment-guidance-industry\u0022\u003EChronic Hepatitis D Virus Infection: Developing Drugs for Treatment Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/132137\/download\u0022\u003EPDF (323.63 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (323.63 KB) of Chronic Hepatitis D Virus Infection: Developing Drugs for Treatment Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/01\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"01\/01\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-4042\u0022\u003EFDA-2019-D-4042\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222019-10-31T08:55:10-04:00\u0022\u003E2019-10-31 08:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/assessing-user-fees-under-generic-drug-user-fee-amendments-2022\u0022\u003EAssessing User Fees Under the Generic Drug User Fee Amendments of 2022\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/132138\/download\u0022\u003EPDF (550.06 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (550.06 KB) of Assessing User Fees Under the Generic Drug User Fee Amendments of 2022\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/09\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Generic Drugs","field_topics":"User Fees","topics-product":"User Fees, Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-0880\u0022\u003EFDA-2012-D-0880\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-06-08T13:35:16-04:00\u0022\u003E2023-06-08 13:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-review-staff-and-industry-good-review-management-principles-and-practices-pdufa-products\u0022\u003EGuidance for Review Staff and Industry Good Review Management Principles and Practices for PDUFA Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/132157\/download\u0022\u003EPDF (701.94 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (701.94 KB) of Guidance for Review Staff and Industry Good Review Management Principles and Practices for PDUFA Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/01\/2005","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222019-12-18T07:50:21-05:00\u0022\u003E2019-12-18 07:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-256-compounding-animal-drugs-bulk-drug-substances\u0022\u003ECVM GFI #256 - Compounding Animal Drugs from Bulk Drug Substances\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/132567\/download\u0022\u003EPDF (404.91 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (404.91 KB) of CVM GFI #256 - Compounding Animal Drugs from Bulk Drug Substances\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/10\/2022","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Compounding","field_topics":"","topics-product":"Compounding","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"10\/15\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-4533\u0022\u003EFDA-2018-D-4533\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222026-08-26T14:12:46-04:00\u0022\u003E2026-08-26 14:12\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/transdermal-and-topical-delivery-systems-product-development-and-quality-considerations\u0022\u003ETransdermal and Topical Delivery Systems - Product Development and Quality Considerations\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/132674\/download\u0022\u003EPDF (408.04 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (408.04 KB) of Transdermal and Topical Delivery Systems - Product Development and Quality Considerations\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/21\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality, Drug Competition Action Plan","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality, Drug Competition Action Plan","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"02\/19\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-4447\u0022\u003EFDA-2019-D-4447\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T08:25:28-04:00\u0022\u003E2020-05-06 08:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/certificates-confidentiality\u0022\u003ECertificates of Confidentiality: Guidance for Sponsors, Sponsor-Investigators, Researchers, Industry, and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/132966\/download\u0022\u003EPDF (167 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (167 KB) of Certificates of Confidentiality: Guidance for Sponsors, Sponsor-Investigators, Researchers, Industry, and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/13\/2020","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Policy, Legislation, and International Affairs,Office of Policy\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Tobacco Products\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program\u003Cbr\u003E\u003Cbr\u003ECenter for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of the Chief Scientist","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP)","field_topics":"Research","topics-product":"Research, Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"01\/08\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-3592 \u0022\u003EFDA-2019-D-3592 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222024-10-01T07:06:00-04:00\u0022\u003E2024-10-01 07:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/compliance-policy-limited-modifications-certain-marketed-tobacco-products\u0022\u003ECompliance Policy for Limited Modifications to Certain Marketed Tobacco Products: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/133009\/download\u0022\u003EPDF (283.2 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (283.2 KB) of Compliance Policy for Limited Modifications to Certain Marketed Tobacco Products: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/26\/2019","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"","field_topics":"Compliance","topics-product":"Compliance, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-5324\u0022\u003EFDA-2019-D-5324\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222020-02-14T14:25:17-05:00\u0022\u003E2020-02-14 14:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clinical-immunogenicity-considerations-biosimilar-and-interchangeable-insulin-products\u0022\u003EClinical Immunogenicity Considerations for Biosimilar and Interchangeable Insulin Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/133014\/download\u0022\u003EPDF (165.86 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (165.86 KB) of Clinical Immunogenicity Considerations for Biosimilar and Interchangeable Insulin Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/25\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Biosimilars","field_topics":"","topics-product":"Biosimilars","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"01\/28\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/ FDA-2019-D-5255\u0022\u003E FDA-2019-D-5255\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-05-06T11:30:41-04:00\u0022\u003E2020-05-06 11:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/interstitial-cystitisbladder-pain-syndrome-establishing-drug-development-programs-treatment\u0022\u003EInterstitial Cystitis\/Bladder Pain Syndrome: Establishing Drug Development Programs for Treatment: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/169118\/download\u0022\u003EPDF (295.3 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (295.3 KB) of Interstitial Cystitis\/Bladder Pain Syndrome: Establishing Drug Development Programs for Treatment: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/02\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"08\/04\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-4656\u0022\u003EFDA-2019-D-4656\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-06-05T09:59:31-04:00\u0022\u003E2023-06-05 09:59\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/magnetic-resonance-mr-receive-only-coil-performance-criteria-safety-and-performance-based-pathway\u0022\u003EMagnetic Resonance (MR) Receive-only Coil - Performance Criteria for Safety and Performance Based Pathway: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/133250\/download\u0022\u003EPDF (446.23 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (446.23 KB) of Magnetic Resonance (MR) Receive-only Coil - Performance Criteria for Safety and Performance Based Pathway: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/11\/2020","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Radiology","field_topics":"Premarket","topics-product":"Premarket, 510(k), Radiology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-1650\u0022\u003EFDA-2019-D-1650\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222020-12-10T08:56:11-05:00\u0022\u003E2020-12-10 08:56\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/development-locally-applied-corticosteroid-products-short-term-treatment-symptoms-associated\u0022\u003EDevelopment of Locally Applied Corticosteroid Products for the Short-Term Treatment of Symptoms Associated with Internal or External Hemorrhoids Guidance for Industry: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/133256\/download\u0022\u003EPDF (94.79 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (94.79 KB) of Development of Locally Applied Corticosteroid Products for the Short-Term Treatment of Symptoms Associated with Internal or External Hemorrhoids Guidance for Industry: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/09\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"02\/07\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-4433\u0022\u003EFDA-2019-D-4433\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-28T13:05:15-04:00\u0022\u003E2020-04-28 13:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/fdara-implementation-guidance-pediatric-studies-molecularly-targeted-oncology-drugs-amendments-sec\u0022\u003EFDARA Implementation Guidance for Pediatric Studies of Molecularly Targeted Oncology Drugs: Amendments to Sec. 505B of the FD\u0026amp;C Act: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/133440\/download\u0022\u003EPDF (154.18 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (154.18 KB) of FDARA Implementation Guidance for Pediatric Studies of Molecularly Targeted Oncology Drugs: Amendments to Sec. 505B of the FD\u0026amp;C Act: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/24\/2021","field_issuing_office_taxonomy":"Oncology Center of Excellence\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Pediatric Product Development","field_topics":"Clinical Trials","topics-product":"Clinical Trials, Administrative \/ Procedural, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"02\/12\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-4751\u0022\u003EFDA-2019-D-4751\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T09:37:16-04:00\u0022\u003E2024-04-11 09:37\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/importation-certain-fda-approved-human-prescription-drugs-including-biological-products-and\u0022\u003EImportation of Certain FDA- Approved Human Prescription Drugs, Including Biological Products, and Combination Products under Section 801(d)(1)(B) of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/142474\/download\u0022\u003EPDF (340.57 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (340.57 KB) of Importation of Certain FDA- Approved Human Prescription Drugs, Including Biological Products, and Combination Products under Section 801(d)(1)(B) of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/01\/2020","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products","field_health_topics":"","term_node_tid":"Labeling, Chemistry, Manufacturing, and Controls (CMC), Combination Products, Pharmaceutical Quality","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Labeling, Chemistry, Manufacturing, and Controls (CMC), Combination Products, Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"02\/21\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-5743\u0022\u003EFDA-2019-D-5743\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222024-11-05T16:09:05-05:00\u0022\u003E2024-11-05 16:09\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/bridging-drug-device-and-biologic-device-combination-products\u0022\u003EBridging for Drug-Device and Biologic-Device Combination Products: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/133676\/download\u0022\u003EPDF (323.45 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (323.45 KB) of Bridging for Drug-Device and Biologic-Device Combination Products: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/19\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products","field_health_topics":"","term_node_tid":"Combination Products","field_topics":"","topics-product":"Combination Products","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"02\/18\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-5585\u0022\u003EFDA-2019-D-5585\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222020-07-06T12:05:37-04:00\u0022\u003E2020-07-06 12:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/requesting-fda-feedback-combination-products\u0022\u003ERequesting FDA Feedback on Combination Products : Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/133768\/download\u0022\u003EPDF (595.72 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (595.72 KB) of Requesting FDA Feedback on Combination Products : Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/04\/2020","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Combination Products, Over-the-Counter Drugs","field_topics":"","topics-product":"Combination Products, Over-the-Counter Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"02\/24\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-4739\u0022\u003EFDA-2019-D-4739\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222021-01-20T16:19:29-05:00\u0022\u003E2021-01-20 16:19\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/submission-plans-cigarette-packages-and-cigarette-advertisements-revised\u0022\u003ESubmission of Plans for Cigarette Packages and Cigarette Advertisements (Revised)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/133839\/download\u0022\u003EPDF (539.45 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (539.45 KB) of Submission of Plans for Cigarette Packages and Cigarette Advertisements (Revised)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/12\/2024","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-5364\u0022\u003EFDA-2019-D-5364\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222024-09-12T10:21:47-04:00\u0022\u003E2024-09-12 10:21\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/postmarketing-studies-and-clinical-trials-implementation-section-505o3-federal-food-drug-and\u0022\u003EPostmarketing Studies and Clinical Trials\u2014Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/131980\/download\u0022\u003EPDF (335.12 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (335.12 KB) of Postmarketing Studies and Clinical Trials\u2014Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/12\/2011","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Device \u0026amp; Drug Safety","field_topics":"","topics-product":"Device \u0026amp; Drug Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0283\u0022\u003EFDA-2009-D-0283\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222021-05-12T13:50:04-04:00\u0022\u003E2021-05-12 13:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/peripheral-percutaneous-transluminal-angioplasty-pta-and-specialty-catheters-premarket-notification\u0022\u003EPeripheral Percutaneous Transluminal Angioplasty (PTA) and Specialty Catheters - Premarket Notification (510(k)) Submissions: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/134016\/download\u0022\u003EPDF (1.04 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.04 MB) of Peripheral Percutaneous Transluminal Angioplasty (PTA) and Specialty Catheters - Premarket Notification (510(k)) Submissions: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/14\/2023","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Cardiovascular , Labeling","field_topics":"Premarket","topics-product":"Premarket, 510(k), Cardiovascular , Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-5422\u0022\u003EFDA-2019-D-5422\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222023-04-13T08:53:57-04:00\u0022\u003E2023-04-13 08:53\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/arthroscopy-pump-tubing-sets-intended-multiple-patient-use-premarket-notification-510k-submissions\u0022\u003EArthroscopy Pump Tubing Sets Intended for Multiple Patient Use - Premarket Notification (510(k)) Submissions: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/134667\/download\u0022\u003EPDF (596.38 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (596.38 KB) of Arthroscopy Pump Tubing Sets Intended for Multiple Patient Use - Premarket Notification (510(k)) Submissions: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/23\/2021","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Orthopedic","field_topics":"Premarket","topics-product":"Premarket, 510(k), Orthopedic","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-5606\u0022\u003EFDA-2019-D-5606\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222021-12-22T08:50:10-05:00\u0022\u003E2021-12-22 08:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/interpreting-sameness-gene-therapy-products-under-orphan-drug-regulations\u0022\u003EInterpreting Sameness of Gene Therapy Products Under the Orphan Drug Regulations: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/134731\/download\u0022\u003EPDF (222.06 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (222.06 KB) of Interpreting Sameness of Gene Therapy Products Under the Orphan Drug Regulations: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/29\/2021","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Orphan Products Development","field_health_topics":"","term_node_tid":"Gene Therapy","field_topics":"","topics-product":"Gene Therapy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"07\/28\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-5392 \u0022\u003EFDA-2019-D-5392 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222022-03-15T01:37:03-04:00\u0022\u003E2022-03-15 01:37\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-fish-and-fishery-products-hazards-and-controls\u0022\u003EGuidance for Industry: Fish and Fishery Products Hazards and Controls\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"06\/01\/2022","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Seafood\/Seafood Product","field_topics":"","topics-product":"Seafood\/Seafood Product","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0287\u0022\u003EFDA-2011-D-0287\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:04:14-04:00\u0022\u003E2024-10-01 07:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-labeling-foods-need-refrigeration-consumers\u0022\u003EGuidance on Labeling of Foods That Need Refrigeration by Consumers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/134845\/download\u0022\u003EPDF (99.77 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (99.77 KB) of Guidance on Labeling of Foods That Need Refrigeration by Consumers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/24\/1997","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1996-D-0012\u0022\u003EFDA-1996-D-0012\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:06:02-04:00\u0022\u003E2024-10-01 07:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-entity-compliance-guide-revision-nutrition-and-supplement-facts-labels\u0022\u003ESmall Entity Compliance Guide: Revision of the Nutrition and Supplement Facts Labels\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/134505\/download\u0022\u003EPDF (1.05 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.05 MB) of Small Entity Compliance Guide: Revision of the Nutrition and Supplement Facts Labels\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/03\/2020","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling, Nutrition Label","field_topics":"","topics-product":"Labeling, Nutrition Label","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-N-1210\u0022\u003EFDA-2012-N-1210\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Human Foods Program","field_regulated_product_field":"Dietary Supplements, Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-10T16:36:46-04:00\u0022\u003E2025-03-10 16:36\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/promotional-labeling-and-advertising-considerations-prescription-biological-reference-products\u0022\u003EPromotional Labeling and Advertising Considerations for Prescription Biological Reference Products, Biosimilar Products, and Interchangeable Biosimilar Products: Questions and Answers: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/134862\/download\u0022\u003EPDF (269.98 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (269.98 KB) of Promotional Labeling and Advertising Considerations for Prescription Biological Reference Products, Biosimilar Products, and Interchangeable Biosimilar Products: Questions and Answers: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/09\/2025","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Advertising","field_topics":"","topics-product":"Advertising","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-5473\u0022\u003EFDA-2019-D-5473\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222025-12-10T10:51:03-05:00\u0022\u003E2025-12-10 10:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/mucopolysaccharidosis-type-iii-sanfilippo-syndrome-developing-drugs-treatment-guidance-industry\u0022\u003EMucopolysaccharidosis Type III (Sanfilippo Syndrome): Developing Drugs for Treatment Guidance for Industry: Draft Guidance for Industy\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/134893\/download\u0022\u003EPDF (242.58 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (242.58 KB) of Mucopolysaccharidosis Type III (Sanfilippo Syndrome): Developing Drugs for Treatment Guidance for Industry: Draft Guidance for Industy\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/04\/2020","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"05\/05\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-5404\u0022\u003EFDA-2019-D-5404\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222020-05-14T11:28:27-04:00\u0022\u003E2020-05-14 11:28\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/biosimilars-and-interchangeable-biosimilars-licensure-fewer-all-conditions-use-which-reference\u0022\u003EBiosimilars and Interchangeable Biosimilars: Licensure for Fewer Than All Conditions of Use for Which the Reference Product Has Been Licensed Guidance for Industry: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/134932\/download\u0022\u003EPDF (378.7 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (378.7 KB) of Biosimilars and Interchangeable Biosimilars: Licensure for Fewer Than All Conditions of Use for Which the Reference Product Has Been Licensed Guidance for Industry: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/07\/2020","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Biosimilars","field_topics":"","topics-product":"Biosimilars","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"04\/06\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-5270\u0022\u003EFDA-2019-D-5270\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222020-04-09T12:20:33-04:00\u0022\u003E2020-04-09 12:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/product-name-placement-size-and-prominence-advertising-and-promotional-labeling-final\u0022\u003EProduct Name Placement, Size, and Prominence in Advertising and Promotional Labeling-Final\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/87202\/download\u0022\u003EPDF (111.38 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (111.38 KB) of Product Name Placement, Size, and Prominence in Advertising and Promotional Labeling-Final\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/12\/2017","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Advertising","field_topics":"","topics-product":"Advertising","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1999-D-4079\u0022\u003EFDA-1999-D-4079\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-09-30T08:55:13-04:00\u0022\u003E2021-09-30 08:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/product-recalls-including-removals-and-corrections\u0022\u003EProduct Recalls, Including Removals and Corrections: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/136987\/download\u0022\u003EPDF (190.98 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (190.98 KB) of Product Recalls, Including Removals and Corrections: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/02\/2020","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program\u003Cbr\u003E\u003Cbr\u003ECenter for Tobacco Products\u003Cbr\u003E\u003Cbr\u003ECenter for Veterinary Medicine","field_health_topics":"","term_node_tid":"","field_topics":"Recalls","topics-product":"Recalls, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222024-10-01T07:06:04-04:00\u0022\u003E2024-10-01 07:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-262-pre-submission-consultation-process-animal-food-additive-petitions-or-generally\u0022\u003ECVM GFI #262 Pre-Submission Consultation Process for Animal Food Additive Petitions or Generally Recognized as Safe (GRAS) Notices\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/134995\/download\u0022\u003EPDF (194.72 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (194.72 KB) of CVM GFI #262 Pre-Submission Consultation Process for Animal Food Additive Petitions or Generally Recognized as Safe (GRAS) Notices\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/11\/2020","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Food Additives, Generally Recognized as Safe (GRAS)","field_topics":"","topics-product":"Animal Food Additives, Generally Recognized as Safe (GRAS)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"04\/13\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0064\u0022\u003EFDA-2020-D-0064\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222021-01-20T15:40:07-05:00\u0022\u003E2021-01-20 15:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/supplemental-draft-guidance-industry-mitigation-strategies-protect-food-against-intentional\u0022\u003ESupplemental Draft Guidance for Industry: Mitigation Strategies to Protect Food Against Intentional Adulteration\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/135122\/download\u0022\u003EPDF (459.08 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (459.08 KB) of Supplemental Draft Guidance for Industry: Mitigation Strategies to Protect Food Against Intentional Adulteration\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/13\/2020","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1398\u0022\u003EFDA-2018-D-1398\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-18T13:30:32-04:00\u0022\u003E2025-03-18 13:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-555450-foods-adulteration-involving-infestation-and-1080-rodenticide\u0022\u003ECPG Sec 555.450 Foods - Adulteration Involving Infestation and 1080 Rodenticide \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/127705\/download\u0022\u003EPDF (8.99 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (8.99 KB) of CPG Sec 555.450 Foods - Adulteration Involving Infestation and 1080 Rodenticide \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/01\/1980","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T15:43:01-04:00\u0022\u003E2025-03-17 15:43\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/specifications-preparing-and-submitting-electronic-icsrs-and-icsr-attachments\u0022\u003ESpecifications for Preparing and Submitting Electronic ICSRs and ICSR Attachments\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/132096\/download\u0022\u003EPDF (313.86 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (313.86 KB) of Specifications for Preparing and Submitting Electronic ICSRs and ICSR Attachments\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/14\/2020","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Safety - Issues, Errors, and Problems","field_topics":"","topics-product":"Safety - Issues, Errors, and Problems","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/None found\u0022\u003ENone found\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-20T11:20:07-04:00\u0022\u003E2020-04-20 11:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommendations-submission-loincr-codes-regulatory-applications-us-food-and-drug-administration\u0022\u003ERecommendations for the Submission of LOINC\u00ae Codes in Regulatory Applications to the U.S. Food and Drug Administration: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/109376\/download\u0022\u003EPDF (235.85 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (235.85 KB) of Recommendations for the Submission of LOINC\u00ae Codes in Regulatory Applications to the U.S. Food and Drug Administration: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/01\/2017","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6982\u0022\u003EFDA-2017-D-6982\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-20T11:30:23-04:00\u0022\u003E2020-04-20 11:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/points-consider-manufacture-and-testing-monoclonal-antibody-products-human-use\u0022\u003EPoints to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/76798\/download\u0022\u003EPDF (1011.66 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1011.66 KB) of Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/28\/1997","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1994-D-0318\u0022\u003EFDA-1994-D-0318\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-20T11:15:40-04:00\u0022\u003E2020-04-20 11:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/study-data-technical-conformance-guide-technical-specifications-document\u0022\u003EStudy Data Technical Conformance Guide - Technical Specifications Document\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/153632\/download\u0022\u003EPDF (1.33 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.33 MB) of Study Data Technical Conformance Guide - Technical Specifications Document\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/08\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"05\/07\/2014","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0092\u0022\u003EFDA-2014-D-0092\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222026-10-08T16:25:31-04:00\u0022\u003E2026-10-08 16:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/good-laboratory-practice-regulations-management-briefings-post-conference-report-aug-1979\u0022\u003EGood Laboratory Practice Regulations Management Briefings, Post Conference Report, Aug 1979: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"08\/31\/1979","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Food \u0026amp; Color Additives, Investigational New Drug Application (INDA), Pharmacology\/Toxicology","field_topics":"Clinical Trials, Compliance","topics-product":"Clinical Trials, Compliance, Food \u0026amp; Color Additives, Investigational New Drug Application (INDA), Pharmacology\/Toxicology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1976-N-0476-0380\u0022\u003EFDA-1976-N-0476-0380\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222024-10-24T14:52:43-04:00\u0022\u003E2024-10-24 14:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-264-standardized-medicated-feed-assay-limits\u0022\u003ECVM GFI #264 Standardized Medicated Feed Assay Limits\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/135515\/download\u0022\u003EPDF (85.07 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (85.07 KB) of CVM GFI #264 Standardized Medicated Feed Assay Limits\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/27\/2020","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Feed, Chemistry, Manufacturing, and Controls (CMC), Current Good Manufacturing Practice (CGMP), Target Animal \u2013 Safety, Target Animal \u2013 Effectiveness, Human Food Safety, Investigational New Animal Drug (INAD)","field_topics":"","topics-product":"Animal Feed, Chemistry, Manufacturing, and Controls (CMC), Current Good Manufacturing Practice (CGMP), Target Animal \u2013 Safety, Target Animal \u2013 Effectiveness, Human Food Safety, Investigational New Animal Drug (INAD)","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"06\/26\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-5664\u0022\u003EFDA-2019-D-5664\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222020-04-27T06:05:08-04:00\u0022\u003E2020-04-27 06:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/drug-master-files-guidelines\u0022\u003EDrug Master Files: Guidelines\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"06\/18\/2014","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pharmaceutical Quality","field_topics":"","topics-product":"Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0397\u0022\u003EFDA-2014-D-0397\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-02-27T17:55:08-05:00\u0022\u003E2020-02-27 17:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/internetsocial-media-platforms-character-space-limitations-presenting-risk-and-benefit-information-0\u0022\u003EInternet\/Social Media Platforms with Character Space Limitations\u2014 Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/88551\/download\u0022\u003EPDF (176.42 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (176.42 KB) of Internet\/Social Media Platforms with Character Space Limitations\u2014 Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/18\/2014","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Advertising","field_topics":"","topics-product":"Advertising","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0397\u0022\u003EFDA-2014-D-0397\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-24T15:05:03-04:00\u0022\u003E2020-04-24 15:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/fda-regional-implementation-guide-e2br3-electronic-transmission-individual-case-safety-reports-drug\u0022\u003EFDA Regional Implementation Guide for E2B(R3) Electronic Transmission of Individual Case Safety Reports for Drug and Biological Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/180748\/download\u0022\u003EPDF (466.88 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (466.88 KB) of FDA Regional Implementation Guide for E2B(R3) Electronic Transmission of Individual Case Safety Reports for Drug and Biological Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/01\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Safety","field_topics":"","topics-product":"ICH-Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-1280\u0022\u003EFDA-2016-D-1280\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-08-09T16:10:32-04:00\u0022\u003E2024-08-09 16:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/electronic-transmission-individual-case-safety-reports-implementation-guide-data-elements-and\u0022\u003EThe Electronic Transmission of Individual Case Safety Reports Implementation Guide \u2014 Data Elements and Message Specification \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/81904\/download\u0022\u003EPDF (2.5 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (2.5 MB) of The Electronic Transmission of Individual Case Safety Reports Implementation Guide \u2014 Data Elements and Message Specification \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/27\/2014","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Safety","field_topics":"","topics-product":"ICH-Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-02-07T08:50:51-05:00\u0022\u003E2025-02-07 08:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e2br3-electronic-transmission-individual-case-safety-reports-implementation-guide-appendix\u0022\u003EE2B(R3) The Electronic Transmission of Individual Case Safety Reports Implementation Guide \u2014Appendix to the Implementation Guide \u2014 Backwards and Forwards Compatibility\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/81913\/download\u0022\u003EPDF (597.38 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (597.38 KB) of E2B(R3) The Electronic Transmission of Individual Case Safety Reports Implementation Guide \u2014Appendix to the Implementation Guide \u2014 Backwards and Forwards Compatibility\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/29\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Safety","field_topics":"","topics-product":"ICH-Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0720\u0022\u003EFDA-2011-D-0720\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-05-18T11:49:39-04:00\u0022\u003E2022-05-18 11:49\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/rems-fdas-application-statutory-factors-determining-when-rems-necessary-guidance-industry\u0022\u003E REMS: FDA\u2019s Application of Statutory Factors in Determining When a REMS Is Necessary Guidance for Industry \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/100307\/download\u0022\u003EPDF (110.01 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (110.01 KB) of REMS: FDA\u2019s Application of Statutory Factors in Determining When a REMS Is Necessary Guidance for Industry \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/04\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/2019-06663 \u0022\u003E2019-06663 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-02-27T20:15:02-05:00\u0022\u003E2020-02-27 20:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/questions-and-answers-current-good-manufacturing-practices-drugs\u0022\u003EQuestions and Answers on Current Good Manufacturing Practices for Drugs\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"03\/30\/2018","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_topics":"","topics-product":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6821\u0022\u003EFDA-2017-D-6821\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-02-11T16:49:03-05:00\u0022\u003E2025-02-11 16:49\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/policy-coronavirus-disease-2019-tests-revised\u0022\u003EPolicy for Coronavirus Disease-2019 Tests (Revised): Guidance for Developers and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/135659\/download\u0022\u003EPDF (372.44 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (372.44 KB) of Policy for Coronavirus Disease-2019 Tests (Revised): Guidance for Developers and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/12\/2023","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"Coronavirus","term_node_tid":"CLIA (Clinical Laboratory Improvement Amendments), Immunology \u0026amp; Microbiology , IVDs (In Vitro Diagnostic Devices)","field_topics":"Premarket","topics-product":"Premarket, Coronavirus, CLIA (Clinical Laboratory Improvement Amendments), Immunology \u0026amp; Microbiology , IVDs (In Vitro Diagnostic Devices)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0987\u0022\u003EFDA-2020-D-0987\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222024-12-30T13:16:28-05:00\u0022\u003E2024-12-30 13:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/soft-hydrophilic-daily-wear-contact-lenses-performance-criteria-safety-and-performance-based-pathway\u0022\u003ESoft (Hydrophilic) Daily Wear Contact Lenses - Performance Criteria for Safety and Performance Based Pathway: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/135629\/download\u0022\u003EPDF (565.55 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (565.55 KB) of Soft (Hydrophilic) Daily Wear Contact Lenses - Performance Criteria for Safety and Performance Based Pathway: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/28\/2023","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Ophthalmic","field_topics":"Premarket","topics-product":"Premarket, 510(k), Ophthalmic","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-4843\u0022\u003EFDA-2019-D-4843\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222023-03-27T09:25:16-04:00\u0022\u003E2023-03-27 09:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/inclusion-older-adults-cancer-clinical-trials\u0022\u003EInclusion of Older Adults in Cancer Clinical Trials: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/156616\/download\u0022\u003EPDF (299.75 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (299.75 KB) of Inclusion of Older Adults in Cancer Clinical Trials: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/02\/2022","field_issuing_office_taxonomy":"Oncology Center of Excellence\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-5572\u0022\u003EFDA-2019-D-5572\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222022-03-02T13:55:04-05:00\u0022\u003E2022-03-02 13:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/contact-dermatitis-topical-drug-products-cutaneous-application-human-safety-assessment-guidance\u0022\u003EContact Dermatitis From Topical Drug Products for Cutaneous Application: Human Safety Assessment Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/135888\/download\u0022\u003EPDF (55.51 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (55.51 KB) of Contact Dermatitis From Topical Drug Products for Cutaneous Application: Human Safety Assessment Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/06\/2020","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"05\/08\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0043\u0022\u003EFDA-2020-D-0043\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-03-06T09:37:51-05:00\u0022\u003E2020-03-06 09:37\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/type-2-diabetes-mellitus-evaluating-safety-new-drugs-improving-glycemic-control-guidance-industry\u0022\u003EType 2 Diabetes Mellitus: Evaluating the Safety of New Drugs for Improving Glycemic Control Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/135936\/download\u0022\u003EPDF (222.39 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (222.39 KB) of Type 2 Diabetes Mellitus: Evaluating the Safety of New Drugs for Improving Glycemic Control Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/10\/2020","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"06\/08\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-N-6084\u0022\u003EFDA-2019-N-6084\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-03-10T09:25:16-04:00\u0022\u003E2020-03-10 09:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/providing-regulatory-submissions-alternate-electronic-format-guidance-industry\u0022\u003EProviding Regulatory Submissions in Alternate Electronic Format Guidance for Industry: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/159388\/download\u0022\u003EPDF (264.37 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (264.37 KB) of Providing Regulatory Submissions in Alternate Electronic Format Guidance for Industry: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/24\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Electronic Submissions","topics-product":"Electronic Submissions, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0420\u0022\u003EFDA-2020-D-0420\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222022-06-24T08:45:37-04:00\u0022\u003E2022-06-24 08:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/restricted-delivery-systems-flow-restrictors-oral-liquid-drug-products-guidance-industry\u0022\u003ERestricted Delivery Systems: Flow Restrictors for Oral Liquid Drug Products Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/136170\/download\u0022\u003EPDF (143.43 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (143.43 KB) of Restricted Delivery Systems: Flow Restrictors for Oral Liquid Drug Products Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/17\/2020","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Device \u0026amp; Drug Safety","field_topics":"","topics-product":"Device \u0026amp; Drug Safety","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"05\/18\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0567\u0022\u003EFDA-2020-D-0567\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222020-03-17T09:07:50-04:00\u0022\u003E2020-03-17 09:07\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/required-warnings-cigarette-packages-and-advertisements-small-entity-compliance-guide-revised\u0022\u003ERequired Warnings for Cigarette Packages and Advertisements: Small Entity Compliance Guide (Revised): Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/136185\/download\u0022\u003EPDF (805.23 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (805.23 KB) of Required Warnings for Cigarette Packages and Advertisements: Small Entity Compliance Guide (Revised): Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/12\/2024","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0988\u0022\u003EFDA-2020-D-0988\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222024-09-12T10:21:44-04:00\u0022\u003E2024-09-12 10:21\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/enforcement-policy-non-invasive-remote-monitoring-devices-used-support-patient-monitoring\u0022\u003EEnforcement Policy for Non-Invasive Remote Monitoring Devices Used to Support Patient Monitoring: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/136290\/download\u0022\u003EPDF (562.96 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (562.96 KB) of Enforcement Policy for Non-Invasive Remote Monitoring Devices Used to Support Patient Monitoring: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/19\/2023","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Labeling","field_topics":"Premarket","topics-product":"Premarket, 510(k), Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-4356\u0022\u003EFDA-2023-D-4356\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222023-10-18T11:02:01-04:00\u0022\u003E2023-10-18 11:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/enforcement-policy-face-masks-and-barrier-face-coverings-during-coronavirus-disease-covid-19-public\u0022\u003EEnforcement Policy for Face Masks and Barrier Face Coverings During the Coronavirus Disease (COVID-19) Public Health Emergency : Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/136449\/download\u0022\u003EPDF (527.83 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (527.83 KB) of Enforcement Policy for Face Masks and Barrier Face Coverings During the Coronavirus Disease (COVID-19) Public Health Emergency : Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/05\/2023","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"Coronavirus","term_node_tid":"Labeling","field_topics":"Premarket","topics-product":"Premarket, Coronavirus, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1138\u0022\u003EFDA-2020-D-1138\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222023-09-05T09:09:01-04:00\u0022\u003E2023-09-05 09:09\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/standards-prompt-review-efficacy-supplements-including-priority-efficacy-supplements\u0022\u003EStandards for the Prompt Review of Efficacy Supplements, Including Priority Efficacy Supplements : Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72048\/download\u0022\u003EPDF (75.79 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (75.79 KB) of Standards for the Prompt Review of Efficacy Supplements, Including Priority Efficacy Supplements : Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/01\/1998","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/98-0276\u0022\u003E98-0276\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222021-03-18T21:34:59-04:00\u0022\u003E2021-03-18 21:34\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-480300-lack-expiration-date-stability-data-0\u0022\u003ECPG Sec. 480.300 Lack of Expiration Date of Stability Data \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72066\/download\u0022\u003EPDF (66.71 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (66.71 KB) of CPG Sec. 480.300 Lack of Expiration Date of Stability Data \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-14T11:45:40-04:00\u0022\u003E2020-04-14 11:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-490100-process-validation-requirements-drug-products-and-active-pharmaceutical-ingredients-0\u0022\u003ECPG Sec. 490.100 Process Validation Requirements for Drug Products and Active Pharmaceutical Ingredients Subject to Pre-Market Approval \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71756\/download\u0022\u003EPDF (124.71 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (124.71 KB) of CPG Sec. 490.100 Process Validation Requirements for Drug Products and Active Pharmaceutical Ingredients Subject to Pre-Market Approval \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/12\/2004","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-04-14T12:20:08-04:00\u0022\u003E2020-04-14 12:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/technical-considerations-demonstrating-reliability-emergency-use-injectors-submitted-under-bla-nda\u0022\u003ETechnical Considerations for Demonstrating Reliability of Emergency-Use Injectors Submitted under a BLA, NDA or ANDA: Draft Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/137158\/download\u0022\u003EPDF (451.26 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (451.26 KB) of Technical Considerations for Demonstrating Reliability of Emergency-Use Injectors Submitted under a BLA, NDA or ANDA: Draft Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/21\/2020","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Combination Products","field_topics":"","topics-product":"Combination Products","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"06\/22\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-5573\u0022\u003EFDA-2019-D-5573\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222020-04-21T14:25:25-04:00\u0022\u003E2020-04-21 14:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/classification-posterior-cervical-screw-systems-small-entity-compliance-guide\u0022\u003EClassification of Posterior Cervical Screw Systems: Small Entity Compliance Guide: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/137500\/download\u0022\u003EPDF (58.41 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (58.41 KB) of Classification of Posterior Cervical Screw Systems: Small Entity Compliance Guide: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/04\/2020","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Orthopedic, Premarket Approval (PMA)","field_topics":"","topics-product":"Orthopedic, Premarket Approval (PMA)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-N-3785\u0022\u003EFDA-2015-N-3785\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222020-05-01T11:40:03-04:00\u0022\u003E2020-05-01 11:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-271-reporting-and-mitigating-animal-drug-shortages\u0022\u003ECVM GFI #271 Reporting and Mitigating Animal Drug Shortages\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/137722\/download\u0022\u003EPDF (262.94 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (262.94 KB) of CVM GFI #271 Reporting and Mitigating Animal Drug Shortages\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/12\/2023","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"Coronavirus","term_node_tid":"Animal Drugs, Chemistry, Manufacturing, and Controls (CMC)","field_topics":"Postmarket","topics-product":"Postmarket, Coronavirus, Animal Drugs, Chemistry, Manufacturing, and Controls (CMC)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1140\u0022\u003EFDA-2020-D-1140\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222023-05-12T05:43:46-04:00\u0022\u003E2023-05-12 05:43\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-returning-refrigerated-transport-vehicles-and-refrigerated-storage-units-food-uses\u0022\u003EGuidance for Industry: Returning Refrigerated Transport Vehicles and Refrigerated Storage Units to Food Uses After Using Them to Preserve Human Remains\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/137964\/download\u0022\u003EPDF (230.96 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (230.96 KB) of Guidance for Industry: Returning Refrigerated Transport Vehicles and Refrigerated Storage Units to Food Uses After Using Them to Preserve Human Remains\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/20\/2023","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Transportation","field_topics":"","topics-product":"Transportation","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1139\u0022\u003EFDA-2020-D-1139\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Animal \u0026amp; Veterinary, Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T14:30:02-04:00\u0022\u003E2025-03-17 14:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-exports-under-fda-export-reform-and-enhancement-act-1996\u0022\u003E Guidance for Industry: Exports Under the FDA Export Reform and Enhancement Act of 1996 : Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/138075\/download\u0022\u003EPDF (527.72 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (527.72 KB) of Guidance for Industry: Exports Under the FDA Export Reform and Enhancement Act of 1996 : Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/01\/1996","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222020-05-26T12:45:22-04:00\u0022\u003E2020-05-26 12:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/additional-recommendations-testing-whole-blood-blood-components-source-plasma-and-source-leukocytes\u0022\u003EAdditional Recommendations for Testing Whole Blood, Blood Components, Source Plasma and Source Leukocytes for Antibody to Hepatitis C Virus Encoded Antigen (Anti-HCV): Memorandum to Registered Blood and Plasma Establishments\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70714\/download\u0022\u003EPDF (13.24 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (13.24 KB) of Additional Recommendations for Testing Whole Blood, Blood Components, Source Plasma and Source Leukocytes for Antibody to Hepatitis C Virus Encoded Antigen (Anti-HCV): Memorandum to Registered Blood and Plasma Establishments\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/16\/1996","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Blood","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0498\u0022\u003EFDA-2022-D-0498\u003C\/a\u003E","field_communication_type":"Memorandum","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222022-04-28T15:53:04-04:00\u0022\u003E2022-04-28 15:53\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/additional-recommendations-donor-screening-licensed-test-hiv-1-antigen\u0022\u003EAdditional Recommendations for Donor Screening With a Licensed Test for HIV-1 Antigen: Memorandum to Registered Blood and Plasma Establishments\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70719\/download\u0022\u003EPDF (43.42 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (43.42 KB) of Additional Recommendations for Donor Screening With a Licensed Test for HIV-1 Antigen: Memorandum to Registered Blood and Plasma Establishments\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/14\/1996","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Blood","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0499\u0022\u003EFDA-2022-D-0499\u003C\/a\u003E","field_communication_type":"Memorandum","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222022-04-28T15:57:33-04:00\u0022\u003E2022-04-28 15:57\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/donor-deferral-due-red-blood-cell-loss-during-collection-source-plasma-automated-plasmapheresis\u0022\u003EDonor Deferral Due to Red Blood Cell Loss During Collection of Source Plasma by Automated Plasmapheresis \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70729\/download\u0022\u003EPDF (118.98 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (118.98 KB) of Donor Deferral Due to Red Blood Cell Loss During Collection of Source Plasma by Automated Plasmapheresis \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/04\/1995","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Blood","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0500\u0022\u003EFDA-2022-D-0500\u003C\/a\u003E","field_communication_type":"Memorandum","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222022-04-28T16:00:34-04:00\u0022\u003E2022-04-28 16:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommendations-donor-screening-licensed-test-hiv-1-antigen\u0022\u003ERecommendations for Donor Screening with a Licensed Test for HIV-1 Antigen: Memorandum to All Registered Blood Establishments\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70745\/download\u0022\u003EPDF (28.72 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (28.72 KB) of Recommendations for Donor Screening with a Licensed Test for HIV-1 Antigen: Memorandum to All Registered Blood Establishments\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/08\/1995","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Blood","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0501\u0022\u003EFDA-2022-D-0501\u003C\/a\u003E","field_communication_type":"Memorandum","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222022-04-28T16:07:33-04:00\u0022\u003E2022-04-28 16:07\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/revised-recommendations-red-blood-cell-immunization-programs-source-plasma-donors\u0022\u003ERevised Recommendations for Red Blood Cell Immunization Programs for Source Plasma Donors: Memorandum to Licensed Establishments\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70771\/download\u0022\u003EPDF (2.67 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (2.67 MB) of Revised Recommendations for Red Blood Cell Immunization Programs for Source Plasma Donors: Memorandum to Licensed Establishments\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/14\/1995","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Blood","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-S-0611\u0022\u003EFDA-2013-S-0611\u003C\/a\u003E","field_communication_type":"Memorandum","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222020-07-16T16:05:14-04:00\u0022\u003E2020-07-16 16:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/postapproval-changes-drug-substances-guidance-industry\u0022\u003EPostapproval Changes to Drug Substances Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/115733\/download\u0022\u003EPDF (392.75 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (392.75 KB) of Postapproval Changes to Drug Substances Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/11\/2018","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Veterinary Medicine","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC)","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC)","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"11\/09\/2018","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-3151\u0022\u003EFDA-2018-D-3151\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-05-25T16:19:37-04:00\u0022\u003E2022-05-25 16:19\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/revised-recommendations-testing-whole-blood-blood-components-source-plasma-and-source-leukocytes\u0022\u003ERevised Recommendations for Testing Whole Blood, Blood Components, Source Plasma and Source Leukocytes for Antibody to Hepatitis C Virus Encoded Antigen (Anti-HCV)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70924\/download\u0022\u003EPDF (18.91 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (18.91 KB) of Revised Recommendations for Testing Whole Blood, Blood Components, Source Plasma and Source Leukocytes for Antibody to Hepatitis C Virus Encoded Antigen (Anti-HCV)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/05\/1993","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Blood","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-S-0612\u0022\u003EFDA-2013-S-0612\u003C\/a\u003E","field_communication_type":"Memorandum","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222020-07-16T09:20:03-04:00\u0022\u003E2020-07-16 09:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommendations-regarding-license-amendments-and-procedures-gamma-irradiation-blood-products\u0022\u003ERecommendations Regarding License Amendments and Procedures for Gamma Irradiation of Blood Products \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70934\/download\u0022\u003EPDF (39.83 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (39.83 KB) of Recommendations Regarding License Amendments and Procedures for Gamma Irradiation of Blood Products \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/22\/1993","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Blood","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-S-0613\u0022\u003EFDA-2013-S-0613\u003C\/a\u003E","field_communication_type":"Memorandum","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222020-07-16T09:20:18-04:00\u0022\u003E2020-07-16 09:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/revised-recommendations-testing-whole-blood-blood-components-source-plasma-and-source-leukocytes-0\u0022\u003ERevised Recommendations for Testing Whole Blood, Blood Components, Source Plasma and Source Leukocytes for Antibody to Hepatitis C Virus Encoded Antigen (Anti-HCV)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70972\/download\u0022\u003EPDF (673.83 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (673.83 KB) of Revised Recommendations for Testing Whole Blood, Blood Components, Source Plasma and Source Leukocytes for Antibody to Hepatitis C Virus Encoded Antigen (Anti-HCV)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/23\/1992","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Blood","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-S-0613\u0022\u003EFDA-2013-S-0613\u003C\/a\u003E","field_communication_type":"Memorandum","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222020-07-16T09:25:03-04:00\u0022\u003E2020-07-16 09:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/plasma-derived-therapeutic-plasma-exchange\u0022\u003EPlasma Derived from Therapeutic Plasma Exchange\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70938\/download\u0022\u003EPDF (15.85 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (15.85 KB) of Plasma Derived from Therapeutic Plasma Exchange\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/14\/1984","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Blood","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-S-0613\u0022\u003EFDA-2013-S-0613\u003C\/a\u003E","field_communication_type":"Memorandum","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222020-07-16T09:40:03-04:00\u0022\u003E2020-07-16 09:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/consumer-directed-broadcast-advertisements\u0022\u003EConsumer-Directed Broadcast Advertisements: Guidance for Industry \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/75406\/download\u0022\u003EPDF (25.43 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (25.43 KB) of Consumer-Directed Broadcast Advertisements: Guidance for Industry \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/01\/1999","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Advertising","field_topics":"","topics-product":"Advertising","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1997-D-0048\u0022\u003EFDA-1997-D-0048\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Drugs","changed":"\u003Ctime datetime=\u00222020-05-22T07:25:20-04:00\u0022\u003E2020-05-22 07:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/enforcement-policy-certain-supplements-approved-premarket-approval-pma-or-humanitarian-device\u0022\u003EEnforcement Policy for Certain Supplements for Approved Premarket Approval (PMA) or Humanitarian Device Exemption (HDE) Submissions: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/138265\/download\u0022\u003EPDF (425.37 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (425.37 KB) of Enforcement Policy for Certain Supplements for Approved Premarket Approval (PMA) or Humanitarian Device Exemption (HDE) Submissions: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/02\/2023","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"HUD\/HDE, Premarket Approval (PMA)","field_topics":"","topics-product":"HUD\/HDE, Premarket Approval (PMA)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-4595\u0022\u003EFDA-2023-D-4595\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222023-11-01T09:08:28-04:00\u0022\u003E2023-11-01 09:08\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q3cr8-impurities-guidance-residual-solvents\u0022\u003EQ3C(R8) Impurities: Guidance for Residual Solvents: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/138334\/download\u0022\u003EPDF (213.55 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (213.55 KB) of Q3C(R8) Impurities: Guidance for Residual Solvents: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/10\/2021","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1301\u0022\u003EFDA-2020-D-1301\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-08-12T10:57:03-04:00\u0022\u003E2026-08-12 10:57\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/orange-book-questions-and-answers-guidance-industry\u0022\u003EOrange Book Questions and Answers Guidance for Industry: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/160167\/download\u0022\u003EPDF (365.98 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (365.98 KB) of Orange Book Questions and Answers Guidance for Industry: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/22\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Generic Drugs","field_topics":"","topics-product":"Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1068\u0022\u003EFDA-2020-D-1068\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-07-22T08:45:41-04:00\u0022\u003E2022-07-22 08:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/institutional-review-board-irb-review-individual-patient-expanded-access-submissions-investigational\u0022\u003EInstitutional Review Board (IRB) Review of Individual Patient Expanded Access Submissions for Investigational Drugs and Biological Products: Guidance for IRBs and Clinical Investigators\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/171902\/download\u0022\u003EPDF (152.78 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (152.78 KB) of Institutional Review Board (IRB) Review of Individual Patient Expanded Access Submissions for Investigational Drugs and Biological Products: Guidance for IRBs and Clinical Investigators\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/11\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOncology Center of Excellence","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP)","field_topics":"","topics-product":"Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-3452\u0022\u003EFDA-2023-D-3452\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-09-11T10:02:15-04:00\u0022\u003E2023-09-11 10:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/accidental-radioactive-contamination-human-food-and-animal-feeds\u0022\u003EAccidental Radioactive Contamination of Human Food and Animal Feeds: Recommendations for State and Local Agencies\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/74043\/download\u0022\u003EPDF (995 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (995 KB) of Accidental Radioactive Contamination of Human Food and Animal Feeds: Recommendations for State and Local Agencies\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/13\/1998","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Radiological Health","field_topics":"","topics-product":"Radiological Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222021-04-27T09:55:07-04:00\u0022\u003E2021-04-27 09:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/review-and-update-device-establishment-inspection-processes-and-standards\u0022\u003EReview and Update of Device Establishment Inspection Processes and Standards: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/139466\/download\u0022\u003EPDF (51.51 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (51.51 KB) of Review and Update of Device Establishment Inspection Processes and Standards: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/29\/2020","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"06\/26\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-0914\u0022\u003EFDA-2019-D-0914\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222024-11-05T16:08:53-05:00\u0022\u003E2024-11-05 16:08\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/development-anti-infective-drug-products-pediatric-population\u0022\u003EDevelopment of Anti-Infective Drug Products for the Pediatric Population : Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/139586\/download\u0022\u003EPDF (91.93 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (91.93 KB) of Development of Anti-Infective Drug Products for the Pediatric Population : Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/09\/2021","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Pediatric Product Development","field_topics":"","topics-product":"Clinical - Medical, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1518\u0022\u003EFDA-2020-D-1518\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T09:28:31-04:00\u0022\u003E2024-04-11 09:28\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/development-and-licensure-vaccines-prevent-covid-19\u0022\u003EDevelopment and Licensure of Vaccines to Prevent COVID-19: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/139638\/download\u0022\u003EPDF (407.08 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (407.08 KB) of Development and Licensure of Vaccines to Prevent COVID-19: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/19\/2023","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Infectious Disease, Coronavirus","term_node_tid":"Vaccines","field_topics":"","topics-product":"Infectious Disease, Coronavirus, Vaccines","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1137\u0022\u003EFDA-2020-D-1137\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222026-08-03T15:22:04-04:00\u0022\u003E2026-08-03 15:22\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-267-biomarkers-and-surrogate-endpoints-clinical-studies-support-effectiveness-new-animal\u0022\u003ECVM GFI #267 Biomarkers and Surrogate Endpoints in Clinical Studies to Support Effectiveness of New Animal Drugs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/138160\/download\u0022\u003EPDF (367.79 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (367.79 KB) of CVM GFI #267 Biomarkers and Surrogate Endpoints in Clinical Studies to Support Effectiveness of New Animal Drugs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/06\/2021","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Investigational New Animal Drug (INAD), New Animal Drug Application (NADA), Target Animal \u2013 Effectiveness","field_topics":"Premarket","topics-product":"Premarket, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA), Target Animal \u2013 Effectiveness","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"10\/13\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1402\u0022\u003EFDA-2020-D-1402\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222021-10-05T08:55:35-04:00\u0022\u003E2021-10-05 08:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-266-use-real-world-data-and-real-world-evidence-support-effectiveness-new-animal-drugs\u0022\u003ECVM GFI #266 Use of Real-World Data and Real-World Evidence to Support Effectiveness of New Animal Drugs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/139953\/download\u0022\u003EPDF (376.32 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (376.32 KB) of CVM GFI #266 Use of Real-World Data and Real-World Evidence to Support Effectiveness of New Animal Drugs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/06\/2021","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Investigational New Animal Drug (INAD), New Animal Drug Application (NADA), Target Animal \u2013 Effectiveness","field_topics":"Premarket","topics-product":"Premarket, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA), Target Animal \u2013 Effectiveness","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"10\/13\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1400\u0022\u003EFDA-2020-D-1400\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222021-10-05T08:55:54-04:00\u0022\u003E2021-10-05 08:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-265-use-data-foreign-investigational-studies-support-effectiveness-new-animal-drugs\u0022\u003ECVM GFI #265 Use of Data from Foreign Investigational Studies to Support Effectiveness of New Animal Drugs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/138159\/download\u0022\u003EPDF (334.06 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (334.06 KB) of CVM GFI #265 Use of Data from Foreign Investigational Studies to Support Effectiveness of New Animal Drugs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/06\/2021","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Investigational New Animal Drug (INAD), New Animal Drug Application (NADA), Target Animal \u2013 Effectiveness","field_topics":"Premarket","topics-product":"Premarket, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA), Target Animal \u2013 Effectiveness","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"10\/13\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1396\u0022\u003EFDA-2020-D-1396\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222021-10-05T08:55:27-04:00\u0022\u003E2021-10-05 08:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-268-adaptive-and-other-innovative-designs-effectiveness-studies-new-animal-drugs\u0022\u003ECVM GFI #268 Adaptive and Other Innovative Designs for Effectiveness Studies of New Animal Drugs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/139971\/download\u0022\u003EPDF (420.35 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (420.35 KB) of CVM GFI #268 Adaptive and Other Innovative Designs for Effectiveness Studies of New Animal Drugs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/06\/2021","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Investigational New Animal Drug (INAD), New Animal Drug Application (NADA), Target Animal \u2013 Effectiveness","field_topics":"Premarket","topics-product":"Premarket, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA), Target Animal \u2013 Effectiveness","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"10\/13\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1401\u0022\u003EFDA-2020-D-1401\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222021-10-05T08:55:31-04:00\u0022\u003E2021-10-05 08:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/appeal-options-available-mammography-facilities-concerning-adverse-accreditation-decisions\u0022\u003EAppeal Options Available to Mammography Facilities Concerning Adverse Accreditation Decisions, Suspension\/Revocation of Certificates, or Patient and Referring Provider Notification Orders: Guidance for Mammography Facilities and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/140242\/download\u0022\u003EPDF (335.19 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (335.19 KB) of Appeal Options Available to Mammography Facilities Concerning Adverse Accreditation Decisions, Suspension\/Revocation of Certificates, or Patient and Referring Provider Notification Orders: Guidance for Mammography Facilities and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/10\/2024","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Radiological Health, Radiology","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Administrative \/ Procedural, Radiological Health, Radiology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1317\u0022\u003EFDA-2020-D-1317\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222024-09-10T09:00:21-04:00\u0022\u003E2024-09-10 09:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cannabis-and-cannabis-derived-compounds-quality-considerations-clinical-research-guidance-industry\u0022\u003ECannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research Guidance for Industry: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/164690\/download\u0022\u003EPDF (383.62 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (383.62 KB) of Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research Guidance for Industry: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/23\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1079\u0022\u003EFDA-2020-D-1079\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-03-28T16:26:02-04:00\u0022\u003E2024-03-28 16:26\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/setting-endotoxin-limits-during-development-investigational-oncology-drugs-and-biological-products\u0022\u003ESetting Endotoxin Limits During Development of Investigational Oncology Drugs and Biological Products Guidance for Industry: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/140410\/download\u0022\u003EPDF (79.5 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (79.5 KB) of Setting Endotoxin Limits During Development of Investigational Oncology Drugs and Biological Products Guidance for Industry: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/28\/2020","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"10\/28\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1294\u0022\u003EFDA-2020-D-1294\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222020-09-01T09:50:20-04:00\u0022\u003E2020-09-01 09:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-480200-expiration-dating-unit-dose-repackaged-drugs\u0022\u003ECPG Sec. 480.200 Expiration Dating of Unit Dose Repackaged Drugs\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"02\/28\/1995","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"07\/30\/2020","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-08-14T13:30:25-04:00\u0022\u003E2020-08-14 13:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/drug-drug-interaction-assessment-therapeutic-proteins-guidance-industry\u0022\u003EDrug-Drug Interaction Assessment for Therapeutic Proteins Guidance for Industry: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/140909\/download\u0022\u003EPDF (358.31 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (358.31 KB) of Drug-Drug Interaction Assessment for Therapeutic Proteins Guidance for Industry: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/22\/2023","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Pharmacology","field_topics":"","topics-product":"Clinical - Pharmacology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"11\/09\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1480\u0022\u003EFDA-2020-D-1480\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222024-08-09T22:05:17-04:00\u0022\u003E2024-08-09 22:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/evaluating-cancer-drugs-patients-central-nervous-system-metastases\u0022\u003EEvaluating Cancer Drugs in Patients with Central Nervous System Metastases: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/141507\/download\u0022\u003EPDF (319.18 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (319.18 KB) of Evaluating Cancer Drugs in Patients with Central Nervous System Metastases: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/01\/2021","field_issuing_office_taxonomy":"Oncology Center of Excellence\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"10\/26\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0938\u0022\u003EFDA-2020-D-0938\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-07-03T16:35:04-04:00\u0022\u003E2021-07-03 16:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/principles-selecting-developing-modifying-and-adapting-patient-reported-outcome-instruments-use\u0022\u003EPrinciples for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation: Guidance for Industry and Food and Drug Administration Staff, And Other Stakeholders\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/141565\/download\u0022\u003EPDF (436.61 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (436.61 KB) of Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation: Guidance for Industry and Food and Drug Administration Staff, And Other Stakeholders\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/26\/2022","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Premarket, Postmarket","topics-product":"Premarket, Postmarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1564\u0022\u003EFDA-2020-D-1564\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222022-01-25T08:50:35-05:00\u0022\u003E2022-01-25 08:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/control-nitrosamine-impurities-human-drugs\u0022\u003EControl of Nitrosamine Impurities in Human Drugs: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/141720\/download\u0022\u003EPDF (665 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (665 KB) of Control of Nitrosamine Impurities in Human Drugs: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/05\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_topics":"","topics-product":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1530\u0022\u003EFDA-2020-D-1530\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-09-04T08:45:05-04:00\u0022\u003E2024-09-04 08:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/assessing-covid-19-related-symptoms-outpatient-adult-and-adolescent-subjects-clinical-trials-drugs\u0022\u003EAssessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment : Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/167275\/download\u0022\u003EPDF (303.02 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (303.02 KB) of Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment : Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/22\/2024","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"Infectious Disease, Coronavirus","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Infectious Disease, Coronavirus, Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1824\u0022\u003EFDA-2020-D-1824\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222024-02-22T10:23:01-05:00\u0022\u003E2024-02-22 10:23\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/geriatric-information-human-prescription-drug-and-biological-product-labeling-guidance-industry\u0022\u003EGeriatric Information in Human Prescription Drug and Biological Product Labeling Guidance for Industry: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/142162\/download\u0022\u003EPDF (348.12 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (348.12 KB) of Geriatric Information in Human Prescription Drug and Biological Product Labeling Guidance for Industry: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/15\/2020","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"11\/16\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1621\u0022\u003EFDA-2020-D-1621\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222020-09-15T09:00:52-04:00\u0022\u003E2020-09-15 09:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/biocompatibility-testing-medical-devices-standards-specific-information-accreditation-scheme\u0022\u003EBiocompatibility Testing of Medical Devices - Standards Specific Information for the Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program: Guidance for Industry, Accreditation Bodies, Testing Laboratories, and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/142388\/download\u0022\u003EPDF (871.63 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (871.63 KB) of Biocompatibility Testing of Medical Devices - Standards Specific Information for the Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program: Guidance for Industry, Accreditation Bodies, Testing Laboratories, and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/25\/2020","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-3805\u0022\u003EFDA-2019-D-3805\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222023-09-19T15:03:05-04:00\u0022\u003E2023-09-19 15:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/basic-safety-and-essential-performance-medical-electrical-equipment-medical-electrical-systems-and\u0022\u003EBasic Safety and Essential Performance of Medical Electrical Equipment, Medical Electrical Systems, and Laboratory Medical Equipment - Standards Specific Information for the Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program: Guidance for Industry, Accreditation Bodies, Testing Laboratories, and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/142385\/download\u0022\u003EPDF (607.78 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (607.78 KB) of Basic Safety and Essential Performance of Medical Electrical Equipment, Medical Electrical Systems, and Laboratory Medical Equipment - Standards Specific Information for the Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program: Guidance for Industry, Accreditation Bodies, Testing Laboratories, and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/25\/2020","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-3805\u0022\u003EFDA-2019-D-3805\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222023-09-19T15:03:01-04:00\u0022\u003E2023-09-19 15:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/questions-and-answers-m7r2-assessment-and-control-dna-reactive-mutagenic-impurities-pharmaceuticals\u0022\u003EQuestions and Answers | M7(R2) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals To Limit Potential Carcinogenic Risk: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/170460\/download\u0022\u003EPDF (291.4 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (291.4 KB) of Questions and Answers | M7(R2) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals To Limit Potential Carcinogenic Risk: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/25\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Multidisciplinary","field_topics":"","topics-product":"ICH-Multidisciplinary","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-N-1790\u0022\u003EFDA-2020-N-1790\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-07-25T10:10:46-04:00\u0022\u003E2023-07-25 10:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/failure-respond-anda-complete-response-letter-within-regulatory-timeframe-guidance-industry\u0022\u003EFailure to Respond to an ANDA Complete Response Letter Within the Regulatory Timeframe Guidance for Industry: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/160166\/download\u0022\u003EPDF (280.99 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (280.99 KB) of Failure to Respond to an ANDA Complete Response Letter Within the Regulatory Timeframe Guidance for Industry: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/14\/2022","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Drug Competition Action Plan, Generic Drugs","field_topics":"User Fees","topics-product":"User Fees, Drug Competition Action Plan, Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1548\u0022\u003EFDA-2020-D-1548\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222022-12-14T15:53:32-05:00\u0022\u003E2022-12-14 15:53\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e14-and-s7b-clinical-and-nonclinical-evaluation-qtqtc-interval-prolongation-and-proarrhythmic\u0022\u003EE14 and S7B Clinical and Nonclinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential--Questions and Answers (R1): Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/161198\/download\u0022\u003EPDF (518.63 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (518.63 KB) of E14 and S7B Clinical and Nonclinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential--Questions and Answers (R1): Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/30\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Efficacy, ICH-Safety","field_topics":"","topics-product":"ICH-Efficacy, ICH-Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1791\u0022\u003EFDA-2020-D-1791\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-10-30T08:47:46-04:00\u0022\u003E2026-10-30 08:47\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/use-physiologically-based-pharmacokinetic-analyses-biopharmaceutics-applications-oral-drug-product\u0022\u003EThe Use of Physiologically Based Pharmacokinetic Analyses \u2014 Biopharmaceutics Applications for Oral Drug Product Development, Manufacturing Changes, and Controls : Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/142500\/download\u0022\u003EPDF (223.33 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (223.33 KB) of The Use of Physiologically Based Pharmacokinetic Analyses \u2014 Biopharmaceutics Applications for Oral Drug Product Development, Manufacturing Changes, and Controls : Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/30\/2020","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"11\/30\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1517\u0022\u003EFDA-2020-D-1517\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-09-30T09:10:05-04:00\u0022\u003E2020-09-30 09:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/renal-cell-carcinoma-developing-drugs-and-biologics-adjuvant-treatment\u0022\u003ERenal Cell Carcinoma: Developing Drugs and Biologics for Adjuvant Treatment: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/159510\/download\u0022\u003EPDF (256.94 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (256.94 KB) of Renal Cell Carcinoma: Developing Drugs and Biologics for Adjuvant Treatment: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/27\/2022","field_issuing_office_taxonomy":"Oncology Center of Excellence\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"Premarket","topics-product":"Premarket, Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"12\/01\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1496\u0022\u003EFDA-2020-D-1496\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222022-06-28T17:03:36-04:00\u0022\u003E2022-06-28 17:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/bladder-cancer-developing-drugs-and-biologics-adjuvant-treatment\u0022\u003EBladder Cancer: Developing Drugs and Biologics for Adjuvant Treatment: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/159509\/download\u0022\u003EPDF (310.11 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (310.11 KB) of Bladder Cancer: Developing Drugs and Biologics for Adjuvant Treatment: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/28\/2022","field_issuing_office_taxonomy":"Oncology Center of Excellence\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"Premarket","topics-product":"Premarket, Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"12\/01\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1497\u0022\u003EFDA-2020-D-1497\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222022-06-28T17:03:44-04:00\u0022\u003E2022-06-28 17:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-608100-human-labeled-drugs-distributed-and-used-animal-medicine-withdrawn-772006\u0022\u003ECPG Sec. 608.100 Human-Labeled Drugs Distributed and Used in Animal Medicine (Withdrawn 7\/7\/2006)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/07\/2006","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222020-10-05T12:40:02-04:00\u0022\u003E2020-10-05 12:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-675400-rendered-animal-feed-ingredients-withdrawn-4302019\u0022\u003ECPG Sec. 675.400 Rendered Animal Feed Ingredients (Withdrawn 4\/30\/2019)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"11\/12\/1998","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Feed","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Feed","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222020-10-05T12:40:05-04:00\u0022\u003E2020-10-05 12:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-615100-extralabel-use-new-animal-drugs-food-producing-animals-revoked-09241998-63-fr-51074\u0022\u003ECPG Sec. 615.100 Extralabel Use of New Animal Drugs in Food Producing Animals - Revoked on 09\/24\/1998 (63 FR 51074)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/24\/1998","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Drugs","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222020-10-05T12:40:07-04:00\u0022\u003E2020-10-05 12:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-616100-streptomycin-residues-cattle-tissues-withdrawn-772006\u0022\u003ECPG Sec. 616.100 Streptomycin Residues in Cattle Tissues (Withdrawn 7\/7\/2006)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/06\/2006","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Animal Drugs, Human Food Safety","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Animal Drugs, Human Food Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222020-10-05T12:50:15-04:00\u0022\u003E2020-10-05 12:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-690300-canned-pet-food-withdrawn-4302019\u0022\u003ECPG Sec. 690.300 Canned Pet Food (Withdrawn 4\/30\/2019)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"06\/10\/2004","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Pet Food","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, Pet Food","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Regulatory Affairs","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222020-10-05T12:45:32-04:00\u0022\u003E2020-10-05 12:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/premenopausal-women-breast-cancer-developing-drugs-treatment\u0022\u003EPremenopausal Women with Breast Cancer: Developing Drugs for Treatment: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/142638\/download\u0022\u003EPDF (250.02 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (250.02 KB) of Premenopausal Women with Breast Cancer: Developing Drugs for Treatment: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/17\/2021","field_issuing_office_taxonomy":"Oncology Center of Excellence\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"12\/07\/2020","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1553\u0022\u003EFDA-2020-D-1553\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222021-06-17T11:50:06-04:00\u0022\u003E2021-06-17 11:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-us-agent-voluntary-identification-system-vis-food-facility-registration\u0022\u003EGuidance for Industry: U.S. Agent Voluntary Identification System (VIS) for Food Facility Registration\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/142968\/download\u0022\u003EPDF (133.08 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (133.08 KB) of Guidance for Industry: U.S. Agent Voluntary Identification System (VIS) for Food Facility Registration\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/16\/2020","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"Registration","topics-product":"Registration, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-1002\u0022\u003EFDA-2012-D-1002\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:06:11-04:00\u0022\u003E2024-10-01 07:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/annual-status-report-information-and-other-submissions-postmarketing-requirements-and-commitments\u0022\u003EAnnual Status Report Information and Other Submissions for Postmarketing Requirements and Commitments: Using Forms FDA 3988 and FDA 3989 Guidance for Industry: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/172038\/download\u0022\u003EPDF (309.7 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (309.7 KB) of Annual Status Report Information and Other Submissions for Postmarketing Requirements and Commitments: Using Forms FDA 3988 and FDA 3989 Guidance for Industry: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/15\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-N-3771\u0022\u003EFDA-2018-N-3771\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-09-15T09:43:45-04:00\u0022\u003E2023-09-15 09:43\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/wholesale-distributor-verification-requirement-saleable-returned-drug-product-compliance-policy\u0022\u003EWholesale Distributor Verification Requirement for Saleable Returned Drug Product\u2014Compliance Policy Guidance for Industry: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/143208\/download\u0022\u003EPDF (68.96 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (68.96 KB) of Wholesale Distributor Verification Requirement for Saleable Returned Drug Product\u2014Compliance Policy Guidance for Industry: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/20\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOffice of Regulatory Affairs","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-4212\u0022\u003EFDA-2019-D-4212\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222020-10-23T09:55:33-04:00\u0022\u003E2020-10-23 09:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/tobacco-products-principles-designing-and-conducting-tobacco-product-perception-and-intention\u0022\u003ETobacco Products: Principles for Designing and Conducting Tobacco Product Perception and Intention Studies\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/143322\/download\u0022\u003EPDF (448.17 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (448.17 KB) of Tobacco Products: Principles for Designing and Conducting Tobacco Product Perception and Intention Studies\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/23\/2022","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-4188\u0022\u003EFDA-2019-D-4188\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222022-08-23T09:45:47-04:00\u0022\u003E2022-08-23 09:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/draft-guidance-industry-voluntary-disclosure-sesame-allergen\u0022\u003EDraft Guidance for Industry: Voluntary Disclosure of Sesame as an Allergen\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/143521\/download\u0022\u003EPDF (94.6 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (94.6 KB) of Draft Guidance for Industry: Voluntary Disclosure of Sesame as an Allergen\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/10\/2020","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Allergens","field_topics":"","topics-product":"Allergens","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"02\/25\/2021","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0530\u0022\u003EFDA-2020-D-0530\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-12T10:25:16-04:00\u0022\u003E2025-03-12 10:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/biosimilarity-and-interchangeability-additional-draft-qas-biosimilar-development-and-bpci-act\u0022\u003EBiosimilarity and Interchangeability: Additional Draft Q\u0026amp;As on Biosimilar Development and the BPCI Act (Revision 1): Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/172169\/download\u0022\u003EPDF (310.57 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (310.57 KB) of Biosimilarity and Interchangeability: Additional Draft Q\u0026amp;As on Biosimilar Development and the BPCI Act (Revision 1): Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/18\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Biosimilars, Prescription Drugs","field_topics":"","topics-product":"Biosimilars, Prescription Drugs","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0611\u0022\u003EFDA-2011-D-0611\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222023-09-15T08:45:36-04:00\u0022\u003E2023-09-15 08:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cross-labeling-oncology-drugs-combination-regimens\u0022\u003ECross Labeling Oncology Drugs in Combination Regimens\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/162806\/download\u0022\u003EPDF (240.89 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (240.89 KB) of Cross Labeling Oncology Drugs in Combination Regimens\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/02\/2022","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-2107\u0022\u003EFDA-2020-D-2107\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222022-11-08T14:51:31-05:00\u0022\u003E2022-11-08 14:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clinical-drug-interaction-studies-combined-oral-contraceptives-guidance-industry\u0022\u003EClinical Drug Interaction Studies With Combined Oral Contraceptives Guidance for Industry: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/143849\/download\u0022\u003EPDF (432.1 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (432.1 KB) of Clinical Drug Interaction Studies With Combined Oral Contraceptives Guidance for Industry: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/08\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Pharmacology","field_topics":"","topics-product":"Clinical - Pharmacology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"02\/22\/2021","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1848\u0022\u003EFDA-2020-D-1848\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-06-08T10:34:39-04:00\u0022\u003E2023-06-08 10:34\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/evaluation-gastric-ph-dependent-drug-interactions-acid-reducing-agents-study-design-data-analysis\u0022\u003EEvaluation of Gastric pH-Dependent Drug Interactions With Acid-Reducing Agents: Study Design, Data Analysis, and Clinical Implications Guidance for Industry: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/166156\/download\u0022\u003EPDF (428.9 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (428.9 KB) of Evaluation of Gastric pH-Dependent Drug Interactions With Acid-Reducing Agents: Study Design, Data Analysis, and Clinical Implications Guidance for Industry: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/10\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Pharmacology","field_topics":"","topics-product":"Clinical - Pharmacology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"02\/26\/2021","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1794\u0022\u003EFDA-2020-D-1794\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-04-05T12:42:16-04:00\u0022\u003E2024-04-05 12:42\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/compliance-policy-guide-cpg-sec-110650-weekly-entry-filing-guidance-industry-and-fda-staff\u0022\u003ECompliance Policy Guide CPG Sec. 110.650 Weekly Entry Filing Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/144074\/download\u0022\u003EPDF (75.88 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (75.88 KB) of Compliance Policy Guide CPG Sec. 110.650 Weekly Entry Filing Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/30\/2020","field_issuing_office_taxonomy":"Office of Inspections and Investigations","field_health_topics":"","term_node_tid":"Export, Import","field_topics":"Compliance","topics-product":"Compliance, Export, Import","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-3904\u0022\u003EFDA-2019-D-3904\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of the Commissioner","field_regulated_product_field":"Cosmetics, Dietary Supplements, Food \u0026amp; Beverages, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222024-11-05T16:09:07-05:00\u0022\u003E2024-11-05 16:09\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-enforcement-policy-providing-acceptable-unique-facility-identifier-ufi-2020-food\u0022\u003EGuidance for Industry: Enforcement Policy for Providing an Acceptable Unique Facility Identifier (UFI) for the 2020 Food Facility Registration Biennial Renewal Period\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/143997\/download\u0022\u003EPDF (60.7 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (60.7 KB) of Guidance for Industry: Enforcement Policy for Providing an Acceptable Unique Facility Identifier (UFI) for the 2020 Food Facility Registration Biennial Renewal Period\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/30\/2021","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"Registration","topics-product":"Registration, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-1002\u0022\u003EFDA-2012-D-1002\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-07T09:22:36-05:00\u0022\u003E2025-03-07 09:22\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/best-practices-developing-proprietary-names-human-nonprescription-drug-products-draft-guidance\u0022\u003EBest Practices in Developing Proprietary Names for Human Nonprescription Drug Products; Draft Guidance for Industry: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/144257\/download\u0022\u003EPDF (219.59 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (219.59 KB) of Best Practices in Developing Proprietary Names for Human Nonprescription Drug Products; Draft Guidance for Industry: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/08\/2020","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Safety - Issues, Errors, and Problems","field_topics":"","topics-product":"Safety - Issues, Errors, and Problems","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"02\/08\/2021","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0770\u0022\u003EFDA-2020-D-0770\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-12-08T10:45:06-05:00\u0022\u003E2020-12-08 10:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/dry-eye-developing-drugs-treatment-guidance-industry\u0022\u003EDry Eye: Developing Drugs for Treatment Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/144594\/download\u0022\u003EPDF (234.58 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (234.58 KB) of Dry Eye: Developing Drugs for Treatment Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/16\/2020","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"03\/17\/2021","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-2214\u0022\u003EFDA-2020-D-2214\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-12-18T17:20:30-05:00\u0022\u003E2020-12-18 17:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/consumer-antiseptic-rub-final-rule-questions-and-answers-guidance-industry\u0022\u003EConsumer Antiseptic Rub Final Rule Questions and Answers Guidance for Industry: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/144833\/download\u0022\u003EPDF (146.36 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (146.36 KB) of Consumer Antiseptic Rub Final Rule Questions and Answers Guidance for Industry: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/30\/2020","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Over-the-Counter Drugs","field_topics":"","topics-product":"Over-the-Counter Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-N-0124 \u0022\u003EFDA-2016-N-0124 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222020-12-30T08:50:03-05:00\u0022\u003E2020-12-30 08:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/ind-submissions-individualized-antisense-oligonucleotide-drug-products-administrative-and-procedural\u0022\u003EIND Submissions for Individualized Antisense Oligonucleotide Drug Products: Administrative and Procedural Recommendations Guidance for Sponsor-Investigators: Draft Guidance for Sponsor-Investigators\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/144872\/download\u0022\u003EPDF (95.13 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (95.13 KB) of IND Submissions for Individualized Antisense Oligonucleotide Drug Products: Administrative and Procedural Recommendations Guidance for Sponsor-Investigators: Draft Guidance for Sponsor-Investigators\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/04\/2021","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"03\/04\/2021","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-2199\u0022\u003EFDA-2020-D-2199\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-01-04T08:51:06-05:00\u0022\u003E2021-01-04 08:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/human-gene-therapy-neurodegenerative-diseases\u0022\u003EHuman Gene Therapy for Neurodegenerative Diseases: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/144886\/download\u0022\u003EPDF (310.87 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (310.87 KB) of Human Gene Therapy for Neurodegenerative Diseases: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/21\/2022","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Gene Therapy, Pediatric Product Development","field_topics":"","topics-product":"Gene Therapy, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-2101\u0022\u003EFDA-2020-D-2101\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-04-11T11:03:53-04:00\u0022\u003E2024-04-11 11:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/policy-testing-alcohol-ethanol-and-isopropyl-alcohol-methanol\u0022\u003EPolicy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/173005\/download\u0022\u003EPDF (292.4 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (292.4 KB) of Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/17\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Veterinary Medicine","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP)","field_topics":"","topics-product":"Current Good Manufacturing Practice (CGMP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-2016\u0022\u003EFDA-2020-D-2016\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Drugs","changed":"\u003Ctime datetime=\u00222023-10-17T10:03:46-04:00\u0022\u003E2023-10-17 10:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/manufacturing-considerations-licensed-and-investigational-cellular-and-gene-therapy-products-during\u0022\u003EManufacturing Considerations for Licensed and Investigational Cellular and Gene Therapy Products During COVID-19 Public Health Emergency: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/145301\/download\u0022\u003EPDF (162.02 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (162.02 KB) of Manufacturing Considerations for Licensed and Investigational Cellular and Gene Therapy Products During COVID-19 Public Health Emergency: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/19\/2021","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Coronavirus","term_node_tid":"Gene Therapy","field_topics":"","topics-product":"Coronavirus, Gene Therapy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1137\u0022\u003EFDA-2020-D-1137\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222021-01-20T15:26:39-05:00\u0022\u003E2021-01-20 15:26\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/protection-human-subjects-categories-research-may-be-reviewed-institutional-review-board-irb-through\u0022\u003EProtection of Human Subjects: Categories of Research That May Be Reviewed by the Institutional Review Board (IRB) Through an Expedited Review Procedure: Guidance for Institutional Review Boards and Clinical Investigators\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/144917\/download\u0022\u003EPDF (126.43 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (126.43 KB) of Protection of Human Subjects: Categories of Research That May Be Reviewed by the Institutional Review Board (IRB) Through an Expedited Review Procedure: Guidance for Institutional Review Boards and Clinical Investigators\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/09\/1998","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP)","field_topics":"Clinical Trials","topics-product":"Clinical Trials, Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"03\/10\/1998","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1997-N-0257\u0022\u003EFDA-1997-N-0257\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222023-03-24T15:05:03-04:00\u0022\u003E2023-03-24 15:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-consultation-procedures-under-fdas-1992-statement-policy-foods-derived-new-plant\u0022\u003EGuidance for Industry: Consultation Procedures under FDA\u0026#039;s 1992 Statement of Policy for Foods Derived from New Plant Varieties\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/01\/1997","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:06:13-04:00\u0022\u003E2024-10-01 07:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/policy-evaluating-impact-viral-mutations-covid-19-tests-revised\u0022\u003EPolicy for Evaluating Impact of Viral Mutations on COVID-19 Tests (Revised): Guidance for Test Developers and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/146171\/download\u0022\u003EPDF (430.26 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (430.26 KB) of Policy for Evaluating Impact of Viral Mutations on COVID-19 Tests (Revised): Guidance for Test Developers and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/12\/2023","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"Coronavirus","term_node_tid":"IVDs (In Vitro Diagnostic Devices)","field_topics":"Premarket","topics-product":"Premarket, Coronavirus, IVDs (In Vitro Diagnostic Devices)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0987\u0022\u003EFDA-2020-D-0987\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222024-12-30T13:16:10-05:00\u0022\u003E2024-12-30 13:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/development-monoclonal-antibody-products-targeting-sars-cov-2-emergency-use-authorization\u0022\u003EDevelopment of Monoclonal Antibody Products Targeting SARS-CoV-2 for Emergency Use Authorization\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/146173\/download\u0022\u003EPDF (317.69 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (317.69 KB) of Development of Monoclonal Antibody Products Targeting SARS-CoV-2 for Emergency Use Authorization\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/21\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1136\u0022\u003EFDA-2020-D-1136\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-12-21T08:30:52-05:00\u0022\u003E2023-12-21 08:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/covid-19-developing-drugs-and-biological-products-treatment-or-prevention\u0022\u003ECOVID-19: Developing Drugs and Biological Products for Treatment or Prevention: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/186273\/download\u0022\u003EPDF (372.61 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (372.61 KB) of COVID-19: Developing Drugs and Biological Products for Treatment or Prevention: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/24\/2023","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"Infectious Disease, Coronavirus","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Infectious Disease, Coronavirus, Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1370\u0022\u003EFDA-2020-D-1370\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222025-05-02T06:57:02-04:00\u0022\u003E2025-05-02 06:57\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/container-closure-system-and-component-changes-glass-vials-and-stoppers\u0022\u003EContainer Closure System and Component Changes: Glass Vials and Stoppers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/167925\/download\u0022\u003EPDF (466.34 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (466.34 KB) of Container Closure System and Component Changes: Glass Vials and Stoppers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/24\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6821\u0022\u003EFDA-2017-D-6821\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222024-07-24T10:48:31-04:00\u0022\u003E2024-07-24 10:48\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/continuation-series-letters-communicating-interim-and-informal-generic-drug-policy-and-guidance\u0022\u003EContinuation of a series of letters communicating interim and informal generic drug policy and guidance. Availability of Policy and Procedure Guides, and further operational changes to the generic drug review program\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"06\/01\/1990","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Generic Drugs","field_topics":"","topics-product":"Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Industry Letter","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-03-08T17:25:02-05:00\u0022\u003E2021-03-08 17:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/seventh-series-letters-about-act-providing-guidance-130-day-exclusivity-provision-section-505j4biv\u0022\u003ESeventh of a series of letters about the Act providing guidance on the \u0026quot;130-day exclusivity\u0026quot; provision of section 505(j)(4)(B)(iv) of the FD\u0026amp;C\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"07\/29\/1988","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Generic Drugs","field_topics":"","topics-product":"Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Industry Letter","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-03-08T18:05:13-05:00\u0022\u003E2021-03-08 18:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/nonclinical-testing-individualized-antisense-oligonucleotide-drug-products-severely-debilitating-or\u0022\u003ENonclinical Testing of Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases Guidance for Sponsor-Investigators: Draft Guidance for Sponsor-Investigators\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/147876\/download\u0022\u003EPDF (85.72 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (85.72 KB) of Nonclinical Testing of Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases Guidance for Sponsor-Investigators: Draft Guidance for Sponsor-Investigators\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/26\/2021","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pharmacology\/Toxicology","field_topics":"","topics-product":"Pharmacology\/Toxicology","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0320\u0022\u003EFDA-2021-D-0320\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-04-26T08:50:10-04:00\u0022\u003E2021-04-26 08:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q3dr2-guideline-elemental-impurities\u0022\u003EQ3D(R2) \u2013 Guideline for Elemental Impurities: International Council for Harmonisation; Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/148474\/download\u0022\u003EPDF (968.57 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (968.57 KB) of Q3D(R2) \u2013 Guideline for Elemental Impurities: International Council for Harmonisation; Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/14\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-1156\u0022\u003EFDA-2013-D-1156\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222022-09-14T08:45:03-04:00\u0022\u003E2022-09-14 08:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/postmarketing-studies-and-clinical-trials-implementation-section-505o3-federal-food-drug-and-0\u0022\u003EPostmarketing Studies and Clinical Trials\u2014Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act Guidance for Industry: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/148646\/download\u0022\u003EPDF (372.7 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (372.7 KB) of Postmarketing Studies and Clinical Trials\u2014Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act Guidance for Industry: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/25\/2019","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Safety - Issues, Errors, and Problems","field_topics":"","topics-product":"Safety - Issues, Errors, and Problems","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0283\u0022\u003EFDA-2009-D-0283\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222022-02-01T14:31:04-05:00\u0022\u003E2022-02-01 14:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/information-sheet-guidance-sponsors-clinical-investigators-and-irbs-frequently-asked-questions\u0022\u003EInformation Sheet Guidance for Sponsors, Clinical Investigators, and IRBs Frequently Asked Questions Statement of Investigator (Form FDA 1572) (Revision 1): Draft Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs Frequently Asked Questions Statement of Investigator (Form FDA 1572) (Revision 1)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/148810\/download\u0022\u003EPDF (96.64 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (96.64 KB) of Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs Frequently Asked Questions Statement of Investigator (Form FDA 1572) (Revision 1): Draft Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs Frequently Asked Questions Statement of Investigator (Form FDA 1572) (Revision 1)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/19\/2021","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"07\/15\/2021","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0406\u0022\u003EFDA-2008-D-0406\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222022-02-01T14:16:05-05:00\u0022\u003E2022-02-01 14:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/feasibility-and-early-feasibility-clinical-studies-certain-medical-devices-intended-therapeutically\u0022\u003EFeasibility and Early Feasibility Clinical Studies for Certain Medical Devices Intended to Therapeutically Improve Glycemic Control in Patients with Type 2 Diabetes Mellitus: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/148765\/download\u0022\u003EPDF (476.29 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (476.29 KB) of Feasibility and Early Feasibility Clinical Studies for Certain Medical Devices Intended to Therapeutically Improve Glycemic Control in Patients with Type 2 Diabetes Mellitus: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/06\/2022","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Gastroenterology-Urology , Investigational Device Exemption (IDE)","field_topics":"Premarket","topics-product":"Premarket, Gastroenterology-Urology , Investigational Device Exemption (IDE)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0131\u0022\u003EFDA-2021-D-0131\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222022-05-05T10:03:33-04:00\u0022\u003E2022-05-05 10:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/chemotherapy-induced-nausea-and-vomiting-developing-drugs-prevention-guidance-industry\u0022\u003EChemotherapy-Induced Nausea and Vomiting: Developing Drugs for Prevention Guidance for Industry: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/148829\/download\u0022\u003EPDF (113.5 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (113.5 KB) of Chemotherapy-Induced Nausea and Vomiting: Developing Drugs for Prevention Guidance for Industry: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/19\/2021","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"07\/19\/2021","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0351\u0022\u003EFDA-2021-D-0351\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-02-01T14:11:10-05:00\u0022\u003E2022-02-01 14:11\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/adjusting-covariates-randomized-clinical-trials-drugs-and-biological-products\u0022\u003EAdjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/148910\/download\u0022\u003EPDF (357.25 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (357.25 KB) of Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/26\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-0934\u0022\u003EFDA-2019-D-0934\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222024-04-08T11:18:46-04:00\u0022\u003E2024-04-08 11:18\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/ich-q12-implementation-considerations-fda-regulated-products\u0022\u003EICH Q12: Implementation Considerations for FDA-Regulated Products: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/148947\/download\u0022\u003EPDF (173.68 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (173.68 KB) of ICH Q12: Implementation Considerations for FDA-Regulated Products: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/20\/2021","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"10\/12\/2021","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0166\u0022\u003EFDA-2021-D-0166\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222021-09-10T08:25:06-04:00\u0022\u003E2021-09-10 08:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/tobacco-product-user-fees-responses-frequently-asked-questions\u0022\u003ETobacco Product User Fees: Responses to Frequently Asked Questions \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/154697\/download\u0022\u003EPDF (233.19 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (233.19 KB) of Tobacco Product User Fees: Responses to Frequently Asked Questions \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/08\/2021","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0373\u0022\u003EFDA-2021-D-0373\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222021-12-14T09:01:05-05:00\u0022\u003E2021-12-14 09:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/oral-drug-products-administered-enteral-feeding-tube-in-vitro-testing-and-labeling-recommendations\u0022\u003EOral Drug Products Administered Via Enteral Feeding Tube: In Vitro Testing and Labeling Recommendations: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/149688\/download\u0022\u003EPDF (180.48 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (180.48 KB) of Oral Drug Products Administered Via Enteral Feeding Tube: In Vitro Testing and Labeling Recommendations: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/02\/2021","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Labeling, Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Labeling, Pharmaceutical Quality","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"08\/02\/2021","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0391\u0022\u003EFDA-2021-D-0391\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222022-02-01T14:05:04-05:00\u0022\u003E2022-02-01 14:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/enhanced-drug-distribution-security-package-level-under-drug-supply-chain-security-act\u0022\u003EEnhanced Drug Distribution Security at the Package Level Under the Drug Supply Chain Security Act: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/171666\/download\u0022\u003EPDF (430.51 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (430.51 KB) of Enhanced Drug Distribution Security at the Package Level Under the Drug Supply Chain Security Act: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/30\/2023","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-2024\u0022\u003EFDA-2020-D-2024\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222024-11-05T16:09:17-05:00\u0022\u003E2024-11-05 16:09\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/core-patient-reported-outcomes-cancer-clinical-trials\u0022\u003ECore Patient-Reported Outcomes in Cancer Clinical Trials: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/149994\/download\u0022\u003EPDF (288.64 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (288.64 KB) of Core Patient-Reported Outcomes in Cancer Clinical Trials: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/17\/2024","field_issuing_office_taxonomy":"Oncology Center of Excellence\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"Clinical Trials","topics-product":"Clinical Trials, Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"08\/09\/2021","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-2303\u0022\u003EFDA-2020-D-2303\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222024-10-17T09:05:31-04:00\u0022\u003E2024-10-17 09:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/remanufacturing-medical-devices\u0022\u003ERemanufacturing of Medical Devices: Guidance for Industry, Entities That Perform Servicing or Remanufacturing, and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/150141\/download\u0022\u003EPDF (573.92 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (573.92 KB) of Remanufacturing of Medical Devices: Guidance for Industry, Entities That Perform Servicing or Remanufacturing, and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/10\/2024","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-N-3741\u0022\u003EFDA-2018-N-3741\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222024-05-09T09:02:16-04:00\u0022\u003E2024-05-09 09:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cancer-clinical-trial-eligibility-criteria-available-therapy-non-curative-settings\u0022\u003ECancer Clinical Trial Eligibility Criteria: Available Therapy in Non-Curative Settings: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/150244\/download\u0022\u003EPDF (243.71 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (243.71 KB) of Cancer Clinical Trial Eligibility Criteria: Available Therapy in Non-Curative Settings: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/27\/2022","field_issuing_office_taxonomy":"Oncology Center of Excellence\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"Clinical Trials","topics-product":"Clinical Trials, Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"08\/24\/2021","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1802\u0022\u003EFDA-2020-D-1802\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222022-07-27T08:50:23-04:00\u0022\u003E2022-07-27 08:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/sponsor-responsibilities-safety-reporting-requirements-and-safety-assessment-ind-and\u0022\u003ESponsor Responsibilities - Safety Reporting Requirements and Safety Assessment for IND and Bioavailability\/Bioequivalence Studies: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/150356\/download\u0022\u003EPDF (522.14 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (522.14 KB) of Sponsor Responsibilities - Safety Reporting Requirements and Safety Assessment for IND and Bioavailability\/Bioequivalence Studies: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/15\/2025","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Device \u0026amp; Drug Safety, Safety - Issues, Errors, and Problems","field_topics":"","topics-product":"Device \u0026amp; Drug Safety, Safety - Issues, Errors, and Problems","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"09\/24\/2021","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-2099\u0022\u003EFDA-2020-D-2099\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-12-15T09:04:03-05:00\u0022\u003E2025-12-15 09:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/assessment-adhesion-topical-and-transdermal-systems-submitted-new-drug-applications\u0022\u003EAssessment of Adhesion for Topical and Transdermal Systems Submitted in New Drug Applications : Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/150509\/download\u0022\u003EPDF (186.49 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (186.49 KB) of Assessment of Adhesion for Topical and Transdermal Systems Submitted in New Drug Applications : Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/01\/2021","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-2323\u0022\u003EFDA-2020-D-2323\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-02-01T11:05:14-05:00\u0022\u003E2022-02-01 11:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/fda-oversight-food-covered-systems-recognition-arrangements\u0022\u003EFDA Oversight of Food Covered by Systems Recognition Arrangements\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/150676\/download\u0022\u003EPDF (237.45 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (237.45 KB) of FDA Oversight of Food Covered by Systems Recognition Arrangements\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/21\/2022","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Export, Import, Investigational Use","field_topics":"","topics-product":"Export, Import, Investigational Use","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-1997\u0022\u003EFDA-2019-D-1997\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T09:07:29-04:00\u0022\u003E2024-10-01 09:07\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/rabies-developing-monoclonal-antibody-cocktails-passive-immunization-component-post-exposure\u0022\u003ERabies: Developing Monoclonal Antibody Cocktails for the Passive Immunization Component of Post-Exposure Prophylaxis Guidance for Industry: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/151102\/download\u0022\u003EPDF (208.66 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (208.66 KB) of Rabies: Developing Monoclonal Antibody Cocktails for the Passive Immunization Component of Post-Exposure Prophylaxis Guidance for Industry: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/28\/2021","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"10\/27\/2021","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0519\u0022\u003EFDA-2021-D-0519\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-02-01T10:50:13-05:00\u0022\u003E2022-02-01 10:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pharmacokinetic-based-criteria-supporting-alternative-dosing-regimens-programmed-cell-death-receptor\u0022\u003EPharmacokinetic-Based Criteria for Supporting Alternative Dosing Regimens of Programmed Cell Death Receptor-1 (PD-1) or Programmed Cell Death-Ligand 1 (PD-L1) Blocking Antibodies for Treatment of Patients with Cancer: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/151745\/download\u0022\u003EPDF (230.43 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (230.43 KB) of Pharmacokinetic-Based Criteria for Supporting Alternative Dosing Regimens of Programmed Cell Death Receptor-1 (PD-1) or Programmed Cell Death-Ligand 1 (PD-L1) Blocking Antibodies for Treatment of Patients with Cancer: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/06\/2022","field_issuing_office_taxonomy":"Oncology Center of Excellence\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Pharmacology","field_topics":"","topics-product":"Clinical - Pharmacology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0691\u0022\u003EFDA-2021-D-0691\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-12-06T08:59:16-05:00\u0022\u003E2022-12-06 08:59\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/denture-base-resins-performance-criteria-safety-and-performance-based-pathway\u0022\u003EDenture Base Resins - Performance Criteria for Safety and Performance Based Pathway: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/151777\/download\u0022\u003EPDF (486.03 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (486.03 KB) of Denture Base Resins - Performance Criteria for Safety and Performance Based Pathway: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/13\/2022","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k)","field_topics":"Premarket","topics-product":"Premarket, 510(k)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0603\u0022\u003EFDA-2021-D-0603\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222022-04-12T10:04:35-04:00\u0022\u003E2022-04-12 10:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/facet-screw-systems-performance-criteria-safety-and-performance-based-pathway\u0022\u003EFacet Screw Systems - Performance Criteria for Safety and Performance Based Pathway: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/151776\/download\u0022\u003EPDF (618.36 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (618.36 KB) of Facet Screw Systems - Performance Criteria for Safety and Performance Based Pathway: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/13\/2022","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k)","field_topics":"Premarket","topics-product":"Premarket, 510(k)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0604\u0022\u003EFDA-2021-D-0604\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222022-04-12T10:04:23-04:00\u0022\u003E2022-04-12 10:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/technical-specifications-submitting-clinical-trial-data-sets-treatment-noncirrhotic-nonalcoholic\u0022\u003ETechnical Specifications for Submitting Clinical Trial Data Sets for Treatment of Noncirrhotic Nonalcoholic Steatohepatitis (NASH): Guidance for Industry Technical Specifications Document\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/151870\/download\u0022\u003EPDF (1.24 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.24 MB) of Technical Specifications for Submitting Clinical Trial Data Sets for Treatment of Noncirrhotic Nonalcoholic Steatohepatitis (NASH): Guidance for Industry Technical Specifications Document\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/13\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1216\u0022\u003EFDA-2018-D-1216\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-12-13T08:00:06-05:00\u0022\u003E2024-12-13 08:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/s12-nonclinical-biodistribution-considerations-gene-therapy-products\u0022\u003ES12 NONCLINICAL BIODISTRIBUTION CONSIDERATIONS FOR GENE THERAPY PRODUCTS: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/167605\/download\u0022\u003EPDF (276.84 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (276.84 KB) of S12 NONCLINICAL BIODISTRIBUTION CONSIDERATIONS FOR GENE THERAPY PRODUCTS: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/01\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Safety","field_topics":"","topics-product":"ICH-Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0875\u0022\u003EFDA-2021-D-0875\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222023-05-02T09:20:17-04:00\u0022\u003E2023-05-02 09:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q2r1-validation-analytical-procedures-text-and-methodology-guidance-industry\u0022\u003EQ2(R1) Validation of Analytical Procedures: Text and Methodology Guidance for Industry: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/152208\/download\u0022\u003EPDF (209.53 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (209.53 KB) of Q2(R1) Validation of Analytical Procedures: Text and Methodology Guidance for Industry: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/16\/2021","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6821\u0022\u003EFDA-2017-D-6821\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222021-09-20T06:31:23-04:00\u0022\u003E2021-09-20 06:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/questions-and-answers-quality-related-controlled-correspondence-guidance-industry\u0022\u003EQuestions and Answers on Quality Related Controlled Correspondence Guidance for Industry: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/152281\/download\u0022\u003EPDF (114.24 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (114.24 KB) of Questions and Answers on Quality Related Controlled Correspondence Guidance for Industry: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/20\/2021","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pharmaceutical Quality","field_topics":"","topics-product":"Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6821\u0022\u003EFDA-2017-D-6821\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-10-04T11:25:13-04:00\u0022\u003E2021-10-04 11:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-254-donor-eligibility-animal-cells-tissues-and-cell-and-tissue-based-products\u0022\u003ECVM GFI #254 Donor Eligibility for Animal Cells, Tissues, and Cell- and Tissue-Based Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/147151\/download\u0022\u003EPDF (499.21 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (499.21 KB) of CVM GFI #254 Donor Eligibility for Animal Cells, Tissues, and Cell- and Tissue-Based Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/20\/2022","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Cell-Based Products, Chemistry, Manufacturing, and Controls (CMC), Current Good Manufacturing Practice (CGMP), Investigational New Animal Drug (INAD), New Animal Drug Application (NADA)","field_topics":"Premarket","topics-product":"Premarket, Animal Cell-Based Products, Chemistry, Manufacturing, and Controls (CMC), Current Good Manufacturing Practice (CGMP), Investigational New Animal Drug (INAD), New Animal Drug Application (NADA)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"11\/22\/2021","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0401\u0022\u003EFDA-2021-D-0401\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222022-10-19T09:23:01-04:00\u0022\u003E2022-10-19 09:23\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-253-current-good-manufacturing-practice-animal-cells-tissues-and-cell-and-tissue-based\u0022\u003ECVM GFI #253 Current Good Manufacturing Practice for Animal Cells, Tissues, and Cell- and Tissue-Based Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/147150\/download\u0022\u003EPDF (471.34 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (471.34 KB) of CVM GFI #253 Current Good Manufacturing Practice for Animal Cells, Tissues, and Cell- and Tissue-Based Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/20\/2022","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Cell-Based Products, Chemistry, Manufacturing, and Controls (CMC), Current Good Manufacturing Practice (CGMP), Investigational New Animal Drug (INAD), New Animal Drug Application (NADA)","field_topics":"Premarket","topics-product":"Premarket, Animal Cell-Based Products, Chemistry, Manufacturing, and Controls (CMC), Current Good Manufacturing Practice (CGMP), Investigational New Animal Drug (INAD), New Animal Drug Application (NADA)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"11\/22\/2021","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0399\u0022\u003EFDA-2021-D-0399\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222022-10-19T09:22:16-04:00\u0022\u003E2022-10-19 09:22\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/nontuberculous-mycobacterial-pulmonary-disease-caused-mycobacterium-avium-complex-developing-drugs\u0022\u003ENontuberculous Mycobacterial Pulmonary Disease Caused by Mycobacterium avium Complex: Developing Drugs for Treatment : Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/171783\/download\u0022\u003EPDF (259.74 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (259.74 KB) of Nontuberculous Mycobacterial Pulmonary Disease Caused by Mycobacterium avium Complex: Developing Drugs for Treatment : Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/05\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0544\u0022\u003EFDA-2021-D-0544\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-09-05T08:24:46-04:00\u0022\u003E2023-09-05 08:24\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/electronic-submission-template-medical-device-510k-submissions\u0022\u003EElectronic Submission Template for Medical Device 510(k) Submissions: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/152429\/download\u0022\u003EPDF (455.72 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (455.72 KB) of Electronic Submission Template for Medical Device 510(k) Submissions: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/02\/2023","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0872\u0022\u003EFDA-2021-D-0872\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222023-10-02T09:04:31-04:00\u0022\u003E2023-10-02 09:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/studying-multiple-versions-cellular-or-gene-therapy-product-early-phase-clinical-trial\u0022\u003EStudying Multiple Versions of a Cellular or Gene Therapy Product in an Early-Phase Clinical Trial: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/152536\/download\u0022\u003EPDF (346.16 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (346.16 KB) of Studying Multiple Versions of a Cellular or Gene Therapy Product in an Early-Phase Clinical Trial: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/04\/2022","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Gene Therapy","field_topics":"Clinical Trials","topics-product":"Clinical Trials, Gene Therapy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0776\u0022\u003EFDA-2021-D-0776\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222022-11-18T10:38:31-05:00\u0022\u003E2022-11-18 10:38\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/microbiological-quality-considerations-non-sterile-drug-manufacturing\u0022\u003EMicrobiological Quality Considerations in Non-Sterile Drug Manufacturing: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/152527\/download\u0022\u003EPDF (283.29 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (283.29 KB) of Microbiological Quality Considerations in Non-Sterile Drug Manufacturing: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/29\/2021","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"12\/29\/2021","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0432\u0022\u003EFDA-2021-D-0432\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-10-14T14:55:04-04:00\u0022\u003E2021-10-14 14:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/investigator-responsibilities-safety-reporting-investigational-drugs-and-devices\u0022\u003EInvestigator Responsibilities \u2013 Safety Reporting for Investigational Drugs and Devices: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/152530\/download\u0022\u003EPDF (285.31 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (285.31 KB) of Investigator Responsibilities \u2013 Safety Reporting for Investigational Drugs and Devices: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/15\/2025","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOncology Center of Excellence","field_health_topics":"","term_node_tid":"Device \u0026amp; Drug Safety","field_topics":"","topics-product":"Device \u0026amp; Drug Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"11\/29\/2021","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0368\u0022\u003EFDA-2021-D-0368\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-12-15T08:58:04-05:00\u0022\u003E2025-12-15 08:58\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/benefit-risk-assessment-new-drug-and-biological-products\u0022\u003EBenefit-Risk Assessment for New Drug and Biological Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/152544\/download\u0022\u003EPDF (398.36 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (398.36 KB) of Benefit-Risk Assessment for New Drug and Biological Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/17\/2023","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-2316\u0022\u003EFDA-2020-D-2316\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222024-08-09T22:18:08-04:00\u0022\u003E2024-08-09 22:18\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/s1br1-addendum-s1b-testing-carcinogenicity-pharmaceuticals\u0022\u003ES1B(R1) Addendum to S1B Testing for Carcinogenicity of Pharmaceuticals: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/152777\/download\u0022\u003EPDF (791.15 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (791.15 KB) of S1B(R1) Addendum to S1B Testing for Carcinogenicity of Pharmaceuticals: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/02\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Safety","field_topics":"","topics-product":"ICH-Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0669\u0022\u003EFDA-2021-D-0669\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-11-01T08:59:56-04:00\u0022\u003E2022-11-01 08:59\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q13-continuous-manufacturing-drug-substances-and-drug-products\u0022\u003EQ13 Continuous Manufacturing of Drug Substances and Drug Products: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/165775\/download\u0022\u003EPDF (1.15 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.15 MB) of Q13 Continuous Manufacturing of Drug Substances and Drug Products: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-1047\u0022\u003EFDA-2021-D-1047\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-03-01T09:17:10-05:00\u0022\u003E2023-03-01 09:17\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/reporting-amount-listed-drugs-and-biological-products-technical-conformance-guide\u0022\u003EReporting Amount of Listed Drugs and Biological Products Technical Conformance Guide: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/153612\/download\u0022\u003EPDF (480.04 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (480.04 KB) of Reporting Amount of Listed Drugs and Biological Products Technical Conformance Guide: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/26\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Veterinary Medicine","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-1031\u0022\u003EFDA-2021-D-1031\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-10-17T15:01:34-04:00\u0022\u003E2024-10-17 15:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-temporary-permits-interstate-shipment-experimental-packs-food-varying-requirements\u0022\u003EGuidance for Industry: Temporary Permits for Interstate Shipment of Experimental Packs of Food Varying from the Requirements of Definitions and Standards of Identity\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/153639\/download\u0022\u003EPDF (244.21 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (244.21 KB) of Guidance for Industry: Temporary Permits for Interstate Shipment of Experimental Packs of Food Varying from the Requirements of Definitions and Standards of Identity\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/01\/2021","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-4484\u0022\u003EFDA-2016-D-4484\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T14:48:16-05:00\u0022\u003E2025-03-06 14:48\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/manufacture-blood-components-using-pathogen-reduction-device-blood-establishments-questions-and\u0022\u003EManufacture of Blood Components Using a Pathogen Reduction Device in Blood Establishments: Questions and Answers: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/153786\/download\u0022\u003EPDF (334 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (334 KB) of Manufacture of Blood Components Using a Pathogen Reduction Device in Blood Establishments: Questions and Answers: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/03\/2021","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Blood","term_node_tid":"Blood Products, Product Safety","field_topics":"","topics-product":"Blood, Blood Products, Product Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6784\u0022\u003EFDA-2017-D-6784\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222021-11-08T09:46:05-05:00\u0022\u003E2021-11-08 09:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/content-premarket-submissions-device-software-functions\u0022\u003EContent of Premarket Submissions for Device Software Functions: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/153781\/download\u0022\u003EPDF (1.47 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.47 MB) of Content of Premarket Submissions for Device Software Functions: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/14\/2023","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Digital Health","field_topics":"Premarket","topics-product":"Premarket, Digital Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0775\u0022\u003EFDA-2021-D-0775\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222023-08-14T09:29:31-04:00\u0022\u003E2023-08-14 09:29\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-110100-certification-exports-withdrawn-11042021\u0022\u003ECPG Sec. 110.100 Certification for Exports (Withdrawn 11\/04\/2021)\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"10\/01\/1980","field_issuing_office_taxonomy":"Office of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1996-D-0405\u0022\u003EFDA-1996-D-0405\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222024-10-24T14:52:41-04:00\u0022\u003E2024-10-24 14:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/ind-submissions-individualized-antisense-oligonucleotide-drug-products-severely-debilitating-or-life\u0022\u003EIND Submissions for Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases: Clinical Recommendations: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/154663\/download\u0022\u003EPDF (92.5 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (92.5 KB) of IND Submissions for Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases: Clinical Recommendations: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/08\/2021","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"02\/07\/2022","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-1140\u0022\u003EFDA-2021-D-1140\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-10-21T11:12:01-04:00\u0022\u003E2022-10-21 11:12\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/considerations-use-real-world-data-and-real-world-evidence-support-regulatory-decision-making-drug\u0022\u003EConsiderations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/171667\/download\u0022\u003EPDF (218.37 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (218.37 KB) of Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/30\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOncology Center of Excellence","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"Real World Data \/ Real World Evidence (RWD\/RWE)","topics-product":"Real World Data \/ Real World Evidence (RWD\/RWE), Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-1214\u0022\u003EFDA-2021-D-1214\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-08-30T09:49:16-04:00\u0022\u003E2023-08-30 09:49\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/chronic-rhinosinusitis-nasal-polyps-developing-drugs-treatment\u0022\u003EChronic Rhinosinusitis with Nasal Polyps: Developing Drugs for Treatment : Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/154724\/download\u0022\u003EPDF (221.18 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (221.18 KB) of Chronic Rhinosinusitis with Nasal Polyps: Developing Drugs for Treatment : Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/28\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Pediatric Product Development","field_topics":"","topics-product":"Clinical - Medical, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-1096\u0022\u003EFDA-2021-D-1096\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222025-01-31T13:59:52-05:00\u0022\u003E2025-01-31 13:59\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/bowel-cleansing-colonoscopy-efficacy-and-safety-considerations-developing-new-products\u0022\u003EBowel Cleansing for Colonoscopy: Efficacy and Safety Considerations for Developing New Products : Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/154760\/download\u0022\u003EPDF (98.37 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (98.37 KB) of Bowel Cleansing for Colonoscopy: Efficacy and Safety Considerations for Developing New Products : Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/10\/2021","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"02\/10\/2022","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0406\u0022\u003EFDA-2021-D-0406\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222021-12-10T08:56:03-05:00\u0022\u003E2021-12-10 08:56\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cover-letter-attachments-controlled-correspondences-and-anda-submissions\u0022\u003ECover Letter Attachments for Controlled Correspondences and ANDA Submissions: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/154762\/download\u0022\u003EPDF (333.78 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (333.78 KB) of Cover Letter Attachments for Controlled Correspondences and ANDA Submissions: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/05\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Generic Drugs","field_topics":"","topics-product":"Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0861\u0022\u003EFDA-2021-D-0861\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-06-05T13:37:46-04:00\u0022\u003E2023-06-05 13:37\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/referencing-definition-device-federal-food-drug-and-cosmetic-act-guidance-regulatory-documents\u0022\u003EReferencing the Definition of \u0026quot;Device\u0026quot; in the Federal Food, Drug, and Cosmetic Act in Guidance, Regulatory Documents, Communications, and Other Public Documents: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/154866\/download\u0022\u003EPDF (501.85 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (501.85 KB) of Referencing the Definition of \u0026quot;Device\u0026quot; in the Federal Food, Drug, and Cosmetic Act in Guidance, Regulatory Documents, Communications, and Other Public Documents: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/14\/2022","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0997\u0022\u003EFDA-2021-D-0997\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222022-11-10T08:47:32-05:00\u0022\u003E2022-11-10 08:47\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/inspection-injectable-products-visible-particulates\u0022\u003EInspection of Injectable Products for Visible Particulates: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/154868\/download\u0022\u003EPDF (192.36 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (192.36 KB) of Inspection of Injectable Products for Visible Particulates: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/16\/2021","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Veterinary Medicine","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"02\/15\/2022","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0241\u0022\u003EFDA-2021-D-0241\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Drugs","changed":"\u003Ctime datetime=\u00222021-12-17T13:31:05-05:00\u0022\u003E2021-12-17 13:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/validation-and-verification-analytical-testing-methods-used-tobacco-products\u0022\u003EValidation and Verification of Analytical Testing Methods Used for Tobacco Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/155033\/download\u0022\u003EPDF (473.47 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (473.47 KB) of Validation and Verification of Analytical Testing Methods Used for Tobacco Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/06\/2025","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0756\u0022\u003EFDA-2021-D-0756\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222025-01-06T13:25:16-05:00\u0022\u003E2025-01-06 13:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/technical-considerations-medical-devices-physiologic-closed-loop-control-technology\u0022\u003ETechnical Considerations for Medical Devices with Physiologic Closed-Loop Control Technology: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/154994\/download\u0022\u003EPDF (591.96 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (591.96 KB) of Technical Considerations for Medical Devices with Physiologic Closed-Loop Control Technology: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/29\/2023","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Combination Products, Clinical - Medical, Digital Health","field_topics":"Premarket","topics-product":"Premarket, Combination Products, Clinical - Medical, Digital Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"02\/22\/2022","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0996\u0022\u003EFDA-2021-D-0996\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222023-10-06T13:31:02-04:00\u0022\u003E2023-10-06 13:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/assessing-credibility-computational-modeling-and-simulation-medical-device-submissions\u0022\u003EAssessing the Credibility of Computational Modeling and Simulation in Medical Device Submissions: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/154985\/download\u0022\u003EPDF (1.3 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.3 MB) of Assessing the Credibility of Computational Modeling and Simulation in Medical Device Submissions: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/17\/2023","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Digital Health","field_topics":"Premarket","topics-product":"Premarket, Digital Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"03\/24\/2022","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0980\u0022\u003EFDA-2021-D-0980\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222023-11-16T11:06:01-05:00\u0022\u003E2023-11-16 11:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/transition-plan-medical-devices-fall-within-enforcement-policies-issued-during-coronavirus-disease\u0022\u003ETransition Plan for Medical Devices That Fall Within Enforcement Policies Issued During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency: Guidance for Industry, Other Stakeholders, and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/155038\/download\u0022\u003EPDF (528.07 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (528.07 KB) of Transition Plan for Medical Devices That Fall Within Enforcement Policies Issued During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency: Guidance for Industry, Other Stakeholders, and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/27\/2023","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"Coronavirus","term_node_tid":"","field_topics":"Premarket, Postmarket","topics-product":"Premarket, Postmarket, Coronavirus, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-1118\u0022\u003EFDA-2021-D-1118\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222023-03-24T08:51:02-04:00\u0022\u003E2023-03-24 08:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/transition-plan-medical-devices-issued-emergency-use-authorizations-euas-related-coronavirus-disease\u0022\u003ETransition Plan for Medical Devices Issued Emergency Use Authorizations (EUAs) Related to Coronavirus Disease 2019 (COVID-19): Guidance for Industry, Other Stakeholders, and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/155039\/download\u0022\u003EPDF (607.88 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (607.88 KB) of Transition Plan for Medical Devices Issued Emergency Use Authorizations (EUAs) Related to Coronavirus Disease 2019 (COVID-19): Guidance for Industry, Other Stakeholders, and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/27\/2023","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"Coronavirus","term_node_tid":"","field_topics":"Premarket, Postmarket","topics-product":"Premarket, Postmarket, Coronavirus, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-1149\u0022\u003EFDA-2021-D-1149\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222023-03-24T08:51:07-04:00\u0022\u003E2023-03-24 08:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/digital-health-technologies-remote-data-acquisition-clinical-investigations\u0022\u003EDigital Health Technologies for Remote Data Acquisition in Clinical Investigations\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/155022\/download\u0022\u003EPDF (459.63 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (459.63 KB) of Digital Health Technologies for Remote Data Acquisition in Clinical Investigations\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/22\/2023","field_issuing_office_taxonomy":"Oncology Center of Excellence\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-1128\u0022\u003EFDA-2021-D-1128\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-06-23T14:35:35-04:00\u0022\u003E2026-06-23 14:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/notifying-fda-permanent-discontinuance-or-interruption-manufacturing-device-under-section-506j-fdc\u0022\u003ENotifying FDA of a Permanent Discontinuance or Interruption in Manufacturing of a Device Under Section 506J of the FD\u0026amp;C Act: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/155245\/download\u0022\u003EPDF (626.22 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (626.22 KB) of Notifying FDA of a Permanent Discontinuance or Interruption in Manufacturing of a Device Under Section 506J of the FD\u0026amp;C Act: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/07\/2025","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Postmarket","topics-product":"Postmarket, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0053\u0022\u003EFDA-2022-D-0053\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222025-01-06T09:45:51-05:00\u0022\u003E2025-01-06 09:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/collecting-and-providing-702b-portions-fda-official-samples\u0022\u003ECollecting and Providing 702(b) Portions of FDA Official Samples: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/155621\/download\u0022\u003EPDF (315.09 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (315.09 KB) of Collecting and Providing 702(b) Portions of FDA Official Samples: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/01\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Allergenics, Blood Products, Allergens, Animal Feed, Combination Products, Current Good Manufacturing Practice (CGMP), Chemistry, Manufacturing, and Controls (CMC), Human Food Safety","field_topics":"","topics-product":"Allergenics, Blood Products, Allergens, Animal Feed, Combination Products, Current Good Manufacturing Practice (CGMP), Chemistry, Manufacturing, and Controls (CMC), Human Food Safety","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0593\u0022\u003EFDA-2021-D-0593\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:06:15-04:00\u0022\u003E2024-10-01 07:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/revising-anda-labeling-following-revision-rld-labeling-guidance-industry\u0022\u003ERevising ANDA Labeling Following Revision of the RLD Labeling Guidance for Industry: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/175654\/download\u0022\u003EPDF (280.85 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (280.85 KB) of Revising ANDA Labeling Following Revision of the RLD Labeling Guidance for Industry: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/24\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Generic Drugs","field_topics":"","topics-product":"Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"03\/25\/2022","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0092 \u0022\u003EFDA-2022-D-0092 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-01-24T08:59:08-05:00\u0022\u003E2024-01-24 08:59\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/formal-meetings-between-food-and-drug-administration-and-sponsors-or-requestors-over-counter\u0022\u003EFormal Meetings Between the Food and Drug Administration and Sponsors or Requestors of Over-the-Counter Monograph Drugs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/155864\/download\u0022\u003EPDF (359.33 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (359.33 KB) of Formal Meetings Between the Food and Drug Administration and Sponsors or Requestors of Over-the-Counter Monograph Drugs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/14\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0080\u0022\u003EFDA-2022-D-0080\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-07-15T10:50:47-04:00\u0022\u003E2026-07-15 10:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clinical-pharmacology-considerations-antibody-drug-conjugates-guidance-industry\u0022\u003EClinical Pharmacology Considerations for Antibody-Drug Conjugates Guidance for Industry: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/155997\/download\u0022\u003EPDF (320.72 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (320.72 KB) of Clinical Pharmacology Considerations for Antibody-Drug Conjugates Guidance for Industry: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Pharmacology","field_topics":"","topics-product":"Clinical - Pharmacology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-1051\u0022\u003EFDA-2021-D-1051\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222024-03-28T09:54:01-04:00\u0022\u003E2024-03-28 09:54\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/development-non-opioid-analgesics-acute-pain\u0022\u003EDevelopment of Non-Opioid Analgesics for Acute Pain\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/156063\/download\u0022\u003EPDF (278.19 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (278.19 KB) of Development of Non-Opioid Analgesics for Acute Pain\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/13\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-N-0556\u0022\u003EFDA-2021-N-0556\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-05-13T13:03:32-04:00\u0022\u003E2026-05-13 13:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-258-use-tracers-animal-food-type-medicated-articles-and-medicated-feeds\u0022\u003ECVM GFI #258 Use of Tracers in Animal Food, Type A Medicated Articles, and Medicated Feeds\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/156527\/download\u0022\u003EPDF (197.32 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (197.32 KB) of CVM GFI #258 Use of Tracers in Animal Food, Type A Medicated Articles, and Medicated Feeds\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/19\/2022","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Food Additives, Chemistry, Manufacturing, and Controls (CMC), Labeling, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA)","field_topics":"","topics-product":"Animal Food Additives, Chemistry, Manufacturing, and Controls (CMC), Labeling, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"05\/02\/2022","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-1246\u0022\u003EFDA-2021-D-1246\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222022-10-18T08:52:17-04:00\u0022\u003E2022-10-18 08:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-current-good-manufacturing-practice-and-preventive-controls-foreign-supplier\u0022\u003EGuidance for Industry: Current Good Manufacturing Practice and Preventive Controls, Foreign Supplier Verification Programs, Intentional Adulteration, and Produce Safety Regulations: Enforcement Policy Regarding Certain Provisions\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/156729\/download\u0022\u003EPDF (307.88 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (307.88 KB) of Guidance for Industry: Current Good Manufacturing Practice and Preventive Controls, Foreign Supplier Verification Programs, Intentional Adulteration, and Produce Safety Regulations: Enforcement Policy Regarding Certain Provisions\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/11\/2022","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003ECenter for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0563\u0022\u003EFDA-2021-D-0563\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T14:01:02-05:00\u0022\u003E2025-03-06 14:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/human-gene-therapy-products-incorporating-human-genome-editing\u0022\u003EHuman Gene Therapy Products Incorporating Human Genome Editing: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/156894\/download\u0022\u003EPDF (458.17 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (458.17 KB) of Human Gene Therapy Products Incorporating Human Genome Editing: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/29\/2024","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Gene Therapy","field_topics":"","topics-product":"Gene Therapy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0398\u0022\u003EFDA-2021-D-0398\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-08-09T22:22:46-04:00\u0022\u003E2024-08-09 22:22\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/considerations-development-chimeric-antigen-receptor-car-t-cell-products\u0022\u003EConsiderations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/156896\/download\u0022\u003EPDF (516.23 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (516.23 KB) of Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/31\/2024","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmacology\/Toxicology, Gene Therapy","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmacology\/Toxicology, Gene Therapy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0404\u0022\u003EFDA-2021-D-0404\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-08-09T22:10:45-04:00\u0022\u003E2024-08-09 22:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/certain-ophthalmic-products-policy-regarding-compliance-21-cfr-part-4-guidance-industry\u0022\u003ECertain Ophthalmic Products: Policy Regarding Compliance With 21 CFR Part 4 Guidance for Industry: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/157067\/download\u0022\u003EPDF (239 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (239 KB) of Certain Ophthalmic Products: Policy Regarding Compliance With 21 CFR Part 4 Guidance for Industry: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/22\/2022","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Combination Products","field_topics":"","topics-product":"Combination Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0192\u0022\u003EFDA-2022-D-0192\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222022-03-22T08:48:05-04:00\u0022\u003E2022-03-22 08:48\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/m7r2-addendum-application-principles-ich-m7-guideline-calculation-compound-specific-acceptable\u0022\u003EM7(R2) ADDENDUM: APPLICATION OF THE PRINCIPLES OF THE ICH M7 GUIDELINE TO CALCULATION OF COMPOUND-SPECIFIC ACCEPTABLE INTAKES: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/170459\/download\u0022\u003EPDF (1.34 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.34 MB) of M7(R2) ADDENDUM: APPLICATION OF THE PRINCIPLES OF THE ICH M7 GUIDELINE TO CALCULATION OF COMPOUND-SPECIFIC ACCEPTABLE INTAKES: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/25\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Multidisciplinary","field_topics":"","topics-product":"ICH-Multidisciplinary","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0055\u0022\u003EFDA-2022-D-0055\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-07-25T10:04:01-04:00\u0022\u003E2023-07-25 10:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/use-whole-slide-imaging-nonclinical-toxicology-studies-questions-and-answers\u0022\u003EUse of Whole Slide Imaging in Nonclinical Toxicology Studies: Questions and Answers: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/168431\/download\u0022\u003EPDF (124.61 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (124.61 KB) of Use of Whole Slide Imaging in Nonclinical Toxicology Studies: Questions and Answers: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/24\/2023","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program","field_health_topics":"","term_node_tid":"Pharmacology\/Toxicology","field_topics":"","topics-product":"Pharmacology\/Toxicology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-1268\u0022\u003EFDA-2021-D-1268\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs, Medical Devices, Tobacco","changed":"\u003Ctime datetime=\u00222024-10-01T14:20:01-04:00\u0022\u003E2024-10-01 14:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e8r1-general-considerations-clinical-studies\u0022\u003EE8(R1) General Considerations for Clinical Studies\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/157560\/download\u0022\u003EPDF (376.69 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (376.69 KB) of E8(R1) General Considerations for Clinical Studies\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/08\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Efficacy","field_topics":"","topics-product":"ICH-Efficacy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-3049\u0022\u003EFDA-2019-D-3049\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-04-08T08:45:07-04:00\u0022\u003E2022-04-08 08:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/orthopedic-fracture-fixation-plates-performance-criteria-safety-and-performance-based-pathway\u0022\u003EOrthopedic Fracture Fixation Plates - Performance Criteria for Safety and Performance Based Pathway: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/157491\/download\u0022\u003EPDF (447.92 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (447.92 KB) of Orthopedic Fracture Fixation Plates - Performance Criteria for Safety and Performance Based Pathway: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/11\/2022","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k)","field_topics":"Premarket","topics-product":"Premarket, 510(k)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0552\u0022\u003EFDA-2022-D-0552\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222022-04-08T10:04:04-04:00\u0022\u003E2022-04-08 10:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/surgical-sutures-performance-criteria-safety-and-performance-based-pathway\u0022\u003ESurgical Sutures - Performance Criteria for Safety and Performance Based Pathway: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/157490\/download\u0022\u003EPDF (395.53 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (395.53 KB) of Surgical Sutures - Performance Criteria for Safety and Performance Based Pathway: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/11\/2022","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k)","field_topics":"Premarket","topics-product":"Premarket, 510(k)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0552\u0022\u003EFDA-2022-D-0552\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222022-04-08T10:04:07-04:00\u0022\u003E2022-04-08 10:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/considerations-waiver-requests-ph-adjusters-generic-drug-products-intended-parenteral-ophthalmic-or\u0022\u003EConsiderations for Waiver Requests for pH Adjusters in Generic Drug Products Intended for Parenteral, Ophthalmic, or Otic Use: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/157655\/download\u0022\u003EPDF (358.58 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (358.58 KB) of Considerations for Waiver Requests for pH Adjusters in Generic Drug Products Intended for Parenteral, Ophthalmic, or Otic Use: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/17\/2025","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Generic Drugs","field_topics":"","topics-product":"Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0108\u0022\u003EFDA-2022-D-0108\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-11-17T10:31:22-05:00\u0022\u003E2025-11-17 10:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/celiac-disease-developing-drugs-adjunctive-treatment-gluten-free-diet\u0022\u003ECeliac Disease: Developing Drugs for Adjunctive Treatment to a Gluten-Free Diet\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/157682\/download\u0022\u003EPDF (296.08 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (296.08 KB) of Celiac Disease: Developing Drugs for Adjunctive Treatment to a Gluten-Free Diet\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/15\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research,Office of New Drugs\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"06\/14\/2022","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-1238\u0022\u003EFDA-2021-D-1238\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-04-18T11:13:04-04:00\u0022\u003E2022-04-18 11:13\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-fda-staff-and-interested-parties-evaluating-public-health-importance-food-allergens-other\u0022\u003EGuidance for FDA Staff and Interested Parties: Evaluating the Public Health Importance of Food Allergens Other Than the Major Food Allergens Listed in the Federal Food, Drug, and Cosmetic Act\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/157637\/download\u0022\u003EPDF (660.05 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (660.05 KB) of Guidance for FDA Staff and Interested Parties: Evaluating the Public Health Importance of Food Allergens Other Than the Major Food Allergens Listed in the Federal Food, Drug, and Cosmetic Act\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/06\/2025","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Allergens, Labeling","field_topics":"","topics-product":"Allergens, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-N-0553\u0022\u003EFDA-2021-N-0553\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-01-06T09:03:21-05:00\u0022\u003E2025-01-06 09:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-policy-regarding-n-acetyl-l-cysteine\u0022\u003EGuidance for Industry: Policy Regarding N-acetyl-L-cysteine\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/157784\/download\u0022\u003EPDF (219.41 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (219.41 KB) of Guidance for Industry: Policy Regarding N-acetyl-L-cysteine\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/01\/2022","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0490 \u0022\u003EFDA-2022-D-0490 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Dietary Supplements","changed":"\u003Ctime datetime=\u00222025-03-12T10:14:01-04:00\u0022\u003E2025-03-12 10:14\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/draft-guidance-industry-action-levels-lead-juice\u0022\u003EDraft Guidance for Industry: Action Levels for Lead in Juice\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/157949\/download\u0022\u003EPDF (283.96 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (283.96 KB) of Draft Guidance for Industry: Action Levels for Lead in Juice\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/27\/2022","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Juice, Lead","field_topics":"","topics-product":"Juice, Lead","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"06\/28\/2022","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-5609\u0022\u003EFDA-2019-D-5609\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T08:45:08-04:00\u0022\u003E2024-10-01 08:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/draft-guidance-industry-questions-and-answers-accredited-third-party-certification-program\u0022\u003EDraft Guidance for Industry: Questions and Answers on the Accredited Third-Party Certification Program\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/157965\/download\u0022\u003EPDF (442.68 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (442.68 KB) of Draft Guidance for Industry: Questions and Answers on the Accredited Third-Party Certification Program\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/28\/2022","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Import","field_topics":"","topics-product":"Import","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"07\/28\/2022","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0370\u0022\u003EFDA-2022-D-0370\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-06T11:31:08-05:00\u0022\u003E2025-03-06 11:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/crohns-disease-developing-drugs-treatment\u0022\u003ECrohn\u2019s Disease: Developing Drugs for Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/158001\/download\u0022\u003EPDF (305.09 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (305.09 KB) of Crohn\u2019s Disease: Developing Drugs for Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/28\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"06\/28\/2022","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0091\u0022\u003EFDA-2022-D-0091\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-10-31T10:50:17-04:00\u0022\u003E2022-10-31 10:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/use-circulating-tumor-deoxyribonucleic-acid-early-stage-solid-tumor-drug-development-guidance\u0022\u003EUse of Circulating Tumor Deoxyribonucleic Acid for Early-Stage Solid Tumor Drug Development; Guidance for Industry; Availability\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/183874\/download\u0022\u003EPDF (303.41 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (303.41 KB) of Use of Circulating Tumor Deoxyribonucleic Acid for Early-Stage Solid Tumor Drug Development; Guidance for Industry; Availability\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/27\/2024","field_issuing_office_taxonomy":"Oncology Center of Excellence","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/Docket No. FDA-2022-D-0084\u0022\u003EDocket No. FDA-2022-D-0084\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"","changed":"\u003Ctime datetime=\u00222024-11-27T09:44:12-05:00\u0022\u003E2024-11-27 09:44\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clinical-pharmacology-considerations-human-radiolabeled-mass-balance-studies\u0022\u003EClinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/158178\/download\u0022\u003EPDF (271.51 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (271.51 KB) of Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/26\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Pharmacology","field_topics":"","topics-product":"Clinical - Pharmacology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"08\/04\/2022","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0113\u0022\u003EFDA-2022-D-0113\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-09-27T07:43:16-04:00\u0022\u003E2024-09-27 07:43\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/fostering-medical-device-improvement-fda-activities-and-engagement-voluntary-improvement-program\u0022\u003EFostering Medical Device Improvement: FDA Activities and Engagement with the Voluntary Improvement Program: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/158180\/download\u0022\u003EPDF (684.81 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (684.81 KB) of Fostering Medical Device Improvement: FDA Activities and Engagement with the Voluntary Improvement Program: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/15\/2023","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP)","field_topics":"Postmarket","topics-product":"Postmarket, Current Good Manufacturing Practice (CGMP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0109\u0022\u003EFDA-2022-D-0109\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222023-09-14T08:55:01-04:00\u0022\u003E2023-09-14 08:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/benefit-risk-considerations-product-quality-assessments\u0022\u003EBenefit-Risk Considerations for Product Quality Assessments\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/158204\/download\u0022\u003EPDF (317.92 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (317.92 KB) of Benefit-Risk Considerations for Product Quality Assessments\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/09\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"07\/10\/2022","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0168\u0022\u003EFDA-2022-D-0168\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-05-10T09:09:10-04:00\u0022\u003E2022-05-10 09:09\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-272-practices-prevent-unsafe-contamination-animal-feed-drug-carryover\u0022\u003ECVM GFI #272 Practices to Prevent Unsafe Contamination of Animal Feed from Drug Carryover\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/157979\/download\u0022\u003EPDF (262.79 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (262.79 KB) of CVM GFI #272 Practices to Prevent Unsafe Contamination of Animal Feed from Drug Carryover\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/30\/2023","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Feed, Current Good Manufacturing Practice (CGMP), Safety - Issues, Errors, and Problems","field_topics":"","topics-product":"Animal Feed, Current Good Manufacturing Practice (CGMP), Safety - Issues, Errors, and Problems","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"08\/08\/2022","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0173\u0022\u003EFDA-2022-D-0173\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222023-01-27T08:49:31-05:00\u0022\u003E2023-01-27 08:49\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/risk-management-plans-mitigate-potential-drug-shortages\u0022\u003ERisk Management Plans to Mitigate the Potential for Drug Shortages\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/158487\/download\u0022\u003EPDF (375.4 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (375.4 KB) of Risk Management Plans to Mitigate the Potential for Drug Shortages\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/19\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_topics":"","topics-product":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"07\/19\/2022","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0277\u0022\u003EFDA-2022-D-0277\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-05-20T08:59:07-04:00\u0022\u003E2022-05-20 08:59\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/draft-guidance-industry-policy-regarding-certain-new-dietary-ingredients-and-dietary-supplements\u0022\u003EDraft Guidance for Industry: Policy Regarding Certain New Dietary Ingredients and Dietary Supplements Subject to the Requirement for Pre-market Notification\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/158369\/download\u0022\u003EPDF (233.96 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (233.96 KB) of Draft Guidance for Industry: Policy Regarding Certain New Dietary Ingredients and Dietary Supplements Subject to the Requirement for Pre-market Notification\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/19\/2022","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"07\/19\/2022","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0281\u0022\u003EFDA-2022-D-0281\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Dietary Supplements","changed":"\u003Ctime datetime=\u00222025-03-06T10:37:46-05:00\u0022\u003E2025-03-06 10:37\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/compliance-policy-regarding-blood-and-blood-component-donation-suitability-donor-eligibility-and\u0022\u003ECompliance Policy Regarding Blood and Blood Component Donation Suitability, Donor Eligibility and Source Plasma Quarantine Hold Requirements: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/158608\/download\u0022\u003EPDF (285.14 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (285.14 KB) of Compliance Policy Regarding Blood and Blood Component Donation Suitability, Donor Eligibility and Source Plasma Quarantine Hold Requirements: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/14\/2026","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Blood, Coronavirus","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood, Coronavirus, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"10\/18\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0588\u0022\u003EFDA-2022-D-0588\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222026-10-14T09:44:23-04:00\u0022\u003E2026-10-14 09:44\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/blood-pressure-and-pulse-donor-eligibility-requirements-compliance-policy\u0022\u003EBlood Pressure and Pulse Donor Eligibility Requirements \u2013 Compliance Policy: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/158609\/download\u0022\u003EPDF (245.08 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (245.08 KB) of Blood Pressure and Pulse Donor Eligibility Requirements \u2013 Compliance Policy: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/14\/2026","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Blood","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"07\/25\/2022","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0362\u0022\u003EFDA-2022-D-0362\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222026-10-14T09:44:16-04:00\u0022\u003E2026-10-14 09:44\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/antibacterial-therapies-patients-unmet-medical-need-treatment-serious-bacterial-diseases-questions\u0022\u003EAntibacterial Therapies for Patients With an Unmet Medical Need for the Treatment of Serious Bacterial Diseases \u2013 Questions and Answers: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/158589\/download\u0022\u003EPDF (289.25 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (289.25 KB) of Antibacterial Therapies for Patients With an Unmet Medical Need for the Treatment of Serious Bacterial Diseases \u2013 Questions and Answers: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/26\/2025","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research,Office of New Drugs","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"06\/25\/2022","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0744\u0022\u003EFDA-2013-D-0744\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-06-27T08:05:01-04:00\u0022\u003E2025-06-27 08:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/importation-prescription-drugs-final-rule-questions-and-answers-small-entity-compliance-guide\u0022\u003EImportation of Prescription Drugs Final Rule Questions and Answers; Small Entity Compliance Guide\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/158659\/download\u0022\u003EPDF (232.73 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (232.73 KB) of Importation of Prescription Drugs Final Rule Questions and Answers; Small Entity Compliance Guide\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/25\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Import","field_topics":"","topics-product":"Import","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0958\u0022\u003EFDA-2021-D-0958\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-11-05T16:09:12-05:00\u0022\u003E2024-11-05 16:09\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q9r1-quality-risk-management\u0022\u003EQ9(R1) Quality Risk Management\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/167721\/download\u0022\u003EPDF (435.74 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (435.74 KB) of Q9(R1) Quality Risk Management\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/03\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0705\u0022\u003EFDA-2022-D-0705\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-05-29T10:53:34-04:00\u0022\u003E2026-05-29 10:53\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/voluntary-consensus-standards-recognition-program-regenerative-medicine-therapies\u0022\u003EVoluntary Consensus Standards Recognition Program for Regenerative Medicine Therapies: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/159237\/download\u0022\u003EPDF (289.04 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (289.04 KB) of Voluntary Consensus Standards Recognition Program for Regenerative Medicine Therapies: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/19\/2023","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Tissue","field_topics":"","topics-product":"Tissue","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0745\u0022\u003EFDA-2022-D-0745\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222023-11-27T16:10:46-05:00\u0022\u003E2023-11-27 16:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/non-clinical-performance-assessment-tissue-containment-systems-used-during-power-morcellation\u0022\u003ENon-Clinical Performance Assessment of Tissue Containment Systems Used During Power Morcellation Procedures: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/159294\/download\u0022\u003EPDF (362.84 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (362.84 KB) of Non-Clinical Performance Assessment of Tissue Containment Systems Used During Power Morcellation Procedures: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/26\/2023","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Clinical - Medical, General \u0026amp; Plastic Surgery , Obstetrical \u0026amp; Gynecological","field_topics":"Premarket","topics-product":"Premarket, Clinical - Medical, General \u0026amp; Plastic Surgery , Obstetrical \u0026amp; Gynecological","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0737\u0022\u003EFDA-2022-D-0737\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222023-05-25T08:47:01-04:00\u0022\u003E2023-05-25 08:47\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/non-penicillin-beta-lactam-drugs-cgmp-framework-preventing-cross-contamination-0\u0022\u003ENon-Penicillin Beta-Lactam Drugs: A CGMP Framework for Preventing Cross-Contamination: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/159358\/download\u0022\u003EPDF (461.3 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (461.3 KB) of Non-Penicillin Beta-Lactam Drugs: A CGMP Framework for Preventing Cross-Contamination: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/24\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_topics":"","topics-product":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"08\/23\/2022","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0104\u0022\u003EFDA-2011-D-0104\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-06-24T08:19:31-04:00\u0022\u003E2022-06-24 08:19\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/considerations-rescinding-breakthrough-therapy-designation\u0022\u003EConsiderations for Rescinding Breakthrough Therapy Designation \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/159359\/download\u0022\u003EPDF (251.13 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (251.13 KB) of Considerations for Rescinding Breakthrough Therapy Designation \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/24\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOncology Center of Excellence","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"08\/23\/2022","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-1152\u0022\u003EFDA-2021-D-1152\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-06-24T10:58:31-04:00\u0022\u003E2022-06-24 10:58\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clinical-pharmacology-considerations-development-oligonucleotide-therapeutics\u0022\u003EClinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/159414\/download\u0022\u003EPDF (322.17 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (322.17 KB) of Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/14\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Pharmacology","field_topics":"","topics-product":"Clinical - Pharmacology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"09\/25\/2022","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0235\u0022\u003EFDA-2022-D-0235\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-07-29T13:51:02-04:00\u0022\u003E2024-07-29 13:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-selecting-developing-or-modifying-fit-purpose-clinical-outcome\u0022\u003EPatient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/159500\/download\u0022\u003EPDF (1.05 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.05 MB) of Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/22\/2025","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Pediatric Product Development","field_topics":"","topics-product":"Administrative \/ Procedural, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-1385\u0022\u003EFDA-2022-D-1385\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-01-26T10:06:48-05:00\u0022\u003E2026-01-26 10:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/identifying-trading-partners-under-drug-supply-chain-security-act\u0022\u003EIdentifying Trading Partners Under the Drug Supply Chain Security Act\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/159621\/download\u0022\u003EPDF (308.96 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (308.96 KB) of Identifying Trading Partners Under the Drug Supply Chain Security Act\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/05\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"09\/05\/2022","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-1956\u0022\u003EFDA-2017-D-1956\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-07-05T11:08:01-04:00\u0022\u003E2022-07-05 11:08\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/human-prescription-drug-and-biological-products-labeling-dosing-based-weight-or-body-surface-area\u0022\u003EHuman Prescription Drug and Biological Products--Labeling for Dosing Based on Weight or Body Surface Area for Ready-to-Use Containers--\u201cDose Banding\u201d\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/172571\/download\u0022\u003EPDF (261.22 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (261.22 KB) of Human Prescription Drug and Biological Products--Labeling for Dosing Based on Weight or Body Surface Area for Ready-to-Use Containers--\u201cDose Banding\u201d\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/02\/2023","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0219\u0022\u003EFDA-2022-D-0219\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-10-02T10:43:01-04:00\u0022\u003E2023-10-02 10:43\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/evaluation-therapeutic-equivalence\u0022\u003EEvaluation of Therapeutic Equivalence\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/160054\/download\u0022\u003EPDF (362.08 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (362.08 KB) of Evaluation of Therapeutic Equivalence\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/21\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Drug Competition Action Plan, Generic Drugs","field_topics":"","topics-product":"Drug Competition Action Plan, Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0528\u0022\u003EFDA-2022-D-0528\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-09-02T12:42:46-04:00\u0022\u003E2026-09-02 12:42\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/conducting-remote-regulatory-assessments-questions-and-answers\u0022\u003EConducting Remote Regulatory Assessments Questions and Answers: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/160173\/download\u0022\u003EPDF (393.28 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (393.28 KB) of Conducting Remote Regulatory Assessments Questions and Answers: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/24\/2025","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Tobacco Products\u003Cbr\u003E\u003Cbr\u003ECenter for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of the Chief Medical Officer,Office of Combination Products","field_health_topics":"","term_node_tid":"Records, Import","field_topics":"Compliance, Investigation \u0026amp; Enforcement, Inspection, Electronic Submissions, Regulation, Administration","topics-product":"Compliance, Investigation \u0026amp; Enforcement, Inspection, Electronic Submissions, Regulation, Administration, Records, Import","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0810\u0022\u003EFDA-2022-D-0810\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Cosmetics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Tobacco","changed":"\u003Ctime datetime=\u00222025-06-30T10:10:16-04:00\u0022\u003E2025-06-30 10:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/real-time-oncology-review-rtor\u0022\u003EReal-Time Oncology Review (RTOR) : Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/173641\/download\u0022\u003EPDF (257.79 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (257.79 KB) of Real-Time Oncology Review (RTOR) : Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/07\/2023","field_issuing_office_taxonomy":"Oncology Center of Excellence","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0823\u0022\u003EFDA-2022-D-0823\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222023-11-07T11:54:01-05:00\u0022\u003E2023-11-07 11:54\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/changes-disposable-manufacturing-materials-questions-and-answers-guidance-industry\u0022\u003EChanges to Disposable Manufacturing Materials: Questions and Answers Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/160300\/download\u0022\u003EPDF (296.49 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (296.49 KB) of Changes to Disposable Manufacturing Materials: Questions and Answers Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/29\/2022","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pharmaceutical Quality","field_topics":"","topics-product":"Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6821\u0022\u003EFDA-2017-D-6821\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-07-29T08:45:09-04:00\u0022\u003E2022-07-29 08:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/contact-lens-care-products-labeling\u0022\u003EContact Lens Care Products Labeling: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/79409\/download\u0022\u003EPDF (109.95 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (109.95 KB) of Contact Lens Care Products Labeling: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/15\/2010","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Ophthalmic","field_topics":"Premarket","topics-product":"Premarket, 510(k), Ophthalmic","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222022-08-01T12:33:16-04:00\u0022\u003E2022-08-01 12:33\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/electronic-submission-expedited-safety-reports-ind-exempt-babe-studies-guidance-industry\u0022\u003EElectronic Submission of Expedited Safety Reports From IND-Exempt BA\/BE Studies Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/177371\/download\u0022\u003EPDF (256.74 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (256.74 KB) of Electronic Submission of Expedited Safety Reports From IND-Exempt BA\/BE Studies Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/01\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Generic Drugs","field_topics":"Electronic Submissions","topics-product":"Electronic Submissions, Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-1173\u0022\u003EFDA-2022-D-1173\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-04-01T09:15:02-04:00\u0022\u003E2024-04-01 09:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/hydrogen-peroxide-based-contact-lens-care-products-consumer-labeling-recommendations-premarket\u0022\u003EHydrogen Peroxide-Based Contact Lens Care Products: Consumer Labeling Recommendations - Premarket Notification (510(k)) Submissions: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/160909\/download\u0022\u003EPDF (671.09 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (671.09 KB) of Hydrogen Peroxide-Based Contact Lens Care Products: Consumer Labeling Recommendations - Premarket Notification (510(k)) Submissions: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/27\/2023","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Labeling, Ophthalmic","field_topics":"Premarket","topics-product":"Premarket, 510(k), Labeling, Ophthalmic","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0986\u0022\u003EFDA-2022-D-0986\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222023-07-26T09:01:31-04:00\u0022\u003E2023-07-26 09:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e11a-pediatric-extrapolation\u0022\u003EE11A Pediatric Extrapolation\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/161190\/download\u0022\u003EPDF (473.47 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (473.47 KB) of E11A Pediatric Extrapolation\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/30\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Efficacy, Pediatric Product Development","field_topics":"","topics-product":"ICH-Efficacy, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-1562\u0022\u003EFDA-2022-D-1562\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-01-03T10:11:02-05:00\u0022\u003E2025-01-03 10:11\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/m12-drug-interaction-studies\u0022\u003EM12 Drug Interaction Studies\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/161199\/download\u0022\u003EPDF (824.34 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (824.34 KB) of M12 Drug Interaction Studies\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/02\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research,Office of Regulatory Policy\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Multidisciplinary","field_topics":"","topics-product":"ICH-Multidisciplinary","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-1527\u0022\u003EFDA-2022-D-1527\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-05-27T12:57:46-04:00\u0022\u003E2026-05-27 12:57\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q2r2-validation-analytical-procedures\u0022\u003EQ2(R2) Validation of Analytical Procedures\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/161201\/download\u0022\u003EPDF (637.6 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (637.6 KB) of Q2(R2) Validation of Analytical Procedures\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/06\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research,Office of Regulatory Policy","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-1503\u0022\u003EFDA-2022-D-1503\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-03-07T06:41:16-05:00\u0022\u003E2024-03-07 06:41\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q14-analytical-procedure-development\u0022\u003EQ14 Analytical Procedure Development\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/161202\/download\u0022\u003EPDF (1.05 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.05 MB) of Q14 Analytical Procedure Development\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/07\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research,Office of Regulatory Policy\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-1503\u0022\u003EFDA-2022-D-1503\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-03-07T10:49:04-05:00\u0022\u003E2024-03-07 10:49\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/policy-monkeypox-tests-address-public-health-emergency\u0022\u003EPolicy for Monkeypox Tests to Address the Public Health Emergency: Guidance for Laboratories, Commercial Manufacturers and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/161443\/download\u0022\u003EPDF (599.02 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (599.02 KB) of Policy for Monkeypox Tests to Address the Public Health Emergency: Guidance for Laboratories, Commercial Manufacturers and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/07\/2022","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-1908\u0022\u003EFDA-2022-D-1908\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222022-09-13T08:40:02-04:00\u0022\u003E2022-09-13 08:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/quantitative-labeling-sodium-potassium-and-phosphorus-human-over-counter-and-prescription-drug\u0022\u003EQuantitative Labeling of Sodium, Potassium, and Phosphorus for Human Over-the-Counter and Prescription Drug Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/161194\/download\u0022\u003EPDF (266.67 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (266.67 KB) of Quantitative Labeling of Sodium, Potassium, and Phosphorus for Human Over-the-Counter and Prescription Drug Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/08\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"11\/08\/2022","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0528\u0022\u003EFDA-2021-D-0528\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-05-10T15:31:01-04:00\u0022\u003E2023-05-10 15:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/statement-identity-and-strength-content-and-format-labeling-human-nonprescription-drug-products\u0022\u003EStatement of Identity and Strength \u2014 Content and Format of Labeling for Human Nonprescription Drug Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/161186\/download\u0022\u003EPDF (266.17 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (266.17 KB) of Statement of Identity and Strength \u2014 Content and Format of Labeling for Human Nonprescription Drug Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/08\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research,Office of New Drugs","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"11\/08\/2022","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-1837\u0022\u003EFDA-2022-D-1837\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-09-13T11:16:31-04:00\u0022\u003E2022-09-13 11:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/how-obtain-covered-product-authorization\u0022\u003EHow To Obtain a Covered Product Authorization\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/161730\/download\u0022\u003EPDF (340.48 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (340.48 KB) of How To Obtain a Covered Product Authorization\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/21\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"11\/21\/2022","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-1358\u0022\u003EFDA-2022-D-1358\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-09-22T10:48:17-04:00\u0022\u003E2022-09-22 10:48\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/exemption-and-exclusion-certain-requirements-drug-supply-chain-security-act-distribution-fda\u0022\u003EExemption and Exclusion From Certain Requirements of the Drug Supply Chain Security Act for the Distribution of FDA-Approved Naloxone Products During the Opioid Public Health Emergency Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/161750\/download\u0022\u003EPDF (185.47 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (185.47 KB) of Exemption and Exclusion From Certain Requirements of the Drug Supply Chain Security Act for the Distribution of FDA-Approved Naloxone Products During the Opioid Public Health Emergency Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/22\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research,Office of Regulatory Policy","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-1847\u0022\u003EFDA-2022-D-1847\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-09-22T08:45:12-04:00\u0022\u003E2022-09-22 08:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/data-standards-catalog\u0022\u003EData Standards Catalog\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/185927\/download\u0022\u003EXLSX (764.88 KB)\u003Cspan class=\u0022sr-only\u0022\u003EXLSX (764.88 KB) of Data Standards Catalog\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/24\/2025","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program\u003Cbr\u003E\u003Cbr\u003ECenter for Veterinary Medicine","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-03-25T09:48:46-04:00\u0022\u003E2025-03-25 09:48\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/ethical-considerations-clinical-investigations-medical-products-involving-children\u0022\u003EEthical Considerations for Clinical Investigations of Medical Products Involving Children: Draft Guidance for Industry, Sponsors, and IRBs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/161740\/download\u0022\u003EPDF (433.98 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (433.98 KB) of Ethical Considerations for Clinical Investigations of Medical Products Involving Children: Draft Guidance for Industry, Sponsors, and IRBs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/26\/2022","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Pediatric Therapeutics\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Pediatric Product Development","field_topics":"","topics-product":"Clinical - Medical, Pediatric Product Development","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0738\u0022\u003EFDA-2022-D-0738\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222024-04-12T14:48:46-04:00\u0022\u003E2024-04-12 14:48\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/providing-over-counter-monograph-submissions-electronic-format\u0022\u003EProviding Over-the-Counter Monograph Submissions in Electronic Format\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/161822\/download\u0022\u003EPDF (269.74 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (269.74 KB) of Providing Over-the-Counter Monograph Submissions in Electronic Format\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/25\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Electronic Submissions","topics-product":"Electronic Submissions, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-2059\u0022\u003EFDA-2022-D-2059\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-07-25T09:54:31-04:00\u0022\u003E2024-07-25 09:54\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/facility-readiness-goal-date-decisions-under-gdufa\u0022\u003EFacility Readiness: Goal Date Decisions Under GDUFA\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/162018\/download\u0022\u003EPDF (252.05 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (252.05 KB) of Facility Readiness: Goal Date Decisions Under GDUFA\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/18\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Generic Drugs","field_topics":"","topics-product":"Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-1981\u0022\u003EFDA-2022-D-1981\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-06-18T15:46:03-04:00\u0022\u003E2024-06-18 15:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/review-drug-master-files-advance-certain-anda-submissions-under-gdufa\u0022\u003EReview of Drug Master Files in Advance of Certain ANDA Submissions Under GDUFA \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/162019\/download\u0022\u003EPDF (272.69 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (272.69 KB) of Review of Drug Master Files in Advance of Certain ANDA Submissions Under GDUFA \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/17\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Generic Drugs, Pharmaceutical Quality, Drug Competition Action Plan","field_topics":"User Fees","topics-product":"User Fees, Chemistry, Manufacturing, and Controls (CMC), Generic Drugs, Pharmaceutical Quality, Drug Competition Action Plan","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-2061\u0022\u003EFDA-2022-D-2061\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-10-17T08:00:05-04:00\u0022\u003E2024-10-17 08:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/characterizing-collecting-and-reporting-immune-mediated-adverse-reactions-cancer-immunotherapeutic\u0022\u003ECharacterizing, Collecting, and Reporting Immune-Mediated Adverse Reactions in Cancer Immunotherapeutic Clinical Trials: Draft Guidance for Industry; Availability \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/162341\/download\u0022\u003EPDF (301.07 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (301.07 KB) of Characterizing, Collecting, and Reporting Immune-Mediated Adverse Reactions in Cancer Immunotherapeutic Clinical Trials: Draft Guidance for Industry; Availability \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/17\/2022","field_issuing_office_taxonomy":"Oncology Center of Excellence\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-1744\u0022\u003EFDA-2022-D-1744\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222022-10-17T11:04:31-04:00\u0022\u003E2022-10-17 11:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/acute-myeloid-leukemia-developing-drugs-and-biological-products-treatment-0\u0022\u003EAcute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment: Guidance for Industry; Availability\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/162362\/download\u0022\u003EPDF (437.72 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (437.72 KB) of Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment: Guidance for Industry; Availability\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/17\/2022","field_issuing_office_taxonomy":"Oncology Center of Excellence\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Pediatric Product Development","field_topics":"","topics-product":"Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1298\u0022\u003EFDA-2020-D-1298\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T11:30:09-04:00\u0022\u003E2024-04-11 11:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-entity-compliance-guide-laboratory-accreditation-analyses-foods-what-you-need-know\u0022\u003ESmall Entity Compliance Guide: Laboratory Accreditation for Analyses of Foods - What You Need to Know\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/162315\/download\u0022\u003EPDF (505.15 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (505.15 KB) of Small Entity Compliance Guide: Laboratory Accreditation for Analyses of Foods - What You Need to Know\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/19\/2022","field_issuing_office_taxonomy":"Human Foods Program\u003Cbr\u003E\u003Cbr\u003ECenter for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-1126\u0022\u003EFDA-2022-D-1126\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:06:19-04:00\u0022\u003E2024-10-01 07:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/breakthrough-devices-program\u0022\u003EBreakthrough Devices Program: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/162413\/download\u0022\u003EPDF (872.3 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (872.3 KB) of Breakthrough Devices Program: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/14\/2023","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-5966\u0022\u003EFDA-2017-D-5966\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222023-09-14T16:18:03-04:00\u0022\u003E2023-09-14 16:18\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/physicochemical-and-structural-q3-characterization-topical-drug-products-submitted-andas\u0022\u003EPhysicochemical and Structural (Q3) Characterization of Topical Drug Products Submitted in ANDAs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/162471\/download\u0022\u003EPDF (265.45 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (265.45 KB) of Physicochemical and Structural (Q3) Characterization of Topical Drug Products Submitted in ANDAs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/17\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research,Office of Regulatory Policy","field_health_topics":"","term_node_tid":"Drug Competition Action Plan, Generic Drugs","field_topics":"User Fees, Electronic Submissions","topics-product":"User Fees, Electronic Submissions, Drug Competition Action Plan, Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-1864\u0022\u003EFDA-2022-D-1864\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-03-18T14:37:01-04:00\u0022\u003E2026-03-18 14:37\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/in-vitro-permeation-test-studies-topical-drug-products-submitted-andas\u0022\u003EIn Vitro Permeation Test Studies for Topical Drug Products Submitted in ANDAs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/162475\/download\u0022\u003EPDF (689.03 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (689.03 KB) of In Vitro Permeation Test Studies for Topical Drug Products Submitted in ANDAs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/21\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research,Office of Regulatory Policy","field_health_topics":"","term_node_tid":"Generic Drugs","field_topics":"","topics-product":"Generic Drugs","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-1862\u0022\u003EFDA-2022-D-1862\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-11-30T15:20:16-05:00\u0022\u003E2022-11-30 15:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/in-vitro-release-test-studies-topical-drug-products-submitted-andas\u0022\u003EIn Vitro Release Test Studies for Topical Drug Products Submitted in ANDAs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/162476\/download\u0022\u003EPDF (252.01 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (252.01 KB) of In Vitro Release Test Studies for Topical Drug Products Submitted in ANDAs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/21\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research,Office of Regulatory Policy","field_health_topics":"","term_node_tid":"Generic Drugs","field_topics":"","topics-product":"Generic Drugs","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-1859\u0022\u003EFDA-2022-D-1859\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-10-21T09:05:16-04:00\u0022\u003E2022-10-21 09:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/topical-dermatologic-corticosteroids-in-vivo-bioequivalence\u0022\u003ETopical Dermatologic Corticosteroids: In Vivo Bioequivalence\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/162457\/download\u0022\u003EPDF (347.37 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (347.37 KB) of Topical Dermatologic Corticosteroids: In Vivo Bioequivalence\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/14\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Drug Competition Action Plan, Generic Drugs","field_topics":"","topics-product":"Drug Competition Action Plan, Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-2170\u0022\u003EFDA-2022-D-2170\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-07-13T08:45:19-04:00\u0022\u003E2026-07-13 08:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/investigational-new-drug-application-submissions-individualized-antisense-oligonucleotide-drug\u0022\u003EInvestigational New Drug Application Submissions for Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases: Chemistry, Manufacturing, and Controls Recommendations, Guidance for Sponsor-Investigators : Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/154664\/download\u0022\u003EPDF (149.36 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (149.36 KB) of Investigational New Drug Application Submissions for Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases: Chemistry, Manufacturing, and Controls Recommendations, Guidance for Sponsor-Investigators : Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/07\/2021","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC)","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC)","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"02\/07\/2022","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-1139\u0022\u003EFDA-2021-D-1139\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-10-21T11:20:02-04:00\u0022\u003E2022-10-21 11:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clostridioides-difficile-infection-developing-drugs-treatment-reduction-recurrence-and-prevention\u0022\u003EClostridioides difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, and Prevention\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/162692\/download\u0022\u003EPDF (281.66 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (281.66 KB) of Clostridioides difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, and Prevention\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/08\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-1261\u0022\u003EFDA-2022-D-1261\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-05-11T15:32:01-04:00\u0022\u003E2026-05-11 15:32\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/measuring-growth-and-evaluating-pubertal-development-pediatric-clinical-trials-draft-guidance\u0022\u003EMeasuring Growth and Evaluating Pubertal Development in Pediatric Clinical Trials; Draft Guidance for Industry; Availability \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/162725\/download\u0022\u003EPDF (291.6 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (291.6 KB) of Measuring Growth and Evaluating Pubertal Development in Pediatric Clinical Trials; Draft Guidance for Industry; Availability \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/31\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research,Office of New Drugs\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Pediatric Product Development","field_topics":"","topics-product":"Clinical - Medical, Pediatric Product Development","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"01\/03\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0760\u0022\u003EFDA-2022-D-0760\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T09:36:46-04:00\u0022\u003E2024-04-11 09:36\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/assessing-user-fees-under-over-counter-monograph-drug-user-fee-program\u0022\u003EAssessing User Fees Under the Over-the-Counter Monograph Drug User Fee Program\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/162759\/download\u0022\u003EPDF (360.98 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (360.98 KB) of Assessing User Fees Under the Over-the-Counter Monograph Drug User Fee Program\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/01\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"User Fees","topics-product":"User Fees, ","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/2021-709\u0022\u003E2021-709\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-11-01T08:47:46-04:00\u0022\u003E2022-11-01 08:47\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/expanded-access-investigational-drugs-treatment-use-questions-and-answers\u0022\u003EExpanded Access to Investigational Drugs for Treatment Use: Questions and Answers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/162793\/download\u0022\u003EPDF (496.53 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (496.53 KB) of Expanded Access to Investigational Drugs for Treatment Use: Questions and Answers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/15\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0446\u0022\u003EFDA-2013-D-0446\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-04-17T08:07:01-04:00\u0022\u003E2026-04-17 08:07\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/sameness-evaluations-anda-active-ingredients\u0022\u003ESameness Evaluations in an ANDA \u2014 Active Ingredients\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/163018\/download\u0022\u003EPDF (378.63 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (378.63 KB) of Sameness Evaluations in an ANDA \u2014 Active Ingredients\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/08\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research,Office of Generic Drugs","field_health_topics":"","term_node_tid":"Drug Competition Action Plan, Generic Drugs","field_topics":"","topics-product":"Drug Competition Action Plan, Generic Drugs","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"01\/08\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0697\u0022\u003EFDA-2022-D-0697\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-01-11T16:23:31-05:00\u0022\u003E2023-01-11 16:23\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q5ar2-viral-safety-evaluation-biotechnology-products-derived-cell-lines-human-or-animal-origin\u0022\u003EQ5A(R2) Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/163115\/download\u0022\u003EPDF (661.29 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (661.29 KB) of Q5A(R2) Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/10\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-2512\u0022\u003EFDA-2022-D-2512\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-01-12T07:38:01-05:00\u0022\u003E2024-01-12 07:38\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/compounding-certain-beta-lactam-products-shortage-under-section-503a-federal-food-drug-and-cosmetic\u0022\u003ECompounding Certain Beta-Lactam Products in Shortage Under Section 503A of the Federal Food Drug and Cosmetic Act\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/163367\/download\u0022\u003EPDF (233.57 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (233.57 KB) of Compounding Certain Beta-Lactam Products in Shortage Under Section 503A of the Federal Food Drug and Cosmetic Act\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/18\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-2922\u0022\u003EFDA-2022-D-2922\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222022-11-18T16:02:05-05:00\u0022\u003E2022-11-18 16:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-276-effectiveness-anthelmintics-specific-recommendations-products-proposed-prevention\u0022\u003ECVM GFI #276 Effectiveness of Anthelmintics: Specific Recommendations for Products Proposed for the Prevention of Heartworm Disease in Dogs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/163319\/download\u0022\u003EPDF (274.34 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (274.34 KB) of CVM GFI #276 Effectiveness of Anthelmintics: Specific Recommendations for Products Proposed for the Prevention of Heartworm Disease in Dogs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/26\/2024","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Anthelmintics, Investigational New Animal Drug (INAD), Target Animal \u2013 Effectiveness","field_topics":"Premarket","topics-product":"Premarket, Anthelmintics, Investigational New Animal Drug (INAD), Target Animal \u2013 Effectiveness","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"05\/01\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-2899\u0022\u003EFDA-2022-D-2899\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222024-06-25T08:54:17-04:00\u0022\u003E2024-06-25 08:54\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/statistical-approaches-establishing-bioequivalence\u0022\u003EStatistical Approaches to Establishing Bioequivalence\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/163638\/download\u0022\u003EPDF (609.25 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (609.25 KB) of Statistical Approaches to Establishing Bioequivalence\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/29\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Biopharmaceutics, Generic Drugs","field_topics":"","topics-product":"Biopharmaceutics, Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2001-D-0197\u0022\u003EFDA-2001-D-0197\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-05-28T08:45:14-04:00\u0022\u003E2026-05-28 08:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/andas-pre-submission-facility-correspondence-related-prioritized-generic-drug-submissions\u0022\u003EANDAs: Pre-Submission Facility Correspondence Related to Prioritized Generic Drug Submissions\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/187029\/download\u0022\u003EPDF (344.42 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (344.42 KB) of ANDAs: Pre-Submission Facility Correspondence Related to Prioritized Generic Drug Submissions\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/16\/2025","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research,Office of Pharmaceutical Quality","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Generic Drugs, Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Generic Drugs, Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-3101\u0022\u003EFDA-2017-D-3101\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-08-20T12:16:15-04:00\u0022\u003E2026-08-20 12:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e19-selective-approach-safety-data-collection-specific-late-stage-pre-approval-or-post-approval\u0022\u003EE19 A Selective Approach to Safety Data Collection in Specific Late-Stage Pre-Approval or Post-Approval Clinical Trials\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/163670\/download\u0022\u003EPDF (273.95 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (273.95 KB) of E19 A Selective Approach to Safety Data Collection in Specific Late-Stage Pre-Approval or Post-Approval Clinical Trials\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/05\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-1828\u0022\u003EFDA-2019-D-1828\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"","changed":"\u003Ctime datetime=\u00222024-07-29T14:18:46-04:00\u0022\u003E2024-07-29 14:18\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/content-human-factors-information-medical-device-marketing-submissions\u0022\u003EContent of Human Factors Information in Medical Device Marketing Submissions: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/163694\/download\u0022\u003EPDF (1022.88 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1022.88 KB) of Content of Human Factors Information in Medical Device Marketing Submissions: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/29\/2026","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Safety - Issues, Errors, and Problems","field_topics":"Premarket","topics-product":"Premarket, Safety - Issues, Errors, and Problems","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-4599 \u0022\u003EFDA-2015-D-4599 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222026-08-03T09:45:02-04:00\u0022\u003E2026-08-03 09:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/voluntary-malfunction-summary-reporting-vmsr-program-manufacturers\u0022\u003EVoluntary Malfunction Summary Reporting (VMSR) Program for Manufacturers: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/163692\/download\u0022\u003EPDF (932.93 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (932.93 KB) of Voluntary Malfunction Summary Reporting (VMSR) Program for Manufacturers: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/29\/2024","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-2873\u0022\u003EFDA-2022-D-2873\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222024-08-28T09:16:17-04:00\u0022\u003E2024-08-28 09:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-volume-parenteral-drug-products-and-pharmacy-bulk-packages-parenteral-nutrition-aluminum\u0022\u003ESmall Volume Parenteral Drug Products and Pharmacy Bulk Packages for Parenteral Nutrition: Aluminum Content and Labeling Recommendations\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/163799\/download\u0022\u003EPDF (424.58 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (424.58 KB) of Small Volume Parenteral Drug Products and Pharmacy Bulk Packages for Parenteral Nutrition: Aluminum Content and Labeling Recommendations\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/03\/2025","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"09\/02\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-2301\u0022\u003EFDA-2022-D-2301\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-07-03T09:00:46-04:00\u0022\u003E2025-07-03 09:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/controlled-correspondence-related-generic-drug-development\u0022\u003EControlled Correspondence Related to Generic Drug Development\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/164111\/download\u0022\u003EPDF (385.76 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (385.76 KB) of Controlled Correspondence Related to Generic Drug Development\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/18\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Drug Competition Action Plan, Generic Drugs","field_topics":"","topics-product":"Drug Competition Action Plan, Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-1167\u0022\u003EFDA-2014-D-1167\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-03-18T11:56:02-04:00\u0022\u003E2024-03-18 11:56\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/m11-clinical-electronic-structured-harmonised-protocol\u0022\u003EM11 Clinical Electronic Structured Harmonised Protocol: Guidance Document, M11 Template, and Technical Specification Document\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"05\/20\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research,Office of Regulatory Policy","field_health_topics":"","term_node_tid":"ICH-Multidisciplinary","field_topics":"","topics-product":"ICH-Multidisciplinary","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-3054\u0022\u003EFDA-2022-D-3054\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-09-29T12:11:34-04:00\u0022\u003E2026-09-29 12:11\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/rems-document-technical-conformance-guide\u0022\u003EREMS Document Technical Conformance Guide\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/164344\/download\u0022\u003EPDF (545.79 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (545.79 KB) of REMS Document Technical Conformance Guide\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/04\/2023","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Safety - Issues, Errors, and Problems","field_topics":"","topics-product":"Safety - Issues, Errors, and Problems","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-01-04T16:51:03-05:00\u0022\u003E2023-01-04 16:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/photobiomodulation-pbm-devices-premarket-notification-510k-submissions\u0022\u003EPhotobiomodulation (PBM) Devices - Premarket Notification [510(k)] Submissions: Draft Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/164417\/download\u0022\u003EPDF (699.6 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (699.6 KB) of Photobiomodulation (PBM) Devices - Premarket Notification [510(k)] Submissions: Draft Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/12\/2023","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"03\/13\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-3116\u0022\u003EFDA-2022-D-3116\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222023-01-11T08:49:30-05:00\u0022\u003E2023-01-11 08:49\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/optimizing-dosage-human-prescription-drugs-and-biological-products-treatment-oncologic-diseases\u0022\u003EOptimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases: Guidance for Industry; Availability \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/164555\/download\u0022\u003EPDF (311.33 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (311.33 KB) of Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases: Guidance for Industry; Availability \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/08\/2024","field_issuing_office_taxonomy":"Oncology Center of Excellence\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-2827\u0022\u003EFDA-2022-D-2827\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"","changed":"\u003Ctime datetime=\u00222024-08-09T09:28:01-04:00\u0022\u003E2024-08-09 09:28\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/mpox-development-drugs-and-biological-products-guidance-industry\u0022\u003EMpox: Development of Drugs and Biological Products; Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/164642\/download\u0022\u003EPDF (259.22 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (259.22 KB) of Mpox: Development of Drugs and Biological Products; Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/19\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"03\/21\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-2395\u0022\u003EFDA-2022-D-2395\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-01-23T11:58:46-05:00\u0022\u003E2023-01-23 11:58\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/compounding-certain-ibuprofen-oral-suspension-products-under-section-503b-federal-food-drug-and\u0022\u003ECompounding Certain Ibuprofen Oral Suspension Products Under Section 503B of the Federal Food, Drug, and Cosmetic Act\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/164693\/download\u0022\u003EPDF (382.05 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (382.05 KB) of Compounding Certain Ibuprofen Oral Suspension Products Under Section 503B of the Federal Food, Drug, and Cosmetic Act\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/09\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Compounding","field_topics":"","topics-product":"Compounding","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-0169\u0022\u003EFDA-2023-D-0169\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-04-12T12:54:16-04:00\u0022\u003E2023-04-12 12:54\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-action-levels-lead-processed-food-intended-babies-and-young-children\u0022\u003EGuidance for Industry: Action Levels for Lead in Processed Food Intended for Babies and Young Children\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/164684\/download\u0022\u003EPDF (464.11 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (464.11 KB) of Guidance for Industry: Action Levels for Lead in Processed Food Intended for Babies and Young Children\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/06\/2025","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Infant Formula \u0026amp; Foods, Lead","field_topics":"","topics-product":"Infant Formula \u0026amp; Foods, Lead","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0278\u0022\u003EFDA-2022-D-0278\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-01-06T09:03:15-05:00\u0022\u003E2025-01-06 09:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommendations-evaluating-donor-eligibility-using-individual-risk-based-questions-reduce-risk-human\u0022\u003ERecommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/164829\/download\u0022\u003EPDF (291.33 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (291.33 KB) of Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/11\/2023","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Blood, Coronavirus, HIV\/AIDS","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood, Coronavirus, HIV\/AIDS, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-1211\u0022\u003EFDA-2015-D-1211\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222025-01-31T14:19:50-05:00\u0022\u003E2025-01-31 14:19\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/acromegaly-developing-drugs-treatment\u0022\u003EAcromegaly: Developing Drugs for Treatment\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"01\/30\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Pharmacology","field_topics":"","topics-product":"Clinical - Pharmacology","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"03\/31\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-2658\u0022\u003EFDA-2022-D-2658\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-01-22T16:10:11-05:00\u0022\u003E2025-01-22 16:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/early-lyme-disease-manifested-erythema-migrans-developing-drugs-treatment\u0022\u003EEarly Lyme Disease as Manifested by Erythema Migrans: Developing Drugs for Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/164949\/download\u0022\u003EPDF (306.17 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (306.17 KB) of Early Lyme Disease as Manifested by Erythema Migrans: Developing Drugs for Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/26\/2025","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pediatric Product Development, Clinical - Antimicrobial","field_topics":"","topics-product":"Pediatric Product Development, Clinical - Antimicrobial","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-2315\u0022\u003EFDA-2022-D-2315\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-07-09T09:42:16-04:00\u0022\u003E2025-07-09 09:42\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/considerations-design-and-conduct-externally-controlled-trials-drug-and-biological-products\u0022\u003EConsiderations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/164960\/download\u0022\u003EPDF (336.1 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (336.1 KB) of Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/01\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOncology Center of Excellence","field_health_topics":"","term_node_tid":"","field_topics":"Real World Data \/ Real World Evidence (RWD\/RWE)","topics-product":"Real World Data \/ Real World Evidence (RWD\/RWE), ","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"05\/02\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-2983\u0022\u003EFDA-2022-D-2983\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-01-31T08:49:01-05:00\u0022\u003E2023-01-31 08:49\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/m13a-bioequivalence-immediate-release-solid-oral-dosage-forms\u0022\u003EM13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/165049\/download\u0022\u003EPDF (391.49 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (391.49 KB) of M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/30\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Multidisciplinary","field_topics":"","topics-product":"ICH-Multidisciplinary","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"04\/03\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-0093\u0022\u003EFDA-2023-D-0093\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-11-01T08:55:02-04:00\u0022\u003E2024-11-01 08:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-protein-efficiency-ratio-rat-bioassay-studies-demonstrate-new-infant-formula\u0022\u003EGuidance for Industry: Protein Efficiency Ratio (PER) Rat Bioassay Studies to Demonstrate that a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/165173\/download\u0022\u003EPDF (1.28 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.28 MB) of Guidance for Industry: Protein Efficiency Ratio (PER) Rat Bioassay Studies to Demonstrate that a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/21\/2026","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Infant Formula \u0026amp; Foods","field_topics":"","topics-product":"Infant Formula \u0026amp; Foods","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-2424\u0022\u003EFDA-2022-D-2424\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222026-05-21T08:47:28-04:00\u0022\u003E2026-05-21 08:47\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/considerations-long-term-clinical-neurodevelopmental-safety-studies-neonatal-product-development\u0022\u003EConsiderations for Long-Term Clinical Neurodevelopmental Safety Studies in Neonatal Product Development: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/165239\/download\u0022\u003EPDF (375.34 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (375.34 KB) of Considerations for Long-Term Clinical Neurodevelopmental Safety Studies in Neonatal Product Development: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/17\/2024","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of the Chief Medical Officer,Office of Pediatric Therapeutics","field_health_topics":"","term_node_tid":"Clinical - Medical, Pediatric Product Development","field_topics":"","topics-product":"Clinical - Medical, Pediatric Product Development","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0112\u0022\u003EFDA-2022-D-0112\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222024-10-17T08:58:16-04:00\u0022\u003E2024-10-17 08:58\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/product-specific-guidance-meetings-between-fda-and-anda-applicants-under-gdufa\u0022\u003EProduct-Specific Guidance Meetings Between FDA and ANDA Applicants Under GDUFA: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/165468\/download\u0022\u003EPDF (371.05 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (371.05 KB) of Product-Specific Guidance Meetings Between FDA and ANDA Applicants Under GDUFA: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/20\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research,Office of Generic Drugs","field_health_topics":"","term_node_tid":"Drug Competition Action Plan, Generic Drugs","field_topics":"","topics-product":"Drug Competition Action Plan, Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-0044\u0022\u003EFDA-2023-D-0044\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-08-20T10:13:29-04:00\u0022\u003E2024-08-20 10:13\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/draft-guidance-industry-labeling-plant-based-milk-alternatives-and-voluntary-nutrient-statements\u0022\u003EDraft Guidance for Industry: Labeling of Plant-Based Milk Alternatives and Voluntary Nutrient Statements\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/165420\/download\u0022\u003EPDF (971.3 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (971.3 KB) of Draft Guidance for Industry: Labeling of Plant-Based Milk Alternatives and Voluntary Nutrient Statements\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/10\/2023","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling, Nutrition","field_topics":"","topics-product":"Labeling, Nutrition","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"07\/31\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-0451\u0022\u003EFDA-2023-D-0451\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-05T10:01:04-05:00\u0022\u003E2025-03-05 10:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/neovascular-age-related-macular-degeneration-developing-drugs-treatment\u0022\u003ENeovascular Age-Related Macular Degeneration: Developing Drugs for Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/165606\/download\u0022\u003EPDF (238.91 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (238.91 KB) of Neovascular Age-Related Macular Degeneration: Developing Drugs for Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/24\/2023","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"05\/30\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0073\u0022\u003EFDA-2022-D-0073\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-03-03T07:59:31-05:00\u0022\u003E2023-03-03 07:59\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/potency-assay-considerations-monoclonal-antibodies-and-other-therapeutic-proteins-targeting-viral\u0022\u003EPotency Assay Considerations for Monoclonal Antibodies and Other Therapeutic Proteins Targeting Viral Pathogens\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/165746\/download\u0022\u003EPDF (315.61 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (315.61 KB) of Potency Assay Considerations for Monoclonal Antibodies and Other Therapeutic Proteins Targeting Viral Pathogens\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research,Office of Pharmaceutical Quality","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"05\/01\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-0202\u0022\u003EFDA-2023-D-0202\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-03-02T11:56:41-05:00\u0022\u003E2023-03-02 11:56\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/development-local-anesthetic-drug-products-prolonged-duration-effect\u0022\u003EDevelopment of Local Anesthetic Drug Products With Prolonged Duration of Effect\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/166210\/download\u0022\u003EPDF (302.96 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (302.96 KB) of Development of Local Anesthetic Drug Products With Prolonged Duration of Effect\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/13\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-0608\u0022\u003EFDA-2023-D-0608\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-05-13T13:10:16-04:00\u0022\u003E2026-05-13 13:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/electronic-systems-electronic-records-and-electronic-signatures-clinical-investigations-questions\u0022\u003EElectronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations: Questions and Answers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/166215\/download\u0022\u003EPDF (545.68 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (545.68 KB) of Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations: Questions and Answers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/01\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Clinical Policy and Programs","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"05\/15\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-1105\u0022\u003EFDA-2017-D-1105\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-10-02T10:17:16-04:00\u0022\u003E2024-10-02 10:17\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pharmacogenomic-data-submissions-0\u0022\u003EPharmacogenomic Data Submissions\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/166258\/download\u0022\u003EPDF (306.62 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (306.62 KB) of Pharmacogenomic Data Submissions\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/17\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"06\/20\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-2856\u0022\u003EFDA-2022-D-2856\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-03-23T12:56:01-04:00\u0022\u003E2023-03-23 12:56\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clinical-trial-considerations-support-accelerated-approval-oncology-therapeutics\u0022\u003EClinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/166431\/download\u0022\u003EPDF (311.67 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (311.67 KB) of Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/24\/2023","field_issuing_office_taxonomy":"Oncology Center of Excellence","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"05\/26\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-0110\u0022\u003EFDA-2023-D-0110\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"","changed":"\u003Ctime datetime=\u00222023-03-27T13:23:46-04:00\u0022\u003E2023-03-27 13:23\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/draft-guidance-industry-questions-and-answers-about-dietary-guidance-statements-food-labeling\u0022\u003EDraft Guidance for Industry: Questions and Answers About Dietary Guidance Statements in Food Labeling\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/166342\/download\u0022\u003EPDF (1.87 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.87 MB) of Draft Guidance for Industry: Questions and Answers About Dietary Guidance Statements in Food Labeling\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/24\/2023","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling, Nutrition","field_topics":"","topics-product":"Labeling, Nutrition","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"09\/25\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-1027\u0022\u003EFDA-2023-D-1027\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:06:23-04:00\u0022\u003E2024-10-01 07:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/orthopedic-non-spinal-bone-plates-screws-and-washers-premarket-notification-510k-submissions\u0022\u003EOrthopedic Non-Spinal Bone Plates, Screws, and Washers - Premarket Notification (510(k)) Submissions: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/166507\/download\u0022\u003EPDF (637.26 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (637.26 KB) of Orthopedic Non-Spinal Bone Plates, Screws, and Washers - Premarket Notification (510(k)) Submissions: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/22\/2024","field_issuing_office_taxonomy":"Center for Devices and Radiological Health,Office of Product Evaluation and Quality,Office of Health Technology VI - Orthopedic Devices","field_health_topics":"","term_node_tid":"510(k), Orthopedic","field_topics":"Premarket","topics-product":"Premarket, 510(k), Orthopedic","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-0488\u0022\u003EFDA-2023-D-0488\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222024-11-21T09:05:46-05:00\u0022\u003E2024-11-21 09:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-281-infectious-otitis-externa-drugs-topical-use-dogs\u0022\u003ECVM GFI #281 Infectious Otitis Externa Drugs for Topical Use in Dogs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/166404\/download\u0022\u003EPDF (312.66 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (312.66 KB) of CVM GFI #281 Infectious Otitis Externa Drugs for Topical Use in Dogs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/31\/2023","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Drugs, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA), Target Animal \u2013 Effectiveness, Target Animal \u2013 Safety, Labeling","field_topics":"Premarket","topics-product":"Premarket, Animal Drugs, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA), Target Animal \u2013 Effectiveness, Target Animal \u2013 Safety, Labeling","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"05\/30\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-0606\u0022\u003EFDA-2023-D-0606\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222023-03-30T08:49:01-04:00\u0022\u003E2023-03-30 08:49\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/marketing-submission-recommendations-predetermined-change-control-plan-artificial-intelligence\u0022\u003EMarketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/166704\/download\u0022\u003EPDF (650.58 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (650.58 KB) of Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/18\/2025","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products","field_health_topics":"","term_node_tid":"Digital Health","field_topics":"Premarket","topics-product":"Premarket, Digital Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-2628\u0022\u003EFDA-2022-D-2628\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222025-08-18T11:09:31-04:00\u0022\u003E2025-08-18 11:09\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/research-involving-children-subjects-and-not-otherwise-approvable-institutional-review-board-process\u0022\u003EResearch Involving Children as Subjects and Not Otherwise Approvable by an Institutional Review Board: Process for Referrals to Food and Drug Administration and Office for Human Research Protections: Draft Guidance for Institutional Review Boards, Investigators, and Sponsors\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/166731\/download\u0022\u003EPDF (400.45 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (400.45 KB) of Research Involving Children as Subjects and Not Otherwise Approvable by an Institutional Review Board: Process for Referrals to Food and Drug Administration and Office for Human Research Protections: Draft Guidance for Institutional Review Boards, Investigators, and Sponsors\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/30\/2023","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Pediatric Therapeutics","field_health_topics":"","term_node_tid":"Pediatric Product Development","field_topics":"","topics-product":"Pediatric Product Development","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"05\/30\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0142\u0022\u003EFDA-2022-D-0142\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222024-04-11T11:28:31-04:00\u0022\u003E2024-04-11 11:28\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/identification-medicinal-products-implementation-and-use\u0022\u003EIdentification of Medicinal Products \u2014 Implementation and Use\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/166736\/download\u0022\u003EPDF (285.67 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (285.67 KB) of Identification of Medicinal Products \u2014 Implementation and Use\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/30\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Electronic Submissions","topics-product":"Electronic Submissions, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-0266\u0022\u003EFDA-2023-D-0266\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-03-31T08:57:31-04:00\u0022\u003E2023-03-31 08:57\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-278-human-user-safety-new-and-abbreviated-new-animal-drug-applications\u0022\u003ECVM GFI #278 Human User Safety in New and Abbreviated New Animal Drug Applications\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/166696\/download\u0022\u003EPDF (359.66 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (359.66 KB) of CVM GFI #278 Human User Safety in New and Abbreviated New Animal Drug Applications\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/21\/2024","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Drugs, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA), Labeling, Safety - Issues, Errors, and Problems, Pharmacology\/Toxicology","field_topics":"Premarket","topics-product":"Premarket, Animal Drugs, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA), Labeling, Safety - Issues, Errors, and Problems, Pharmacology\/Toxicology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"06\/05\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-0592\u0022\u003EFDA-2023-D-0592\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222024-06-20T08:50:52-04:00\u0022\u003E2024-06-20 08:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-incorporating-clinical-outcome-assessments-endpoints-regulatory\u0022\u003EPatient-Focused Drug Development: Incorporating Clinical Outcome Assessments Into Endpoints for Regulatory Decision-Making\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/166830\/download\u0022\u003EPDF (739.7 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (739.7 KB) of Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments Into Endpoints for Regulatory Decision-Making\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/05\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"07\/05\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-0026\u0022\u003EFDA-2023-D-0026\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-04-05T11:01:02-04:00\u0022\u003E2023-04-05 11:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/notifying-fda-discontinuance-or-interruption-manufacturing-finished-products-or-active\u0022\u003ENotifying FDA of a Discontinuance or Interruption in Manufacturing of Finished Products or Active Pharmaceutical Ingredients Under Section 506C of the FD\u0026amp;C Act\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/166837\/download\u0022\u003EPDF (316.88 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (316.88 KB) of Notifying FDA of a Discontinuance or Interruption in Manufacturing of Finished Products or Active Pharmaceutical Ingredients Under Section 506C of the FD\u0026amp;C Act\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/06\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"06\/05\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1057\u0022\u003EFDA-2020-D-1057\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-02-05T16:20:02-05:00\u0022\u003E2024-02-05 16:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/over-counter-monograph-order-requests-format-and-content\u0022\u003EOver-the-Counter Monograph Order Requests: Format and Content\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/167035\/download\u0022\u003EPDF (334.61 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (334.61 KB) of Over-the-Counter Monograph Order Requests: Format and Content\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/13\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Over-the-Counter Drugs","field_topics":"","topics-product":"Over-the-Counter Drugs","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"06\/12\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-1188\u0022\u003EFDA-2023-D-1188\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-04-13T17:25:46-04:00\u0022\u003E2023-04-13 17:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-transition-temporary-policy-during-covid-19-public-health-emergency-regarding\u0022\u003EGuidance for Industry: Transition from Temporary Policy During the COVID-19 Public Health Emergency Regarding the Qualified Exemption from the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/166928\/download\u0022\u003EPDF (201.29 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (201.29 KB) of Guidance for Industry: Transition from Temporary Policy During the COVID-19 Public Health Emergency Regarding the Qualified Exemption from the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/14\/2023","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Produce","field_topics":"","topics-product":"Produce","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-1031\u0022\u003EFDA-2023-D-1031\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T14:26:38-04:00\u0022\u003E2025-03-17 14:26\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/acute-radiation-syndrome-developing-drugs-prevention-and-treatment\u0022\u003EAcute Radiation Syndrome: Developing Drugs for Prevention and Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/167172\/download\u0022\u003EPDF (313.75 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (313.75 KB) of Acute Radiation Syndrome: Developing Drugs for Prevention and Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/19\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Animal Rule, Pediatric Product Development","field_topics":"","topics-product":"Animal Rule, Pediatric Product Development","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"07\/19\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-1146\u0022\u003EFDA-2023-D-1146\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T11:29:22-04:00\u0022\u003E2024-04-11 11:29\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/conducting-clinical-trials-decentralized-elements\u0022\u003EConducting Clinical Trials With Decentralized Elements\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/167696\/download\u0022\u003EPDF (528.44 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (528.44 KB) of Conducting Clinical Trials With Decentralized Elements\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/18\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003EOncology Center of Excellence","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"08\/01\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-2870\u0022\u003EFDA-2022-D-2870\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-10-16T16:08:02-04:00\u0022\u003E2025-10-16 16:08\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/assessing-user-fees-under-prescription-drug-user-fee-amendments-2022\u0022\u003EAssessing User Fees Under the Prescription Drug User Fee Amendments of 2022\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/167877\/download\u0022\u003EPDF (386.18 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (386.18 KB) of Assessing User Fees Under the Prescription Drug User Fee Amendments of 2022\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/01\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"User Fees","topics-product":"User Fees, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6821\u0022\u003EFDA-2017-D-6821\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-02-07T11:26:46-05:00\u0022\u003E2024-02-07 11:26\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/testing-glycerin-propylene-glycol-maltitol-solution-hydrogenated-starch-hydrolysate-sorbitol\u0022\u003ETesting of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/167974\/download\u0022\u003EPDF (283.72 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (283.72 KB) of Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/08\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Compliance","topics-product":"Compliance, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-1573 \u0022\u003EFDA-2023-D-1573 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"","changed":"\u003Ctime datetime=\u00222023-07-10T11:58:00-04:00\u0022\u003E2023-07-10 11:58\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cpg-sec-555250-draft-major-food-allergen-labeling-and-cross-contact\u0022\u003ECPG Sec 555.250 DRAFT: Major Food Allergen Labeling and Cross-contact\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/168000\/download\u0022\u003EPDF (290.97 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (290.97 KB) of CPG Sec 555.250 DRAFT: Major Food Allergen Labeling and Cross-contact\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/09\/2023","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"Investigation \u0026amp; Enforcement","topics-product":"Investigation \u0026amp; Enforcement, ","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"07\/17\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-1103\u0022\u003EFDA-2023-D-1103\u003C\/a\u003E","field_communication_type":"Compliance Policy Guide (CPG)","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T15:36:31-04:00\u0022\u003E2025-03-17 15:36\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pediatric-drug-development-regulatory-considerations-complying-pediatric-research-equity-act-and\u0022\u003EPediatric Drug Development: Regulatory Considerations \u2014 Complying With the Pediatric Research Equity Act and Qualifying for Pediatric Exclusivity Under the Best Pharmaceuticals for Children Act\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/168201\/download\u0022\u003EPDF (515.66 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (515.66 KB) of Pediatric Drug Development: Regulatory Considerations \u2014 Complying With the Pediatric Research Equity Act and Qualifying for Pediatric Exclusivity Under the Best Pharmaceuticals for Children Act\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/17\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Pediatric Product Development","field_topics":"","topics-product":"Administrative \/ Procedural, Pediatric Product Development","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"07\/17\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2005-D-0460\u0022\u003EFDA-2005-D-0460\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T11:29:46-04:00\u0022\u003E2024-04-11 11:29\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pediatric-drug-development-under-pediatric-research-equity-act-and-best-pharmaceuticals-children-act\u0022\u003EPediatric Drug Development Under the Pediatric Research Equity Act and the Best Pharmaceuticals for Children Act: Scientific Considerations\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/168202\/download\u0022\u003EPDF (324.33 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (324.33 KB) of Pediatric Drug Development Under the Pediatric Research Equity Act and the Best Pharmaceuticals for Children Act: Scientific Considerations\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/17\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Pediatric Product Development","field_topics":"","topics-product":"Administrative \/ Procedural, Pediatric Product Development","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"07\/17\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2005-D-0460\u0022\u003EFDA-2005-D-0460\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T11:29:52-04:00\u0022\u003E2024-04-11 11:29\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-entity-compliance-guide-requirements-additional-traceability-records-certain-foods-what-you\u0022\u003ESmall Entity Compliance Guide: Requirements for Additional Traceability Records for Certain Foods: What You Need to Know About the FDA Regulation\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/168142\/download\u0022\u003EPDF (457.97 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (457.97 KB) of Small Entity Compliance Guide: Requirements for Additional Traceability Records for Certain Foods: What You Need to Know About the FDA Regulation\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/18\/2023","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-1336\u0022\u003EFDA-2023-D-1336\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:06:24-04:00\u0022\u003E2024-10-01 07:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/generally-accepted-scientific-knowledge-applications-drug-and-biological-products-nonclinical\u0022\u003EGenerally Accepted Scientific Knowledge in Applications for Drug and Biological Products: Nonclinical Information\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/168408\/download\u0022\u003EPDF (249.65 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (249.65 KB) of Generally Accepted Scientific Knowledge in Applications for Drug and Biological Products: Nonclinical Information\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/24\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Pharmacology\/Toxicology","field_topics":"","topics-product":"Pharmacology\/Toxicology","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"07\/24\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-1618\u0022\u003EFDA-2023-D-1618\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-05-27T13:57:01-04:00\u0022\u003E2023-05-27 13:57\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/diabetes-mellitus-efficacy-endpoints-clinical-trials-investigating-antidiabetic-drugs-and-biological\u0022\u003EDiabetes Mellitus: Efficacy Endpoints for Clinical Trials Investigating Antidiabetic Drugs and Biological Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/168475\/download\u0022\u003EPDF (267.14 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (267.14 KB) of Diabetes Mellitus: Efficacy Endpoints for Clinical Trials Investigating Antidiabetic Drugs and Biological Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/25\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Pediatric Product Development","field_topics":"","topics-product":"Clinical - Medical, Pediatric Product Development","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"08\/24\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-0625\u0022\u003EFDA-2023-D-0625\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-04-11T11:29:15-04:00\u0022\u003E2024-04-11 11:29\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/migraine-developing-drugs-preventive-treatment\u0022\u003EMigraine: Developing Drugs for Preventive Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/168871\/download\u0022\u003EPDF (278.4 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (278.4 KB) of Migraine: Developing Drugs for Preventive Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/01\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"08\/01\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-1729\u0022\u003EFDA-2022-D-1729\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-06-01T10:52:16-04:00\u0022\u003E2023-06-01 10:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e6r3-good-clinical-practice-gcp\u0022\u003EE6(R3) Good Clinical Practice (GCP)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/169090\/download\u0022\u003EPDF (765.2 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (765.2 KB) of E6(R3) Good Clinical Practice (GCP)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/08\/2025","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Efficacy","field_topics":"","topics-product":"ICH-Efficacy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"09\/05\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-1955\u0022\u003EFDA-2023-D-1955\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-12-09T15:00:49-05:00\u0022\u003E2025-12-09 15:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-279-demonstrating-bioequivalence-type-medicated-articles-containing-active-pharmaceutical\u0022\u003ECVM GFI #279 Demonstrating Bioequivalence for Type A Medicated Articles Containing Active Pharmaceutical Ingredient(s) Considered to be Poorly Soluble in Aqueous Media, That Exhibit Little to No Systemic Bioavailability, and Are Locally Acting\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/168684\/download\u0022\u003EPDF (317.41 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (317.41 KB) of CVM GFI #279 Demonstrating Bioequivalence for Type A Medicated Articles Containing Active Pharmaceutical Ingredient(s) Considered to be Poorly Soluble in Aqueous Media, That Exhibit Little to No Systemic Bioavailability, and Are Locally Acting\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/21\/2024","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Generic Animal Drugs, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA)","field_topics":"Premarket","topics-product":"Premarket, Generic Animal Drugs, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"10\/16\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-1275\u0022\u003EFDA-2023-D-1275\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222024-06-20T08:50:46-04:00\u0022\u003E2024-06-20 08:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-insanitary-conditions-preparation-packing-and-holding-tattoo-inks-and-risk\u0022\u003EGuidance for Industry: Insanitary Conditions in the Preparation, Packing, and Holding of Tattoo Inks and the Risk of Microbial Contamination \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/183019\/download\u0022\u003EPDF (295.45 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (295.45 KB) of Guidance for Industry: Insanitary Conditions in the Preparation, Packing, and Holding of Tattoo Inks and the Risk of Microbial Contamination \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/22\/2024","field_issuing_office_taxonomy":"Office of the Commissioner,Office of the Chief Scientist","field_health_topics":"","term_node_tid":"Tattoos","field_topics":"","topics-product":"Tattoos","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"09\/11\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-1083\u0022\u003EFDA-2023-D-1083\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Cosmetics","changed":"\u003Ctime datetime=\u00222024-10-24T13:45:47-04:00\u0022\u003E2024-10-24 13:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/oncology-drug-products-used-certain-in-vitro-diagnostic-tests-pilot-program\u0022\u003EOncology Drug Products Used with Certain In Vitro Diagnostic Tests: Pilot Program: Guidance for Industry, Clinical Laboratories, and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/169616\/download\u0022\u003EPDF (279.32 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (279.32 KB) of Oncology Drug Products Used with Certain In Vitro Diagnostic Tests: Pilot Program: Guidance for Industry, Clinical Laboratories, and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/20\/2023","field_issuing_office_taxonomy":"Oncology Center of Excellence\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-2275\u0022\u003EFDA-2022-D-2275\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-06-20T09:29:00-04:00\u0022\u003E2023-06-20 09:29\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/formal-dispute-resolution-and-administrative-hearings-final-administrative-orders-under-section-505g\u0022\u003EFormal Dispute Resolution and Administrative Hearings of Final Administrative Orders Under Section 505G of the Federal Food, Drug, and Cosmetic Act\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/169628\/download\u0022\u003EPDF (368.39 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (368.39 KB) of Formal Dispute Resolution and Administrative Hearings of Final Administrative Orders Under Section 505G of the Federal Food, Drug, and Cosmetic Act\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/22\/2025","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-2204\u0022\u003EFDA-2023-D-2204\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-12-23T08:13:48-05:00\u0022\u003E2025-12-23 08:13\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/alternative-procedures-manufacture-cold-stored-platelets-intended-treatment-active-bleeding-when\u0022\u003EAlternative Procedures for the Manufacture of Cold-Stored Platelets Intended for the Treatment of Active Bleeding when Conventional Platelets Are Not Available or Their Use Is Not Practical: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/169714\/download\u0022\u003EPDF (320.29 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (320.29 KB) of Alternative Procedures for the Manufacture of Cold-Stored Platelets Intended for the Treatment of Active Bleeding when Conventional Platelets Are Not Available or Their Use Is Not Practical: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/23\/2023","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Blood","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-2034\u0022\u003EFDA-2023-D-2034\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222023-09-26T14:16:31-04:00\u0022\u003E2023-09-26 14:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/psychedelic-drugs-considerations-clinical-investigations\u0022\u003EPsychedelic Drugs: Considerations for Clinical Investigations\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/169694\/download\u0022\u003EPDF (301.48 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (301.48 KB) of Psychedelic Drugs: Considerations for Clinical Investigations\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/14\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-1987\u0022\u003EFDA-2023-D-1987\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-07-15T10:47:31-04:00\u0022\u003E2026-07-15 10:47\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/presenting-quantitative-efficacy-and-risk-information-direct-consumer-dtc-promotional-labeling-and\u0022\u003EPresenting Quantitative Efficacy and Risk Information in Direct-to-Consumer (DTC) Promotional Labeling and Advertisements\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/169803\/download\u0022\u003EPDF (323.03 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (323.03 KB) of Presenting Quantitative Efficacy and Risk Information in Direct-to-Consumer (DTC) Promotional Labeling and Advertisements\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/12\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Veterinary Medicine","field_health_topics":"","term_node_tid":"Advertising","field_topics":"","topics-product":"Advertising","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-2613\u0022\u003EFDA-2018-D-2613\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-12-11T09:34:20-05:00\u0022\u003E2023-12-11 09:34\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/patient-matched-guides-orthopedic-implants\u0022\u003EPatient-Matched Guides for Orthopedic Implants: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/169792\/download\u0022\u003EPDF (432.59 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (432.59 KB) of Patient-Matched Guides for Orthopedic Implants: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/07\/2026","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Orthopedic","field_topics":"Premarket","topics-product":"Premarket, Orthopedic","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-2370\u0022\u003EFDA-2023-D-2370\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222026-05-06T10:36:31-04:00\u0022\u003E2026-05-06 10:36\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/prohibition-wholesaling-under-section-503b-federal-food-drug-and-cosmetic-act\u0022\u003EProhibition on Wholesaling Under Section 503B of the Federal Food, Drug, and Cosmetic Act\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/169838\/download\u0022\u003EPDF (215.86 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (215.86 KB) of Prohibition on Wholesaling Under Section 503B of the Federal Food, Drug, and Cosmetic Act\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/27\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Compounding","field_topics":"","topics-product":"Compounding","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"08\/28\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-0939\u0022\u003EFDA-2023-D-0939\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-06-27T11:17:31-04:00\u0022\u003E2023-06-27 11:17\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/submitting-nonclinical-datasets-evaluation-rodent-carcinogenicity-studies-pharmaceuticals\u0022\u003ESubmitting Nonclinical Datasets for Evaluation of Rodent Carcinogenicity Studies of Pharmaceuticals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/169654\/download\u0022\u003EPDF (330.1 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (330.1 KB) of Submitting Nonclinical Datasets for Evaluation of Rodent Carcinogenicity Studies of Pharmaceuticals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/01\/2021","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"","changed":"\u003Ctime datetime=\u00222023-07-05T12:33:01-04:00\u0022\u003E2023-07-05 12:33\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/manufacturing-changes-and-comparability-human-cellular-and-gene-therapy-products\u0022\u003EManufacturing Changes and Comparability for Human Cellular and Gene Therapy Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/170198\/download\u0022\u003EPDF (426.13 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (426.13 KB) of Manufacturing Changes and Comparability for Human Cellular and Gene Therapy Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/13\/2023","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Gene Therapy","field_topics":"","topics-product":"Gene Therapy","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"11\/13\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-2436\u0022\u003EFDA-2023-D-2436\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222023-08-24T10:40:32-04:00\u0022\u003E2023-08-24 10:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/postmarketing-studies-and-clinical-trials-determining-good-cause-noncompliance-section-505o3eii\u0022\u003EPostmarketing Studies and Clinical Trials: Determining Good Cause for Noncompliance with Section 505(o)(3)(E)(ii) of the Federal Food, Drug, and Cosmetic Act: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/170187\/download\u0022\u003EPDF (301.83 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (301.83 KB) of Postmarketing Studies and Clinical Trials: Determining Good Cause for Noncompliance with Section 505(o)(3)(E)(ii) of the Federal Food, Drug, and Cosmetic Act: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/14\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"09\/12\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-0559\u0022\u003EFDA-2023-D-0559\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"","changed":"\u003Ctime datetime=\u00222023-07-14T10:00:48-04:00\u0022\u003E2023-07-14 10:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clinical-considerations-studies-devices-intended-treat-opioid-use-disorder\u0022\u003EClinical Considerations for Studies of Devices Intended to Treat Opioid Use Disorder: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/170561\/download\u0022\u003EPDF (538.76 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (538.76 KB) of Clinical Considerations for Studies of Devices Intended to Treat Opioid Use Disorder: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/11\/2024","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-0466\u0022\u003EFDA-2023-D-0466\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222024-07-10T08:50:19-04:00\u0022\u003E2024-07-10 08:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommended-acceptable-intake-limits-nitrosamine-drug-substance-related-impurities\u0022\u003ERecommended Acceptable Intake Limits for Nitrosamine Drug Substance-Related Impurities\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/170794\/download\u0022\u003EPDF (727.18 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (727.18 KB) of Recommended Acceptable Intake Limits for Nitrosamine Drug Substance-Related Impurities\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/07\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pharmacology\/Toxicology","field_topics":"","topics-product":"Pharmacology\/Toxicology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-1530\u0022\u003EFDA-2020-D-1530\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-08-04T08:49:46-04:00\u0022\u003E2023-08-04 08:49\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pdufa-waivers-reductions-and-refunds-fixed-combinations-and-single-entity-versions-previously\u0022\u003EPDUFA Waivers, Reductions, and Refunds for Fixed- Combinations and Single-Entity Versions of Previously Approved Antiretrovirals under PEPFAR\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/170813\/download\u0022\u003EPDF (274.72 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (274.72 KB) of PDUFA Waivers, Reductions, and Refunds for Fixed- Combinations and Single-Entity Versions of Previously Approved Antiretrovirals under PEPFAR\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/03\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"User Fees","topics-product":"User Fees, ","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"10\/02\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1635\u0022\u003EFDA-2018-D-1635\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"","changed":"\u003Ctime datetime=\u00222023-08-04T13:18:16-04:00\u0022\u003E2023-08-04 13:18\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-registration-and-listing-cosmetic-product-facilities-and-products\u0022\u003EGuidance for Industry: Registration and Listing of Cosmetic Product Facilities and Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/170732\/download\u0022\u003EPDF (382.42 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (382.42 KB) of Guidance for Industry: Registration and Listing of Cosmetic Product Facilities and Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/11\/2024","field_issuing_office_taxonomy":"Office of the Commissioner,Office of the Chief Scientist","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"01\/13\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-1716\u0022\u003EFDA-2023-D-1716\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Cosmetics","changed":"\u003Ctime datetime=\u00222025-01-16T11:22:16-05:00\u0022\u003E2025-01-16 11:22\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/qtc-information-human-prescription-drug-and-biological-product-labeling\u0022\u003EQTc Information in Human Prescription Drug and Biological Product Labeling: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/170814\/download\u0022\u003EPDF (354.56 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (354.56 KB) of QTc Information in Human Prescription Drug and Biological Product Labeling: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/03\/2025","field_issuing_office_taxonomy":"Oncology Center of Excellence\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"10\/10\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-2439\u0022\u003EFDA-2023-D-2439\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222025-12-02T09:07:32-05:00\u0022\u003E2025-12-02 09:07\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/classification-categories-certain-supplements-under-bsufa-iii\u0022\u003EClassification Categories for Certain Supplements Under BsUFA III\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/170906\/download\u0022\u003EPDF (279.88 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (279.88 KB) of Classification Categories for Certain Supplements Under BsUFA III\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/08\/2025","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Biosimilars","field_topics":"","topics-product":"Biosimilars","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"10\/10\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-1954\u0022\u003EFDA-2023-D-1954\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-09-08T09:05:05-04:00\u0022\u003E2025-09-08 09:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/postmarketing-approaches-obtain-data-populations-underrepresented-clinical-trials-drugs-and\u0022\u003EPostmarketing Approaches to Obtain Data on Populations Underrepresented in Clinical Trials for Drugs and Biological Products \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/170899\/download\u0022\u003EPDF (342.52 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (342.52 KB) of Postmarketing Approaches to Obtain Data on Populations Underrepresented in Clinical Trials for Drugs and Biological Products \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/10\/2023","field_issuing_office_taxonomy":"Oncology Center of Excellence","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-2629 \u0022\u003EFDA-2022-D-2629 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222023-08-10T08:51:37-04:00\u0022\u003E2023-08-10 08:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/enhanced-drug-distribution-security-requirements-under-section-582g1-federal-food-drug-and-cosmetic\u0022\u003EEnhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act--Compliance Policies\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/171592\/download\u0022\u003EPDF (259.61 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (259.61 KB) of Enhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act--Compliance Policies\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/28\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-1909\u0022\u003EFDA-2023-D-1909\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-11-05T16:09:15-05:00\u0022\u003E2024-11-05 16:09\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/wholesale-distributor-verification-requirement-saleable-returned-drug-product-and-dispenser-0\u0022\u003EWholesale Distributor Verification Requirement for Saleable Returned Drug Product and Dispenser Verification Requirements When Investigating a Suspect or Illegitimate Product\u2014Compliance Policies\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/171677\/download\u0022\u003EPDF (242 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (242 KB) of Wholesale Distributor Verification Requirement for Saleable Returned Drug Product and Dispenser Verification Requirements When Investigating a Suspect or Illegitimate Product\u2014Compliance Policies\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/01\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-4212\u0022\u003EFDA-2019-D-4212\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-11-05T16:09:17-05:00\u0022\u003E2024-11-05 16:09\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/post-warning-letter-meetings-under-gdufa\u0022\u003EPost-Warning Letter Meetings Under GDUFA\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/171785\/download\u0022\u003EPDF (292.75 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (292.75 KB) of Post-Warning Letter Meetings Under GDUFA\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/20\/2025","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Generic Drugs","field_topics":"","topics-product":"Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-3370\u0022\u003EFDA-2023-D-3370\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-06-20T09:22:02-04:00\u0022\u003E2025-06-20 09:22\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/evidentiary-expectations-510k-implant-devices\u0022\u003EEvidentiary Expectations for 510(k) Implant Devices: Draft Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/171835\/download\u0022\u003EPDF (815.33 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (815.33 KB) of Evidentiary Expectations for 510(k) Implant Devices: Draft Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/07\/2023","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"510(k)","field_topics":"Premarket","topics-product":"Premarket, 510(k)","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"12\/06\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-3132\u0022\u003EFDA-2023-D-3132\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222023-09-06T09:17:07-04:00\u0022\u003E2023-09-06 09:17\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommendations-use-clinical-data-premarket-notification-510k-submissions\u0022\u003ERecommendations for the Use of Clinical Data in Premarket Notification [510(k)] Submissions: Draft Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/171837\/download\u0022\u003EPDF (561.13 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (561.13 KB) of Recommendations for the Use of Clinical Data in Premarket Notification [510(k)] Submissions: Draft Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/07\/2023","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"510(k)","field_topics":"Premarket","topics-product":"Premarket, 510(k)","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"12\/06\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-3133\u0022\u003EFDA-2023-D-3133\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222023-09-06T09:17:15-04:00\u0022\u003E2023-09-06 09:17\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/best-practices-selecting-predicate-device-support-premarket-notification-510k-submission\u0022\u003EBest Practices for Selecting a Predicate Device to Support a Premarket Notification [510(k)] Submission: Draft Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/171838\/download\u0022\u003EPDF (593.27 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (593.27 KB) of Best Practices for Selecting a Predicate Device to Support a Premarket Notification [510(k)] Submission: Draft Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/07\/2023","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"510(k)","field_topics":"Premarket","topics-product":"Premarket, 510(k)","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"12\/06\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-3134\u0022\u003EFDA-2023-D-3134\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222023-09-06T09:17:11-04:00\u0022\u003E2023-09-06 09:17\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/endogenous-cushings-syndrome-developing-drugs-treatment\u0022\u003EEndogenous Cushing\u2019s Syndrome: Developing Drugs for Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/171900\/download\u0022\u003EPDF (359.45 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (359.45 KB) of Endogenous Cushing\u2019s Syndrome: Developing Drugs for Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/08\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"11\/07\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-3518\u0022\u003EFDA-2023-D-3518\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-09-08T09:56:46-04:00\u0022\u003E2023-09-08 09:56\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clinical-pharmacology-considerations-peptide-drug-products\u0022\u003EClinical Pharmacology Considerations for Peptide Drug Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/171901\/download\u0022\u003EPDF (308.77 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (308.77 KB) of Clinical Pharmacology Considerations for Peptide Drug Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/14\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Pharmacology","field_topics":"","topics-product":"Clinical - Pharmacology","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"12\/11\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-3391\u0022\u003EFDA-2023-D-3391\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-12-13T17:05:01-05:00\u0022\u003E2023-12-13 17:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-282-informed-consent-forms-studies-enroll-client-owned-companion-animals\u0022\u003ECVM GFI #282 Informed Consent Forms for Studies that Enroll Client-Owned Companion Animals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/172056\/download\u0022\u003EPDF (323.88 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (323.88 KB) of CVM GFI #282 Informed Consent Forms for Studies that Enroll Client-Owned Companion Animals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/15\/2023","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Investigational New Animal Drug (INAD), New Animal Drug Application (NADA), Target Animal \u2013 Effectiveness","field_topics":"Premarket","topics-product":"Premarket, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA), Target Animal \u2013 Effectiveness","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"11\/14\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-2654\u0022\u003EFDA-2023-D-2654\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222023-09-14T08:50:31-04:00\u0022\u003E2023-09-14 08:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/labeling-biosimilar-and-interchangeable-biosimilar-products\u0022\u003ELabeling for Biosimilar and Interchangeable Biosimilar Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/172170\/download\u0022\u003EPDF (359.65 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (359.65 KB) of Labeling for Biosimilar and Interchangeable Biosimilar Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/18\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Biosimilars","field_topics":"","topics-product":"Biosimilars","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"11\/17\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-0643\u0022\u003EFDA-2016-D-0643\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-09-18T15:27:03-04:00\u0022\u003E2023-09-18 15:27\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/regulatory-considerations-prescription-drug-use-related-software\u0022\u003ERegulatory Considerations for Prescription Drug Use-Related Software\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/172165\/download\u0022\u003EPDF (404.43 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (404.43 KB) of Regulatory Considerations for Prescription Drug Use-Related Software\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/20\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003EOncology Center of Excellence\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of the Chief Medical Officer,Office of Combination Products","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"12\/18\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-2482\u0022\u003EFDA-2023-D-2482\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-10-20T09:01:34-04:00\u0022\u003E2026-10-20 09:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/demonstrating-substantial-evidence-effectiveness-one-adequate-and-well-controlled-clinical\u0022\u003EDemonstrating Substantial Evidence of Effectiveness With One Adequate and Well-Controlled Clinical Investigation and Confirmatory Evidence\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/172166\/download\u0022\u003EPDF (308.11 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (308.11 KB) of Demonstrating Substantial Evidence of Effectiveness With One Adequate and Well-Controlled Clinical Investigation and Confirmatory Evidence\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/19\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOncology Center of Excellence\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"12\/18\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-2318\u0022\u003EFDA-2023-D-2318\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-11-30T13:44:46-05:00\u0022\u003E2023-11-30 13:44\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/considerations-conduct-clinical-trials-medical-products-during-major-disruptions-due-disasters-and\u0022\u003EConsiderations for the Conduct of Clinical Trials of Medical Products During Major Disruptions Due to Disasters and Public Health Emergencies\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/172258\/download\u0022\u003EPDF (470.23 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (470.23 KB) of Considerations for the Conduct of Clinical Trials of Medical Products During Major Disruptions Due to Disasters and Public Health Emergencies\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/21\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003EOncology Center of Excellence","field_health_topics":"","term_node_tid":"","field_topics":"Emergencies","topics-product":"Emergencies, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-3550\u0022\u003EFDA-2023-D-3550\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-10-04T17:44:16-04:00\u0022\u003E2023-10-04 17:44\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/alternative-tools-assessing-drug-manufacturing-facilities-identified-pending-applications\u0022\u003EAlternative Tools: Assessing Drug Manufacturing Facilities Identified in Pending Applications\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/172290\/download\u0022\u003EPDF (292.83 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (292.83 KB) of Alternative Tools: Assessing Drug Manufacturing Facilities Identified in Pending Applications\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/11\/2025","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_topics":"","topics-product":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-3031\u0022\u003EFDA-2023-D-3031\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-09-11T13:10:05-04:00\u0022\u003E2025-09-11 13:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-273-defining-durations-use-approved-medically-important-antimicrobial-drugs-fed-food\u0022\u003ECVM GFI #273 Defining Durations of Use for Approved Medically Important Antimicrobial Drugs Fed to Food-Producing Animals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/172362\/download\u0022\u003EPDF (523.07 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (523.07 KB) of CVM GFI #273 Defining Durations of Use for Approved Medically Important Antimicrobial Drugs Fed to Food-Producing Animals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/26\/2023","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Antimicrobial Resistance, Labeling, New Animal Drug Application (NADA)","field_topics":"Premarket","topics-product":"Premarket, Antimicrobial Resistance, Labeling, New Animal Drug Application (NADA)","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"01\/05\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-2925\u0022\u003EFDA-2023-D-2925\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222023-11-22T08:53:31-05:00\u0022\u003E2023-11-22 08:53\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/draft-guidance-industry-standards-growing-harvesting-packing-and-holding-sprouts-human-consumption\u0022\u003EDraft Guidance for Industry: Standards for the Growing, Harvesting, Packing, and Holding of Sprouts for Human Consumption \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/172400\/download\u0022\u003EPDF (698.43 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (698.43 KB) of Draft Guidance for Industry: Standards for the Growing, Harvesting, Packing, and Holding of Sprouts for Human Consumption \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/28\/2023","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Vegetable Products","field_topics":"","topics-product":"Vegetable Products","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"03\/27\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-0175\u0022\u003EFDA-2017-D-0175\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-17T14:14:46-04:00\u0022\u003E2025-03-17 14:14\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/electronic-submission-template-medical-device-de-novo-requests\u0022\u003EElectronic Submission Template for Medical Device De Novo Requests: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/172450\/download\u0022\u003EPDF (664.24 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (664.24 KB) of Electronic Submission Template for Medical Device De Novo Requests: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/23\/2024","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"Premarket, Electronic Submissions","topics-product":"Premarket, Electronic Submissions, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-3788\u0022\u003EFDA-2023-D-3788\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222024-08-22T09:01:18-04:00\u0022\u003E2024-08-22 09:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/graft-versus-host-diseases-developing-drugs-biological-products-and-certain-devices-prevention-or\u0022\u003EGraft-versus-Host Diseases: Developing Drugs, Biological Products, and Certain Devices for Prevention or Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/172524\/download\u0022\u003EPDF (511.08 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (511.08 KB) of Graft-versus-Host Diseases: Developing Drugs, Biological Products, and Certain Devices for Prevention or Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/28\/2023","field_issuing_office_taxonomy":"Oncology Center of Excellence","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"11\/28\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-3900\u0022\u003EFDA-2023-D-3900\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222023-09-28T11:08:26-04:00\u0022\u003E2023-09-28 11:08\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/antimicrobial-susceptibility-test-ast-system-devices-updating-breakpoints-device-labeling\u0022\u003EAntimicrobial Susceptibility Test (AST) System Devices \u2013 Updating Breakpoints in Device Labeling: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/172463\/download\u0022\u003EPDF (340.66 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (340.66 KB) of Antimicrobial Susceptibility Test (AST) System Devices \u2013 Updating Breakpoints in Device Labeling: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/29\/2023","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Antimicrobial Resistance","field_topics":"","topics-product":"Antimicrobial Resistance","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-4045 \u0022\u003EFDA-2023-D-4045 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222023-09-28T13:53:16-04:00\u0022\u003E2023-09-28 13:53\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/stimulant-use-disorders-developing-drugs-treatment\u0022\u003EStimulant Use Disorders: Developing Drugs for Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/172703\/download\u0022\u003EPDF (290.1 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (290.1 KB) of Stimulant Use Disorders: Developing Drugs for Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/13\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-1848\u0022\u003EFDA-2023-D-1848\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-05-13T13:11:02-04:00\u0022\u003E2026-05-13 13:11\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/quality-considerations-topical-ophthalmic-drug-products\u0022\u003EQuality Considerations for Topical Ophthalmic Drug Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/172937\/download\u0022\u003EPDF (361.23 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (361.23 KB) of Quality Considerations for Topical Ophthalmic Drug Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/27\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"02\/26\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-4177\u0022\u003EFDA-2023-D-4177\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-12-28T10:03:01-05:00\u0022\u003E2023-12-28 10:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/diabetic-foot-infections-developing-drugs-treatment\u0022\u003EDiabetic Foot Infections: Developing Drugs for Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/173006\/download\u0022\u003EPDF (401.35 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (401.35 KB) of Diabetic Foot Infections: Developing Drugs for Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/17\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-4067\u0022\u003EFDA-2023-D-4067\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-06-17T11:01:50-04:00\u0022\u003E2024-06-17 11:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/communications-firms-health-care-providers-regarding-scientific-information-unapproved-uses\u0022\u003ECommunications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved\/Cleared Medical Products: Questions and Answers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/184871\/download\u0022\u003EPDF (418.56 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (418.56 KB) of Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved\/Cleared Medical Products: Questions and Answers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/06\/2025","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0053\u0022\u003EFDA-2008-D-0053\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-01-06T14:43:01-05:00\u0022\u003E2025-01-06 14:43\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guia-para-la-industria-evaluacion-de-la-inocuidad-de-los-cultivos-alimentarios-para-el-consumo\u0022\u003EGu\u00eda para la industria: Evaluaci\u00f3n de la inocuidad de los cultivos alimentarios para el consumo humano afectados por las inundaciones \u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"09\/17\/2018","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0733\u0022\u003EFDA-2011-D-0733\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:06:26-04:00\u0022\u003E2024-10-01 07:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/remote-interactive-evaluations-drug-manufacturing-and-bioresearch-monitoring-facilities\u0022\u003ERemote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/173286\/download\u0022\u003EPDF (310.2 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (310.2 KB) of Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/26\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Veterinary Medicine","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_topics":"","topics-product":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"12\/26\/2023","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-4416\u0022\u003EFDA-2023-D-4416\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-10-25T08:45:27-04:00\u0022\u003E2023-10-25 08:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/submitting-patient-reported-outcome-data-cancer-clinical-trials\u0022\u003ESubmitting Patient-Reported Outcome Data in Cancer Clinical Trials\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/173581\/download\u0022\u003EPDF (851.69 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (851.69 KB) of Submitting Patient-Reported Outcome Data in Cancer Clinical Trials\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/06\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOncology Center of Excellence","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1216\u0022\u003EFDA-2018-D-1216\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-11-03T08:45:18-04:00\u0022\u003E2023-11-03 08:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/submitting-clinical-trial-datasets-and-documentation-clinical-outcome-assessments-using-item\u0022\u003ESubmitting Clinical Trial Datasets and Documentation for Clinical Outcome Assessments Using Item Response Theory\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/173587\/download\u0022\u003EPDF (284.09 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (284.09 KB) of Submitting Clinical Trial Datasets and Documentation for Clinical Outcome Assessments Using Item Response Theory\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/06\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1216\u0022\u003EFDA-2018-D-1216\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"","changed":"\u003Ctime datetime=\u00222023-11-06T17:37:01-05:00\u0022\u003E2023-11-06 17:37\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-compliance-policy-cosmetic-product-facility-registration-and-cosmetic-product\u0022\u003EGuidance for Industry: Compliance Policy for Cosmetic Product Facility Registration and Cosmetic Product Listing\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/173606\/download\u0022\u003EPDF (217.95 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (217.95 KB) of Guidance for Industry: Compliance Policy for Cosmetic Product Facility Registration and Cosmetic Product Listing\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/08\/2023","field_issuing_office_taxonomy":"Office of the Commissioner,Office of the Chief Scientist","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-1716\u0022\u003EFDA-2023-D-1716\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Cosmetics","changed":"\u003Ctime datetime=\u00222024-08-23T12:39:04-04:00\u0022\u003E2024-08-23 12:39\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/translation-good-laboratory-practice-study-reports-questions-and-answers\u0022\u003ETranslation of Good Laboratory Practice Study Reports: Questions and Answers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/173989\/download\u0022\u003EPDF (192.09 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (192.09 KB) of Translation of Good Laboratory Practice Study Reports: Questions and Answers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/21\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"02\/20\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-4719\u0022\u003EFDA-2023-D-4719\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Drugs, Food \u0026amp; Beverages, Medical Devices, Tobacco","changed":"\u003Ctime datetime=\u00222024-08-09T22:18:09-04:00\u0022\u003E2024-08-09 22:18\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-entity-compliance-guide-milk-and-cream-products-and-yogurt-products-final-rule-revoke\u0022\u003ESmall Entity Compliance Guide: Milk and Cream Products and Yogurt Products; Final Rule to Revoke the Standards for Lowfat Yogurt and Nonfat Yogurt and To Amend the Standard for Yogurt\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/174050\/download\u0022\u003EPDF (605.72 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (605.72 KB) of Small Entity Compliance Guide: Milk and Cream Products and Yogurt Products; Final Rule to Revoke the Standards for Lowfat Yogurt and Nonfat Yogurt and To Amend the Standard for Yogurt\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/27\/2023","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Dairy","field_topics":"","topics-product":"Dairy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-4722\u0022\u003EFDA-2023-D-4722\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:06:27-04:00\u0022\u003E2024-10-01 07:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-284-using-relative-supersaturation-support-urinary-tract-health-claims-adult-maintenance-cat\u0022\u003ECVM GFI #284 Using Relative Supersaturation to Support \u201cUrinary Tract Health\u201d Claims for Adult Maintenance Cat Food\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/173985\/download\u0022\u003EPDF (629.36 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (629.36 KB) of CVM GFI #284 Using Relative Supersaturation to Support \u201cUrinary Tract Health\u201d Claims for Adult Maintenance Cat Food\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/15\/2024","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Feed, Labeling","field_topics":"","topics-product":"Animal Feed, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"02\/28\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-4095\u0022\u003EFDA-2023-D-4095\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222024-10-11T08:53:16-04:00\u0022\u003E2024-10-11 08:53\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/interim-policy-compounding-using-bulk-drug-substances-under-section-503a-federal-food-drug-and\u0022\u003EInterim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/174456\/download\u0022\u003EPDF (333.04 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (333.04 KB) of Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/06\/2025","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Compounding","field_topics":"","topics-product":"Administrative \/ Procedural, Compounding","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"01\/08\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-3517\u0022\u003EFDA-2015-D-3517\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-01-07T09:59:46-05:00\u0022\u003E2025-01-07 09:59\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/advanced-manufacturing-technologies-designation-program\u0022\u003EAdvanced Manufacturing Technologies Designation Program\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/174651\/download\u0022\u003EPDF (350.54 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (350.54 KB) of Advanced Manufacturing Technologies Designation Program\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/31\/2024","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-4974\u0022\u003EFDA-2023-D-4974\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-12-30T13:53:48-05:00\u0022\u003E2025-12-30 13:53\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/draft-guidance-industry-menu-labeling-supplemental-guidance-edition-2\u0022\u003EDraft Guidance for Industry: Menu Labeling Supplemental Guidance (Edition 2)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/174528\/download\u0022\u003EPDF (183.69 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (183.69 KB) of Draft Guidance for Industry: Menu Labeling Supplemental Guidance (Edition 2)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/13\/2023","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling, Nutrition","field_topics":"","topics-product":"Labeling, Nutrition","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"02\/12\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-F-0172\u0022\u003EFDA-2011-F-0172\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-12T10:01:31-04:00\u0022\u003E2025-03-12 10:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-283-priority-zoonotic-animal-drug-designation-and-review-process\u0022\u003ECVM GFI #283 Priority Zoonotic Animal Drug Designation and Review Process\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/174635\/download\u0022\u003EPDF (365.16 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (365.16 KB) of CVM GFI #283 Priority Zoonotic Animal Drug Designation and Review Process\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/26\/2024","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Drugs, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA)","field_topics":"Premarket","topics-product":"Premarket, Animal Drugs, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"02\/16\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-3740\u0022\u003EFDA-2023-D-3740\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222024-06-25T08:53:13-04:00\u0022\u003E2024-06-25 08:53\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clarification-compliance-requirements-certain-manufacturers-who-incorporate-certified-class-i-laser\u0022\u003EClarification of Compliance Requirements for Certain Manufacturers Who Incorporate Certified Class I Laser Products into Their Products (Laser Notice 42)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/74030\/download\u0022\u003EPDF (57.9 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (57.9 KB) of Clarification of Compliance Requirements for Certain Manufacturers Who Incorporate Certified Class I Laser Products into Their Products (Laser Notice 42)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/18\/1989","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Radiological Health","field_topics":"","topics-product":"Radiological Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-0957\u0022\u003EFDA-2020-D-0957\u003C\/a\u003E","field_communication_type":"Memorandum","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222023-12-18T14:09:46-05:00\u0022\u003E2023-12-18 14:09\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/510k-third-party-review-program-and-third-party-emergency-use-authorization-eua-review\u0022\u003E510(k) Third Party Review Program and Third Party Emergency Use Authorization (EUA) Review: Guidance for Industry, Food and Drug Administration Staff, and Third Party Review Organizations\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/85284\/download\u0022\u003EPDF (600.95 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (600.95 KB) of 510(k) Third Party Review Program and Third Party Emergency Use Authorization (EUA) Review: Guidance for Industry, Food and Drug Administration Staff, and Third Party Review Organizations\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/21\/2024","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Administrative \/ Procedural","field_topics":"Premarket","topics-product":"Premarket, 510(k), Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-2565\u0022\u003EFDA-2016-D-2565\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222024-11-20T09:01:21-05:00\u0022\u003E2024-11-20 09:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/master-protocols-drug-and-biological-product-development\u0022\u003EMaster Protocols for Drug and Biological Product Development\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/174976\/download\u0022\u003EPDF (1.37 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.37 MB) of Master Protocols for Drug and Biological Product Development\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/24\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Pediatric Product Development","field_topics":"","topics-product":"Clinical - Medical, Pediatric Product Development","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"08\/24\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-5259\u0022\u003EFDA-2023-D-5259\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222026-07-06T13:52:05-04:00\u0022\u003E2026-07-06 13:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/direct-consumer-prescription-drug-advertisements-presentation-major-statement-clear-conspicuous-and\u0022\u003EDirect-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format Final Rule Questions and Answers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/175074\/download\u0022\u003EPDF (254.05 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (254.05 KB) of Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format Final Rule Questions and Answers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/26\/2023","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Advertising","field_topics":"","topics-product":"Advertising","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-N-0582\u0022\u003EFDA-2009-N-0582\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-12-26T10:37:46-05:00\u0022\u003E2023-12-26 10:37\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/reformulating-drug-products-contain-carbomers-manufactured-benzene\u0022\u003EReformulating Drug Products That Contain Carbomers Manufactured With Benzene\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/175083\/download\u0022\u003EPDF (293.9 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (293.9 KB) of Reformulating Drug Products That Contain Carbomers Manufactured With Benzene\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/28\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-5408\u0022\u003EFDA-2023-D-5408\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222023-12-27T08:45:24-05:00\u0022\u003E2023-12-27 08:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/potency-assurance-cellular-and-gene-therapy-products\u0022\u003EPotency Assurance for Cellular and Gene Therapy Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/175132\/download\u0022\u003EPDF (364.34 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (364.34 KB) of Potency Assurance for Cellular and Gene Therapy Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/27\/2023","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Gene Therapy","field_topics":"","topics-product":"Gene Therapy","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"03\/27\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-4299\u0022\u003EFDA-2023-D-4299\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222023-12-28T09:04:31-05:00\u0022\u003E2023-12-28 09:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/characterization-metallic-coatings-andor-calcium-phosphate-coatings-orthopedic-devices\u0022\u003ECharacterization of Metallic Coatings and\/or Calcium Phosphate Coatings on Orthopedic Devices: Draft Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/175564\/download\u0022\u003EPDF (698.17 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (698.17 KB) of Characterization of Metallic Coatings and\/or Calcium Phosphate Coatings on Orthopedic Devices: Draft Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/23\/2024","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Orthopedic","field_topics":"Premarket","topics-product":"Premarket, Orthopedic","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"03\/22\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-5430\u0022\u003EFDA-2023-D-5430\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222024-01-22T09:24:20-05:00\u0022\u003E2024-01-22 09:24\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-286-vich-gl60-good-manufacturing-practice-active-pharmaceutical-ingredients-used-veterinary\u0022\u003ECVM GFI #286 (VICH GL60) - Good Manufacturing Practice for Active Pharmaceutical Ingredients Used in Veterinary Medicinal Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/175603\/download\u0022\u003EPDF (634.23 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (634.23 KB) of CVM GFI #286 (VICH GL60) - Good Manufacturing Practice for Active Pharmaceutical Ingredients Used in Veterinary Medicinal Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/25\/2024","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP), Chemistry, Manufacturing, and Controls (CMC), Generic Animal Drugs, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA), VICH","field_topics":"Postmarket, Premarket, Compliance","topics-product":"Postmarket, Premarket, Compliance, Current Good Manufacturing Practice (CGMP), Chemistry, Manufacturing, and Controls (CMC), Generic Animal Drugs, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA), VICH","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"03\/25\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-4761\u0022\u003EFDA-2023-D-4761\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222024-01-24T08:49:46-05:00\u0022\u003E2024-01-24 08:49\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/collection-race-and-ethnicity-data-clinical-trials-and-clinical-studies-fda-regulated-medical\u0022\u003ECollection of Race and Ethnicity Data in Clinical Trials and Clinical Studies for FDA-Regulated Medical Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/175746\/download\u0022\u003EPDF (287.57 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (287.57 KB) of Collection of Race and Ethnicity Data in Clinical Trials and Clinical Studies for FDA-Regulated Medical Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/30\/2024","field_issuing_office_taxonomy":"Oncology Center of Excellence\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Minority Health and Health Equity\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Women\u0026#039;s Health\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Clinical Policy and Programs\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Pediatric Therapeutics","field_health_topics":"","term_node_tid":"Clinical - Medical, Pediatric Product Development","field_topics":"","topics-product":"Clinical - Medical, Pediatric Product Development","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"04\/29\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-3561\u0022\u003EFDA-2016-D-3561\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-02-03T12:12:36-05:00\u0022\u003E2025-02-03 12:12\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/reporting-amount-listed-drugs-and-biological-products-under-section-510j3-fdc-act\u0022\u003EReporting Amount of Listed Drugs and Biological Products Under Section 510(j)(3) of the FD\u0026amp;C Act\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/175933\/download\u0022\u003EPDF (577.54 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (577.54 KB) of Reporting Amount of Listed Drugs and Biological Products Under Section 510(j)(3) of the FD\u0026amp;C Act\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/05\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-1031\u0022\u003EFDA-2021-D-1031\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-03-01T16:15:02-05:00\u0022\u003E2024-03-01 16:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/draft-guidance-industry-recommendations-collecting-representative-samples-food-testing-used-evidence\u0022\u003EDraft Guidance for Industry: Recommendations for Collecting Representative Samples for Food Testing Used as Evidence for Release of Certain Fish and Fishery Products Subject to Detention Without Physical Examination (DWPE) and Removal of a Foreign Manufacturer\u2019s Goods from DWPE\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/175948\/download\u0022\u003EPDF (345.36 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (345.36 KB) of Draft Guidance for Industry: Recommendations for Collecting Representative Samples for Food Testing Used as Evidence for Release of Certain Fish and Fishery Products Subject to Detention Without Physical Examination (DWPE) and Removal of a Foreign Manufacturer\u2019s Goods from DWPE\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/05\/2024","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Seafood\/Seafood Product","field_topics":"","topics-product":"Seafood\/Seafood Product","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"06\/25\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-5303\u0022\u003EFDA-2023-D-5303\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-10-01T07:06:29-04:00\u0022\u003E2024-10-01 07:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/use-data-monitoring-committees-clinical-trials\u0022\u003EUse of Data Monitoring Committees in Clinical Trials\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/176107\/download\u0022\u003EPDF (402.09 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (402.09 KB) of Use of Data Monitoring Committees in Clinical Trials\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/13\/2024","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"04\/15\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2001-D-0219\u0022\u003EFDA-2001-D-0219\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-02-13T11:27:46-05:00\u0022\u003E2024-02-13 11:27\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/charging-investigational-drugs-under-ind-questions-and-answers\u0022\u003ECharging for Investigational Drugs Under an IND: Questions and Answers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/176308\/download\u0022\u003EPDF (266.07 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (266.07 KB) of Charging for Investigational Drugs Under an IND: Questions and Answers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/14\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-D-0447\u0022\u003EFDA-2013-D-0447\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-02-16T12:20:16-05:00\u0022\u003E2024-02-16 12:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/medical-device-user-fee-small-business-qualification-and-determination\u0022\u003EMedical Device User Fee Small Business Qualification and Determination: Guidance for Industry, Food and Drug Administration Staff and Foreign Governments\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/176439\/download\u0022\u003EPDF (468.24 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (468.24 KB) of Medical Device User Fee Small Business Qualification and Determination: Guidance for Industry, Food and Drug Administration Staff and Foreign Governments\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/31\/2025","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"User Fees","topics-product":"User Fees, Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1873\u0022\u003EFDA-2018-D-1873\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222025-07-30T09:31:21-04:00\u0022\u003E2025-07-30 09:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-foods-derived-plants-produced-using-genome-editing\u0022\u003EGuidance for Industry: Foods Derived from Plants Produced Using Genome Editing\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/176427\/download\u0022\u003EPDF (414.23 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (414.23 KB) of Guidance for Industry: Foods Derived from Plants Produced Using Genome Editing\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/21\/2024","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Bioengineering \/ GMOs","field_topics":"","topics-product":"Bioengineering \/ GMOs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-4658\u0022\u003EFDA-2019-D-4658\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222026-01-12T13:34:49-05:00\u0022\u003E2026-01-12 13:34\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/key-information-and-facilitating-understanding-informed-consent-guidance-sponsors-investigators-and\u0022\u003EKey Information and Facilitating Understanding in Informed Consent Guidance for Sponsors, Investigators, and Institutional Review Boards\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/176663\/download\u0022\u003EPDF (450.28 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (450.28 KB) of Key Information and Facilitating Understanding in Informed Consent Guidance for Sponsors, Investigators, and Institutional Review Boards\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Clinical Policy and Programs","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"04\/30\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-2997\u0022\u003EFDA-2022-D-2997\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-03-05T09:31:36-05:00\u0022\u003E2024-03-05 09:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-new-dietary-ingredient-notification-procedures-and-timeframes-dietary-supplements\u0022\u003EGuidance for Industry: New Dietary Ingredient Notification Procedures and Timeframes - Dietary Supplements\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/176512\/download\u0022\u003EPDF (321.79 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (321.79 KB) of Guidance for Industry: New Dietary Ingredient Notification Procedures and Timeframes - Dietary Supplements\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/05\/2024","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Ingredients","field_topics":"","topics-product":"Ingredients","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-5280\u0022\u003EFDA-2023-D-5280\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Dietary Supplements","changed":"\u003Ctime datetime=\u00222024-10-01T14:19:34-04:00\u0022\u003E2024-10-01 14:19\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/annual-reportable-labeling-changes-new-drug-applications-and-abbreviated-new-drug-applications\u0022\u003EAnnual Reportable Labeling Changes for New Drug Applications and Abbreviated New Drug Applications for Nonprescription Drug Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/176915\/download\u0022\u003EPDF (276.49 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (276.49 KB) of Annual Reportable Labeling Changes for New Drug Applications and Abbreviated New Drug Applications for Nonprescription Drug Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/13\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"05\/13\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-5616\u0022\u003EFDA-2023-D-5616\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-03-13T08:35:46-04:00\u0022\u003E2024-03-13 08:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e2dr1-post-approval-safety-data-definitions-and-standards-management-and-reporting-individual-case\u0022\u003EE2D(R1) Post-Approval Safety Data: Definitions and Standards for Management and Reporting of Individual Case Safety Reports\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/176977\/download\u0022\u003EPDF (389 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (389 KB) of E2D(R1) Post-Approval Safety Data: Definitions and Standards for Management and Reporting of Individual Case Safety Reports\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/03\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Efficacy","field_topics":"","topics-product":"ICH-Efficacy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-0803\u0022\u003EFDA-2024-D-0803\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-04-08T11:25:49-04:00\u0022\u003E2026-04-08 11:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/evaluation-thermal-effects-medical-devices-produce-tissue-heating-andor-cooling\u0022\u003EEvaluation of Thermal Effects of Medical Devices that Produce Tissue Heating and\/or Cooling: Draft Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/177004\/download\u0022\u003EPDF (604.7 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (604.7 KB) of Evaluation of Thermal Effects of Medical Devices that Produce Tissue Heating and\/or Cooling: Draft Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/15\/2024","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"05\/14\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-0664\u0022\u003EFDA-2024-D-0664\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222024-03-14T09:15:40-04:00\u0022\u003E2024-03-14 09:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-285-manufacture-batches-support-original-nadas-anadas-and-cnadas\u0022\u003ECVM GFI #285 - Manufacture of Batches in Support of Original NADAs, ANADAs, and CNADAs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/176991\/download\u0022\u003EPDF (250.85 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (250.85 KB) of CVM GFI #285 - Manufacture of Batches in Support of Original NADAs, ANADAs, and CNADAs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/18\/2024","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP), Chemistry, Manufacturing, and Controls (CMC), Generic Animal Drugs, New Animal Drug Application (NADA), Investigational New Animal Drug (INAD)","field_topics":"Premarket","topics-product":"Premarket, Current Good Manufacturing Practice (CGMP), Chemistry, Manufacturing, and Controls (CMC), Generic Animal Drugs, New Animal Drug Application (NADA), Investigational New Animal Drug (INAD)","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"05\/17\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-1054\u0022\u003EFDA-2024-D-1054\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222024-03-15T08:48:16-04:00\u0022\u003E2024-03-15 08:48\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/real-world-evidence-considerations-regarding-non-interventional-studies-drug-and-biological-products\u0022\u003EReal-World Evidence: Considerations Regarding Non-Interventional Studies for Drug and Biological Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/177128\/download\u0022\u003EPDF (263.5 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (263.5 KB) of Real-World Evidence: Considerations Regarding Non-Interventional Studies for Drug and Biological Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/21\/2024","field_issuing_office_taxonomy":"Oncology Center of Excellence\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Real World Data \/ Real World Evidence (RWD\/RWE)","topics-product":"Real World Data \/ Real World Evidence (RWD\/RWE), ","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"06\/18\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-5470\u0022\u003EFDA-2023-D-5470\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-04-08T09:29:03-04:00\u0022\u003E2024-04-08 09:29\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/animal-studies-dental-bone-grafting-material-devices-premarket-notification-510k-submissions\u0022\u003EAnimal Studies for Dental Bone Grafting Material Devices - Premarket Notification (510(k)) Submissions: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/177340\/download\u0022\u003EPDF (376.21 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (376.21 KB) of Animal Studies for Dental Bone Grafting Material Devices - Premarket Notification (510(k)) Submissions: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/22\/2025","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Dental ","field_topics":"Premarket","topics-product":"Premarket, 510(k), Dental ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-1242\u0022\u003EFDA-2024-D-1242\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222025-08-21T09:16:04-04:00\u0022\u003E2025-08-21 09:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/data-integrity-in-vivo-bioavailability-and-bioequivalence-studies\u0022\u003EData Integrity for In Vivo Bioavailability and Bioequivalence Studies\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/177404\/download\u0022\u003EPDF (339.61 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (339.61 KB) of Data Integrity for In Vivo Bioavailability and Bioequivalence Studies\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/03\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Generic Drugs","field_topics":"","topics-product":"Generic Drugs","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"07\/03\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-1245\u0022\u003EFDA-2024-D-1245\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-04-02T08:45:31-04:00\u0022\u003E2024-04-02 08:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/draft-guidance-industry-new-dietary-ingredient-notification-master-files-dietary-supplements\u0022\u003EDraft Guidance for Industry: New Dietary Ingredient Notification Master Files for Dietary Supplements\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/177097\/download\u0022\u003EPDF (282.89 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (282.89 KB) of Draft Guidance for Industry: New Dietary Ingredient Notification Master Files for Dietary Supplements\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/03\/2024","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"06\/03\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-0706\u0022\u003EFDA-2024-D-0706\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Dietary Supplements, Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-02-28T13:13:32-05:00\u0022\u003E2025-02-28 13:13\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cancer-clinical-trial-eligibility-criteria-laboratory-values\u0022\u003ECancer Clinical Trial Eligibility Criteria: Laboratory Values: Guidance for Industry, IRBs, and Clinical Investigators\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/178013\/download\u0022\u003EPDF (277.14 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (277.14 KB) of Cancer Clinical Trial Eligibility Criteria: Laboratory Values: Guidance for Industry, IRBs, and Clinical Investigators\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/27\/2026","field_issuing_office_taxonomy":"Oncology Center of Excellence\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Clinical Trials","topics-product":"Clinical Trials, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-1402\u0022\u003EFDA-2024-D-1402\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222026-07-27T10:16:25-04:00\u0022\u003E2026-07-27 10:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cancer-clinical-trial-eligibility-criteria-washout-periods-and-concomitant-medications\u0022\u003ECancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications: Guidance for Industry, IRBs, and Clinical Investigators\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/178016\/download\u0022\u003EPDF (261.42 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (261.42 KB) of Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications: Guidance for Industry, IRBs, and Clinical Investigators\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/27\/2026","field_issuing_office_taxonomy":"Oncology Center of Excellence\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Clinical Trials","topics-product":"Clinical Trials, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-1376 \u0022\u003EFDA-2024-D-1376 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222026-07-27T10:16:26-04:00\u0022\u003E2026-07-27 10:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cancer-clinical-trial-eligibility-criteria-performance-status\u0022\u003ECancer Clinical Trial Eligibility Criteria: Performance Status: Guidance for Industry, IRBs, and Clinical Investigators\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/178018\/download\u0022\u003EPDF (303.99 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (303.99 KB) of Cancer Clinical Trial Eligibility Criteria: Performance Status: Guidance for Industry, IRBs, and Clinical Investigators\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/27\/2026","field_issuing_office_taxonomy":"Oncology Center of Excellence\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Clinical Trials","topics-product":"Clinical Trials, ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-1377 \u0022\u003EFDA-2024-D-1377 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222026-07-27T10:16:19-04:00\u0022\u003E2026-07-27 10:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/content-and-format-composition-statement-and-corresponding-statement-ingredients-labeling-ndas-and\u0022\u003EContent and Format of Composition Statement and Corresponding Statement of Ingredients in Labeling in NDAs and ANDAs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/178099\/download\u0022\u003EPDF (406.3 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (406.3 KB) of Content and Format of Composition Statement and Corresponding Statement of Ingredients in Labeling in NDAs and ANDAs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/29\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Drug Competition Action Plan, Generic Drugs","field_topics":"Electronic Submissions","topics-product":"Electronic Submissions, Drug Competition Action Plan, Generic Drugs","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"06\/28\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-1461\u0022\u003EFDA-2024-D-1461\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-04-29T09:45:01-04:00\u0022\u003E2024-04-29 09:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-287-raw-data-safety-and-effectiveness-studies\u0022\u003ECVM GFI #287 - Raw Data for Safety and Effectiveness Studies\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/177901\/download\u0022\u003EPDF (239.79 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (239.79 KB) of CVM GFI #287 - Raw Data for Safety and Effectiveness Studies\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/04\/2025","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Environmental Safety, Human Food Safety, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA), Target Animal \u2013 Effectiveness, Target Animal \u2013 Safety","field_topics":"Premarket","topics-product":"Premarket, Environmental Safety, Human Food Safety, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA), Target Animal \u2013 Effectiveness, Target Animal \u2013 Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"06\/28\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-1613\u0022\u003EFDA-2024-D-1613\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222025-06-04T15:47:46-04:00\u0022\u003E2025-06-04 15:47\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/considerations-use-human-and-animal-derived-materials-manufacture-cell-and-gene-therapy-and-tissue\u0022\u003EConsiderations for the Use of Human-and Animal-Derived Materials in the Manufacture of Cell and Gene Therapy and Tissue-Engineered Medical Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/178022\/download\u0022\u003EPDF (319.89 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (319.89 KB) of Considerations for the Use of Human-and Animal-Derived Materials in the Manufacture of Cell and Gene Therapy and Tissue-Engineered Medical Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/29\/2024","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Gene Therapy, Tissue, Xenotransplantation","field_topics":"","topics-product":"Gene Therapy, Tissue, Xenotransplantation","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-1244\u0022\u003EFDA-2024-D-1244\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-05-15T10:21:46-04:00\u0022\u003E2024-05-15 10:21\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/safety-testing-human-allogeneic-cells-expanded-use-cell-based-medical-products\u0022\u003ESafety Testing of Human Allogeneic Cells Expanded for Use in Cell-Based Medical Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/178113\/download\u0022\u003EPDF (289.31 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (289.31 KB) of Safety Testing of Human Allogeneic Cells Expanded for Use in Cell-Based Medical Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/29\/2024","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Gene Therapy","field_topics":"","topics-product":"Gene Therapy","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-1243\u0022\u003EFDA-2024-D-1243\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-05-15T10:02:49-04:00\u0022\u003E2024-05-15 10:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/consideration-enforcement-policies-in-vitro-diagnostic-tests-during-section-564-declared-emergency\u0022\u003EConsideration of Enforcement Policies for In Vitro Diagnostic Tests During a Section 564 Declared Emergency: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/178123\/download\u0022\u003EPDF (535.16 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (535.16 KB) of Consideration of Enforcement Policies for In Vitro Diagnostic Tests During a Section 564 Declared Emergency: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/23\/2025","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"IVDs (In Vitro Diagnostic Devices)","field_topics":"Outbreak","topics-product":"Outbreak, IVDs (In Vitro Diagnostic Devices)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-5365\u0022\u003EFDA-2023-D-5365\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222025-09-22T09:12:31-04:00\u0022\u003E2025-09-22 09:12\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/small-entity-compliance-guide-revocation-uses-partially-hydrogenated-oils-foods\u0022\u003ESmall Entity Compliance Guide: Revocation of Uses of Partially Hydrogenated Oils in Foods\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/178185\/download\u0022\u003EPDF (237.6 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (237.6 KB) of Small Entity Compliance Guide: Revocation of Uses of Partially Hydrogenated Oils in Foods\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/29\/2024","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-1669\u0022\u003EFDA-2024-D-1669\u003C\/a\u003E","field_communication_type":"Small Entity Compliance Guide","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-02-28T09:15:47-05:00\u0022\u003E2025-02-28 09:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-187b-heritable-intentional-genomic-alterations-animals-approval-process\u0022\u003ECVM GFI #187B Heritable Intentional Genomic Alterations in Animals: The Approval Process\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/150658\/download\u0022\u003EPDF (418.88 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (418.88 KB) of CVM GFI #187B Heritable Intentional Genomic Alterations in Animals: The Approval Process\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/07\/2025","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Investigational New Animal Drug (INAD), New Animal Drug Application (NADA)","field_topics":"Premarket, Biotechnology","topics-product":"Premarket, Biotechnology, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"07\/31\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-2648\u0022\u003EFDA-2019-D-2648\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222025-07-01T14:46:31-04:00\u0022\u003E2025-07-01 14:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-290-vich-gl61-pharmaceutical-development\u0022\u003ECVM GFI #290 (VICH GL61) \u2013 Pharmaceutical Development\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/178155\/download\u0022\u003EPDF (910.11 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (910.11 KB) of CVM GFI #290 (VICH GL61) \u2013 Pharmaceutical Development\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/06\/2024","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Quality, Generic Animal Drugs, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA), VICH","field_topics":"Premarket, Postmarket","topics-product":"Premarket, Postmarket, Chemistry, Manufacturing, and Controls (CMC), Quality, Generic Animal Drugs, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA), VICH","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"07\/05\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-1133\u0022\u003EFDA-2024-D-1133\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222024-05-03T08:49:31-04:00\u0022\u003E2024-05-03 08:49\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/rems-logic-model-framework-link-program-design-assessment\u0022\u003EREMS Logic Model: A Framework to Link Program Design With Assessment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/178291\/download\u0022\u003EPDF (968.23 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (968.23 KB) of REMS Logic Model: A Framework to Link Program Design With Assessment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/07\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Safety - Issues, Errors, and Problems","field_topics":"","topics-product":"Safety - Issues, Errors, and Problems","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"08\/05\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-1032\u0022\u003EFDA-2024-D-1032\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-05-07T09:10:32-04:00\u0022\u003E2024-05-07 09:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/platform-technology-designation-program-drug-development\u0022\u003EPlatform Technology Designation Program for Drug Development\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/178938\/download\u0022\u003EPDF (350.67 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (350.67 KB) of Platform Technology Designation Program for Drug Development\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/28\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"07\/29\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-1829\u0022\u003EFDA-2024-D-1829\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222024-05-29T10:11:06-04:00\u0022\u003E2024-05-29 10:11\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/processes-and-practices-applicable-bioresearch-monitoring-inspections\u0022\u003EProcesses and Practices Applicable to Bioresearch Monitoring Inspections: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/179027\/download\u0022\u003EPDF (205.44 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (205.44 KB) of Processes and Practices Applicable to Bioresearch Monitoring Inspections: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/19\/2025","field_issuing_office_taxonomy":"Office of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Clinical Policy and Programs\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program\u003Cbr\u003E\u003Cbr\u003ECenter for Tobacco Products\u003Cbr\u003E\u003Cbr\u003ECenter for Veterinary Medicine","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Bioequivalence, Biopharmaceutics, Biosimilars, Investigational New Drug Application (INDA), Food \u0026amp; Color Additives, Generic Drugs, HUD\/HDE, Investigational Device Exemption (IDE), Premarket Approval (PMA), IVDs (In Vitro Diagnostic Devices), Investigational New Animal Drug (INAD), New Animal Drug Application (NADA), Vaccines","field_topics":"Clinical Trials, Compliance, Postmarket, Premarket, Investigation \u0026amp; Enforcement, Inspection, International","topics-product":"Clinical Trials, Compliance, Postmarket, Premarket, Investigation \u0026amp; Enforcement, Inspection, International, Administrative \/ Procedural, Bioequivalence, Biopharmaceutics, Biosimilars, Investigational New Drug Application (INDA), Food \u0026amp; Color Additives, Generic Drugs, HUD\/HDE, Investigational Device Exemption (IDE), Premarket Approval (PMA), IVDs (In Vitro Diagnostic Devices), Investigational New Animal Drug (INAD), New Animal Drug Application (NADA), Vaccines","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"08\/05\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-5021\u0022\u003EFDA-2023-D-5021\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Animal \u0026amp; Veterinary, Biologics, Dietary Supplements, Drugs, Food \u0026amp; Beverages, Medical Devices, Radiation-Emitting Products, Tobacco","changed":"\u003Ctime datetime=\u00222025-12-18T16:32:18-05:00\u0022\u003E2025-12-18 16:32\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/standardized-format-electronic-submission-marketing-applications-content-planning-bioresearch\u0022\u003EStandardized Format for Electronic Submission for Marketing Applications Content for the Planning of Bioresearch Monitoring (BIMO) Inspections for Center of Biologics Evaluation and Research Submissions\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/179136\/download\u0022\u003EPDF (300.15 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (300.15 KB) of Standardized Format for Electronic Submission for Marketing Applications Content for the Planning of Bioresearch Monitoring (BIMO) Inspections for Center of Biologics Evaluation and Research Submissions\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/05\/2024","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Electronic Submissions","topics-product":"Electronic Submissions, ","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"08\/05\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-2221\u0022\u003EFDA-2024-D-2221\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-12-06T15:32:46-05:00\u0022\u003E2024-12-06 15:32\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/considerations-demonstrating-interchangeability-reference-product-update\u0022\u003EConsiderations in Demonstrating Interchangeability With a Reference Product: Update\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/179456\/download\u0022\u003EPDF (240.79 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (240.79 KB) of Considerations in Demonstrating Interchangeability With a Reference Product: Update\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/21\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Biosimilars","field_topics":"","topics-product":"Biosimilars","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"08\/20\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-0154\u0022\u003EFDA-2017-D-0154\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-06-21T09:46:04-04:00\u0022\u003E2024-06-21 09:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-288-chemistry-manufacturing-and-controls-support-recombinant-protein-products-veterinary\u0022\u003ECVM GFI #288 Chemistry, Manufacturing, and Controls in Support of Recombinant Protein Products for Veterinary Medicinal Use\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/179274\/download\u0022\u003EPDF (433.9 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (433.9 KB) of CVM GFI #288 Chemistry, Manufacturing, and Controls in Support of Recombinant Protein Products for Veterinary Medicinal Use\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/24\/2024","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Investigational New Animal Drug (INAD), New Animal Drug Application (NADA)","field_topics":"Premarket, Biotechnology","topics-product":"Premarket, Biotechnology, Chemistry, Manufacturing, and Controls (CMC), Investigational New Animal Drug (INAD), New Animal Drug Application (NADA)","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"08\/23\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-1668\u0022\u003EFDA-2024-D-1668\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222024-06-21T09:01:23-04:00\u0022\u003E2024-06-21 09:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-292-chemistry-manufacturing-and-controls-considerations-type-medicated-articles\u0022\u003ECVM GFI #292 Chemistry, Manufacturing, and Controls Considerations for Type A Medicated Articles\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/179219\/download\u0022\u003EPDF (332.33 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (332.33 KB) of CVM GFI #292 Chemistry, Manufacturing, and Controls Considerations for Type A Medicated Articles\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/24\/2024","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Current Good Manufacturing Practice (CGMP), Generic Animal Drugs, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA)","field_topics":"Premarket","topics-product":"Premarket, Chemistry, Manufacturing, and Controls (CMC), Current Good Manufacturing Practice (CGMP), Generic Animal Drugs, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA)","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"08\/23\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-1202\u0022\u003EFDA-2024-D-1202\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222024-06-21T09:01:24-04:00\u0022\u003E2024-06-21 09:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/essential-drug-delivery-performance-characteristics-devices-intended-deliver-drugs-and-biological\u0022\u003EEssential Drug Delivery Performance Characteristics for Devices Intended to Deliver Drugs and Biological Products: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/179545\/download\u0022\u003EPDF (613.1 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (613.1 KB) of Essential Drug Delivery Performance Characteristics for Devices Intended to Deliver Drugs and Biological Products: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/29\/2026","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Combination Products, Pediatric Product Development","field_topics":"","topics-product":"Combination Products, Pediatric Product Development","field_final_guidance_1":"Draft","open-comment":" Yes ","field_comment_close_date":"01\/28\/2027","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-2560\u0022\u003EFDA-2024-D-2560\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222026-10-29T10:46:31-04:00\u0022\u003E2026-10-29 10:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/m14-general-principles-planning-designing-analyzing-and-reporting-non-interventional-studies-utilize\u0022\u003EM14 General Principles on Planning, Designing, Analyzing, and Reporting of Non-interventional Studies That Utilize Real-World Data for Safety Assessment of Medicines\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/179795\/download\u0022\u003EPDF (632.89 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (632.89 KB) of M14 General Principles on Planning, Designing, Analyzing, and Reporting of Non-interventional Studies That Utilize Real-World Data for Safety Assessment of Medicines\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/03\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Multidisciplinary","field_topics":"","topics-product":"ICH-Multidisciplinary","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-2754\u0022\u003EFDA-2024-D-2754\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-03-04T09:17:03-05:00\u0022\u003E2026-03-04 09:17\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/purpose-and-content-use-related-risk-analyses-drugs-biological-products-and-combination-products\u0022\u003EPurpose and Content of Use-Related Risk Analyses for Drugs, Biological Products, and Combination Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/179858\/download\u0022\u003EPDF (324.44 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (324.44 KB) of Purpose and Content of Use-Related Risk Analyses for Drugs, Biological Products, and Combination Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/08\/2024","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"09\/09\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-2484\u0022\u003EFDA-2024-D-2484\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222024-07-09T07:55:16-04:00\u0022\u003E2024-07-09 07:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pediatric-inflammatory-bowel-disease-developing-drugs-treatment\u0022\u003EPediatric Inflammatory Bowel Disease: Developing Drugs for Treatment\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/180126\/download\u0022\u003EPDF (388.92 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (388.92 KB) of Pediatric Inflammatory Bowel Disease: Developing Drugs for Treatment\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/19\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Pediatric Product Development","field_topics":"","topics-product":"Clinical - Medical, Pediatric Product Development","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"09\/17\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-2682\u0022\u003EFDA-2024-D-2682\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-07-25T09:47:10-04:00\u0022\u003E2024-07-25 09:47\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommendations-investigational-and-licensed-covid-19-convalescent-plasma\u0022\u003ERecommendations for Investigational and Licensed COVID-19 Convalescent Plasma: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/180209\/download\u0022\u003EPDF (299 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (299 KB) of Recommendations for Investigational and Licensed COVID-19 Convalescent Plasma: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/19\/2024","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Blood, Infectious Disease Treatment, Coronavirus","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood, Infectious Disease Treatment, Coronavirus, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-2442\u0022\u003EFDA-2024-D-2442\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222024-07-22T08:46:03-04:00\u0022\u003E2024-07-22 08:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/postapproval-manufacturing-changes-biosimilar-and-interchangeable-biosimilar-products-questions-and\u0022\u003EPostapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Questions and Answers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/180206\/download\u0022\u003EPDF (282.51 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (282.51 KB) of Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Questions and Answers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/09\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Biosimilars","field_topics":"","topics-product":"Biosimilars","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-2581\u0022\u003EFDA-2024-D-2581\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222026-10-13T11:41:41-04:00\u0022\u003E2026-10-13 11:41\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/m12-drug-interaction-studies-questions-and-answers\u0022\u003EM12 Drug Interaction Studies: Questions and Answers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/180488\/download\u0022\u003EPDF (258.44 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (258.44 KB) of M12 Drug Interaction Studies: Questions and Answers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/02\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Multidisciplinary","field_topics":"","topics-product":"ICH-Multidisciplinary","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-1527\u0022\u003EFDA-2022-D-1527\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-05-27T12:51:02-04:00\u0022\u003E2026-05-27 12:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-293-fda-enforcement-policy-aafco-defined-animal-feed-ingredients\u0022\u003ECVM GFI #293 - FDA Enforcement Policy for AAFCO-Defined Animal Feed Ingredients\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/180441\/download\u0022\u003EPDF (311.52 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (311.52 KB) of CVM GFI #293 - FDA Enforcement Policy for AAFCO-Defined Animal Feed Ingredients\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/24\/2024","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Food Additives, Labeling","field_topics":"Postmarket, Premarket","topics-product":"Postmarket, Premarket, Animal Food Additives, Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"09\/09\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-2977\u0022\u003EFDA-2024-D-2977\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222024-10-23T10:40:46-04:00\u0022\u003E2024-10-23 10:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-294-animal-food-ingredient-consultation-afic\u0022\u003ECVM GFI #294 - Animal Food Ingredient Consultation (AFIC)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/180442\/download\u0022\u003EPDF (397.81 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (397.81 KB) of CVM GFI #294 - Animal Food Ingredient Consultation (AFIC)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/31\/2025","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Food Additives, Labeling, Safety - Issues, Errors, and Problems","field_topics":"Premarket","topics-product":"Premarket, Animal Food Additives, Labeling, Safety - Issues, Errors, and Problems","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"09\/09\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-2978\u0022\u003EFDA-2024-D-2978\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222025-08-01T13:34:46-04:00\u0022\u003E2025-08-01 13:34\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/draft-guidance-industry-voluntary-sodium-reduction-goals-edition-2\u0022\u003EDraft Guidance for Industry: Voluntary Sodium Reduction Goals (Edition 2)\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/180784\/download\u0022\u003EPDF (529.93 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (529.93 KB) of Draft Guidance for Industry: Voluntary Sodium Reduction Goals (Edition 2)\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/15\/2024","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"01\/13\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2014-D-0055\u0022\u003EFDA-2014-D-0055\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222024-11-01T15:01:11-04:00\u0022\u003E2024-11-01 15:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/predetermined-change-control-plans-medical-devices\u0022\u003EPredetermined Change Control Plans for Medical Devices: Draft Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/180978\/download\u0022\u003EPDF (1.39 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.39 MB) of Predetermined Change Control Plans for Medical Devices: Draft Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/22\/2024","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"11\/20\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-2338\u0022\u003EFDA-2024-D-2338\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222024-08-22T08:58:01-04:00\u0022\u003E2024-08-22 08:58\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/mammography-quality-standards-act-and-regulation-amendments-small-entity-compliance-guide\u0022\u003EMammography Quality Standards Act and Regulation Amendments: Small Entity Compliance Guide: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/181152\/download\u0022\u003EPDF (864.29 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (864.29 KB) of Mammography Quality Standards Act and Regulation Amendments: Small Entity Compliance Guide: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/26\/2024","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-N-0134\u0022\u003EFDA-2013-N-0134\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices, Radiation-Emitting Products","changed":"\u003Ctime datetime=\u00222024-08-23T08:48:03-04:00\u0022\u003E2024-08-23 08:48\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/enforcement-policy-required-warnings-cigarette-packages-and-advertisements\u0022\u003EEnforcement Policy for Required Warnings for Cigarette Packages and Advertisements\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/181776\/download\u0022\u003EPDF (131.88 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (131.88 KB) of Enforcement Policy for Required Warnings for Cigarette Packages and Advertisements\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/13\/2024","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-3742\u0022\u003EFDA-2024-D-3742\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222024-09-12T10:22:34-04:00\u0022\u003E2024-09-12 10:22\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/considerations-generating-clinical-evidence-oncology-multiregional-clinical-development-programs\u0022\u003EConsiderations for Generating Clinical Evidence from Oncology Multiregional Clinical Development Programs \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/181824\/download\u0022\u003EPDF (306.07 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (306.07 KB) of Considerations for Generating Clinical Evidence from Oncology Multiregional Clinical Development Programs \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/16\/2024","field_issuing_office_taxonomy":"Oncology Center of Excellence","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"11\/18\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-3163\u0022\u003EFDA-2024-D-3163\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-09-16T09:53:01-04:00\u0022\u003E2024-09-16 09:53\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/integrating-randomized-controlled-trials-drug-and-biological-products-routine-clinical-practice\u0022\u003EIntegrating Randomized Controlled Trials for Drug and Biological Products Into Routine Clinical Practice: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/181871\/download\u0022\u003EPDF (320.1 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (320.1 KB) of Integrating Randomized Controlled Trials for Drug and Biological Products Into Routine Clinical Practice: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/18\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOncology Center of Excellence","field_health_topics":"","term_node_tid":"","field_topics":"Real World Data \/ Real World Evidence (RWD\/RWE)","topics-product":"Real World Data \/ Real World Evidence (RWD\/RWE), ","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"12\/17\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-2052\u0022\u003EFDA-2024-D-2052\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-09-18T08:48:16-04:00\u0022\u003E2024-09-18 08:48\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/chemical-analysis-biocompatibility-assessment-medical-devices\u0022\u003EChemical Analysis for Biocompatibility Assessment of Medical Devices: Draft Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/181952\/download\u0022\u003EPDF (1002.96 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1002.96 KB) of Chemical Analysis for Biocompatibility Assessment of Medical Devices: Draft Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/20\/2024","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC)","field_topics":"Premarket","topics-product":"Premarket, Chemistry, Manufacturing, and Controls (CMC)","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"12\/19\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-4165\u0022\u003EFDA-2024-D-4165\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222024-10-21T08:59:16-04:00\u0022\u003E2024-10-21 08:59\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/accreditation-scheme-conformity-assessment-asca-program\u0022\u003EThe Accreditation Scheme for Conformity Assessment (ASCA) Program: Draft Guidance for Industry, Accreditation Bodies, Testing Laboratories, and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/182017\/download\u0022\u003EPDF (1.42 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.42 MB) of The Accreditation Scheme for Conformity Assessment (ASCA) Program: Draft Guidance for Industry, Accreditation Bodies, Testing Laboratories, and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/23\/2024","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"12\/23\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-3805\u0022\u003EFDA-2019-D-3805\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222024-10-18T08:48:16-04:00\u0022\u003E2024-10-18 08:48\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/basic-safety-and-essential-performance-medical-electrical-equipment-medical-electrical-systems-and-0\u0022\u003EBasic Safety and Essential Performance of Medical Electrical Equipment, Medical Electrical Systems, and Laboratory Medical Equipment - Standards Specific Information for the Accreditation Scheme for Conformity Assessment (ASCA) Program: Draft Guidance for Industry, Accreditation Bodies, Testing Laboratories, and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/182020\/download\u0022\u003EPDF (657.84 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (657.84 KB) of Basic Safety and Essential Performance of Medical Electrical Equipment, Medical Electrical Systems, and Laboratory Medical Equipment - Standards Specific Information for the Accreditation Scheme for Conformity Assessment (ASCA) Program: Draft Guidance for Industry, Accreditation Bodies, Testing Laboratories, and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/23\/2024","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"12\/23\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-3805\u0022\u003EFDA-2019-D-3805\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222024-10-18T08:48:21-04:00\u0022\u003E2024-10-18 08:48\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/biocompatibility-testing-medical-devices-standards-specific-information-accreditation-scheme-0\u0022\u003EBiocompatibility Testing of Medical Devices - Standards Specific Information for the Accreditation Scheme for Conformity Assessment (ASCA) Program : Draft Guidance for Industry, Accreditation Bodies, Testing Laboratories, and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/182026\/download\u0022\u003EPDF (4.71 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (4.71 MB) of Biocompatibility Testing of Medical Devices - Standards Specific Information for the Accreditation Scheme for Conformity Assessment (ASCA) Program : Draft Guidance for Industry, Accreditation Bodies, Testing Laboratories, and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/23\/2024","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Premarket","topics-product":"Premarket, ","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"12\/23\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-3805\u0022\u003EFDA-2019-D-3805\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222024-10-18T08:48:25-04:00\u0022\u003E2024-10-18 08:48\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/air-powered-dental-handpieces-and-air-motors-performance-criteria-safety-and-performance-based\u0022\u003EAir Powered Dental Handpieces and Air Motors - Performance Criteria for Safety and Performance Based Pathway: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/182279\/download\u0022\u003EPDF (519.17 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (519.17 KB) of Air Powered Dental Handpieces and Air Motors - Performance Criteria for Safety and Performance Based Pathway: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/30\/2024","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Dental ","field_topics":"Premarket","topics-product":"Premarket, 510(k), Dental ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-4168\u0022\u003EFDA-2024-D-4168\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222024-09-27T09:40:51-04:00\u0022\u003E2024-09-27 09:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/dental-cements-performance-criteria-safety-and-performance-based-pathway\u0022\u003EDental Cements - Performance Criteria for Safety and Performance Based Pathway: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/182280\/download\u0022\u003EPDF (528.42 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (528.42 KB) of Dental Cements - Performance Criteria for Safety and Performance Based Pathway: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/30\/2024","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Dental ","field_topics":"Premarket","topics-product":"Premarket, 510(k), Dental ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-4171\u0022\u003EFDA-2024-D-4171\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222024-09-27T09:40:48-04:00\u0022\u003E2024-09-27 09:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/dental-ceramics-performance-criteria-safety-and-performance-based-pathway\u0022\u003EDental Ceramics - Performance Criteria for Safety and Performance Based Pathway: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/182281\/download\u0022\u003EPDF (450.79 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (450.79 KB) of Dental Ceramics - Performance Criteria for Safety and Performance Based Pathway: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/30\/2024","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Dental ","field_topics":"Premarket","topics-product":"Premarket, 510(k), Dental ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-4169\u0022\u003EFDA-2024-D-4169\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222024-09-27T09:45:47-04:00\u0022\u003E2024-09-27 09:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/dental-impression-materials-performance-criteria-safety-and-performance-based-pathway\u0022\u003EDental Impression Materials - Performance Criteria for Safety and Performance Based Pathway: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/182282\/download\u0022\u003EPDF (473.92 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (473.92 KB) of Dental Impression Materials - Performance Criteria for Safety and Performance Based Pathway: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/30\/2024","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Dental ","field_topics":"Premarket","topics-product":"Premarket, 510(k), Dental ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-4170\u0022\u003EFDA-2024-D-4170\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222024-09-27T11:14:46-04:00\u0022\u003E2024-09-27 11:14\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/endosseous-dental-implants-and-endosseous-dental-implant-abutments-performance-criteria-safety-and\u0022\u003EEndosseous Dental Implants and Endosseous Dental Implant Abutments - Performance Criteria for Safety and Performance Based Pathway: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/182616\/download\u0022\u003EPDF (304.94 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (304.94 KB) of Endosseous Dental Implants and Endosseous Dental Implant Abutments - Performance Criteria for Safety and Performance Based Pathway: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/15\/2024","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Dental ","field_topics":"Premarket","topics-product":"Premarket, 510(k), Dental ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-4409\u0022\u003EFDA-2024-D-4409\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222024-10-11T08:48:31-04:00\u0022\u003E2024-10-11 08:48\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/temporary-policies-compounding-certain-parenteral-drug-products\u0022\u003ETemporary Policies for Compounding Certain Parenteral Drug Products: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/182632\/download\u0022\u003EPDF (133.59 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (133.59 KB) of Temporary Policies for Compounding Certain Parenteral Drug Products: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/11\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Compounding","field_topics":"","topics-product":"Compounding","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-4774\u0022\u003EFDA-2024-D-4774\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-10-17T08:49:46-04:00\u0022\u003E2024-10-17 08:49\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommendations-development-blood-collection-processing-and-storage-systems-manufacture-blood\u0022\u003ERecommendations for the Development of Blood Collection, Processing, and Storage Systems for the Manufacture of Blood Components Using the Buffy Coat Method\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/182751\/download\u0022\u003EPDF (317.34 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (317.34 KB) of Recommendations for the Development of Blood Collection, Processing, and Storage Systems for the Manufacture of Blood Components Using the Buffy Coat Method\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/16\/2026","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Blood","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood, Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-2732\u0022\u003EFDA-2024-D-2732\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222026-09-17T09:13:02-04:00\u0022\u003E2026-09-17 09:13\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/postoperative-nausea-and-vomiting-developing-drugs-prevention\u0022\u003EPostoperative Nausea and Vomiting: Developing Drugs for Prevention\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/182757\/download\u0022\u003EPDF (256.27 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (256.27 KB) of Postoperative Nausea and Vomiting: Developing Drugs for Prevention\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/17\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"12\/17\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-3993\u0022\u003EFDA-2024-D-3993\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-10-18T10:52:47-04:00\u0022\u003E2024-10-18 10:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/drug-interaction-information-human-prescription-drug-and-biological-product-labeling\u0022\u003EDrug Interaction Information in Human Prescription Drug and Biological Product Labeling\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/182893\/download\u0022\u003EPDF (548.42 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (548.42 KB) of Drug Interaction Information in Human Prescription Drug and Biological Product Labeling\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/21\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling, Clinical - Pharmacology","field_topics":"","topics-product":"Labeling, Clinical - Pharmacology","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"01\/21\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-3903\u0022\u003EFDA-2024-D-3903\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-12-11T11:05:03-05:00\u0022\u003E2024-12-11 11:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/nonclinical-safety-assessment-oligonucleotide-based-therapeutics\u0022\u003ENonclinical Safety Assessment of Oligonucleotide-Based Therapeutics\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/183496\/download\u0022\u003EPDF (354.31 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (354.31 KB) of Nonclinical Safety Assessment of Oligonucleotide-Based Therapeutics\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/15\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pharmacology\/Toxicology","field_topics":"","topics-product":"Pharmacology\/Toxicology","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"01\/14\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-4624\u0022\u003EFDA-2024-D-4624\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-11-15T09:38:46-05:00\u0022\u003E2024-11-15 09:38\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/frequently-asked-questions-developing-potential-cellular-and-gene-therapy-products\u0022\u003EFrequently Asked Questions \u2014 Developing Potential Cellular and Gene Therapy Products: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/183631\/download\u0022\u003EPDF (461.02 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (461.02 KB) of Frequently Asked Questions \u2014 Developing Potential Cellular and Gene Therapy Products: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/19\/2026","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Gene Therapy","field_topics":"","topics-product":"Gene Therapy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-4311\u0022\u003EFDA-2024-D-4311\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222026-08-20T09:53:04-04:00\u0022\u003E2026-08-20 09:53\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/transitional-enforcement-policy-ethylene-oxide-sterilization-facility-changes-class-iii-devices\u0022\u003ETransitional Enforcement Policy for Ethylene Oxide Sterilization Facility Changes for Class III Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/183833\/download\u0022\u003EPDF (483.14 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (483.14 KB) of Transitional Enforcement Policy for Ethylene Oxide Sterilization Facility Changes for Class III Devices: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/26\/2024","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Premarket Approval (PMA), HUD\/HDE","field_topics":"","topics-product":"Premarket Approval (PMA), HUD\/HDE","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-2274\u0022\u003EFDA-2024-D-2274\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222024-11-25T10:37:46-05:00\u0022\u003E2024-11-25 10:37\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommended-followup-testing-ames-positive-drug-active-ingredient-or-metabolite-support-first-human\u0022\u003ERecommended Followup Testing for an Ames-Positive Drug (Active Ingredient) or Metabolite To Support First-in-Human Clinical Trials With Healthy Subjects\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/183844\/download\u0022\u003EPDF (592.48 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (592.48 KB) of Recommended Followup Testing for an Ames-Positive Drug (Active Ingredient) or Metabolite To Support First-in-Human Clinical Trials With Healthy Subjects\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/27\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pharmacology\/Toxicology","field_topics":"","topics-product":"Pharmacology\/Toxicology","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"02\/25\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-4540\u0022\u003EFDA-2024-D-4540\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-11-27T10:48:31-05:00\u0022\u003E2024-11-27 10:48\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/assessment-ovarian-toxicity-premenopausal-adults-during-drug-development-oncologic-products\u0022\u003EAssessment of Ovarian Toxicity in Premenopausal Adults During Drug Development for Oncologic Products \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/183839\/download\u0022\u003EPDF (249.56 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (249.56 KB) of Assessment of Ovarian Toxicity in Premenopausal Adults During Drug Development for Oncologic Products \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/26\/2024","field_issuing_office_taxonomy":"Oncology Center of Excellence\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-4643\u0022\u003EFDA-2024-D-4643\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222024-11-26T09:00:06-05:00\u0022\u003E2024-11-26 09:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/draft-guidance-industry-notifying-fda-permanent-discontinuance-manufacture-or-interruption\u0022\u003EDraft Guidance for Industry: Notifying FDA of a Permanent Discontinuance in the Manufacture or an Interruption of the Manufacture of an Infant Formula\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/183873\/download\u0022\u003EPDF (246.02 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (246.02 KB) of Draft Guidance for Industry: Notifying FDA of a Permanent Discontinuance in the Manufacture or an Interruption of the Manufacture of an Infant Formula\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/02\/2024","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Infant Formula \u0026amp; Foods","field_topics":"","topics-product":"Infant Formula \u0026amp; Foods","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"02\/03\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-1334\u0022\u003EFDA-2024-D-1334\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-03-12T09:56:31-04:00\u0022\u003E2025-03-12 09:56\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/accelerated-approval-expedited-program-serious-conditions\u0022\u003EAccelerated Approval \u2013 Expedited Program for Serious Conditions\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/184120\/download\u0022\u003EPDF (382.28 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (382.28 KB) of Accelerated Approval \u2013 Expedited Program for Serious Conditions\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/05\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"02\/04\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-2033\u0022\u003EFDA-2024-D-2033\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-12-05T09:08:01-05:00\u0022\u003E2024-12-05 09:08\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/protocol-deviations-clinical-investigations-drugs-biological-products-and-devices\u0022\u003EProtocol Deviations for Clinical Investigations of Drugs, Biological Products, and Devices\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/184745\/download\u0022\u003EPDF (274.83 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (274.83 KB) of Protocol Deviations for Clinical Investigations of Drugs, Biological Products, and Devices\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/30\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003EOncology Center of Excellence","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"02\/28\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-5016\u0022\u003EFDA-2023-D-5016\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-12-30T14:20:16-05:00\u0022\u003E2024-12-30 14:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e6r3-good-clinical-practice-annex-2\u0022\u003EE6(R3) Good Clinical Practice: Annex 2\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/184746\/download\u0022\u003EPDF (717.99 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (717.99 KB) of E6(R3) Good Clinical Practice: Annex 2\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/30\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Efficacy","field_topics":"","topics-product":"ICH-Efficacy","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"02\/28\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-5601\u0022\u003EFDA-2024-D-5601\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222024-12-30T10:00:46-05:00\u0022\u003E2024-12-30 10:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/m15-general-principles-model-informed-drug-development\u0022\u003EM15 General Principles for Model-Informed Drug Development\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/184747\/download\u0022\u003EPDF (370.13 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (370.13 KB) of M15 General Principles for Model-Informed Drug Development\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/02\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Multidisciplinary","field_topics":"New Approach Methodologies","topics-product":"New Approach Methodologies, ICH-Multidisciplinary","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-5580\u0022\u003EFDA-2024-D-5580\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-07-24T08:41:47-04:00\u0022\u003E2026-07-24 08:41\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/combined-food-and-drug-administration-and-sponsor-oncologic-drugs-advisory-committee-briefing\u0022\u003ECombined Food and Drug Administration and Sponsor Oncologic Drugs Advisory Committee Briefing Document\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/184762\/download\u0022\u003EPDF (221.49 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (221.49 KB) of Combined Food and Drug Administration and Sponsor Oncologic Drugs Advisory Committee Briefing Document\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/27\/2024","field_issuing_office_taxonomy":"Oncology Center of Excellence","field_health_topics":"","term_node_tid":"Prescription Drugs, Oncology","field_topics":"","topics-product":"Prescription Drugs, Oncology","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-4490\u0022\u003EFDA-2024-D-4490\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222025-01-03T09:12:02-05:00\u0022\u003E2025-01-03 09:12\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/considerations-complying-21-cfr-211110\u0022\u003EConsiderations for Complying with 21 CFR 211.110\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/184825\/download\u0022\u003EPDF (265.65 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (265.65 KB) of Considerations for Complying with 21 CFR 211.110\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/06\/2025","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Veterinary Medicine","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_topics":"","topics-product":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"04\/07\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-5374\u0022\u003EFDA-2024-D-5374\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-01-06T09:11:03-05:00\u0022\u003E2025-01-06 09:11\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-260-type-vii-veterinary-master-file-research-and-development-and-risk-reviews\u0022\u003ECVM GFI #260 - Type VII Veterinary Master File for Research and Development and Risk Reviews\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/184869\/download\u0022\u003EPDF (350.05 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (350.05 KB) of CVM GFI #260 - Type VII Veterinary Master File for Research and Development and Risk Reviews\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/14\/2026","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Cell-Based Products","field_topics":"Biotechnology, Cellular \u0026amp; Gene Therapy","topics-product":"Biotechnology, Cellular \u0026amp; Gene Therapy, Animal Cell-Based Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-5376\u0022\u003EFDA-2024-D-5376\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222026-08-14T08:52:03-04:00\u0022\u003E2026-08-14 08:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-251-heritable-intentional-genomic-alterations-animals-food-producing-species-use-models\u0022\u003ECVM GFI #251 - Heritable Intentional Genomic Alterations in Animals of Food-Producing Species for Use as Models of Disease\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/184862\/download\u0022\u003EPDF (321.79 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (321.79 KB) of CVM GFI #251 - Heritable Intentional Genomic Alterations in Animals of Food-Producing Species for Use as Models of Disease\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/07\/2025","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Cell-Based Products","field_topics":"Biotechnology, Cellular \u0026amp; Gene Therapy, Premarket","topics-product":"Biotechnology, Cellular \u0026amp; Gene Therapy, Premarket, Animal Cell-Based Products","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"03\/10\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-4778\u0022\u003EFDA-2024-D-4778\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222025-01-06T08:54:07-05:00\u0022\u003E2025-01-06 08:54\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/pulse-oximeters-medical-purposes-non-clinical-and-clinical-performance-testing-labeling-and\u0022\u003EPulse Oximeters for Medical Purposes - Non-Clinical and Clinical Performance Testing, Labeling, and Premarket Submission Recommendations: Draft Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/184896\/download\u0022\u003EPDF (993.27 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (993.27 KB) of Pulse Oximeters for Medical Purposes - Non-Clinical and Clinical Performance Testing, Labeling, and Premarket Submission Recommendations: Draft Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/07\/2025","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Pediatric Product Development","field_topics":"Premarket","topics-product":"Premarket, Pediatric Product Development","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"03\/10\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-N-4976\u0022\u003EFDA-2023-N-4976\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222025-06-04T14:36:47-04:00\u0022\u003E2025-06-04 14:36\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/draft-guidance-industry-labeling-plant-based-alternatives-animal-derived-foods\u0022\u003EDraft Guidance for Industry: Labeling of Plant-Based Alternatives to Animal-Derived Foods\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/184810\/download\u0022\u003EPDF (796.68 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (796.68 KB) of Draft Guidance for Industry: Labeling of Plant-Based Alternatives to Animal-Derived Foods\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/06\/2025","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"05\/07\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-1102\u0022\u003EFDA-2022-D-1102\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-02-25T15:17:02-05:00\u0022\u003E2025-02-25 15:17\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/draft-guidance-industry-establishing-sanitation-programs-low-moisture-ready-eat-human-foods-and\u0022\u003EDraft Guidance for Industry: Establishing Sanitation Programs for Low-Moisture Ready-to-Eat Human Foods and Taking Corrective Actions Following a Pathogen Contamination Event\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/184815\/download\u0022\u003EPDF (468.96 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (468.96 KB) of Draft Guidance for Industry: Establishing Sanitation Programs for Low-Moisture Ready-to-Eat Human Foods and Taking Corrective Actions Following a Pathogen Contamination Event\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/06\/2025","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"05\/07\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-2604\u0022\u003EFDA-2024-D-2604\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222025-05-29T08:57:31-04:00\u0022\u003E2025-05-29 08:57\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommendations-reduce-risk-transmission-hepatitis-b-virus-hbv-human-cells-tissues-and-cellular-and\u0022\u003ERecommendations to Reduce the Risk of Transmission of Hepatitis B Virus (HBV) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\/Ps): Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/184899\/download\u0022\u003EPDF (328.38 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (328.38 KB) of Recommendations to Reduce the Risk of Transmission of Hepatitis B Virus (HBV) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\/Ps): Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/06\/2025","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Hepatitis B","term_node_tid":"Tissue","field_topics":"","topics-product":"Hepatitis B, Tissue","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0465\u0022\u003EFDA-2022-D-0465\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222025-02-19T13:32:07-05:00\u0022\u003E2025-02-19 13:32\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommendations-reduce-risk-transmission-disease-agents-associated-sepsis-human-cells-tissues-and\u0022\u003ERecommendations to Reduce the Risk of Transmission of Disease Agents Associated with Sepsis by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\/Ps): Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/186261\/download\u0022\u003EPDF (273.87 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (273.87 KB) of Recommendations to Reduce the Risk of Transmission of Disease Agents Associated with Sepsis by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\/Ps): Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/02\/2025","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Tissue","field_topics":"","topics-product":"Tissue","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"07\/07\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-3067\u0022\u003EFDA-2024-D-3067\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222025-05-05T07:32:31-04:00\u0022\u003E2025-05-05 07:32\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommendations-reduce-risk-transmission-mycobacterium-tuberculosis-mtb-human-cells-tissues-and\u0022\u003ERecommendations to Reduce the Risk of Transmission of Mycobacterium tuberculosis (Mtb) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\/Ps): Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/186259\/download\u0022\u003EPDF (421.93 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (421.93 KB) of Recommendations to Reduce the Risk of Transmission of Mycobacterium tuberculosis (Mtb) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\/Ps): Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/02\/2025","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Tuberculosis","term_node_tid":"Tissue","field_topics":"","topics-product":"Tuberculosis, Tissue","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"07\/07\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-3863\u0022\u003EFDA-2024-D-3863\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222025-05-05T07:33:31-04:00\u0022\u003E2025-05-05 07:33\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/artificial-intelligence-enabled-device-software-functions-lifecycle-management-and-marketing\u0022\u003EArtificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations: Draft Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/184856\/download\u0022\u003EPDF (1.52 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.52 MB) of Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations: Draft Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/07\/2025","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Digital Health","field_topics":"Postmarket, Premarket","topics-product":"Postmarket, Premarket, Digital Health","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"04\/07\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-4488\u0022\u003EFDA-2024-D-4488\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222025-01-06T09:42:06-05:00\u0022\u003E2025-01-06 09:42\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommendations-reduce-risk-transmission-human-immunodeficiency-virus-hiv-human-cells-tissues-and\u0022\u003ERecommendations to Reduce the Risk of Transmission of Human Immunodeficiency Virus (HIV) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\/Ps): Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/184903\/download\u0022\u003EPDF (382.71 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (382.71 KB) of Recommendations to Reduce the Risk of Transmission of Human Immunodeficiency Virus (HIV) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\/Ps): Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/06\/2025","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"HIV\/AIDS","term_node_tid":"Tissue","field_topics":"","topics-product":"HIV\/AIDS, Tissue","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0467\u0022\u003EFDA-2022-D-0467\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222025-02-19T13:32:35-05:00\u0022\u003E2025-02-19 13:32\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommendations-determining-eligibility-donors-human-cells-tissues-and-cellular-and-tissue-based\u0022\u003ERecommendations for Determining Eligibility of Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\/Ps): Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/184904\/download\u0022\u003EPDF (943.06 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (943.06 KB) of Recommendations for Determining Eligibility of Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\/Ps): Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/06\/2025","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Tissue","field_topics":"","topics-product":"Tissue","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0464\u0022\u003EFDA-2022-D-0464\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222025-01-21T11:58:01-05:00\u0022\u003E2025-01-21 11:58\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/validation-certain-in-vitro-diagnostic-devices-emerging-pathogens-during-section-564-declared-emergency\u0022\u003EValidation of Certain In Vitro Diagnostic Devices for Emerging Pathogens During a Section 564 Declared Emergency: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/184852\/download\u0022\u003EPDF (641.15 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (641.15 KB) of Validation of Certain In Vitro Diagnostic Devices for Emerging Pathogens During a Section 564 Declared Emergency: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/10\/2026","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"IVDs (In Vitro Diagnostic Devices)","field_topics":"","topics-product":"IVDs (In Vitro Diagnostic Devices)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-2707\u0022\u003EFDA-2024-D-2707\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222026-11-09T08:52:46-05:00\u0022\u003E2026-11-09 08:52\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/accelerated-approval-and-considerations-determining-whether-confirmatory-trial-underway\u0022\u003EAccelerated Approval and Considerations for Determining Whether a Confirmatory Trial is Underway\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/184831\/download\u0022\u003EPDF (277.18 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (277.18 KB) of Accelerated Approval and Considerations for Determining Whether a Confirmatory Trial is Underway\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/07\/2025","field_issuing_office_taxonomy":"Oncology Center of Excellence","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-3334\u0022\u003EFDA-2024-D-3334\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222025-01-06T09:48:33-05:00\u0022\u003E2025-01-06 09:48\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommendations-reduce-risk-transmission-hepatitis-c-virus-hcv-human-cells-tissues-and-cellular-and\u0022\u003ERecommendations to Reduce the Risk of Transmission of Hepatitis C Virus (HCV) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\/Ps): Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/184901\/download\u0022\u003EPDF (327.3 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (327.3 KB) of Recommendations to Reduce the Risk of Transmission of Hepatitis C Virus (HCV) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\/Ps): Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/06\/2025","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Hepatitis C","term_node_tid":"Tissue","field_topics":"","topics-product":"Hepatitis C, Tissue","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0466\u0022\u003EFDA-2022-D-0466\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222025-02-19T13:32:36-05:00\u0022\u003E2025-02-19 13:32\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/considerations-use-artificial-intelligence-support-regulatory-decision-making-drug-and-biological\u0022\u003EConsiderations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products: Draft Guidance for Industry and Other Interested Parties\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/184830\/download\u0022\u003EPDF (407.1 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (407.1 KB) of Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products: Draft Guidance for Industry and Other Interested Parties\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/07\/2025","field_issuing_office_taxonomy":"Center for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations\u003Cbr\u003E\u003Cbr\u003EOncology Center of Excellence\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of the Chief Medical Officer,Office of Combination Products","field_health_topics":"","term_node_tid":"Artificial Intelligence","field_topics":"","topics-product":"Artificial Intelligence","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"04\/07\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-4689\u0022\u003EFDA-2024-D-4689\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-01-07T14:27:01-05:00\u0022\u003E2025-01-07 14:27\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/considerations-including-tissue-biopsies-clinical-trials\u0022\u003EConsiderations for Including Tissue Biopsies in Clinical Trials\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/184884\/download\u0022\u003EPDF (310.94 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (310.94 KB) of Considerations for Including Tissue Biopsies in Clinical Trials\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/07\/2025","field_issuing_office_taxonomy":"Oncology Center of Excellence","field_health_topics":"","term_node_tid":"Pediatric Product Development","field_topics":"","topics-product":"Pediatric Product Development","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"03\/10\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-2402\u0022\u003EFDA-2024-D-2402\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222025-06-04T14:42:37-04:00\u0022\u003E2025-06-04 14:42\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/developing-drugs-optical-imaging\u0022\u003EDeveloping Drugs for Optical Imaging\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/184943\/download\u0022\u003EPDF (335.16 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (335.16 KB) of Developing Drugs for Optical Imaging\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/07\/2025","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"04\/08\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-3780\u0022\u003EFDA-2024-D-3780\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-01-08T14:31:46-05:00\u0022\u003E2025-01-08 14:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommendations-reduce-risk-transfusion-transmitted-malaria-0\u0022\u003ERecommendations to Reduce the Risk of Transfusion-Transmitted Malaria: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/185138\/download\u0022\u003EPDF (335.94 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (335.94 KB) of Recommendations to Reduce the Risk of Transfusion-Transmitted Malaria: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/15\/2025","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Blood","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood, Blood Products","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2000-D-0187\u0022\u003EFDA-2000-D-0187\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222025-01-17T09:01:29-05:00\u0022\u003E2025-01-17 09:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/prevention-and-treatment-chemotherapy-induced-peripheral-neuropathy-developing-drug-and-biological\u0022\u003EPrevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy: Developing Drug and Biological Products in Oncology\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/185154\/download\u0022\u003EPDF (246.3 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (246.3 KB) of Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy: Developing Drug and Biological Products in Oncology\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/17\/2025","field_issuing_office_taxonomy":"Oncology Center of Excellence","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"03\/18\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-5663 \u0022\u003EFDA-2024-D-5663 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222025-01-16T14:12:04-05:00\u0022\u003E2025-01-16 14:12\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/data-standards-drug-and-biological-product-submissions-containing-real-world-data\u0022\u003EData Standards for Drug and Biological Product Submissions Containing Real-World Data: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/153341\/download\u0022\u003EPDF (457.27 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (457.27 KB) of Data Standards for Drug and Biological Product Submissions Containing Real-World Data: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/21\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"Real World Data \/ Real World Evidence (RWD\/RWE)","topics-product":"Real World Data \/ Real World Evidence (RWD\/RWE), ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"01\/21\/2022","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0548\u0022\u003EFDA-2021-D-0548\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222025-01-31T18:53:31-05:00\u0022\u003E2025-01-31 18:53\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/investigating-and-reporting-adverse-reactions-related-human-cells-tissues-and-cellular-and-tissue\u0022\u003EInvestigating and Reporting Adverse Reactions Related to Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\/Ps) Regulated Solely under Section 361 of the Public Health Service Act and 21 CFR Part 1271: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/91082\/download\u0022\u003EPDF (442.55 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (442.55 KB) of Investigating and Reporting Adverse Reactions Related to Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\/Ps) Regulated Solely under Section 361 of the Public Health Service Act and 21 CFR Part 1271: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/08\/2016","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Tissue","field_topics":"","topics-product":"Tissue","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2015-D-0309\u0022\u003EFDA-2015-D-0309\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222025-02-02T23:05:16-05:00\u0022\u003E2025-02-02 23:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/preclinical-assessment-investigational-cellular-and-gene-therapy-products\u0022\u003EPreclinical Assessment of Investigational Cellular and Gene Therapy Products: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/87564\/download\u0022\u003EPDF (186.49 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (186.49 KB) of Preclinical Assessment of Investigational Cellular and Gene Therapy Products: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/01\/2013","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Gene Therapy","field_topics":"Cellular \u0026amp; Gene Therapy","topics-product":"Cellular \u0026amp; Gene Therapy, Gene Therapy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-1038\u0022\u003EFDA-2012-D-1038\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222025-02-02T23:25:46-05:00\u0022\u003E2025-02-02 23:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/characterization-and-qualification-cell-substrates-and-other-biological-materials-used-production\u0022\u003ECharacterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/78428\/download\u0022\u003EPDF (406.87 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (406.87 KB) of Characterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/01\/2010","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Vaccines","field_topics":"","topics-product":"Vaccines","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2006-D-0223\u0022\u003EFDA-2006-D-0223\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222025-02-02T23:41:12-05:00\u0022\u003E2025-02-02 23:41\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/toxicity-grading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-clinical\u0022\u003EToxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73679\/download\u0022\u003EPDF (197.79 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (197.79 KB) of Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/27\/2007","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Vaccines","field_topics":"","topics-product":"Vaccines","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2005-D-0272\u0022\u003EFDA-2005-D-0272\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222025-02-02T23:54:31-05:00\u0022\u003E2025-02-02 23:54\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/content-and-review-chemistry-manufacturing-and-control-cmc-information-human-somatic-cell-therapy\u0022\u003E Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug Applications (INDs): Guidance for FDA Reviewers and Sponsors\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73624\/download\u0022\u003EPDF (209.11 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (209.11 KB) of Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug Applications (INDs): Guidance for FDA Reviewers and Sponsors\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/01\/2008","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Gene Therapy","field_topics":"Cellular \u0026amp; Gene Therapy","topics-product":"Cellular \u0026amp; Gene Therapy, Gene Therapy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0206\u0022\u003EFDA-2008-D-0206\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222025-02-03T00:11:46-05:00\u0022\u003E2025-02-03 00:11\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommendations-collecting-red-blood-cells-automated-apheresis-methods-technical-correction-february\u0022\u003ERecommendations for Collecting Red Blood Cells by Automated Apheresis Methods - Technical Correction February 2001: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72714\/download\u0022\u003EPDF (85.31 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (85.31 KB) of Recommendations for Collecting Red Blood Cells by Automated Apheresis Methods - Technical Correction February 2001: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/13\/2001","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Blood Products","field_topics":"","topics-product":"Blood Products","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1998-D-0851\u0022\u003EFDA-1998-D-0851\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222025-02-03T00:50:46-05:00\u0022\u003E2025-02-03 00:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/providing-regulatory-submissions-center-biologics-evaluation-and-research-cber-electronic-format\u0022\u003EProviding Regulatory Submissions to the Center for Biologics Evaluation and Research (CBER) in Electronic Format - Biologics Marketing Applications: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/77755\/download\u0022\u003EPDF (729.69 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (729.69 KB) of Providing Regulatory Submissions to the Center for Biologics Evaluation and Research (CBER) in Electronic Format - Biologics Marketing Applications: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/01\/1999","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1998-D-0850\u0022\u003EFDA-1998-D-0850\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222025-02-03T01:10:16-05:00\u0022\u003E2025-02-03 01:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/content-and-format-chemistry-manufacturing-and-controls-information-and-establishment-description-1\u0022\u003EContent and Format of Chemistry, Manufacturing and Controls Information and Establishment Description Information for a Vaccine or Related Product: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/73614\/download\u0022\u003EPDF (154.55 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (154.55 KB) of Content and Format of Chemistry, Manufacturing and Controls Information and Establishment Description Information for a Vaccine or Related Product: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/05\/1999","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Vaccines","field_topics":"","topics-product":"Vaccines","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1998-D-0854\u0022\u003EFDA-1998-D-0854\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222025-02-03T01:25:31-05:00\u0022\u003E2025-02-03 01:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/how-complete-vaccine-adverse-event-reporting-system-form-vaers-1\u0022\u003EHow to Complete the Vaccine Adverse Event Reporting System Form (VAERS-1): Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/76517\/download\u0022\u003EPDF (128 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (128 KB) of How to Complete the Vaccine Adverse Event Reporting System Form (VAERS-1): Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/09\/1998","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Vaccines","field_topics":"","topics-product":"Vaccines","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0487\u0022\u003EFDA-2022-D-0487\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222025-02-03T01:47:46-05:00\u0022\u003E2025-02-03 01:47\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/volume-limits-automated-collection-source-plasma\u0022\u003EVolume Limits for Automated Collection of Source Plasma\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70951\/download\u0022\u003EPDF (43.45 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (43.45 KB) of Volume Limits for Automated Collection of Source Plasma\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/04\/1992","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Blood","term_node_tid":"Blood Products, Device \u0026amp; Drug Safety","field_topics":"","topics-product":"Blood, Blood Products, Device \u0026amp; Drug Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2013-S-0613\u0022\u003EFDA-2013-S-0613\u003C\/a\u003E","field_communication_type":"Memorandum","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222025-02-03T02:00:46-05:00\u0022\u003E2025-02-03 02:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/survey-methodologies-assess-rems-goals-relate-knowledge\u0022\u003ESurvey Methodologies to Assess REMS Goals That Relate to Knowledge\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/119789\/download\u0022\u003EPDF (601.87 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (601.87 KB) of Survey Methodologies to Assess REMS Goals That Relate to Knowledge\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/01\/2019","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Good Clinical Practice (GCP)","field_topics":"","topics-product":"Administrative \/ Procedural, Good Clinical Practice (GCP)","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-4629\u0022\u003EFDA-2018-D-4629\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-02-03T08:39:46-05:00\u0022\u003E2025-02-03 08:39\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/assessment-abuse-potential-drugs\u0022\u003EAssessment of Abuse Potential of Drugs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/116739\/download\u0022\u003EPDF (895.35 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (895.35 KB) of Assessment of Abuse Potential of Drugs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/18\/2017","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2010-D-0026 \u0022\u003EFDA-2010-D-0026 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-02-03T10:18:31-05:00\u0022\u003E2025-02-03 10:18\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/clinical-decision-support-software\u0022\u003EClinical Decision Support Software: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/109618\/download\u0022\u003EPDF (720.85 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (720.85 KB) of Clinical Decision Support Software: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/29\/2026","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural, Digital Health","field_topics":"","topics-product":"Administrative \/ Procedural, Digital Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6569\u0022\u003EFDA-2017-D-6569\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222026-01-29T11:12:10-05:00\u0022\u003E2026-01-29 11:12\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/collection-race-and-ethnicity-data-clinical-trials\u0022\u003ECollection of Race and Ethnicity Data in Clinical Trials: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/75453\/download\u0022\u003EPDF (847.91 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (847.91 KB) of Collection of Race and Ethnicity Data in Clinical Trials: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/26\/2016","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Minority Health and Health Equity\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Women\u0026#039;s Health","field_health_topics":"","term_node_tid":"Clinical - Medical, Investigational Device Exemption (IDE)","field_topics":"","topics-product":"Clinical - Medical, Investigational Device Exemption (IDE)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2016-D-3561\u0022\u003EFDA-2016-D-3561\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222025-02-03T12:12:31-05:00\u0022\u003E2025-02-03 12:12\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/contents-complete-submission-evaluation-proprietary-names\u0022\u003EContents of a Complete Submission for the Evaluation of Proprietary Names\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72144\/download\u0022\u003EPDF (189.13 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (189.13 KB) of Contents of a Complete Submission for the Evaluation of Proprietary Names\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/11\/2016","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling, Safety - Issues, Errors, and Problems","field_topics":"","topics-product":"Labeling, Safety - Issues, Errors, and Problems","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2008-D-0592\u0022\u003EFDA-2008-D-0592\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-02-03T14:03:31-05:00\u0022\u003E2025-02-03 14:03\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/m10-bioanalytical-method-validation-and-study-sample-analysis\u0022\u003EM10 Bioanalytical Method Validation and Study Sample Analysis\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/162903\/download\u0022\u003EPDF (233.8 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (233.8 KB) of M10 Bioanalytical Method Validation and Study Sample Analysis\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/04\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, ICH-Multidisciplinary","field_topics":"","topics-product":"Clinical - Medical, ICH-Multidisciplinary","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-1469\u0022\u003EFDA-2019-D-1469\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-02-03T14:42:46-05:00\u0022\u003E2025-02-03 14:42\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e2a-clinical-safety-data-management-definitions-and-standards-expedited-reporting\u0022\u003EE2A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71188\/download\u0022\u003EPDF (48.84 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (48.84 KB) of E2A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/1995","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Efficacy","field_topics":"","topics-product":"ICH-Efficacy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1993-D-0128\u0022\u003EFDA-1993-D-0128\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-02-03T14:56:46-05:00\u0022\u003E2025-02-03 14:56\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/immunogenicity-information-human-prescription-therapeutic-protein-and-select-drug-product-labeling\u0022\u003EImmunogenicity Information in Human Prescription Therapeutic Protein and Select Drug Product Labeling--Content and Format: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/155871\/download\u0022\u003EPDF (536.63 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (536.63 KB) of Immunogenicity Information in Human Prescription Therapeutic Protein and Select Drug Product Labeling--Content and Format: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/03\/2022","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"04\/05\/2022","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-1041\u0022\u003EFDA-2021-D-1041\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222025-02-04T09:06:16-05:00\u0022\u003E2025-02-04 09:06\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/postmarketing-adverse-event-reporting-nonprescription-human-drug-products-marketed-without-approved\u0022\u003EPostmarketing Adverse Event Reporting for Nonprescription Human Drug Products Marketed Without an Approved Application\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/77193\/download\u0022\u003EPDF (286.95 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (286.95 KB) of Postmarketing Adverse Event Reporting for Nonprescription Human Drug Products Marketed Without an Approved Application\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/17\/2009","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Over-the-Counter Drugs","field_topics":"","topics-product":"Over-the-Counter Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2007-D-0434\u0022\u003EFDA-2007-D-0434\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-02-03T15:09:46-05:00\u0022\u003E2025-02-03 15:09\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/exception-informed-consent-requirements-emergency-research\u0022\u003EException from Informed Consent Requirements for Emergency Research: Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/80554\/download\u0022\u003EPDF (1.47 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.47 MB) of Exception from Informed Consent Requirements for Emergency Research: Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/01\/2013","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP)","field_topics":"","topics-product":"Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2006-D-0464\u0022\u003EFDA-2006-D-0464\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222025-02-03T15:21:02-05:00\u0022\u003E2025-02-03 15:21\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/exploratory-ind-studies\u0022\u003EExploratory IND Studies: Guidance for Industry, Investigators, and Reviewers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72325\/download\u0022\u003EPDF (390.87 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (390.87 KB) of Exploratory IND Studies: Guidance for Industry, Investigators, and Reviewers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/12\/2006","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Good Clinical Practice (GCP), Pharmacology\/Toxicology","field_topics":"","topics-product":"Good Clinical Practice (GCP), Pharmacology\/Toxicology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-02-03T15:26:16-05:00\u0022\u003E2025-02-03 15:26\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/exposure-response-relationships-study-design-data-analysis-and-regulatory-applications\u0022\u003EExposure-Response Relationships \u2014 Study Design, Data Analysis, and Regulatory Applications\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71277\/download\u0022\u003EPDF (646.6 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (646.6 KB) of Exposure-Response Relationships \u2014 Study Design, Data Analysis, and Regulatory Applications\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/05\/2003","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Pharmacology","field_topics":"","topics-product":"Clinical - Pharmacology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2002-D-0177\u0022\u003EFDA-2002-D-0177\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-02-03T15:32:16-05:00\u0022\u003E2025-02-03 15:32\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/real-world-data-assessing-electronic-health-records-and-medical-claims-data-support-regulatory\u0022\u003EReal-World Data: Assessing Electronic Health Records and Medical Claims Data To Support Regulatory Decision-Making for Drug and Biological Products: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/152503\/download\u0022\u003EPDF (494.78 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (494.78 KB) of Real-World Data: Assessing Electronic Health Records and Medical Claims Data To Support Regulatory Decision-Making for Drug and Biological Products: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/25\/2024","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOncology Center of Excellence","field_health_topics":"","term_node_tid":"","field_topics":"Real World Data \/ Real World Evidence (RWD\/RWE)","topics-product":"Real World Data \/ Real World Evidence (RWD\/RWE), ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2020-D-2307\u0022\u003EFDA-2020-D-2307\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222025-02-03T15:35:31-05:00\u0022\u003E2025-02-03 15:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/fda-acceptance-foreign-clinical-studies-not-conducted-under-ind-frequently-asked-questions\u0022\u003EFDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND: Frequently Asked Questions: Guidance for Industry and FDA Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/83209\/download\u0022\u003EPDF (180.65 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (180.65 KB) of FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND: Frequently Asked Questions: Guidance for Industry and FDA Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/2012","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Good Clinical Practice (GCP)","field_topics":"","topics-product":"Clinical - Medical, Good Clinical Practice (GCP)","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222025-02-03T15:41:02-05:00\u0022\u003E2025-02-03 15:41\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/real-world-data-assessing-registries-support-regulatory-decision-making-drug-and-biological-products\u0022\u003EReal-World Data: Assessing Registries To Support Regulatory Decision-Making for Drug and Biological Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/154449\/download\u0022\u003EPDF (297.76 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (297.76 KB) of Real-World Data: Assessing Registries To Support Regulatory Decision-Making for Drug and Biological Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/22\/2023","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOncology Center of Excellence","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"Real World Data \/ Real World Evidence (RWD\/RWE)","topics-product":"Real World Data \/ Real World Evidence (RWD\/RWE), Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-1146\u0022\u003EFDA-2021-D-1146\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222025-02-03T15:44:47-05:00\u0022\u003E2025-02-03 15:44\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/gingivitis-development-and-evaluation-drugs-treatment-or-prevention\u0022\u003EGingivitis: Development and Evaluation of Drugs for Treatment or Prevention\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71536\/download\u0022\u003EPDF (1.04 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.04 MB) of Gingivitis: Development and Evaluation of Drugs for Treatment or Prevention\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/28\/2005","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Pediatric Product Development","field_topics":"","topics-product":"Clinical - Medical, Pediatric Product Development","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-02-03T15:53:31-05:00\u0022\u003E2025-02-03 15:53\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e7-studies-support-special-populations-geriatrics-questions-and-answers\u0022\u003EE7 Studies in Support of Special Populations; Geriatrics; Questions and Answers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/78220\/download\u0022\u003EPDF (84.94 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (84.94 KB) of E7 Studies in Support of Special Populations; Geriatrics; Questions and Answers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/01\/2012","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Efficacy","field_topics":"","topics-product":"ICH-Efficacy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0528\u0022\u003EFDA-2009-D-0528\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-02-03T15:56:02-05:00\u0022\u003E2025-02-03 15:56\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/s7b-nonclinical-evaluation-potential-delayed-ventricular-repolarization-qt-interval-prolongation\u0022\u003ES7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72043\/download\u0022\u003EPDF (270.96 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (270.96 KB) of S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/20\/2005","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Safety","field_topics":"","topics-product":"ICH-Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2004-D-0366\u0022\u003EFDA-2004-D-0366\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222026-10-30T08:51:32-04:00\u0022\u003E2026-10-30 08:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/s2a-specific-aspects-regulatory-genotoxicity-tests-pharmaceuticals\u0022\u003ES2A Specific Aspects of Regulatory Genotoxicity Tests for Pharmaceuticals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71959\/download\u0022\u003EPDF (374.97 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (374.97 KB) of S2A Specific Aspects of Regulatory Genotoxicity Tests for Pharmaceuticals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/24\/1996","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Safety","field_topics":"","topics-product":"ICH-Safety","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1994-D-0134\u0022\u003EFDA-1994-D-0134\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-02-04T08:43:31-05:00\u0022\u003E2025-02-04 08:43\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/vaginal-microbicidesdevelopment-prevention-hiv-infection-pdf\u0022\u003EVaginal Microbicides:Development for the Prevention of HIV Infection PDF\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/85288\/download\u0022\u003EPDF (380.04 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (380.04 KB) of Vaginal Microbicides:Development for the Prevention of HIV Infection PDF\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/19\/2014","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-1120\u0022\u003EFDA-2012-D-1120\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-02-04T08:47:31-05:00\u0022\u003E2025-02-04 08:47\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/women-and-minorities-guidance-requirements\u0022\u003EWomen and Minorities Guidance Requirements\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/72599\/download\u0022\u003EPDF (100.01 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (100.01 KB) of Women and Minorities Guidance Requirements\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/20\/1998","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-02-04T08:53:02-05:00\u0022\u003E2025-02-04 08:53\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e4-dose-response-information-support-drug-registration\u0022\u003EE4 Dose-Response Information to Support Drug Registration\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71279\/download\u0022\u003EPDF (189.12 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (189.12 KB) of E4 Dose-Response Information to Support Drug Registration\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/01\/1996","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Efficacy","field_topics":"","topics-product":"ICH-Efficacy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1993-D-0183\u0022\u003EFDA-1993-D-0183\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-02-04T09:01:04-05:00\u0022\u003E2025-02-04 09:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/environmental-assessment-human-drug-and-biologics-applications\u0022\u003EEnvironmental Assessment of Human Drug and Biologics Applications: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/70809\/download\u0022\u003EPDF (561.15 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (561.15 KB) of Environmental Assessment of Human Drug and Biologics Applications: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/27\/1998","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-1998-D-0278\u0022\u003EFDA-1998-D-0278\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-02-04T10:02:26-05:00\u0022\u003E2025-02-04 10:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/demonstrating-substantial-evidence-effectiveness-human-drug-and-biological-products\u0022\u003EDemonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/133660\/download\u0022\u003EPDF (353.61 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (353.61 KB) of Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/24\/2026","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOncology Center of Excellence","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"09\/22\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-4964\u0022\u003EFDA-2019-D-4964\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222026-06-25T11:26:47-04:00\u0022\u003E2026-06-25 11:26\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/warnings-and-precautions-contraindications-and-boxed-warning-sections-labeling-human-prescription\u0022\u003EWarnings and Precautions, Contraindications, and Boxed Warning Sections of Labeling for Human Prescription Drug and Biological Products \u2014 Content and Format\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/71866\/download\u0022\u003EPDF (110.98 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (110.98 KB) of Warnings and Precautions, Contraindications, and Boxed Warning Sections of Labeling for Human Prescription Drug and Biological Products \u2014 Content and Format\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/12\/2011","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0694\u0022\u003EFDA-2011-D-0694\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-02-04T14:51:29-05:00\u0022\u003E2025-02-04 14:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/tissue-agnostic-drug-development-oncology\u0022\u003ETissue Agnostic Drug Development in Oncology: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/162346\/download\u0022\u003EPDF (348.18 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (348.18 KB) of Tissue Agnostic Drug Development in Oncology: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/17\/2022","field_issuing_office_taxonomy":"Oncology Center of Excellence\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0286 \u0022\u003EFDA-2022-D-0286 \u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222025-02-05T10:48:16-05:00\u0022\u003E2025-02-05 10:48\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e2br3-electronic-transmission-individual-case-safety-reports-implementation-guide-data-elements-and\u0022\u003EE2B(R3) Electronic Transmission of Individual Case Safety Reports Implementation Guide \u2014 Data Elements and Message Specification; and Appendix to the Implementation Guide \u2014 Backwards and Forwards Compatibility\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/81904\/download\u0022\u003EPDF (343.52 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (343.52 KB) of E2B(R3) Electronic Transmission of Individual Case Safety Reports Implementation Guide \u2014 Data Elements and Message Specification; and Appendix to the Implementation Guide \u2014 Backwards and Forwards Compatibility\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/01\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Efficacy","field_topics":"","topics-product":"ICH-Efficacy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0720\u0022\u003EFDA-2011-D-0720\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-10-01T08:40:17-04:00\u0022\u003E2026-10-01 08:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/electronic-submission-template-medical-device-q-submissions\u0022\u003EElectronic Submission Template for Medical Device Q-Submissions: Draft Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/186664\/download\u0022\u003EPDF (390.05 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (390.05 KB) of Electronic Submission Template for Medical Device Q-Submissions: Draft Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/29\/2025","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"07\/28\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2025-D-1082\u0022\u003EFDA-2025-D-1082\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222025-05-28T10:40:17-04:00\u0022\u003E2025-05-28 10:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/replacing-color-additives-approved-or-marketed-drug-products\u0022\u003EReplacing Color Additives in Approved or Marketed Drug Products: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/186692\/download\u0022\u003EPDF (286.82 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (286.82 KB) of Replacing Color Additives in Approved or Marketed Drug Products: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/29\/2025","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"07\/29\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2025-D-0507\u0022\u003EFDA-2025-D-0507\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-05-30T08:04:35-04:00\u0022\u003E2025-05-30 08:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/m13b-bioequivalence-immediate-release-solid-oral-dosage-forms-additional-strengths-biowaiver\u0022\u003EM13B Bioequivalence for Immediate-Release Solid Oral Dosage Forms: Additional Strengths Biowaiver: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/186703\/download\u0022\u003EPDF (995.48 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (995.48 KB) of M13B Bioequivalence for Immediate-Release Solid Oral Dosage Forms: Additional Strengths Biowaiver: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/30\/2025","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Multidisciplinary","field_topics":"","topics-product":"ICH-Multidisciplinary","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"08\/01\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-0093\u0022\u003EFDA-2023-D-0093\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-06-02T10:36:31-04:00\u0022\u003E2025-06-02 10:36\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommendations-complying-over-counter-monograph-procedure-minor-changes-c001-minor-changes-solid\u0022\u003ERecommendations for Complying With Over-the-Counter Monograph Procedure for Minor Changes C001: Minor Changes to Solid Oral Dosage Forms for Certain Over-the-Counter Monograph Drugs: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/186760\/download\u0022\u003EPDF (348 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (348 KB) of Recommendations for Complying With Over-the-Counter Monograph Procedure for Minor Changes C001: Minor Changes to Solid Oral Dosage Forms for Certain Over-the-Counter Monograph Drugs: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/04\/2025","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Over-the-Counter Drugs","field_topics":"","topics-product":"Over-the-Counter Drugs","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"10\/03\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2025-D-1358\u0022\u003EFDA-2025-D-1358\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-06-05T09:40:46-04:00\u0022\u003E2025-06-05 09:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/transfer-premarket-notification-510k-clearance-questions-and-answers\u0022\u003ETransfer of a Premarket Notification (510(k)) Clearance \u2013 Questions and Answers: Draft Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/186765\/download\u0022\u003EPDF (337.84 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (337.84 KB) of Transfer of a Premarket Notification (510(k)) Clearance \u2013 Questions and Answers: Draft Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/05\/2025","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"08\/04\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-1528\u0022\u003EFDA-2024-D-1528\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222025-06-04T09:16:16-04:00\u0022\u003E2025-06-04 09:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/hernia-mesh-package-labeling-recommendations\u0022\u003EHernia Mesh \u2013 Package Labeling Recommendations: Draft Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/186797\/download\u0022\u003EPDF (357.35 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (357.35 KB) of Hernia Mesh \u2013 Package Labeling Recommendations: Draft Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/06\/2025","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), General \u0026amp; Plastic Surgery , Labeling","field_topics":"","topics-product":"510(k), General \u0026amp; Plastic Surgery , Labeling","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"08\/05\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2025-D-1150\u0022\u003EFDA-2025-D-1150\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222025-06-05T08:57:31-04:00\u0022\u003E2025-06-05 08:57\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q1-stability-testing-drug-substances-and-drug-products\u0022\u003EQ1 Stability Testing of Drug Substances and Drug Products: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/187161\/download\u0022\u003EPDF (1.56 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.56 MB) of Q1 Stability Testing of Drug Substances and Drug Products: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/23\/2025","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"08\/25\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2025-D-1106\u0022\u003EFDA-2025-D-1106\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-06-24T08:09:16-04:00\u0022\u003E2025-06-24 08:09\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cybersecurity-medical-devices-quality-management-system-considerations-and-content-premarket\u0022\u003ECybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/119933\/download\u0022\u003EPDF (1.14 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.14 MB) of Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/03\/2026","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Digital Health","field_topics":"Premarket","topics-product":"Premarket, Digital Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-1158\u0022\u003EFDA-2021-D-1158\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222026-02-03T12:17:03-05:00\u0022\u003E2026-02-03 12:17\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/unique-device-identifier-requirements-combination-products\u0022\u003EUnique Device Identifier Requirements for Combination Products: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/187245\/download\u0022\u003EPDF (336.2 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (336.2 KB) of Unique Device Identifier Requirements for Combination Products: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/25\/2025","field_issuing_office_taxonomy":"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"09\/24\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/ FDA-2025-D-0176\u0022\u003E FDA-2025-D-0176\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222025-06-26T09:43:46-04:00\u0022\u003E2025-06-26 09:43\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/myelodysplastic-syndromes-developing-drug-and-biological-products-treatment\u0022\u003EMyelodysplastic Syndromes: Developing Drug and Biological Products for Treatment: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/187373\/download\u0022\u003EPDF (499.11 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (499.11 KB) of Myelodysplastic Syndromes: Developing Drug and Biological Products for Treatment: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/02\/2025","field_issuing_office_taxonomy":"Oncology Center of Excellence","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"09\/01\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2025-D-0649\u0022\u003EFDA-2025-D-0649\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222025-07-02T09:51:17-04:00\u0022\u003E2025-07-02 09:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/recommendations-reducing-risk-transfusion-transmitted-hepatitis-b-virus\u0022\u003ERecommendations for Reducing the Risk of Transfusion-Transmitted Hepatitis B Virus: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/187587\/download\u0022\u003EPDF (310.58 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (310.58 KB) of Recommendations for Reducing the Risk of Transfusion-Transmitted Hepatitis B Virus: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/03\/2026","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"Hepatitis B","term_node_tid":"Blood Products, Testing","field_topics":"","topics-product":"Hepatitis B, Blood Products, Testing","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-5942\u0022\u003EFDA-2024-D-5942\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222026-11-04T10:17:15-05:00\u0022\u003E2026-11-04 10:17\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/development-cancer-drugs-use-novel-combination-determining-contribution-individual-drugs-effects\u0022\u003EDevelopment of Cancer Drugs for Use in Novel Combination - Determining the Contribution of the Individual Drugs\u2019 Effects: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/187589\/download\u0022\u003EPDF (326.46 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (326.46 KB) of Development of Cancer Drugs for Use in Novel Combination - Determining the Contribution of the Individual Drugs\u2019 Effects: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/17\/2025","field_issuing_office_taxonomy":"Oncology Center of Excellence","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"09\/15\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2025-D-1071\u0022\u003EFDA-2025-D-1071\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222025-07-16T09:20:31-04:00\u0022\u003E2025-07-16 09:20\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e21-inclusion-pregnant-and-breastfeeding-women-clinical-trials\u0022\u003EE21 Inclusion of Pregnant and Breastfeeding Women in Clinical Trials: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/187755\/download\u0022\u003EPDF (429.62 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (429.62 KB) of E21 Inclusion of Pregnant and Breastfeeding Women in Clinical Trials: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/21\/2025","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Women\u0026#039;s Health","field_health_topics":"","term_node_tid":"ICH-Efficacy","field_topics":"","topics-product":"ICH-Efficacy","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"09\/19\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2025-D-1797\u0022\u003EFDA-2025-D-1797\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-07-22T08:55:31-04:00\u0022\u003E2025-07-22 08:55\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/diversity-action-plans-improve-enrollment-participants-underrepresented-populations-clinical-studies\u0022\u003EDiversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"","field_issue_datetime":"06\/26\/2024","field_issuing_office_taxonomy":"Oncology Center of Excellence\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Minority Health and Health Equity\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Women\u0026#039;s Health","field_health_topics":"","term_node_tid":"Pediatric Product Development","field_topics":"","topics-product":"Pediatric Product Development","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"09\/26\/2024","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2021-D-0789\u0022\u003EFDA-2021-D-0789\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs, Medical Devices","changed":"\u003Ctime datetime=\u00222025-07-25T11:00:01-04:00\u0022\u003E2025-07-25 11:00\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/study-sex-differences-clinical-evaluation-medical-products\u0022\u003EStudy of Sex Differences in the Clinical Evaluation of Medical Products \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/184907\/download\u0022\u003EPDF (333.64 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (333.64 KB) of Study of Sex Differences in the Clinical Evaluation of Medical Products \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/15\/2025","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Women\u0026#039;s Health\u003Cbr\u003E\u003Cbr\u003EOffice of the Commissioner,Office of Clinical Policy and Programs","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-4245\u0022\u003EFDA-2024-D-4245\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-12-15T11:48:48-05:00\u0022\u003E2025-12-15 11:48\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/oncology-therapeutic-radiopharmaceuticals-dosage-optimization-during-clinical-development\u0022\u003EOncology Therapeutic Radiopharmaceuticals: Dosage Optimization During Clinical Development: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/188270\/download\u0022\u003EPDF (362.51 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (362.51 KB) of Oncology Therapeutic Radiopharmaceuticals: Dosage Optimization During Clinical Development: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/19\/2025","field_issuing_office_taxonomy":"Oncology Center of Excellence","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"10\/20\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2025-D-1757\u0022\u003EFDA-2025-D-1757\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-08-18T09:27:16-04:00\u0022\u003E2025-08-18 09:27\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/approaches-assessment-overall-survival-oncology-clinical-trials\u0022\u003EApproaches to Assessment of Overall Survival in Oncology Clinical Trials: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/188274\/download\u0022\u003EPDF (399.31 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (399.31 KB) of Approaches to Assessment of Overall Survival in Oncology Clinical Trials: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/19\/2025","field_issuing_office_taxonomy":"Oncology Center of Excellence","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"10\/20\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-5850\u0022\u003EFDA-2024-D-5850\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Biologics, Drugs","changed":"\u003Ctime datetime=\u00222025-08-18T10:15:02-04:00\u0022\u003E2025-08-18 10:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/development-non-opioid-analgesics-chronic-pain\u0022\u003EDevelopment of Non-Opioid Analgesics for Chronic Pain\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/188612\/download\u0022\u003EPDF (397.05 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (397.05 KB) of Development of Non-Opioid Analgesics for Chronic Pain\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/13\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical, Pain Relievers","field_topics":"","topics-product":"Clinical - Medical, Pain Relievers","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2025-D-0610\u0022\u003EFDA-2025-D-0610\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-05-13T13:12:16-04:00\u0022\u003E2026-05-13 13:12\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/erosive-esophagitis-developing-drugs-treatment\u0022\u003EErosive Esophagitis: Developing Drugs for Treatment: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/188761\/download\u0022\u003EPDF (275.33 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (275.33 KB) of Erosive Esophagitis: Developing Drugs for Treatment: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/17\/2025","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"11\/17\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2025-D-0346\u0022\u003EFDA-2025-D-0346\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-09-17T08:48:16-04:00\u0022\u003E2025-09-17 08:48\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/symptomatic-nonerosive-gastroesophageal-reflux-disease-developing-drugs-treatment\u0022\u003ESymptomatic Nonerosive Gastroesophageal Reflux Disease: Developing Drugs for Treatment: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/188760\/download\u0022\u003EPDF (262.62 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (262.62 KB) of Symptomatic Nonerosive Gastroesophageal Reflux Disease: Developing Drugs for Treatment: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/17\/2025","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"11\/17\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2025-D-0331\u0022\u003EFDA-2025-D-0331\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-09-17T08:48:19-04:00\u0022\u003E2025-09-17 08:48\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/disseminated-coccidioidomycosis-developing-drugs-treatment\u0022\u003EDisseminated Coccidioidomycosis: Developing Drugs for Treatment: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/188759\/download\u0022\u003EPDF (299.19 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (299.19 KB) of Disseminated Coccidioidomycosis: Developing Drugs for Treatment: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/17\/2025","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"11\/17\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2025-D-1308\u0022\u003EFDA-2025-D-1308\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-09-17T08:47:01-04:00\u0022\u003E2025-09-17 08:47\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/safety-labeling-changes-implementation-section-505o4-fdc-act\u0022\u003ESafety Labeling Changes\u2014Implementation of Section 505(o)(4) of the FD\u0026amp;C Act: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/188793\/download\u0022\u003EPDF (349.37 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (349.37 KB) of Safety Labeling Changes\u2014Implementation of Section 505(o)(4) of the FD\u0026amp;C Act: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/18\/2025","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Labeling","field_topics":"","topics-product":"Labeling","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"11\/18\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0164\u0022\u003EFDA-2011-D-0164\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-09-19T09:04:02-04:00\u0022\u003E2025-09-19 09:04\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/malaria-developing-drugs-treatment\u0022\u003EMalaria: Developing Drugs for Treatment: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/188817\/download\u0022\u003EPDF (326.7 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (326.7 KB) of Malaria: Developing Drugs for Treatment: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/23\/2025","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Antimicrobial","field_topics":"","topics-product":"Clinical - Antimicrobial","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"12\/22\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2025-D-0918\u0022\u003EFDA-2025-D-0918\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-09-23T07:57:02-04:00\u0022\u003E2025-09-23 07:57\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/expedited-programs-regenerative-medicine-therapies-serious-conditions-0\u0022\u003EExpedited Programs for Regenerative Medicine Therapies for Serious Conditions: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/188874\/download\u0022\u003EPDF (326.54 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (326.54 KB) of Expedited Programs for Regenerative Medicine Therapies for Serious Conditions: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/24\/2025","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research,Office of Therapeutic Products","field_health_topics":"","term_node_tid":"Gene Therapy","field_topics":"","topics-product":"Gene Therapy","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6159\u0022\u003EFDA-2017-D-6159\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222025-09-25T09:46:46-04:00\u0022\u003E2025-09-25 09:46\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/postapproval-methods-capture-safety-and-efficacy-data-cell-and-gene-therapy-products\u0022\u003EPostapproval Methods to Capture Safety and Efficacy Data for Cell and Gene Therapy Products: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/188891\/download\u0022\u003EPDF (322.48 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (322.48 KB) of Postapproval Methods to Capture Safety and Efficacy Data for Cell and Gene Therapy Products: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/24\/2025","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research,Office of Therapeutic Products","field_health_topics":"","term_node_tid":"Gene Therapy","field_topics":"","topics-product":"Gene Therapy","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2025-D-3049\u0022\u003EFDA-2025-D-3049\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222025-11-04T11:45:50-05:00\u0022\u003E2025-11-04 11:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/innovative-designs-clinical-trials-cellular-and-gene-therapy-products-small-populations\u0022\u003EInnovative Designs for Clinical Trials of Cellular and Gene Therapy Products in Small Populations: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/188892\/download\u0022\u003EPDF (374.1 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (374.1 KB) of Innovative Designs for Clinical Trials of Cellular and Gene Therapy Products in Small Populations: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/24\/2025","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research,Office of Therapeutic Products","field_health_topics":"","term_node_tid":"Gene Therapy, Pediatric Product Development","field_topics":"","topics-product":"Gene Therapy, Pediatric Product Development","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2025-D-3403\u0022\u003EFDA-2025-D-3403\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222026-01-26T10:08:18-05:00\u0022\u003E2026-01-26 10:08\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e20-adaptive-designs-clinical-trials\u0022\u003EE20 Adaptive Designs for Clinical Trials\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/188961\/download\u0022\u003EPDF (807.25 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (807.25 KB) of E20 Adaptive Designs for Clinical Trials\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/30\/2025","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Efficacy","field_topics":"","topics-product":"ICH-Efficacy","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"12\/01\/2025","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2025-D-3023\u0022\u003EFDA-2025-D-3023\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-09-30T08:44:31-04:00\u0022\u003E2025-09-30 08:44\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/technical-specifications-submitting-clinical-trial-data-sets-response-assessments-treatments-acute\u0022\u003ETechnical Specifications for Submitting Clinical Trial Data Sets for Response Assessments for Treatments of Acute Leukemias: Guidance for Industry Technical Specifications Document\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/189220\/download\u0022\u003EPDF (525.2 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (525.2 KB) of Technical Specifications for Submitting Clinical Trial Data Sets for Response Assessments for Treatments of Acute Leukemias: Guidance for Industry Technical Specifications Document\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/14\/2025","field_issuing_office_taxonomy":"Oncology Center of Excellence\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-1216\u0022\u003EFDA-2018-D-1216\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"","changed":"\u003Ctime datetime=\u00222025-10-14T08:51:31-04:00\u0022\u003E2025-10-14 08:51\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-299-dual-labeling-fully-approved-and-conditionally-approved-new-animal-drugs-new-world\u0022\u003ECVM GFI #299 -Dual Labeling for Fully Approved and Conditionally Approved New Animal Drugs with a New World Screwworm-Related Indication: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/189207\/download\u0022\u003EPDF (217.56 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (217.56 KB) of CVM GFI #299 -Dual Labeling for Fully Approved and Conditionally Approved New Animal Drugs with a New World Screwworm-Related Indication: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/14\/2025","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2025-D-4500\u0022\u003EFDA-2025-D-4500\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222025-10-15T09:08:18-04:00\u0022\u003E2025-10-15 09:08\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/quality-management-system-information-certain-premarket-submission-reviews\u0022\u003EQuality Management System Information for Certain Premarket Submission Reviews: Draft Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/189345\/download\u0022\u003EPDF (572.7 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (572.7 KB) of Quality Management System Information for Certain Premarket Submission Reviews: Draft Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/27\/2025","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP), HUD\/HDE, Premarket Approval (PMA)","field_topics":"","topics-product":"Current Good Manufacturing Practice (CGMP), HUD\/HDE, Premarket Approval (PMA)","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"01\/16\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2025-D-4051\u0022\u003EFDA-2025-D-4051\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222025-11-14T09:14:34-05:00\u0022\u003E2025-11-14 09:14\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/menstrual-products-performance-testing-and-labeling-recommendations\u0022\u003EMenstrual Products - Performance Testing and Labeling Recommendations: Draft Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/189362\/download\u0022\u003EPDF (757.77 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (757.77 KB) of Menstrual Products - Performance Testing and Labeling Recommendations: Draft Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/28\/2025","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"510(k), Labeling, Obstetrical \u0026amp; Gynecological","field_topics":"Premarket","topics-product":"Premarket, 510(k), Labeling, Obstetrical \u0026amp; Gynecological","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"01\/16\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2025-D-5107\u0022\u003EFDA-2025-D-5107\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222025-11-14T09:14:43-05:00\u0022\u003E2025-11-14 09:14\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/scientific-considerations-demonstrating-biosimilarity-reference-product-updated-recommendations\u0022\u003EScientific Considerations in Demonstrating Biosimilarity to a Reference Product:\u00a0Updated Recommendations for Assessing the Need for Comparative Efficacy Studies: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/189366\/download\u0022\u003EPDF (240.54 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (240.54 KB) of Scientific Considerations in Demonstrating Biosimilarity to a Reference Product:\u00a0Updated Recommendations for Assessing the Need for Comparative Efficacy Studies: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/29\/2025","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research,Office of New Drugs,Office of Therapeutic Biologics and Biosimilars","field_health_topics":"","term_node_tid":"Biosimilars","field_topics":"","topics-product":"Biosimilars","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"01\/20\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-D-0605\u0022\u003EFDA-2011-D-0605\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-11-20T08:54:32-05:00\u0022\u003E2025-11-20 08:54\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cross-center-master-files-where-submit\u0022\u003ECross-Center Master Files: Where to Submit: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/189693\/download\u0022\u003EPDF (288.24 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (288.24 KB) of Cross-Center Master Files: Where to Submit: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/25\/2025","field_issuing_office_taxonomy":"Office of the Commissioner,Office of the Chief Medical Officer,Office of Combination Products\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Veterinary Medicine","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"02\/24\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2025-D-5715\u0022\u003EFDA-2025-D-5715\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"","changed":"\u003Ctime datetime=\u00222025-11-25T09:28:47-05:00\u0022\u003E2025-11-25 09:28\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q3e-guideline-extractables-and-leachables\u0022\u003EQ3E Guideline for Extractables and Leachables\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/189890\/download\u0022\u003EPDF (1.26 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.26 MB) of Q3E Guideline for Extractables and Leachables\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/28\/2025","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"01\/30\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2025-D-4678\u0022\u003EFDA-2025-D-4678\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-12-01T08:36:29-05:00\u0022\u003E2025-12-01 08:36\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/q3e-guideline-extractables-and-leachables-supporting-documentation-class-3-leachable-monographs\u0022\u003EQ3E Guideline for Extractables and Leachables: Supporting Documentation: Class 3 Leachable Monographs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/189891\/download\u0022\u003EPDF (818.41 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (818.41 KB) of Q3E Guideline for Extractables and Leachables: Supporting Documentation: Class 3 Leachable Monographs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/28\/2025","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Quality","field_topics":"","topics-product":"ICH-Quality","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"01\/30\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2025-D-4678\u0022\u003EFDA-2025-D-4678\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-12-01T08:35:17-05:00\u0022\u003E2025-12-01 08:35\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/monoclonal-antibodies-streamlined-nonclinical-safety-studies\u0022\u003EMonoclonal Antibodies: Streamlined Nonclinical Safety Studies: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/189920\/download\u0022\u003EPDF (257.12 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (257.12 KB) of Monoclonal Antibodies: Streamlined Nonclinical Safety Studies: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/02\/2025","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pharmacology\/Toxicology","field_topics":"New Approach Methodologies","topics-product":"New Approach Methodologies, Pharmacology\/Toxicology","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"02\/02\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2025-D-4634\u0022\u003EFDA-2025-D-4634\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-07-24T08:39:02-04:00\u0022\u003E2026-07-24 08:39\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/enhancing-participation-clinical-trials-eligibility-criteria-enrollment-practices-and-trial-designs\u0022\u003EEnhancing Participation in Clinical Trials \u2014 Eligibility Criteria, Enrollment Practices, and Trial Designs: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/190162\/download\u0022\u003EPDF (365.94 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (365.94 KB) of Enhancing Participation in Clinical Trials \u2014 Eligibility Criteria, Enrollment Practices, and Trial Designs: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"12\/15\/2025","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Medical","field_topics":"","topics-product":"Clinical - Medical","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-D-1264\u0022\u003EFDA-2019-D-1264\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222025-12-15T11:07:03-05:00\u0022\u003E2025-12-15 11:07\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/questions-and-answers-regarding-mandatory-cosmetics-recalls-guidance-industry\u0022\u003EQuestions and Answers Regarding Mandatory Cosmetics Recalls: Guidance for Industry : Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/190625\/download\u0022\u003EPDF (236.89 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (236.89 KB) of Questions and Answers Regarding Mandatory Cosmetics Recalls: Guidance for Industry : Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/22\/2026","field_issuing_office_taxonomy":"Office of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2025-D-2246\u0022\u003EFDA-2025-D-2246\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Cosmetics","changed":"\u003Ctime datetime=\u00222026-10-22T08:49:04-04:00\u0022\u003E2026-10-22 08:49\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/use-bayesian-methodology-clinical-trials-drug-and-biological-products\u0022\u003EUse of Bayesian Methodology in Clinical Trials of Drug and Biological Products: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/190505\/download\u0022\u003EPDF (451.17 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (451.17 KB) of Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/09\/2026","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pediatric Product Development","field_topics":"Biostatistics","topics-product":"Biostatistics, Pediatric Product Development","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2025-D-3217\u0022\u003EFDA-2025-D-3217\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-01-26T10:05:03-05:00\u0022\u003E2026-01-26 10:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/m4qr2-common-technical-document-registration-pharmaceuticals-human-use-quality\u0022\u003EM4Q(R2) The Common Technical Document for the Registration of Pharmaceuticals for Human Use: Quality\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/190641\/download\u0022\u003EPDF (639.02 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (639.02 KB) of M4Q(R2) The Common Technical Document for the Registration of Pharmaceuticals for Human Use: Quality\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/20\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Multidisciplinary","field_topics":"","topics-product":"ICH-Multidisciplinary","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"03\/23\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2025-D-2275\u0022\u003EFDA-2025-D-2275\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-01-21T07:45:49-05:00\u0022\u003E2026-01-21 07:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/minimal-residual-disease-and-complete-response-multiple-myeloma-use-endpoints-support-accelerated\u0022\u003EMinimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/190647\/download\u0022\u003EPDF (349.78 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (349.78 KB) of Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/21\/2026","field_issuing_office_taxonomy":"Oncology Center of Excellence\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2025-D-2616\u0022\u003EFDA-2025-D-2616\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"","changed":"\u003Ctime datetime=\u00222026-01-20T08:57:14-05:00\u0022\u003E2026-01-20 08:57\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/fda-records-access-authority-cosmetic-products\u0022\u003EFDA Records Access Authority for Cosmetic Products: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/190681\/download\u0022\u003EPDF (306.96 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (306.96 KB) of FDA Records Access Authority for Cosmetic Products: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/21\/2026","field_issuing_office_taxonomy":"Office of Inspections and Investigations","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2025-D-2243\u0022\u003EFDA-2025-D-2243\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Cosmetics","changed":"\u003Ctime datetime=\u00222026-01-21T13:54:51-05:00\u0022\u003E2026-01-21 13:54\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cuffless-non-invasive-blood-pressure-measuring-devices-clinical-performance-testing-and-evaluation\u0022\u003ECuffless Non-invasive Blood Pressure Measuring Devices \u2013 Clinical Performance Testing and Evaluation: Draft Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/190675\/download\u0022\u003EPDF (302 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (302 KB) of Cuffless Non-invasive Blood Pressure Measuring Devices \u2013 Clinical Performance Testing and Evaluation: Draft Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"01\/23\/2026","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Cardiovascular ","field_topics":"Premarket","topics-product":"Premarket, Cardiovascular ","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"03\/24\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2025-D-0851\u0022\u003EFDA-2025-D-0851\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222026-01-22T09:58:19-05:00\u0022\u003E2026-01-22 09:58\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/computer-software-assurance-production-and-quality-management-system-software\u0022\u003EComputer Software Assurance for Production and Quality Management System Software: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/188844\/download\u0022\u003EPDF (734.63 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (734.63 KB) of Computer Software Assurance for Production and Quality Management System Software: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/03\/2026","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP), Digital Health","field_topics":"Postmarket","topics-product":"Postmarket, Current Good Manufacturing Practice (CGMP), Digital Health","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2022-D-0795\u0022\u003EFDA-2022-D-0795\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222026-02-05T07:59:33-05:00\u0022\u003E2026-02-05 07:59\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/e22-general-considerations-patient-preference-studies\u0022\u003EE22 General Considerations for Patient Preference Studies\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/190946\/download\u0022\u003EPDF (791.53 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (791.53 KB) of E22 General Considerations for Patient Preference Studies\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/06\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"ICH-Efficacy","field_topics":"","topics-product":"ICH-Efficacy","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"04\/07\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2026-D-0207\u0022\u003EFDA-2026-D-0207\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-02-06T08:11:49-05:00\u0022\u003E2026-02-06 08:11\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/certification-process-designated-medical-gases\u0022\u003ECertification Process for Designated Medical Gases: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/191040\/download\u0022\u003EPDF (339.77 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (339.77 KB) of Certification Process for Designated Medical Gases: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/11\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Veterinary Medicine","field_health_topics":"","term_node_tid":"Administrative \/ Procedural","field_topics":"","topics-product":"Administrative \/ Procedural","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"04\/13\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2012-D-1197\u0022\u003EFDA-2012-D-1197\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-02-27T11:40:02-05:00\u0022\u003E2026-02-27 11:40\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/defining-durations-use-certain-medically-important-antimicrobial-drugs-food-producing-animals\u0022\u003EDefining Durations of Use for Certain Medically Important Antimicrobial Drugs for Food-Producing Animals\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/191092\/download\u0022\u003EPDF (1.01 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.01 MB) of Defining Durations of Use for Certain Medically Important Antimicrobial Drugs for Food-Producing Animals\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/12\/2026","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"02\/12\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-2925\u0022\u003EFDA-2023-D-2925\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222026-02-12T12:17:34-05:00\u0022\u003E2026-02-12 12:17\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/questions-and-answers-about-requirements-additional-traceability-records-certain-foods\u0022\u003EQuestions and Answers About Requirements for Additional Traceability Records for Certain Foods: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/191182\/download\u0022\u003EPDF (407.19 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (407.19 KB) of Questions and Answers About Requirements for Additional Traceability Records for Certain Foods: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/19\/2026","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"05\/21\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2025-D-2837\u0022\u003EFDA-2025-D-2837\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222026-02-19T09:32:31-05:00\u0022\u003E2026-02-19 09:32\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/considerations-use-plausible-mechanism-framework-develop-individualized-therapies-target-specific\u0022\u003EConsiderations for the use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/191247\/download\u0022\u003EPDF (379.65 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (379.65 KB) of Considerations for the use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"02\/23\/2026","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Gene Therapy","field_topics":"","topics-product":"Gene Therapy","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"04\/27\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2026-D-1256\u0022\u003EFDA-2026-D-1256\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222026-02-25T08:31:09-05:00\u0022\u003E2026-02-25 08:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/new-clinical-investigation-exclusivity-3-year-exclusivity-drug-products-questions-and-answers\u0022\u003ENew Clinical Investigation Exclusivity (3-Year Exclusivity) for Drug Products: Questions and Answers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/191368\/download\u0022\u003EPDF (263.87 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (263.87 KB) of New Clinical Investigation Exclusivity (3-Year Exclusivity) for Drug Products: Questions and Answers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/03\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Drug Competition Action Plan, Generic Drugs","field_topics":"Electronic Submissions","topics-product":"Electronic Submissions, Drug Competition Action Plan, Generic Drugs","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"05\/04\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2024-D-4388\u0022\u003EFDA-2024-D-4388\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-03-04T19:48:18-05:00\u0022\u003E2026-03-04 19:48\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/responding-fda-form-483-observations-conclusion-drug-cgmp-inspection\u0022\u003EResponding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/191427\/download\u0022\u003EPDF (321.8 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (321.8 KB) of Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/06\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Veterinary Medicine\u003Cbr\u003E\u003Cbr\u003EOffice of Inspections and Investigations","field_health_topics":"","term_node_tid":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_topics":"","topics-product":"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"05\/08\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2025-D-1504\u0022\u003EFDA-2025-D-1504\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-03-09T09:27:46-04:00\u0022\u003E2026-03-09 09:27\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/flavored-electronic-nicotine-delivery-systems-ends-premarket-applications-considerations-related\u0022\u003EFlavored Electronic Nicotine Delivery Systems (ENDS) Premarket Applications \u2013 Considerations Related to Youth Risk: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/191455\/download\u0022\u003EPDF (398.15 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (398.15 KB) of Flavored Electronic Nicotine Delivery Systems (ENDS) Premarket Applications \u2013 Considerations Related to Youth Risk: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/11\/2026","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"05\/11\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2026-D-1817\u0022\u003EFDA-2026-D-1817\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Tobacco Products","field_regulated_product_field":"Tobacco","changed":"\u003Ctime datetime=\u00222026-03-11T13:15:31-04:00\u0022\u003E2026-03-11 13:15\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/medical-devices-indications-associated-weight-loss-premarket-considerations\u0022\u003EMedical Devices with Indications Associated with Weight Loss - Premarket Considerations: Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/191489\/download\u0022\u003EPDF (1.38 MB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (1.38 MB) of Medical Devices with Indications Associated with Weight Loss - Premarket Considerations: Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/13\/2026","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"Gastroenterology-Urology ","field_topics":"Premarket","topics-product":"Premarket, Gastroenterology-Urology ","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2019-N-4060\u0022\u003EFDA-2019-N-4060\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222026-03-12T09:42:16-04:00\u0022\u003E2026-03-12 09:42\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/general-considerations-use-new-approach-methodologies-drug-development\u0022\u003EGeneral Considerations for the Use of New Approach Methodologies in Drug Development\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/191589\/download\u0022\u003EPDF (285.2 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (285.2 KB) of General Considerations for the Use of New Approach Methodologies in Drug Development\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"03\/18\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Pharmacology\/Toxicology, Pediatric Product Development","field_topics":"New Approach Methodologies","topics-product":"New Approach Methodologies, Pharmacology\/Toxicology, Pediatric Product Development","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"05\/18\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2025-D-6131\u0022\u003EFDA-2025-D-6131\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-07-24T08:41:15-04:00\u0022\u003E2026-07-24 08:41\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/bioanalytical-method-validation-biomarkers\u0022\u003EBioanalytical Method Validation for Biomarkers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/185276\/download\u0022\u003EPDF (218.49 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (218.49 KB) of Bioanalytical Method Validation for Biomarkers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/10\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Pharmacology","field_topics":"","topics-product":"Clinical - Pharmacology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6821\u0022\u003EFDA-2017-D-6821\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-04-22T14:44:01-04:00\u0022\u003E2026-04-22 14:44\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/safety-assessment-genome-editing-human-gene-therapy-products-using-next-generation-sequencing\u0022\u003ESafety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/191966\/download\u0022\u003EPDF (390.18 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (390.18 KB) of Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/14\/2026","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research,Office of Therapeutic Products","field_health_topics":"","term_node_tid":"Gene Therapy","field_topics":"","topics-product":"Gene Therapy","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"07\/14\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2026-D-1255\u0022\u003EFDA-2026-D-1255\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222026-06-24T10:56:33-04:00\u0022\u003E2026-06-24 10:56\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/establishing-impurity-specifications-antibiotics\u0022\u003EEstablishing Impurity Specifications for Antibiotics\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/192017\/download\u0022\u003EPDF (326.41 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (326.41 KB) of Establishing Impurity Specifications for Antibiotics\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/20\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"06\/22\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2025-D-6130\u0022\u003EFDA-2025-D-6130\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-04-20T09:07:31-04:00\u0022\u003E2026-04-20 09:07\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/compliance-policy-regarding-premarket-and-other-requirements-certain-niosh-approved-air-purifying\u0022\u003ECompliance Policy Regarding Premarket and Other Requirements for Certain NIOSH Approved Air-Purifying Respirators: Draft Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/192018\/download\u0022\u003EPDF (638.45 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (638.45 KB) of Compliance Policy Regarding Premarket and Other Requirements for Certain NIOSH Approved Air-Purifying Respirators: Draft Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"04\/20\/2026","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"06\/19\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2025-D-7121\u0022\u003EFDA-2025-D-7121\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222026-04-17T08:50:31-04:00\u0022\u003E2026-04-17 08:50\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/chemistry-manufacturing-and-controls-flexibilities-developing-human-cellular-and-gene-therapy\u0022\u003EChemistry, Manufacturing, and Controls Flexibilities for Developing Human Cellular and Gene Therapy Products for a Biologics License Application: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/192321\/download\u0022\u003EPDF (299.17 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (299.17 KB) of Chemistry, Manufacturing, and Controls Flexibilities for Developing Human Cellular and Gene Therapy Products for a Biologics License Application: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/05\/2026","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Gene Therapy","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Gene Therapy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2026-D-4692\u0022\u003EFDA-2026-D-4692\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222026-07-07T12:25:16-04:00\u0022\u003E2026-07-07 12:25\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/submitting-continuous-glucose-monitoring-data-clinical-trials\u0022\u003ESubmitting Continuous Glucose Monitoring Data in Clinical Trials \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/192367\/download\u0022\u003EPDF (830.3 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (830.3 KB) of Submitting Continuous Glucose Monitoring Data in Clinical Trials \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/06\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6821\u0022\u003EFDA-2017-D-6821\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-05-07T09:17:31-04:00\u0022\u003E2026-05-07 09:17\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/enforcement-priorities-certain-new-tobacco-products-marketed-without-premarket-authorization\u0022\u003EEnforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/192403\/download\u0022\u003EPDF (313.21 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (313.21 KB) of Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/08\/2026","field_issuing_office_taxonomy":"Center for Tobacco Products","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2026-D-5083\u0022\u003EFDA-2026-D-5083\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Tobacco Products","field_regulated_product_field":"","changed":"\u003Ctime datetime=\u00222026-05-13T13:33:36-04:00\u0022\u003E2026-05-13 13:33\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/oncology-pharmaceuticals-streamlined-nonclinical-safety-studies-biologics-and-conjugated-products\u0022\u003EOncology Pharmaceuticals: Streamlined Nonclinical Safety Studies for Biologics and Conjugated Products: Draft Guidance\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/192723\/download\u0022\u003EPDF (231.64 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (231.64 KB) of Oncology Pharmaceuticals: Streamlined Nonclinical Safety Studies for Biologics and Conjugated Products: Draft Guidance\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"05\/29\/2026","field_issuing_office_taxonomy":"Oncology Center of Excellence","field_health_topics":"","term_node_tid":"","field_topics":"New Approach Methodologies","topics-product":"New Approach Methodologies, ","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"07\/30\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2026- D-2839\u0022\u003EFDA-2026- D-2839\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of the Commissioner","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-07-24T08:36:46-04:00\u0022\u003E2026-07-24 08:36\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/leveraging-prior-knowledge-development-human-gene-therapy-products-incorporating-genome-editing\u0022\u003ELeveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/192810\/download\u0022\u003EPDF (447.57 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (447.57 KB) of Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/02\/2026","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research,Office of Therapeutic Products","field_health_topics":"","term_node_tid":"Gene Therapy","field_topics":"","topics-product":"Gene Therapy","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"09\/01\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2026-D-1257\u0022\u003EFDA-2026-D-1257\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222026-08-26T09:31:38-04:00\u0022\u003E2026-08-26 09:31\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/certain-postapproval-requirements-and-resources-andas\u0022\u003ECertain Postapproval Requirements and Resources for ANDAs\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/192866\/download\u0022\u003EPDF (284.12 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (284.12 KB) of Certain Postapproval Requirements and Resources for ANDAs\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/04\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Generic Drugs","field_topics":"","topics-product":"Generic Drugs","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6821\u0022\u003EFDA-2017-D-6821\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-06-04T11:33:02-04:00\u0022\u003E2026-06-04 11:33\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/forms-fda-3542a-and-fda-3542-questions-and-answers\u0022\u003EForms FDA 3542a and FDA 3542: Questions and Answers\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/193076\/download\u0022\u003EPDF (250.6 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (250.6 KB) of Forms FDA 3542a and FDA 3542: Questions and Answers\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/15\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Drug Competition Action Plan, Generic Drugs","field_topics":"","topics-product":"Drug Competition Action Plan, Generic Drugs","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2026-D-2698\u0022\u003EFDA-2026-D-2698\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-06-12T08:45:50-04:00\u0022\u003E2026-06-12 08:45\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/submitting-clinical-trial-datasets-evaluate-impact-immunogenicity-pharmacokinetics-drug\u0022\u003ESubmitting Clinical Trial Datasets to Evaluate the Impact of Immunogenicity on the Pharmacokinetics of a Drug\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/193208\/download\u0022\u003EPDF (352.15 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (352.15 KB) of Submitting Clinical Trial Datasets to Evaluate the Impact of Immunogenicity on the Pharmacokinetics of a Drug\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/18\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Pharmacology","field_topics":"","topics-product":"Clinical - Pharmacology","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6821\u0022\u003EFDA-2017-D-6821\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-06-18T08:30:26-04:00\u0022\u003E2026-06-18 08:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/quantitative-systems-pharmacology-qsp-based-dose-selection-minimum-anticipated-biological-effect\u0022\u003EQuantitative Systems Pharmacology (QSP)-Based Dose Selection for Minimum Anticipated Biological Effect Level (MABEL) in First-in-Human (FIH) Trials\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/193230\/download\u0022\u003EPDF (265.78 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (265.78 KB) of Quantitative Systems Pharmacology (QSP)-Based Dose Selection for Minimum Anticipated Biological Effect Level (MABEL) in First-in-Human (FIH) Trials\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"06\/24\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Clinical - Pharmacology","field_topics":"New Approach Methodologies","topics-product":"New Approach Methodologies, Clinical - Pharmacology","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"07\/24\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2026-D-6539\u0022\u003EFDA-2026-D-6539\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-07-24T08:43:31-04:00\u0022\u003E2026-07-24 08:43\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/biosimilar-and-interchangeable-biosimilar-products-considerations-container-closure-systems-and\u0022\u003EBiosimilar and Interchangeable Biosimilar Products: Considerations for Container Closure Systems and Device Constituent Parts\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/193917\/download\u0022\u003EPDF (301.41 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (301.41 KB) of Biosimilar and Interchangeable Biosimilar Products: Considerations for Container Closure Systems and Device Constituent Parts\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"07\/31\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Biosimilars","field_topics":"","topics-product":"Biosimilars","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"10\/02\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2026-D-4272\u0022\u003EFDA-2026-D-4272\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-08-21T11:30:05-04:00\u0022\u003E2026-08-21 11:30\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/container-closure-systems-human-drugs-and-biological-products\u0022\u003EContainer Closure Systems for Human Drugs and Biological Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/194220\/download\u0022\u003EPDF (566.37 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (566.37 KB) of Container Closure Systems for Human Drugs and Biological Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/13\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_topics":"","topics-product":"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"10\/13\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2026-D-7957\u0022\u003EFDA-2026-D-7957\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-08-18T08:14:31-04:00\u0022\u003E2026-08-18 08:14\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/determining-whether-submit-anda-or-505b2-application-0\u0022\u003EDetermining Whether to Submit an ANDA or a 505(b)(2) Application\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/194279\/download\u0022\u003EPDF (330.21 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (330.21 KB) of Determining Whether to Submit an ANDA or a 505(b)(2) Application\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/17\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Drug Competition Action Plan, Generic Drugs","field_topics":"","topics-product":"Drug Competition Action Plan, Generic Drugs","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"10\/19\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-5974\u0022\u003EFDA-2017-D-5974\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-08-18T08:16:05-04:00\u0022\u003E2026-08-18 08:16\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/potency-assessment-active-immunotherapy-products\u0022\u003EPotency Assessment of Active Immunotherapy Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/194324\/download\u0022\u003EPDF (375.16 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (375.16 KB) of Potency Assessment of Active Immunotherapy Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/19\/2026","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research,Office of Therapeutic Products","field_health_topics":"","term_node_tid":"Gene Therapy","field_topics":"","topics-product":"Gene Therapy","field_final_guidance_1":"Draft","open-comment":" Yes ","field_comment_close_date":"11\/18\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2026-D-8561\u0022\u003EFDA-2026-D-8561\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222026-08-25T11:01:44-04:00\u0022\u003E2026-08-25 11:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/draft-cvm-gfi-256b-compounding-animal-drugs-bulk-drug-substances-compounding-under-cgmp-federally\u0022\u003EDraft CVM GFI #256B - Compounding Animal Drugs from Bulk Drug Substances: Compounding under CGMP in Federally-Registered Facilities\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/194414\/download\u0022\u003EPDF (331.64 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (331.64 KB) of Draft CVM GFI #256B - Compounding Animal Drugs from Bulk Drug Substances: Compounding under CGMP in Federally-Registered Facilities\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"08\/28\/2026","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" Yes ","field_comment_close_date":"11\/27\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2018-D-4533\u0022\u003EFDA-2018-D-4533\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222026-08-31T15:02:47-04:00\u0022\u003E2026-08-31 15:02\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/temporary-policies-compounding-certain-starter-parenteral-nutrition-drug-products-neonates\u0022\u003ETemporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/194633\/download\u0022\u003EPDF (391.23 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (391.23 KB) of Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/08\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Compounding","field_topics":"","topics-product":"Compounding","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2026-D-9571\u0022\u003EFDA-2026-D-9571\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-09-09T09:05:31-04:00\u0022\u003E2026-09-09 09:05\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/electronic-submission-template-premarket-approval-applications-pma\u0022\u003EElectronic Submission Template for Premarket Approval Applications (PMA): Draft Guidance for Industry and Food and Drug Administration Staff \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/194874\/download\u0022\u003EPDF (451.92 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (451.92 KB) of Electronic Submission Template for Premarket Approval Applications (PMA): Draft Guidance for Industry and Food and Drug Administration Staff \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/18\/2026","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Premarket Approval (PMA)","field_topics":"Electronic Submissions","topics-product":"Electronic Submissions, Premarket Approval (PMA)","field_final_guidance_1":"Draft","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2026-D-9429\u0022\u003EFDA-2026-D-9429\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222026-09-17T09:28:46-04:00\u0022\u003E2026-09-17 09:28\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-298-vich-gl62-target-animal-safety-evaluation-veterinary-monoclonal-antibody-products\u0022\u003ECVM GFI #298 (VICH GL62) \u2013 Target Animal Safety Evaluation for Veterinary Monoclonal Antibody Products\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/194837\/download\u0022\u003EPDF (397.65 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (397.65 KB) of CVM GFI #298 (VICH GL62) \u2013 Target Animal Safety Evaluation for Veterinary Monoclonal Antibody Products\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/18\/2026","field_issuing_office_taxonomy":"Center for Veterinary Medicine","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" Yes ","field_comment_close_date":"11\/17\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2026-D-7233\u0022\u003EFDA-2026-D-7233\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Veterinary Medicine","field_regulated_product_field":"Animal \u0026amp; Veterinary","changed":"\u003Ctime datetime=\u00222026-09-17T09:18:02-04:00\u0022\u003E2026-09-17 09:18\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/robotically-assisted-surgical-devices-premarket-submissions\u0022\u003ERobotically-Assisted Surgical Devices - Premarket Submissions: Draft Guidance for Industry and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/194987\/download\u0022\u003EPDF (819.89 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (819.89 KB) of Robotically-Assisted Surgical Devices - Premarket Submissions: Draft Guidance for Industry and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"09\/25\/2026","field_issuing_office_taxonomy":"Center for Devices and Radiological Health","field_health_topics":"","term_node_tid":"General \u0026amp; Plastic Surgery ","field_topics":"Premarket","topics-product":"Premarket, General \u0026amp; Plastic Surgery ","field_final_guidance_1":"Draft","open-comment":" Yes ","field_comment_close_date":"11\/24\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2026-N-9505\u0022\u003EFDA-2026-N-9505\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Medical Devices","changed":"\u003Ctime datetime=\u00222026-09-24T09:10:08-04:00\u0022\u003E2026-09-24 09:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/enforcement-policy-delay-requirements-submit-international-mail-tracking-number-and-mail-service\u0022\u003EEnforcement Policy to Delay Requirements to Submit International Mail Tracking Number and Mail Service Name Until May 1, 2027: Guidance for Industry: Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/195075\/download\u0022\u003EPDF (221.63 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (221.63 KB) of Enforcement Policy to Delay Requirements to Submit International Mail Tracking Number and Mail Service Name Until May 1, 2027: Guidance for Industry: Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/01\/2026","field_issuing_office_taxonomy":"Office of Inspections and Investigations,Office of Field Operations \u0026amp; Response\u003Cbr\u003E\u003Cbr\u003EHuman Foods Program\u003Cbr\u003E\u003Cbr\u003ECenter for Veterinary Medicine","field_health_topics":"","term_node_tid":"Animal Food Additives, Livestock Feed, Food \u0026amp; Beverage Safety, Food \u0026amp; Color Additives, Juice, Human Food Safety, Import, Export","field_topics":"Compliance, Investigation \u0026amp; Enforcement, Inspection, International","topics-product":"Compliance, Investigation \u0026amp; Enforcement, Inspection, International, Animal Food Additives, Livestock Feed, Food \u0026amp; Beverage Safety, Food \u0026amp; Color Additives, Juice, Human Food Safety, Import, Export","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2011-N-0179\u0022\u003EFDA-2011-N-0179\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Office of Inspections and Investigations","field_regulated_product_field":"Animal \u0026amp; Veterinary, Dietary Supplements, Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222026-10-01T06:10:14-04:00\u0022\u003E2026-10-01 06:10\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-requirements-additional-traceability-records-certain-foods-enforcement-policy\u0022\u003EGuidance for Industry: Requirements for Additional Traceability Records for Certain Foods: Enforcement Policy for Certain Retail Food Establishments and Restaurants\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/195213\/download\u0022\u003EPDF (225.03 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (225.03 KB) of Guidance for Industry: Requirements for Additional Traceability Records for Certain Foods: Enforcement Policy for Certain Retail Food Establishments and Restaurants\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/08\/2026","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Draft","open-comment":" Yes ","field_comment_close_date":"11\/23\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2025-D-6952\u0022\u003EFDA-2025-D-6952\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222026-10-08T09:01:58-04:00\u0022\u003E2026-10-08 09:01\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-new-dietary-ingredient-ndi-notifications-and-related-issues-identity-and-safety\u0022\u003EGuidance for Industry: New Dietary Ingredient (NDI) Notifications and Related Issues; Identity and Safety Information About the NDI\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/195770\/download\u0022\u003EPDF (683.45 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (683.45 KB) of Guidance for Industry: New Dietary Ingredient (NDI) Notifications and Related Issues; Identity and Safety Information About the NDI\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/19\/2026","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"","field_topics":"","topics-product":"","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2025-D-6501\u0022\u003EFDA-2025-D-6501\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Dietary Supplements","changed":"\u003Ctime datetime=\u00222026-10-19T08:54:17-04:00\u0022\u003E2026-10-19 08:54\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/submitting-clinical-trial-data-evaluate-ability-operate-motor-vehicle\u0022\u003ESubmitting Clinical Trial Data to Evaluate the Ability to Operate a Motor Vehicle\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/195806\/download\u0022\u003EPDF (710.97 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (710.97 KB) of Submitting Clinical Trial Data to Evaluate the Ability to Operate a Motor Vehicle\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/20\/2026","field_issuing_office_taxonomy":"Center for Drug Evaluation and Research","field_health_topics":"","term_node_tid":"Technical Specifications","field_topics":"","topics-product":"Technical Specifications","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2017-D-6821\u0022\u003EFDA-2017-D-6821\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Drug Evaluation and Research","field_regulated_product_field":"Drugs","changed":"\u003Ctime datetime=\u00222026-10-20T12:13:31-04:00\u0022\u003E2026-10-20 12:13\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/action-levels-cadmium-processed-food-intended-babies-and-young-children-draft-guidance-industry\u0022\u003EAction Levels for Cadmium in Processed Food Intended for Babies and Young Children: Draft Guidance for Industry\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/195793\/download\u0022\u003EPDF (332.98 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (332.98 KB) of Action Levels for Cadmium in Processed Food Intended for Babies and Young Children: Draft Guidance for Industry\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/22\/2026","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Infant Formula \u0026amp; Foods, Prepared Food","field_topics":"","topics-product":"Infant Formula \u0026amp; Foods, Prepared Food","field_final_guidance_1":"Draft","open-comment":" Yes ","field_comment_close_date":"12\/22\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2025-D-4023\u0022\u003EFDA-2025-D-4023\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222026-11-02T15:27:32-05:00\u0022\u003E2026-11-02 15:27\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/draft-guidance-industry-us-origin-statements-seafood\u0022\u003EDraft Guidance for Industry: U.S.-Origin Statements on Seafood\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/195682\/download\u0022\u003EPDF (358.03 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (358.03 KB) of Draft Guidance for Industry: U.S.-Origin Statements on Seafood\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/23\/2026","field_issuing_office_taxonomy":"Human Foods Program","field_health_topics":"","term_node_tid":"Seafood\/Seafood Product","field_topics":"","topics-product":"Seafood\/Seafood Product","field_final_guidance_1":"Draft","open-comment":" Yes ","field_comment_close_date":"12\/28\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2026-D-6729\u0022\u003EFDA-2026-D-6729\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Human Foods Program","field_regulated_product_field":"Food \u0026amp; Beverages","changed":"\u003Ctime datetime=\u00222026-10-23T16:18:47-04:00\u0022\u003E2026-10-23 16:18\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/individualized-human-genome-editing-products-considerations-bla-submission-and-postapproval\u0022\u003EIndividualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/195887\/download\u0022\u003EPDF (384.05 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (384.05 KB) of Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/27\/2026","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research,Office of Therapeutic Products","field_health_topics":"","term_node_tid":"Gene Therapy","field_topics":"","topics-product":"Gene Therapy","field_final_guidance_1":"Draft","open-comment":" Yes ","field_comment_close_date":"11\/27\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2026-D-11783\u0022\u003EFDA-2026-D-11783\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222026-10-27T08:54:01-04:00\u0022\u003E2026-10-27 08:54\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/electronic-submission-template-investigational-device-exemption-ide-applications\u0022\u003EElectronic Submission Template for Investigational Device Exemption (IDE) Applications: Draft Guidance for Sponsors and Food and Drug Administration Staff\u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/195797\/download\u0022\u003EPDF (451.99 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (451.99 KB) of Electronic Submission Template for Investigational Device Exemption (IDE) Applications: Draft Guidance for Sponsors and Food and Drug Administration Staff\u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"10\/28\/2026","field_issuing_office_taxonomy":"Center for Devices and Radiological Health\u003Cbr\u003E\u003Cbr\u003ECenter for Biologics Evaluation and Research","field_health_topics":"","term_node_tid":"Investigational Device Exemption (IDE)","field_topics":"Electronic Submissions","topics-product":"Electronic Submissions, Investigational Device Exemption (IDE)","field_final_guidance_1":"Draft","open-comment":" Yes ","field_comment_close_date":"12\/28\/2026","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2026-D-11188\u0022\u003EFDA-2026-D-11188\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Devices and Radiological Health","field_regulated_product_field":"Biologics, Medical Devices","changed":"\u003Ctime datetime=\u00222026-10-27T09:09:34-04:00\u0022\u003E2026-10-27 09:09\u003C\/time\u003E\n"},{"title":"\u003Ca href=\u0022\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-potency-assurance-cellular-and-gene-therapy-products\u0022\u003E Guidance for Industry: Potency Assurance for Cellular and Gene Therapy Products \u003C\/a\u003E","field_associated_media_2":"\u003Ca href=\u0022\/media\/196183\/download\u0022\u003EPDF (477.85 KB)\u003Cspan class=\u0022sr-only\u0022\u003EPDF (477.85 KB) of Guidance for Industry: Potency Assurance for Cellular and Gene Therapy Products \u003C\/span\u003E\u003C\/a\u003E","field_issue_datetime":"11\/02\/2026","field_issuing_office_taxonomy":"Center for Biologics Evaluation and Research,Office of Therapeutic Products","field_health_topics":"","term_node_tid":"Gene Therapy","field_topics":"","topics-product":"Gene Therapy","field_final_guidance_1":"Final","open-comment":" No ","field_comment_close_date":"","field_docket_number":"\u003Ca href=\u0022https:\/\/www.regulations.gov\/docket\/FDA-2023-D-4299\u0022\u003EFDA-2023-D-4299\u003C\/a\u003E","field_communication_type":"Guidance Document","field_center":"Center for Biologics Evaluation and Research","field_regulated_product_field":"Biologics","changed":"\u003Ctime datetime=\u00222026-11-02T08:53:47-05:00\u0022\u003E2026-11-02 08:53\u003C\/time\u003E\n"}]